Identification	O
of	O
APC2	O
,	O
a	O
homologue	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
tumour	I-Disease
suppressor	O
.	O

The	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
APC	I-Disease
)	I-Disease
tumour	I-Disease
-	O
suppressor	O
protein	O
controls	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O

Complex	O
formation	O
induces	O
the	O
rapid	O
degradation	O
of	O
betacatenin	O
.	O

In	O
colon	B-Disease
carcinoma	I-Disease
cells	O
,	O
loss	O
of	O
APC	O
leads	O
to	O
the	O
accumulation	O
of	O
betacatenin	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
Tcf	O
-	O
4	O
transcription	O
factor	O
(	O
reviewed	O
in	O
[	O
1	O
]	O
[	O
2	O
]	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
genomic	O
structure	O
of	O
APC	O
homologues	O
.	O

Mammalian	O
APC2	O
,	O
which	O
closely	O
resembles	O
APC	O
in	O
overall	O
domain	O
structure	O
,	O
was	O
functionally	O
analyzed	O
and	O
shown	O
to	O
contain	O
two	O
SAMP	O
domains	O
,	O
both	O
of	O
which	O
are	O
required	O
for	O
binding	O
to	O
conductin	O
.	O

Like	O
APC	O
,	O
APC2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin	O
-	O
Tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC	O
-	O
/	O
-	O
colon	B-Disease
carcinoma	I-Disease
cells	O
.	O

Human	O
APC2	O
maps	O
to	O
chromosome	O
19p13	O
.	O

3	O
.	O

APC	O
and	O
APC2	O
may	O
therefore	O
have	O
comparable	O
functions	O
in	O
development	O
and	O
cancer	B-Disease
.	O

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	B-Disease
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O

The	O
frequency	O
,	O
origin	O
,	O
and	O
phenotypic	O
expression	O
of	O
a	O
germline	O
MSH2	O
gene	O
mutation	O
previously	O
identified	O
in	O
seven	O
kindreds	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
cancer	I-Disease
syndrome	I-Disease
(	O
HNPCC	B-Disease
)	O
was	O
investigated	O
.	O

The	O
mutation	O
(	O
A	O
-	O
-	O
>	O
T	O
at	O
nt943	O
+	O
3	O
)	O
disrupts	O
the	O
3	O
splice	O
site	O
of	O
exon	O
5	O
leading	O
to	O
the	O
deletion	O
of	O
this	O
exon	O
from	O
MSH2	O
mRNA	O
and	O
represents	O
the	O
only	O
frequent	O
MSH2	O
mutation	O
so	O
far	O
reported	O
.	O

Although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	B-Disease
cancer	I-Disease
families	O
analysed	O
from	O
eastern	O
England	O
,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
English	O
HNPCC	B-Disease
kindreds	O
analysed	O
.	O

In	O
contrast	O
,	O
the	O
MSH2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	O
colorectal	B-Disease
families	O
from	O
Newfoundland	O
.	O

To	O
investigate	O
the	O
origin	O
of	O
this	O
mutation	O
in	O
colorectal	B-Disease
cancer	I-Disease
families	O
from	O
England	O
(	O
n	O
=	O
4	O
)	O
,	O
Newfoundland	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
n	O
=	O
3	O
)	O
,	O
haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
linked	O
to	O
MSH2	O
was	O
performed	O
.	O

Within	O
the	O
English	O
and	O
US	O
families	O
there	O
was	O
little	O
evidence	O
for	O
a	O
recent	O
common	O
origin	O
of	O
the	O
MSH2	O
splice	O
site	O
mutation	O
in	O
most	O
families	O
.	O

In	O
contrast	O
,	O
a	O
common	O
haplotype	O
was	O
identified	O
at	O
the	O
two	O
flanking	O
markers	O
(	O
CA5	O
and	O
D2S288	O
)	O
in	O
eight	O
of	O
the	O
Newfoundland	O
families	O
.	O

These	O
findings	O
suggested	O
a	O
founder	O
effect	O
within	O
Newfoundland	O
similar	O
to	O
that	O
reported	O
by	O
others	O
for	O
two	O
MLH1	O
mutations	O
in	O
Finnish	O
HNPCC	B-Disease
families	O
.	O

We	O
calculated	O
age	O
related	O
risks	O
of	O
all	O
,	O
colorectal	B-Disease
,	I-Disease
endometrial	I-Disease
,	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
nt943	O
+	O
3	O
A	O
-	O
-	O
>	O
T	O
MSH2	O
mutation	O
carriers	O
(	O
n	O
=	O
76	O
)	O
for	O
all	O
patients	O
and	O
for	O
men	O
and	O
women	O
separately	O
.	O

For	O
both	O
sexes	O
combined	O
,	O
the	O
penetrances	O
at	O
age	O
60	O
years	O
for	O
all	O
cancers	B-Disease
and	O
for	O
colorectal	B-Disease
cancer	I-Disease
were	O
0	O
.	O

86	O
and	O
0	O
.	O

57	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
males	O
than	O
females	O
(	O
0	O
.	O
63	O
v	O
0	O
.	O
30	O
and	O
0	O
.	O
84	O
v	O
0	O
.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O

For	O
females	O
there	O
was	O
a	O
high	O
risk	O
of	O
endometrial	B-Disease
cancer	I-Disease
(	O
0	O
.	O
5	O
at	O
age	O
60	O
years	O
)	O
and	O
premenopausal	B-Disease
ovarian	I-Disease
cancer	I-Disease
(	O
0	O
.	O
2	O
at	O
50	O
years	O
)	O
.	O

These	O
intersex	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
risks	O
have	O
implications	O
for	O
screening	O
programmes	O
and	O
for	O
attempts	O
to	O
identify	O
colorectal	B-Disease
cancer	I-Disease
susceptibility	O
modifiers	O
.	O

Age	O
of	O
onset	O
in	O
Huntington	B-Disease
disease	I-Disease
:	O
sex	O
specific	O
influence	O
of	O
apolipoprotein	O
E	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
.	O

Age	O
of	O
onset	O
(	O
AO	O
)	O
of	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	B-Disease
gene	O
.	O

Apolipoprotein	O
E	O
(	O
APOE	O
)	O
genotype	O
,	O
in	O
turn	O
,	O
is	O
known	O
to	O
influence	O
AO	O
in	O
Alzheimer	B-Disease
disease	I-Disease
,	O
rendering	O
the	O
APOE	O
gene	O
a	O
likely	O
candidate	O
to	O
affect	O
AO	O
in	O
other	O
neurological	B-Disease
diseases	I-Disease
too	O
.	O

We	O
therefore	O
determined	O
APOE	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
in	O
the	O
HD	B-Disease
gene	O
for	O
138	O
HD	B-Disease
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
CAG	O
repeat	O
length	O
.	O

Genotyping	O
for	O
APOE	O
was	O
performed	O
blind	O
to	O
clinical	O
information	O
.	O

In	O
addition	O
to	O
highlighting	O
the	O
effect	O
of	O
the	O
normal	O
repeat	O
length	O
upon	O
AO	O
in	O
maternally	O
inherited	O
HD	B-Disease
and	O
in	O
male	O
patients	O
,	O
we	O
show	O
that	O
the	O
APOE	O
epsilon2epsilon3	O
genotype	O
is	O
associated	O
with	O
significantly	O
earlier	O
AO	O
in	O
males	O
than	O
in	O
females	O
.	O

Such	O
a	O
sex	O
difference	O
in	O
AO	O
was	O
not	O
apparent	O
for	O
any	O
of	O
the	O
other	O
APOE	O
genotypes	O
.	O

Our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B-Disease
in	O
HD	B-Disease
may	O
allow	O
interacting	O
genes	O
to	O
exert	O
gender	O
specific	O
effects	O
upon	O
AO	O
.	O

Familial	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
associated	O
with	O
recurrent	O
bacteremic	B-Disease
infections	I-Disease
due	I-Disease
to	I-Disease
Neisseria	I-Disease
.	O

The	O
serum	O
of	O
a	O
29	O
-	O
year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	B-Disease
gonococcal	I-Disease
infection	I-Disease
and	O
a	O
history	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
was	O
found	O
to	O
lack	O
serum	O
hemolytic	O
complement	O
activity	O
.	O

The	O
seventh	O
component	O
of	O
complement	O
(	O
C7	O
)	O
was	O
not	O
detected	O
by	O
functional	O
or	O
immunochemical	O
assays	O
,	O
whereas	O
other	O
components	O
were	O
normal	O
by	O
hemolytic	O
and	O
immunochemical	O
assessment	O
.	O

Her	O
fresh	O
serum	O
lacked	O
complement	O
-	O
mediated	O
bactericidal	O
activity	O
against	O
Neisseria	O
gonorrhoeae	O
,	O
but	O
the	O
addition	O
of	O
fresh	O
normal	O
serum	O
or	O
purified	O
C7	O
restored	O
bactericidal	O
activity	O
as	O
well	O
as	O
hemolytic	O
activity	O
.	O

The	O
absence	B-Disease
of	I-Disease
functional	I-Disease
C7	I-Disease
activity	O
could	O
not	O
be	O
accounted	O
for	O
on	O
the	O
basis	O
of	O
an	O
inhibitor	O
.	O

Opsonization	O
and	O
generation	O
of	O
chemotactic	O
activity	O
functioned	O
normally	O
.	O

Complete	B-Disease
absence	I-Disease
of	I-Disease
C7	I-Disease
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	O
syndrome	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight	O
-	O
year	O
-	O
old	O
son	O
.	O

HLA	O
histocompatibility	O
typing	O
of	O
the	O
family	O
members	O
did	O
not	O
demonstrate	O
evidence	O
for	O
genetic	O
linkage	O
of	O
C7	B-Disease
deficiency	I-Disease
with	O
the	O
major	O
histocompatibility	O
loci	O
.	O

This	O
report	O
represents	O
the	O
first	O
cases	O
of	O
C7	B-Disease
deficiency	I-Disease
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	B-Disease
neisseria	I-Disease
infections	I-Disease
.	O

Increased	O
incidence	O
of	O
cancer	B-Disease
in	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
.	O

OBJECTIVE	O
Previous	O
reports	O
have	O
suggested	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
among	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
(	O
CHH	B-Disease
)	O
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	O
among	O
patients	O
with	O
CHH	B-Disease
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

STUDY	O
DESIGN	O
One	O
hundred	O
twenty	O
-	O
two	O
patients	O
with	O
CHH	B-Disease
were	O
identified	O
through	O
2	O
countrywide	O
epidemiologic	O
surveys	O
in	O
1974	O
and	O
in	O
1986	O
.	O

Their	O
parents	O
and	O
nonaffected	O
siblings	O
were	O
identified	O
through	O
the	O
Population	O
Register	O
Center	O
.	O

This	O
cohort	O
underwent	O
follow	O
-	O
up	O
for	O
cancer	B-Disease
incidence	O
through	O
the	O
Finnish	O
Cancer	O
Registry	O
to	O
the	O
end	O
of	O
1995	O
.	O

RESULTS	O
A	O
statistically	O
significant	O
excess	O
risk	O
of	O
cancer	B-Disease
was	O
seen	O
among	O
the	O
patients	O
with	O
CHH	B-Disease
(	O
standardized	O
incidence	O
ratio	O
6	O
.	O
9	O
,	O
95	O
%	O
confidence	O
interval	O
2	O
.	O
3	O
to	O
16	O
)	O
,	O
which	O
was	O
mainly	O
attributable	O
to	O
non	B-Disease
-	I-Disease
Hodgkins	I-Disease
lymphoma	I-Disease
(	O
standardized	O
incidence	O
ratio	O
90	O
,	O
95	O
%	O
confidence	O
interval	O
18	O
to	O
264	O
)	O
.	O

In	O
addition	O
,	O
a	O
significant	O
excess	O
risk	O
of	O
basal	B-Disease
cell	I-Disease
carcinoma	I-Disease
was	O
seen	O
(	O
standardized	O
incidence	O
ratio	O
35	O
,	O
95	O
%	O
confidence	O
interval	O
7	O
.	O
2	O
to	O
102	O
)	O
.	O

The	O
cancer	B-Disease
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B-Disease
incidence	O
in	O
the	O
Finnish	O
population	O
.	O

CONCLUSIONS	O
This	O
study	O
confirms	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
,	O
especially	O
non	B-Disease
-	I-Disease
Hodgkins	I-Disease
lymphoma	I-Disease
,	O
probably	O
attributable	O
to	O
defective	O
immunity	O
,	O
among	O
patients	O
with	O
CHH	B-Disease
.	O

Genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
.	O

Dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
(	I-Disease
DPD	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
characterised	O
by	O
thymine	O
-	O
uraciluria	O
in	O
homozygous	O
deficient	O
patients	O
and	O
has	O
been	O
associated	O
with	O
a	O
variable	O
clinical	O
phenotype	O
.	O

In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
DPD	B-Disease
deficiency	I-Disease
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	B-Disease
of	I-Disease
DPD	I-Disease
.	O

In	O
this	O
group	O
of	O
patients	O
,	O
7	O
different	O
mutations	O
have	O
been	O
identified	O
,	O
including	O
2	O
deletions	O
[	O
295	O
-	O
298delTCAT	O
,	O
1897delC	O
]	O
,	O
1	O
splice	O
-	O
site	O
mutation	O
[	O
IVS14	O
+	O
1G	O
>	O
A	O
)	O
]	O
and	O
4	O
missense	O
mutations	O
(	O
85T	O
>	O
C	O
,	O
703C	O
>	O
T	O
,	O
2658G	O
>	O
A	O
,	O
2983G	O
>	O
T	O
)	O
.	O

Analysis	O
of	O
the	O
prevalence	O
of	O
the	O
various	O
mutations	O
among	O
DPD	B-Disease
patients	O
has	O
shown	O
that	O
the	O
G	O
-	O
-	O
>	O
A	O
point	O
mutation	O
in	O
the	O
invariant	O
splice	O
donor	O
site	O
is	O
by	O
far	O
the	O
most	O
common	O
(	O
52	O
%	O
)	O
,	O
whereas	O
the	O
other	O
six	O
mutations	O
are	O
less	O
frequently	O
observed	O
.	O

A	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed	O
,	O
with	O
convulsive	B-Disease
disorders	I-Disease
,	O
motor	B-Disease
retardation	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
being	O
the	O
most	O
abundant	O
manifestations	O
.	O

A	O
clear	O
correlation	O
between	O
the	O
genotype	O
and	O
phenotype	O
has	O
not	O
been	O
established	O
.	O

An	O
altered	O
beta	O
-	O
alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	B-Disease
abnormalities	I-Disease
encountered	O
in	O
patients	O
with	O
DPD	B-Disease
deficiency	I-Disease
.	O

Fibroblast	O
growth	O
factor	O
homologous	O
factor	O
2	O
(	O
FHF2	O
)	O
:	O
gene	O
structure	O
,	O
expression	O
and	O
mapping	O
to	O
the	O
Borjeson	B-Disease
-	I-Disease
Forssman	I-Disease
-	I-Disease
Lehmann	I-Disease
syndrome	I-Disease
region	O
in	O
Xq26	O
delineated	O
by	O
a	O
duplication	O
breakpoint	O
in	O
a	O
BFLS	B-Disease
-	O
like	O
patient	O
.	O

Borjeson	B-Disease
-	I-Disease
Forssman	I-Disease
-	I-Disease
Lehmann	I-Disease
syndrome	I-Disease
(	O
BFLS	B-Disease
)	O
is	O
a	O
syndromal	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
,	O
which	O
maps	O
by	O
linkage	O
to	O
the	O
q26	O
region	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

We	O
have	O
identified	O
a	O
male	O
patient	O
with	O
BFLS	B-Disease
-	O
like	O
features	O
and	O
a	O
duplication	O
,	O
46	O
,	O
Y	O
,	O
dup	O
(	O
X	O
)	O
(	O
q26q28	O
)	O
,	O
inherited	O
from	O
his	O
phenotypically	O
normal	O
mother	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
using	O
yeast	O
artificial	O
chromosome	O
clones	O
from	O
Xq26	O
localised	O
the	O
duplication	O
breakpoint	O
to	O
an	O
approximately	O
400	O
-	O
kb	O
interval	O
in	O
the	O
Xq26	O
.	O

3	O
region	O
between	O
DXS155	O
and	O
DXS294	O
/	O
DXS730	O
.	O

Database	O
searches	O
and	O
analysis	O
of	O
available	O
genomic	O
DNA	O
sequence	O
from	O
the	O
region	O
revealed	O
the	O
presence	O
of	O
the	O
fibroblast	O
growth	O
factor	O
homologous	O
factor	O
gene	O
,	O
FHF2	O
,	O
within	O
the	O
duplication	O
breakpoint	O
interval	O
.	O

The	O
gene	O
structure	O
of	O
FHF2	O
was	O
determined	O
and	O
two	O
new	O
exons	O
were	O
identified	O
,	O
including	O
a	O
new	O
5	O
end	O
exon	O
,	O
1B	O
.	O

FHF2	O
is	O
a	O
large	O
gene	O
extending	O
over	O
approximately	O
200	O
kb	O
in	O
Xq26	O
.	O

3	O
and	O
is	O
composed	O
of	O
at	O
least	O
seven	O
exons	O
.	O

It	O
shows	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
and	O
alternative	O
transcription	O
starts	O
.	O

Northern	O
blot	O
hybridisation	O
showed	O
highest	O
expression	O
in	O
brain	O
and	O
skeletal	O
muscle	O
.	O

The	O
FHF2	O
gene	O
localisation	O
and	O
tissue	O
-	O
specific	O
expression	O
pattern	O
suggest	O
it	O
to	O
be	O
a	O
candidate	O
gene	O
for	O
familial	O
cases	O
of	O
the	O
BFLS	B-Disease
syndrome	I-Disease
and	O
other	O
syndromal	O
and	O
non	O
-	O
specific	O
forms	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
mapping	O
to	O
the	O
region	O
.	O

Germline	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
mutations	O
predispose	O
to	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
and	O
colorectal	B-Disease
cancer	I-Disease
.	O

Inherited	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
were	O
described	O
recently	O
in	O
three	O
Maori	O
kindreds	O
with	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
.	O

Familial	B-Disease
gastric	I-Disease
cancer	I-Disease
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	B-Disease
cancer	I-Disease
susceptibility	O
in	O
non	O
-	O
Maori	O
populations	O
is	O
due	O
to	O
germline	O
CDH1	O
mutations	O
.	O

Therefore	O
,	O
we	O
screened	O
eight	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
kindreds	O
of	O
British	O
and	O
Irish	O
origin	O
for	O
germline	O
CDH1	O
mutations	O
,	O
by	O
SSCP	O
analysis	O
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences	O
.	O

Each	O
family	O
contained	O
(	O
i	O
)	O
two	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years	O
;	O
or	O
(	O
ii	O
)	O
three	O
or	O
more	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
.	O

Novel	O
germline	O
CDH1	O
mutations	O
(	O
a	O
nonsense	O
and	O
a	O
splice	O
site	O
)	O
were	O
detected	O
in	O
two	O
families	O
(	O
25	O
%	O
)	O
.	O

Both	O
mutations	O
were	O
predicted	O
to	O
truncate	O
the	O
E	O
-	O
cadherin	O
protein	O
in	O
the	O
signal	O
peptide	O
domain	O
.	O

In	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non	O
-	O
penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancer	I-Disease
;	O
thus	O
,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
,	O
a	O
CDH1	O
mutation	O
carrier	O
developed	O
colorectal	B-Disease
cancer	I-Disease
at	O
age	O
30	O
years	O
.	O

We	O
have	O
confirmed	O
that	O
germline	O
mutations	O
in	O
the	O
CDH1	O
gene	O
cause	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
in	O
non	O
-	O
Maori	O
populations	O
.	O

However	O
,	O
only	O
a	O
minority	O
of	O
familial	O
gastric	B-Disease
cancers	I-Disease
can	O
be	O
accounted	O
for	O
by	O
CDH1	O
mutations	O
.	O

Loss	O
of	O
E	O
-	O
cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	B-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
CDH1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	B-Disease
cancer	I-Disease
.	O

Thus	O
,	O
CDH1	O
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancers	I-Disease
.	O

A	O
zinc	O
finger	O
truncation	O
of	O
murine	O
WT1	O
results	O
in	O
the	O
characteristic	O
urogenital	B-Disease
abnormalities	I-Disease
of	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
.	O

The	O
Wilms	B-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
,	O
WT1	O
,	O
plays	O
a	O
key	O
role	O
in	O
urogenital	O
development	O
,	O
and	O
WT1	B-Disease
dysfunction	I-Disease
is	O
implicated	O
in	O
both	O
neoplastic	B-Disease
(	O
Wilms	B-Disease
tumor	I-Disease
,	O
mesothelioma	B-Disease
,	O
leukemias	B-Disease
,	O
and	O
breast	B-Disease
cancer	I-Disease
)	O
and	O
nonneoplastic	B-Disease
(	O
glomerulosclerosis	B-Disease
)	O
disease	O
.	O

The	O
analysis	O
of	O
diseases	O
linked	O
specifically	O
with	O
WT1	O
mutations	O
,	O
such	O
as	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	B-Disease
)	O
,	O
can	O
provide	O
valuable	O
insight	O
concerning	O
the	O
role	O
of	O
WT1	O
in	O
development	O
and	O
disease	O
.	O

DDS	B-Disease
is	O
a	O
rare	O
childhood	O
disease	O
characterized	O
by	O
a	O
nephropathy	B-Disease
involving	O
mesangial	B-Disease
sclerosis	I-Disease
,	O
XY	O
pseudohermaphroditism	B-Disease
,	O
and	O
/	O
or	O
Wilms	B-Disease
tumor	I-Disease
(	O
WT	B-Disease
)	O
.	O

DDS	B-Disease
patients	O
are	O
constitutionally	O
heterozygous	O
for	O
exonic	O
point	O
mutations	O
in	O
WT1	O
,	O
which	O
include	O
mutations	O
predicted	O
to	O
truncate	O
the	O
protein	O
within	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
(	O
ZF	O
)	O
region	O
.	O

We	O
report	O
that	O
heterozygosity	O
for	O
a	O
targeted	O
murine	O
Wt1	O
allele	O
,	O
Wt1	O
(	O
tmT396	O
)	O
,	O
which	O
truncates	O
ZF3	O
at	O
codon	O
396	O
,	O
induces	O
mesangial	B-Disease
sclerosis	I-Disease
characteristic	O
of	O
DDS	B-Disease
in	O
adult	O
heterozygous	O
and	O
chimeric	O
mice	O
.	O

Male	B-Disease
genital	I-Disease
defects	I-Disease
also	O
were	O
evident	O
and	O
there	O
was	O
a	O
single	O
case	O
of	O
Wilms	B-Disease
tumor	I-Disease
in	O
which	O
the	O
transcript	O
of	O
the	O
nontargeted	O
allele	O
showed	O
an	O
exon	O
9	O
skipping	O
event	O
,	O
implying	O
a	O
causal	O
link	O
between	O
Wt1	B-Disease
dysfunction	I-Disease
and	O
Wilms	B-Disease
tumorigenesis	I-Disease
in	O
mice	O
.	O

However	O
,	O
the	O
mutant	O
WT1	O
(	O
tmT396	O
)	O
protein	O
accounted	O
for	O
only	O
5	O
%	O
of	O
WT1	O
in	O
both	O
heterozygous	O
embryonic	O
stem	O
cells	O
and	O
the	O
WT	B-Disease
.	O

This	O
has	O
implications	O
regarding	O
the	O
mechanism	O
by	O
which	O
the	O
mutant	O
allele	O
exerts	O
its	O
effect	O
.	O

Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1	O
.	O

Hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption	O
.	O

We	O
recently	O
reported	O
that	O
HFE	O
,	O
the	O
protein	O
defective	O
in	O
HH	B-Disease
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
in	O
duodenal	O
crypt	O
cells	O
and	O
proposed	O
that	O
mutations	O
in	O
HFE	O
attenuate	O
the	O
uptake	O
of	O
transferrin	O
-	O
bound	O
iron	O
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells	O
,	O
leading	O
to	O
up	O
-	O
regulation	O
of	O
transporters	O
for	O
dietary	O
iron	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
HFE	O
-	O
/	O
-	O
mice	O
have	O
increased	O
duodenal	O
expression	O
of	O
the	O
divalent	O
metal	O
transporter	O
(	O
DMT1	O
)	O
.	O

By	O
4	O
weeks	O
of	O
age	O
,	O
the	O
HFE	O
-	O
/	O
-	O
mice	O
demonstrated	O
iron	O
loading	O
when	O
compared	O
with	O
HFE	O
+	O
/	O
+	O
littermates	O
,	O
with	O
elevated	O
transferrin	O
saturations	O
(	O
68	O
.	O
4	O
%	O
vs	O
.	O
49	O
.	O
8	O
%	O
)	O
and	O
elevated	O
liver	O
iron	O
concentrations	O
(	O
985	O
micrograms	O
vs	O
.	O
381	O
micrograms	O
)	O
.	O

By	O
using	O
Northern	O
blot	O
analyses	O
,	O
we	O
quantitated	O
duodenal	O
expression	O
of	O
both	O
classes	O
of	O
DMT1	O
transcripts	O
one	O
containing	O
an	O
iron	O
responsive	O
element	O
(	O
IRE	O
)	O
,	O
called	O
DMT1	O
(	O
IRE	O
)	O
,	O
and	O
one	O
containing	O
no	O
IRE	O
,	O
called	O
DMT1	O
(	O
non	O
-	O
IRE	O
)	O
.	O

The	O
positive	O
control	O
for	O
DMT1	O
up	O
-	O
regulation	O
was	O
a	O
murine	O
model	O
of	O
dietary	B-Disease
iron	I-Disease
deficiency	I-Disease
that	O
demonstrated	O
greatly	O
increased	O
levels	O
of	O
duodenal	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
.	O

HFE	O
-	O
/	O
-	O
mice	O
also	O
demonstrated	O
an	O
increase	O
in	O
duodenal	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
(	O
average	O
7	O
.	O
7	O
-	O
fold	O
)	O
,	O
despite	O
their	O
elevated	O
transferrin	O
saturation	O
and	O
hepatic	O
iron	O
content	O
.	O

Duodenal	O
expression	O
of	O
DMT1	O
(	O
non	O
-	O
IRE	O
)	O
was	O
not	O
increased	O
,	O
nor	O
was	O
hepatic	O
expression	O
of	O
DMT1	O
increased	O
.	O

These	O
data	O
support	O
the	O
model	O
for	O
HH	O
in	O
which	O
HFE	O
mutations	O
lead	O
to	O
inappropriately	O
low	O
crypt	O
cell	O
iron	O
,	O
with	O
resultant	O
stabilization	O
of	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
,	O
up	O
-	O
regulation	O
of	O
DMT1	O
,	O
and	O
increased	O
absorption	O
of	O
dietary	O
iron	O
.	O

Neurophysiologic	O
follow	O
-	O
up	O
of	O
long	O
-	O
term	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
.	O

OBJECTIVE	O
To	O
monitor	O
the	O
effects	O
of	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
by	O
means	O
of	O
somatosensory	O
evoked	O
potentials	O
(	O
SEPs	O
)	O
and	O
motor	O
evoked	O
potentials	O
(	O
MEPs	O
)	O
.	O

BACKGROUND	O
SEPs	O
and	O
MEPs	O
have	O
proved	O
useful	O
in	O
revealing	O
signs	O
of	O
progressively	O
severe	O
,	O
central	O
dying	B-Disease
-	I-Disease
back	I-Disease
axonopathy	I-Disease
in	O
early	O
stages	O
of	O
adult	O
-	O
onset	O
ALD	B-Disease
.	O

METHODS	O
Eight	O
patients	O
with	O
adult	O
-	O
onset	O
ALD	B-Disease
underwent	O
clinical	O
examination	O
,	O
brain	O
and	O
spine	O
MRI	O
,	O
and	O
SEP	O
and	O
MEP	O
studies	O
before	O
and	O
after	O
3	O
years	O
of	O
Lorenzos	O
oil	O
dietary	O
therapy	O
.	O

RESULTS	O
Before	O
treatment	O
,	O
brain	O
MRI	O
was	O
normal	O
in	O
five	O
patients	O
.	O

Three	O
of	O
these	O
patients	O
had	O
pure	O
spinal	B-Disease
SEP	I-Disease
abnormalities	I-Disease
and	O
in	O
the	O
remaining	O
two	O
patients	O
SEPs	O
showed	O
signs	O
of	O
involvement	O
of	O
both	O
the	O
spinal	O
and	O
cerebral	O
somatosensory	O
tracts	O
.	O

After	O
treatment	O
,	O
the	O
three	O
patients	O
with	O
pure	O
spinal	B-Disease
abnormalities	I-Disease
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
,	O
whereas	O
the	O
two	O
patients	O
with	O
a	O
more	O
advanced	O
stage	O
of	O
disease	O
(	O
exhibited	O
by	O
SEPs	O
)	O
showed	O
substantially	O
unchanged	O
clinical	O
and	O
neurophysiologic	O
features	O
.	O

The	O
patients	O
with	O
abnormal	O
brain	O
MRI	O
at	O
the	O
onset	O
of	O
treatment	O
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
.	O

CONCLUSIONS	O
Lorenzos	O
oil	O
therapy	O
had	O
no	O
effect	O
on	O
patients	O
with	O
evidence	O
of	O
inflammatory	B-Disease
brain	I-Disease
lesions	I-Disease
.	O

Moreover	O
,	O
in	O
patients	O
without	O
clear	O
signs	O
of	O
inflammatory	O
damage	O
,	O
this	O
treatment	O
does	O
not	O
modify	O
significantly	O
the	O
natural	O
course	O
of	O
the	O
disease	O
.	O

However	O
,	O
because	O
effective	O
treatments	O
should	O
begin	O
before	O
the	O
onset	O
of	O
severe	O
neurologic	O
symptoms	O
,	O
SEPs	O
and	O
MEPs	O
should	O
be	O
considered	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
other	O
experimental	O
treatments	O
in	O
the	O
patient	O
with	O
a	O
negative	O
brain	O
MRI	O
.	O

GCH1	O
mutation	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
.	O

The	O
authors	O
report	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
GCH1	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
and	O
no	O
obvious	O
family	O
history	O
of	O
dystonia	B-Disease
.	O

The	O
patient	O
responded	O
positively	O
to	O
treatment	O
with	O
L	O
-	O
dopa	O
.	O

These	O
findings	O
demonstrate	O
that	O
GCH1	O
mutations	O
must	O
be	O
considered	O
even	O
in	O
patients	O
with	O
dystonic	B-Disease
symptoms	O
not	O
typical	O
of	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
.	O

Germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
Korean	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
.	O

We	O
extensively	O
analyzed	O
genomic	O
DNA	O
and	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
from	O
62	O
unrelated	O
Korean	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
for	O
identification	O
of	O
germline	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
mutations	O
.	O

We	O
adopted	O
both	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
a	O
method	O
of	O
analysis	O
involving	O
the	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
followed	O
by	O
a	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

DNA	O
sequencing	O
confirmed	O
all	O
alterations	O
represented	O
by	O
aberrant	O
bands	O
.	O

Germline	O
mutations	O
were	O
identified	O
in	O
38	O
patients	O
(	O
61	O
%	O
)	O
.	O

Nineteen	O
of	O
the	O
detected	O
mutations	O
were	O
presumed	O
to	O
be	O
novel	O
,	O
thus	O
emphasizing	O
the	O
heterogeneity	O
of	O
the	O
mutational	O
spectrum	O
in	O
Korean	O
FAP	B-Disease
patients	O
.	O

In	O
the	O
initial	O
48	O
patients	O
,	O
SSCP	O
analysis	O
was	O
followed	O
by	O
PTT	O
for	O
those	O
patients	O
for	O
whom	O
no	O
detectable	O
mutations	O
were	O
found	O
by	O
SSCP	O
.	O

Using	O
this	O
combined	O
approach	O
,	O
we	O
identified	O
germline	O
APC	B-Disease
gene	O
mutations	O
in	O
29	O
of	O
the	O
48	O
FAP	B-Disease
patients	O
(	O
60	O
%	O
)	O
,	O
including	O
6	O
patients	O
in	O
whom	O
SSCP	O
analysis	O
failed	O
to	O
distinguish	O
the	O
mutant	O
allele	O
.	O

In	O
the	O
14	O
later	O
patients	O
,	O
we	O
identified	O
truncating	O
mutations	O
in	O
9	O
patients	O
(	O
64	O
%	O
)	O
using	O
PTT	O
only	O
.	O

Our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
PTT	O
was	O
superior	O
to	O
that	O
with	O
SSCP	O
,	O
and	O
suggest	O
that	O
PTT	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
FAP	B-Disease
patients	O
.	O

Molecular	O
epidemiology	O
of	O
C9	B-Disease
deficiency	I-Disease
heterozygotes	O
with	O
an	O
Arg95Stop	O
mutation	O
of	O
the	O
C9	O
gene	O
in	O
Japan	O
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	I-Disease
in	O
Japan	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries	O
.	O

Genetic	O
analyses	O
of	O
Japanese	O
C9	B-Disease
deficiency	I-Disease
have	O
shown	O
that	O
a	O
C	O
-	O
to	O
-	O
T	O
transition	O
leading	O
to	O
TGA	O
stop	O
codon	O
for	O
Arg95	O
in	O
exon	O
4	O
of	O
the	O
C9	O
gene	O
(	O
Arg95Stop	O
)	O
is	O
common	O
in	O
Japanese	O
C9	B-Disease
deficiency	I-Disease
.	O

To	O
determine	O
the	O
prevalence	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
in	O
a	O
Japanese	O
population	O
,	O
we	O
collected	O
DNA	O
samples	O
from	O
300	O
individuals	O
in	O
two	O
of	O
the	O
four	O
main	O
islands	O
of	O
Japan	O
.	O

Heterozygote	O
detection	O
was	O
performed	O
with	O
an	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
,	O
followed	O
by	O
confirmation	O
with	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Twenty	O
individuals	O
were	O
heterozygous	O
for	O
the	O
Arg95Stop	O
mutation	O
.	O

None	O
was	O
homozygous	O
.	O

The	O
prevalence	O
of	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
was	O
6	O
.	O

7	O
%	O
(	O
20	O
/	O
300	O
)	O
.	O

An	O
estimated	O
frequency	O
(	O
0	O
.	O
12	O
%	O
)	O
of	O
complete	O
C9	B-Disease
deficiency	I-Disease
due	O
to	O
homozygous	O
Arg95Stop	O
mutation	O
was	O
consistent	O
with	O
frequencies	O
determined	O
by	O
serological	O
studies	O

The	O
hereditary	B-Disease
hemochromatosis	I-Disease
protein	O
,	O
HFE	O
,	O
specifically	O
regulates	O
transferrin	O
-	O
mediated	O
iron	O
uptake	O
in	O
HeLa	O
cells	O
.	O

HFE	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
Feder	O
,	O
J	O
.	O

N	O
.	O
,	O
Gnirke	O
,	O
A	O
.	O
,	O
Thomas	O
,	O
W	O
.	O
,	O
Tsuchihashi	O
,	O
Z	O
.	O
,	O
Ruddy	O
,	O
D	O
.	O

A	O
.	O
,	O
Basava	O
,	O
A	O
.	O
,	O
Dormishian	O
,	O
F	O
.	O
,	O
Domingo	O
,	O
R	O
.	O

J	O
.	O
,	O
Ellis	O
,	O
M	O
.	O

C	O
.	O
,	O
Fullan	O
,	O
A	O
.	O
,	O
Hinton	O
,	O
L	O
.	O

M	O
.	O
,	O
Jones	O
,	O
N	O
.	O

L	O
.	O
,	O
Kimmel	O
,	O
B	O
.	O

E	O
.	O
,	O
Kronmal	O
,	O
G	O
.	O

S	O
.	O
,	O
Lauer	O
,	O
P	O
.	O
,	O
Lee	O
,	O
V	O
.	O

K	O
.	O
,	O
Loeb	O
,	O
D	O
.	O

B	O
.	O
,	O
Mapa	O
,	O
F	O
.	O

A	O
.	O
,	O
McClelland	O
,	O
E	O
.	O
,	O
Meyer	O
,	O
N	O
.	O

C	O
.	O
,	O
Mintier	O
,	O
G	O
.	O

A	O
.	O
,	O
Moeller	O
,	O
N	O
.	O
,	O
Moore	O
,	O
T	O
.	O
,	O
Morikang	O
,	O
E	O
.	O
,	O
Prasss	O
,	O
C	O
.	O

E	O
.	O
,	O
Quintana	O
,	O
L	O
.	O
,	O
Starnes	O
,	O
S	O
.	O

M	O
.	O
,	O
Schatzman	O
,	O
R	O
.	O

C	O
.	O
,	O
Brunke	O
,	O
K	O
.	O

J	O
.	O
,	O
Drayna	O
,	O
D	O
.	O

T	O
.	O
,	O
Risch	O
,	O
N	O
.	O

J	O
.	O
,	O
Bacon	O
,	O
B	O
.	O

R	O
.	O
,	O
and	O
Wolff	O
,	O
R	O
.	O

R	O
.	O

(	O
1996	O
)	O
Nat	O
.	O

Genet	O
.	O

13	O
,	O
399	O
-	O
408	O
)	O
.	O

At	O
the	O
cell	O
surface	O
,	O
HFE	O
complexes	O
with	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
,	O
increasing	O
the	O
dissociation	O
constant	O
of	O
transferrin	O
(	O
Tf	O
)	O
for	O
its	O
receptor	O
10	O
-	O
fold	O
(	O
Gross	O
,	O
C	O
.	O

N	O
.	O
,	O
Irrinki	O
,	O
A	O
.	O
,	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
and	O
Enns	O
,	O
C	O
.	O
A	O
.	O
(	O
1998	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
273	O
,	O
22068	O
-	O
22074	O
;	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
Penny	O
,	O
D	O
.	O
M	O
.	O
,	O
Irrinki	O
,	O
A	O
.	O
,	O
Lee	O
,	O
V	O
.	O
K	O
.	O
,	O
Lebron	O
,	O
J	O
.	O
A	O
.	O
,	O
Watson	O
,	O
N	O
.	O
,	O
Tsuchihashi	O
,	O
Z	O
.	O
,	O
Sigal	O
,	O
E	O
.	O
,	O
Bjorkman	O
,	O
P	O
.	O
J	O
.	O
,	O
and	O
Schatzman	O
,	O
R	O
.	O
C	O
.	O
(	O
1998	O
)	O
Proc	O
.	O
Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
S	O
A	O
95	O
,	O
1472	O
-	O
1477	O
)	O
.	O

HFE	O
does	O
not	O
remain	O
at	O
the	O
cell	O
surface	O
,	O
but	O
traffics	O
with	O
TfR	O
to	O
Tf	O
-	O
positive	O
internal	O
compartments	O
(	O
Gross	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Using	O
a	O
HeLa	O
cell	O
line	O
in	O
which	O
the	O
expression	O
of	O
HFE	O
is	O
controlled	O
by	O
tetracycline	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
HFE	O
reduces	O
55Fe	O
uptake	O
from	O
Tf	O
by	O
33	O
%	O
but	O
does	O
not	O
affect	O
the	O
endocytic	O
or	O
exocytic	O
rates	O
of	O
TfR	O
cycling	O
.	O

Therefore	O
,	O
HFE	O
appears	O
to	O
reduce	O
cellular	O
acquisition	O
of	O
iron	O
from	O
Tf	O
within	O
endocytic	O
compartments	O
.	O

HFE	O
specifically	O
reduces	O
iron	O
uptake	O
from	O
Tf	O
,	O
as	O
non	O
-	O
Tf	O
-	O
mediated	O
iron	O
uptake	O
from	O
Fe	O
-	O
nitrilotriacetic	O
acid	O
is	O
not	O
altered	O
.	O

These	O
results	O
explain	O
the	O
decreased	O
ferritin	O
levels	O
seen	O
in	O
our	O
HeLa	O
cell	O
system	O
and	O
demonstrate	O
the	O
specific	O
control	O
of	O
HFE	O
over	O
the	O
Tf	O
-	O
mediated	O
pathway	O
of	O
iron	O
uptake	O
.	O

These	O
results	O
also	O
have	O
implications	O
for	O
the	O
understanding	O
of	O
cellular	O
iron	O
homeostasis	O
in	O
organs	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
heart	O
,	O
and	O
spleen	O
that	O
are	O
iron	O
loaded	O
in	O
hereditary	B-Disease
hemochromatotic	I-Disease
individuals	O
lacking	O
functional	O
HFE	O
.	O

Mutation	O
and	O
haplotype	O
studies	O
of	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	O
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O

The	O
FMF	B-Disease
gene	O
(	O
MEFV	O
)	O
was	O
cloned	O
recently	O
,	O
and	O
four	O
missense	O
mutations	O
were	O
identified	O
.	O

Here	O
we	O
present	O
data	O
from	O
non	O
-	O
Ashkenazi	O
Jewish	O
and	O
Arab	O
patients	O
in	O
whom	O
we	O
had	O
not	O
originally	O
found	O
mutations	O
and	O
from	O
a	O
new	O
,	O
more	O
ethnically	O
diverse	O
panel	O
.	O

Among	O
90	O
symptomatic	O
mutation	O
-	O
positive	O
individuals	O
,	O
11	O
mutations	O
accounted	O
for	O
79	O
%	O
of	O
carrier	O
chromosomes	O
.	O

Of	O
the	O
two	O
mutations	O
that	O
are	O
novel	O
,	O
one	O
alters	O
the	O
same	O
residue	O
(	O
680	O
)	O
as	O
a	O
previously	O
known	O
mutation	O
,	O
and	O
the	O
other	O
(	O
P369S	O
)	O
is	O
located	O
in	O
exon	O
3	O
.	O

Consistent	O
with	O
another	O
recent	O
report	O
,	O
the	O
E148Q	O
mutation	O
was	O
observed	O
in	O
patients	O
of	O
several	O
ethnicities	O
and	O
on	O
multiple	O
microsatellite	O
haplotypes	O
,	O
but	O
haplotype	O
data	O
indicate	O
an	O
ancestral	O
relationships	O
between	O
non	O
-	O
Jewish	O
Italian	O
and	O
Ashkenazi	O
Jewish	O
patients	O
with	O
FMF	B-Disease
and	O
other	O
affected	O
populations	O
.	O

Among	O
approximately	O
200	O
anonymous	O
Ashkenazi	O
Jewish	O
DNA	O
samples	O
,	O
the	O
MEFV	O
carrier	O
frequency	O
was	O
21	O
%	O
,	O
with	O
E148Q	O
the	O
most	O
common	O
mutation	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
reduced	O
penetrance	O
among	O
Ashkenazi	O
Jews	O
,	O
especially	O
for	O
E148Q	O
,	O
P369S	O
,	O
and	O
K695R	O
.	O

Nevertheless	O
,	O
E148Q	O
helps	O
account	O
for	O
recessive	O
inheritance	O
in	O
an	O
Ashkenazi	O
family	O
previously	O
reported	O
as	O
an	O
unusual	O
case	O
of	O
dominantly	O
inherited	O
FMF	B-Disease
.	O

The	O
presence	O
of	O
three	O
frequent	O
MEFV	O
mutations	O
in	O
multiple	O
Mediterranean	O
populations	O
strongly	O
suggests	O
a	O
heterozygote	O
advantage	O
in	O
this	O
geographic	O
region	O
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
with	O
defective	O
Fas	O
:	O
genotype	O
influences	O
penetrance	O
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
is	O
a	O
disorder	B-Disease
of	I-Disease
lymphocyte	I-Disease
homeostasis	I-Disease
and	I-Disease
immunological	I-Disease
tolerance	I-Disease
.	O

Most	O
patients	O
have	O
a	O
heterozygous	O
mutation	O
in	O
the	O
APT1	O
gene	O
,	O
which	O
encodes	O
Fas	O
(	O
CD95	O
,	O
APO	O
-	O
1	O
)	O
,	O
mediator	O
of	O
an	O
apoptotic	O
pathway	O
crucial	O
to	O
lymphocyte	O
homeostasis	O
.	O

Of	O
17	O
unique	O
APT1	O
mutations	O
in	O
unrelated	O
ALPS	B-Disease
probands	O
,	O
12	O
(	O
71	O
%	O
)	O
occurred	O
in	O
exons	O
7	O
-	O
9	O
,	O
which	O
encode	O
the	O
intracellular	O
portion	O
of	O
Fas	O
.	O

In	O
vitro	O
,	O
activated	O
lymphocytes	O
from	O
all	O
17	O
patients	O
showed	O
apoptotic	O
defects	O
when	O
exposed	O
to	O
an	O
anti	O
-	O
Fas	O
agonist	O
monoclonal	O
antibody	O
.	O

Similar	O
defects	O
were	O
found	O
in	O
a	O
Fas	O
-	O
negative	O
cell	O
line	O
transfected	O
with	O
cDNAs	O
bearing	O
each	O
of	O
the	O
mutations	O
.	O

In	O
cotransfection	O
experiments	O
,	O
Fas	O
constructs	O
with	O
either	O
intra	O
-	O
or	O
extracellular	O
mutations	O
caused	O
dominant	O
inhibition	O
of	O
apoptosis	O
mediated	O
by	O
wild	O
-	O
type	O
Fas	O
.	O

Two	O
missense	O
Fas	O
variants	O
,	O
not	O
restricted	O
to	O
patients	O
with	O
ALPS	B-Disease
,	O
were	O
identified	O
.	O

Variant	O
A	O
(	O
-	O
1	O
)	O
T	O
at	O
the	O
Fas	O
signal	O
-	O
sequence	O
cleavage	O
site	O
,	O
which	O
mediates	O
apoptosis	O
less	O
well	O
than	O
wild	O
-	O
type	O
Fas	O
and	O
is	O
partially	O
inhibitory	O
,	O
was	O
present	O
in	O
13	O
%	O
of	O
African	O
American	O
alleles	O
.	O

Among	O
the	O
ALPS	B-Disease
-	O
associated	O
Fas	O
mutants	O
,	O
dominant	O
inhibition	O
of	O
apoptosis	O
was	O
much	O
more	O
pronounced	O
in	O
mutants	O
affecting	O
the	O
intracellular	O
,	O
versus	O
extracellular	O
,	O
portion	O
of	O
the	O
Fas	O
receptor	O
.	O

Mutations	O
causing	O
disruption	O
of	O
the	O
intracellular	O
Fas	O
death	O
domain	O
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
ALPS	B-Disease
phenotype	O
features	O
in	O
mutation	O
-	O
bearing	O
relatives	O
.	O

Significant	O
ALPS	B-Disease
-	O
related	O
morbidity	O
occurred	O
in	O
44	O
%	O
of	O
relatives	O
with	O
intracellular	O
mutations	O
,	O
versus	O
0	O
%	O
of	O
relatives	O
with	O
extracellular	O
mutations	O
.	O

Thus	O
,	O
the	O
location	O
of	O
mutations	O
within	O
APT1	O
strongly	O
influences	O
the	O
development	O
and	O
the	O
severity	O
of	O
ALPS	B-Disease
.	O

Multicentric	O
origin	O
of	O
hemochromatosis	B-Disease
gene	O
(	O
HFE	O
)	O
mutations	O
.	O

Genetic	B-Disease
hemochromatosis	I-Disease
(	O
GH	B-Disease
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry	O
.	O

In	O
northwestern	O
Europe	O
,	O
>	O
80	O
%	O
of	O
GH	B-Disease
patients	O
are	O
homozygous	O
for	O
one	O
mutation	O
,	O
the	O
substitution	O
of	O
tyrosine	O
for	O
cysteine	O
at	O
position	O
282	O
(	O
C282Y	O
)	O
in	O
the	O
unprocessed	O
protein	O
.	O

In	O
a	O
proportion	O
of	O
GH	B-Disease
patients	O
,	O
two	O
mutations	O
are	O
present	O
,	O
C282Y	O
and	O
H63D	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
second	O
mutation	O
is	O
such	O
that	O
it	O
appears	O
to	O
predispose	O
1	O
%	O
-	O
2	O
%	O
of	O
compound	O
heterozygotes	O
to	O
expression	O
of	O
the	O
disease	O
.	O

The	O
distribution	O
of	O
the	O
two	O
mutations	O
differ	O
,	O
C282Y	O
being	O
limited	O
to	O
those	O
of	O
northwestern	O
European	O
ancestry	O
and	O
H63D	O
being	O
found	O
at	O
allele	O
frequencies	O
>	O
5	O
%	O
,	O
in	O
Europe	O
,	O
in	O
countries	O
bordering	O
the	O
Mediterranean	O
,	O
in	O
the	O
Middle	O
East	O
,	O
and	O
in	O
the	O
Indian	O
subcontinent	O
.	O

The	O
C282Y	O
mutation	O
occurs	O
on	O
a	O
haplotype	O
that	O
extends	O
<	O
/	O
=	O
6	O
Mb	O
,	O
suggesting	O
that	O
this	O
mutation	O
has	O
arisen	O
during	O
the	O
past	O
2	O
,	O
000	O
years	O
.	O

The	O
H63D	O
mutation	O
is	O
older	O
and	O
does	O
not	O
occur	O
on	O
such	O
a	O
large	O
extended	O
haplotype	O
,	O
the	O
haplotype	O
in	O
this	O
case	O
extending	O
<	O
/	O
=	O
700	O
kb	O
.	O

Here	O
we	O
report	O
the	O
finding	O
of	O
the	O
H63D	O
and	O
C282Y	O
mutations	O
on	O
new	O
haplotypes	O
.	O

In	O
Sri	O
Lanka	O
we	O
have	O
found	O
H63D	O
on	O
three	O
new	O
haplotypes	O
and	O
have	O
found	O
C282Y	O
on	O
one	O
new	O
haplotype	O
,	O
demonstrating	O
that	O
these	O
mutations	O
have	O
arisen	O
independently	O
on	O
this	O
island	O
.	O

These	O
results	O
suggest	O
that	O
the	O
HFE	O
gene	O
has	O
been	O
the	O
subject	O
of	O
selection	O
pressure	O
.	O

These	O
selection	O
pressures	O
could	O
be	O
due	O
to	O
infectious	B-Disease
diseases	I-Disease
,	O
environmental	O
conditions	O
,	O
or	O
other	O
genetic	B-Disease
disorders	I-Disease
such	O
as	O
anemia	B-Disease
.	O

A	O
retrospective	O
anonymous	O
pilot	O
study	O
in	O
screening	O
newborns	O
for	O
HFE	O
mutations	O
in	O
Scandinavian	O
populations	O
.	O

We	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(	O
DBS	O
)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
Scandinavia	O
for	O
mutations	O
in	O
HFE	O
,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	B-Disease
.	O

We	O
have	O
found	O
C282Y	O
allele	O
frequencies	O
of	O
2	O
.	O

3	O
%	O
(	O
+	O
2	O
.	O
0	O
%	O
)	O
(	O
-	O
1	O
.	O
3	O
%	O
)	O
in	O
Greenland	O
,	O
4	O
.	O

5	O
%	O
+	O
/	O
-	O
1	O
.	O

9	O
%	O
in	O
Iceland	O
,	O
5	O
.	O

1	O
%	O
+	O
/	O
-	O
2	O
.	O

3	O
%	O
in	O
the	O
Faeroe	O
Islands	O
,	O
and	O
8	O
.	O

2	O
%	O
+	O
/	O
-	O
2	O
.	O

7	O
%	O
in	O
Denmark	O
.	O

The	O
high	O
prevalence	O
of	O
HFE	O
mutations	O
in	O
Denmark	O
suggests	O
that	O
population	O
screening	O
for	O
the	O
C282Y	O
mutation	O
could	O
be	O
highly	O
advantageous	O
in	O
terms	O
of	O
preventive	O
health	O
care	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
evaluation	O
of	O
C282Y	O
homozygotes	O
and	O
H63D	O
/	O
C282Y	O
compound	O
heterozygotes	O
will	O
give	O
an	O
indication	O
of	O
the	O
penetrance	O
of	O
the	O
mutations	O
.	O

Identification	O
of	O
the	O
mutation	O
in	O
the	O
alkaptonuria	B-Disease
mouse	O
model	O
.	O

Alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
,	O
an	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O

We	O
used	O
RT	O
-	O
PCR	O
to	O
amplify	O
the	O
Hgd	O
cDNA	O
from	O
Hgd	O
(	O
aku	O
)	O
/	O
Hgd	O
(	O
aku	O
)	O
mice	O
.	O

Two	O
products	O
shorter	O
than	O
the	O
wild	O
-	O
type	O
product	O
were	O
amplified	O
.	O

Restriction	O
mapping	O
and	O
DNA	O
sequencing	O
were	O
then	O
used	O
to	O
identify	O
the	O
Hgd	O
(	O
aku	O
)	O
mouse	O
mutation	O
,	O
found	O
to	O
be	O
a	O
single	O
base	O
change	O
in	O
a	O
splice	O
donor	O
consensus	O
sequence	O
,	O
causing	O
exon	O
skipping	O
and	O
frame	O
-	O
shifted	O
products	O
.	O

This	O
base	O
change	O
allowed	O
us	O
to	O
create	O
a	O
non	O
-	O
radioactive	O
genotyping	O
assay	O
for	O
this	O
allele	O
.	O

Non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
associated	O
with	O
enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
is	O
caused	O
by	O
PDS	B-Disease
mutations	O
.	O

Enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
(	O
EVA	B-Disease
)	O
,	O
known	O
as	O
the	O
most	O
common	O
form	O
of	O
inner	B-Disease
ear	I-Disease
abnormality	I-Disease
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	O
interest	O
because	O
this	O
anomaly	O
is	O
inherited	O
in	O
a	O
recessive	O
manner	O
.	O

The	O
locus	O
for	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
EVA	B-Disease
has	O
been	O
mapped	O
to	O
the	O
same	O
chromosomal	O
region	O
,	O
7q31	O
,	O
as	O
the	O
Pendred	B-Disease
syndrome	I-Disease
locus	O
.	O

In	O
the	O
present	O
study	O
,	O
seven	O
mutations	O
in	O
the	O
PDS	B-Disease
gene	O
(	O
PDS	O
)	O
,	O
the	O
gene	O
responsible	O
for	O
Pendred	B-Disease
syndrome	I-Disease
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
EVA	B-Disease
.	O

One	O
family	O
is	O
homozygous	O
,	O
three	O
families	O
are	O
compound	O
heterozygotes	O
,	O
and	O
two	O
families	O
are	O
heterozygous	O
but	O
with	O
no	O
other	O
mutation	O
detected	O
.	O

The	O
present	O
results	O
provide	O
evidence	O
that	O
mutations	O
in	O
PDS	O
cause	O
both	O
syndromic	B-Disease
and	I-Disease
non	I-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
.	O
.	O

Mutational	O
analysis	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
.	O

BACKGROUND	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disease	I-Disease
characterized	O
by	O
progressive	O
neurologic	B-Disease
dysfunction	I-Disease
,	O
occasionally	O
associated	O
with	O
adrenal	B-Disease
insufficiency	I-Disease
.	O

The	O
classic	O
form	O
of	O
ALD	B-Disease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
)	O
,	O
with	O
rapid	O
neurologic	B-Disease
deterioration	I-Disease
leading	O
to	O
a	O
vegetative	O
state	O
.	O

Adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	B-Disease
dysfunction	I-Disease
.	O

Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B-Disease
and	O
Addison	B-Disease
disease	I-Disease
only	O
also	O
have	O
been	O
recognized	O
.	O

Despite	O
discovery	O
of	O
the	O
causative	O
gene	O
,	O
a	O
molecular	O
basis	O
for	O
the	O
diverse	O
clinical	O
presentations	O
remains	O
to	O
be	O
elucidated	O
.	O

OBJECTIVES	O
To	O
conduct	O
mutational	O
analyses	O
in	O
29	O
Japanese	O
patients	O
with	O
ALD	B-Disease
from	O
29	O
unrelated	O
families	O
,	O
to	O
obtain	O
knowledge	O
of	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
,	O
and	O
to	O
study	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
Japanese	O
patients	O
.	O

METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
.	O

We	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
ALD	B-Disease
by	O
genomic	O
Southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
RNA	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts	O
,	O
lymphoblastoid	O
cells	O
,	O
or	O
peripheral	O
blood	O
leukocytes	O
.	O

RESULTS	O
Three	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O

The	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations	O
,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ALD	B-Disease
gene	O
.	O

Eighteen	O
(	O
69	O
%	O
)	O
of	O
26	O
mutations	O
were	O
missense	O
mutations	O
.	O

Most	O
missense	O
mutations	O
involved	O
amino	O
acids	O
conserved	O
in	O
homologous	O
gene	O
products	O
,	O
including	O
PMP70	O
,	O
mALDRP	O
,	O
and	O
Pxa1p	O
.	O

The	O
AG	O
dinucleotide	O
deletion	O
at	O
position	O
1081	O
-	O
1082	O
,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
be	O
the	O
most	O
common	O
mutation	O
in	O
white	O
patients	O
(	O
12	O
%	O
-	O
17	O
%	O
)	O
,	O
was	O
also	O
identified	O
as	O
the	O
most	O
common	O
mutation	O
in	O
Japanese	O
patients	O
(	O
12	O
%	O
)	O
.	O

All	O
phenotypes	O
were	O
associated	O
with	O
mutations	O
resulting	O
in	O
protein	O
truncation	O
or	O
subtle	O
amino	O
acid	O
changes	O
.	O

There	O
were	O
no	O
differences	O
in	O
phenotypic	O
expressions	O
between	O
missense	O
mutations	O
involving	O
conserved	O
amino	O
acids	O
and	O
those	O
involving	O
nonconserved	O
amino	O
acids	O
.	O

CONCLUSIONS	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	B-Disease
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	B-Disease
.	O
.	O

A	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta	O
-	O
catenin	O
.	O

WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O

In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta	O
-	O
catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O

One	O
of	O
the	O
target	O
genes	O
for	O
beta	O
-	O
catenin	O
/	O
TCF	O
encodes	O
c	O
-	O
MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B-Disease
,	O
particularly	O
in	O
the	O
colon	O
.	O

Most	O
colon	B-Disease
cancers	I-Disease
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta	O
-	O
catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	B-Disease
and	I-Disease
some	I-Disease
other	I-Disease
cancers	I-Disease
harbour	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-Disease
tumours	I-Disease
resembling	O
pilomatricomas	B-Disease
.	O

Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B-Disease
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta	O
-	O
catenin	O
-	O
stabilizing	O
mutations	O
.	O

Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
.	O

We	O
found	O
nuclear	O
LEF	O
-	O
1	O
in	O
the	O
dividing	O
tumour	B-Disease
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	B-Disease
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O

At	O
least	O
75	O
%	O
of	O
these	O
tumours	B-Disease
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	B-Disease
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta	O
-	O
catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
.	O

The	O
Pendred	B-Disease
syndrome	I-Disease
gene	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O

Pendred	B-Disease
syndrome	I-Disease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-Disease
deafness	I-Disease
and	O
characterized	O
by	O
congenital	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
and	O
goitre	B-Disease
.	O

This	O
disorder	O
was	O
mapped	O
to	O
chromosome	O
7	O
and	O
the	O
gene	O
causing	O
Pendred	B-Disease
syndrome	I-Disease
(	O
PDS	B-Disease
)	O
was	O
subsequently	O
identified	O
by	O
positional	O
cloning	O
.	O

PDS	O
encodes	O
a	O
putative	O
transmembrane	O
protein	O
designated	O
pendrin	O
.	O

Pendrin	O
is	O
closely	O
related	O
to	O
a	O
family	O
of	O
sulfate	O
transport	O
proteins	O
that	O
includes	O
the	O
rat	O
sulfate	O
-	O
anion	O
transporter	O
(	O
encoded	O
by	O
Sat	O
-	O
1	O
;	O
29	O
%	O
amino	O
acid	O
sequence	O
identity	O
)	O
,	O
the	O
human	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
transporter	O
(	O
encoded	O
by	O
DTD	O
;	O
32	O
%	O
)	O
and	O
the	O
human	O
sulfate	O
transporter	O
downregulated	O
in	O
adenoma	B-Disease
(	O
encoded	O
by	O
DRA	O
;	O
45	O
%	O
)	O
.	O

On	O
the	O
basis	O
of	O
this	O
homology	O
and	O
the	O
presence	O
of	O
a	O
slightly	O
modified	O
sulfate	O
-	O
transporter	O
signature	O
sequence	O
comprising	O
its	O
putative	O
second	O
transmembrane	O
domain	O
,	O
pendrin	O
has	O
been	O
proposed	O
to	O
function	O
as	O
a	O
sulfate	O
transporter	O
.	O

We	O
were	O
unable	O
to	O
detect	O
evidence	O
of	O
sulfate	O
transport	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
Xenopus	O
laevis	O
oocytes	O
by	O
microinjection	O
of	O
PDS	O
cRNA	O
or	O
in	O
Sf9	O
cells	O
following	O
infection	O
with	O
PDS	O
-	O
recombinant	O
baculovirus	O
.	O

The	O
rates	O
of	O
transport	O
for	O
iodide	O
and	O
chloride	O
were	O
significantly	O
increased	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
both	O
cell	O
systems	O
.	O

Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B-Disease
syndrome	I-Disease
.	O
.	O

HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	B-Disease
probands	O
:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O

Hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
of	O
iron	O
metabolism	O
.	O

The	O
HFE	O
candidate	O
gene	O
encoding	O
an	O
HLA	O
class	O
I	O
-	O
like	O
protein	O
involved	O
in	O
HH	B-Disease
was	O
identified	O
in	O
1996	O
.	O

Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B-Disease
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	O
HH	B-Disease
chromosomes	O
.	O

We	O
report	O
here	O
on	O
the	O
analysis	O
of	O
C282Y	O
,	O
H63D	O
,	O
and	O
the	O
193A	O
-	O
-	O
>	O
T	O
substitution	O
leading	O
to	O
the	O
S65C	O
missense	O
substitution	O
in	O
a	O
large	O
series	O
of	O
probands	O
and	O
controls	O
.	O

The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	B-Disease
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
HH	B-Disease
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation	O
.	O

In	O
addition	O
,	O
our	O
screening	O
showed	O
that	O
the	O
S65C	O
substitution	O
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	O
without	O
an	O
assigned	O
mutation	O
.	O

This	O
substitution	O
accounted	O
for	O
7	O
.	O

8	O
%	O
of	O
HH	B-Disease
chromosomes	O
that	O
were	O
neither	O
C282Y	O
nor	O
H63D	O
.	O

This	O
enrichment	O
of	O
S65C	O
among	O
HH	B-Disease
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O

Germline	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
more	O
accurate	O
frequency	O
estimates	O
of	O
breast	B-Disease
cancer	I-Disease
susceptibility	O
gene	O
1	O
(	O
BRCA1	O
)	O
germline	O
alterations	O
in	O
the	O
ovarian	B-Disease
cancer	I-Disease
population	O
.	O

To	O
achieve	O
this	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O

This	O
is	O
the	O
first	O
population	O
-	O
based	O
ovarian	B-Disease
cancer	I-Disease
study	O
reporting	O
BRCA1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region	O
.	O

One	O
hundred	O
and	O
seven	O
ovarian	B-Disease
cancer	I-Disease
cases	O
were	O
analyzed	O
for	O
BRCA1	O
alterations	O
using	O
the	O
RNase	O
mismatch	O
cleavage	O
assay	O
followed	O
by	O
direct	O
sequencing	O
.	O

Two	O
truncating	O
mutations	O
,	O
962del4	O
and	O
3600del11	O
,	O
were	O
identified	O
.	O

Both	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

Several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	B-Disease
.	O

The	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
Caucasian	O
cancer	B-Disease
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele	O
-	O
specific	O
amplification	O
.	O

The	O
rare	O
form	O
of	O
the	O
Q356R	O
polymorphism	O
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
associated	O
with	O
a	O
family	O
history	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
suggesting	O
that	O
this	O
polymorphism	O
may	O
influence	O
ovarian	B-Disease
cancer	I-Disease
risk	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
some	O
uncharacterized	O
variants	O
and	O
rare	O
forms	O
of	O
polymorphisms	O
in	O
determining	O
ovarian	B-Disease
cancer	I-Disease
risk	O
,	O
and	O
highlight	O
the	O
necessity	O
to	O
screen	O
for	O
missense	O
alterations	O
as	O
well	O
as	O
truncating	O
mutations	O
in	O
this	O
population	O
.	O

Adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-Disease
protein	I-Disease
deficiency	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
:	O
implications	O
for	O
therapy	O
.	O

Inherited	B-Disease
defects	I-Disease
in	O
the	O
peroxisomal	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
adrenoleukodystrophy	B-Disease
protein	O
(	O
ALDP	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B-Disease
disorder	I-Disease
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

Three	O
other	O
peroxisomal	O
ABC	O
transporters	O
currently	O
are	O
known	O
adrenoleukodystrophy	O
-	O
related	O
protein	O
(	O
ALDRP	O
)	O
,	O
70	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
and	O
PMP70	O
-	O
related	O
protein	O
.	O

By	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cDNAs	O
encoding	O
ALDP	O
and	O
its	O
closest	O
relative	O
ALDRP	O
,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta	O
-	O
oxidation	O
in	O
fibroblasts	O
of	O
X	B-Disease
-	I-Disease
ALD	I-Disease
patients	O
.	O

The	O
pathognomonic	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
could	O
also	O
be	O
prevented	O
by	O
overexpression	O
of	O
ALDRP	O
in	O
immortalized	O
X	O
-	O
ALD	O
cells	O
.	O

Immunofluorescence	O
analysis	O
demonstrated	O
that	O
the	O
functional	O
replacement	O
of	O
ALDP	O
by	O
ALDRP	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
mutated	O
ALDP	O
itself	O
.	O

Moreover	O
,	O
we	O
were	O
able	O
to	O
restore	O
the	O
peroxisomal	O
beta	O
-	O
oxidation	O
defect	O
in	O
the	O
liver	O
of	O
ALDP	O
-	O
deficient	O
mice	O
by	O
stimulation	O
of	O
ALDRP	O
and	O
PMP70	O
gene	O
expression	O
through	O
a	O
dietary	O
treatment	O
with	O
the	O
peroxisome	O
proliferator	O
fenofibrate	O
.	O

These	O
results	O
suggest	O
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	O
in	O
X	B-Disease
-	I-Disease
ALD	I-Disease
could	O
be	O
possible	O
by	O
drug	O
-	O
induced	O
overexpression	O
or	O
ectopic	O
expression	O
of	O
ALDRP	O
.	O
.	O

Centrosome	O
amplification	O
and	O
a	O
defective	O
G2	O
-	O
M	O
cell	O
cycle	O
checkpoint	O
induce	O
genetic	O
instability	O
in	O
BRCA1	O
exon	O
11	O
isoform	O
-	O
deficient	O
cells	O
.	O

Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	B-Disease
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

To	O
study	O
mechanisms	O
underlying	O
BRCA1	O
-	O
related	O
tumorigenesis	O
,	O
we	O
derived	O
mouse	O
embryonic	O
fibroblast	O
cells	O
carrying	O
a	O
targeted	O
deletion	O
of	O
exon	O
11	O
of	O
the	O
Brca1	O
gene	O
.	O

We	O
show	O
that	O
the	O
mutant	O
cells	O
maintain	O
an	O
intact	O
G1	O
-	O
S	O
cell	O
cycle	O
checkpoint	O
and	O
proliferate	O
poorly	O
.	O

However	O
,	O
a	O
defective	O
G2	O
-	O
M	O
checkpoint	O
in	O
these	O
cells	O
is	O
accompanied	O
by	O
extensive	O
chromosomal	B-Disease
abnormalities	I-Disease
.	O

Mutant	O
fibroblasts	O
contain	O
multiple	O
,	O
functional	O
centrosomes	O
,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation	O
,	O
abnormal	O
nuclear	O
division	O
,	O
and	O
aneuploidy	B-Disease
.	O

These	O
data	O
uncover	O
an	O
essential	O
role	O
of	O
BRCA1	O
in	O
maintaining	O
genetic	O
stability	O
through	O
the	O
regulation	O
of	O
centrosome	O
duplication	O
and	O
the	O
G2	O
-	O
M	O
checkpoint	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
role	O
of	O
BRCA1	O
in	O
tumorigenesis	O
.	O
.	O

Defective	O
CD95	O
/	O
APO	O
-	O
1	O
/	O
Fas	O
signal	O
complex	O
formation	O
in	O
the	O
human	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
,	I-Disease
type	I-Disease
Ia	I-Disease
.	O

Heterozygous	O
mutations	O
in	O
the	O
CD95	O
(	O
APO	O
-	O
1	O
/	O
Fas	O
)	O
receptor	O
occur	O
in	O
most	O
individuals	O
with	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism	O
.	O

We	O
show	O
that	O
local	O
or	O
global	O
alterations	O
in	O
the	O
structure	O
of	O
the	O
cytoplasmic	O
death	O
domain	O
from	O
nine	O
independent	O
ALPS	B-Disease
CD95	O
death	O
-	O
domain	O
mutations	O
result	O
in	O
a	O
failure	O
to	O
bind	O
the	O
FADD	O
/	O
MORT1	O
signaling	O
protein	O
.	O

Despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele	O
,	O
lymphocytes	O
from	O
ALPS	B-Disease
patients	O
showed	O
markedly	O
decreased	O
FADD	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking	O
.	O

These	O
data	O
suggest	O
that	O
intracytoplasmic	O
CD95	O
mutations	O
in	O
ALPS	B-Disease
impair	O
apoptosis	O
chiefly	O
by	O
disrupting	O
death	O
-	O
domain	O
interactions	O
with	O
the	O
signaling	O
protein	O
FADD	O
/	O
MORT1	O
.	O
.	O

Analysis	O
of	O
alkaptonuria	B-Disease
(	O
AKU	B-Disease
)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
CCC	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

We	O
recently	O
showed	O
that	O
alkaptonuria	B-Disease
(	O
AKU	B-Disease
)	O
is	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	B-Disease
pedigrees	O
.	O

These	O
analyses	O
identified	O
two	O
novel	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
INV4	O
+	O
31A	O
-	O
-	O
>	O
G	O
and	O
INV11	O
+	O
18A	O
-	O
-	O
>	O
G	O
)	O
and	O
six	O
novel	O
AKU	B-Disease
mutations	O
(	O
INV1	O
-	O
1G	O
-	O
-	O
>	O
A	O
,	O
W60G	O
,	O
Y62C	O
,	O
A122D	O
,	O
P230T	O
,	O
and	O
D291E	O
)	O
,	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	O
found	O
in	O
AKU	B-Disease
.	O

Reexamination	O
of	O
all	O
29	O
mutations	O
and	O
polymorphisms	O
thus	O
far	O
described	O
in	O
HGO	O
shows	O
that	O
these	O
nucleotide	O
changes	O
are	O
not	O
randomly	O
distributed	O
;	O
the	O
CCC	O
sequence	O
motif	O
and	O
its	O
inverted	O
complement	O
,	O
GGG	O
,	O
are	O
preferentially	O
mutated	O
.	O

These	O
analyses	O
also	O
demonstrated	O
that	O
the	O
nucleotide	O
substitutions	O
in	O
HGO	O
do	O
not	O
involve	O
CpG	O
dinucleotides	O
,	O
which	O
illustrates	O
important	O
differences	O
between	O
HGO	O
and	O
other	O
genes	O
for	O
the	O
occurrence	O
of	O
mutation	O
at	O
specific	O
short	O
-	O
sequence	O
motifs	O
.	O

Because	O
the	O
CCC	O
sequence	O
motifs	O
comprise	O
a	O
significant	O
proportion	O
(	O
34	O
.	O
5	O
%	O
)	O
of	O
all	O
mutated	O
bases	O
that	O
have	O
been	O
observed	O
in	O
HGO	O
,	O
we	O
conclude	O
that	O
the	O
CCC	O
triplet	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
HGO	O
.	O

Fabry	B-Disease
disease	I-Disease
:	O
identification	O
of	O
novel	O
alpha	O
-	O
galactosidase	O
A	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches	O
.	O

Fabry	B-Disease
disease	I-Disease
(	O
FD	B-Disease
)	O
(	O
angiokeratoma	B-Disease
corporis	I-Disease
diffusum	I-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
inborn	I-Disease
error	I-Disease
of	I-Disease
glycosphingolipid	I-Disease
metabolism	I-Disease
caused	O
by	O
defects	O
in	O
the	O
lysosomal	O
alpha	O
-	O
galactosidase	O
A	O
gene	O
(	O
GLA	O
)	O
.	O

The	O
enzymatic	O
defect	O
leads	O
to	O
the	O
systemic	O
accumulation	O
of	O
neutral	O
glycosphingolipids	O
with	O
terminal	O
alpha	O
-	O
galactosyl	O
moieties	O
.	O

Clinically	O
,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	B-Disease
,	O
severe	B-Disease
acroparesthesia	I-Disease
,	O
renal	B-Disease
failure	I-Disease
,	O
and	O
vasculopathy	B-Disease
of	I-Disease
the	I-Disease
heart	I-Disease
and	I-Disease
brain	I-Disease
.	O

While	O
demonstration	O
of	O
alpha	B-Disease
-	I-Disease
galactosidase	I-Disease
deficiency	I-Disease
in	O
leukocytes	O
is	O
diagnostic	O
in	O
affected	O
males	O
,	O
enzymatic	O
detection	O
of	O
female	O
carriers	O
is	O
often	O
inconclusive	O
,	O
due	O
to	O
random	O
X	O
-	O
chromosomal	O
inactivation	O
,	O
underlining	O
the	O
need	O
of	O
molecular	O
investigations	O
for	O
accurate	O
genetic	O
counseling	O
.	O

By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence	O
-	O
based	O
detection	O
systems	O
,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha	B-Disease
-	I-Disease
Gal	I-Disease
A	I-Disease
deficiency	I-Disease
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
FD	B-Disease
.	O

The	O
mutational	O
spectrum	O
included	O
five	O
missense	O
mutations	O
(	O
C202W	O
,	O
C223G	O
,	O
N224D	O
,	O
R301Q	O
,	O
and	O
Q327K	O
)	O
and	O
one	O
splice	O
-	O
site	O
mutation	O
[	O
IVS3	O
G	O
(	O
-	O
1	O
)	O
-	O
-	O
>	O
C	O
]	O
.	O

Studies	O
at	O
the	O
mRNA	O
level	O
showed	O
that	O
the	O
latter	O
led	O
to	O
altered	O
pre	O
-	O
mRNA	O
splicing	O
with	O
consequent	O
alteration	O
of	O
the	O
mRNA	O
translational	O
reading	O
frame	O
and	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
of	O
translation	O
.	O

By	O
use	O
of	O
this	O
strategy	O
,	O
carrier	O
status	O
was	O
accurately	O
assessed	O
in	O
all	O
seven	O
at	O
-	O
risk	O
females	O
tested	O
,	O
whereas	O
enzymatic	O
dosages	O
failed	O
to	O
diagnose	O
or	O
exclude	O
heterozygosity	O
.	O
.	O

Prenatal	O
diagnosis	O
by	O
FISH	O
in	O
a	O
family	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
caused	O
by	O
duplication	O
of	O
PLP	O
gene	O
.	O

A	O
diagnosis	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
MIM	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	O
boy	O
.	O

No	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
had	O
been	O
found	O
.	O

The	O
boys	O
maternal	O
aunt	O
came	O
for	O
prenatal	O
diagnosis	O
when	O
16	O
+	O
weeks	O
pregnant	O
and	O
carrying	O
a	O
male	O
fetus	O
.	O

Samples	O
were	O
tested	O
for	O
duplication	O
of	O
the	O
PLP	O
gene	O
,	O
by	O
interphase	O
FISH	O
,	O
in	O
lymphocyte	O
preparations	O
from	O
the	O
proband	O
,	O
his	O
aunt	O
and	O
an	O
amniotic	O
fluid	O
cell	O
preparation	O
from	O
the	O
fetus	O
.	O

The	O
proband	O
was	O
found	O
to	O
carry	O
the	O
duplication	O
,	O
thus	O
confirming	O
the	O
diagnosis	O
of	O
Pelizaeus	B-Disease
Merzbacher	I-Disease
disease	I-Disease
,	O
but	O
neither	O
the	O
aunt	O
nor	O
the	O
fetus	O
carried	O
a	O
duplication	O
.	O
.	O

Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O

Inactivation	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O

Patients	O
with	O
familial	B-Disease
APC	I-Disease
(	O
FAP	B-Disease
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
and	O
develop	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	O
subsequent	O
carcinomas	B-Disease
early	O
in	O
life	O
.	O

The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	B-Disease
mutation	O
(	O
genotype	O
-	O
phenotype	O
correlation	O
)	O
.	O

Together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
APC	B-Disease
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B-Disease
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B-Disease
mutants	O
.	O

Loss	O
of	O
APC	B-Disease
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta	O
-	O
catenin	O
-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B-Disease
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B-Disease
.	O

Wild	O
-	O
type	O
APC	B-Disease
activity	O
in	O
beta	O
-	O
catenin	O
-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B-Disease
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O

In	O
contrast	O
,	O
mutant	O
APC	B-Disease
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B-Disease
polyposis	I-Disease
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	O
-	O
type	O
APC	B-Disease
activity	O
.	O

These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
FAP	B-Disease
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B-Disease
tumor	I-Disease
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
.	O

BRCA1	O
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex	O
.	O

Germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
tumor	O
-	O
suppressor	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

BRCA1	O
contains	O
a	O
carboxyl	O
-	O
terminal	O
domain	O
(	O
BRCT	O
)	O
that	O
is	O
shared	O
with	O
several	O
other	O
proteins	O
involved	O
in	O
maintaining	O
genome	O
integrity	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
function	O
of	O
BRCA1	O
,	O
we	O
sought	O
to	O
isolate	O
proteins	O
that	O
interact	O
with	O
the	O
BRCT	O
domain	O
.	O

Purified	O
BRCT	O
polypeptide	O
was	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
human	O
placenta	O
cDNA	O
expression	O
library	O
by	O
Far	O
Western	O
analysis	O
.	O

Here	O
we	O
report	O
that	O
BRCA1	O
interacts	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
Rb	O
-	O
binding	O
proteins	O
,	O
RbAp46	O
and	O
RbAp48	O
,	O
as	O
well	O
as	O
with	O
Rb	O
.	O

Moreover	O
,	O
the	O
BRCT	O
domain	O
associates	O
with	O
the	O
histone	O
deacetylases	O
HDAC1	O
and	O
HDAC2	O
.	O

These	O
results	O
demonstrate	O
that	O
BRCA1	O
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex	O
,	O
and	O
therefore	O
may	O
explain	O
the	O
involvement	O
of	O
BRCA1	O
in	O
multiple	O
processes	O
such	O
as	O
transcription	O
,	O
DNA	O
repair	O
,	O
and	O
recombination	O
.	O
.	O

Combined	B-Disease
genetic	I-Disease
deficiency	I-Disease
of	I-Disease
C6	I-Disease
and	I-Disease
C7	I-Disease
in	O
man	O
.	O

By	O
routine	O
screening	O
of	O
sera	O
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub	B-Disease
-	I-Disease
total	I-Disease
deficiency	I-Disease
of	I-Disease
C6	I-Disease
and	I-Disease
C7	I-Disease
.	O

No	O
clinical	O
disease	O
was	O
associated	O
with	O
this	O
deficiency	O
which	O
was	O
transmitted	O
through	O
the	O
subjects	O
family	O
as	O
a	O
single	O
genetic	O
characteristic	O
,	O
the	O
C6	B-Disease
deficiency	I-Disease
being	O
associated	O
with	O
a	O
silent	O
allele	O
at	O
the	O
structural	O
locus	O
.	O

The	O
propositus	O
was	O
found	O
to	O
have	O
low	O
quantities	O
of	O
an	O
abnormal	O
C6	O
which	O
was	O
both	O
antigenically	O
deficient	O
and	O
smaller	O
in	O
size	O
than	O
normal	O
C6	O
(	O
110	O
,	O
000	O
daltons	O
compared	O
with	O
140	O
,	O
000	O
daltons	O
)	O
and	O
small	O
quantities	O
of	O
apparently	O
normal	O
C7	O
.	O

It	O
is	O
concluded	O
that	O
the	O
most	O
likely	O
explanation	O
for	O
this	O
defect	O
is	O
that	O
the	O
subject	O
has	O
a	O
structural	O
mutation	O
in	O
his	O
C6	O
gene	O
which	O
produces	O
hyopsynthesis	O
not	O
only	O
of	O
C6	O
but	O
also	O
of	O
the	O
closely	O
linked	O
gene	O
for	O
C7	O
.	O

These	O
findings	O
suggest	O
the	O
possibility	O
that	O
C6	O
and	O
C7	O
may	O
function	O
as	O
a	O
single	O
genetic	O
unit	O
and	O
that	O
the	O
primary	O
transcript	O
copied	O
from	O
the	O
genome	O
includes	O
information	O
for	O
both	O
proteins	O
.	O
.	O

Changes	O
at	O
P183	O
of	O
emerin	O
weaken	O
its	O
protein	O
-	O
protein	O
interactions	O
resulting	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
muscular	I-Disease
dystrophy	I-Disease
characterized	O
by	O
early	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
,	I-Disease
Achilles	I-Disease
tendons	I-Disease
and	I-Disease
spine	I-Disease
,	O
slowly	O
progressive	O
muscle	B-Disease
wasting	I-Disease
and	O
weakness	B-Disease
,	O
and	O
cardiomyopathy	B-Disease
associated	O
with	O
cardiac	B-Disease
conduction	I-Disease
defects	I-Disease
.	O

The	O
emerin	O
gene	O
has	O
been	O
mapped	O
to	O
Xq28	O
and	O
encodes	O
a	O
34	O
-	O
kDa	O
serine	O
-	O
rich	O
protein	O
,	O
emerin	O
,	O
which	O
has	O
been	O
localized	O
to	O
the	O
nuclear	O
envelope	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
and	O
cardiac	O
muscle	O
.	O

Mutations	O
spanning	O
the	O
emerin	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
EDMD	B-Disease
.	O

We	O
present	O
here	O
the	O
effect	O
,	O
on	O
emerin	O
protein	O
expression	O
,	O
of	O
two	O
missense	O
mutations	O
identified	O
in	O
unrelated	O
EDMD	B-Disease
patients	O
.	O

These	O
alterations	O
predict	O
the	O
replacement	O
of	O
a	O
proline	O
residue	O
at	O
position	O
183	O
with	O
either	O
a	O
histidine	O
or	O
a	O
threonine	O
.	O

Biochemical	O
analysis	O
has	O
demonstrated	O
that	O
the	O
mobility	O
and	O
expression	O
levels	O
of	O
the	O
mutant	O
forms	O
of	O
emerin	O
are	O
indistinguishable	O
from	O
that	O
of	O
wild	O
-	O
type	O
emerin	O
,	O
but	O
that	O
they	O
have	O
weakened	O
interactions	O
with	O
nuclear	O
lamina	O
components	O
.	O

In	O
comparison	O
with	O
the	O
usual	O
EDMD	B-Disease
phenotype	O
,	O
patients	O
with	O
P183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms	O
,	O
elbow	B-Disease
contractures	I-Disease
,	O
ankle	B-Disease
contractures	I-Disease
,	O
upper	B-Disease
limb	I-Disease
weakness	I-Disease
and	O
lower	B-Disease
limb	I-Disease
weakness	I-Disease
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	B-Disease
involvement	I-Disease
.	O

This	O
is	O
the	O
first	O
report	O
of	O
protein	O
studies	O
on	O
patients	O
with	O
missense	O
mutations	O
resulting	O
in	O
the	O
clinical	O
features	O
of	O
EDMD	B-Disease
.	O

These	O
studies	O
demonstrate	O
the	O
importance	O
of	O
proline	O
183	O
for	O
the	O
proper	O
structure	O
/	O
function	O
of	O
emerin	O
.	O
.	O

Microdeletions	O
at	O
chromosome	O
bands	O
1q32	O
-	O
q41	O
as	O
a	O
cause	O
of	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
.	O

Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
comprising	O
cleft	B-Disease
lip	I-Disease
and	O
/	O
or	O
cleft	B-Disease
palate	I-Disease
and	O
lip	B-Disease
pits	I-Disease
.	O

We	O
reported	O
previously	O
a	O
family	O
whose	O
underlying	O
mutation	O
is	O
a	O
500	O
-	O
800	O
kb	O
deletion	O
localized	O
to	O
chromosome	O
bands	O
1q32	O
-	O
q41	O
[	O
Sander	O
et	O
al	O
.	O
,	O
1994	O
Hum	O
Mol	O
Genet	O
3	O
576	O
-	O
578	O
]	O
.	O

Along	O
with	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
and	O
lip	B-Disease
pits	I-Disease
,	O
affected	O
relatives	O
exhibit	O
developmental	B-Disease
delays	I-Disease
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted	O
.	O

To	O
further	O
localize	O
the	O
VWS	B-Disease
gene	O
we	O
searched	O
for	O
other	O
deletions	O
that	O
cause	O
VWS	B-Disease
.	O

An	O
allele	O
loss	O
assay	O
was	O
performed	O
using	O
a	O
novel	O
highly	O
polymorphic	O
marker	O
,	O
D1S3753	O
.	O

From	O
a	O
panel	O
of	O
37	O
unrelated	O
individuals	O
,	O
we	O
detected	O
an	O
allele	O
loss	O
in	O
one	O
family	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
deletion	O
.	O

In	O
this	O
family	O
,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
VWS	B-Disease
.	O

Surprisingly	O
,	O
mapping	O
of	O
the	O
new	O
deletion	O
showed	O
that	O
it	O
extended	O
0	O
.	O

2	O
-	O
1	O
Mb	O
beyond	O
the	O
proximal	O
breakpoint	O
for	O
the	O
deletion	O
described	O
previously	O
.	O

No	O
deletions	O
were	O
detected	O
in	O
seven	O
cases	O
of	O
popliteal	B-Disease
pterygia	I-Disease
syndrome	I-Disease
,	O
76	O
cases	O
of	O
mixed	O
syndromic	B-Disease
forms	I-Disease
of	I-Disease
cleft	I-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
,	O
and	O
178	O
cases	O
of	O
nonsyndromic	B-Disease
cleft	I-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
.	O

Splicing	O
defects	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
,	O
ATM	O
:	O
underlying	O
mutations	O
and	O
consequences	O
.	O

Mutations	O
resulting	O
in	O
defective	O
splicing	O
constitute	O
a	O
significant	O
proportion	O
(	O
30	O
/	O
62	O
[	O
48	O
%	O
]	O
)	O
of	O
a	O
new	O
series	O
of	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
AT	B-Disease
)	O
that	O
were	O
detected	O
by	O
the	O
protein	O
-	O
truncation	O
assay	O
followed	O
by	O
sequence	O
analysis	O
of	O
genomic	O
DNA	O
.	O

Fewer	O
than	O
half	O
of	O
the	O
splicing	O
mutations	O
involved	O
the	O
canonical	O
AG	O
splice	O
-	O
acceptor	O
site	O
or	O
GT	O
splice	O
-	O
donor	O
site	O
.	O

A	O
higher	O
percentage	O
of	O
mutations	O
occurred	O
at	O
less	O
stringently	O
conserved	O
sites	O
,	O
including	O
silent	O
mutations	O
of	O
the	O
last	O
nucleotide	O
of	O
exons	O
,	O
mutations	O
in	O
nucleotides	O
other	O
than	O
the	O
conserved	O
AG	O
and	O
GT	O
in	O
the	O
consensus	O
splice	O
sites	O
,	O
and	O
creation	O
of	O
splice	O
-	O
acceptor	O
or	O
splice	O
-	O
donor	O
sites	O
in	O
either	O
introns	O
or	O
exons	O
.	O

These	O
splicing	O
mutations	O
led	O
to	O
a	O
variety	O
of	O
consequences	O
,	O
including	O
exon	O
skipping	O
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
intron	O
retention	O
,	O
activation	O
of	O
cryptic	O
splice	O
sites	O
,	O
or	O
creation	O
of	O
new	O
splice	O
sites	O
.	O

In	O
addition	O
,	O
5	O
of	O
12	O
nonsense	O
mutations	O
and	O
1	O
missense	O
mutation	O
were	O
associated	O
with	O
deletion	O
in	O
the	O
cDNA	O
of	O
the	O
exons	O
in	O
which	O
the	O
mutations	O
occurred	O
.	O

No	O
ATM	O
protein	O
was	O
detected	O
by	O
western	O
blotting	O
in	O
any	O
AT	B-Disease
cell	O
line	O
in	O
which	O
splicing	O
mutations	O
were	O
identified	O
.	O

Several	O
cases	O
of	O
exon	O
skipping	O
in	O
both	O
normal	O
controls	O
and	O
patients	O
for	O
whom	O
no	O
underlying	O
defect	O
could	O
be	O
found	O
in	O
genomic	O
DNA	O
were	O
also	O
observed	O
,	O
suggesting	O
caution	O
in	O
the	O
interpretation	O
of	O
exon	O
deletions	O
observed	O
in	O
ATM	O
cDNA	O
when	O
there	O
is	O
no	O
accompanying	O
identification	O
of	O
genomic	O
mutations	O
.	O
.	O

Alpha	O
-	O
cardiac	O
actin	O
is	O
a	O
novel	O
disease	O
gene	O
in	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
.	O

We	O
identified	O
the	O
alpha	O
-	O
cardiac	O
actin	O
gene	O
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
(	O
FHC	B-Disease
)	O
.	O

Linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
FHC	B-Disease
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied	O
,	O
with	O
lod	O
scores	O
varying	O
between	O
-	O
2	O
.	O

5	O
and	O
-	O
6	O
.	O

0	O
0	O
.	O

Further	O
linkage	O
analyses	O
of	O
plausible	O
candidate	O
genes	O
highly	O
expressed	O
in	O
the	O
adult	O
human	O
heart	O
identified	O
ACTC	O
as	O
the	O
most	O
likely	O
disease	O
gene	O
,	O
showing	O
a	O
maximal	O
lod	O
score	O
of	O
3	O
.	O

6	O
6	O
.	O

Mutation	O
analysis	O
of	O
ACTC	O
revealed	O
an	O
Ala295Ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
(	O
IDC	B-Disease
)	O
.	O

Overgrowth	B-Disease
of	I-Disease
oral	I-Disease
mucosa	I-Disease
and	I-Disease
facial	I-Disease
skin	I-Disease
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B-Disease
.	O

Aspartylglucosaminuria	B-Disease
(	O
AGU	B-Disease
)	O
is	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
aspartylglucosaminidase	I-Disease
(	O
AGA	O
)	O
.	O

The	O
main	O
symptom	O
is	O
progressive	O
mental	B-Disease
retardation	I-Disease
.	O

A	O
spectrum	O
of	O
different	O
mutations	O
has	O
been	O
reported	O
in	O
this	O
disease	O
,	O
one	O
missense	O
mutation	O
(	O
Cys163Ser	O
)	O
being	O
responsible	O
for	O
the	O
majority	O
of	O
Finnish	O
cases	O
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	B-Disease
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O

Biopsy	O
specimens	O
of	O
16	O
oral	O
lesions	O
,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth	O
,	O
plus	O
two	O
facial	B-Disease
lesions	I-Disease
were	O
studied	O
histologically	O
.	O

Immunohistochemical	O
staining	O
for	O
AGA	O
was	O
performed	O
on	O
15	O
oral	O
specimens	O
.	O

Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B-Disease
of	I-Disease
the	I-Disease
facial	I-Disease
skin	I-Disease
already	O
common	O
in	O
childhood	O
.	O

Of	O
44	O
patients	O
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B-Disease
angiofibromas	I-Disease
,	O
tumours	B-Disease
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	B-Disease
sclerosis	I-Disease
.	O

Oedemic	B-Disease
buccal	I-Disease
mucosa	I-Disease
(	O
leucoedema	B-Disease
)	O
and	O
gingival	B-Disease
overgrowths	I-Disease
were	O
more	O
frequent	O
in	O
AGU	B-Disease
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Of	O
16	O
oral	B-Disease
mucosal	I-Disease
lesions	I-Disease
studied	O
histologically	O
,	O
15	O
represented	O
fibroepithelial	B-Disease
or	I-Disease
epithelial	I-Disease
hyperplasias	I-Disease
and	O
were	O
reactive	O
in	O
nature	O
.	O

Cytoplasmic	O
vacuolisation	O
was	O
evident	O
in	O
four	O
.	O

Immunohistochemically	O
,	O
expression	O
of	O
AGA	O
in	O
AGU	B-Disease
patients	O
mucosal	B-Disease
lesions	I-Disease
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O

Thus	O
,	O
the	O
high	O
frequency	O
of	O
mucosal	B-Disease
overgrowth	I-Disease
in	O
AGU	B-Disease
patients	O
does	O
not	O
appear	O
to	O
be	O
directly	O
associated	O
with	O
lysosomal	O
storage	O
or	O
with	O
alterations	O
in	O
the	O
level	O
of	O
AGA	O
expression	O
.	O

Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	B-Disease
syndrome	I-Disease
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene	O
.	O

The	O
oculocerebrorenal	B-Disease
syndrome	I-Disease
of	I-Disease
Lowe	I-Disease
(	O
OCRL	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
characterized	O
by	O
major	O
abnormalities	B-Disease
of	I-Disease
eyes	I-Disease
,	I-Disease
nervous	I-Disease
system	I-Disease
,	I-Disease
and	I-Disease
kidneys	I-Disease
.	O

Mutations	O
in	O
the	O
OCRL1	O
gene	O
have	O
been	O
associated	O
with	O
the	O
disease	O
.	O

OCRL1	O
encodes	O
a	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
biphosphate	O
(	O
PtdIns	O
[	O
4	O
,	O
5	O
]	O
P2	O
)	O
5	O
-	O
phosphatase	O
.	O

We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	B-Disease
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in	O
-	O
frame	O
deletion	O
.	O

Among	O
the	O
new	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
(	O
R317X	O
and	O
E558X	O
)	O
and	O
three	O
other	O
frameshift	O
mutations	O
caused	O
premature	O
termination	O
of	O
the	O
protein	O
.	O

A	O
missense	O
mutation	O
,	O
R483G	O
,	O
was	O
located	O
in	O
the	O
highly	O
conserved	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
5	O
-	O
phosphatase	O
domain	O
.	O

Finally	O
,	O
one	O
frameshift	O
mutation	O
,	O
2799delC	O
,	O
modifies	O
the	O
C	O
-	O
terminal	O
part	O
of	O
OCRL1	O
,	O
with	O
an	O
extension	O
of	O
six	O
amino	O
acids	O
.	O

Altogether	O
,	O
70	O
%	O
of	O
missense	O
mutations	O
are	O
located	O
in	O
exon	O
15	O
,	O
and	O
52	O
%	O
of	O
all	O
mutations	O
cluster	O
in	O
exons	O
11	O
-	O
15	O
.	O

We	O
also	O
identified	O
two	O
new	O
microsatellite	O
markers	O
for	O
the	O
OCRL1	O
locus	O
,	O
and	O
we	O
detected	O
a	O
germline	O
mosaicism	O
in	O
one	O
family	O
.	O

This	O
observation	O
has	O
direct	O
implications	O
for	O
genetic	O
counseling	O
of	O
Lowe	B-Disease
syndrome	I-Disease
families	O
.	O
.	O

MEFV	O
-	O
Gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
:	O
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
M694V	O
homozygous	O
genotype	O
-	O
genetic	O
and	O
therapeutic	O
implications	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessively	B-Disease
inherited	I-Disease
disorder	I-Disease
that	O
is	O
common	O
in	O
patients	O
of	O
Armenian	O
ancestry	O
.	O

To	O
date	O
,	O
its	O
diagnosis	O
,	O
which	O
can	O
be	O
made	O
only	O
retrospectively	O
,	O
is	O
one	O
of	O
exclusion	O
,	O
based	O
entirely	O
on	O
nonspecific	O
clinical	O
signs	O
that	O
result	O
from	O
serosal	B-Disease
inflammation	I-Disease
and	O
that	O
may	O
lead	O
to	O
unnecessary	O
surgery	O
.	O

Renal	B-Disease
amyloidosis	I-Disease
,	O
prevented	O
by	O
colchicine	O
,	O
is	O
the	O
most	O
severe	O
complication	O
of	O
FMF	B-Disease
,	O
a	O
disorder	O
associated	O
with	O
mutations	O
in	O
the	O
MEFV	O
gene	O
.	O

To	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV	O
-	O
gene	O
analysis	O
,	O
we	O
investigated	O
90	O
Armenian	O
FMF	B-Disease
patients	O
from	O
77	O
unrelated	O
families	O
that	O
were	O
not	O
selected	O
through	O
genetic	O
-	O
linkage	O
analysis	O
.	O

Eight	O
mutations	O
,	O
one	O
of	O
which	O
(	O
R408Q	O
)	O
is	O
new	O
,	O
were	O
found	O
to	O
account	O
for	O
93	O
%	O
of	O
the	O
163	O
independent	O
FMF	B-Disease
alleles	O
,	O
with	O
both	O
FMF	B-Disease
alleles	O
identified	O
in	O
89	O
%	O
of	O
the	O
patients	O
.	O

In	O
several	O
instances	O
,	O
family	O
studies	O
provided	O
molecular	O
evidence	O
for	O
pseudodominant	O
transmission	O
and	O
incomplete	O
penetrance	O
of	O
the	O
disease	O
phenotype	O
.	O

The	O
M694V	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	B-Disease
amyloidosis	I-Disease
and	O
arthritis	B-Disease
,	O
compared	O
with	O
other	O
genotypes	O
(	O
P	O
=	O
.	O
0002	O
and	O
P	O
=	O
.	O
006	O
,	O
respectively	O
)	O
.	O

The	O
demonstration	O
of	O
both	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV	O
analysis	O
and	O
particular	O
modes	O
of	O
inheritance	O
should	O
lead	O
to	O
new	O
ways	O
for	O
management	O
of	O
FMF	O
-	O
including	O
genetic	O
counseling	O
and	O
therapeutic	O
decisions	O
in	O
affected	O
families	O
.	O

Noninvasive	O
test	O
for	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
using	O
hair	O
root	O
analysis	O
.	O

Identification	O
of	O
the	O
FMR1	O
gene	O
and	O
the	O
repeat	O
-	O
amplification	O
mechanism	O
causing	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
led	O
to	O
development	O
of	O
reliable	O
DNA	O
-	O
based	O
diagnostic	O
methods	O
,	O
including	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
.	O

Both	O
methods	O
are	O
performed	O
on	O
DNA	O
isolated	O
from	O
peripheral	O
blood	O
cells	O
and	O
measure	O
the	O
repeat	O
size	O
in	O
FMR1	O
.	O

Using	O
an	O
immunocytochemical	O
technique	O
on	O
blood	O
smears	O
,	O
we	O
recently	O
developed	O
a	O
novel	O
test	O
for	O
identification	O
of	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
.	O

This	O
method	O
,	O
also	O
called	O
"	O
antibody	O
test	O
,	O
"	O
uses	O
monoclonal	O
antibodies	O
against	O
the	O
FMR1	O
gene	O
product	O
(	O
FMRP	O
)	O
and	O
is	O
based	O
on	O
absence	O
of	O
FMRP	O
in	O
patients	O
cells	O
.	O

Here	O
we	O
describe	O
a	O
new	O
diagnostic	O
test	O
to	O
identify	O
male	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
on	O
the	O
basis	O
of	O
lack	O
of	O
FMRP	O
in	O
their	O
hair	O
roots	O
.	O

Expression	O
of	O
FMRP	O
in	O
hair	O
roots	O
was	O
studied	O
by	O
use	O
of	O
an	O
FMRP	O
-	O
specific	O
antibody	O
test	O
,	O
and	O
the	O
percentage	O
of	O
FMRP	O
-	O
expressing	O
hair	O
roots	O
in	O
controls	O
and	O
in	O
male	O
fragile	B-Disease
X	I-Disease
patients	O
was	O
determined	O
.	O

Control	O
individuals	O
showed	O
clear	O
expression	O
of	O
FMRP	O
in	O
nearly	O
every	O
hair	O
root	O
,	O
whereas	O
male	O
fragile	B-Disease
X	I-Disease
patients	O
lacked	O
expression	O
of	O
FMRP	O
in	O
almost	O
all	O
their	O
hair	O
roots	O
.	O

Mentally	B-Disease
retarded	I-Disease
female	O
patients	O
with	O
a	O
full	O
mutation	O
showed	O
FMRP	O
expression	O
in	O
only	O
some	O
of	O
their	O
hair	O
roots	O
(	O
<	O
55	O
%	O
)	O
,	O
and	O
no	O
overlap	O
with	O
normal	O
female	O
controls	O
was	O
observed	O
.	O

The	O
advantages	O
of	O
this	O
test	O
are	O
(	O
1	O
)	O
plucking	O
of	O
hair	O
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	B-Disease
retarded	I-Disease
patient	O
,	O
(	O
2	O
)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	O
center	O
,	O
and	O
(	O
3	O
)	O
the	O
result	O
of	O
the	O
test	O
is	O
available	O
within	O
5	O
h	O
of	O
plucking	O
.	O

In	O
addition	O
,	O
this	O
test	O
enabled	O
us	O
to	O
identify	O
two	O
fragile	B-Disease
X	I-Disease
patients	O
who	O
did	O
not	O
show	O
the	O
full	O
mutation	O
by	O
analysis	O
of	O
DNA	O
isolated	O
from	O
blood	O
cells	O
.	O
.	O

In	O
Swedish	O
families	O
with	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
,	O
linkage	O
to	O
the	O
HPC1	O
locus	O
on	O
chromosome	O
1q24	O
-	O
25	O
is	O
restricted	O
to	O
families	O
with	O
early	O
-	O
onset	O
prostate	B-Disease
cancer	I-Disease
.	O

Prostate	B-Disease
cancer	I-Disease
clusters	O
in	O
some	O
families	O
,	O
and	O
an	O
estimated	O
5	O
%	O
-	O
10	O
%	O
of	O
all	O
cases	O
are	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
prostate	O
cancer	O
-	O
susceptibility	O
genes	O
.	O

We	O
previously	O
reported	O
evidence	O
of	O
linkage	O
to	O
the	O
1q24	O
-	O
25	O
region	O
(	O
HPC1	O
)	O
in	O
91	O
North	O
American	O
and	O
Swedish	O
families	O
each	O
with	O
multiple	O
cases	O
of	O
prostate	B-Disease
cancer	I-Disease
(	O
Smith	O
et	O
al	O
.	O
1996	O
)	O
.	O

In	O
the	O
present	O
report	O
we	O
analyze	O
40	O
(	O
12	O
original	O
and	O
28	O
newly	O
identified	O
)	O
Swedish	O
families	O
with	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
(	O
HPC	B-Disease
)	O
that	O
,	O
on	O
the	O
basis	O
of	O
40	O
markers	O
spanning	O
a	O
25	O
-	O
cM	O
interval	O
within	O
1q24	O
-	O
25	O
,	O
have	O
evidence	O
of	O
linkage	O
.	O

In	O
the	O
complete	O
set	O
of	O
families	O
,	O
a	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
of	O
1	O
.	O

10	O
was	O
observed	O
at	O
D1S413	O
(	O
at	O
a	O
recombination	O
fraction	O
[	O
theta	O
]	O
of	O
.	O
1	O
)	O
,	O
with	O
a	O
maximum	O
NPL	O
(	O
nonparametric	O
linkage	O
)	O
Z	O
score	O
of	O
1	O
.	O

64	O
at	O
D1S202	O
(	O
P	O
=	O
.	O
05	O
)	O
.	O

The	O
evidence	O
of	O
linkage	O
to	O
this	O
region	O
originated	O
almost	O
exclusively	O
from	O
the	O
subset	O
of	O
12	O
early	O
-	O
onset	O
(	O
age	O
<	O
65	O
years	O
)	O
families	O
,	O
which	O
yielded	O
a	O
maximum	O
LOD	O
score	O
of	O
2	O
.	O

38	O
at	O
D1S413	O
(	O
straight	O
theta	O
=	O
0	O
)	O
and	O
an	O
NPL	O
Z	O
score	O
of	O
1	O
.	O

95	O
at	O
D1S422	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

Estimates	O
from	O
heterogeneity	O
tests	O
suggest	O
that	O
,	O
within	O
Sweden	O
,	O
as	O
many	O
as	O
50	O
%	O
of	O
early	O
-	O
onset	O
families	O
had	O
evidence	O
of	O
linkage	O
to	O
the	O
HPC1	O
region	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
of	O
linkage	O
to	O
HPC1	O
in	O
a	O
subset	O
of	O
families	O
with	O
prostate	B-Disease
cancer	I-Disease
,	O
particularly	O
those	O
with	O
an	O
early	O
age	O
at	O
diagnosis	O
.	O

Molecular	O
basis	O
of	O
feline	O
beta	B-Disease
-	I-Disease
glucuronidase	I-Disease
deficiency	I-Disease
:	O
an	O
animal	O
model	O
of	O
mucopolysaccharidosis	B-Disease
VII	I-Disease
.	O

A	O
family	O
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	O
and	O
biochemical	O
abnormalities	O
consistent	O
with	O
mucopolysaccharidosis	B-Disease
VII	I-Disease
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
beta	B-Disease
-	I-Disease
glucuronidase	I-Disease
deficiency	I-Disease
.	O

beta	O
-	O
Glucuronidase	O
activity	O
was	O
undetectable	O
in	O
affected	O
cat	O
fibroblasts	O
and	O
restored	O
by	O
retroviral	O
gene	O
transfer	O
of	O
rat	O
beta	O
-	O
glucuronidase	O
cDNA	O
.	O

beta	O
-	O
Glucuronidase	O
mRNA	O
was	O
normal	O
in	O
affected	O
cat	O
testis	O
by	O
Northern	O
blot	O
analysis	O
.	O

Normal	O
feline	O
beta	O
-	O
glucuronidase	O
cDNA	O
was	O
cloned	O
and	O
characterized	O
,	O
and	O
amplified	O
from	O
affected	O
cat	O
fibroblasts	O
by	O
reverse	O
transcription	O
coupled	O
polymerase	O
chain	O
reaction	O
.	O

There	O
was	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
the	O
affected	O
cat	O
cDNA	O
that	O
predicted	O
an	O
E351K	O
substitution	O
,	O
destroyed	O
a	O
BssSI	O
site	O
,	O
and	O
eliminated	O
GUSB	O
enzymatic	O
activity	O
in	O
expression	O
studies	O
.	O

Multiple	O
species	O
comparison	O
and	O
the	O
crystal	O
structure	O
of	O
human	O
beta	O
-	O
glucuronidase	O
indicated	O
that	O
E351	O
is	O
a	O
highly	O
conserved	O
residue	O
most	O
likely	O
essential	O
in	O
maintenance	O
of	O
the	O
enzymes	O
conformation	O
.	O

BssSI	O
digestion	O
of	O
polymerase	O
chain	O
reaction	O
products	O
amplified	O
from	O
genomic	O
DNA	O
indicated	O
that	O
affected	O
cats	O
were	O
homozygous	O
and	O
cats	O
with	O
half	O
-	O
normal	O
beta	O
-	O
glucuronidase	O
activity	O
were	O
heterozygous	O
for	O
the	O
missense	O
mutation	O
.	O

Carriers	O
identified	O
in	O
this	O
manner	O
produced	O
affected	O
kittens	O
in	O
prospective	O
breedings	O
,	O
and	O
a	O
feline	O
MPS	B-Disease
VII	I-Disease
breeding	O
colony	O
has	O
been	O
established	O
.	O
.	O

A	O
common	O
molecular	O
basis	O
for	O
rearrangement	B-Disease
disorders	I-Disease
on	O
chromosome	O
22q11	O
.	O

The	O
chromosome	O
22q11	O
region	O
is	O
susceptible	O
to	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
and	O
malignant	B-Disease
tumors	I-Disease
.	O

Three	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
,	O
cat	B-Disease
-	I-Disease
eye	I-Disease
syndrome	I-Disease
,	O
der	B-Disease
(	I-Disease
)	I-Disease
syndrome	I-Disease
and	O
velo	B-Disease
-	I-Disease
cardio	I-Disease
-	I-Disease
facial	I-Disease
syndrome	I-Disease
/	O
DiGeorge	B-Disease
syndrome	I-Disease
(	O
VCFS	B-Disease
/	O
DGS	B-Disease
)	O
are	O
associated	O
with	O
tetrasomy	O
,	O
trisomy	O
or	O
monosomy	O
,	O
respectively	O
,	O
for	O
part	O
of	O
chromosome	O
22q11	O
.	O

VCFS	B-Disease
/	O
DGS	B-Disease
is	O
the	O
most	O
common	O
syndrome	O
associated	O
with	O
22q11	O
rearrangements	O
.	O

In	O
order	O
to	O
determine	O
whether	O
there	O
are	O
particular	O
regions	O
on	O
22q11	O
that	O
are	O
prone	O
to	O
rearrangements	O
,	O
the	O
deletion	O
end	O
-	O
points	O
in	O
a	O
large	O
number	O
of	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
were	O
defined	O
by	O
haplotype	O
analysis	O
.	O

Most	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
have	O
a	O
similar	O
3	O
Mb	O
deletion	O
,	O
some	O
have	O
a	O
nested	O
distal	O
deletion	O
breakpoint	O
resulting	O
in	O
a	O
1	O
.	O

5	O
Mb	O
deletion	O
and	O
a	O
few	O
rare	O
patients	O
have	O
unique	O
deletions	O
or	O
translocations	O
.	O

The	O
high	O
prevalence	O
of	O
the	O
disorder	O
in	O
the	O
population	O
and	O
the	O
fact	O
that	O
most	O
cases	O
occur	O
sporadically	O
suggest	O
that	O
sequences	O
at	O
or	O
near	O
the	O
breakpoints	O
confer	O
susceptibility	O
to	O
chromosome	O
rearrangements	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
developed	O
hamster	O
-	O
human	O
somatic	O
hybrid	O
cell	O
lines	O
from	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	O
within	O
similar	O
low	O
copy	O
repeats	O
,	O
termed	O
LCR22s	O
.	O

To	O
support	O
this	O
idea	O
further	O
,	O
we	O
identified	O
a	O
family	O
that	O
carries	O
an	O
interstitial	O
duplication	O
of	O
the	O
same	O
3	O
Mb	O
region	O
that	O
is	O
deleted	O
in	O
VCFS	B-Disease
/	O
DGS	B-Disease
patients	O
.	O

We	O
present	O
models	O
to	O
explain	O
how	O
the	O
LCR22s	O
can	O
mediate	O
different	O
homologous	O
recombination	O
events	O
,	O
thereby	O
generating	O
a	O
number	O
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	B-Disease
anomaly	I-Disease
disorders	I-Disease
.	O

We	O
identified	O
five	O
additional	O
copies	O
of	O
the	O
LCR22	O
on	O
22q11	O
that	O
may	O
mediate	O
other	O
rearrangements	O
leading	O
to	O
disease	O
.	O

Functional	O
consequences	O
of	O
mutations	O
in	O
the	O
early	O
growth	O
response	O
2	O
gene	O
(	O
EGR2	O
)	O
correlate	O
with	O
severity	O
of	O
human	O
myelinopathies	B-Disease
.	O

The	O
early	O
growth	O
response	O
2	O
gene	O
(	O
EGR2	O
)	O
is	O
a	O
Cys2His2zinc	O
finger	O
transcription	O
factor	O
which	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
peripheral	O
nervous	O
system	O
myelination	O
.	O

This	O
idea	O
is	O
based	O
partly	O
on	O
the	O
phenotype	O
of	O
homozygous	O
Krox20	O
(	O
Egr2	O
)	O
knockout	O
mice	O
,	O
which	O
display	O
hypomyelination	B-Disease
of	I-Disease
the	I-Disease
PNS	I-Disease
and	O
a	O
block	O
of	O
Schwann	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

Mutations	O
in	O
the	O
human	O
EGR2	O
gene	O
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	B-Disease
peripheral	I-Disease
neuropathies	I-Disease
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
type	I-Disease
1	I-Disease
,	O
Dejerine	B-Disease
-	I-Disease
Sottas	I-Disease
syndrome	I-Disease
and	O
congenital	B-Disease
hypomyelinating	I-Disease
neuropathy	I-Disease
.	O

Three	O
of	O
the	O
four	O
EGR2	O
mutations	O
are	O
dominant	O
and	O
occur	O
within	O
the	O
zinc	O
finger	O
DNA	O
-	O
binding	O
domain	O
.	O

The	O
fourth	O
mutation	O
is	O
recessive	O
and	O
affects	O
the	O
inhibitory	O
domain	O
(	O
R1	O
)	O
that	O
binds	O
the	O
NAB	O
transcriptional	O
co	O
-	O
repressors	O
.	O

A	O
combination	O
of	O
DNA	O
-	O
binding	O
assays	O
and	O
transcriptional	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
functional	O
consequences	O
of	O
these	O
mutations	O
.	O

The	O
zinc	O
finger	O
mutations	O
affect	O
DNA	O
binding	O
and	O
the	O
amount	O
of	O
residual	O
binding	O
directly	O
correlates	O
with	O
disease	O
severity	O
.	O

The	O
R1	O
domain	O
mutation	O
prevents	O
interaction	O
of	O
EGR2	O
with	O
the	O
NAB	O
co	O
-	O
repressors	O
and	O
thereby	O
increases	O
transcriptional	O
activity	O
.	O

These	O
data	O
provide	O
insight	O
into	O
the	O
possible	O
disease	O
mechanisms	O
underlying	O
EGR2	O
mutations	O
and	O
the	O
reason	O
for	O
varying	O
severity	O
and	O
differences	O
in	O
inheritance	O
patterns	O
.	O
.	O

Autosomal	B-Disease
recessive	I-Disease
familial	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
with	O
continued	O
secretion	O
of	O
mutant	O
weakly	O
active	O
vasopressin	O
.	O

Familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
post	O
-	O
natal	O
development	O
of	O
arginine	B-Disease
vasopressin	I-Disease
(	I-Disease
AVP	I-Disease
)	I-Disease
deficiency	I-Disease
due	O
to	O
mutations	O
in	O
the	O
AVP	O
gene	O
.	O

All	O
published	O
mutations	O
affect	O
the	O
signal	O
peptide	O
or	O
the	O
neurophysin	O
-	O
II	O
carrier	O
protein	O
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone	O
,	O
leading	O
to	O
neuronal	B-Disease
damage	I-Disease
.	O

We	O
studied	O
an	O
unusual	O
Palestinian	O
family	O
consisting	O
of	O
asymptomatic	O
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	O
with	O
neurohypophyseal	B-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
suggesting	O
autosomal	O
recessive	O
inheritance	O
.	O

All	O
three	O
affected	O
children	O
were	O
homozygous	O
and	O
the	O
parents	O
heterozygous	O
for	O
a	O
single	O
novel	O
mutation	O
(	O
C301	O
-	O
>	O
T	O
)	O
in	O
exon	O
1	O
,	O
replacing	O
Pro7	O
of	O
mature	O
AVP	O
with	O
Leu	O
(	O
Leu	O
-	O
AVP	O
)	O
.	O

Leu	O
-	O
AVP	O
was	O
a	O
weak	O
agonist	O
with	O
approximately	O
30	O
-	O
fold	O
reduced	O
binding	O
to	O
the	O
human	O
V2	O
receptor	O
.	O

Measured	O
by	O
radioimmunoassay	O
with	O
a	O
synthetic	O
Leu	O
-	O
AVP	O
standard	O
,	O
serum	O
Leu	O
-	O
AVP	O
levels	O
were	O
elevated	O
in	O
all	O
three	O
children	O
and	O
further	O
increased	O
during	O
water	O
deprivation	O
to	O
as	O
high	O
as	O
30	O
times	O
normal	O
.	O

The	O
youngest	O
child	O
(	O
2	O
years	O
old	O
)	O
was	O
only	O
mildly	O
affected	O
but	O
had	O
Leu	O
-	O
AVP	O
levels	O
similar	O
to	O
her	O
severely	O
affected	O
8	O
-	O
year	O
-	O
old	O
brother	O
,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	B-Disease
of	I-Disease
active	I-Disease
AVP	I-Disease
in	O
very	O
young	O
children	O
.	O
.	O

X	O
inactivation	O
and	O
somatic	O
cell	O
selection	O
rescue	O
female	O
mice	O
carrying	O
a	O
Piga	O
-	O
null	O
mutation	O
.	O

A	O
somatic	O
mutation	O
in	O
the	O
X	O
linked	O
PIGA	O
gene	O
is	O
responsible	O
for	O
the	O
deficiency	B-Disease
of	I-Disease
glycosyl	I-Disease
phosphatidylinositol	I-Disease
(	I-Disease
GPI	I-Disease
)	I-Disease
-	I-Disease
anchored	I-Disease
proteins	I-Disease
on	O
blood	O
cells	O
from	O
patients	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
.	O

No	O
inherited	O
form	O
of	O
GPI	B-Disease
-	I-Disease
anchor	I-Disease
deficiency	I-Disease
has	O
been	O
described	O
.	O

Because	O
conventional	O
Piga	O
gene	O
knockout	O
is	O
associated	O
with	O
high	O
embryonic	B-Disease
lethality	I-Disease
in	O
chimeric	O
mice	O
,	O
we	O
used	O
the	O
Cre	O
/	O
loxP	O
system	O
.	O

We	O
generated	O
mice	O
in	O
which	O
two	O
loxP	O
sites	O
flank	O
part	O
of	O
Piga	O
exon	O
2	O
.	O

After	O
crossbreeding	O
with	O
female	O
mice	O
of	O
the	O
EIIa	O
-	O
cre	O
strain	O
,	O
the	O
floxed	O
allele	O
undergoes	O
Cre	O
-	O
mediated	O
recombination	O
with	O
high	O
efficiency	O
during	O
early	O
embryonic	O
development	O
.	O

Because	O
of	O
X	O
chromosome	O
inactivation	O
,	O
female	O
offspring	O
are	O
mosaic	O
for	O
cells	O
that	O
express	O
or	O
lack	O
GPI	O
-	O
linked	O
proteins	O
.	O

Analysis	O
of	O
mosaic	O
mice	O
showed	O
that	O
in	O
heart	O
,	O
lung	O
,	O
kidney	O
,	O
brain	O
,	O
and	O
liver	O
,	O
mainly	O
wild	O
-	O
type	O
Piga	O
is	O
active	O
,	O
suggesting	O
that	O
these	O
tissues	O
require	O
GPI	O
-	O
linked	O
proteins	O
.	O

The	O
salient	O
exceptions	O
were	O
spleen	O
,	O
thymus	O
,	O
and	O
red	O
blood	O
cells	O
,	O
which	O
had	O
almost	O
equal	O
numbers	O
of	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
or	O
the	O
recombined	O
allele	O
,	O
implying	O
that	O
GPI	O
-	O
linked	O
proteins	O
are	O
not	O
essential	O
for	O
the	O
derivation	O
of	O
these	O
tissues	O
.	O

PIGA	O
(	O
-	O
)	O
cells	O
had	O
no	O
growth	O
advantage	O
,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
.	O
.	O

The	O
C282Y	O
mutation	O
causing	O
hereditary	B-Disease
hemochromatosis	I-Disease
does	O
not	O
produce	O
a	O
null	O
allele	O
.	O

Targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	B-Disease
gene	O
(	O
Hfe	O
)	O
locus	O
.	O

The	O
first	O
mutation	O
deletes	O
a	O
large	O
portion	O
of	O
the	O
coding	O
sequence	O
,	O
generating	O
a	O
null	O
allele	O
.	O

The	O
second	O
mutation	O
introduces	O
a	O
missense	O
mutation	O
(	O
C282Y	O
)	O
into	O
the	O
Hfe	O
locus	O
,	O
but	O
otherwise	O
leaves	O
the	O
gene	O
intact	O
.	O

This	O
mutation	O
is	O
identical	O
to	O
the	O
disease	O
-	O
causing	O
mutation	O
in	O
patients	O
with	O
hereditary	B-Disease
hemochromatosis	I-Disease
.	O

Mice	O
carrying	O
each	O
of	O
the	O
two	O
mutations	O
were	O
bred	O
and	O
analyzed	O
.	O

Homozygosity	O
for	O
either	O
mutation	O
results	O
in	O
postnatal	O
iron	O
loading	O
.	O

The	O
effects	O
of	O
the	O
null	O
mutation	O
are	O
more	O
severe	O
than	O
the	O
effects	O
of	O
the	O
C282Y	O
mutation	O
.	O

Mice	O
heterozygous	O
for	O
either	O
mutation	O
accumulate	O
more	O
iron	O
than	O
normal	O
controls	O
.	O

Interestingly	O
,	O
although	O
liver	O
iron	O
stores	O
are	O
greatly	O
increased	O
,	O
splenic	O
iron	O
is	O
decreased	O
.	O

We	O
conclude	O
that	O
the	O
C282Y	O
mutation	O
does	O
not	O
result	O
in	O
a	O
null	O
allele	O
.	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
identification	O
of	O
a	O
missense	O
mutation	O
associated	O
with	O
a	O
milder	O
phenotype	O
.	O

Direct	O
sequencing	O
of	O
the	O
emerin	O
gene	O
in	O
22	O
families	O
with	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EMD	B-Disease
)	O
revealed	O
mutations	O
in	O
21	O
(	O
95	O
%	O
)	O
,	O
confirming	O
that	O
emerin	O
mutations	O
can	O
be	O
identified	O
in	O
the	O
majority	O
of	O
families	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
EMD	I-Disease
.	O

Most	O
emerin	O
mutations	O
result	O
in	O
absence	O
of	O
the	O
protein	O
.	O

In	O
this	O
study	O
three	O
mutations	O
(	O
a	O
missense	O
mutation	O
Pro183Thr	O
and	O
two	O
in	O
-	O
frame	O
deletions	O
removing	O
residues	O
95	O
-	O
99	O
and	O
236	O
-	O
241	O
,	O
respectively	O
)	O
were	O
unusual	O
in	O
being	O
associated	O
with	O
expression	O
of	O
mutant	O
protein	O
.	O

The	O
phenotype	O
in	O
these	O
families	O
was	O
compared	O
in	O
detail	O
with	O
the	O
clinical	O
features	O
in	O
cases	O
with	O
typical	O
null	O
mutations	O
.	O

For	O
the	O
in	O
-	O
frame	O
deletions	O
there	O
were	O
no	O
significant	O
differences	O
.	O

In	O
the	O
family	O
with	O
the	O
missense	O
mutation	O
the	O
phenotype	O
was	O
milder	O
.	O

Age	O
at	O
onset	O
was	O
later	O
for	O
first	O
symptoms	O
and	O
for	O
development	O
of	O
ankle	B-Disease
contractures	I-Disease
and	O
muscle	B-Disease
weakness	I-Disease
.	O

These	O
findings	O
have	O
diagnostic	O
implications	O
as	O
well	O
as	O
pointing	O
to	O
functionally	O
important	O
regions	O
of	O
the	O
emerin	O
protein	O
.	O
.	O

Severe	O
clinical	O
expression	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
is	O
a	O
relatively	O
rare	O
benign	B-Disease
neuromuscular	I-Disease
disorder	I-Disease
which	O
can	O
vary	O
remarkably	O
in	O
onset	O
,	O
course	O
and	O
severity	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
TCTAC	O
deletion	O
spanning	O
the	O
nucleotides	O
631	O
-	O
635	O
of	O
the	O
emerin	O
gene	O
caused	O
an	O
unusually	O
severe	O
disease	O
phenotype	O
including	O
loss	B-Disease
of	I-Disease
ambulation	I-Disease
and	O
severe	O
muscle	B-Disease
wasting	I-Disease
in	O
two	O
affected	O
brothers	O
.	O

The	O
same	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
an	O
unrelated	O
family	O
showing	O
a	O
significantly	O
milder	O
phenotype	O
.	O

The	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
.	O

Common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
do	O
not	O
contribute	O
to	O
early	O
prostate	B-Disease
cancer	I-Disease
in	O
Jewish	O
men	O
.	O

BACKGROUND	O
Families	O
with	O
a	O
high	O
incidence	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
and	O
subsequently	O
shown	O
to	O
have	O
terminating	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
,	O
appear	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
prostate	B-Disease
cancer	I-Disease
among	O
male	O
relatives	O
.	O

We	O
aimed	O
to	O
determine	O
whether	O
the	O
common	O
germline	O
mutations	O
of	O
BRCA1	O
or	O
BRCA2	O
in	O
Ashkenazi	O
Jewish	O
men	O
predisposed	O
them	O
to	O
prostate	B-Disease
cancer	I-Disease
.	O

METHODS	O
We	O
examined	O
genomic	O
DNA	O
from	O
83	O
(	O
for	O
BRCA1	O
185delAG	O
)	O
or	O
82	O
(	O
for	O
BRCA2	O
6174delT	O
)	O
Ashkenazi	O
Jewish	O
prostate	B-Disease
cancer	I-Disease
patients	O
,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	O
age	O
,	O
for	O
the	O
most	O
common	O
germline	O
mutation	O
in	O
each	O
gene	O
seen	O
in	O
the	O
Ashkenazi	O
population	O
.	O

RESULTS	O
Our	O
study	O
should	O
have	O
been	O
able	O
to	O
detect	O
a	O
4	O
-	O
5	O
-	O
fold	O
increase	O
in	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
due	O
to	O
mutation	O
of	O
BRCA1	O
or	O
BRCA2	O
.	O

However	O
,	O
only	O
one	O
(	O
1	O
.	O
15	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
-	O
3	O
.	O
6	O
%	O
)	O
of	O
the	O
patients	O
was	O
heterozygous	O
for	O
the	O
BRCA1	O
mutant	O
allele	O
,	O
and	O
only	O
two	O
were	O
heterozygous	O
for	O
the	O
BRCA2	O
mutation	O
(	O
2	O
.	O
4	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
-	O
6	O
.	O
2	O
%	O
)	O
.	O

CONCLUSIONS	O
The	O
incidence	O
of	O
each	O
of	O
the	O
germline	O
mutations	O
in	O
these	O
prostate	B-Disease
cancer	I-Disease
patients	O
closely	O
matched	O
their	O
incidence	O
(	O
about	O
1	O
%	O
)	O
in	O
the	O
general	O
Ashkenazi	O
Jewish	O
population	O
.	O

This	O
suggests	O
that	O
unlike	O
cases	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
do	O
not	O
significantly	O
predispose	O
men	O
to	O
prostate	B-Disease
cancer	I-Disease

Beta	O
-	O
catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B-Disease
.	O

Hepatoblastoma	B-Disease
is	O
a	O
rare	O
malignant	B-Disease
tumor	I-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O

Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B-Disease
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O

In	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	B-Disease
tumor	I-Disease
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	B-Disease
tumorigenesis	O
.	O

A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta	O
-	O
catenin	O
,	O
a	O
transcription	O
-	O
activating	O
protein	O
with	O
oncogenic	O
potential	O
.	O

In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta	O
-	O
catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B-Disease
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
,	O
we	O
observed	O
increased	O
beta	O
-	O
catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-Disease
.	O

Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
(	O
CTNNB1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	B-Disease
samples	O
.	O

Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta	O
-	O
catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-Disease
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	B-Disease
type	O
.	O

Genes	O
Chromosomes	O
Cancer	O
25	O
399	O
-	O
402	O
,	O
1999	O
.	O
.	O

Decrease	O
in	O
GTP	O
cyclohydrolase	O
I	O
gene	O
expression	O
caused	O
by	O
inactivation	O
of	O
one	O
allele	O
in	O
hereditary	B-Disease
progressive	I-Disease
dystonia	I-Disease
with	O
marked	O
diurnal	O
fluctuation	O
.	O

Hereditary	B-Disease
progressive	I-Disease
dystonia	I-Disease
with	O
marked	O
diurnal	O
fluctuation	O
(	O
HPD	B-Disease
;	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
,	O
DRD	B-Disease
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
the	O
GTP	O
cyclohydrolase	O
I	O
(	O
GCH1	O
)	O
gene	O
.	O

In	O
this	O
study	O
,	O
we	O
quantified	O
the	O
mRNA	O
level	O
of	O
GCH1	O
in	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-	O
stimulated	O
mononuclear	O
blood	O
cells	O
from	O
one	O
Japanese	O
family	O
that	O
do	O
not	O
have	O
a	O
mutation	O
in	O
the	O
coding	O
region	O
or	O
splice	O
junctions	O
of	O
the	O
gene	O
.	O

The	O
results	O
showed	O
that	O
the	O
amounts	O
of	O
the	O
GCH1	O
mRNA	O
were	O
decreased	O
to	O
about	O
40	O
%	O
of	O
the	O
normal	O
level	O
in	O
both	O
patients	O
and	O
carriers	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
GCH1	O
mRNA	O
was	O
transcribed	O
from	O
only	O
one	O
allele	O
,	O
indicating	O
that	O
the	O
other	O
allele	O
was	O
in	O
an	O
inactive	O
state	O
.	O

These	O
results	O
suggest	O
that	O
some	O
novel	O
mutations	O
should	O
exist	O
on	O
one	O
of	O
the	O
alleles	O
in	O
some	O
unknown	O
region	O
of	O
the	O
GCH1	O
gene	O
,	O
and	O
may	O
decrease	O
the	O
GCH1	O
mRNA	O
causing	O
the	O
HPD	B-Disease
/	O
DRD	B-Disease
symptoms	O
.	O
.	O

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B-Disease
syndrome	I-Disease
thyrocytes	O
.	O

Pendred	B-Disease
syndrome	I-Disease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-Disease
deafness	I-Disease
,	O
characterized	O
by	O
dyshormonogenic	B-Disease
goiter	I-Disease
associated	O
with	O
sensory	B-Disease
-	I-Disease
neural	I-Disease
deafness	I-Disease
.	O

The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	B-Disease
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B-Disease
goiter	I-Disease
and	O
sensory	B-Disease
-	I-Disease
neural	I-Disease
deafness	I-Disease
remains	O
an	O
enigma	O
.	O

PDS	O
codes	O
for	O
a	O
novel	O
protein	O
,	O
pendrin	O
,	O
which	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
sufate	O
transporters	O
.	O

Mechanisms	O
by	O
which	O
abnormal	O
sulfate	O
transport	O
could	O
deleteriously	O
affect	O
iodide	O
organification	O
have	O
been	O
proposed	O
.	O

We	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
Pendred	B-Disease
syndrome	I-Disease
patients	O
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O

This	O
suggests	O
that	O
pendrin	O
in	O
fact	O
may	O
not	O
be	O
a	O
sulfate	O
transporter	O
,	O
and	O
emphasizes	O
the	O
importance	O
of	O
functional	O
studies	O
on	O
this	O
novel	O
protein	O
.	O
.	O

Small	O
deletions	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produce	O
kniest	B-Disease
dysplasia	I-Disease
.	O

Kniest	B-Disease
dysplasia	I-Disease
is	O
a	O
moderately	O
severe	O
type	B-Disease
II	I-Disease
collagenopathy	I-Disease
,	O
characterized	O
by	O
short	O
trunk	O
and	O
limbs	O
,	O
kyphoscoliosis	B-Disease
,	O
midface	B-Disease
hypoplasia	I-Disease
,	O
severe	O
myopia	B-Disease
,	O
and	O
hearing	B-Disease
loss	I-Disease
.	O

Mutations	O
in	O
the	O
gene	O
that	O
encodes	O
type	O
II	O
collagen	O
(	O
COL2A1	O
)	O
,	O
the	O
predominant	O
protein	O
of	O
cartilage	O
,	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
individuals	O
with	O
Kniest	B-Disease
dysplasia	I-Disease
.	O

All	O
but	O
two	O
of	O
these	O
previously	O
described	O
mutations	O
cause	O
in	O
-	O
frame	O
deletions	O
in	O
type	O
II	O
collagen	O
,	O
either	O
by	O
small	O
deletions	O
in	O
the	O
gene	O
or	O
splice	O
site	O
alterations	O
.	O

Furthermore	O
,	O
all	O
but	O
one	O
of	O
these	O
mutations	O
is	O
located	O
between	O
exons	O
12	O
and	O
24	O
in	O
the	O
COL2A1	O
gene	O
.	O

We	O
used	O
heteroduplex	O
analysis	O
to	O
identify	O
sequence	O
anomalies	O
in	O
five	O
individuals	O
with	O
Kniest	B-Disease
dysplasia	I-Disease
.	O

Sequencing	O
of	O
the	O
index	O
patients	O
genomic	O
DNA	O
identified	O
four	O
new	O
dominant	O
mutations	O
in	O
COL2A1	O
that	O
result	O
in	O
Kniest	B-Disease
dysplasia	I-Disease
a	O
21	O
-	O
bp	O
deletion	O
in	O
exon	O
16	O
,	O
an	O
18	O
-	O
bp	O
deletion	O
in	O
exon	O
19	O
,	O
and	O
4	O
-	O
bp	O
deletions	O
in	O
the	O
splice	O
donor	O
sites	O
of	O
introns	O
14	O
and	O
20	O
.	O

A	O
previously	O
described	O
28	O
-	O
bp	O
deletion	O
at	O
the	O
COL2A1	O
exon	O
12	O
-	O
intron	O
12	O
junction	O
,	O
deleting	O
the	O
splice	O
donor	O
site	O
,	O
was	O
identified	O
in	O
the	O
fifth	O
case	O
.	O

The	O
latter	O
three	O
mutations	O
are	O
predicted	O
to	O
result	O
in	O
exon	O
skipping	O
in	O
the	O
mRNA	O
encoded	O
from	O
the	O
mutant	O
allele	O
.	O

These	O
data	O
suggest	O
that	O
Kniest	B-Disease
dysplasia	I-Disease
results	O
from	O
shorter	O
type	O
II	O
collagen	O
monomers	O
,	O
and	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
specific	O
COL2A1	O
domain	O
,	O
which	O
may	O
span	O
from	O
exons	O
12	O
to	O
24	O
,	O
leads	O
to	O
the	O
Kniest	B-Disease
dysplasia	I-Disease
phenotype	O
.	O
.	O

Classical	B-Disease
galactosemia	I-Disease
and	O
mutations	O
at	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
gene	O
.	O

Classical	B-Disease
galactosemia	I-Disease
is	O
caused	O
by	O
a	O
deficiency	O
in	O
activity	O
of	O
the	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
caused	O
by	O
mutations	O
at	O
the	O
GALT	O
gene	O
.	O

The	O
disorder	O
exhibits	O
considerable	O
allelic	O
heterogeneity	O
and	O
,	O
at	O
the	O
end	O
of	O
1998	O
,	O
more	O
than	O
150	O
different	O
base	O
changes	O
were	O
recorded	O
in	O
24	O
different	O
populations	O
and	O
ethnic	O
groups	O
in	O
15	O
countries	O
worldwide	O
.	O

The	O
mutations	O
most	O
frequently	O
cited	O
are	O
Q188R	O
,	O
K285N	O
,	O
S135L	O
,	O
and	O
N314D	O
.	O

Q188R	O
is	O
the	O
most	O
common	O
mutation	O
in	O
European	O
populations	O
or	O
in	O
those	O
predominantly	O
of	O
European	O
descent	O
.	O

Overall	O
,	O
it	O
accounts	O
for	O
60	O
-	O
70	O
%	O
of	O
mutant	O
chromosomes	O
,	O
but	O
there	O
are	O
significant	O
differences	O
in	O
its	O
relative	O
frequency	O
in	O
individual	O
populations	O
.	O

Individuals	O
homoallelic	O
for	O
Q188R	O
tend	O
to	O
have	O
a	O
severe	O
phenotype	O
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
virtually	O
complete	O
loss	O
of	O
enzyme	O
activity	O
observed	O
in	O
in	O
vitro	O
expression	O
systems	O
.	O

Globally	O
,	O
K285N	O
is	O
rarer	O
,	O
but	O
in	O
many	O
European	O
populations	O
it	O
can	O
be	O
found	O
on	O
25	O
-	O
40	O
%	O
of	O
mutant	O
chromosomes	O
.	O

It	O
is	O
invariably	O
associated	O
with	O
a	O
severe	O
phenotype	O
.	O

S135L	O
is	O
found	O
almost	O
exclusively	O
in	O
African	O
Americans	O
.	O

In	O
vitro	O
expression	O
results	O
are	O
discrepant	O
,	O
but	O
some	O
individuals	O
carrying	O
S135L	O
appear	O
to	O
exhibit	O
GALT	O
activity	O
in	O
some	O
tissues	O
.	O

Duarte	O
1	O
(	O
or	O
Los	O
Angeles	O
)	O
and	O
Duarte	O
2	O
(	O
or	O
Duarte	O
)	O
variants	O
carry	O
the	O
same	O
amino	O
acid	O
substitution	O
,	O
N314D	O
,	O
even	O
though	O
D1	O
is	O
associated	O
with	O
increased	O
erythrocyte	O
GALT	O
activity	O
and	O
D2	O
with	O
reduced	O
activity	O
.	O

N314D	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
other	O
base	O
changes	O
that	O
differ	O
on	O
the	O
D1	O
and	O
D2	O
alleles	O
.	O

N314D	O
does	O
not	O
impair	O
GALT	O
activity	O
in	O
in	O
vitro	O
expression	O
systems	O
.	O

However	O
,	O
there	O
are	O
differences	O
in	O
the	O
abundance	O
of	O
GALT	O
protein	O
in	O
lymphoblastoid	O
cells	O
lines	O
from	O
D2	O
and	O
D1	O
individuals	O
.	O

It	O
is	O
unclear	O
whether	O
the	O
specific	O
molecular	O
changes	O
that	O
distinguish	O
the	O
D1	O
and	O
D2	O
alleles	O
account	O
for	O
the	O
different	O
activities	O
.	O

The	O
considerable	O
genetic	O
heterogeneity	O
documented	O
to	O
date	O
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	O
heterogeneity	O
that	O
is	O
observed	O
in	O
galactosemia	B-Disease
.	O

The	O
additional	O
effects	O
of	O
nonallelic	O
variation	O
and	O
other	O
constitutional	O
factors	O
on	O
phenotypic	O
variability	O
remain	O
to	O
be	O
elucidated	O
.	O
.	O

Mutations	O
of	O
the	O
VHL	B-Disease
gene	O
in	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
:	O
definition	O
of	O
a	O
risk	O
factor	O
for	O
VHL	B-Disease
patients	O
to	O
develop	O
an	O
RCC	B-Disease
.	O

To	O
investigate	O
the	O
nature	O
of	O
somatic	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	B-Disease
)	O
mutations	O
,	O
we	O
analyzed	O
173	O
primary	O
sporadic	O
human	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
for	O
mutations	O
of	O
the	O
VHL	B-Disease
tumor	I-Disease
suppressor	O
gene	O
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
of	O
DNA	O
.	O

We	O
detected	O
abnormal	O
SSCP	O
pattern	O
in	O
73	O
samples	O
.	O

After	O
sequencing	O
,	O
we	O
identified	O
microdeletions	O
in	O
58	O
%	O
of	O
cases	O
,	O
microinsertions	O
in	O
17	O
%	O
,	O
nonsense	O
mutations	O
in	O
8	O
%	O
,	O
and	O
missense	O
mutations	O
in	O
17	O
%	O
.	O

Among	O
these	O
mutations	O
,	O
50	O
%	O
correspond	O
to	O
new	O
mutations	O
.	O

VHL	B-Disease
mutations	O
were	O
found	O
only	O
in	O
the	O
nonpapillary	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
RCC	B-Disease
)	O
subtype	O
,	O
as	O
previously	O
reported	O
.	O

To	O
compare	O
somatic	O
and	O
germline	O
mutations	O
,	O
we	O
used	O
the	O
VHL	B-Disease
database	O
,	O
which	O
includes	O
507	O
mutations	O
.	O

The	O
study	O
of	O
mutational	O
events	O
revealed	O
a	O
significant	O
difference	O
between	O
somatic	O
and	O
germline	O
mutations	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
observed	O
in	O
78	O
%	O
of	O
somatic	O
mutations	O
vs	O
only	O
37	O
%	O
in	O
germline	O
mutations	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
postulated	O
that	O
a	O
specific	O
pattern	O
of	O
VHL	B-Disease
mutations	O
is	O
associated	O
with	O
sporadic	B-Disease
RCC	I-Disease
.	O

This	O
pattern	O
corresponds	O
to	O
mutations	O
leading	O
mainly	O
to	O
truncated	O
proteins	O
with	O
few	O
specific	O
missense	O
mutations	O
.	O

We	O
then	O
analyzed	O
the	O
occurrence	O
of	O
RCC	B-Disease
in	O
VHL	B-Disease
families	O
,	O
based	O
on	O
the	O
nature	O
of	O
mutations	O
.	O

We	O
observed	O
RCC	B-Disease
in	O
at	O
least	O
one	O
member	O
of	O
the	O
VHL	B-Disease
families	O
in	O
77	O
%	O
of	O
cases	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
versus	O
55	O
%	O
in	O
cases	O
with	O
missense	O
mutations	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Thus	O
,	O
mutations	O
resulting	O
in	O
truncated	O
proteins	O
may	O
lead	O
to	O
a	O
higher	O
risk	O
of	O
RCC	B-Disease
in	O
VHL	B-Disease
patients	O

Defective	O
CTLA	O
-	O
4	O
cycling	O
pathway	O
in	O
Chediak	B-Disease
-	I-Disease
Higashi	I-Disease
syndrome	I-Disease
:	O
a	O
possible	O
mechanism	O
for	O
deregulation	O
of	O
T	O
lymphocyte	O
activation	O
.	O

Cytotoxic	O
T	O
lymphocyte	O
-	O
associated	O
antigen	O
4	O
(	O
CTLA	O
-	O
4	O
,	O
also	O
known	O
as	O
CD152	O
)	O
has	O
been	O
shown	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
activation	O
.	O

Its	O
membrane	O
expression	O
is	O
highly	O
regulated	O
by	O
endocytosis	O
and	O
trafficking	O
through	O
the	O
secretory	O
lysosome	O
pathway	O
.	O

Chediak	B-Disease
-	I-Disease
Higashi	I-Disease
syndrome	I-Disease
(	O
CHS	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
trafficking	O
regulator	O
gene	O
,	O
LYST	O
.	O

It	O
results	O
in	O
defective	O
membrane	O
targeting	O
of	O
the	O
proteins	O
present	O
in	O
secretory	O
lysosomes	O
,	O
and	O
it	O
is	O
associated	O
with	O
a	O
variety	O
of	O
features	O
,	O
including	O
a	O
lymphoproliferative	B-Disease
syndrome	I-Disease
with	O
hemophagocytosis	B-Disease
.	O

The	O
murine	O
equivalent	O
of	O
CHS	B-Disease
,	O
beige	O
mice	O
,	O
present	O
similar	O
characteristics	O
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	B-Disease
syndrome	I-Disease
.	O

We	O
show	O
herein	O
that	O
CTLA	O
-	O
4	O
is	O
present	O
in	O
enlarged	O
,	O
abnormal	O
vesicles	O
in	O
CHS	B-Disease
T	O
cells	O
and	O
is	O
not	O
properly	O
expressed	O
at	O
the	O
cell	O
surface	O
after	O
T	O
cell	O
activation	O
,	O
whereas	O
its	O
surface	O
expression	O
is	O
not	O
impaired	O
.	O

It	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	O
of	O
CTLA	O
-	O
4	O
by	O
CHS	B-Disease
T	O
cells	O
is	O
involved	O
in	O
the	O
generation	O
of	O
lymphoproliferative	B-Disease
disease	I-Disease
.	O

This	O
observation	O
may	O
provide	O
insight	O
into	O
the	O
role	O
of	O
CTLA	O
-	O
4	O
in	O
humans	O
.	O
.	O

Proteolipoprotein	O
gene	O
analysis	O
in	O
82	O
patients	O
with	O
sporadic	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
Disease	I-Disease
:	O
duplications	O
,	O
the	O
major	O
cause	O
of	O
the	O
disease	O
,	O
originate	O
more	O
frequently	O
in	O
male	O
germ	O
cells	O
,	O
but	O
point	O
mutations	O
do	O
not	O
.	O

The	O
Clinical	O
European	O
Network	O
on	O
Brain	B-Disease
Dysmyelinating	I-Disease
Disease	I-Disease
.	O

Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
Disease	I-Disease
(	O
PMD	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
developmental	I-Disease
defect	I-Disease
of	I-Disease
myelination	I-Disease
affecting	O
the	O
central	O
nervous	O
system	O
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(	O
PLP	O
)	O
locus	O
.	O

Investigating	O
82	O
strictly	O
selected	O
sporadic	O
cases	O
of	O
PMD	B-Disease
,	O
we	O
found	O
PLP	O
mutations	O
in	O
77	O
%	O
;	O
complete	O
PLP	O
-	O
gene	O
duplications	O
were	O
the	O
most	O
frequent	O
abnormality	O
(	O
62	O
%	O
)	O
,	O
whereas	O
point	O
mutations	O
in	O
coding	O
or	O
splice	O
-	O
site	O
regions	O
of	O
the	O
gene	O
were	O
involved	O
less	O
frequently	O
(	O
38	O
%	O
)	O
.	O

We	O
analyzed	O
the	O
maternal	O
status	O
of	O
56	O
cases	O
to	O
determine	O
the	O
origin	O
of	O
both	O
types	O
of	O
PLP	O
mutation	O
,	O
since	O
this	O
is	O
relevant	O
to	O
genetic	O
counseling	O
.	O

In	O
the	O
22	O
point	O
mutations	O
,	O
68	O
%	O
of	O
mothers	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
a	O
value	O
identical	O
to	O
the	O
two	O
-	O
thirds	O
of	O
carrier	O
mothers	O
that	O
would	O
be	O
expected	O
if	O
there	O
were	O
an	O
equal	O
mutation	O
rate	O
in	O
male	O
and	O
female	O
germ	O
cells	O
.	O

In	O
sharp	O
contrast	O
,	O
among	O
the	O
34	O
duplicated	O
cases	O
,	O
91	O
%	O
of	O
mothers	O
were	O
carriers	O
,	O
a	O
value	O
significantly	O
(	O
chi2	O
=	O
9	O
.	O
20	O
,	O
P	O
<	O
.	O
01	O
)	O
in	O
favor	O
of	O
a	O
male	O
bias	O
,	O
with	O
an	O
estimation	O
of	O
the	O
male	O
/	O
female	O
mutation	O
frequency	O
(	O
k	O
)	O
of	O
9	O
.	O

3	O
3	O
.	O

Moreover	O
,	O
we	O
observed	O
the	O
occurrence	O
of	O
de	O
novo	O
mutations	O
between	O
parental	O
and	O
grandparental	O
generations	O
in	O
17	O
three	O
-	O
generation	O
families	O
,	O
which	O
allowed	O
a	O
direct	O
estimation	O
of	O
the	O
k	O
value	O
(	O
k	O
=	O
11	O
)	O
.	O

Again	O
,	O
a	O
significant	O
male	O
mutation	O
imbalance	O
was	O
observed	O
only	O
for	O
the	O
duplications	O
.	O

Chromosome	O
breakage	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
and	I-Disease
Angelman	I-Disease
syndromes	I-Disease
involves	O
recombination	O
between	O
large	O
,	O
transcribed	O
repeats	O
at	O
proximal	O
and	O
distal	O
breakpoints	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
and	O
Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
are	O
distinct	O
neurobehavioral	B-Disease
disorders	I-Disease
that	O
most	O
often	O
arise	O
from	O
a	O
4	O
-	O
Mb	O
deletion	O
of	O
chromosome	O
15q11	O
-	O
q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis	O
,	O
respectively	O
.	O

At	O
a	O
de	O
novo	O
frequency	O
of	O
approximately	O
.	O

67	O
-	O
1	O
/	O
10	O
,	O
000	O
births	O
,	O
these	O
deletions	O
represent	O
a	O
common	O
structural	O
chromosome	O
change	O
in	O
the	O
human	O
genome	O
.	O

To	O
elucidate	O
the	O
mechanism	O
underlying	O
these	O
events	O
,	O
we	O
characterized	O
the	O
regions	O
that	O
contain	O
two	O
proximal	O
breakpoint	O
clusters	O
and	O
a	O
distal	O
cluster	O
.	O

Novel	O
DNA	O
sequences	O
potentially	O
associated	O
with	O
the	O
breakpoints	O
were	O
positionally	O
cloned	O
from	O
YACs	O
within	O
or	O
near	O
these	O
regions	O
.	O

Analyses	O
of	O
rodent	O
-	O
human	O
somatic	O
-	O
cell	O
hybrids	O
,	O
YAC	O
contigs	O
,	O
and	O
FISH	O
of	O
normal	O
or	O
rearranged	O
chromosomes	O
15	O
identified	O
duplicated	O
sequences	O
(	O
the	O
END	O
repeats	O
)	O
at	O
or	O
near	O
the	O
breakpoints	O
.	O

The	O
END	O
-	O
repeat	O
units	O
are	O
derived	O
from	O
large	O
genomic	O
duplications	O
of	O
a	O
novel	O
gene	O
(	O
HERC2	O
)	O
,	O
many	O
copies	O
of	O
which	O
are	O
transcriptionally	O
active	O
in	O
germline	O
tissues	O
.	O

One	O
of	O
five	O
PWS	B-Disease
/	O
AS	B-Disease
patients	O
analyzed	O
to	O
date	O
has	O
an	O
identifiable	O
,	O
rearranged	O
HERC2	O
transcript	O
derived	O
from	O
the	O
deletion	O
event	O
.	O

We	O
postulate	O
that	O
the	O
END	O
repeats	O
flanking	O
15q11	O
-	O
q13	O
mediate	O
homologous	O
recombination	O
resulting	O
in	O
deletion	O
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
active	O
transcription	O
of	O
these	O
repeats	O
in	O
male	O
and	O
female	O
germ	O
cells	O
may	O
facilitate	O
the	O
homologous	O
recombination	O
process	O
.	O

Linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
family	O
with	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	O
locus	O
for	O
cleft	B-Disease
palate	I-Disease
at	O
17p11	O
.	O
2	O
-	O
11	O
.	O
1	O
.	O

van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
,	O
which	O
has	O
been	O
mapped	O
to	O
1q32	O
-	O
41	O
,	O
is	O
characterized	O
by	O
pits	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
sinuses	I-Disease
of	I-Disease
the	I-Disease
lower	I-Disease
lip	I-Disease
,	O
cleft	B-Disease
lip	I-Disease
/	I-Disease
palate	I-Disease
(	O
CL	B-Disease
/	I-Disease
P	I-Disease
)	O
,	O
cleft	B-Disease
palate	I-Disease
(	O
CP	B-Disease
)	O
,	O
bifid	B-Disease
uvula	I-Disease
,	O
and	O
hypodontia	B-Disease
(	O
H	B-Disease
)	O
.	O

The	O
expression	O
of	O
VWS	B-Disease
,	O
which	O
has	O
incomplete	O
penetrance	O
,	O
is	O
highly	O
variable	O
.	O

Both	O
the	O
occurrence	O
of	O
CL	B-Disease
/	I-Disease
P	I-Disease
and	O
CP	B-Disease
within	O
the	O
same	O
genealogy	O
and	O
a	O
recurrence	O
risk	O
<	O
40	O
%	O
for	O
CP	B-Disease
among	O
descendants	O
with	O
VWS	B-Disease
have	O
suggested	O
that	O
the	O
development	O
of	O
clefts	B-Disease
in	O
this	O
syndrome	O
is	O
influenced	O
by	O
modifying	O
genes	O
at	O
other	O
loci	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
conducted	O
linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
kindred	O
with	O
VWS	B-Disease
,	O
considering	O
as	O
affected	O
the	O
individuals	O
with	O
CP	B-Disease
,	O
regardless	O
of	O
whether	O
it	O
is	O
associated	O
with	O
other	O
clinical	O
signs	O
of	O
VWS	B-Disease
.	O

Our	O
results	O
suggest	O
that	O
a	O
gene	O
at	O
17p11	O
.	O

2	O
-	O
11	O
2	O
-	O
11	O
.	O

1	O
,	O
together	O
with	O
the	O
VWS	B-Disease
gene	O
at	O
1p32	O
-	O
41	O
,	O
enhances	O
the	O
probability	O
of	O
CP	B-Disease
in	O
an	O
individual	O
carrying	O
the	O
two	O
at	O
-	O
risk	O
genes	O
.	O

If	O
this	O
hypothesis	O
is	O
confirmed	O
in	O
other	O
VWS	B-Disease
pedigrees	O
,	O
it	O
will	O
represent	O
one	O
of	O
the	O
first	O
examples	O
of	O
a	O
gene	O
,	O
mapped	O
through	O
linkage	O
analysis	O
,	O
which	O
modifies	O
the	O
expression	O
of	O
a	O
major	O
gene	O
.	O

New	O
mutations	O
,	O
polymorphisms	O
,	O
and	O
rare	O
variants	O
in	O
the	O
ATM	O
gene	O
detected	O
by	O
a	O
novel	O
SSCP	O
strategy	O
.	O

The	O
gene	O
for	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
,	O
ATM	O
,	O
spans	O
about	O
150	O
kb	O
of	O
genomic	O
DNA	O
.	O

ATM	O
mutations	O
are	O
found	O
along	O
the	O
entire	O
gene	O
,	O
with	O
no	O
evidence	O
of	O
a	O
mutational	O
hot	O
spot	O
.	O

Using	O
DNA	O
as	O
the	O
starting	O
material	O
,	O
we	O
screened	O
the	O
ATM	O
gene	O
in	O
92	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
,	O
using	O
an	O
optimized	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
that	O
detected	O
all	O
previously	O
known	O
mutations	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
segments	O
being	O
analyzed	O
.	O

To	O
expedite	O
screening	O
,	O
we	O
sequentially	O
loaded	O
the	O
SSCP	O
gels	O
with	O
three	O
different	O
sets	O
of	O
PCR	O
products	O
that	O
were	O
pretested	O
to	O
avoid	O
overlapping	O
patterns	O
.	O

Many	O
of	O
the	O
DNA	O
changes	O
we	O
detected	O
were	O
intragenic	O
polymorphisms	O
.	O

Of	O
an	O
expected	O
177	O
unknown	O
mutations	O
,	O
we	O
detected	O
approximately	O
70	O
%	O
,	O
mostly	O
protein	O
truncating	O
mutations	O
(	O
that	O
would	O
have	O
been	O
detectable	O
by	O
protein	O
truncation	O
testing	O
if	O
RNA	O
starting	O
material	O
had	O
been	O
available	O
)	O
.	O

Mutations	O
have	O
now	O
been	O
defined	O
for	O
every	O
exon	O
of	O
the	O
ATM	O
gene	O
.	O

Herein	O
,	O
we	O
present	O
35	O
new	O
mutations	O
and	O
34	O
new	O
intragenic	O
polymorphisms	O
or	O
rare	O
variants	O
within	O
the	O
ATM	O
gene	O
.	O

This	O
is	O
the	O
most	O
comprehensive	O
compilation	O
of	O
ATM	O
polymorphisms	O
assembled	O
to	O
date	O
.	O

Defining	O
polymorphic	O
sites	O
as	O
well	O
as	O
mutations	O
in	O
the	O
ATM	O
gene	O
will	O
be	O
of	O
great	O
importance	O
in	O
designing	O
automated	O
methods	O
for	O
detecting	O
mutations	O
.	O
.	O

A	O
novel	O
frameshift	O
mutation	O
in	O
the	O
McLeod	B-Disease
syndrome	I-Disease
gene	O
in	O
a	O
Japanese	O
family	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
XK	O
gene	O
(	O
XK	O
)	O
in	O
a	O
Japanese	O
patient	O
with	O
McLeod	B-Disease
syndrome	I-Disease
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	O
showed	O
progressive	O
muscular	B-Disease
atrophy	I-Disease
,	O
choreic	B-Disease
movement	I-Disease
,	O
elevated	O
level	O
of	O
serum	O
creatinine	O
kinase	O
,	O
and	O
acanthocytosis	B-Disease
.	O

The	O
expression	O
level	O
of	O
all	O
the	O
Kell	O
antigens	O
in	O
erythrocyte	O
was	O
decreased	O
and	O
molecular	O
analysis	O
revealed	O
a	O
single	O
-	O
base	O
(	O
T	O
)	O
deletion	O
at	O
the	O
nucleotide	O
position	O
1095	O
in	O
XK	O
.	O

This	O
deletion	O
caused	O
a	O
frameshift	O
in	O
translation	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
the	O
amino	O
acid	O
position	O
408	O
.	O

We	O
conclude	O
this	O
single	O
-	O
base	O
deletion	O
causes	O
defective	O
Kx	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
the	O
McLeod	B-Disease
phenotype	O
in	O
this	O
patient	O
.	O
.	O

Association	O
of	O
BRCA1	O
with	O
the	O
hRad50	O
-	O
hMre11	O
-	O
p95	O
complex	O
and	O
the	O
DNA	O
damage	O
response	O
.	O

BRCA1	O
encodes	O
a	O
tumor	B-Disease
suppressor	O
that	O
is	O
mutated	O
in	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
BRCA1	O
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
hRad50	O
,	O
which	O
forms	O
a	O
complex	O
with	O
hMre11	O
and	O
p95	O
/	O
nibrin	O
.	O

Upon	O
irradiation	O
,	O
BRCA1	O
was	O
detected	O
in	O
discrete	O
foci	O
in	O
the	O
nucleus	O
,	O
which	O
colocalize	O
with	O
hRad50	O
.	O

Formation	O
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
BRCA1	O
,	O
hRad50	O
,	O
hMre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC	O
/	O
1937	O
breast	B-Disease
cancer	I-Disease
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
BRCA1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	O
-	O
type	O
BRCA1	O
.	O

Ectopic	O
expression	O
of	O
wild	O
-	O
type	O
,	O
but	O
not	O
mutated	O
,	O
BRCA1	O
in	O
these	O
cells	O
rendered	O
them	O
less	O
sensitive	O
to	O
the	O
DNA	O
damage	O
agent	O
,	O
methyl	O
methanesulfonate	O
.	O

These	O
data	O
suggest	O
that	O
BRCA1	O
is	O
important	O
for	O
the	O
cellular	O
responses	O
to	O
DNA	O
damage	O
that	O
are	O
mediated	O
by	O
the	O
hRad50	O
-	O
hMre11	O
-	O
p95	O
complex	O
.	O
.	O

Relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
in	O
females	O
with	O
phenylalanine	B-Disease
hydroxylase	I-Disease
deficiency	I-Disease
:	O
report	O
from	O
the	O
Maternal	B-Disease
Phenylketonuria	I-Disease
Collaborative	O
Study	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
(	O
PKU	B-Disease
)	O
.	O

METHODOLOGY	O
PAH	O
gene	O
mutations	O
were	O
examined	O
in	O
222	O
hyperphenylalaninemic	B-Disease
females	O
enrolled	O
in	O
the	O
Maternal	B-Disease
PKU	I-Disease
Collaborative	O
Study	O
(	O
MPKUCS	O
)	O
.	O

A	O
total	O
of	O
84	O
different	O
mutations	O
were	O
detected	O
,	O
and	O
complete	O
genotype	O
was	O
obtained	O
in	O
199	O
individuals	O
.	O

Based	O
on	O
previous	O
knowledge	O
about	O
mutation	O
-	O
phenotype	O
associations	O
,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(	O
severe	O
PKU	B-Disease
,	O
moderate	O
PKU	B-Disease
,	O
mild	O
PKU	B-Disease
,	O
and	O
mild	B-Disease
hyperphenylalaninemia	I-Disease
[	O
MHP	B-Disease
]	O
)	O
.	O

Then	O
,	O
189	O
MPKUCS	O
subjects	O
were	O
grouped	O
according	O
to	O
the	O
various	O
combinations	O
of	O
mutation	O
classifications	O
.	O

The	O
sample	O
sizes	O
were	O
large	O
enough	O
for	O
statistical	O
testing	O
in	O
four	O
groups	O
with	O
at	O
least	O
one	O
mutation	O
that	O
completely	O
abolishes	O
enzyme	O
activity	O
.	O

These	O
patients	O
are	O
considered	O
functionally	O
hemizygous	O
.	O

RESULTS	O
The	O
biochemical	O
phenotype	O
predicted	O
from	O
the	O
genotype	O
in	O
functionally	O
hemizygous	O
patients	O
was	O
related	O
significantly	O
to	O
the	O
assigned	O
phenylalanine	O
level	O
.	O

Cognitive	O
performance	O
(	O
IQ	O
)	O
was	O
also	O
significantly	O
related	O
to	O
genotype	O
.	O

The	O
IQ	O
of	O
PAH	B-Disease
-	I-Disease
deficient	I-Disease
mothers	O
with	O
a	O
severe	O
PKU	B-Disease
mutation	O
in	O
combination	O
with	O
a	O
MHP	B-Disease
mutation	O
or	O
a	O
mild	O
PKU	B-Disease
mutation	O
was	O
99	O
and	O
96	O
,	O
respectively	O
,	O
whereas	O
the	O
IQ	O
of	O
PKU	B-Disease
mothers	O
with	O
two	O
severe	O
PKU	B-Disease
mutations	O
or	O
with	O
one	O
severe	O
and	O
one	O
moderate	O
PKU	B-Disease
mutation	O
was	O
83	O
and	O
84	O
,	O
respectively	O
.	O

Of	O
the	O
patients	O
with	O
PKU	B-Disease
,	O
92	O
%	O
had	O
been	O
treated	O
during	O
childhood	O
.	O

Those	O
who	O
were	O
untreated	O
or	O
treated	O
late	O
had	O
lower	O
than	O
average	O
IQ	O
scores	O
for	O
their	O
group	O
of	O
mutation	O
combinations	O
.	O

Females	O
with	O
moderate	O
or	O
mild	O
PKU	B-Disease
who	O
were	O
treated	O
early	O
and	O
treated	O
for	O
>	O
6	O
years	O
showed	O
IQ	O
scores	O
10	O
points	O
above	O
average	O
for	O
their	O
group	O
.	O

CONCLUSIONS	O
The	O
reproductive	O
outcome	O
in	O
maternal	B-Disease
phenylketonuria	I-Disease
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances	O
.	O

Both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
PKU	B-Disease
.	O

The	O
significant	O
relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
observed	O
in	O
the	O
present	O
study	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
PKU	B-Disease
who	O
plan	O
pregnancy	O
.	O
.	O

Spinal	B-Disease
xanthomatosis	I-Disease
:	O
a	O
variant	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
.	O

We	O
describe	O
seven	O
Dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive	O
,	O
mainly	O
spinal	B-Disease
cord	I-Disease
syndrome	I-Disease
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

MRI	O
demonstrated	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	O
cord	O
.	O

Post	O
-	O
mortem	O
examination	O
of	O
one	O
of	O
the	O
patients	O
showed	O
extensive	O
myelin	O
loss	O
in	O
these	O
columns	O
.	O

An	O
array	O
of	O
genotypes	O
was	O
found	O
in	O
these	O
patients	O
.	O

We	O
conclude	O
that	O
spinal	B-Disease
xanthomatosis	I-Disease
is	O
a	O
clinical	O
and	O
radiological	O
separate	O
entity	O
of	O
CTX	B-Disease
that	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
chronic	B-Disease
myelopathy	I-Disease
.	O
.	O

A	O
transgene	O
insertion	O
creating	O
a	O
heritable	O
chromosome	O
deletion	O
mouse	O
model	O
of	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
and	I-Disease
angelman	I-Disease
syndromes	I-Disease
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
and	O
Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
result	O
from	O
the	O
loss	O
of	O
function	O
of	O
imprinted	O
genes	O
in	O
human	O
chromosome	O
15q11	O
-	O
q13	O
.	O

The	O
central	O
part	O
of	O
mouse	O
chromosome	O
7	O
is	O
homologous	O
to	O
human	O
15q11	O
-	O
q13	O
,	O
with	O
conservation	O
of	O
both	O
gene	O
order	O
and	O
imprinted	O
features	O
.	O

We	O
report	O
here	O
the	O
characterization	O
of	O
a	O
transgene	O
insertion	O
(	O
Epstein	O
-	O
Barr	O
virus	O
Latent	O
Membrane	O
Protein	O
2A	O
,	O
LMP2A	O
)	O
into	O
mouse	O
chromosome	O
7C	O
,	O
which	O
has	O
resulted	O
in	O
mouse	O
models	O
for	O
PWS	B-Disease
and	O
AS	B-Disease
dependent	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

Epigenotype	O
(	O
allelic	O
expression	O
and	O
DNA	O
methylation	O
)	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
analyses	O
indicate	O
that	O
the	O
transgene	O
-	O
induced	O
mutation	O
has	O
generated	O
a	O
complete	O
deletion	O
of	O
the	O
PWS	B-Disease
/	O
AS	B-Disease
-	O
homologous	O
region	O
but	O
has	O
not	O
deleted	O
flanking	O
loci	O
.	O

Because	O
the	O
intact	O
chromosome	O
7	O
,	O
opposite	O
the	O
deleted	O
homolog	O
,	O
maintains	O
the	O
correct	O
imprint	O
in	O
somatic	O
cells	O
of	O
PWS	B-Disease
and	O
AS	B-Disease
mice	O
and	O
establishes	O
the	O
correct	O
imprint	O
in	O
male	O
and	O
female	O
germ	O
cells	O
of	O
AS	B-Disease
mice	O
,	O
homologous	O
association	O
and	O
replication	O
asynchrony	O
are	O
not	O
part	O
of	O
the	O
imprinting	O
mechanism	O
.	O

This	O
heritable	O
-	O
deletion	O
mouse	O
model	O
will	O
be	O
particularly	O
useful	O
for	O
the	O
identification	O
of	O
the	O
etiological	O
genes	O
and	O
mechanisms	O
,	O
phenotypic	O
basis	O
,	O
and	O
investigation	O
of	O
therapeutic	O
approaches	O
for	O
PWS	B-Disease
.	O
.	O

Linkage	O
analysis	O
of	O
5	O
novel	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
kindreds	O
to	O
1q32	O
-	O
q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait	O
.	O

van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
vWS	B-Disease
,	O
MIM	O
119300	O
)	O
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
clefting	I-Disease
condition	I-Disease
with	O
cardinal	O
features	O
of	O
mucous	B-Disease
cysts	I-Disease
(	O
lower	B-Disease
-	I-Disease
lip	I-Disease
pits	I-Disease
)	O
and	O
clefts	B-Disease
to	I-Disease
the	I-Disease
lip	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
palate	I-Disease
.	O

The	O
vWS	B-Disease
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32	O
-	O
q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping	O
.	O

We	O
have	O
investigated	O
5	O
novel	O
vWS	B-Disease
families	O
through	O
probands	O
attended	O
for	O
cleft	B-Disease
lip	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
palate	I-Disease
repair	O
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau	O
,	O
Paris	O
,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vWS	B-Disease
region	O
in	O
1q32	O
-	O
q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees	O
.	O

Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
6	O
microsatellite	O
markers	O
(	O
D1S249	O
,	O
D1S425	O
,	O
D1S491	O
,	O
D1S205	O
,	O
D1S414	O
,	O
D1S425	O
)	O
,	O
yielding	O
a	O
maximum	O
cumulative	O
LOD	O
score	O
of	O
Z	O
=	O
3	O
.	O

27	O
at	O
theta	O
=	O
0	O
.	O

00	O
for	O
D1S245	O
.	O

The	O
innermost	O
four	O
markers	O
were	O
found	O
to	O
be	O
tightly	O
linked	O
to	O
one	O
another	O
,	O
with	O
no	O
evidence	O
for	O
recombination	O
.	O

Our	O
results	O
support	O
linkage	O
of	O
vWS	B-Disease
within	O
a	O
region	O
of	O
tightly	O
linked	O
markers	O
and	O
do	O
not	O
favour	O
locus	O
heterogeneity	O
of	O
the	O
disease	O
trait	O
.	O

Null	O
mutation	O
of	O
the	O
murine	O
ATP7B	O
(	O
Wilson	B-Disease
disease	I-Disease
)	O
gene	O
results	O
in	O
intracellular	B-Disease
copper	I-Disease
accumulation	I-Disease
and	O
late	B-Disease
-	I-Disease
onset	I-Disease
hepatic	I-Disease
nodular	I-Disease
transformation	I-Disease
.	O

The	O
Atp7b	O
protein	O
is	O
a	O
copper	O
-	O
transporting	O
ATPase	O
expressed	O
predominantly	O
in	O
the	O
liver	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
most	O
other	O
tissues	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
gene	O
lead	O
to	O
Wilson	B-Disease
disease	I-Disease
,	O
a	O
copper	B-Disease
toxicity	I-Disease
disorder	I-Disease
characterized	O
by	O
dramatic	O
build	O
-	O
up	O
of	O
intracellular	O
hepatic	O
copper	O
with	O
subsequent	O
hepatic	B-Disease
and	I-Disease
neuro	I-Disease
-	I-Disease
logical	I-Disease
abnormalities	I-Disease
.	O

Using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
ATP7B	O
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(	O
null	O
)	O
for	O
the	O
Wilson	B-Disease
disease	I-Disease
gene	O
.	O

The	O
ATP7B	O
null	O
mice	O
display	O
a	O
gradual	O
accumulation	O
of	O
hepatic	O
copper	O
that	O
increases	O
to	O
a	O
level	O
60	O
-	O
fold	O
greater	O
than	O
normal	O
by	O
5	O
months	O
of	O
age	O
.	O

An	O
increase	O
in	O
copper	O
concentration	O
was	O
also	O
observed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo	O
-	O
zygous	O
mutants	O
,	O
although	O
milk	O
from	O
the	O
mutant	O
glands	O
was	O
copper	B-Disease
deficient	I-Disease
.	O

Morphological	B-Disease
abnormalities	I-Disease
resembling	O
cirrhosis	B-Disease
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	O
mutants	O
older	O
than	O
7	O
months	O
of	O
age	O
.	O

Progeny	O
of	O
the	O
homozygous	O
mutant	O
females	O
demonstrated	O
neurological	B-Disease
abnormalities	I-Disease
and	O
growth	B-Disease
retardation	I-Disease
characteristic	O
of	O
copper	B-Disease
deficiency	I-Disease
.	O

Copper	O
concentration	O
in	O
the	O
livers	O
of	O
the	O
newborn	O
homozygous	O
null	O
mutants	O
was	O
decreased	O
dramatically	O
.	O

In	O
summary	O
,	O
inactivation	O
of	O
the	O
murine	O
ATP7B	O
gene	O
produces	O
a	O
form	O
of	O
cirrhotic	B-Disease
liver	I-Disease
disease	I-Disease
that	O
resembles	O
Wilson	B-Disease
disease	I-Disease
in	O
humans	O
and	O
the	O
toxic	O
milk	O
phenotype	O
in	O
the	O
mouse	O
.	O
.	O

French	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
patients	O
do	O
not	O
exhibit	O
gametic	O
segregation	O
distortion	O
:	O
a	O
sperm	O
typing	O
analysis	O
.	O

Segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	B-Disease
repeat	I-Disease
disorders	I-Disease
.	O

On	O
the	O
basis	O
of	O
a	O
sperm	O
typing	O
study	O
performed	O
in	O
patients	O
of	O
Japanese	O
descent	O
with	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
,	O
it	O
was	O
reported	O
that	O
disease	O
alleles	O
are	O
preferentially	O
transmitted	O
during	O
meiosis	O
.	O

We	O
performed	O
a	O
sperm	O
typing	O
study	O
of	O
five	O
MJD	B-Disease
patients	O
of	O
French	O
descent	O
and	O
analysis	O
of	O
the	O
pooled	O
data	O
shows	O
a	O
ratio	O
of	O
mutant	O
to	O
normal	O
alleles	O
of	O
379	O
436	O
(	O
46	O
.	O
5	O
53	O
.	O
5	O
%	O
)	O
,	O
which	O
does	O
not	O
support	O
meiotic	O
segregation	O
distortion	O
.	O

To	O
confirm	O
these	O
results	O
,	O
sperm	O
typing	O
analysis	O
was	O
also	O
performed	O
using	O
a	O
polymorphic	O
marker	O
,	O
D14S1050	O
,	O
closely	O
linked	O
to	O
the	O
MJD1	O
gene	O
.	O

Among	O
910	O
sperm	O
analyzed	O
,	O
the	O
allele	O
linked	O
to	O
the	O
disease	O
chromosome	O
was	O
detected	O
in	O
50	O
.	O

3	O
%	O
of	O
the	O
samples	O
and	O
the	O
allele	O
linked	O
to	O
the	O
normal	O
chromosome	O
was	O
found	O
in	O
49	O
.	O

6	O
%	O
of	O
the	O
sperm	O
.	O

The	O
difference	O
in	O
frequency	O
of	O
these	O
two	O
alleles	O
is	O
not	O
significant	O
(	O
P	O
=	O
0	O
.	O
8423	O
)	O
.	O

Likelihood	O
-	O
based	O
analysis	O
of	O
segregation	O
distortion	O
in	O
the	O
single	O
sperm	O
data	O
using	O
the	O
SPERMSEG	O
program	O
also	O
showed	O
no	O
support	O
for	O
segregation	O
distortion	O
at	O
the	O
gamete	O
level	O
in	O
this	O
patient	O
population	O
.	O

The	O
previous	O
report	O
on	O
the	O
Japanese	O
patients	O
also	O
suggested	O
that	O
disease	O
allele	O
stability	O
may	O
be	O
influenced	O
by	O
a	O
trans	O
effect	O
of	O
an	O
intragenic	O
polymorphism	O
(	O
987	O
G	O
/	O
C	O
)	O
in	O
the	O
wild	O
-	O
type	O
allele	O
.	O

All	O
of	O
the	O
French	O
patients	O
were	O
heterozygous	O
for	O
this	O
polymorphism	O
.	O

However	O
,	O
analysis	O
of	O
the	O
variance	O
in	O
repeat	O
number	O
in	O
sperm	O
from	O
the	O
French	O
MJD	B-Disease
patients	O
overlapped	O
significantly	O
with	O
the	O
variance	O
in	O
repeat	O
number	O
observed	O
in	O
the	O
C	O
/	O
C	O
homozygous	O
Japanese	O
patients	O
.	O

Missense	O
mutation	O
in	O
the	O
alternative	O
splice	O
region	O
of	O
the	O
PAX6	O
gene	O
in	O
eye	B-Disease
anomalies	I-Disease
.	O

The	O
PAX6	O
gene	O
is	O
involved	O
in	O
ocular	O
morphogenesis	O
,	O
and	O
PAX6	O
mutations	O
have	O
been	O
detected	O
in	O
various	O
types	O
of	O
ocular	B-Disease
anomalies	I-Disease
,	O
including	O
aniridia	B-Disease
,	O
Peters	B-Disease
anomaly	I-Disease
,	O
corneal	B-Disease
dystrophy	I-Disease
,	O
congenital	B-Disease
cataract	I-Disease
,	O
and	O
foveal	B-Disease
hypoplasia	I-Disease
.	O

The	O
gene	O
encodes	O
a	O
transcriptional	O
regulator	O
that	O
recognizes	O
target	O
genes	O
through	O
its	O
paired	O
-	O
type	O
DNA	O
-	O
binding	O
domain	O
.	O

The	O
paired	O
domain	O
is	O
composed	O
of	O
two	O
distinct	O
DNA	O
-	O
binding	O
subdomains	O
,	O
the	O
N	O
-	O
terminal	O
subdomain	O
(	O
NTS	O
)	O
and	O
the	O
C	O
-	O
terminal	O
subdomain	O
(	O
CTS	O
)	O
,	O
which	O
bind	O
respective	O
consensus	O
DNA	O
sequences	O
.	O

The	O
human	O
PAX6	O
gene	O
produces	O
two	O
alternative	O
splice	O
isoforms	O
that	O
have	O
the	O
distinct	O
structure	O
of	O
the	O
paired	O
domain	O
.	O

The	O
insertion	O
,	O
into	O
the	O
NTS	O
,	O
of	O
14	O
additional	O
amino	O
acids	O
encoded	O
by	O
exon	O
5a	O
abolishes	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
NTS	O
and	O
unmasks	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
the	O
CTS	O
.	O

Thus	O
,	O
exon	O
5a	O
appears	O
to	O
function	O
as	O
a	O
molecular	O
switch	O
that	O
specifies	O
target	O
genes	O
.	O

We	O
ascertained	O
a	O
novel	O
missense	O
mutation	O
in	O
four	O
pedigrees	O
with	O
Peters	B-Disease
anomaly	I-Disease
,	O
congenital	B-Disease
cataract	I-Disease
,	O
Axenfeldt	B-Disease
anomaly	I-Disease
,	O
and	O
/	O
or	O
foveal	B-Disease
hypoplasia	I-Disease
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
is	O
the	O
first	O
mutation	O
identified	O
in	O
the	O
splice	O
-	O
variant	O
region	O
.	O

A	O
T	O
-	O
-	O
>	O
A	O
transition	O
at	O
the	O
20th	O
nucleotide	O
position	O
of	O
exon	O
5a	O
results	O
in	O
a	O
Val	O
-	O
-	O
>	O
Asp	O
(	O
GTC	O
-	O
-	O
>	O
GAC	O
)	O
substitution	O
at	O
the	O
7th	O
codon	O
of	O
the	O
alternative	O
splice	O
region	O
.	O

Functional	O
analyses	O
demonstrated	O
that	O
the	O
V54D	O
mutation	O
slightly	O
increased	O
NTS	O
binding	O
and	O
decreased	O
CTS	O
transactivation	O
activity	O
to	O
almost	O
half	O
.	O
.	O

Penetrances	O
of	O
BRCA1	O
1675delA	O
and	O
1135insA	O
with	O
respect	O
to	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
.	O

For	O
genetic	O
counseling	O
and	O
predictive	O
testing	O
in	O
families	O
with	O
inherited	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	O
should	O
be	O
known	O
.	O

We	O
have	O
previously	O
reported	O
two	O
BRCA1	O
founder	O
mutations	O
in	O
the	O
Norwegian	O
population	O
.	O

Index	O
cases	O
for	O
the	O
present	O
study	O
were	O
found	O
two	O
different	O
ways	O
through	O
a	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancers	I-Disease
(	O
n	O
=	O
16	O
)	O
and	O
through	O
our	O
family	O
cancer	B-Disease
clinic	O
(	O
n	O
=	O
14	O
)	O
.	O

Altogether	O
,	O
20	O
of	O
the	O
patients	O
had	O
BRCA1	O
1675delA	O
,	O
and	O
10	O
had	O
1135insA	O
.	O

Their	O
relatives	O
were	O
described	O
with	O
respect	O
to	O
absence	O
/	O
presence	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

Of	O
133	O
living	O
female	O
relatives	O
,	O
83	O
(	O
62	O
%	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
a	O
mutation	O
.	O

No	O
difference	O
,	O
in	O
penetrance	O
and	O
expression	O
,	O
between	O
the	O
two	O
mutations	O
were	O
found	O
,	O
whereas	O
differences	O
according	O
to	O
method	O
of	O
ascertainment	O
were	O
seen	O
.	O

The	O
overall	O
findings	O
were	O
that	O
disease	O
started	O
to	O
occur	O
at	O
age	O
30	O
years	O
and	O
that	O
by	O
age	O
50	O
years	O
48	O
%	O
of	O
the	O
mutation	O
-	O
carrying	O
women	O
had	O
experienced	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

More	O
ovarian	B-Disease
cancers	I-Disease
than	O
breast	B-Disease
cancers	I-Disease
were	O
recorded	O
.	O

Both	O
penetrance	O
and	O
expression	O
(	O
breast	B-Disease
cancer	I-Disease
vs	O
.	O
ovarian	B-Disease
cancer	I-Disease
)	O
were	O
different	O
from	O
those	O
in	O
reports	O
of	O
the	O
Ashkenazi	O
founder	O
mutations	O
.	O

Whether	O
the	O
reported	O
differences	O
reflect	O
true	O
differences	O
and	O
/	O
or	O
methodological	O
problems	O
is	O
discussed	O
.	O

An	O
observed	O
excess	O
of	O
mutation	O
carriers	O
could	O
not	O
be	O
accounted	O
for	O
by	O
methodological	O
problems	O
;	O
possible	O
explanations	O
were	O
a	O
"	O
true	O
"	O
low	O
penetrance	O
or	O
preferential	O
segregation	O
.	O
.	O

The	O
dermatofibrosarcoma	B-Disease
protuberans	I-Disease
-	O
associated	O
collagen	O
type	O
Ialpha1	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
B	O
-	O
chain	O
fusion	O
gene	O
generates	O
a	O
transforming	O
protein	O
that	O
is	O
processed	O
to	O
functional	O
PDGF	O
-	O
BB	O
.	O

Dermatofibrosarcoma	B-Disease
protuberans	I-Disease
(	O
DFSP	B-Disease
)	O
displays	O
chromosomal	O
rearrangements	O
involving	O
chromosome	O
17	O
and	O
22	O
,	O
which	O
fuse	O
the	O
collagen	O
type	O
Ialpha1	O
(	O
COLIA1	O
)	O
gene	O
to	O
the	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
B	O
-	O
chain	O
(	O
PDGFB	O
)	O
gene	O
.	O

To	O
characterize	O
the	O
functional	O
and	O
structural	O
properties	O
of	O
the	O
COLIA1	O
/	O
PDGFB	O
fusion	O
protein	O
,	O
we	O
generated	O
a	O
stable	O
NIH3T3	O
cell	O
line	O
that	O
contained	O
a	O
tumor	O
-	O
derived	O
chimeric	O
gene	O
resulting	O
from	O
a	O
COIA1	O
intron	O
7	O
-	O
PDGFB	O
intron	O
1	O
fusion	O
.	O

Expression	O
of	O
the	O
fusion	O
protein	O
led	O
to	O
morphological	O
transformation	O
and	O
increased	O
growth	O
rate	O
of	O
these	O
cells	O
.	O

The	O
PDGF	O
receptor	O
kinase	O
inhibitor	O
CGP57148B	O
reversed	O
the	O
transformed	O
phenotype	O
and	O
reduced	O
the	O
growth	O
rate	O
of	O
COLIA1	O
/	O
PDGFB	O
-	O
expressing	O
cells	O
but	O
had	O
no	O
effects	O
on	O
control	O
cells	O
.	O

The	O
presence	O
of	O
dimeric	O
COLIA1	O
/	O
PDGFB	O
precursors	O
was	O
demonstrated	O
through	O
PDGFB	O
immunoprecipitations	O
of	O
metabolically	O
labeled	O
cells	O
and	O
also	O
by	O
PDGFB	O
immunoprecipitations	O
followed	O
by	O
immunoblotting	O
with	O
COLIA1	O
antibodies	O
.	O

Pulse	O
-	O
chase	O
studies	O
demonstrated	O
that	O
the	O
COLIA1	O
/	O
PDGFB	O
precursor	O
was	O
processed	O
to	O
an	O
end	O
product	O
that	O
was	O
indistinguishable	O
from	O
wild	O
-	O
type	O
PDGF	O
-	O
BB	O
.	O

Finally	O
,	O
COLIA1	O
/	O
PDGFB	O
-	O
expressing	O
cells	O
generated	O
tumors	B-Disease
after	O
s	O
.	O

c	O
c	O
.	O
injection	O
into	O
nude	O
mice	O
,	O
and	O
tumor	B-Disease
growth	O
was	O
reduced	O
by	O
treatment	O
with	O
CGP57148B	O
.	O

We	O
conclude	O
that	O
the	O
COLIA1	O
/	O
PDGFB	O
fusion	O
associated	O
with	O
DFSP	B-Disease
contributes	O
to	O
tumor	B-Disease
development	O
through	O
ectopic	O
production	O
of	O
PDGF	O
-	O
BB	O
and	O
the	O
formation	O
of	O
an	O
autocrine	O
loop	O
.	O

Our	O
findings	O
,	O
thus	O
,	O
suggest	O
that	O
PDGF	O
receptors	O
could	O
be	O
a	O
target	O
for	O
pharmacological	O
treatment	O
of	O
DFSP	B-Disease
and	O
giant	B-Disease
cell	I-Disease
fibroblastoma	I-Disease
,	O
e	O
.	O
g	O
.	O
,	O
through	O
the	O
use	O
of	O
PDGF	O
receptor	O
kinase	O
inhibitors	O
such	O
as	O
CGP57148B	O
.	O

Identification	O
of	O
a	O
common	O
PEX1	O
mutation	O
in	O
Zellweger	B-Disease
syndrome	I-Disease
.	O

The	O
Zellweger	B-Disease
spectrum	I-Disease
of	I-Disease
disease	I-Disease
,	O
encompassing	O
Zellweger	B-Disease
syndrome	I-Disease
and	O
the	O
progressively	O
milder	O
phenotypes	O
of	O
neonatal	B-Disease
adrenoleukodystrophy	I-Disease
and	O
infantile	B-Disease
Refsum	I-Disease
disease	I-Disease
,	O
is	O
due	O
to	O
a	O
failure	O
to	O
form	O
functional	O
peroxisomes	O
.	O

Cell	O
fusion	O
complementation	O
studies	O
demonstrated	O
that	O
these	O
diseases	O
are	O
genetically	O
heterogeneous	O
,	O
with	O
two	O
-	O
thirds	O
of	O
all	O
patients	O
lying	O
within	O
a	O
single	O
complementation	O
group	O
,	O
CG1	O
.	O

Molecular	O
genetic	O
and	O
cell	O
biology	O
studies	O
have	O
shown	O
that	O
PEX1	O
is	O
deficient	O
in	O
many	O
CG1	O
patients	O
.	O

However	O
,	O
previous	O
studies	O
have	O
focused	O
on	O
mildly	O
affected	O
patients	O
and	O
there	O
is	O
still	O
no	O
report	O
of	O
two	O
mutant	O
PEX1	O
alleles	O
in	O
any	O
Zellweger	B-Disease
syndrome	I-Disease
patient	O
.	O

Furthermore	O
,	O
mutations	O
in	O
the	O
PMP70	O
gene	O
have	O
also	O
been	O
identified	O
in	O
two	O
Zellweger	B-Disease
syndrome	I-Disease
patients	O
from	O
CG1	O
,	O
raising	O
the	O
possibility	O
that	O
CG1	O
patients	O
may	O
represent	O
a	O
mixture	O
of	O
PEX1	O
-	O
deficient	O
and	O
PMP70	O
-	O
deficient	O
individuals	O
.	O

To	O
address	O
the	O
molecular	O
basis	O
of	O
disease	O
in	O
Zellweger	B-Disease
syndrome	I-Disease
patients	O
from	O
CG1	O
,	O
we	O
examined	O
all	O
24	O
PEX1	O
exons	O
in	O
four	O
patients	O
,	O
including	O
both	O
patients	O
that	O
have	O
mutations	O
in	O
PMP70	O
.	O

PEX1	O
mutations	O
were	O
detected	O
in	O
all	O
four	O
patients	O
,	O
including	O
a	O
1	O
-	O
bp	O
insertion	O
(	O
c	O
.	O
2097insT	O
)	O
in	O
exon	O
13	O
that	O
was	O
present	O
in	O
three	O
of	O
the	O
four	O
patients	O
.	O

Subsequent	O
studies	O
demonstrated	O
that	O
this	O
mutation	O
is	O
present	O
in	O
one	O
-	O
half	O
of	O
all	O
CG1	O
patients	O
and	O
correlates	O
with	O
the	O
Zellweger	B-Disease
syndrome	I-Disease
phenotype	O
.	O

As	O
this	O
mutation	O
leads	O
to	O
a	O
loss	O
of	O
protein	O
function	O
its	O
frequency	O
makes	O
it	O
the	O
most	O
common	O
cause	O
of	O
Zellweger	B-Disease
syndrome	I-Disease
,	O
helping	O
to	O
explain	O
the	O
high	O
percentage	O
of	O
patients	O
that	O
belong	O
to	O
CG1	O
.	O

Novel	O
mutations	O
in	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
protein	O
gene	O
and	O
their	O
effects	O
on	O
transcriptional	O
,	O
translational	O
,	O
and	O
clinical	O
phenotypes	O
.	O

Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
immunodeficiency	I-Disease
characterized	O
by	O
thrombocytopenia	B-Disease
,	O
eczema	B-Disease
,	O
and	O
recurrent	O
infections	O
,	O
and	O
caused	O
by	O
mutations	O
in	O
the	O
WAS	B-Disease
protein	O
(	O
WASP	O
)	O
gene	O
.	O

WASP	O
contains	O
several	O
functional	O
domains	O
through	O
which	O
it	O
interacts	O
with	O
proteins	O
involved	O
in	O
intracellular	O
signaling	O
and	O
regulation	O
of	O
the	O
actin	O
cytoskeleton	O
.	O

In	O
this	O
report	O
,	O
17	O
WASP	O
gene	O
mutations	O
were	O
identified	O
,	O
12	O
of	O
which	O
are	O
novel	O
.	O

DNA	O
of	O
affected	O
males	O
and	O
obligate	O
carriers	O
was	O
PCR	O
amplified	O
and	O
analyzed	O
by	O
SSCA	O
,	O
heteroduplex	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O

The	O
effects	O
of	O
the	O
mutations	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
were	O
ascertained	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analyses	O
.	O

All	O
missense	O
mutations	O
were	O
located	O
in	O
exons	O
1	O
-	O
4	O
.	O

Most	O
of	O
the	O
nonsense	O
,	O
frameshift	O
and	O
splice	O
site	O
mutations	O
were	O
found	O
in	O
exons	O
6	O
-	O
11	O
.	O

Mutations	O
that	O
alter	O
splice	O
sites	O
led	O
to	O
the	O
synthesis	O
of	O
several	O
types	O
of	O
mRNAs	O
,	O
a	O
fraction	O
of	O
which	O
represented	O
the	O
normally	O
spliced	O
product	O
.	O

The	O
presence	O
of	O
normally	O
spliced	O
transcripts	O
was	O
correlated	O
with	O
a	O
milder	O
phenotype	O
.	O

When	O
one	O
such	O
case	O
was	O
studied	O
by	O
Western	O
blotting	O
,	O
reduced	O
amounts	O
of	O
normal	O
-	O
size	O
WASP	O
were	O
present	O
.	O

In	O
other	O
cases	O
as	O
well	O
,	O
a	O
correlation	O
was	O
found	O
between	O
the	O
amount	O
of	O
normal	O
or	O
mutant	O
WASP	O
present	O
and	O
the	O
phenotypes	O
of	O
the	O
affected	O
individuals	O
.	O

No	O
protein	O
was	O
detected	O
in	O
two	O
individuals	O
with	O
severe	O
WAS	B-Disease
.	O

Reduced	O
levels	O
of	O
a	O
normal	O
-	O
size	O
WASP	O
with	O
a	O
missense	O
mutation	O
were	O
seen	O
in	O
two	O
individuals	O
with	O
XLT	B-Disease
.	O

It	O
is	O
concluded	O
that	O
mutation	O
analysis	O
at	O
the	O
DNA	O
level	O
is	O
not	O
sufficient	O
for	O
predicting	O
clinical	O
course	O
.	O

Studies	O
at	O
the	O
transcript	O
and	O
protein	O
level	O
are	O
needed	O
for	O
a	O
better	O
assessment	O
.	O
.	O

Aminoglycoside	O
antibiotics	O
restore	O
dystrophin	O
function	O
to	O
skeletal	O
muscles	O
of	O
mdx	O
mice	O
.	O

Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene	O
,	O
leading	O
to	O
the	O
absence	O
of	O
the	O
dystrophin	O
protein	O
in	O
striated	O
muscle	O
.	O

A	O
significant	O
number	O
of	O
these	O
mutations	O
are	O
premature	O
stop	O
codons	O
.	O

On	O
the	O
basis	O
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	O
codons	O
in	O
cultured	O
cells	O
,	O
we	O
tested	O
the	O
effect	O
of	O
gentamicin	O
on	O
cultured	O
muscle	O
cells	O
from	O
the	O
mdx	O
mouse	O
-	O
an	O
animal	O
model	O
for	O
DMD	B-Disease
that	O
possesses	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
dystrophin	O
gene	O
.	O

Exposure	O
of	O
mdx	O
myotubes	O
to	O
gentamicin	O
led	O
to	O
the	O
expression	O
and	O
localization	O
of	O
dystrophin	O
to	O
the	O
cell	O
membrane	O
.	O

We	O
then	O
evaluated	O
the	O
effects	O
of	O
differing	O
dosages	O
of	O
gentamicin	O
on	O
expression	O
and	O
functional	O
protection	O
of	O
the	O
muscles	O
of	O
mdx	O
mice	O
.	O

We	O
identified	O
a	O
treatment	O
regimen	O
that	O
resulted	O
in	O
the	O
presence	O
of	O
dystrophin	O
in	O
the	O
cell	O
membrane	O
in	O
all	O
striated	O
muscles	O
examined	O
and	O
that	O
provided	O
functional	O
protection	O
against	O
muscular	B-Disease
injury	I-Disease
.	O

To	O
our	O
knowledge	O
,	O
our	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
aminoglycosides	O
can	O
suppress	O
stop	O
codons	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	O
.	O

Furthermore	O
,	O
these	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	B-Disease
dystrophy	I-Disease
and	O
other	O
diseases	O
caused	O
by	O
premature	O
stop	O
codon	O
mutations	O
.	O

This	O
treatment	O
could	O
prove	O
effective	O
in	O
up	O
to	O
15	O
%	O
of	O
patients	O
with	O
DMD	B-Disease
.	O
.	O

Loss	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
product	O
causes	O
oxidative	O
damage	O
in	O
target	O
organs	O
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
is	O
characterized	O
by	O
a	O
markedly	O
increased	O
sensitivity	O
to	O
ionizing	O
radiation	O
,	O
increased	O
incidence	O
of	O
cancer	B-Disease
,	O
and	O
neurodegeneration	B-Disease
,	O
especially	O
of	O
the	O
cerebellar	O
Purkinje	O
cells	O
.	O

Ionizing	O
radiation	O
oxidizes	O
macromolecules	O
and	O
causes	O
tissue	O
damage	O
through	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

We	O
therefore	O
hypothesized	O
that	O
A	B-Disease
-	I-Disease
T	I-Disease
is	O
due	O
to	O
oxidative	O
damage	O
resulting	O
from	O
loss	O
of	O
function	O
of	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
gene	O
product	O
.	O

To	O
assess	O
this	O
hypothesis	O
,	O
we	O
employed	O
an	O
animal	O
model	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
,	O
the	O
mouse	O
with	O
a	O
disrupted	O
Atm	O
gene	O
.	O

We	O
show	O
that	O
organs	O
which	O
develop	O
pathologic	O
changes	O
in	O
the	O
Atm	O
-	O
deficient	O
mice	O
are	O
targets	O
of	O
oxidative	O
damage	O
,	O
and	O
that	O
cerebellar	O
Purkinje	O
cells	O
are	O
particularly	O
affected	O
.	O

These	O
observations	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
phenotype	O
and	O
lay	O
a	O
rational	O
foundation	O
for	O
therapeutic	O
intervention	O
.	O
.	O

Recessively	O
inherited	O
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
with	O
normal	O
stature	O
,	O
club	B-Disease
foot	I-Disease
,	O
and	O
double	B-Disease
layered	I-Disease
patella	I-Disease
caused	O
by	O
a	O
DTDST	O
mutation	O
.	O

We	O
have	O
observed	O
over	O
25	O
different	O
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulphate	O
transporter	O
gene	O
(	O
DTDST	O
)	O
in	O
association	O
with	O
the	O
recessive	B-Disease
disorders	I-Disease
achondrogenesis	B-Disease
1B	I-Disease
,	O
atelosteogenesis	B-Disease
2	I-Disease
,	O
and	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O

The	O
c862t	O
(	O
R279W	O
)	O
transition	O
is	O
the	O
most	O
common	O
mutation	O
in	O
non	O
-	O
Finnish	O
patients	O
,	O
but	O
in	O
these	O
disorders	O
it	O
is	O
usually	O
combined	O
with	O
other	O
DTDST	O
mutations	O
.	O

We	O
had	O
not	O
seen	O
a	O
case	O
of	O
homozygosity	O
for	O
c862t	O
(	O
R279W	O
)	O
until	O
we	O
analysed	O
DNA	O
from	O
a	O
36	O
year	O
old	O
male	O
with	O
tall	O
-	O
normal	O
stature	O
(	O
180	O
cm	O
)	O
who	O
asked	O
for	O
genetic	O
counselling	O
for	O
suspected	O
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
.	O

He	O
was	O
treated	O
for	O
club	B-Disease
foot	I-Disease
and	O
hip	B-Disease
dysplasia	I-Disease
at	O
birth	O
.	O

Skeletal	O
changes	O
consistent	O
with	O
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
,	O
with	O
the	O
peculiar	O
finding	O
of	O
a	O
double	B-Disease
layered	I-Disease
patella	I-Disease
,	O
were	O
recognised	O
during	O
childhood	O
.	O

Cleft	B-Disease
palate	I-Disease
,	O
swelling	B-Disease
of	I-Disease
the	I-Disease
ear	I-Disease
pinna	I-Disease
,	O
and	O
hitch	B-Disease
hiker	I-Disease
thumb	I-Disease
were	O
absent	O
.	O

He	O
was	O
found	O
to	O
be	O
homozygous	O
,	O
and	O
both	O
healthy	O
parents	O
heterozygous	O
,	O
for	O
the	O
R279W	O
mutation	O
in	O
DTDST	O
,	O
and	O
his	O
fibroblasts	O
showed	O
a	O
sulphate	O
incorporation	O
defect	O
typical	O
of	O
DTDST	B-Disease
disorders	I-Disease
.	O

Counselling	O
was	O
given	O
for	O
a	O
recessive	B-Disease
disorder	I-Disease
,	O
thereby	O
considerably	O
reducing	O
the	O
probability	O
of	O
affected	O
offspring	O
.	O

Multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
is	O
more	O
frequently	O
caused	O
by	O
dominant	O
mutations	O
in	O
the	O
COMP	O
(	O
EDM1	B-Disease
,	O
McKusick	O
132400	O
)	O
and	O
COL9A2	O
genes	O
(	O
EDM2	B-Disease
,	O
McKusick	O
600204	O
)	O
.	O

A	O
few	O
other	O
patients	O
and	O
families	O
with	O
features	O
similar	O
to	O
our	O
proband	O
have	O
been	O
described	O
previously	O
and	O
considered	O
to	O
have	O
autosomal	O
recessive	O
MED	B-Disease
(	O
EDM4	B-Disease
,	O
McKusick	O
226900	O
)	O
.	O

This	O
observation	O
confirms	O
the	O
existence	O
of	O
this	O
entity	O
and	O
assigns	O
it	O
to	O
the	O
phenotypic	O
spectrum	O
associated	O
with	O
mutations	O
at	O
the	O
DTDST	O
locus	O
.	O
.	O

Homozygosity	O
for	O
a	O
novel	O
DTDST	O
mutation	O
in	O
a	O
child	O
with	O
a	O
'	O
broad	O
bone	O
-	O
platyspondylic	O
'	O
variant	O
of	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O

Atypical	O
or	O
variant	O
forms	O
of	O
well	O
-	O
known	O
chondrodysplasias	B-Disease
may	O
pose	O
diagnostic	O
problems	O
.	O

We	O
report	O
on	O
a	O
girl	O
with	O
clinical	O
features	O
suggesting	O
diastrophic	B-Disease
dysplasia	I-Disease
but	O
with	O
unusual	O
radiographic	O
features	O
including	O
severe	O
platyspondyly	B-Disease
,	O
wide	O
metaphyses	O
,	O
and	O
fibular	O
overgrowth	O
,	O
which	O
are	O
partially	O
reminiscent	O
of	O
metatropic	B-Disease
dysplasia	I-Disease
.	O

The	O
diagnosis	O
was	O
clarified	O
by	O
molecular	O
analysis	O
of	O
the	O
DTDST	O
gene	O
,	O
which	O
revealed	O
homozygosity	O
for	O
a	O
previously	O
undescribed	O
mutation	O
leading	O
to	O
a	O
Q454P	O
substitution	O
in	O
the	O
10th	O
transmembrane	O
domain	O
of	O
the	O
DTDST	O
sulfate	O
transporter	O
.	O

Molecular	O
analysis	O
may	O
be	O
of	O
particular	O
value	O
in	O
such	O
atypical	O
cases	O
.	O
.	O

The	O
type	O
of	O
somatic	O
mutation	O
at	O
APC	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
is	O
determined	O
by	O
the	O
site	O
of	O
the	O
germline	O
mutation	O
:	O
a	O
new	O
facet	O
to	O
Knudson	O
'	O
s	O
'	O
two	O
-	O
hit	O
'	O
hypothesis	O
.	O

APC	O
is	O
often	O
cited	O
as	O
a	O
prime	O
example	O
of	O
a	O
tumor	B-Disease
suppressor	O
gene	O
.	O

Truncating	O
germline	O
and	O
somatic	O
mutations	O
(	O
or	O
,	O
infrequently	O
,	O
allelic	O
loss	O
)	O
occur	O
in	O
tumors	B-Disease
in	O
FAP	B-Disease
(	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
)	O
.	O

Most	O
sporadic	B-Disease
colorectal	I-Disease
cancers	I-Disease
also	O
have	O
two	O
APC	B-Disease
mutations	O
.	O

Clues	O
from	O
attenuated	B-Disease
polyposis	I-Disease
,	O
missense	O
germline	O
variants	O
with	O
mild	O
disease	O
and	O
the	O
somatic	O
mutation	O
cluster	O
region	O
(	O
codons	O
1	O
,	O
250	O
-	O
1	O
,	O
450	O
)	O
indicate	O
,	O
however	O
,	O
that	O
APC	B-Disease
mutations	O
might	O
not	O
result	O
in	O
simple	O
loss	O
of	O
protein	O
function	O
.	O

We	O
have	O
found	O
that	O
FAP	B-Disease
patients	O
with	O
germline	O
APC	B-Disease
mutations	O
within	O
a	O
small	O
region	O
(	O
codons	O
1	O
,	O
194	O
-	O
1	O
,	O
392	O
at	O
most	O
)	O
mainly	O
show	O
allelic	O
loss	O
in	O
their	O
colorectal	B-Disease
adenomas	I-Disease
,	O
in	O
contrast	O
to	O
other	O
FAP	B-Disease
patients	O
,	O
whose	O
second	O
hits	O
tend	O
to	O
occur	O
by	O
truncating	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O

Our	O
results	O
indicate	O
that	O
different	O
APC	B-Disease
mutations	O
provide	O
cells	O
with	O
different	O
selective	O
advantages	O
,	O
with	O
mutations	O
close	O
to	O
codon	O
1	O
,	O
300	O
providing	O
the	O
greatest	O
advantage	O
.	O

Allelic	O
loss	O
is	O
selected	O
strongly	O
in	O
cells	O
with	O
one	O
mutation	O
near	O
codon	O
1	O
,	O
300	O
.	O

A	O
different	O
germline	O
-	O
somatic	O
APC	B-Disease
mutation	O
association	O
exists	O
in	O
FAP	B-Disease
desmoids	I-Disease
.	O

APC	O
is	O
not	O
,	O
therefore	O
,	O
a	O
classical	O
tumor	B-Disease
suppressor	O
.	O

Our	O
findings	O
also	O
indicate	O
a	O
new	O
mechanism	O
for	O
disease	O
severity	O
if	O
a	O
broader	O
spectrum	O
of	O
mutations	O
is	O
selected	O
in	O
tumors	B-Disease
,	O
the	O
somatic	O
mutation	O
rate	O
is	O
effectively	O
higher	O
and	O
more	O
tumors	B-Disease
grow	O
.	O
.	O

Mxi1	O
mutations	O
in	O
human	O
neurofibrosarcomas	B-Disease
.	O

Mxi1	O
is	O
thought	O
to	O
negatively	O
regulate	O
Myc	O
function	O
and	O
may	O
therefore	O
be	O
a	O
potential	O
tumor	B-Disease
suppressor	O
gene	O
.	O

Little	O
effort	O
has	O
yet	O
been	O
made	O
to	O
find	O
alterations	O
involving	O
this	O
gene	O
in	O
human	O
solid	B-Disease
tumors	I-Disease
.	O

We	O
screened	O
31	O
human	O
gastric	B-Disease
cancers	I-Disease
,	O
7	O
esophageal	B-Disease
cancers	I-Disease
,	O
85	O
bone	B-Disease
and	I-Disease
soft	I-Disease
tissue	I-Disease
tumors	I-Disease
of	O
various	O
types	O
,	O
including	O
4	O
neurofibrosarcomas	B-Disease
.	O

We	O
also	O
examined	O
29	O
human	O
tumor	B-Disease
cell	O
lines	O
consisting	O
of	O
12	O
esophageal	B-Disease
cancers	I-Disease
,	O
7	O
glioma	B-Disease
/	O
glioblastomas	B-Disease
and	O
10	O
others	O
for	O
Mxi1	O
mutations	O
in	O
exons	O
1	O
,	O
2	O
,	O
4	O
(	O
HLH	O
domain	O
)	O
,	O
5	O
and	O
6	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
subsequent	O
sequencing	O
revealed	O
three	O
distinct	O
polymorphisms	O
in	O
the	O
intron	O
-	O
exon	O
boundary	O
upstream	O
from	O
exon	O
6	O
.	O

We	O
discovered	O
a	O
missense	O
mutation	O
,	O
GCA	O
to	O
GTA	O
(	O
Ala	O
54	O
Val	O
)	O
,	O
in	O
exon	O
2	O
in	O
a	O
neurofibrosarcoma	B-Disease
patient	O
(	O
case	O
1	O
)	O
,	O
two	O
missense	O
mutations	O
,	O
AAA	O
to	O
CAA	O
(	O
Lys	O
118	O
Gln	O
)	O
and	O
GAA	O
to	O
GGA	O
(	O
Glu	O
154	O
Gly	O
)	O
in	O
exon	O
5	O
of	O
another	O
neurofibrosarcoma	B-Disease
patient	O
(	O
case	O
2	O
)	O
,	O
and	O
3	O
amino	O
acid	O
substitutions	O
,	O
GTG	O
to	O
GCG	O
(	O
Val	O
179	O
Ala	O
)	O
,	O
GTT	O
to	O
GCT	O
(	O
Val	O
181	O
Ala	O
)	O
and	O
TTC	O
to	O
CTC	O
(	O
Phe	O
186	O
Leu	O
)	O
,	O
in	O
a	O
third	O
neurofibrosarcoma	B-Disease
patient	O
(	O
case	O
3	O
)	O
.	O

In	O
case	O
3	O
,	O
loss	O
of	O
heterozygosity	O
was	O
also	O
demonstrated	O
by	O
informative	O
(	O
TTC	O
)	O
3	O
/	O
(	O
TTC	O
)	O
2	O
polymorphism	O
.	O

Our	O
data	O
demonstrate	O
that	O
mutations	O
occur	O
in	O
the	O
Mxi1	O
gene	O
in	O
neurofibrosarcoma	B-Disease
.	O

Missense	O
mutations	O
in	O
the	O
functional	O
domain	O
of	O
Mxi1	O
in	O
these	O
cases	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neurofibrosarcoma	B-Disease
.	O
.	O

A	O
population	O
-	O
based	O
study	O
of	O
the	O
clinical	O
expression	O
of	O
the	O
hemochromatosis	B-Disease
gene	O
.	O

BACKGROUND	O
AND	O
METHODS	O
Hereditary	B-Disease
hemochromatosis	I-Disease
is	O
associated	O
with	O
homozygosity	O
for	O
the	O
C282Y	O
mutation	O
in	O
the	O
hemochromatosis	B-Disease
(	O
HFE	O
)	O
gene	O
on	O
chromosome	O
6	O
,	O
elevated	O
serum	O
transferrin	O
saturation	O
,	O
and	O
excess	B-Disease
iron	I-Disease
deposits	I-Disease
throughout	O
the	O
body	O
.	O

To	O
assess	O
the	O
prevalence	O
and	O
clinical	O
expression	O
of	O
the	O
HFE	O
gene	O
,	O
we	O
conducted	O
a	O
population	O
-	O
based	O
study	O
in	O
Busselton	O
,	O
Australia	O
.	O

In	O
1994	O
,	O
we	O
obtained	O
blood	O
samples	O
for	O
the	O
determination	O
of	O
serum	O
transferrin	O
saturation	O
and	O
ferritin	O
levels	O
and	O
the	O
presence	O
or	O
absence	O
of	O
the	O
C282Y	O
mutation	O
and	O
the	O
H63D	O
mutation	O
(	O
which	O
may	O
contribute	O
to	O
increased	O
hepatic	O
iron	O
levels	O
)	O
in	O
3011	O
unrelated	O
white	O
adults	O
.	O

We	O
evaluated	O
all	O
subjects	O
who	O
had	O
persistently	O
elevated	O
transferrin	O
-	O
saturation	O
values	O
(	O
45	O
percent	O
or	O
higher	O
)	O
or	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
.	O

We	O
recommended	O
liver	O
biopsy	O
for	O
subjects	O
with	O
serum	O
ferritin	O
levels	O
of	O
300	O
ng	O
per	O
milliliter	O
or	O
higher	O
.	O

The	O
subjects	O
were	O
followed	O
for	O
up	O
to	O
four	O
years	O
.	O

RESULTS	O
Sixteen	O
of	O
the	O
subjects	O
(	O
0	O
.	O
5	O
percent	O
)	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
,	O
and	O
424	O
(	O
14	O
.	O
1	O
percent	O
)	O
were	O
heterozygous	O
.	O

The	O
serum	O
transferrin	O
saturation	O
was	O
45	O
percent	O
or	O
higher	O
in	O
15	O
of	O
the	O
16	O
who	O
were	O
homozygous	O
;	O
in	O
1	O
subject	O
it	O
was	O
43	O
percent	O
.	O

Four	O
of	O
the	O
homozygous	O
subjects	O
had	O
previously	O
been	O
given	O
a	O
diagnosis	O
of	O
hemochromatosis	B-Disease
,	O
and	O
12	O
had	O
not	O
.	O

Seven	O
of	O
these	O
12	O
patients	O
had	O
elevated	O
serum	O
ferritin	O
levels	O
in	O
1994	O
;	O
6	O
of	O
the	O
7	O
had	O
further	O
increases	O
in	O
1998	O
,	O
and	O
1	O
had	O
a	O
decrease	O
,	O
although	O
the	O
value	O
remained	O
elevated	O
.	O

The	O
serum	O
ferritin	O
levels	O
in	O
the	O
four	O
other	O
homozygous	O
patients	O
remained	O
in	O
the	O
normal	O
range	O
.	O

Eleven	O
of	O
the	O
16	O
homozygous	O
subjects	O
underwent	O
liver	O
biopsy	O
;	O
3	O
had	O
hepatic	B-Disease
fibrosis	I-Disease
,	O
and	O
1	O
,	O
who	O
had	O
a	O
history	O
of	O
excessive	B-Disease
alcohol	I-Disease
consumption	I-Disease
,	O
had	O
cirrhosis	B-Disease
and	O
mild	O
microvesicular	B-Disease
steatosis	I-Disease
.	O

Eight	O
of	O
the	O
16	O
homozygous	O
subjects	O
had	O
clinical	O
findings	O
that	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
,	O
such	O
as	O
hepatomegaly	B-Disease
,	O
skin	B-Disease
pigmentation	I-Disease
,	O
and	O
arthritis	B-Disease
.	O

CONCLUSIONS	O
In	O
a	O
population	O
of	O
white	O
adults	O
of	O
northern	O
European	O
ancestry	O
,	O
0	O
.	O

5	O
percent	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
in	O
the	O
HFE	O
gene	O
.	O

However	O
,	O
only	O
half	O
of	O
those	O
who	O
were	O
homozygous	O
had	O
clinical	O
features	O
of	O
hemochromatosis	B-Disease
,	O
and	O
one	O
quarter	O
had	O
serum	O
ferritin	O
levels	O
that	O
remained	O
normal	O
over	O
a	O
four	O
-	O
year	O
period	O
.	O

Large	O
heterozygous	O
deletion	O
masquerading	O
as	O
homozygous	O
missense	O
mutation	O
:	O
a	O
pitfall	O
in	O
diagnostic	O
mutation	O
analysis	O
.	O

The	O
clinical	O
use	O
of	O
molecular	O
analyses	O
in	O
recessive	B-Disease
disorders	I-Disease
relies	O
on	O
the	O
exact	O
characterization	O
of	O
both	O
mutant	O
alleles	O
in	O
the	O
affected	O
patient	O
.	O

This	O
can	O
be	O
problematic	O
when	O
only	O
part	O
of	O
the	O
gene	O
is	O
examined	O
or	O
when	O
relevant	O
DNA	O
alterations	O
are	O
not	O
recognized	O
by	O
standard	O
methods	O
.	O

We	O
present	O
a	O
child	O
in	O
whom	O
phenylketonuria	B-Disease
was	O
apparently	O
caused	O
by	O
homozygosity	O
for	O
the	O
mutation	O
E390G	O
in	O
exon	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
.	O

However	O
,	O
the	O
clinical	O
severity	O
of	O
the	O
disease	O
was	O
not	O
quite	O
as	O
mild	O
as	O
expected	O
,	O
the	O
mutation	O
was	O
not	O
identified	O
in	O
the	O
father	O
despite	O
confirmed	O
paternity	O
,	O
and	O
the	O
paternal	O
allele	O
showed	O
a	O
highly	O
unusual	O
pattern	O
of	O
polymorphic	O
markers	O
in	O
the	O
PAH	O
gene	O
.	O

Presence	O
of	O
a	O
large	O
deletion	O
involving	O
exons	O
9	O
,	O
10	O
and	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
was	O
confirmed	O
by	O
long	O
-	O
range	O
PCR	O
.	O

Diagnostic	O
DNA	O
analyses	O
should	O
include	O
a	O
comprehensive	O
examination	O
of	O
the	O
whole	O
relevant	O
gene	O
in	O
the	O
patient	O
and	O
confirmation	O
of	O
carrier	O
status	O
in	O
both	O
parents	O
.	O
.	O

Early	O
onset	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
a	O
boy	O
with	O
emerin	O
gene	O
deletion	O
.	O

A	O
boy	O
developed	O
contractures	B-Disease
of	I-Disease
the	I-Disease
Achilles	I-Disease
tendons	I-Disease
at	O
3	O
years	O
and	O
of	O
the	O
postcervical	O
muscles	O
at	O
7	O
years	O
,	O
although	O
neither	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
nor	O
cardiac	B-Disease
abnormality	I-Disease
were	O
recognized	O
by	O
the	O
age	O
of	O
9	O
years	O
.	O

Muscle	O
computed	O
tomography	O
scanning	O
revealed	O
changes	O
characteristic	O
of	O
muscle	O
involvement	O
.	O

Emerin	O
was	O
not	O
detected	O
in	O
the	O
biopsied	O
muscle	O
,	O
and	O
RT	O
-	O
PCR	O
and	O
PCR	O
-	O
based	O
genomic	O
DNA	O
analyses	O
of	O
the	O
emerin	O
gene	O
demonstrated	O
no	O
amplification	O
product	O
in	O
the	O
patient	O
.	O

These	O
results	O
confirmed	O
the	O
diagnosis	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
,	O
and	O
reinforce	O
the	O
necessity	O
of	O
molecular	O
genetic	O
diagnosis	O
of	O
the	O
membrane	O
protein	O
emerin	O
in	O
younger	O
patients	O
with	O
possible	O
EDMD	B-Disease
before	O
appearance	O
of	O
the	O
typical	O
symptoms	O
,	O
to	O
avoid	O
sudden	B-Disease
cardiac	I-Disease
death	I-Disease
.	O
.	O

Duchenne	B-Disease
/	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
:	O
correlation	O
of	O
phenotype	O
by	O
electroretinography	O
with	O
sites	O
of	O
dystrophin	O
mutations	O
.	O

The	O
dark	O
-	O
adapted	O
electroretinogram	O
(	O
ERG	O
)	O
of	O
patients	O
with	O
Duchenne	B-Disease
and	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
/	O
BMD	B-Disease
)	O
shows	O
a	O
marked	O
reduction	O
in	O
b	O
-	O
wave	O
amplitude	O
.	O

Genotype	O
-	O
phenotype	O
studies	O
of	O
mouse	O
models	O
for	O
DMD	B-Disease
show	O
position	O
-	O
specific	O
effects	O
of	O
the	O
mutations	O
upon	O
the	O
phenotype	O
mice	O
with	O
5	O
defects	O
of	O
dystrophin	O
have	O
normal	O
ERGs	O
,	O
those	O
with	O
defects	O
in	O
the	O
central	O
region	O
have	O
a	O
normal	O
b	O
-	O
wave	O
amplitude	O
associated	O
with	O
prolonged	O
implicit	O
times	O
for	O
both	O
the	O
b	O
-	O
wave	O
and	O
oscillatory	O
potentials	O
,	O
and	O
mice	O
with	O
3	O
defects	O
have	O
a	O
phenotype	O
similar	O
to	O
that	O
seen	O
in	O
DMD	B-Disease
/	O
BMD	B-Disease
patients	O
.	O

The	O
mouse	O
studies	O
suggest	O
a	O
key	O
role	O
for	O
the	O
carboxyl	O
terminal	O
dystrophin	O
isoform	O
,	O
Dp260	O
,	O
in	O
retinal	O
electrophysiology	O
.	O

We	O
have	O
undertaken	O
a	O
systematic	O
evaluation	O
of	O
DMD	B-Disease
/	O
BMD	B-Disease
patients	O
through	O
clinical	O
examination	O
and	O
review	O
of	O
the	O
literature	O
in	O
order	O
to	O
determine	O
whether	O
the	O
position	O
-	O
specific	O
effects	O
of	O
mutations	O
noted	O
in	O
the	O
mouse	O
are	O
present	O
in	O
man	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
man	O
,	O
a	O
wider	O
variation	O
of	O
DMD	B-Disease
defects	I-Disease
correlate	O
with	O
reductions	O
in	O
the	O
b	O
-	O
wave	O
amplitude	O
.	O

Individuals	O
with	O
normal	O
ERGs	O
have	O
mutations	O
predominantly	O
located	O
5	O
of	O
the	O
transcript	O
initiation	O
site	O
of	O
Dp260	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
ERG	O
b	O
-	O
wave	O
phenotype	O
is	O
the	O
mutation	O
position	O
,	O
rather	O
than	O
muscle	B-Disease
disease	I-Disease
severity	O
.	O

Forty	O
-	O
six	O
per	O
cent	O
of	O
patients	O
with	O
mutations	O
5	O
of	O
the	O
Dp260	O
transcript	O
start	O
site	O
have	O
abnormal	O
ERGs	O
,	O
as	O
opposed	O
to	O
94	O
%	O
with	O
more	O
distal	O
mutations	O
.	O

The	O
human	O
genotype	O
-	O
phenotype	O
correlations	O
are	O
consistent	O
with	O
a	O
role	O
for	O
Dp260	O
in	O
normal	O
retinal	O
electrophysiology	O
and	O
may	O
also	O
reflect	O
the	O
expression	O
of	O
other	O
C	O
-	O
terminal	O
dystrophin	O
isoforms	O
and	O
their	O
contributions	O
to	O
retinal	O
signal	O
transmission	O
.	O
.	O

Cis	O
and	O
trans	O
effects	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
mutation	O
in	O
a	O
cell	O
culture	O
model	O
.	O

The	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
has	O
been	O
identified	O
as	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
3	O
-	O
UTR	O
)	O
of	O
the	O
DM	B-Disease
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
pathogenesis	O
remain	O
unknown	O
.	O

Studies	O
using	O
DM	B-Disease
patient	O
materials	O
have	O
often	O
produced	O
confusing	O
results	O
.	O

Therefore	O
,	O
to	O
study	O
the	O
effects	O
of	O
the	O
DM	B-Disease
mutation	O
in	O
a	O
controlled	O
environment	O
,	O
we	O
have	O
established	O
a	O
cell	O
culture	O
model	O
system	O
using	O
C2C12	O
mouse	O
myoblasts	O
.	O

By	O
expressing	O
chimeric	O
reporter	O
constructs	O
containing	O
a	O
reporter	O
gene	O
fused	O
to	O
a	O
human	O
DMPK	O
3	O
-	O
UTR	O
,	O
we	O
identified	O
both	O
cis	O
and	O
trans	O
effects	O
that	O
are	O
mediated	O
by	O
the	O
DM	B-Disease
mutation	O
.	O

Our	O
data	O
show	O
that	O
a	O
mutant	O
DMPK	O
3	O
-	O
UTR	O
,	O
with	O
as	O
few	O
as	O
57	O
CTGs	O
,	O
had	O
a	O
negative	O
cis	O
effect	O
on	O
protein	O
expression	O
and	O
resulted	O
in	O
the	O
aggregation	O
of	O
reporter	O
transcripts	O
into	O
discrete	O
nuclear	O
foci	O
.	O

We	O
determined	O
by	O
deletion	O
analysis	O
that	O
an	O
expanded	O
(	O
CTG	O
)	O
(	O
n	O
)	O
tract	O
alone	O
was	O
sufficient	O
to	O
mediate	O
these	O
cis	O
effects	O
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
the	O
normal	O
DMPK	O
3	O
-	O
UTR	O
mRNA	O
,	O
a	O
mutant	O
DMPK	O
3	O
-	O
UTR	O
mRNA	O
with	O
(	O
CUG	O
)	O
(	O
200	O
)	O
selectively	O
inhibited	O
myogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
.	O

Genetic	O
analysis	O
and	O
the	O
Cre	O
-	O
loxP	O
system	O
were	O
used	O
to	O
clearly	O
demonstrate	O
that	O
the	O
myoblast	O
fusion	O
defect	O
could	O
be	O
rescued	O
by	O
eliminating	O
the	O
expression	O
of	O
the	O
mutant	O
DMPK	O
3	O
-	O
UTR	O
transcript	O
.	O

Characterization	O
of	O
spontaneous	O
deletion	O
events	O
mapped	O
the	O
inhibitory	O
effect	O
to	O
the	O
(	O
CTG	O
)	O
(	O
n	O
)	O
expansion	O
and	O
/	O
or	O
the	O
3	O
end	O
of	O
the	O
DMPK	O
3	O
-	O
UTR	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
the	O
DM	B-Disease
mutation	O
acts	O
in	O
cis	O
to	O
reduce	O
protein	O
production	O
(	O
consistent	O
with	O
DMPK	B-Disease
haploinsufficiency	I-Disease
)	O
and	O
in	O
trans	O
as	O
a	O
riboregulator	O
to	O
inhibit	O
myogenesis	O
.	O
.	O

Coats	B-Disease
'	I-Disease
disease	I-Disease
of	O
the	O
retina	O
(	O
unilateral	B-Disease
retinal	I-Disease
telangiectasis	I-Disease
)	O
caused	O
by	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
:	O
a	O
role	O
for	O
norrin	O
in	O
retinal	O
angiogenesis	O
.	O

Coats	B-Disease
disease	I-Disease
is	O
characterized	O
by	O
abnormal	B-Disease
retinal	I-Disease
vascular	I-Disease
development	I-Disease
(	O
so	O
-	O
called	O
retinal	B-Disease
telangiectasis	I-Disease
)	O
which	O
results	O
in	O
massive	O
intraretinal	B-Disease
and	I-Disease
subretinal	I-Disease
lipid	I-Disease
accumulation	I-Disease
(	O
exudative	B-Disease
retinal	I-Disease
detachment	I-Disease
)	O
.	O

The	O
classical	O
form	O
of	O
Coats	B-Disease
disease	I-Disease
is	O
almost	O
invariably	O
isolated	O
,	O
unilateral	O
and	O
seen	O
in	O
males	O
.	O

A	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
Coats	B-Disease
disease	I-Disease
gave	O
birth	O
to	O
a	O
son	O
affected	O
by	O
Norrie	B-Disease
disease	I-Disease
.	O

Both	O
carried	O
a	O
missense	O
mutation	O
within	O
the	O
NDP	O
gene	O
on	O
chromosome	O
Xp11	O
.	O

2	O
2	O
.	O

Subsequently	O
analysis	O
of	O
the	O
retinas	O
of	O
nine	O
enucleated	O
eyes	O
from	O
males	O
with	O
Coats	B-Disease
disease	I-Disease
demonstrated	O
in	O
one	O
a	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
was	O
not	O
present	O
within	O
non	O
-	O
retinal	O
tissue	O
.	O

We	O
suggest	O
that	O
Coats	B-Disease
telangiectasis	I-Disease
is	O
secondary	O
to	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
results	O
in	O
a	O
deficiency	B-Disease
of	I-Disease
norrin	I-Disease
(	O
the	O
protein	O
product	O
of	O
the	O
NDP	O
gene	O
)	O
within	O
the	O
developing	O
retina	O
.	O

This	O
supports	O
recent	O
observations	O
that	O
the	O
protein	O
is	O
critical	O
for	O
normal	O
retinal	O
vasculogenesis	O
.	O

Hereditary	O
TP53	O
codon	O
292	O
and	O
somatic	O
P16INK4A	O
codon	O
94	O
mutations	O
in	O
a	O
Li	B-Disease
-	I-Disease
Fraumeni	I-Disease
syndrome	I-Disease
family	O
.	O

Li	B-Disease
-	I-Disease
Fraumeni	I-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
that	O
is	O
characterized	O
by	O
various	O
types	O
of	O
cancer	B-Disease
in	O
childhood	O
and	O
adult	O
cases	O
.	O

Although	O
hereditary	O
TP53	O
mutation	O
is	O
very	O
rare	O
in	O
different	O
human	O
cancers	B-Disease
,	O
it	O
has	O
been	O
frequently	O
reported	O
in	O
Li	B-Disease
-	I-Disease
Fraumeni	I-Disease
syndrome	I-Disease
.	O

On	O
the	O
other	O
hand	O
,	O
hereditary	O
mutations	O
of	O
TP57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
,	O
which	O
affect	O
the	O
cell	O
cycle	O
similar	O
to	O
TP53	O
,	O
were	O
observed	O
in	O
some	O
types	O
of	O
cancer	B-Disease
.	O

In	O
a	O
Turkish	O
family	O
with	O
the	O
diagnosis	O
of	O
Li	B-Disease
-	I-Disease
Fraumeni	I-Disease
syndrome	I-Disease
,	O
we	O
analyzed	O
the	O
mutation	O
pattern	O
of	O
TP53	O
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
in	O
the	O
peripheral	O
blood	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
homo	O
/	O
hemizygous	O
deletion	O
)	O
pattern	O
of	O
TP53	O
and	O
P15INK4B	O
/	O
P16INK4A	O
in	O
two	O
tumor	B-Disease
tissues	O
.	O

The	O
propositus	O
had	O
a	O
seminoma	B-Disease
,	O
his	O
daughter	O
a	O
medulloblastoma	B-Disease
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins	O
,	O
a	O
TP53	O
codon	O
292	O
missense	O
point	O
mutation	O
(	O
AAA	O
-	O
-	O
>	O
ATA	O
;	O
Lys	O
-	O
-	O
>	O
Ile	O
)	O
in	O
the	O
peripheral	O
blood	O
cells	O
.	O

Tumor	O
tissue	O
obtained	O
from	O
the	O
propositus	O
with	O
the	O
seminoma	B-Disease
revealed	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
.	O

In	O
the	O
analyses	O
of	O
tumor	B-Disease
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter	O
,	O
a	O
P16INK4A	O
codon	O
94	O
missense	O
point	O
mutation	O
(	O
GCG	O
-	O
-	O
>	O
GAG	O
;	O
Ala	O
-	O
-	O
>	O
Glu	O
)	O
was	O
observed	O
with	O
the	O
hereditary	O
TP53	O
mutation	O
.	O

P16INK4A	O
codon	O
94	O
mutation	O
observed	O
in	O
our	O
family	O
is	O
a	O
novel	O
mutation	O
in	O
Li	B-Disease
-	I-Disease
Fraumeni	I-Disease
syndrome	I-Disease
.	O

No	O
other	O
gene	O
alteration	O
in	O
TP53	O
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
was	O
observed	O
.	O

Existence	O
of	O
the	O
P16INK4A	O
mutation	O
and	O
the	O
hereditary	O
TP53	O
mutation	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
(	O
seminoma	B-Disease
/	O
medulloblastoma	B-Disease
)	O
may	O
be	O
evidence	O
for	O
a	O
common	O
mechanism	O
involved	O
in	O
tumorogenesis	B-Disease
.	O

The	O
gene	O
alterations	O
in	O
TP53	O
and	O
P16INK4A	O
genes	O
may	O
be	O
used	O
as	O
tumor	B-Disease
markers	O
in	O
our	O
family	O
.	O
.	O

A	O
novel	O
mutation	O
in	O
the	O
sodium	O
/	O
iodide	O
symporter	O
gene	O
in	O
the	O
largest	O
family	O
with	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
.	O

We	O
previously	O
reported	O
nine	O
children	O
with	O
an	O
autosomally	O
recessive	O
form	O
of	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
an	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
a	O
large	O
Hutterite	O
family	O
with	O
extensive	O
consanguinity	O
living	O
in	O
central	O
Canada	O
.	O

Since	O
the	O
original	O
report	O
,	O
we	O
have	O
diagnosed	O
congenital	B-Disease
hypothyroidism	I-Disease
by	O
newborn	O
TSH	O
screening	O
in	O
9	O
additional	O
children	O
from	O
the	O
family	O
.	O

We	O
performed	O
direct	O
sequencing	O
of	O
the	O
PCR	O
products	O
of	O
each	O
NIS	O
(	O
sodium	O
/	O
iodide	O
symporter	O
)	O
gene	O
exon	O
with	O
flanking	O
introns	O
amplified	O
from	O
genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
cells	O
of	O
the	O
patients	O
.	O

We	O
identified	O
a	O
novel	O
NIS	O
gene	O
mutation	O
,	O
G395R	O
(	O
Gly395	O
-	O
-	O
>	O
Arg	O
;	O
GGA	O
-	O
-	O
>	O
AGA	O
)	O
,	O
in	O
10	O
patients	O
examined	O
in	O
the	O
present	O
study	O
.	O

All	O
of	O
the	O
parents	O
tested	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
suggesting	O
that	O
the	O
patients	O
were	O
homozygous	O
.	O

The	O
mutation	O
was	O
located	O
in	O
the	O
10th	O
transmembrane	O
helix	O
.	O

Expression	O
experiments	O
by	O
transfection	O
of	O
the	O
mutant	O
NIS	O
complimentary	O
DNA	O
into	O
COS	O
-	O
7	O
cells	O
showed	O
no	O
perchlorate	O
-	O
sensitive	O
iodide	O
uptake	O
,	O
confirming	O
that	O
the	O
mutation	O
is	O
the	O
direct	O
cause	O
of	O
the	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
these	O
patients	O
.	O

A	O
patient	O
who	O
showed	O
an	O
intermediate	O
saliva	O
/	O
serum	O
technetium	O
ratio	O
(	O
14	O
.	O
0	O
;	O
normal	O
,	O
>	O
or	O
=	O
20	O
)	O
and	O
was	O
considered	O
to	O
have	O
a	O
partial	O
or	O
less	O
severe	O
defect	O
in	O
the	O
previous	O
report	O
(	O
IX	O
-	O
24	O
)	O
did	O
not	O
have	O
a	O
NIS	O
gene	O
mutation	O
.	O

It	O
is	O
now	O
possible	O
to	O
use	O
gene	O
diagnostics	O
of	O
this	O
unique	O
NIS	O
mutation	O
to	O
identify	O
patients	O
with	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
an	O
iodide	B-Disease
transport	I-Disease
defect	I-Disease
in	O
this	O
family	O
and	O
to	O
determine	O
the	O
carrier	O
state	O
of	O
potential	O
parents	O
for	O
genetic	O
counseling	O
and	O
arranging	O
rapid	O
and	O
early	O
diagnosis	O
of	O
their	O
infants	O
.	O

Molecular	O
analysis	O
in	O
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
:	O
early	O
diagnosis	O
of	O
an	O
asymptomatic	O
carrier	O
.	O

Familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
FNDI	B-Disease
)	O
is	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hormone	I-Disease
arginine	I-Disease
vasopressin	I-Disease
(	O
AVP	O
)	O
and	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
analyzed	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
in	O
a	O
Spanish	O
kindred	O
.	O

Studies	O
were	O
performed	O
on	O
seven	O
members	O
(	O
four	O
clinically	O
affected	O
)	O
of	O
the	O
family	O
.	O

Patients	O
were	O
diagnosed	O
at	O
the	O
Hospital	O
Universitario	O
Gregorio	O
Maranon	O
(	O
Madrid	O
,	O
Spain	O
)	O
.	O

The	O
entire	O
coding	O
region	O
of	O
the	O
AVP	O
-	O
NPII	O
gene	O
of	O
all	O
family	O
members	O
was	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
.	O

All	O
affected	O
individuals	O
presented	O
a	O
missense	O
mutation	O
(	O
G1757	O
-	O
-	O
>	O
A	O
)	O
that	O
replaces	O
glycine	O
at	O
position	O
23	O
with	O
arginine	O
within	O
the	O
NPII	O
domain	O
.	O

The	O
substitution	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
and	O
was	O
present	O
in	O
heterozygosis	O
.	O

Additionally	O
,	O
one	O
of	O
the	O
asymptomatic	O
relatives	O
(	O
a	O
girl	O
8	O
months	O
old	O
at	O
the	O
time	O
of	O
study	O
)	O
was	O
identified	O
as	O
carrier	O
of	O
the	O
same	O
mutation	O
and	O
developed	O
the	O
disease	O
3	O
months	O
later	O
.	O

The	O
alteration	O
found	O
in	O
the	O
second	O
exon	O
of	O
the	O
gene	O
in	O
this	O
family	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
disease	O
,	O
as	O
all	O
individuals	O
harboring	O
the	O
mutation	O
had	O
been	O
previously	O
diagnosed	O
or	O
have	O
eventually	O
developed	O
FNDI	B-Disease
.	O

Identification	O
of	O
the	O
molecular	O
defect	O
underlying	O
FNDI	B-Disease
in	O
affected	O
families	O
is	O
a	O
powerful	O
tool	O
for	O
early	O
asymptomatic	O
diagnosis	O
in	O
infants	O
.	O
.	O

Deficit	O
of	O
in	O
vivo	O
mitochondrial	O
ATP	O
production	O
in	O
patients	O
with	O
Friedreich	B-Disease
ataxia	I-Disease
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
the	O
most	O
common	O
of	O
the	O
inherited	B-Disease
ataxias	I-Disease
,	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
degenerative	I-Disease
disorder	I-Disease
,	O
characterized	O
clinically	O
by	O
onset	O
before	O
the	O
age	O
of	O
25	O
of	O
progressive	B-Disease
gait	I-Disease
and	I-Disease
limb	I-Disease
ataxia	I-Disease
,	O
absence	B-Disease
of	I-Disease
deep	I-Disease
tendon	I-Disease
reflexes	I-Disease
,	O
extensor	B-Disease
plantar	I-Disease
responses	I-Disease
,	O
and	O
loss	B-Disease
of	I-Disease
position	I-Disease
and	I-Disease
vibration	I-Disease
sense	I-Disease
in	O
the	O
lower	O
limbs	O
.	O

FRDA	B-Disease
is	O
caused	O
by	O
a	O
GAA	O
triplet	O
expansion	O
in	O
the	O
first	O
intron	O
of	O
the	O
FRDA	B-Disease
gene	O
on	O
chromosome	O
9q13	O
in	O
97	O
%	O
of	O
patients	O
.	O

The	O
FRDA	B-Disease
gene	O
encodes	O
a	O
widely	O
expressed	O
210	O
-	O
aa	O
protein	O
,	O
frataxin	O
,	O
which	O
is	O
located	O
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
FRDA	B-Disease
patients	O
.	O

Frataxin	O
function	O
is	O
still	O
unknown	O
but	O
the	O
knockout	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
gene	O
(	O
YFH1	O
)	O
showed	O
a	O
severe	O
defect	O
of	O
mitochondrial	O
respiration	O
and	O
loss	O
of	O
mtDNA	O
associated	O
with	O
elevated	O
intramitochondrial	O
iron	O
.	O

Here	O
we	O
report	O
in	O
vivo	O
evidence	O
of	O
impaired	O
mitochondrial	O
respiration	O
in	O
skeletal	O
muscle	O
of	O
FRDA	B-Disease
patients	O
.	O

Using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	O
rate	O
of	O
muscle	O
mitochondrial	O
ATP	O
production	O
(	O
V	O
(	O
max	O
)	O
)	O
below	O
the	O
normal	O
range	O
in	O
all	O
12	O
FRDA	B-Disease
patients	O
and	O
a	O
strong	O
negative	O
correlation	O
between	O
mitochondrial	O
V	O
(	O
max	O
)	O
and	O
the	O
number	O
of	O
GAA	O
repeats	O
in	O
the	O
smaller	O
allele	O
.	O

Our	O
results	O
show	O
that	O
FRDA	B-Disease
is	O
a	O
nuclear	O
-	O
encoded	O
mitochondrial	B-Disease
disorder	I-Disease
affecting	O
oxidative	O
phosphorylation	O
and	O
give	O
a	O
rationale	O
for	O
treatments	O
aimed	O
to	O
improve	O
mitochondrial	O
function	O
in	O
this	O
condition	O
.	O
.	O

Identification	O
of	O
a	O
novel	O
R21X	O
mutation	O
in	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
ARG1	O
)	O
in	O
four	O
Portuguese	O
patients	O
with	O
argininemia	B-Disease
.	O

Argininemia	B-Disease
is	O
a	O
rare	O
autossomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
cytosolic	I-Disease
liver	I-Disease
-	I-Disease
type	I-Disease
arginase	I-Disease
enzyme	I-Disease
(	O
L	O
-	O
arginine	O
urea	O
-	O
hydrolase	O
;	O
E	O
.	O
C	O
.	O
3	O
.	O
5	O
.	O
3	O
.	O
1	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
molecular	O
basis	O
for	O
argininemia	B-Disease
in	O
four	O
unrelated	O
Portuguese	O
patients	O
(	O
two	O
from	O
northern	O
Portugal	O
and	O
two	O
from	O
Madeira	O
Island	O
)	O
we	O
performed	O
a	O
DNA	O
sequence	O
analysis	O
of	O
all	O
the	O
exons	O
and	O
exon	O
/	O
intron	O
boundaries	O
of	O
the	O
liver	O
-	O
type	O
arginase	O
gene	O
(	O
ARG1	O
)	O
.	O

All	O
patients	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
newly	O
identified	O
C	O
-	O
>	O
T	O
transition	O
in	O
codon	O
21	O
(	O
exon	O
2	O
)	O
substituting	O
arginine	O
for	O
a	O
premature	O
stop	O
codon	O
(	O
R21X	O
CGA	O
to	O
TGA	O
)	O
and	O
generating	O
a	O
NlaIII	O
restriction	O
site	O
.	O

Restriction	O
digestion	O
following	O
PCR	O
amplification	O
of	O
ARG1	O
exon	O
2	O
confirmed	O
the	O
presence	O
of	O
the	O
mutation	O
.	O

Mutation	O
of	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
results	O
in	O
truncation	O
of	O
mRNA	O
expressed	O
in	O
leucocytes	O
in	O
a	O
Japanese	O
family	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
.	O

OBJECTIVES	O
A	O
Japanese	O
family	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
was	O
investigated	O
for	O
a	O
sequence	O
alteration	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
.	O

The	O
expression	O
of	O
CYP27	O
has	O
been	O
mostly	O
explored	O
using	O
cultured	O
fibroblasts	O
,	O
prompting	O
the	O
examination	O
of	O
the	O
transcripts	O
from	O
blood	O
leucocytes	O
as	O
a	O
simple	O
and	O
rapid	O
technique	O
.	O

METHODS	O
An	O
alteration	O
in	O
CYP27	O
of	O
the	O
proband	O
was	O
searched	O
for	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
subsequent	O
sequencing	O
.	O

Samples	O
of	O
RNA	O
were	O
subjected	O
to	O
reverse	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
the	O
product	O
of	O
the	O
proband	O
was	O
amplified	O
with	O
nested	O
primers	O
and	O
sequenced	O
.	O

RESULTS	O
A	O
homozygous	O
G	O
to	O
A	O
transition	O
at	O
the	O
5	O
end	O
of	O
intron	O
7	O
was	O
detected	O
in	O
the	O
patient	O
.	O

In	O
RT	O
-	O
PCR	O
analysis	O
,	O
only	O
a	O
truncated	O
transcript	O
was	O
detected	O
in	O
the	O
patient	O
,	O
whereas	O
both	O
normal	O
and	O
truncated	O
transcripts	O
were	O
detected	O
in	O
the	O
siblings	O
.	O

The	O
sequencing	O
of	O
the	O
patients	O
cDNA	O
fragment	O
disclosed	O
a	O
direct	O
conjuction	O
of	O
exon	O
6	O
and	O
exon	O
8	O
.	O

CONCLUSION	O
The	O
mutation	O
at	O
splice	O
donor	O
site	O
and	O
the	O
truncation	O
of	O
mRNA	O
were	O
identical	O
with	O
those	O
of	O
a	O
recently	O
reported	O
Italian	O
patient	O
,	O
although	O
different	O
in	O
symptomatology	O
.	O

The	O
application	O
of	O
blood	O
leucocytes	O
can	O
be	O
a	O
simple	O
technique	O
on	O
analysing	O
a	O
constructive	O
abnormality	B-Disease
of	I-Disease
CYP27	I-Disease
mRNA	O
.	O
.	O

Clinical	O
and	O
molecular	O
genetic	O
analysis	O
of	O
19	O
Wolfram	B-Disease
syndrome	I-Disease
kindreds	O
demonstrating	O
a	O
wide	O
spectrum	O
of	O
mutations	O
in	O
WFS1	O
.	O

Wolfram	B-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disorder	I-Disease
characterized	O
by	O
juvenile	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
progressive	O
optic	B-Disease
atrophy	I-Disease
.	O

mtDNA	O
deletions	O
have	O
been	O
described	O
,	O
and	O
a	O
gene	O
(	O
WFS1	O
)	O
recently	O
has	O
been	O
identified	O
,	O
on	O
chromosome	O
4p16	O
,	O
encoding	O
a	O
predicted	O
890	O
amino	O
acid	O
transmembrane	O
protein	O
.	O

Direct	O
DNA	O
sequencing	O
was	O
done	O
to	O
screen	O
the	O
entire	O
coding	O
region	O
of	O
the	O
WFS1	O
gene	O
in	O
30	O
patients	O
from	O
19	O
British	O
kindreds	O
with	O
Wolfram	B-Disease
syndrome	I-Disease
.	O

DNA	O
was	O
also	O
screened	O
for	O
structural	O
rearrangements	O
(	O
deletions	O
and	O
duplications	O
)	O
and	O
point	O
mutations	O
in	O
mtDNA	O
.	O

No	O
pathogenic	O
mtDNA	O
mutations	O
were	O
found	O
in	O
our	O
cohort	O
.	O

We	O
identified	O
24	O
mutations	O
in	O
the	O
WFS1	O
gene	O
8	O
nonsense	O
mutations	O
,	O
8	O
missense	O
mutations	O
,	O
3	O
in	O
-	O
frame	O
deletions	O
,	O
1	O
in	O
-	O
frame	O
insertion	O
,	O
and	O
4	O
frameshift	O
mutations	O
.	O

Of	O
these	O
,	O
23	O
were	O
novel	O
mutations	O
,	O
and	O
most	O
occurred	O
in	O
exon	O
8	O
.	O

The	O
majority	O
of	O
patients	O
were	O
compound	O
heterozygotes	O
for	O
two	O
mutations	O
,	O
and	O
there	O
was	O
no	O
common	O
founder	O
mutation	O
.	O

The	O
data	O
were	O
also	O
analyzed	O
for	O
genotype	O
-	O
phenotype	O
relationships	O
.	O

Although	O
some	O
interesting	O
cases	O
were	O
noted	O
,	O
consideration	O
of	O
the	O
small	O
sample	O
size	O
and	O
frequency	O
of	O
each	O
mutation	O
indicated	O
no	O
clear	O
-	O
cut	O
correlations	O
between	O
any	O
of	O
the	O
observed	O
mutations	O
and	O
disease	O
severity	O
.	O

There	O
were	O
no	O
obvious	O
mutation	O
hot	O
spots	O
or	O
clusters	O
.	O

Hence	O
,	O
molecular	O
screening	O
for	O
Wolfram	B-Disease
syndrome	I-Disease
in	O
affected	O
families	O
and	O
for	O
Wolfram	B-Disease
syndrome	I-Disease
-	O
carrier	O
status	O
in	O
subjects	O
with	O
psychiatric	B-Disease
disorders	I-Disease
or	O
diabetes	B-Disease
mellitus	I-Disease
will	O
require	O
complete	O
analysis	O
of	O
exon	O
8	O
and	O
upstream	O
exons	O
.	O
.	O

Late	O
-	O
onset	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
:	O
a	O
subset	O
with	O
distinct	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O
.	O

To	O
determine	O
the	O
prevalence	O
and	O
characterize	O
demographic	O
,	O
clinical	O
,	O
and	O
genetic	O
features	O
of	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
of	O
late	O
onset	O
,	O
all	O
patients	O
experiencing	O
their	O
first	O
FMF	B-Disease
attack	O
at	O
age	O
40	O
years	O
or	O
more	O
were	O
identified	O
using	O
the	O
computerized	O
registry	O
of	O
our	O
FMF	B-Disease
clinic	O
,	O
and	O
then	O
thoroughly	O
interviewed	O
and	O
examined	O
.	O

The	O
control	O
group	O
consisted	O
of	O
40	O
consecutive	O
FMF	B-Disease
patients	O
,	O
who	O
arrived	O
at	O
the	O
FMF	B-Disease
clinic	O
for	O
their	O
regular	O
follow	O
-	O
up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	O
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination	O
.	O

The	O
severity	O
of	O
the	O
disease	O
in	O
patients	O
and	O
controls	O
was	O
determined	O
using	O
a	O
modified	O
score	O
,	O
developed	O
previously	O
.	O

Mutational	O
analysis	O
in	O
the	O
FMF	B-Disease
gene	O
was	O
performed	O
using	O
a	O
commercial	O
kit	O
.	O

Only	O
20	O
of	O
4000	O
(	O
0	O
.	O
5	O
%	O
)	O
patients	O
had	O
late	O
-	O
onset	O
FMF	B-Disease
.	O

These	O
patients	O
were	O
mostly	O
men	O
,	O
of	O
non	O
-	O
North	O
African	O
origin	O
,	O
P	O
<	O
0	O
.	O

05	O
compared	O
to	O
controls	O
.	O

All	O
had	O
abdominal	O
attacks	O
and	O
in	O
most	O
these	O
were	O
the	O
only	O
manifestation	O
of	O
their	O
disease	O
,	O
P	O
<	O
0	O
.	O

001	O
001	O
.	O

None	O
had	O
chronic	O
or	O
prolonged	O
manifestations	O
of	O
FMF	B-Disease
,	O
for	O
example	O
,	O
amyloidosis	B-Disease
,	O
chronic	B-Disease
arthritis	I-Disease
,	O
or	O
protracted	O
myalgia	B-Disease
,	O
P	O
<	O
0	O
.	O

001	O
.	O

The	O
response	O
to	O
treatment	O
was	O
good	O
despite	O
using	O
low	O
colchicine	O
dose	O
,	O
P	O
<	O
0	O
.	O

05	O
.	O

The	O
overall	O
severity	O
score	O
indicated	O
a	O
mild	O
disease	O
,	O
P	O
<	O
0	O
.	O

001	O
.	O

Mutational	O
analysis	O
revealed	O
absence	O
of	O
M694V	O
homozygosity	O
,	O
P	O
<	O
0	O
.	O

01	O
,	O
compared	O
to	O
our	O
regular	O
FMF	B-Disease
population	O
.	O

We	O
conclude	O
that	O
the	O
onset	O
of	O
FMF	B-Disease
in	O
a	O
late	O
age	O
defines	O
a	O
milder	O
form	O
of	O
disease	O
with	O
typical	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O

A	O
highly	O
accurate	O
,	O
low	O
cost	O
test	O
for	O
BRCA1	O
mutations	O
.	O

The	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
is	O
associated	O
with	O
a	O
high	O
frequency	O
of	O
BRCA1	O
mutations	O
.	O

However	O
,	O
the	O
widespread	O
use	O
of	O
BRCA1	O
testing	O
has	O
been	O
limited	O
to	O
date	O
by	O
three	O
principal	O
concerns	O
the	O
fear	O
of	O
loss	O
of	O
health	O
and	O
life	O
insurance	O
,	O
the	O
uncertain	O
clinical	O
value	O
of	O
a	O
positive	O
test	O
result	O
,	O
and	O
the	O
current	O
lack	O
of	O
an	O
inexpensive	O
and	O
sensitive	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
.	O

We	O
have	O
developed	O
an	O
inexpensive	O
system	O
for	O
gene	O
mutational	O
scanning	O
,	O
based	O
on	O
a	O
combination	O
of	O
extensive	O
multiplex	O
PCR	O
amplification	O
and	O
two	O
dimensional	O
electrophoresis	O
.	O

The	O
efficiency	O
of	O
this	O
system	O
,	O
as	O
a	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
,	O
was	O
evaluated	O
in	O
a	O
panel	O
of	O
60	O
samples	O
from	O
high	O
risk	O
women	O
,	O
14	O
of	O
which	O
contained	O
a	O
previously	O
identified	O
mutation	O
in	O
BRCA1	O
.	O

All	O
14	O
mutations	O
were	O
identified	O
,	O
as	O
well	O
as	O
an	O
additional	O
five	O
that	O
had	O
previously	O
escaped	O
detection	O
.	O

In	O
addition	O
to	O
the	O
19	O
mutations	O
,	O
a	O
total	O
of	O
15	O
different	O
polymorphic	O
variants	O
were	O
scored	O
,	O
most	O
of	O
which	O
were	O
recurring	O
.	O

All	O
were	O
confirmed	O
by	O
nucleotide	O
sequencing	O
.	O

The	O
cost	O
of	O
screening	O
per	O
sample	O
was	O
calculated	O
to	O
be	O
approximately	O
US	O
$	O
70	O
for	O
the	O
manual	O
technique	O
used	O
in	O
this	O
study	O
,	O
and	O
may	O
be	O
reduced	O
to	O
approximately	O
US	O
$	O
10	O
with	O
the	O
introduction	O
of	O
commercially	O
available	O
PCR	O
robotics	O
and	O
fluorescent	O
imaging	O
.	O

Implementation	O
of	O
this	O
method	O
of	O
mutation	O
screening	O
in	O
the	O
research	O
and	O
clinical	O
setting	O
should	O
permit	O
rapid	O
accrual	O
of	O
quantitative	O
data	O
on	O
genotype	O
-	O
phenotype	O
associations	O
for	O
the	O
evaluation	O
of	O
diagnostic	O
testing	O
.	O
.	O

Maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
14	I-Disease
in	O
a	O
boy	O
with	O
a	O
normal	O
karyotype	O
.	O

We	O
report	O
on	O
a	O
boy	O
with	O
a	O
maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
14	I-Disease
(	O
UPD	B-Disease
(	O
14	O
)	O
)	O
.	O

At	O
7	O
years	O
of	O
age	O
he	O
was	O
referred	O
to	O
us	O
by	O
the	O
paediatrician	O
because	O
of	O
symptoms	O
of	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

He	O
showed	O
short	B-Disease
stature	I-Disease
,	O
obesity	B-Disease
,	O
mild	O
developmental	B-Disease
delay	I-Disease
,	O
cryptorchidism	B-Disease
,	O
and	O
some	O
mild	O
dysmorphic	B-Disease
features	I-Disease
.	O

The	O
history	O
further	O
indicated	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
at	O
the	O
end	O
of	O
the	O
pregnancy	O
.	O

His	O
mother	O
was	O
44	O
years	O
of	O
age	O
at	O
the	O
time	O
of	O
his	O
birth	O
.	O

After	O
birth	O
he	O
showed	O
hypotonia	B-Disease
with	O
poor	O
sucking	O
,	O
for	O
which	O
gavage	O
feeding	O
was	O
needed	O
.	O

Motor	O
development	O
was	O
delayed	O
.	O

After	O
1	O
year	O
he	O
became	O
obese	B-Disease
despite	O
a	O
normal	O
appetite	O
.	O

Recurrent	O
middle	B-Disease
ear	I-Disease
infections	I-Disease
,	O
a	O
high	O
pain	O
threshold	O
,	O
and	O
a	O
great	O
skill	O
with	O
jigsaw	O
puzzles	O
were	O
reported	O
.	O

There	O
were	O
no	O
behavioural	O
problems	O
or	O
sleep	O
disturbance	O
.	O

Chromosomal	O
analysis	O
was	O
normal	O
(	O
46	O
,	O
XY	O
)	O
.	O

DNA	O
analysis	O
for	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
showed	O
no	O
abnormalities	O
.	O

Two	O
years	O
later	O
he	O
was	O
re	O
-	O
examined	O
because	O
we	O
thought	O
his	O
features	O
fitted	O
the	O
PWS	B-Disease
-	O
like	O
phenotype	O
associated	O
with	O
maternal	O
UPD	B-Disease
(	O
14	O
)	O
.	O

At	O
that	O
time	O
precocious	O
puberty	O
was	O
evident	O
.	O

DNA	O
analysis	O
showed	O
maternal	B-Disease
heterodisomy	I-Disease
for	O
chromosome	O
14	O
.	O

In	O
all	O
the	O
previously	O
described	O
11	O
cases	O
with	O
maternal	O
UPD	B-Disease
(	O
14	O
)	O
,	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
was	O
detected	O
cytogenetically	O
before	O
DNA	O
analysis	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
diagnosis	O
of	O
maternal	O
UPD	B-Disease
(	O
14	O
)	O
based	O
on	O
clinical	O
features	O
.	O

This	O
finding	O
underlines	O
the	O
importance	O
of	O
DNA	O
analysis	O
for	O
maternal	O
UPD	O
(	O
14	O
)	O
in	O
patients	O
with	O
a	O
similar	O
PWS	B-Disease
-	O
like	O
phenotype	O
even	O
without	O
previous	O
identification	O
of	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
.	O
.	O

Clinical	O
and	O
genetic	O
study	O
of	O
Friedreich	B-Disease
ataxia	I-Disease
in	O
an	O
Australian	O
population	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
FRDA	B-Disease
gene	O
that	O
encodes	O
a	O
210	O
-	O
amino	O
acid	O
protein	O
called	O
frataxin	O
.	O

An	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene	O
is	O
present	O
in	O
more	O
than	O
95	O
%	O
of	O
mutant	O
alleles	O
.	O

Of	O
the	O
83	O
people	O
we	O
studied	O
who	O
have	O
mutations	O
in	O
FRDA	O
,	O
78	O
are	O
homozygous	O
for	O
an	O
expanded	O
GAA	O
repeat	O
;	O
the	O
other	O
five	O
patients	O
have	O
an	O
expansion	O
in	O
one	O
allele	O
and	O
a	O
point	O
mutation	O
in	O
the	O
other	O
.	O

Here	O
we	O
present	O
a	O
detailed	O
clinical	O
and	O
genetic	O
study	O
of	O
a	O
subset	O
of	O
51	O
patients	O
homozygous	O
for	O
an	O
expansion	O
of	O
the	O
GAA	O
repeat	O
.	O

We	O
found	O
a	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
of	O
the	O
two	O
expanded	O
alleles	O
and	O
age	O
at	O
onset	O
,	O
age	O
into	O
wheelchair	O
,	O
scoliosis	B-Disease
,	O
impaired	O
vibration	O
sense	O
,	O
and	O
the	O
presence	O
of	O
foot	B-Disease
deformity	I-Disease
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
allele	O
and	O
cardiomyopathy	B-Disease
,	O
diabetes	B-Disease
mellitus	I-Disease
,	O
loss	B-Disease
of	I-Disease
proprioception	I-Disease
,	O
or	O
bladder	B-Disease
symptoms	I-Disease
.	O

The	O
larger	O
allele	O
size	O
correlated	O
with	O
bladder	B-Disease
symptoms	I-Disease
and	O
the	O
presence	O
of	O
foot	B-Disease
deformity	I-Disease
.	O

The	O
duration	O
of	O
disease	O
is	O
correlated	O
with	O
wheelchair	O
use	O
and	O
the	O
presence	O
of	O
diabetes	B-Disease
,	O
scoliosis	B-Disease
,	O
bladder	B-Disease
symptoms	I-Disease
and	O
impaired	B-Disease
proprioception	I-Disease
,	O
and	O
vibration	O
sense	O
but	O
no	O
other	O
complications	O
studied	O
.	O
.	O

Novel	O
mutations	O
in	O
XLRS1	O
causing	O
retinoschisis	B-Disease
,	O
including	O
first	O
evidence	O
of	O
putative	O
leader	O
sequence	O
change	O
.	O

Juvenile	B-Disease
retinoschisis	I-Disease
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O

We	O
screened	O
31	O
new	O
unrelated	O
patients	O
and	O
families	O
for	O
XLRS1	O
mutations	O
in	O
addition	O
to	O
previously	O
reported	O
mutations	O
for	O
60	O
of	O
our	O
families	O
(	O
Retinoschisis	B-Disease
Consortium	O
,	O
Hum	O
Mol	O
Genet	O
1998	O
;	O
7	O
1185	O
-	O
1192	O
)	O
.	O

Twenty	O
-	O
three	O
different	O
mutations	O
including	O
12	O
novel	O
ones	O
were	O
identified	O
in	O
28	O
patients	O
.	O

Mutations	O
identified	O
in	O
this	O
study	O
include	O
19	O
missense	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
,	O
one	O
intragenic	O
deletion	O
,	O
four	O
microdeletions	O
,	O
one	O
insertion	O
,	O
and	O
one	O
intronic	O
sequence	O
substitution	O
that	O
is	O
likely	O
to	O
result	O
in	O
a	O
splice	O
site	O
defect	O
.	O

Two	O
novel	O
mutations	O
,	O
c	O
.	O

38T	O
-	O
-	O
>	O
C	O
(	O
L13P	O
)	O
and	O
c	O
.	O

667T	O
-	O
-	O
>	O
C	O
(	O
C223R	O
)	O
,	O
respectively	O
,	O
present	O
the	O
first	O
genetic	O
evidence	O
for	O
the	O
functional	O
significance	O
of	O
the	O
putative	O
leader	O
peptide	O
sequence	O
and	O
for	O
the	O
functional	O
significance	O
at	O
the	O
carboxyl	O
terminal	O
of	O
the	O
XLRS1	O
protein	O
beyond	O
the	O
discoidin	O
domain	O
.	O

Mutations	O
in	O
25	O
of	O
the	O
families	O
were	O
localized	O
to	O
exons	O
4	O
-	O
6	O
,	O
emphasizing	O
the	O
critical	O
functional	O
significance	O
of	O
the	O
discoidin	O
domain	O
of	O
the	O
XLRS1	O
protein	O

Growth	O
hormone	O
treatment	O
increases	O
CO	O
(	O
2	O
)	O
response	O
,	O
ventilation	O
and	O
central	O
inspiratory	O
drive	O
in	O
children	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

We	O
studied	O
whether	O
the	O
beneficial	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
treatment	O
on	O
growth	O
and	O
body	O
composition	O
in	O
PWS	B-Disease
are	O
accompanied	O
by	O
an	O
improvement	O
in	O
respiratory	O
function	O
.	O

We	O
measured	O
resting	O
ventilation	O
,	O
airway	O
occlusion	O
pressure	O
(	O
P	O
(	O
0	O
.	O
1	O
)	O
)	O
and	O
ventilatory	O
response	O
to	O
CO	O
(	O
2	O
)	O
in	O
nine	O
children	O
,	O
aged	O
7	O
-	O
14	O
years	O
,	O
before	O
and	O
6	O
-	O
9	O
months	O
after	O
the	O
start	O
of	O
GH	O
treatment	O
.	O

During	O
GH	O
treatment	O
,	O
resting	O
ventilation	O
increased	O
by	O
26	O
%	O
,	O
P	O
(	O
0	O
.	O
1	O
)	O
by	O
72	O
%	O
and	O
the	O
response	O
to	O
CO	O
(	O
2	O
)	O
by	O
65	O
%	O
(	O
P	O
<	O
0	O
.	O
002	O
,	O
<	O
0	O
.	O
04	O
and	O
<	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

This	O
observed	O
increase	O
in	O
ventilatory	O
output	O
was	O
not	O
correlated	O
to	O
changes	O
in	O
body	O
mass	O
index	O
.	O

CONCLUSION	O
Treatment	O
of	O
children	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	O
on	O
central	O
respiratory	O
structures	O
.	O

The	O
observed	O
increase	O
in	O
ventilation	O
and	O
inspiratory	O
drive	O
may	O
contribute	O
to	O
the	O
improved	O
activity	O
level	O
reported	O
by	O
parents	O
of	O
PWS	B-Disease
children	O
during	O
growth	O
hormone	O
therapy	O

G130V	O
,	O
a	O
common	O
FRDA	B-Disease
point	O
mutation	O
,	O
appears	O
to	O
have	O
arisen	O
from	O
a	O
common	O
founder	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
is	O
the	O
most	O
common	O
inherited	B-Disease
ataxia	I-Disease
.	O

About	O
98	O
%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
affected	O
gene	O
,	O
FRDA	O
.	O

The	O
other	O
2	O
%	O
are	O
point	O
mutations	O
.	O

Of	O
the	O
17	O
point	O
mutations	O
so	O
far	O
described	O
,	O
three	O
appear	O
to	O
be	O
more	O
common	O
.	O

One	O
of	O
these	O
is	O
the	O
G130V	O
mutation	O
in	O
exon	O
4	O
of	O
FRDA	O
.	O

G130V	O
,	O
when	O
present	O
with	O
an	O
expanded	O
GAA	O
repeat	O
on	O
the	O
other	O
allele	O
,	O
is	O
associated	O
with	O
an	O
atypical	O
FRDA	B-Disease
phenotype	O
.	O

Haplotype	O
analysis	O
was	O
undertaken	O
on	O
the	O
four	O
families	O
who	O
have	O
been	O
described	O
with	O
this	O
mutation	O
.	O

The	O
results	O
suggest	O
a	O
common	O
founder	O
for	O
this	O
mutation	O
.	O

Although	O
marked	O
differences	O
in	O
extragenic	O
marker	O
haplotypes	O
were	O
seen	O
in	O
one	O
family	O
,	O
similar	O
intragenic	O
haplotyping	O
suggests	O
the	O
same	O
mutation	O
founder	O
for	O
this	O
family	O
with	O
the	O
differences	O
explicable	O
by	O
two	O
recombination	O
events	O
.	O
.	O

Synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
the	O
FMR1	O
gene	O
.	O

Most	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
patients	O
have	O
expansion	O
of	O
a	O
(	O
CGG	O
)	O
(	O
n	O
)	O
sequence	O
with	O
>	O
200	O
repeats	O
(	O
full	O
mutation	O
)	O
in	O
the	O
FMR1	O
gene	O
responsible	O
for	O
this	O
condition	O
.	O

Hypermethylation	O
of	O
the	O
expanded	O
repeat	O
and	O
of	O
the	O
FMR1	O
promoter	O
is	O
almost	O
always	O
present	O
and	O
apparently	O
suppresses	O
transcription	O
,	O
resulting	O
in	O
absence	O
of	O
the	O
FMR1	O
protein	O
.	O

We	O
recently	O
showed	O
that	O
transcriptional	O
reactivation	O
of	O
FMR1	O
full	O
mutations	O
can	O
be	O
achieved	O
by	O
inducing	O
DNA	O
demethylation	O
with	O
5	O
-	O
azadeoxycytidine	O
(	O
5	O
-	O
azadC	O
)	O
.	O

The	O
level	O
of	O
histone	O
acetylation	O
is	O
another	O
important	O
factor	O
in	O
regulating	O
gene	O
expression	O
;	O
therefore	O
,	O
we	O
treated	O
lymphoblastoid	O
cell	O
lines	O
of	O
non	O
-	O
mosaic	O
full	O
mutation	O
patients	O
with	O
three	O
drugs	O
capable	O
of	O
inducing	O
histone	O
hyperacetylation	O
.	O

We	O
observed	O
a	O
consistent	O
,	O
although	O
modest	O
,	O
reactivation	O
of	O
the	O
FMR1	O
gene	O
with	O
4	O
-	O
phenylbutyrate	O
,	O
sodium	O
butyrate	O
and	O
trichostatin	O
A	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
.	O

However	O
,	O
we	O
report	O
that	O
combining	O
these	O
drugs	O
with	O
5	O
-	O
azadC	O
results	O
in	O
a	O
2	O
-	O
to	O
5	O
-	O
fold	O
increase	O
in	O
FMR1	O
mRNA	O
levels	O
obtained	O
with	O
5	O
-	O
azadC	O
alone	O
,	O
thus	O
showing	O
a	O
marked	O
synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
FMR1	O
full	O
mutations	O
.	O
.	O

Constitutional	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	B-Disease
)	O
gene	O
deletions	O
detected	O
in	O
VHL	B-Disease
families	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
disease	I-Disease
is	O
an	O
autosomal	B-Disease
dominantly	I-Disease
inherited	I-Disease
cancer	I-Disease
syndrome	I-Disease
predisposing	O
to	O
a	O
variety	O
of	O
tumor	B-Disease
types	O
that	O
include	O
retinal	O
hemangioblastomas	B-Disease
,	O
hemangioblastomas	B-Disease
of	O
the	O
central	O
nervous	O
system	O
,	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
,	O
pancreatic	B-Disease
cysts	I-Disease
and	I-Disease
tumors	I-Disease
,	O
pheochromocytomas	B-Disease
,	O
endolymphatic	B-Disease
sac	I-Disease
tumors	I-Disease
,	O
and	O
epididymal	B-Disease
cystadenomas	I-Disease
[	O
W	O
.	O

M	O
.	O

Linehan	O
et	O
al	O
.	O
,	O
J	O
.	O

Am	O
.	O
Med	O
.	O
Assoc	O
.	O
,	O
273	O
564	O
-	O
570	O
,	O
1995	O
;	O
E	O
.	O
A	O
.	O
Maher	O
and	O
W	O
.	O
G	O
.	O
Kaelin	O
,	O
Jr	O
.	O
,	O
Medicine	O
(	O
Baltimore	O
)	O
,	O
76	O
381	O
-	O
391	O
,	O
1997	O
;	O
W	O
.	O
M	O
.	O
Linehan	O
and	O
R	O
.	O
D	O
.	O
Klausner	O
,	O
In	O
B	O
.	O
Vogelstein	O
and	O
K	O
.	O
Kinzler	O
(	O
eds	O
.	O
)	O
,	O
The	O
Genetic	O
Basis	O
of	O
Human	O
Cancer	O
,	O
pp	O
.	O

455	O
-	O
473	O
,	O
McGraw	O
-	O
Hill	O
,	O
1998	O
]	O
.	O

The	O
VHL	B-Disease
gene	O
was	O
localized	O
to	O
chromosome	O
3p25	O
-	O
26	O
and	O
cloned	O
[	O
F	O
.	O
Latif	O
et	O
al	O
.	O
,	O
Science	O
(	O
Washington	O
DC	O
)	O
,	O
260	O
1317	O
-	O
1320	O
,	O
1993	O
]	O
.	O

Germline	O
mutations	O
in	O
the	O
VHL	B-Disease
gene	O
have	O
been	O
detected	O
in	O
the	O
majority	O
of	O
VHL	B-Disease
kindreds	O
.	O

The	O
reported	O
frequency	O
of	O
detection	O
of	O
VHL	B-Disease
germline	O
mutations	O
has	O
varied	O
from	O
39	O
to	O
80	O
%	O
(	O
J	O
.	O
M	O
.	O
Whaley	O
et	O
al	O
.	O
,	O
Am	O
.	O
J	O
.	O
Hum	O
.	O
Genet	O
.	O
,	O
55	O
1092	O
-	O
1102	O
,	O
1994	O
;	O
Clinical	O
Research	O
Group	O
for	O
Japan	O
,	O
Hum	O
.	O
Mol	O
.	O
Genet	O
.	O
,	O
4	O
2233	O
-	O
2237	O
,	O
1995	O
;	O
F	O
.	O
Chen	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
5	O
66	O
-	O
75	O
,	O
1995	O
;	O
E	O
.	O
R	O
.	O
Maher	O
et	O
al	O
.	O
,	O
J	O
.	O
Med	O
.	O
Genet	O
.	O
,	O
33	O
328	O
-	O
332	O
,	O
1996	O
;	O
B	O
.	O
Zbar	O
,	O
Cancer	O
Surv	O
.	O
,	O
25	O
219	O
-	O
232	O
,	O
1995	O
)	O
.	O

Recently	O
a	O
quantitative	O
Southern	O
blotting	O
procedure	O
was	O
found	O
to	O
improve	O
this	O
frequency	O
(	O
C	O
.	O
Stolle	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
12	O
417	O
-	O
423	O
,	O
1998	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
use	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
as	O
a	O
method	O
to	O
detect	O
and	O
characterize	O
VHL	B-Disease
germline	O
deletions	O
.	O

We	O
reexamined	O
a	O
group	O
of	O
VHL	B-Disease
patients	O
shown	O
previously	O
by	O
single	O
-	O
strand	O
conformation	O
and	O
sequencing	O
analysis	O
not	O
to	O
harbor	O
point	O
mutations	O
in	O
the	O
VHL	B-Disease
locus	O
.	O

We	O
found	O
constitutional	O
deletions	O
in	O
29	O
of	O
30	O
VHL	B-Disease
patients	O
in	O
this	O
group	O
using	O
cosmid	O
and	O
P1	O
probes	O
that	O
cover	O
the	O
VHL	B-Disease
locus	O
.	O

We	O
then	O
tested	O
six	O
phenotypically	O
normal	O
offspring	O
from	O
four	O
of	O
these	O
VHL	B-Disease
families	O
two	O
were	O
found	O
to	O
carry	O
the	O
deletion	O
and	O
the	O
other	O
four	O
were	O
deletion	O
-	O
free	O
.	O

In	O
addition	O
,	O
germline	O
mosaicism	O
of	O
the	O
VHL	B-Disease
gene	O
was	O
identified	O
in	O
one	O
family	O
.	O

In	O
sum	O
,	O
FISH	O
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	O
VHL	B-Disease
germline	O
deletions	O
and	O
practically	O
useful	O
in	O
cases	O
where	O
other	O
methods	O
of	O
screening	O
have	O
failed	O
to	O
detect	O
a	O
VHL	B-Disease
gene	I-Disease
abnormality	I-Disease

Spectrum	O
of	O
hSNF5	O
/	O
INI1	O
somatic	O
mutations	O
in	O
human	O
cancer	B-Disease
and	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

The	O
hSNF5	O
/	O
INI1	O
gene	O
which	O
encodes	O
a	O
member	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
ATP	O
-	O
dependent	O
remodeling	O
complex	O
,	O
is	O
a	O
new	O
tumor	B-Disease
suppressor	O
gene	O
localized	O
on	O
chromosome	O
22q11	O
.	O

2	O
and	O
recently	O
shown	O
to	O
be	O
mutated	O
in	O
malignant	B-Disease
rhabdoid	I-Disease
tumors	I-Disease
.	O

We	O
have	O
searched	O
for	O
hSNF5	O
/	O
INI1	O
mutations	O
in	O
229	O
tumors	B-Disease
of	O
various	O
origins	O
using	O
a	O
screening	O
method	O
based	O
on	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

A	O
total	O
of	O
31	O
homozygous	O
deletions	O
and	O
36	O
point	O
alterations	O
were	O
identified	O
.	O

Point	O
mutations	O
were	O
scattered	O
along	O
the	O
coding	O
sequence	O
and	O
included	O
15	O
nonsense	O
,	O
15	O
frameshift	O
,	O
three	O
splice	O
site	O
,	O
two	O
missense	O
and	O
one	O
editing	O
mutations	O
.	O

Mutations	O
were	O
retrieved	O
in	O
most	O
rhabdoid	B-Disease
tumors	I-Disease
,	O
whatever	O
their	O
sites	O
of	O
occurrence	O
,	O
indicating	O
the	O
common	O
pathogenetic	O
origin	O
of	O
these	O
tumors	B-Disease
.	O

Recurrent	O
hSNF5	O
/	O
INI1	O
alterations	O
were	O
also	O
observed	O
in	O
choroid	B-Disease
plexus	I-Disease
carcinomas	I-Disease
and	O
in	O
a	O
subset	O
of	O
central	O
primitive	O
neuroectodermal	B-Disease
tumors	I-Disease
(	O
cPNETs	O
)	O
and	O
medulloblastomas	B-Disease
.	O

In	O
contrast	O
,	O
hSNF5	O
/	O
INI1	O
point	O
mutations	O
were	O
not	O
detected	O
in	O
breast	B-Disease
cancers	I-Disease
,	O
Wilms	B-Disease
tumors	I-Disease
,	O
gliomas	B-Disease
,	O
ependymomas	B-Disease
,	O
sarcomas	B-Disease
and	O
other	O
tumor	B-Disease
types	O
,	O
even	O
though	O
most	O
analyzed	O
cases	O
harbored	O
loss	O
of	O
heterozygosity	O
at	O
22q11	O
.	O

2	O
loci	O
.	O

These	O
results	O
suggest	O
that	O
rhabdoid	B-Disease
tumors	I-Disease
,	O
choroid	B-Disease
plexus	I-Disease
carcinomas	I-Disease
and	O
a	O
subset	O
of	O
medulloblastomas	B-Disease
and	O
cPNETs	O
share	O
common	O
pathways	O
of	O
oncogenesis	O
related	O
to	O
hSNF5	O
/	O
INI1	O
alteration	O
and	O
that	O
hSNF5	O
/	O
INI1	O
mutations	O
define	O
a	O
genetically	O
homogeneous	O
family	O
of	O
highly	O
aggressive	O
cancers	B-Disease
mainly	O
occurring	O
in	O
young	O
children	O
and	O
frequently	O
,	O
but	O
not	O
always	O
,	O
exhibiting	O
a	O
rhabdoid	B-Disease
phenotype	O

Ataxin	O
-	O
3	O
with	O
an	O
altered	O
conformation	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
is	O
associated	O
with	O
the	O
nuclear	O
matrix	O
.	O

Spinocerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
-	I-Disease
3	I-Disease
or	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
SCA3	B-Disease
/	O
MJD	B-Disease
)	O
is	O
a	O
member	O
of	O
the	O
CAG	B-Disease
/	I-Disease
polyglutamine	I-Disease
repeat	I-Disease
disease	I-Disease
family	O
.	O

In	O
this	O
family	O
of	O
disorders	O
,	O
a	O
normally	O
polymorphic	O
CAG	O
repeat	O
becomes	O
expanded	O
,	O
resulting	O
in	O
expression	O
of	O
an	O
expanded	O
polyglutamine	O
domain	O
in	O
the	O
disease	O
gene	O
product	O
.	O

Experimental	O
models	O
of	O
polyglutamine	B-Disease
disease	I-Disease
implicate	O
the	O
nucleus	O
in	O
pathogenesis	O
;	O
however	O
,	O
the	O
link	O
between	O
intranuclear	O
expression	O
of	O
expanded	O
polyglutamine	O
and	O
neuronal	B-Disease
dysfunction	I-Disease
remains	O
unclear	O
.	O

Here	O
we	O
demonstrate	O
that	O
ataxin	O
-	O
3	O
,	O
the	O
disease	O
protein	O
in	O
SCA3	B-Disease
/	O
MJD	B-Disease
,	O
adopts	O
a	O
unique	O
conformation	O
when	O
expressed	O
within	O
the	O
nucleus	O
of	O
transfected	O
cells	O
.	O

The	O
monoclonal	O
antibody	O
1C2	O
is	O
known	O
preferentially	O
to	O
bind	O
expanded	O
polyglutamine	O
,	O
but	O
we	O
find	O
that	O
it	O
also	O
binds	O
a	O
fragment	O
of	O
ataxin	O
-	O
3	O
containing	O
a	O
normal	O
glutamine	O
repeat	O
.	O

In	O
addition	O
,	O
expression	O
of	O
ataxin	O
-	O
3	O
within	O
the	O
nucleus	O
exposes	O
the	O
glutamine	O
domain	O
of	O
the	O
full	O
-	O
length	O
non	O
-	O
pathological	O
protein	O
,	O
allowing	O
it	O
to	O
bind	O
the	O
monoclonal	O
antibody	O
1C2	O
.	O

Fractionation	O
and	O
immunochemical	O
experiments	O
indicate	O
that	O
this	O
novel	O
conformation	O
of	O
intranuclear	O
ataxin	O
-	O
3	O
is	O
not	O
due	O
to	O
proteolysis	O
,	O
suggesting	O
instead	O
that	O
association	O
with	O
nuclear	O
protein	O
(	O
s	O
)	O
alters	O
the	O
structure	O
of	O
full	O
-	O
length	O
ataxin	O
-	O
3	O
which	O
exposes	O
the	O
polyglutamine	O
domain	O
.	O

This	O
conformationally	O
altered	O
ataxin	O
-	O
3	O
is	O
bound	O
to	O
the	O
nuclear	O
matrix	O
.	O

The	O
pathological	O
form	O
of	O
ataxin	O
-	O
3	O
with	O
an	O
expanded	O
polyglutamine	O
domain	O
also	O
associates	O
with	O
the	O
nuclear	O
matrix	O
.	O

These	O
data	O
suggest	O
that	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
SCA3	B-Disease
/	O
MJD	B-Disease
may	O
be	O
an	O
altered	O
conformation	O
of	O
ataxin	O
-	O
3	O
within	O
the	O
nucleus	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
.	O
.	O

The	O
human	O
MAGEL2	O
gene	O
and	O
its	O
mouse	O
homologue	O
are	O
paternally	O
expressed	O
and	O
mapped	O
to	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
region	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
is	O
a	O
complex	O
neurogenetic	B-Disease
disorder	I-Disease
.	O

The	O
phenotype	O
is	O
likely	O
to	O
be	O
a	O
contiguous	B-Disease
gene	I-Disease
syndrome	I-Disease
involving	O
genes	O
which	O
are	O
paternally	O
expressed	O
only	O
,	O
located	O
in	O
the	O
human	O
15q11	O
-	O
q13	O
region	O
.	O

Four	O
mouse	O
models	O
of	O
PWS	B-Disease
have	O
been	O
reported	O
but	O
these	O
do	O
not	O
definitively	O
allow	O
the	O
delineation	O
of	O
the	O
critical	O
region	O
and	O
the	O
associated	O
genes	O
involved	O
in	O
the	O
aetiology	O
of	O
PWS	B-Disease
.	O

Moreover	O
,	O
targeted	O
mutagenesis	O
of	O
mouse	O
homologues	O
of	O
the	O
human	O
candidate	O
PWS	B-Disease
genes	O
does	O
not	O
appear	O
to	O
result	O
in	O
any	O
of	O
the	O
features	O
of	O
PWS	B-Disease
.	O

Therefore	O
,	O
the	O
isolation	O
of	O
new	O
genes	O
in	O
this	O
region	O
remains	O
crucial	O
for	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
PWS	B-Disease
.	O

In	O
this	O
manuscript	O
,	O
we	O
report	O
the	O
characterization	O
of	O
MAGEL2	O
and	O
its	O
mouse	O
homologue	O
Magel2	O
.	O

These	O
are	O
located	O
in	O
the	O
human	O
15q11	O
-	O
q13	O
and	O
mouse	O
7C	O
regions	O
,	O
in	O
close	O
proximity	O
to	O
NDN	O
/	O
Ndn	O
.	O

By	O
northern	O
blot	O
analysis	O
we	O
did	O
not	O
detect	O
any	O
expression	O
of	O
MAGEL2	O
/	O
Magel2	O
but	O
by	O
RT	O
-	O
PCR	O
analysis	O
,	O
specific	O
expression	O
was	O
detected	O
in	O
fetal	O
and	O
adult	O
brain	O
and	O
in	O
placenta	O
.	O

Both	O
genes	O
are	O
intronless	O
with	O
tandem	O
direct	O
repeat	O
sequences	O
contained	O
within	O
a	O
CpG	O
island	O
in	O
the	O
5	O
-	O
untranscribed	O
region	O
.	O

The	O
transcripts	O
encode	O
putative	O
proteins	O
that	O
are	O
homologous	O
to	O
the	O
MAGE	O
proteins	O
and	O
NDN	O
.	O

Moreover	O
,	O
MAGEL2	O
/	O
Magel2	O
are	O
expressed	O
only	O
from	O
the	O
paternal	O
allele	O
in	O
brain	O
,	O
suggesting	O
a	O
potential	O
role	O
in	O
the	O
aetiology	O
of	O
PWS	B-Disease
and	O
its	O
mouse	O
model	O
,	O
respectively	O
.	O
.	O

cDNA	O
microarrays	O
detect	O
activation	O
of	O
a	O
myogenic	O
transcription	O
program	O
by	O
the	O
PAX3	O
-	O
FKHR	O
fusion	O
oncogene	O
.	O

Alveolar	B-Disease
rhabdomyosarcoma	I-Disease
is	O
an	O
aggressive	O
pediatric	B-Disease
cancer	I-Disease
of	I-Disease
striated	I-Disease
muscle	I-Disease
characterized	O
in	O
60	O
%	O
of	O
cases	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
.	O

This	O
results	O
in	O
the	O
fusion	O
of	O
PAX3	O
,	O
a	O
developmental	O
transcription	O
factor	O
required	O
for	O
limb	O
myogenesis	O
,	O
with	O
FKHR	O
,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors	O
.	O

The	O
resultant	O
PAX3	O
-	O
FKHR	O
gene	O
possesses	O
transforming	O
properties	O
;	O
however	O
,	O
the	O
effects	O
of	O
this	O
chimeric	O
oncogene	O
on	O
gene	O
expression	O
are	O
largely	O
unknown	O
.	O

To	O
investigate	O
the	O
actions	O
of	O
these	O
transcription	O
factors	O
,	O
both	O
Pax3	O
and	O
PAX3	O
-	O
FKHR	O
were	O
introduced	O
into	O
NIH	O
3T3	O
cells	O
,	O
and	O
the	O
resultant	O
gene	O
expression	O
changes	O
were	O
analyzed	O
with	O
a	O
murine	O
cDNA	O
microarray	O
containing	O
2	O
,	O
225	O
elements	O
.	O

We	O
found	O
that	O
PAX3	O
-	O
FKHR	O
but	O
not	O
PAX3	O
activated	O
a	O
myogenic	O
transcription	O
program	O
including	O
the	O
induction	O
of	O
transcription	O
factors	O
MyoD	O
,	O
Myogenin	O
,	O
Six1	O
,	O
and	O
Slug	O
as	O
well	O
as	O
a	O
battery	O
of	O
genes	O
involved	O
in	O
several	O
aspects	O
of	O
muscle	O
function	O
.	O

Notable	O
among	O
this	O
group	O
were	O
the	O
growth	O
factor	O
gene	O
Igf2	O
and	O
its	O
binding	O
protein	O
Igfbp5	O
.	O

Relevance	O
of	O
this	O
model	O
was	O
suggested	O
by	O
verification	O
that	O
three	O
of	O
these	O
genes	O
(	O
IGFBP5	O
,	O
HSIX1	O
,	O
and	O
Slug	O
)	O
were	O
also	O
expressed	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
cell	O
lines	O
.	O

This	O
study	O
utilizes	O
cDNA	O
microarrays	O
to	O
elucidate	O
the	O
pattern	O
of	O
gene	O
expression	O
induced	O
by	O
an	O
oncogenic	O
transcription	O
factor	O
and	O
demonstrates	O
the	O
profound	O
myogenic	O
properties	O
of	O
PAX3	O
-	O
FKHR	O
in	O
NIH	O
3T3	O
cells	O
.	O
.	O

Experimental	O
hemochromatosis	B-Disease
due	O
to	O
MHC	O
class	O
I	O
HFE	B-Disease
deficiency	I-Disease
:	O
immune	O
status	O
and	O
iron	O
metabolism	O
.	O

The	O
puzzling	O
linkage	O
between	O
genetic	O
hemochromatosis	B-Disease
and	O
histocompatibility	O
loci	O
became	O
even	O
more	O
so	O
when	O
the	O
gene	O
involved	O
,	O
HFE	O
,	O
was	O
identified	O
.	O

Indeed	O
,	O
within	O
the	O
well	O
defined	O
,	O
mainly	O
peptide	O
-	O
binding	O
,	O
MHC	O
class	O
I	O
family	O
of	O
molecules	O
,	O
HFE	O
seems	O
to	O
perform	O
an	O
unusual	O
yet	O
essential	O
function	O
.	O

As	O
yet	O
,	O
our	O
understanding	O
of	O
HFE	O
function	O
in	O
iron	O
homeostasis	O
is	O
only	O
partial	O
;	O
an	O
even	O
more	O
open	O
question	O
is	O
its	O
possible	O
role	O
in	O
the	O
immune	O
system	O
.	O

To	O
advance	O
on	O
both	O
of	O
these	O
avenues	O
,	O
we	O
report	O
the	O
deletion	O
of	O
HFE	O
alpha1	O
and	O
alpha2	O
putative	O
ligand	O
binding	O
domains	O
in	O
vivo	O
.	O

HFE	B-Disease
-	I-Disease
deficient	I-Disease
animals	O
were	O
analyzed	O
for	O
a	O
comprehensive	O
set	O
of	O
metabolic	O
and	O
immune	O
parameters	O
.	O

Faithfully	O
mimicking	O
human	O
hemochromatosis	B-Disease
,	O
mice	O
homozygous	O
for	O
this	O
deletion	O
develop	O
iron	O
overload	O
,	O
characterized	O
by	O
a	O
higher	O
plasma	O
iron	O
content	O
and	O
a	O
raised	O
transferrin	O
saturation	O
as	O
well	O
as	O
an	O
elevated	O
hepatic	O
iron	O
load	O
.	O

The	O
primary	O
defect	O
could	O
,	O
indeed	O
,	O
be	O
traced	O
to	O
an	O
augmented	O
duodenal	O
iron	O
absorption	O
.	O

In	O
parallel	O
,	O
measurement	O
of	O
the	O
gut	O
mucosal	O
iron	O
content	O
as	O
well	O
as	O
iron	O
regulatory	O
proteins	O
allows	O
a	O
more	O
informed	O
evaluation	O
of	O
various	O
hypotheses	O
regarding	O
the	O
precise	O
role	O
of	O
HFE	O
in	O
iron	O
homeostasis	O
.	O

Finally	O
,	O
an	O
extensive	O
phenotyping	O
of	O
primary	O
and	O
secondary	O
lymphoid	O
organs	O
including	O
the	O
gut	O
provides	O
no	O
compelling	O
evidence	O
for	O
an	O
obvious	O
immune	O
-	O
linked	O
function	O
for	O
HFE	O
.	O
.	O

Somatic	O
rearrangement	O
of	O
chromosome	O
14	O
in	O
human	O
lymphocytes	O
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
is	O
a	O
rare	O
genetic	B-Disease
disorder	I-Disease
associated	O
with	O
immune	B-Disease
deficiency	I-Disease
,	O
chromosome	B-Disease
instability	I-Disease
,	O
and	O
a	O
predisposition	O
to	O
lymphoid	B-Disease
malignancy	I-Disease
.	O

We	O
have	O
detected	O
chromosomally	O
anomalous	O
clones	O
of	O
lymphocytes	O
in	O
eight	O
patients	O
with	O
this	O
disorder	O
.	O

Chromosome	O
banding	O
disclosed	O
that	O
the	O
clones	O
are	O
consistently	O
marked	O
by	O
structural	O
rearrangement	O
of	O
the	O
long	O
arm	O
(	O
q	O
)	O
of	O
chromosome	O
14	O
.	O

A	O
translocation	O
involving	O
14q	O
was	O
found	O
in	O
clones	O
obtained	O
from	O
seven	O
of	O
the	O
eight	O
patients	O
whereas	O
a	O
ring	O
14	O
chromosome	O
was	O
found	O
in	O
a	O
clone	O
obtained	O
from	O
the	O
other	O
.	O

These	O
findings	O
as	O
well	O
as	O
data	O
obtained	O
by	O
others	O
for	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
suggest	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
the	O
initial	O
chromosomal	O
change	O
in	O
lymphocyte	O
clones	O
of	O
patients	O
with	O
this	O
disorder	O
.	O

Chromosomes	O
of	O
lymphocytes	O
from	O
one	O
of	O
the	O
patients	O
were	O
studied	O
before	O
and	O
after	O
the	O
onset	O
of	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
.	O

Before	O
leukemia	B-Disease
was	O
diagnosed	O
,	O
the	O
patient	O
had	O
a	O
lymphocyte	O
clone	O
with	O
a	O
14q	O
translocation	O
.	O

This	O
clone	O
appears	O
to	O
have	O
given	O
rise	O
to	O
the	O
leukemic	B-Disease
cells	O
.	O

We	O
hypothesize	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
directly	O
related	O
to	O
abnormal	O
growth	O
of	O
lymphocytes	O
and	O
that	O
it	O
may	O
be	O
a	O
step	O
toward	O
the	O
development	O
of	O
lymphoid	B-Disease
malignancies	I-Disease
.	O

Increasing	O
evidence	O
,	O
provided	O
by	O
others	O
,	O
for	O
the	O
nonrandom	O
involvement	O
of	O
14q	O
in	O
African	O
-	O
type	O
Burkitts	B-Disease
lymphoma	I-Disease
and	O
other	O
lymphoid	B-Disease
neoplasms	I-Disease
further	O
strengthens	O
this	O
hypothesis	O
.	O
.	O

Exon	O
9	O
mutations	O
in	O
the	O
WT1	O
gene	O
,	O
without	O
influencing	O
KTS	O
splice	O
isoforms	O
,	O
are	O
also	O
responsible	O
for	O
Frasier	B-Disease
syndrome	I-Disease
.	O

We	O
report	O
new	O
mutations	O
in	O
exon	O
9	O
of	O
the	O
WT1	O
gene	O
that	O
did	O
not	O
alter	O
the	O
ratio	O
of	O
+	O
/	O
-	O
KTS	O
splice	O
isoforms	O
in	O
two	O
unrelated	O
patients	O
with	O
Frasier	B-Disease
syndrome	I-Disease
(	O
FS	B-Disease
)	O
.	O

The	O
mutation	O
of	O
intron	O
9	O
inducing	O
defective	O
alternative	O
splicing	O
was	O
reported	O
to	O
be	O
responsible	O
for	O
this	O
syndrome	O
.	O

The	O
mutations	O
found	O
in	O
our	O
cases	O
occurred	O
in	O
the	O
same	O
exon	O
of	O
the	O
WT1	O
gene	O
as	O
detected	O
in	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	B-Disease
)	O
and	O
could	O
not	O
be	O
explained	O
by	O
the	O
previously	O
proposed	O
mechanism	O
.	O

The	O
results	O
suggest	O
that	O
the	O
two	O
syndromes	O
originate	O
from	O
the	O
same	O
WT1	B-Disease
gene	I-Disease
abnormality	I-Disease
.	O

From	O
a	O
molecular	O
biological	O
point	O
of	O
view	O
,	O
we	O
concluded	O
that	O
the	O
two	O
diseases	O
were	O
not	O
separable	O
,	O
and	O
that	O
FS	B-Disease
should	O
be	O
included	O
as	O
an	O
atypical	O
form	O
of	O
DDS	B-Disease
.	O
.	O

Splice	O
-	O
site	O
mutation	O
in	O
the	O
PDS	B-Disease
gene	O
may	O
result	O
in	O
intrafamilial	O
variability	O
for	O
deafness	B-Disease
in	O
Pendred	B-Disease
syndrome	I-Disease
.	O

Pendred	B-Disease
syndrome	I-Disease
is	O
a	O
recessive	B-Disease
inherited	I-Disease
disorder	I-Disease
that	O
consists	O
of	O
developmental	B-Disease
abnormalities	I-Disease
of	I-Disease
the	I-Disease
cochlea	I-Disease
,	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
,	O
and	O
diffuse	B-Disease
thyroid	I-Disease
enlargement	I-Disease
(	O
goiter	B-Disease
)	O
.	O

This	O
disorder	O
may	O
account	O
for	O
up	O
to	O
10	O
%	O
of	O
cases	O
of	O
hereditary	B-Disease
deafness	I-Disease
.	O

The	O
disease	O
gene	O
(	O
PDS	B-Disease
)	O
has	O
been	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
,	O
and	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
individual	O
exons	O
of	O
the	O
PDS	B-Disease
gene	O
in	O
one	O
Spanish	O
family	O
that	O
shows	O
intrafamilial	O
variability	O
of	O
the	O
deafness	B-Disease
phenotype	O
(	O
two	O
patients	O
with	O
profound	O
and	O
one	O
with	O
moderate	O
-	O
severe	O
deafness	B-Disease
)	O
.	O

We	O
identified	O
a	O
new	O
splice	O
-	O
site	O
mutation	O
affecting	O
intron	O
4	O
of	O
the	O
PDS	B-Disease
gene	O
,	O
at	O
nucleotide	O
position	O
639	O
+	O
7	O
.	O

RNA	O
analysis	O
from	O
lymphocytes	O
of	O
the	O
affected	O
patients	O
showed	O
that	O
mutation	O
639	O
+	O
7A	O
-	O
-	O
>	O
G	O
generates	O
a	O
new	O
donor	O
splice	O
site	O
,	O
leading	O
to	O
an	O
mRNA	O
with	O
an	O
insertion	O
of	O
six	O
nucleotides	O
from	O
intron	O
4	O
of	O
PDS	O
.	O

Since	O
the	O
newly	O
created	O
donor	O
splice	O
site	O
is	O
likely	O
to	O
compete	O
with	O
the	O
normal	O
one	O
,	O
variations	O
of	O
the	O
levels	O
of	O
normal	O
and	O
aberrant	O
transcripts	O
of	O
the	O
PDS	B-Disease
gene	O
in	O
the	O
cochlea	O
may	O
explain	O
the	O
variability	O
in	O
the	O
deafness	B-Disease
presentation	O
.	O
.	O

The	O
molecular	O
basis	O
of	O
Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
:	O
mutation	O
analysis	O
of	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene	O
.	O

Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
(	O
SLS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
ichthyosis	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
spasticity	B-Disease
,	O
and	O
deficient	B-Disease
activity	I-Disease
of	I-Disease
fatty	I-Disease
aldehyde	I-Disease
dehydrogenase	I-Disease
(	O
FALDH	O
)	O
.	O

To	O
define	O
the	O
molecular	O
defects	O
causing	O
SLS	B-Disease
,	O
we	O
performed	O
mutation	O
analysis	O
of	O
the	O
FALDH	O
gene	O
in	O
probands	O
from	O
63	O
kindreds	O
with	O
SLS	B-Disease
.	O

Among	O
these	O
patients	O
,	O
49	O
different	O
mutations	O
-	O
including	O
10	O
deletions	O
,	O
2	O
insertions	O
,	O
22	O
amino	O
acid	O
substitutions	O
,	O
3	O
nonsense	O
mutations	O
,	O
9	O
splice	O
-	O
site	O
defects	O
,	O
and	O
3	O
complex	O
mutations	O
-	O
were	O
found	O
.	O

All	O
of	O
the	O
patients	O
with	O
SLS	B-Disease
were	O
found	O
to	O
carry	O
mutations	O
.	O

Nineteen	O
of	O
the	O
missense	O
mutations	O
resulted	O
in	O
a	O
severe	O
reduction	O
of	O
FALDH	O
enzyme	O
catalytic	O
activity	O
when	O
expressed	O
in	O
mammalian	O
cells	O
,	O
but	O
one	O
mutation	O
(	O
798G	O
-	O
-	O
>	O
C	O
[	O
K266N	O
]	O
)	O
seemed	O
to	O
have	O
a	O
greater	O
effect	O
on	O
mRNA	O
stability	O
.	O

The	O
splice	O
-	O
site	O
mutations	O
led	O
to	O
exon	O
skipping	O
or	O
utilization	O
of	O
cryptic	O
acceptor	O
-	O
splice	O
sites	O
.	O

Thirty	O
-	O
seven	O
mutations	O
were	O
private	O
,	O
and	O
12	O
mutations	O
were	O
seen	O
in	O
two	O
or	O
more	O
probands	O
of	O
European	O
or	O
Middle	O
Eastern	O
descent	O
.	O

Four	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
found	O
in	O
the	O
FALDH	O
gene	O
.	O

At	O
least	O
four	O
of	O
the	O
common	O
mutations	O
(	O
551C	O
-	O
-	O
>	O
T	O
,	O
682C	O
-	O
-	O
>	O
T	O
,	O
733G	O
-	O
-	O
>	O
A	O
,	O
and	O
798	O
+	O
1delG	O
)	O
were	O
associated	O
with	O
multiple	O
SNP	O
haplotypes	O
,	O
suggesting	O
that	O
these	O
mutations	O
originated	O
independently	O
on	O
more	O
than	O
one	O
occasion	O
or	O
were	O
ancient	O
SLS	B-Disease
genes	O
that	O
had	O
undergone	O
intragenic	O
recombination	O
.	O

Our	O
results	O
demonstrate	O
that	O
SLS	B-Disease
is	O
caused	O
by	O
a	O
strikingly	O
heterogeneous	O
group	O
of	O
mutations	O
in	O
the	O
FALDH	O
gene	O
and	O
provide	O
a	O
framework	O
for	O
understanding	O
the	O
genetic	O
basis	O
of	O
SLS	B-Disease
and	O
the	O
development	O
of	O
DNA	O
-	O
based	O
diagnostic	O
tests	O
.	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
cathepsin	O
C	O
gene	O
result	O
in	O
periodontal	B-Disease
disease	I-Disease
and	O
palmoplantar	B-Disease
keratosis	I-Disease
.	O

Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
,	O
or	O
keratosis	B-Disease
palmoplantaris	I-Disease
with	O
periodontopathia	B-Disease
(	O
PLS	B-Disease
,	O
MIM	O
245000	O
)	O
,	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	O
periodontitis	B-Disease
that	O
afflicts	O
patients	O
.	O

Both	O
the	O
deciduous	O
and	O
permanent	O
dentitions	O
are	O
affected	O
,	O
resulting	O
in	O
premature	O
tooth	B-Disease
loss	I-Disease
.	O

Palmoplantar	B-Disease
keratosis	I-Disease
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	O
to	O
overt	O
hyperkeratosis	B-Disease
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life	O
.	O

Keratosis	B-Disease
also	O
affects	O
other	O
sites	O
such	O
as	O
elbows	O
and	O
knees	O
.	O

Most	O
PLS	B-Disease
patients	O
display	O
both	O
periodontitis	B-Disease
and	O
hyperkeratosis	B-Disease
.	O

Some	O
patients	O
have	O
only	O
palmoplantar	B-Disease
keratosis	I-Disease
or	O
periodontitis	B-Disease
,	O
and	O
in	O
rare	O
individuals	O
the	O
periodontitis	B-Disease
is	O
mild	O
and	O
of	O
late	O
onset	O
.	O

The	O
PLS	O
locus	O
has	O
been	O
mapped	O
to	O
chromosome	O
11q14	O
-	O
q21	O
(	O
refs	O
7	O
,	O
8	O
,	O
9	O
)	O
.	O

Using	O
homozygosity	O
mapping	O
in	O
eight	O
small	O
consanguineous	O
families	O
,	O
we	O
have	O
narrowed	O
the	O
candidate	O
region	O
to	O
a	O
1	O
.	O

2	O
-	O
cM	O
interval	O
between	O
D11S4082	O
and	O
D11S931	O
.	O

The	O
gene	O
(	O
CTSC	O
)	O
encoding	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
(	O
or	O
dipeptidyl	O
aminopeptidase	O
I	O
)	O
lies	O
within	O
this	O
interval	O
.	O

We	O
defined	O
the	O
genomic	O
structure	O
of	O
CTSC	O
and	O
found	O
mutations	O
in	O
all	O
eight	O
families	O
.	O

In	O
two	O
of	O
these	O
families	O
we	O
used	O
a	O
functional	O
assay	O
to	O
demonstrate	O
an	O
almost	O
total	O
loss	O
of	O
cathepsin	O
C	O
activity	O
in	O
PLS	B-Disease
patients	O
and	O
reduced	O
activity	O
in	O
obligate	O
carriers	O
.	O

Confirmation	O
of	O
linkage	O
of	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
to	O
chromosome	O
1q32	O
:	O
evidence	O
of	O
association	O
with	O
STR	O
alleles	O
suggests	O
possible	O
unique	O
origin	O
of	O
the	O
disease	O
mutation	O
.	O

Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
craniofacial	I-Disease
disorder	I-Disease
with	O
high	O
penetrance	O
and	O
variable	O
expression	O
.	O

Its	O
clinical	O
features	O
are	O
variably	O
expressed	O
,	O
but	O
include	O
cleft	B-Disease
lip	I-Disease
and	O
/	O
or	O
cleft	B-Disease
palate	I-Disease
,	O
lip	B-Disease
pits	I-Disease
and	O
hypodontia	B-Disease
.	O

All	O
VWS	B-Disease
families	O
studied	O
to	O
date	O
map	O
the	O
disease	O
gene	O
to	O
a	O
<	O
2	O
cM	O
region	O
of	O
chromosome	O
1q32	O
,	O
with	O
no	O
evidence	O
of	O
locus	O
heterogeneity	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
refine	O
the	O
localization	O
of	O
the	O
VWS	B-Disease
gene	O
and	O
to	O
further	O
assess	O
possible	O
heterogeneity	O
.	O

We	O
analyzed	O
four	O
multiplex	O
VWS	B-Disease
families	O
.	O

All	O
available	O
members	O
were	O
clinically	O
assessed	O
and	O
genotyped	O
for	O
19	O
short	O
tandem	O
repeat	O
markers	O
on	O
chromosome	O
1	O
in	O
the	O
VWS	B-Disease
candidate	O
gene	O
region	O
.	O

We	O
performed	O
two	O
-	O
point	O
and	O
multipoint	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
score	O
analyses	O
using	O
a	O
high	O
penetrance	O
autosomal	O
dominant	O
model	O
.	O

All	O
families	O
showed	O
positive	O
LOD	O
scores	O
without	O
any	O
recombination	O
in	O
the	O
candidate	O
region	O
.	O

The	O
largest	O
two	O
-	O
point	O
LOD	O
score	O
was	O
5	O
.	O

87	O
87	O
.	O

Our	O
assay	O
method	O
for	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
provided	O
highly	O
accurate	O
size	O
estimation	O
of	O
marker	O
allele	O
fragment	O
sizes	O
,	O
and	O
therefore	O
enabled	O
us	O
to	O
determine	O
the	O
specific	O
alleles	O
segregating	O
with	O
the	O
VWS	B-Disease
gene	O
in	O
each	O
of	O
our	O
four	O
families	O
.	O

We	O
observed	O
a	O
striking	O
pattern	O
of	O
STR	O
allele	O
sharing	O
at	O
several	O
closely	O
linked	O
loci	O
among	O
our	O
four	O
Caucasian	O
VWS	B-Disease
families	O
recruited	O
at	O
three	O
different	O
locations	O
in	O
the	O
US	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
of	O
a	O
unique	O
origin	O
for	O
a	O
mutation	O
responsible	O
for	O
many	O
or	O
most	O
cases	O
of	O
VWS	B-Disease
.	O

A	O
point	O
mutation	O
Thr	O
(	O
799	O
)	O
Met	O
on	O
the	O
alpha	O
(	O
2	O
)	O
integrin	O
leads	O
to	O
the	O
formation	O
of	O
new	O
human	O
platelet	O
alloantigen	O
Sit	O
(	O
a	O
)	O
and	O
affects	O
collagen	O
-	O
induced	O
aggregation	O
.	O

A	O
new	O
platelet	O
-	O
specific	O
alloantigen	O
,	O
termed	O
Sit	O
(	O
a	O
)	O
,	O
was	O
identified	O
in	O
a	O
severe	O
case	O
of	O
neonatal	B-Disease
alloimmune	I-Disease
thrombocytopenia	I-Disease
.	O

The	O
Sit	O
(	O
a	O
)	O
alloantigen	O
is	O
of	O
low	O
frequency	O
(	O
1	O
/	O
400	O
)	O
in	O
the	O
German	O
population	O
.	O

Immunochemical	O
studies	O
demonstrated	O
that	O
the	O
Sit	O
(	O
a	O
)	O
epitopes	O
reside	O
on	O
platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ia	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
GPIa	O
cDNA	O
derived	O
from	O
Sit	O
(	O
a	O
)	O
-	O
positive	O
platelets	O
showed	O
C	O
(	O
2531	O
)	O
-	O
-	O
>	O
T	O
(	O
2531	O
)	O
point	O
mutation	O
,	O
resulting	O
in	O
Thr	O
(	O
799	O
)	O
Met	O
dimorphism	O
.	O

Analysis	O
of	O
genomic	O
DNA	O
from	O
22	O
Sit	O
(	O
a	O
)	O
-	O
negative	O
normal	O
individuals	O
showed	O
that	O
the	O
Thr	O
(	O
799	O
)	O
is	O
encoded	O
by	O
ACG	O
(	O
2532	O
)	O
(	O
90	O
.	O
9	O
%	O
)	O
or	O
ACA	O
(	O
2532	O
)	O
(	O
9	O
.	O
1	O
%	O
)	O
.	O

To	O
establish	O
a	O
DNA	O
typing	O
technique	O
,	O
we	O
elucidated	O
the	O
organization	O
of	O
the	O
GPIa	O
gene	O
adjacent	O
to	O
the	O
polymorphic	O
bases	O
.	O

The	O
introns	O
(	O
421	O
bp	O
and	O
1	O
.	O
2	O
kb	O
)	O
encompass	O
a	O
142	O
-	O
bp	O
exon	O
with	O
the	O
2	O
polymorphic	O
bases	O
2531	O
and	O
2532	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
on	O
DNA	O
derived	O
from	O
100	O
donors	O
using	O
the	O
restriction	O
enzyme	O
Mae	O
III	O
showed	O
that	O
the	O
Met	O
(	O
799	O
)	O
form	O
of	O
GPIa	O
is	O
restricted	O
to	O
Sit	O
(	O
a	O
)	O
(	O
+	O
)	O
phenotype	O
.	O

Analysis	O
of	O
stable	O
Chinese	O
hamster	O
ovary	O
transfectants	O
expressing	O
allele	O
-	O
specific	O
recombinant	O
forms	O
of	O
GPIa	O
showed	O
that	O
anti	O
-	O
Sit	O
(	O
a	O
)	O
exclusively	O
reacted	O
with	O
the	O
Glu	O
(	O
505	O
)	O
Met	O
(	O
799	O
)	O
,	O
but	O
not	O
with	O
the	O
Glu	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
and	O
the	O
Lys	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
isoforms	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
Br	O
(	O
a	O
)	O
(	O
HPA	O
-	O
5b	O
)	O
only	O
recognized	O
the	O
Lys	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
form	O
,	O
whereas	O
anti	O
-	O
Br	O
(	O
b	O
)	O
(	O
HPA	O
-	O
5a	O
)	O
reacted	O
with	O
both	O
Glu	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
and	O
Glu	O
(	O
505	O
)	O
Met	O
(	O
799	O
)	O
isoforms	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
Met	O
(	O
799	O
)	O
is	O
responsible	O
for	O
formation	O
of	O
the	O
Sit	O
(	O
a	O
)	O
alloantigenic	O
determinants	O
,	O
whereas	O
amino	O
acid	O
505	O
(	O
Lys	O
or	O
Glu	O
)	O
specifically	O
controls	O
the	O
expression	O
of	O
Br	O
(	O
a	O
)	O
and	O
Br	O
(	O
b	O
)	O
epitopes	O
,	O
respectively	O
.	O

Platelet	O
aggregation	O
responses	O
of	O
Sit	O
(	O
a	O
)	O
(	O
+	O
)	O
individuals	O
were	O
diminished	O
in	O
response	O
to	O
collagen	O
,	O
indicating	O
that	O
the	O
Thr	O
(	O
799	O
)	O
Met	O
mutation	O
affects	O
the	O
function	O
of	O
the	O
GPIa	O
/	O
IIa	O
complex	O

Mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
are	O
responsible	O
for	O
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
.	O

Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
(	O
PLS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterised	O
by	O
palmoplantar	B-Disease
hyperkeratosis	I-Disease
and	O
severe	O
early	O
onset	O
periodontitis	B-Disease
that	O
results	O
in	O
the	O
premature	O
loss	O
of	O
the	O
primary	O
and	O
secondary	O
dentitions	O
.	O

A	O
major	O
gene	O
locus	O
for	O
PLS	B-Disease
has	O
been	O
mapped	O
to	O
a	O
2	O
.	O

8	O
cM	O
interval	O
on	O
chromosome	O
11q14	O
.	O

Correlation	O
of	O
physical	O
and	O
genetic	O
maps	O
of	O
this	O
interval	O
indicate	O
it	O
includes	O
at	O
least	O
40	O
ESTs	O
and	O
six	O
known	O
genes	O
including	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
gene	O
(	O
CTSC	O
)	O
.	O

The	O
CTSC	O
message	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
a	O
variety	O
of	O
immune	O
cells	O
including	O
polymorphonuclear	O
leucocytes	O
,	O
macrophages	O
,	O
and	O
their	O
precursors	O
.	O

By	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
CTSC	O
is	O
also	O
expressed	O
in	O
epithelial	O
regions	O
commonly	O
affected	O
by	O
PLS	B-Disease
,	O
including	O
the	O
palms	O
,	O
soles	O
,	O
knees	O
,	O
and	O
oral	O
keratinised	O
gingiva	O
.	O

The	O
4	O
.	O

7	O
kb	O
CTSC	O
gene	O
consists	O
of	O
two	O
exons	O
.	O

Sequence	O
analysis	O
of	O
CTSC	O
from	O
subjects	O
affected	O
with	O
PLS	B-Disease
from	O
five	O
consanguineous	O
Turkish	O
families	O
identified	O
four	O
different	O
mutations	O
.	O

An	O
exon	O
1	O
nonsense	O
mutation	O
(	O
856C	O
-	O
-	O
>	O
T	O
)	O
introduces	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
286	O
.	O

Three	O
exon	O
2	O
mutations	O
were	O
identified	O
,	O
including	O
a	O
single	O
nucleotide	O
deletion	O
(	O
2692delA	O
)	O
of	O
codon	O
349	O
introducing	O
a	O
frameshift	O
and	O
premature	O
termination	O
codon	O
,	O
a	O
2	O
bp	O
deletion	O
(	O
2673	O
-	O
2674delCT	O
)	O
that	O
results	O
in	O
introduction	O
of	O
a	O
stop	O
codon	O
at	O
amino	O
acid	O
343	O
,	O
and	O
a	O
G	O
-	O
-	O
>	O
A	O
substitution	O
in	O
codon	O
429	O
(	O
2931G	O
-	O
-	O
>	O
A	O
)	O
introducing	O
a	O
premature	O
termination	O
codon	O
.	O

All	O
PLS	B-Disease
patients	O
were	O
homozygous	O
for	O
cathepsin	O
C	O
mutations	O
inherited	O
from	O
a	O
common	O
ancestor	O
.	O

Parents	O
and	O
sibs	O
heterozygous	O
for	O
cathepsin	O
C	O
mutations	O
do	O
not	O
show	O
either	O
the	O
palmoplantar	B-Disease
hyperkeratosis	I-Disease
or	O
severe	O
early	O
onset	O
periodontitis	B-Disease
characteristic	O
of	O
PLS	B-Disease
.	O

A	O
more	O
complete	O
understanding	O
of	O
the	O
functional	O
physiology	O
of	O
cathepsin	O
C	O
carries	O
significant	O
implications	O
for	O
understanding	O
normal	O
and	O
abnormal	O
skin	O
development	O
and	O
periodontal	B-Disease
disease	I-Disease
susceptibility	O

Mutational	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
Finnish	O
alkaptonuria	B-Disease
patients	O
.	O

Alkaptonuria	B-Disease
(	O
AKU	B-Disease
)	O
,	O
the	O
prototypic	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
,	O
has	O
recently	O
been	O
shown	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
homogentisate	O
-	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

So	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
AKU	B-Disease
patients	O
of	O
different	O
ethnic	O
origin	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
(	O
R58fs	O
,	O
R330S	O
,	O
and	O
H371R	O
)	O
and	O
one	O
common	O
AKU	B-Disease
mutation	O
(	O
M368V	O
)	O
,	O
detected	O
by	O
mutational	O
and	O
polymorphism	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
five	O
Finnish	O
AKU	B-Disease
pedigrees	O
.	O

The	O
three	O
novel	O
AKU	B-Disease
mutations	O
are	O
most	O
likely	O
specific	O
for	O
the	O
Finnish	O
population	O
and	O
have	O
originated	O
recently	O
.	O
.	O

The	O
identical	O
5	O
'	O
splice	O
-	O
site	O
acceptor	O
mutation	O
in	O
five	O
attenuated	B-Disease
APC	I-Disease
families	O
from	O
Newfoundland	O
demonstrates	O
a	O
founder	O
effect	O
.	O

Inherited	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
predispose	O
carriers	O
to	O
multiple	O
adenomatous	B-Disease
polyps	I-Disease
of	I-Disease
the	I-Disease
colon	I-Disease
and	I-Disease
rectum	I-Disease
and	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O

Mutations	O
located	O
at	O
the	O
extreme	O
5	O
end	O
of	O
the	O
APC	B-Disease
gene	O
,	O
however	O
,	O
are	O
associated	O
with	O
a	O
less	O
severe	O
disease	O
known	O
as	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
AAPC	B-Disease
)	O
.	O

Many	O
individuals	O
with	O
AAPC	B-Disease
develop	O
relatively	O
few	O
colorectal	B-Disease
polyps	I-Disease
but	O
are	O
still	O
at	O
high	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
5	O
APC	B-Disease
germline	O
mutation	O
in	O
five	O
separately	O
ascertained	O
AAPC	B-Disease
families	O
from	O
Newfoundland	O
,	O
Canada	O
.	O

This	O
disease	O
-	O
causing	O
mutation	O
is	O
a	O
single	O
basepair	O
change	O
(	O
G	O
to	O
A	O
)	O
in	O
the	O
splice	O
-	O
acceptor	O
region	O
of	O
APC	B-Disease
intron	O
3	O
that	O
creates	O
a	O
mutant	O
RNA	O
without	O
exon	O
4	O
of	O
APC	O
.	O

The	O
observation	O
of	O
the	O
same	O
APC	B-Disease
mutation	O
in	O
five	O
families	O
from	O
the	O
same	O
geographic	O
area	O
demonstrates	O
a	O
founder	O
effect	O
.	O

Furthermore	O
,	O
the	O
identification	O
of	O
this	O
germline	O
mutation	O
strengthens	O
the	O
correlation	O
between	O
the	O
5	O
location	O
of	O
an	O
APC	B-Disease
disease	O
-	O
causing	O
mutation	O
and	O
the	O
attenuated	B-Disease
polyposis	I-Disease
phenotype	O
.	O
.	O

Alstrom	B-Disease
syndrome	I-Disease
:	O
further	O
evidence	O
for	O
linkage	O
to	O
human	O
chromosome	O
2p13	O
.	O

Alstrom	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
retinal	B-Disease
degeneration	I-Disease
,	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
,	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
and	O
non	B-Disease
-	I-Disease
insulin	I-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
.	O

The	O
gene	O
for	O
Alstrom	B-Disease
syndrome	I-Disease
(	O
ALMS1	O
)	O
has	O
been	O
previously	O
localized	O
to	O
human	O
chromosome	O
2p13	O
by	O
homozygosity	O
mapping	O
in	O
two	O
distinct	O
isolated	O
populations	O
-	O
French	O
Acadian	O
and	O
North	O
African	O
.	O

Pair	O
-	O
wise	O
analyses	O
resulted	O
in	O
maximum	O
lod	O
(	O
logarithm	O
of	O
the	O
odds	O
ratio	O
)	O
scores	O
of	O
3	O
.	O

84	O
and	O
2	O
.	O

9	O
,	O
respectively	O
.	O

To	O
confirm	O
these	O
findings	O
,	O
a	O
large	O
linkage	O
study	O
was	O
performed	O
in	O
twelve	O
additional	O
families	O
segregating	O
for	O
Alstrom	B-Disease
syndrome	I-Disease
.	O

A	O
maximum	O
two	O
-	O
point	O
lod	O
score	O
of	O
7	O
.	O

13	O
(	O
theta	O
=	O
0	O
.	O
00	O
)	O
for	O
marker	O
D2S2110	O
and	O
a	O
maximum	O
cumulative	O
multipoint	O
lod	O
score	O
of	O
9	O
.	O

16	O
for	O
marker	O
D2S2110	O
were	O
observed	O
,	O
further	O
supporting	O
linkage	O
to	O
chromosome	O
2p13	O
.	O

No	O
evidence	O
of	O
genetic	O
heterogeneity	O
was	O
observed	O
in	O
these	O
families	O
.	O

Meiotic	O
recombination	O
events	O
have	O
localized	O
the	O
critical	O
region	O
containing	O
ALMS1	O
to	O
a	O
6	O
.	O

1	O
-	O
cM	O
interval	O
flanked	O
by	O
markers	O
D2S327	O
and	O
D2S286	O
.	O

A	O
fine	O
resolution	O
radiation	O
hybrid	O
map	O
of	O
31	O
genes	O
and	O
markers	O
has	O
been	O
constructed	O
.	O

Pendred	B-Disease
syndrome	I-Disease
:	O
phenotypic	O
variability	O
in	O
two	O
families	O
carrying	O
the	O
same	O
PDS	B-Disease
missense	O
mutation	O
.	O

Pendred	B-Disease
syndrome	I-Disease
comprises	O
congenital	B-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
thyroid	B-Disease
goiter	I-Disease
,	O
and	O
positive	O
perchlorate	O
discharge	O
test	O
.	O

Recently	O
,	O
this	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
was	O
shown	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
PDS	B-Disease
gene	O
,	O
which	O
encodes	O
an	O
anion	O
transporter	O
called	O
pendrin	O
.	O

Molecular	O
analysis	O
of	O
the	O
PDS	B-Disease
gene	O
was	O
performed	O
in	O
two	O
consanguineous	O
large	O
families	O
from	O
Southern	O
Tunisia	O
comprising	O
a	O
total	O
of	O
23	O
individuals	O
affected	O
with	O
profound	O
congenital	B-Disease
deafness	I-Disease
;	O
the	O
same	O
missense	O
mutation	O
,	O
L445W	O
,	O
was	O
identified	O
in	O
all	O
affected	O
individuals	O
.	O

A	O
widened	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
was	O
found	O
in	O
all	O
patients	O
who	O
underwent	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
exploration	O
of	O
the	O
inner	O
ear	O
.	O

In	O
contrast	O
,	O
goiter	B-Disease
was	O
present	O
in	O
only	O
11	O
affected	O
individuals	O
,	O
who	O
interestingly	O
had	O
a	O
normal	O
result	O
of	O
the	O
perchlorate	O
discharge	O
test	O
whenever	O
performed	O
.	O

The	O
present	O
results	O
question	O
the	O
sensitivity	O
of	O
the	O
perchlorate	O
test	O
for	O
the	O
diagnosis	O
of	O
Pendred	B-Disease
syndrome	I-Disease
and	O
support	O
the	O
use	O
of	O
a	O
molecular	O
analysis	O
of	O
the	O
PDS	B-Disease
gene	O
in	O
the	O
assessment	O
of	O
individuals	O
with	O
severe	O
to	O
profound	O
congenital	B-Disease
hearing	I-Disease
loss	I-Disease
associated	O
with	O
inner	B-Disease
ear	I-Disease
morphological	I-Disease
anomaly	I-Disease
even	O
in	O
the	O
absence	O
of	O
a	O
thyroid	B-Disease
goiter	I-Disease
.	O
.	O

Knobloch	B-Disease
syndrome	I-Disease
involving	O
midline	B-Disease
scalp	I-Disease
defect	I-Disease
of	I-Disease
the	I-Disease
frontal	I-Disease
region	I-Disease
.	O

We	O
report	O
on	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
Knobloch	B-Disease
syndrome	I-Disease
.	O

He	O
has	O
vitreoretinal	B-Disease
degeneration	I-Disease
,	O
high	B-Disease
myopia	I-Disease
,	O
cataract	B-Disease
,	O
telecanthus	B-Disease
,	O
hypertelorism	B-Disease
,	O
and	O
a	O
high	B-Disease
-	I-Disease
arched	I-Disease
palate	I-Disease
.	O

He	O
also	O
has	O
a	O
defect	B-Disease
of	I-Disease
the	I-Disease
anterior	I-Disease
midline	I-Disease
scalp	I-Disease
with	O
involvement	O
of	O
the	O
frontal	O
bone	O
as	O
documented	O
by	O
a	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
.	O

The	O
brain	O
was	O
normal	O
on	O
CT	O
scan	O
and	O
magnetic	O
resonance	O
imaging	O
.	O

We	O
present	O
a	O
review	O
of	O
the	O
23	O
published	O
cases	O
with	O
this	O
syndrome	O
.	O

Our	O
patient	O
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	O
nervous	O
system	O
pathology	O
whenever	O
midline	B-Disease
scalp	I-Disease
defects	I-Disease
are	O
present	O
.	O
.	O

The	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
gene	O
hMRE11	O
is	O
mutated	O
in	O
individuals	O
with	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
-	I-Disease
like	I-Disease
disorder	I-Disease
.	O

We	O
show	O
that	O
hypomorphic	O
mutations	O
in	O
hMRE11	O
,	O
but	O
not	O
in	O
ATM	O
,	O
are	O
present	O
in	O
certain	O
individuals	O
with	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
-	I-Disease
like	I-Disease
disorder	I-Disease
(	O
ATLD	B-Disease
)	O
.	O

The	O
cellular	O
features	O
resulting	O
from	O
these	O
hMRE11	O
mutations	O
are	O
similar	O
to	O
those	O
seen	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
as	O
well	O
as	O
NBS	B-Disease
and	O
include	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
,	O
radioresistant	O
DNA	O
synthesis	O
,	O
and	O
abrogation	O
of	O
ATM	O
-	O
dependent	O
events	O
,	O
such	O
as	O
the	O
activation	O
of	O
Jun	O
kinase	O
following	O
exposure	O
to	O
gamma	O
irradiation	O
.	O

Although	O
the	O
mutant	O
hMre11	O
proteins	O
retain	O
some	O
ability	O
to	O
interact	O
with	O
hRad50	O
and	O
Nbs1	O
,	O
formation	O
of	O
ionizing	O
radiation	O
-	O
induced	O
hMre11	O
and	O
Nbs1	O
foci	O
was	O
absent	O
in	O
hMRE11	O
mutant	O
cells	O
.	O

These	O
data	O
demonstrate	O
that	O
ATM	O
and	O
the	O
hMre11	O
/	O
hRad50	O
/	O
Nbs1	O
protein	O
complex	O
act	O
in	O
the	O
same	O
DNA	O
damage	O
response	O
pathway	O
and	O
link	O
hMre11	O
to	O
the	O
complex	O
pathology	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
.	O
.	O

Mutations	O
in	O
TNFRSF11A	O
,	O
affecting	O
the	O
signal	O
peptide	O
of	O
RANK	O
,	O
cause	O
familial	B-Disease
expansile	I-Disease
osteolysis	I-Disease
.	O

Familial	B-Disease
expansile	I-Disease
osteolysis	I-Disease
(	O
FEO	B-Disease
,	O
MIM	O
174810	O
)	O
is	O
a	O
rare	O
,	O
autosomal	B-Disease
dominant	I-Disease
bone	I-Disease
disorder	I-Disease
characterized	O
by	O
focal	O
areas	O
of	O
increased	B-Disease
bone	I-Disease
remodelling	I-Disease
.	O

The	O
osteolytic	B-Disease
lesions	I-Disease
,	O
which	O
develop	O
usually	O
in	O
the	O
long	O
bones	O
during	O
early	O
adulthood	O
,	O
show	O
increased	O
osteoblast	O
and	O
osteoclast	O
activity	O
.	O

Our	O
previous	O
linkage	O
studies	O
mapped	O
the	O
gene	O
responsible	O
for	O
FEO	B-Disease
to	O
an	O
interval	O
of	O
less	O
than	O
5	O
cM	O
between	O
D18S64	O
and	O
D18S51	O
on	O
chromosome	O
18q21	O
.	O

2	O
-	O
21	O
2	O
-	O
21	O
.	O

3	O
in	O
a	O
large	O
Northern	O
Irish	O
family	O
.	O

The	O
gene	O
encoding	O
receptor	O
activator	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
RANK	O
;	O
ref	O
.	O
5	O
)	O
,	O
TNFRSF11A	O
,	O
maps	O
to	O
this	O
region	O
.	O

RANK	O
is	O
essential	O
in	O
osteoclast	O
formation	O
.	O

We	O
identified	O
two	O
heterozygous	O
insertion	O
mutations	O
in	O
exon	O
1	O
of	O
TNFRSF11A	O
in	O
affected	O
members	O
of	O
four	O
families	O
with	O
FEO	B-Disease
or	O
familial	B-Disease
Paget	I-Disease
disease	I-Disease
of	I-Disease
bone	I-Disease
(	O
PDB	B-Disease
)	O
.	O

One	O
was	O
a	O
duplication	O
of	O
18	O
bases	O
and	O
the	O
other	O
a	O
duplication	O
of	O
27	O
bases	O
,	O
both	O
of	O
which	O
affected	O
the	O
signal	O
peptide	O
region	O
of	O
the	O
RANK	O
molecule	O
.	O

Expression	O
of	O
recombinant	O
forms	O
of	O
the	O
mutant	O
RANK	O
proteins	O
revealed	O
perturbations	O
in	O
expression	O
levels	O
and	O
lack	O
of	O
normal	O
cleavage	O
of	O
the	O
signal	O
peptide	O
.	O

Both	O
mutations	O
caused	O
an	O
increase	O
in	O
RANK	O
-	O
mediated	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
signalling	O
in	O
vitro	O
,	O
consistent	O
with	O
the	O
presence	O
of	O
an	O
activating	O
mutation	O
.	O

Cardiac	O
Na	O
(	O
+	O
)	O
channel	O
dysfunction	O
in	O
Brugada	B-Disease
syndrome	I-Disease
is	O
aggravated	O
by	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
.	O

BACKGROUND	O
Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	O
cardiac	O
Na	O
(	O
+	O
)	O
channel	O
alpha	O
-	O
subunit	O
(	O
hH1	O
)	O
are	O
responsible	O
for	O
chromosome	O
3	O
-	O
linked	O
congenital	B-Disease
long	I-Disease
-	I-Disease
QT	I-Disease
syndrome	I-Disease
(	O
LQT3	B-Disease
)	O
and	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	I-Disease
(	O
IVF	B-Disease
)	O
.	O

An	O
auxiliary	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
,	O
widely	O
expressed	O
in	O
excitable	O
tissues	O
,	O
shifts	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	O
inactivation	O
toward	O
more	O
negative	O
potentials	O
and	O
restores	O
normal	O
gating	O
kinetics	O
of	O
brain	O
and	O
skeletal	O
muscle	O
Na	O
(	O
+	O
)	O
channels	O
expressed	O
in	O
Xenopus	O
oocytes	O
but	O
has	O
little	O
if	O
any	O
functional	O
effect	O
on	O
the	O
cardiac	O
isoform	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
altered	O
effects	O
of	O
a	O
human	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
(	O
hbeta	O
(	O
1	O
)	O
)	O
on	O
the	O
heterologously	O
expressed	O
hH1	O
mutation	O
(	O
T1620M	O
)	O
previously	O
associated	O
with	O
IVF	B-Disease
.	O

METHODS	O
AND	O
RESULTS	O
When	O
expressed	O
alone	O
in	O
Xenopus	O
oocytes	O
,	O
T1620M	O
exhibited	O
no	O
persistent	O
currents	O
,	O
in	O
contrast	O
to	O
the	O
LQT3	B-Disease
mutant	O
channels	O
,	O
but	O
the	O
midpoint	O
of	O
steady	O
-	O
state	O
inactivation	O
(	O
V	O
(	O
1	O
/	O
2	O
)	O
)	O
was	O
significantly	O
shifted	O
toward	O
more	O
positive	O
potentials	O
than	O
for	O
wild	O
-	O
type	O
hH1	O
.	O

Coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
did	O
not	O
significantly	O
alter	O
current	O
decay	O
or	O
recovery	O
from	O
inactivation	O
of	O
wild	O
-	O
type	O
hH1	O
;	O
however	O
,	O
it	O
further	O
shifted	O
the	O
V	O
(	O
1	O
/	O
2	O
)	O
and	O
accelerated	O
the	O
recovery	O
from	O
inactivation	O
of	O
T1620M	O
.	O

Oocyte	O
macropatch	O
analysis	O
revealed	O
that	O
the	O
activation	O
kinetics	O
of	O
T1620M	O
were	O
normal	O
.	O

CONCLUSIONS	O
It	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
exposes	O
a	O
more	O
severe	O
functional	O
defect	O
that	O
results	O
in	O
a	O
greater	O
overlap	O
in	O
the	O
relationship	O
between	O
channel	O
inactivation	O
and	O
activation	O
(	O
window	O
current	O
)	O
in	O
T1620M	O
,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
pathophysiological	O
mechanism	O
of	O
IVF	B-Disease
in	O
vivo	O
.	O

One	O
possible	O
explanation	O
for	O
our	O
finding	O
is	O
an	O
altered	O
alpha	O
-	O
/	O
beta	O
(	O
1	O
)	O
-	O
subunit	O
association	O
in	O
the	O
mutant	O
.	O
.	O

Meiotic	O
segregation	O
analysis	O
of	O
RB1	O
alleles	O
in	O
retinoblastoma	B-Disease
pedigrees	O
by	O
use	O
of	O
single	O
-	O
sperm	O
typing	O
.	O

In	O
hereditary	B-Disease
retinoblastoma	I-Disease
,	O
different	O
epidemiological	O
studies	O
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	O
of	O
mutant	O
retinoblastoma	B-Disease
alleles	O
to	O
offspring	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
meiotic	O
drive	O
.	O

To	O
investigate	O
this	O
mechanism	O
,	O
we	O
analyzed	O
sperm	O
samples	O
from	O
six	O
individuals	O
from	O
five	O
unrelated	O
families	O
affected	O
with	O
hereditary	B-Disease
retinoblastoma	I-Disease
.	O

Single	O
-	O
sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	O
of	O
two	O
informative	O
short	O
tandem	O
repeats	O
located	O
either	O
in	O
or	O
close	O
to	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
RB1	O
)	O
.	O

The	O
segregation	O
probability	O
of	O
mutant	O
RB1	O
alleles	O
in	O
sperm	O
samples	O
was	O
assessed	O
by	O
use	O
of	O
the	O
SPERMSEG	O
program	O
,	O
which	O
includes	O
experimental	O
parameters	O
,	O
recombination	O
fractions	O
between	O
the	O
markers	O
,	O
and	O
segregation	O
parameters	O
.	O

A	O
total	O
of	O
2	O
,	O
952	O
single	O
sperm	O
from	O
the	O
six	O
donors	O
were	O
analyzed	O
.	O

We	O
detected	O
a	O
significant	O
segregation	O
distortion	O
in	O
the	O
data	O
as	O
a	O
whole	O
(	O
P	O
=	O
.	O
0099	O
)	O
and	O
a	O
significant	O
heterogeneity	O
in	O
the	O
segregation	O
rate	O
across	O
donors	O
(	O
.	O
0092	O
)	O
.	O

Further	O
analysis	O
shows	O
that	O
this	O
result	O
can	O
be	O
explained	O
by	O
segregation	O
distortion	O
in	O
favor	O
of	O
the	O
normal	O
allele	O
in	O
one	O
donor	O
only	O
and	O
that	O
it	O
does	O
not	O
provide	O
evidence	O
of	O
a	O
significant	O
segregation	O
distortion	O
in	O
the	O
other	O
donors	O
.	O

The	O
segregation	O
distortion	O
favoring	O
the	O
mutant	O
RB1	O
allele	O
does	O
not	O
seem	O
to	O
occur	O
during	O
spermatogenesis	O
,	O
and	O
,	O
thus	O
,	O
meiotic	O
drive	O
may	O
result	O
either	O
from	O
various	O
mechanisms	O
,	O
including	O
a	O
fertilization	O
advantage	O
or	O
a	O
better	O
mobility	O
in	O
sperm	O
bearing	O
a	O
mutant	O
RB1	O
gene	O
,	O
or	O
from	O
the	O
existence	O
of	O
a	O
defectively	O
imprinted	O
gene	O
located	O
on	O
the	O
human	O
X	O
chromosome	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
:	O
an	O
overview	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
,	O
is	O
the	O
most	O
common	O
of	O
the	O
inherited	B-Disease
ataxias	I-Disease
.	O

The	O
recent	O
discovery	O
of	O
the	O
gene	O
that	O
is	O
mutated	O
in	O
this	O
condition	O
,	O
FRDA	O
,	O
has	O
led	O
to	O
rapid	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
Friedreich	B-Disease
ataxia	I-Disease
.	O

About	O
98	O
%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene	O
.	O

This	O
leads	O
to	O
reduced	O
levels	O
of	O
the	O
protein	O
,	O
frataxin	O
.	O

There	O
is	O
mounting	O
evidence	O
to	O
suggest	O
that	O
Friedreich	B-Disease
ataxia	I-Disease
is	O
the	O
result	O
of	O
accumulation	O
of	O
iron	O
in	O
mitochondria	O
leading	O
to	O
excess	O
production	O
of	O
free	O
radicals	O
,	O
which	O
then	O
results	O
in	O
cellular	O
damage	O
and	O
death	O
.	O

Currently	O
there	O
is	O
no	O
known	O
treatment	O
that	O
alters	O
the	O
natural	O
course	O
of	O
the	O
disease	O
.	O

The	O
discovery	O
of	O
the	O
FRDA	B-Disease
gene	O
and	O
its	O
possible	O
function	O
has	O
raised	O
hope	O
that	O
rational	O
therapeutic	O
strategies	O
will	O
be	O
developed	O
.	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
with	O
point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O

BACKGROUND	O
X	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
(	O
XLRS	B-Disease
)	O
is	O
a	O
relatively	O
rare	O
vitreoretinal	B-Disease
dystrophy	I-Disease
that	O
causes	O
visual	B-Disease
loss	I-Disease
in	O
young	O
men	O
.	O

Recently	O
,	O
a	O
gene	O
responsible	O
for	O
this	O
disease	O
,	O
designated	O
XLRS1	O
,	O
was	O
identified	O
,	O
and	O
several	O
deleterious	O
gene	O
mutations	O
were	O
reported	O
.	O

OBJECTIVE	O
To	O
analyze	O
Japanese	O
patients	O
clinically	O
diagnosed	O
as	O
having	O
XLRS	B-Disease
formutational	O
changes	O
in	O
the	O
XLRS1	O
gene	O
.	O

METHODS	O
Ten	O
patients	O
with	O
XLRS	B-Disease
underwent	O
full	O
ophthalmologic	O
examination	O
,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
dilated	O
funduscopy	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
,	O
and	O
all	O
exons	O
of	O
the	O
XLRS1	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
using	O
a	O
direct	O
sequencing	O
method	O
.	O

RESULTS	O
Point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
were	O
identified	O
in	O
all	O
10	O
patients	O
.	O

The	O
mutations	O
were	O
identical	O
in	O
each	O
of	O
2	O
pairs	O
of	O
brothers	O
.	O

Six	O
of	O
the	O
point	O
mutations	O
represented	O
missense	O
mutations	O
,	O
1	O
was	O
a	O
nonsense	O
mutation	O
,	O
and	O
1	O
was	O
a	O
frameshift	O
mutation	O
.	O

Five	O
of	O
the	O
mutations	O
are	O
newly	O
reported	O
herein	O
.	O

CONCLUSIONS	O
The	O
discovery	O
of	O
new	O
point	O
mutations	O
in	O
this	O
study	O
increases	O
the	O
available	O
information	O
regarding	O
the	O
spectrum	O
of	O
genetic	B-Disease
abnormalities	I-Disease
and	O
clinical	O
manifestations	O
of	O
XLRS	B-Disease
.	O

However	O
,	O
the	O
limited	O
data	O
failed	O
to	O
reveal	O
a	O
correlation	O
between	O
mutation	O
and	O
disease	O
phenotype	O
.	O

CLINICAL	O
RELEVANCE	O
Identification	O
of	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
and	O
expanded	O
information	O
on	O
clinical	O
manifestations	O
will	O
facilitate	O
early	O
diagnosis	O
,	O
appropriate	O
early	O
therapy	O
,	O
and	O
genetic	O
counseling	O
regarding	O
the	O
prognosis	O
of	O
XLRS	B-Disease
.	O
.	O

Atm	O
and	O
Bax	O
cooperate	O
in	O
ionizing	O
radiation	O
-	O
induced	O
apoptosis	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
is	O
a	O
hereditary	B-Disease
multisystemic	I-Disease
disease	I-Disease
resulting	O
from	O
mutations	O
of	O
ataxia	B-Disease
telangiectasia	I-Disease
,	O
mutated	O
(	O
ATM	O
)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	B-Disease
,	O
cancer	B-Disease
,	O
immune	B-Disease
defects	I-Disease
,	O
and	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
.	O

The	O
molecular	O
details	O
of	O
ATM	O
function	O
in	O
the	O
nervous	O
system	O
are	O
unclear	O
,	O
although	O
the	O
neurological	B-Disease
lesion	I-Disease
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
becomes	O
apparent	O
early	O
in	O
life	O
,	O
suggesting	O
a	O
developmental	O
origin	O
.	O

The	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
Atm	O
-	O
null	O
mice	O
shows	O
a	O
pronounced	O
defect	O
in	O
apoptosis	O
induced	O
by	O
genotoxic	O
stress	O
,	O
suggesting	O
ATM	O
functions	O
to	O
eliminate	O
neurons	O
with	O
excessive	O
genomic	O
damage	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
death	O
effector	O
Bax	O
is	O
required	O
for	O
a	O
large	O
proportion	O
of	O
Atm	O
-	O
dependent	O
apoptosis	O
in	O
the	O
developing	O
CNS	O
after	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O

Although	O
many	O
of	O
the	O
same	O
regions	O
of	O
the	O
CNS	O
in	O
both	O
Bax	O
-	O
/	O
-	O
and	O
Atm	O
-	O
/	O
-	O
mice	O
were	O
radioresistant	O
,	O
mice	O
nullizygous	O
for	O
both	O
Bax	O
and	O
Atm	O
showed	O
additional	O
reduction	O
in	O
IR	O
-	O
induced	O
apoptosis	O
in	O
the	O
CNS	O
.	O

Therefore	O
,	O
although	O
the	O
major	O
IR	O
-	O
induced	O
apoptotic	O
pathway	O
in	O
the	O
CNS	O
requires	O
Atm	O
and	O
Bax	O
,	O
a	O
p53	O
-	O
dependent	O
collateral	O
pathway	O
exists	O
that	O
has	O
both	O
Atm	O
-	O
and	O
Bax	O
-	O
independent	O
branches	O
.	O

Further	O
,	O
Atm	O
-	O
and	O
Bax	O
-	O
dependent	O
apoptosis	O
in	O
the	O
CNS	O
also	O
required	O
caspase	O
-	O
3	O
activation	O
.	O

These	O
data	O
implicate	O
Bax	O
and	O
caspase	O
-	O
3	O
as	O
death	O
effectors	O
in	O
neurodegenerative	O
pathways	O
.	O
.	O

Haim	B-Disease
-	I-Disease
Munk	I-Disease
syndrome	I-Disease
and	O
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
are	O
allelic	O
mutations	O
in	O
cathepsin	O
C	O
.	O

Of	O
the	O
many	O
palmoplantar	B-Disease
keratoderma	I-Disease
(	I-Disease
PPK	I-Disease
)	I-Disease
conditions	I-Disease
,	O
only	O
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
(	O
PLS	B-Disease
)	O
and	O
Haim	B-Disease
-	I-Disease
Munk	I-Disease
syndrome	I-Disease
(	O
HMS	B-Disease
)	O
are	O
associated	O
with	O
premature	O
periodontal	O
destruction	O
.	O

Although	O
both	O
PLS	B-Disease
and	O
HMS	B-Disease
share	O
the	O
cardinal	O
features	O
of	O
PPK	B-Disease
and	O
severe	O
periodontitis	B-Disease
,	O
a	O
number	O
of	O
additional	O
findings	O
are	O
reported	O
in	O
HMS	B-Disease
including	O
arachnodactyly	B-Disease
,	O
acro	B-Disease
-	I-Disease
osteolysis	I-Disease
,	O
atrophic	B-Disease
changes	I-Disease
of	I-Disease
the	I-Disease
nails	I-Disease
,	O
and	O
a	O
radiographic	B-Disease
deformity	I-Disease
of	I-Disease
the	I-Disease
fingers	I-Disease
.	O

While	O
PLS	B-Disease
cases	O
have	O
been	O
identified	O
throughout	O
the	O
world	O
,	O
HMS	B-Disease
has	O
only	O
been	O
described	O
among	O
descendants	O
of	O
a	O
religious	O
isolate	O
originally	O
from	O
Cochin	O
,	O
India	O
.	O

Parental	O
consanguinity	O
is	O
a	O
characteristic	O
of	O
many	O
cases	O
of	O
both	O
conditions	O
.	O

Although	O
autosomal	O
recessive	O
transmission	O
of	O
PLS	B-Disease
is	O
evident	O
,	O
a	O
more	O
"	O
complex	O
"	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
with	O
phenotypic	O
influences	O
from	O
a	O
closely	O
linked	O
modifying	O
locus	O
has	O
been	O
hypothesised	O
for	O
HMS	B-Disease
.	O

Recently	O
,	O
mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
have	O
been	O
identified	O
as	O
the	O
underlying	O
genetic	B-Disease
defect	I-Disease
in	O
PLS	B-Disease
.	O

To	O
determine	O
if	O
a	O
cathepsin	O
C	O
mutation	O
is	O
also	O
responsible	O
for	O
HMS	B-Disease
,	O
we	O
sequenced	O
the	O
gene	O
in	O
affected	O
and	O
unaffected	O
subjects	O
from	O
the	O
Cochin	O
isolate	O
in	O
which	O
both	O
the	O
PLS	B-Disease
and	O
HMS	B-Disease
phenotypes	O
appear	O
.	O

Here	O
we	O
report	O
identification	O
of	O
a	O
mutation	O
of	O
cathepsin	O
C	O
(	O
exon	O
6	O
,	O
2127A	O
-	O
-	O
>	O
G	O
)	O
that	O
changes	O
a	O
highly	O
conserved	O
amino	O
acid	O
in	O
the	O
cathepsin	O
C	O
peptide	O
.	O

This	O
mutation	O
segregates	O
with	O
HMS	B-Disease
in	O
four	O
nuclear	O
families	O
.	O

Additionally	O
,	O
the	O
existence	O
of	O
a	O
shared	O
common	O
haplotype	O
for	O
genetic	O
loci	O
flanking	O
the	O
cathepsin	O
C	O
gene	O
suggests	O
that	O
affected	O
subjects	O
descended	O
from	O
the	O
Cochin	O
isolate	O
are	O
homozygous	O
for	O
a	O
mutation	O
inherited	O
"	O
identical	O
by	O
descent	O
"	O
from	O
a	O
common	O
ancestor	O
.	O

This	O
finding	O
supports	O
simple	O
autosomal	O
recessive	O
inheritance	O
for	O
HMS	B-Disease
in	O
these	O
families	O
.	O

We	O
also	O
report	O
a	O
mutation	O
of	O
the	O
same	O
exon	O
6	O
CTSC	O
codon	O
(	O
2126C	O
-	O
-	O
>	O
T	O
)	O
in	O
a	O
Turkish	O
family	O
with	O
classical	O
PLS	B-Disease
.	O

These	O
findings	O
provide	O
evidence	O
that	O
PLS	B-Disease
and	O
HMS	B-Disease
are	O
allelic	O
variants	O
of	O
cathepsin	O
C	O
gene	O
mutations	O
.	O
.	O

ATM	O
-	O
heterozygous	O
germline	O
mutations	O
contribute	O
to	O
breast	B-Disease
cancer	I-Disease
-	O
susceptibility	O
.	O

Approximately	O
0	O
.	O

5	O
%	O
-	O
1	O
%	O
of	O
the	O
general	O
population	O
has	O
been	O
estimated	O
to	O
be	O
heterozygous	O
for	O
a	O
germline	O
mutation	O
in	O
the	O
ATM	O
gene	O
.	O

Mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
(	O
MIM	O
208900	O
)	O
.	O

The	O
finding	O
that	O
ATM	O
-	O
heterozygotes	O
have	O
an	O
increased	O
relative	O
risk	O
for	O
breast	B-Disease
cancer	I-Disease
was	O
supported	O
by	O
some	O
studies	O
but	O
not	O
confirmed	O
by	O
others	O
.	O

In	O
view	O
of	O
this	O
discrepancy	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
ATM	O
germline	O
mutations	O
in	O
a	O
selected	O
group	O
of	O
Dutch	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

We	O
have	O
analyzed	O
ATM	O
germline	O
mutations	O
in	O
normal	O
blood	O
lymphocytes	O
,	O
using	O
the	O
protein	O
-	O
truncation	O
test	O
followed	O
by	O
genomic	O
-	O
sequence	O
analysis	O
.	O

A	O
high	O
percentage	O
of	O
ATM	O
germline	O
mutations	O
was	O
demonstrated	O
among	O
patients	O
with	O
sporadic	B-Disease
breast	I-Disease
cancer	I-Disease
.	O

The	O
82	O
patients	O
included	O
in	O
this	O
study	O
had	O
developed	O
breast	B-Disease
cancer	I-Disease
at	O
age	O
<	O
45	O
and	O
had	O
survived	O
>	O
/	O
=	O
5	O
years	O
(	O
mean	O
15	O
years	O
)	O
,	O
and	O
in	O
33	O
(	O
40	O
%	O
)	O
of	O
the	O
patients	O
a	O
contralateral	O
breast	O
tumor	O
had	O
been	O
diagnosed	O
.	O

Among	O
these	O
patients	O
we	O
identified	O
seven	O
(	O
8	O
.	O
5	O
%	O
)	O
ATM	O
germline	O
mutations	O
,	O
of	O
which	O
five	O
are	O
distinct	O
.	O

One	O
splice	O
-	O
site	O
mutation	O
(	O
IVS10	O
-	O
6T	O
-	O
-	O
>	O
G	O
)	O
was	O
detected	O
three	O
times	O
in	O
our	O
series	O
.	O

Four	O
heterozygous	O
carriers	O
were	O
patients	O
with	O
bilateral	O
breast	O
cancer	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
"	O
A	O
-	O
T	O
disease	O
-	O
causing	O
"	O
mutations	O
that	O
might	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
in	O
heterozygotes	O
.	O

We	O
conclude	O
that	O
ATM	O
heterozygotes	O
have	O
an	O
approximately	O
ninefold	O
-	O
increased	O
risk	O
of	O
developing	O
a	O
type	O
of	O
breast	O
cancer	O
characterized	O
by	O
frequent	O
bilateral	O
occurrence	O
,	O
early	O
age	O
at	O
onset	O
,	O
and	O
long	O
-	O
term	O
survival	O
.	O

The	O
specific	O
characteristics	O
of	O
our	O
population	O
of	O
patients	O
may	O
explain	O
why	O
such	O
a	O
high	O
frequency	O
was	O
not	O
found	O
in	O
other	O
series	O
.	O

Human	O
mutations	O
in	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
reflect	O
evolutionary	O
history	O
.	O

Glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
is	O
a	O
cytosolic	O
enzyme	O
encoded	O
by	O
a	O
housekeeping	O
X	O
-	O
linked	O
gene	O
whose	O
main	O
function	O
is	O
to	O
produce	O
NADPH	O
,	O
a	O
key	O
electron	O
donor	O
in	O
the	O
defense	O
against	O
oxidizing	O
agents	O
and	O
in	O
reductive	O
biosynthetic	O
reactions	O
.	O

Inherited	O
G6PD	B-Disease
deficiency	I-Disease
is	O
associated	O
with	O
either	O
episodic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
triggered	O
by	O
fava	O
beans	O
or	O
other	O
agents	O
)	O
or	O
life	B-Disease
-	I-Disease
long	I-Disease
hemolytic	I-Disease
anemia	I-Disease
.	O

We	O
show	O
here	O
that	O
an	O
evolutionary	O
analysis	O
is	O
a	O
key	O
to	O
understanding	O
the	O
biology	O
of	O
a	O
housekeeping	O
gene	O
.	O

From	O
the	O
alignment	O
of	O
the	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
of	O
52	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
species	O
from	O
42	O
different	O
organisms	O
,	O
we	O
found	O
a	O
striking	O
correlation	O
between	O
the	O
aa	O
replacements	O
that	O
cause	O
G6PD	B-Disease
deficiency	I-Disease
in	O
humans	O
and	O
the	O
sequence	O
conservation	O
of	O
G6PD	O
two	O
-	O
thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	O
and	O
moderately	O
conserved	O
(	O
50	O
-	O
99	O
%	O
)	O
aa	O
;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	O
aa	O
(	O
where	O
they	O
might	O
be	O
lethal	O
)	O
or	O
in	O
poorly	O
conserved	O
aa	O
,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
G6PD	B-Disease
deficiency	I-Disease
.	O

This	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
all	O
human	O
mutants	O
have	O
residual	O
enzyme	O
activity	O
and	O
that	O
null	O
mutations	O
are	O
lethal	O
at	O
some	O
stage	O
of	O
development	O
.	O

Comparing	O
the	O
distribution	O
of	O
mutations	O
in	O
a	O
human	O
housekeeping	O
gene	O
with	O
evolutionary	O
conservation	O
is	O
a	O
useful	O
tool	O
for	O
pinpointing	O
amino	O
acid	O
residues	O
important	O
for	O
the	O
stability	O
or	O
the	O
function	O
of	O
the	O
corresponding	O
protein	O
.	O

In	O
view	O
of	O
the	O
current	O
explosive	O
increase	O
in	O
full	O
genome	O
sequencing	O
projects	O
,	O
this	O
tool	O
will	O
become	O
rapidly	O
available	O
for	O
numerous	O
other	O
genes	O
.	O
.	O

Constitutive	O
and	O
regulated	O
modes	O
of	O
splicing	O
produce	O
six	O
major	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
(	O
DMPK	O
)	O
isoforms	O
with	O
distinct	O
properties	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
the	O
most	O
prevalent	O
inherited	B-Disease
neuromuscular	I-Disease
disease	I-Disease
in	O
adults	O
.	O

The	O
genetic	B-Disease
defect	I-Disease
is	O
a	O
CTG	O
triplet	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
(	O
DMPK	O
)	O
gene	O
,	O
consisting	O
of	O
15	O
exons	O
.	O

Using	O
a	O
transgenic	O
DMPK	O
-	O
overexpressor	O
mouse	O
model	O
,	O
we	O
demonstrate	O
here	O
that	O
the	O
endogenous	O
mouse	O
DMPK	O
gene	O
and	O
the	O
human	O
DMPK	O
transgene	O
produce	O
six	O
major	O
alternatively	O
spliced	O
mRNAs	O
which	O
have	O
almost	O
identical	O
cell	O
type	O
-	O
dependent	O
distribution	O
frequencies	O
and	O
expression	O
patterns	O
.	O

Use	O
of	O
a	O
cryptic	O
5	O
splice	O
site	O
in	O
exon	O
8	O
,	O
which	O
results	O
in	O
absence	O
or	O
presence	O
of	O
15	O
nucleotides	O
specifying	O
a	O
VSGGG	O
peptide	O
motif	O
,	O
and	O
/	O
or	O
use	O
of	O
a	O
cryptic	O
3	O
splice	O
site	O
in	O
exon	O
14	O
,	O
which	O
leads	O
to	O
a	O
frameshift	O
in	O
the	O
mRNA	O
reading	O
frame	O
,	O
occur	O
as	O
independent	O
stochastic	O
events	O
in	O
all	O
tissues	O
examined	O
.	O

In	O
contrast	O
,	O
the	O
excision	O
of	O
exons	O
13	O
/	O
14	O
that	O
causes	O
a	O
frameshift	O
and	O
creates	O
a	O
C	O
-	O
terminally	O
truncated	O
protein	O
is	O
clearly	O
cell	O
type	O
dependent	O
and	O
occurs	O
predominantly	O
in	O
smooth	O
muscle	O
.	O

We	O
generated	O
all	O
six	O
full	O
-	O
length	O
mouse	O
cDNAs	O
that	O
result	O
from	O
combinations	O
of	O
these	O
three	O
major	O
splicing	O
events	O
and	O
show	O
that	O
their	O
transfection	O
into	O
cells	O
in	O
culture	O
leads	O
to	O
production	O
of	O
four	O
different	O
approximately	O
74	O
kDa	O
full	O
-	O
length	O
(	O
heart	O
-	O
,	O
skeletal	O
muscle	O
-	O
or	O
brain	O
-	O
specific	O
)	O
and	O
two	O
C	O
-	O
terminally	O
truncated	O
approximately	O
68	O
kDa	O
(	O
smooth	O
muscle	O
-	O
specific	O
)	O
isoforms	O
.	O

Information	O
on	O
DMPK	O
mRNA	O
and	O
protein	O
isoform	O
expression	O
patterns	O
will	O
be	O
useful	O
for	O
recognizing	O
differential	O
effects	O
of	O
(	O
CTG	O
)	O
(	O
n	O
)	O
expansion	O
in	O
DM	B-Disease
manifestation	O
.	O
.	O

Genetic	O
analysis	O
,	O
phenotypic	O
diagnosis	O
,	O
and	O
risk	O
of	O
venous	B-Disease
thrombosis	I-Disease
in	O
families	O
with	O
inherited	O
deficiencies	B-Disease
of	I-Disease
protein	I-Disease
S	I-Disease
.	O

Protein	B-Disease
S	I-Disease
deficiency	I-Disease
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	B-Disease
thrombosis	I-Disease
.	O

Of	O
all	O
the	O
inherited	O
thrombophilic	B-Disease
conditions	I-Disease
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	O
variability	O
,	O
which	O
can	O
lead	O
to	O
inconclusive	O
results	O
.	O

We	O
have	O
overcome	O
this	O
problem	O
by	O
studying	O
a	O
cohort	O
of	O
patients	O
from	O
a	O
single	O
center	O
where	O
the	O
diagnosis	O
was	O
confirmed	O
at	O
the	O
genetic	O
level	O
.	O

Twenty	O
-	O
eight	O
index	O
patients	O
with	O
protein	B-Disease
S	I-Disease
deficiency	I-Disease
and	O
a	O
PROS1	B-Disease
gene	I-Disease
defect	I-Disease
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	O
relatives	O
.	O

To	O
avoid	O
selection	O
bias	O
,	O
we	O
confined	O
analysis	O
of	O
total	O
and	O
free	O
protein	O
S	O
levels	O
and	O
thrombotic	O
risk	O
to	O
the	O
patients	O
relatives	O
.	O

In	O
this	O
group	O
of	O
relatives	O
,	O
a	O
low	O
free	O
protein	O
S	O
level	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
PROS1	B-Disease
gene	I-Disease
defect	I-Disease
(	O
sensitivity	O
97	O
.	O
7	O
%	O
,	O
specificity	O
100	O
%	O
)	O
.	O

First	O
-	O
degree	O
relatives	O
with	O
a	O
PROS1	B-Disease
gene	I-Disease
defect	I-Disease
had	O
a	O
5	O
.	O

0	O
-	O
fold	O
higher	O
risk	O
of	O
thrombosis	B-Disease
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
-	O
16	O
.	O
8	O
)	O
than	O
those	O
with	O
a	O
normal	O
PROS1	O
gene	O
and	O
no	O
other	O
recognized	O
thrombophilic	B-Disease
defect	I-Disease
.	O

Although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B-Disease
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B-Disease
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous	O
.	O

Relatives	O
with	O
splice	O
-	O
site	O
or	O
major	O
structural	O
defects	B-Disease
in	I-Disease
the	I-Disease
PROS1	I-Disease
gene	I-Disease
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	O
event	O
and	O
had	O
significantly	O
lower	O
total	O
and	O
free	O
protein	O
S	O
levels	O
than	O
those	O
relatives	O
having	O
missense	O
mutations	O
.	O

We	O
conclude	O
that	O
persons	O
with	O
PROS1	B-Disease
gene	I-Disease
defects	I-Disease
and	O
protein	B-Disease
S	I-Disease
deficiency	I-Disease
are	O
at	O
increased	O
risk	O
of	O
thrombosis	B-Disease
and	O
that	O
free	O
protein	O
S	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	O
.	O

(	O
Blood	O
.	O
2000	O
;	O
95	O
1935	O
-	O
1941	O
)	O
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
in	O
a	O
child	O
from	O
consanguineous	O
parents	O
:	O
a	O
dominant	O
or	O
recessive	O
disease	O
?	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
is	O
characterized	O
by	O
autoimmune	O
features	O
and	O
lymphoproliferations	O
and	O
is	O
generally	O
caused	O
by	O
defective	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

This	O
report	O
describes	O
a	O
child	O
with	O
clinical	O
features	O
of	O
ALPS	B-Disease
without	O
detectable	O
Fas	O
expression	O
on	O
freshly	O
isolated	O
blood	O
leukocytes	O
.	O

Detection	O
of	O
FAS	O
transcripts	O
via	O
real	O
-	O
time	O
quantitative	O
PCR	O
made	O
a	O
severe	O
transcriptional	O
defect	O
unlikely	O
.	O

Sequencing	O
of	O
the	O
FAS	O
gene	O
revealed	O
a	O
20	O
-	O
nucleotide	O
duplication	O
in	O
the	O
last	O
exon	O
affecting	O
the	O
cytoplasmic	O
signaling	O
domain	O
.	O

The	O
patient	O
was	O
homozygous	O
for	O
this	O
mutation	O
,	O
whereas	O
the	O
consanguineous	O
parents	O
and	O
the	O
siblings	O
were	O
heterozygous	O
.	O

The	O
patient	O
reported	O
here	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Fas	O
-	O
null	O
mouse	O
,	O
inasmuch	O
as	O
she	O
carries	O
an	O
autosomal	O
homozygous	O
mutation	O
in	O
the	O
FAS	O
gene	O
and	O
she	O
shows	O
the	O
severe	O
and	O
accelerated	O
ALPS	B-Disease
phenotype	O
.	O

The	O
heterozygous	O
family	O
members	O
did	O
not	O
have	O
the	O
ALPS	B-Disease
phenotype	O
,	O
indicating	O
that	O
the	O
disease	O
-	O
causing	O
FAS	O
mutation	O
in	O
this	O
family	O
is	O
autosomal	O
recessive	O
.	O
.	O

Identification	O
of	O
novel	O
imprinted	O
transcripts	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
and	O
Angelman	B-Disease
syndrome	I-Disease
deletion	O
region	O
:	O
further	O
evidence	O
for	O
regional	O
imprinting	O
control	O
.	O

Deletions	O
and	O
other	O
abnormalities	O
of	O
human	O
chromosome	O
15q11	O
-	O
q13	O
are	O
associated	O
with	O
two	O
developmental	O
disorders	O
,	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
and	O
Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
.	O

Loss	O
of	O
expression	O
of	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
has	O
been	O
implicated	O
in	O
PWS	B-Disease
.	O

However	O
,	O
the	O
number	O
of	O
imprinted	O
genes	O
that	O
contribute	O
to	O
PWS	B-Disease
,	O
and	O
the	O
range	O
over	O
which	O
the	O
imprinting	O
signal	O
acts	O
to	O
silence	O
one	O
copy	O
of	O
the	O
gene	O
in	O
a	O
parent	O
-	O
of	O
-	O
origin	O
-	O
specific	O
manner	O
,	O
are	O
unknown	O
.	O

To	O
identify	O
additional	O
imprinted	O
genes	O
that	O
could	O
contribute	O
to	O
the	O
PWS	B-Disease
phenotype	O
and	O
to	O
understand	O
the	O
regional	O
control	O
of	O
imprinting	O
in	O
15q11	O
-	O
q13	O
,	O
we	O
have	O
constructed	O
an	O
imprinted	O
transcript	O
map	O
of	O
the	O
PWS	O
-	O
AS	O
deletion	O
interval	O
.	O

The	O
imprinting	O
status	O
of	O
22	O
expressed	O
sequence	O
tags	O
derived	O
from	O
the	O
radiation	O
-	O
hybrid	O
human	O
transcript	O
maps	O
or	O
physical	O
maps	O
was	O
determined	O
in	O
a	O
reverse	O
transcriptase	O
-	O
PCR	O
assay	O
and	O
correlated	O
with	O
the	O
position	O
of	O
the	O
transcripts	O
on	O
the	O
physical	O
map	O
.	O

Seven	O
new	O
paternally	O
expressed	O
transcripts	O
localize	O
to	O
an	O
approximately	O
1	O
.	O

5	O
-	O
Mb	O
domain	O
surrounding	O
the	O
SNRPN	O
-	O
associated	O
imprinting	O
center	O
,	O
which	O
already	O
includes	O
four	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
.	O

All	O
other	O
tested	O
new	O
transcripts	O
in	O
the	O
deletion	O
region	O
were	O
expressed	O
from	O
both	O
alleles	O
.	O

A	O
domain	O
of	O
exclusive	O
paternal	O
expression	O
surrounding	O
the	O
imprinting	O
center	O
suggests	O
strong	O
regional	O
control	O
of	O
the	O
imprinting	O
process	O
.	O

This	O
study	O
provides	O
the	O
means	O
for	O
further	O
investigation	O
of	O
additional	O
genes	O
that	O
cause	O
or	O
modify	O
the	O
phenotypes	O
associated	O
with	O
rearrangements	O
of	O
15q11	O
-	O
q13	O
.	O

Combined	O
analysis	O
of	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
linkage	O
to	O
1q24	O
-	O
25	O
:	O
results	O
from	O
772	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
families	O
from	O
the	O
International	O
Consortium	O
for	O
Prostate	B-Disease
Cancer	I-Disease
Genetics	O
.	O

A	O
previous	O
linkage	O
study	O
provided	O
evidence	O
for	O
a	O
prostate	B-Disease
cancer	I-Disease
-	O
susceptibility	O
locus	O
at	O
1q24	O
-	O
25	O
.	O

Subsequent	O
reports	O
in	O
additional	O
collections	O
of	O
families	O
have	O
yielded	O
conflicting	O
results	O
.	O

In	O
addition	O
,	O
evidence	O
for	O
locus	O
heterogeneity	O
has	O
been	O
provided	O
by	O
the	O
identification	O
of	O
other	O
putative	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
loci	O
on	O
Xq27	O
-	O
28	O
,	O
1q42	O
-	O
43	O
,	O
and	O
1p36	O
.	O

The	O
present	O
study	O
describes	O
a	O
combined	O
analysis	O
for	O
six	O
markers	O
in	O
the	O
1q24	O
-	O
25	O
region	O
in	O
772	O
families	O
affected	O
by	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
and	O
ascertained	O
by	O
the	O
members	O
of	O
the	O
International	O
Consortium	O
for	O
Prostate	B-Disease
Cancer	I-Disease
Genetics	O
(	O
ICPCG	O
)	O
from	O
North	O
America	O
,	O
Australia	O
,	O
Finland	O
,	O
Norway	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
Kingdom	O
.	O

Overall	O
,	O
there	O
was	O
some	O
evidence	O
for	O
linkage	O
,	O
with	O
a	O
peak	O
parametric	O
multipoint	O
LOD	O
score	O
assuming	O
heterogeneity	O
(	O
HLOD	O
)	O
of	O
1	O
.	O

40	O
(	O
P	O
=	O
.	O
01	O
)	O
at	O
D1S212	O
.	O

The	O
estimated	O
proportion	O
of	O
families	O
(	O
alpha	O
)	O
linked	O
to	O
the	O
locus	O
was	O
.	O

06	O
(	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
01	O
-	O
.	O
12	O
)	O
.	O

This	O
evidence	O
was	O
not	O
observed	O
by	O
a	O
nonparametric	O
approach	O
,	O
presumably	O
because	O
of	O
the	O
extensive	O
heterogeneity	O
.	O

Further	O
parametric	O
analysis	O
revealed	O
a	O
significant	O
effect	O
of	O
the	O
presence	O
of	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
within	O
the	O
families	O
.	O

In	O
the	O
subset	O
of	O
491	O
such	O
families	O
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O

In	O
the	O
subset	O
of	O
491	O
such	O
families	O
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O

56	O
(	O
P	O
=	O
.	O
0006	O
)	O
and	O
alpha	O
=	O
.	O

11	O
(	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
04	O
-	O
.	O
19	O
)	O
,	O
compared	O
with	O
HLODs	O
of	O
0	O
in	O
the	O
remaining	O
281	O
families	O
.	O

Within	O
the	O
families	O
with	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
,	O
alpha	O
increased	O
with	O
the	O
early	O
mean	O
age	O
at	O
diagnosis	O
(	O
<	O
65	O
years	O
,	O
alpha	O
=	O
.	O
19	O
,	O
with	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
06	O
-	O
.	O
34	O
)	O
and	O
the	O
number	O
of	O
affected	O
family	O
members	O
(	O
five	O
or	O
more	O
family	O
members	O
,	O
alpha	O
=	O
.	O
15	O
,	O
with	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
04	O
-	O
.	O
28	O
)	O
.	O

The	O
highest	O
value	O
of	O
alpha	O
was	O
observed	O
for	O
the	O
48	O
families	O
that	O
met	O
all	O
three	O
criteria	O
(	O
peak	O
HLOD	O
=	O
2	O
.	O
25	O
,	O
P	O
=	O
.	O
001	O
,	O
alpha	O
=	O
.	O
29	O
,	O
with	O
1	O
-	O
LOD	O
support	O
interval	O
.	O
08	O
-	O
.	O
53	O
)	O
.	O

These	O
results	O
support	O
the	O
finding	O
of	O
a	O
prostate	B-Disease
cancer	I-Disease
-	O
susceptibility	O
gene	O
linked	O
to	O
1q24	O
-	O
25	O
,	O
albeit	O
in	O
a	O
defined	O
subset	O
of	O
prostate	B-Disease
cancer	I-Disease
families	O
.	O

Although	O
HPC1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	O
of	O
all	O
families	O
affected	O
by	O
hereditary	B-Disease
prostate	I-Disease
cancer	I-Disease
,	O
it	O
appears	O
to	O
play	O
a	O
more	O
prominent	O
role	O
in	O
the	O
subset	O
of	O
families	O
with	O
several	O
members	O
affected	O
at	O
an	O
early	O
age	O
and	O
with	O
male	O
-	O
to	O
-	O
male	O
disease	O
transmission	O
.	O

A	O
recurrent	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
CAG	O
repeats	O
causes	O
Huntington	B-Disease
disease	I-Disease
in	O
two	O
sisters	O
.	O

Large	O
intergenerational	O
repeat	O
expansions	O
of	O
the	O
CAG	O
trinucleotide	O
repeat	O
in	O
the	O
HD	B-Disease
gene	O
have	O
been	O
well	O
documented	O
for	O
the	O
male	O
germline	O
.	O

We	O
describe	O
a	O
recurrent	O
large	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
CAG	O
repeats	O
(	O
to	O
66	O
and	O
57	O
repeats	O
,	O
respectively	O
,	O
in	O
two	O
daughters	O
)	O
associated	O
with	O
onset	O
of	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
in	O
the	O
second	O
and	O
third	O
decade	O
in	O
a	O
family	O
without	O
history	O
of	O
HD	B-Disease
.	O

Our	O
findings	O
give	O
evidence	O
of	O
a	O
gonadal	O
mosaicism	O
in	O
the	O
unaffected	O
mother	O
.	O

We	O
hypothesize	O
that	O
large	O
expansions	O
also	O
occur	O
in	O
the	O
female	O
germline	O
and	O
that	O
a	O
negative	O
selection	O
of	O
oocytes	O
with	O
long	O
repeats	O
might	O
explain	O
the	O
different	O
instability	O
behavior	O
of	O
the	O
male	O
and	O
the	O
female	O
germlines	O
.	O
.	O

Abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
in	O
Atm	O
mutant	O
mice	O
.	O

Motor	B-Disease
incoordination	I-Disease
,	O
immune	B-Disease
deficiencies	I-Disease
,	O
and	O
an	O
increased	O
risk	O
of	O
cancer	B-Disease
are	O
the	O
characteristic	O
features	O
of	O
the	O
hereditary	B-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
.	O

Through	O
gene	O
targeting	O
,	O
we	O
have	O
generated	O
a	O
line	O
of	O
Atm	O
mutant	O
mice	O
,	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
.	O

In	O
contrast	O
to	O
other	O
Atm	O
mutant	O
mice	O
,	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
show	O
a	O
lower	O
incidence	O
of	O
thymic	B-Disease
lymphoma	I-Disease
and	O
survive	O
beyond	O
a	O
few	O
months	O
of	O
age	O
.	O

Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	B-Disease
dysfunction	I-Disease
.	O

Even	O
though	O
we	O
found	O
no	O
gross	O
cerebellar	B-Disease
degeneration	I-Disease
in	O
older	O
Atm	O
(	O
y	O
/	O
y	O
)	O
animals	O
,	O
ectopic	O
and	O
abnormally	O
differentiated	O
Purkinje	O
cells	O
were	O
apparent	O
in	O
mutant	O
mice	O
of	O
all	O
ages	O
.	O

These	O
findings	O
establish	O
that	O
some	O
neuropathological	B-Disease
abnormalities	I-Disease
seen	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
also	O
are	O
present	O
in	O
Atm	O
mutant	O
mice	O
.	O

In	O
addition	O
,	O
we	O
report	O
a	O
previously	O
unrecognized	O
effect	O
of	O
Atm	B-Disease
deficiency	I-Disease
on	O
development	O
or	O
maintenance	O
of	O
CD4	O
(	O
+	O
)	O
8	O
(	O
+	O
)	O
thymocytes	O
.	O

We	O
discuss	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
hypothesis	O
that	O
abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
.	O
.	O

Novel	O
mutations	O
of	O
the	O
ATP7B	O
gene	O
in	O
Japanese	O
patients	O
with	O
Wilson	B-Disease
disease	I-Disease
.	O

Wilson	B-Disease
disease	I-Disease
(	O
WD	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
copper	O
accumulation	O
in	O
the	O
liver	O
,	O
brain	O
,	O
kidneys	O
,	O
and	O
corneas	O
,	O
and	O
culminating	O
in	O
copper	O
toxication	O
in	O
these	O
organs	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
mutations	O
of	O
the	O
responsible	O
gene	O
,	O
ATP7B	O
,	O
in	O
four	O
Japanese	O
patients	O
with	O
WD	B-Disease
.	O

By	O
direct	O
sequencing	O
,	O
we	O
identified	O
five	O
mutations	O
,	O
of	O
which	O
two	O
were	O
novel	O
,	O
and	O
16	O
polymorphisms	O
,	O
of	O
which	O
6	O
were	O
novel	O
.	O

The	O
mutations	O
2871delC	O
and	O
2513delA	O
shift	O
the	O
reading	O
frame	O
so	O
that	O
truncated	O
abnormal	O
protein	O
is	O
expected	O
.	O

In	O
contrast	O
to	O
these	O
mutations	O
found	O
in	O
patients	O
with	O
hepatic	O
-	O
type	O
of	O
early	O
onset	O
,	O
the	O
mutations	O
A874V	O
,	O
R778L	O
,	O
and	O
3892delGTC	O
were	O
either	O
missense	O
mutations	O
or	O
in	O
frame	O
1	O
-	O
amino	O
acid	O
deletion	O
,	O
and	O
occurred	O
in	O
the	O
patients	O
with	O
hepato	O
-	O
neurologic	O
type	O
of	O
late	O
onset	O
.	O

The	O
mutations	O
2871delC	O
and	O
R778L	O
have	O
been	O
previously	O
reported	O
in	O
a	O
relatively	O
large	O
number	O
of	O
Japanese	O
patients	O
.	O

In	O
particular	O
,	O
R778L	O
is	O
known	O
to	O
be	O
more	O
prevalent	O
in	O
Asian	O
countries	O
than	O
in	O
other	O
countries	O
of	O
the	O
world	O
.	O

Our	O
data	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
the	O
mutations	O
tend	O
to	O
occur	O
in	O
a	O
population	O
-	O
specific	O
manner	O
.	O

Therefore	O
,	O
the	O
accumulation	O
of	O
the	O
types	O
of	O
mutations	O
in	O
Japanese	O
patients	O
with	O
WD	B-Disease
will	O
facilitate	O
the	O
fast	O
and	O
effective	O
genetic	O
diagnosis	O
of	O
WD	B-Disease
in	O
Japanese	O
patients	O
.	O
.	O

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
protein	O
.	O

The	O
Rho	O
-	O
family	O
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
protein	O
(	O
WASP	O
)	O
family	O
members	O
.	O

Activation	O
relieves	O
an	O
autoinhibitory	O
contact	O
between	O
the	O
GTPase	O
-	O
binding	O
domain	O
and	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
WASP	O
proteins	O
.	O

Here	O
we	O
report	O
the	O
autoinhibited	O
structure	O
of	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
,	O
which	O
can	O
be	O
induced	O
by	O
the	O
C	O
-	O
terminal	O
region	O
or	O
by	O
organic	O
co	O
-	O
solvents	O
.	O

In	O
the	O
autoinhibited	O
complex	O
,	O
intramolecular	O
interactions	O
with	O
the	O
GTPase	O
-	O
binding	O
domain	O
occlude	O
residues	O
of	O
the	O
C	O
terminus	O
that	O
regulate	O
the	O
Arp2	O
/	O
3	O
actin	O
-	O
nucleating	O
complex	O
.	O

Binding	O
of	O
Cdc42	O
to	O
the	O
GTPase	O
-	O
binding	O
domain	O
causes	O
a	O
dramatic	O
conformational	O
change	O
,	O
resulting	O
in	O
disruption	O
of	O
the	O
hydrophobic	O
core	O
and	O
release	O
of	O
the	O
C	O
terminus	O
,	O
enabling	O
its	O
interaction	O
with	O
the	O
actin	O
regulatory	O
machinery	O
.	O

These	O
data	O
show	O
that	O
intrinsically	O
unstructured	O
peptides	O
such	O
as	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
can	O
be	O
induced	O
into	O
distinct	O
structural	O
and	O
functional	O
states	O
depending	O
on	O
context	O
.	O
.	O

hCds1	O
-	O
mediated	O
phosphorylation	O
of	O
BRCA1	O
regulates	O
the	O
DNA	O
damage	O
response	O
.	O

Mutations	O
in	O
the	O
BRCA1	O
(	O
ref	O
.	O
1	O
)	O
tumour	B-Disease
suppressor	O
gene	O
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	O
with	O
inherited	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
and	O
about	O
half	O
of	O
the	O
families	O
with	O
only	O
breast	B-Disease
cancer	I-Disease
.	O

Although	O
the	O
biochemical	O
function	O
of	O
BRCA1	O
is	O
not	O
well	O
understood	O
,	O
it	O
is	O
important	O
for	O
DNA	O
damage	O
repair	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
.	O

BRCA1	O
exists	O
in	O
nuclear	O
foci	O
but	O
is	O
hyperphosphorylated	O
and	O
disperses	O
after	O
DNA	O
damage	O
.	O

It	O
is	O
not	O
known	O
whether	O
BRCA1	O
phosphorylation	O
and	O
dispersion	O
and	O
its	O
function	O
in	O
DNA	O
damage	O
response	O
are	O
related	O
.	O

In	O
yeast	O
the	O
DNA	O
damage	O
response	O
and	O
the	O
replication	O
-	O
block	O
checkpoint	O
are	O
mediated	O
partly	O
through	O
the	O
Cds1	O
kinase	O
family	O
.	O

Here	O
we	O
report	O
that	O
the	O
human	O
Cds1	O
kinase	O
(	O
hCds1	O
/	O
Chk2	O
)	O
regulates	O
BRCA1	O
function	O
after	O
DNA	O
damage	O
by	O
phosphorylating	O
serine	O
988	O
of	O
BRCA1	O
.	O

We	O
show	O
that	O
hCds1	O
and	O
BRCA1	O
interact	O
and	O
co	O
-	O
localize	O
within	O
discrete	O
nuclear	O
foci	O
but	O
separate	O
after	O
gamma	O
irradiation	O
.	O

Phosphorylation	O
of	O
BRCA1	O
at	O
serine	O
988	O
is	O
required	O
for	O
the	O
release	O
of	O
BRCA1	O
from	O
hCds1	O
.	O

This	O
phosphorylation	O
is	O
also	O
important	O
for	O
the	O
ability	O
of	O
BRCA1	O
to	O
restore	O
survival	O
after	O
DNA	O
damage	O
in	O
the	O
BRCA1	O
-	O
mutated	O
cell	O
line	O
HCC1937	O
.	O
.	O

Characterization	O
of	O
the	O
rat	O
spinocerebellar	O
ataxia	O
type	O
3	O
gene	O
.	O

Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
belongs	O
to	O
a	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
neurodegenerative	B-Disease
disorders	I-Disease
characterized	O
by	O
progressive	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
.	O

The	O
disease	O
-	O
causing	O
mutation	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
and	O
expanded	O
(	O
CAG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
a	O
novel	O
gene	O
of	O
unknown	O
function	O
.	O

In	O
Caucasians	O
,	O
repeat	O
expansions	O
in	O
the	O
MJD1	O
gene	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
the	O
clinically	O
distinct	O
autosomal	O
dominant	O
spinocerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
3	I-Disease
(	O
SCA3	B-Disease
)	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
biology	O
of	O
the	O
MJD1	O
/	O
SCA3	O
gene	O
we	O
cloned	O
the	O
rat	O
homologue	O
and	O
studied	O
its	O
expression	O
.	O

The	O
rat	O
and	O
human	O
ataxin	O
-	O
3	O
genes	O
are	O
highly	O
homologous	O
with	O
an	O
overall	O
sequence	O
identity	O
of	O
approximately	O
88	O
%	O
.	O

However	O
,	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
putative	O
protein	O
differs	O
strongly	O
from	O
the	O
published	O
human	O
sequence	O
.	O

The	O
(	O
CAG	O
)	O
n	O
block	O
in	O
the	O
rat	O
cDNA	O
consists	O
of	O
just	O
three	O
interrupted	O
units	O
suggesting	O
that	O
a	O
long	O
polyglutamine	O
stretch	O
is	O
not	O
essential	O
for	O
the	O
normal	O
function	O
of	O
the	O
ataxin	O
-	O
3	O
protein	O
in	O
rodents	O
.	O

The	O
expression	O
pattern	O
of	O
the	O
SCA3	O
gene	O
in	O
various	O
rat	O
and	O
human	O
tissues	O
was	O
investigated	O
by	O
Northern	O
blot	O
analyses	O
.	O

The	O
mature	O
transcript	O
is	O
approximately	O
6	O
kb	O
in	O
length	O
.	O

In	O
rat	O
testis	O
,	O
a	O
smaller	O
transcript	O
of	O
1	O
.	O

3	O
kb	O
was	O
identified	O
.	O

Transcription	O
of	O
rsca3	O
was	O
detected	O
in	O
most	O
rat	O
tissues	O
including	O
brain	O
.	O

Analyzing	O
the	O
expression	O
level	O
of	O
the	O
SCA3	O
gene	O
in	O
several	O
human	O
brain	O
sections	O
revealed	O
no	O
significant	O
higher	O
mRNA	O
level	O
in	O
regions	O
predominantly	O
affected	O
in	O
MJD	B-Disease
.	O

Thus	O
additional	O
molecules	O
and	O
/	O
or	O
regulatory	O
events	O
are	O
necessary	O
to	O
explain	O
the	O
exclusive	O
degeneration	B-Disease
of	I-Disease
certain	I-Disease
brain	I-Disease
areas	I-Disease
.	O

Emerin	B-Disease
,	I-Disease
deficiency	I-Disease
of	O
which	O
causes	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
is	O
localized	O
at	O
the	O
inner	O
nuclear	O
membrane	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
is	O
an	O
inherited	B-Disease
muscle	I-Disease
disorder	I-Disease
characterized	O
by	O
the	O
clinical	O
triad	O
of	O
progressive	O
wasting	B-Disease
of	I-Disease
humero	I-Disease
-	I-Disease
peroneal	I-Disease
muscles	I-Disease
,	O
early	O
contractures	B-Disease
of	I-Disease
the	I-Disease
elbows	I-Disease
,	I-Disease
Achilles	I-Disease
tendons	I-Disease
and	I-Disease
postcervical	I-Disease
muscles	I-Disease
,	O
and	O
cardiac	B-Disease
conduction	I-Disease
block	I-Disease
with	O
a	O
high	O
risk	O
of	O
sudden	B-Disease
death	I-Disease
.	O

The	O
gene	O
for	O
EDMD	B-Disease
on	O
Xq28	O
encodes	O
a	O
novel	O
protein	O
named	O
emerin	O
that	O
localizes	O
at	O
the	O
nuclear	O
membrane	O
of	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
and	O
some	O
other	O
non	O
-	O
muscle	O
tissues	O
.	O

To	O
investigate	O
a	O
possible	O
physiological	O
role	O
for	O
emerin	O
,	O
we	O
examined	O
the	O
ultrastructural	O
localization	O
of	O
the	O
protein	O
in	O
human	O
skeletal	O
muscle	O
and	O
HeLa	O
cells	O
,	O
using	O
ultrathin	O
cryosections	O
.	O

We	O
found	O
that	O
the	O
immune	O
-	O
labeled	O
colloidal	O
gold	O
particles	O
were	O
localized	O
on	O
the	O
nucleoplasmic	O
surface	O
of	O
the	O
inner	O
nuclear	O
membrane	O
,	O
but	O
not	O
on	O
the	O
nuclear	O
pore	O
.	O

Emerin	O
stayed	O
on	O
the	O
cytoplasmic	O
surface	O
of	O
the	O
nuclear	O
lamina	O
,	O
even	O
after	O
detergent	O
treatment	O
that	O
solubilizes	O
membrane	O
lipids	O
and	O
washes	O
out	O
membrane	O
proteins	O
.	O

These	O
results	O
suggest	O
that	O
emerin	O
anchors	O
at	O
the	O
inner	O
nuclear	O
membrane	O
through	O
the	O
hydrophobic	O
stretch	O
,	O
and	O
protrudes	O
from	O
the	O
hydrophilic	O
region	O
to	O
the	O
nucleoplasm	O
where	O
it	O
interacts	O
with	O
the	O
nuclear	O
lamina	O
.	O

We	O
speculate	O
that	O
emerin	O
contributes	O
to	O
maintain	O
the	O
nuclear	O
structure	O
and	O
stability	O
,	O
as	O
well	O
as	O
nuclear	O
functions	O
,	O
particularly	O
in	O
muscle	O
tissues	O
that	O
have	O
severe	O
stress	O
with	O
rigorous	O
contraction	O
-	O
relaxation	O
movements	O
and	O
calcium	O
flux	O
.	O
.	O

Locus	O
heterogeneity	O
in	O
Friedreich	B-Disease
ataxia	I-Disease
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B-Disease
recessive	I-Disease
ataxia	I-Disease
.	O

The	O
disease	O
locus	O
was	O
assigned	O
to	O
chromosome	O
9	O
and	O
the	O
disease	O
gene	O
,	O
STM7	O
/	O
X25	O
,	O
has	O
been	O
isolated	O
.	O

To	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
FRDA	B-Disease
.	O

We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	B-Disease
locus	O
.	O

Studying	O
two	O
siblings	O
with	O
FRDA	B-Disease
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
STM7	O
/	O
X25	O
.	O

Haplotype	O
analysis	O
of	O
the	O
STM7	O
/	O
X25	O
region	O
of	O
chromosome	O
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	O
of	O
chromosome	O
9	O
differs	O
in	O
the	O
patients	O
.	O

Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	B-Disease
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	O
of	O
FRDA	B-Disease
caused	O
by	O
the	O
second	O
locus	O
,	O
FRDA2	O
,	O
we	O
studied	O
an	O
unrelated	O
FRDA	B-Disease
patient	O
with	O
retained	O
tendon	O
reflexes	O
.	O

The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7	O
/	O
X25	O
(	O
GAA	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	B-Disease
cannot	O
be	O
distinguished	O
clinically	O
.	O
.	O

Glycerol	O
as	O
a	O
correlate	O
of	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
:	O
dissection	O
of	O
a	O
complex	O
system	O
by	O
use	O
of	O
a	O
simple	O
genetic	O
trait	O
.	O

Glycerol	O
kinase	O
(	O
GK	O
)	O
represents	O
the	O
primary	O
entry	O
of	O
glycerol	O
into	O
glucose	O
and	O
triglyceride	O
metabolism	O
.	O

Impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
and	O
hypertriglyceridemia	B-Disease
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	B-Disease
mellitus	I-Disease
and	O
cardiovascular	B-Disease
disease	I-Disease
.	O

The	O
relationship	O
between	O
glycerol	O
and	O
the	O
risk	O
of	O
IGT	B-Disease
,	O
however	O
,	O
is	O
poorly	O
understood	O
.	O

We	O
therefore	O
undertook	O
the	O
study	O
of	O
fasting	O
plasma	O
glycerol	O
levels	O
in	O
a	O
cohort	O
of	O
1	O
,	O
056	O
unrelated	O
men	O
and	O
women	O
of	O
French	O
-	O
Canadian	O
descent	O
.	O

Family	O
screening	O
in	O
the	O
initial	O
cohort	O
identified	O
18	O
men	O
from	O
five	O
families	O
with	O
severe	O
hyperglycerolemia	B-Disease
(	O
values	O
above	O
2	O
.	O
0	O
mmol	O
/	O
liter	O
)	O
and	O
demonstrated	O
an	O
X	O
-	O
linked	O
pattern	O
of	O
inheritance	O
.	O

Linkage	O
analysis	O
of	O
the	O
data	O
from	O
12	O
microsatellite	O
markers	O
surrounding	O
the	O
Xp21	O
.	O

3	O
GK	O
gene	O
resulted	O
in	O
a	O
peak	O
LOD	O
score	O
of	O
3	O
.	O

46	O
,	O
centered	O
around	O
marker	O
DXS8039	O
.	O

In	O
addition	O
,	O
since	O
all	O
of	O
the	O
families	O
originated	O
in	O
a	O
population	O
with	O
a	O
proven	O
founder	O
effect	O
-	O
the	O
Saguenay	O
Lac	O
-	O
St	O
.	O

-	O
Jean	O
region	O
of	O
Quebec	O
-	O
a	O
common	O
disease	O
haplotype	O
was	O
sought	O
.	O

Indeed	O
,	O
a	O
six	O
-	O
marker	O
haplotype	O
extending	O
over	O
a	O
region	O
of	O
5	O
.	O

5	O
cM	O
was	O
observed	O
in	O
all	O
families	O
.	O

Resequencing	O
of	O
the	O
GK	O
gene	O
in	O
family	O
members	O
led	O
to	O
the	O
discovery	O
of	O
a	O
N288D	O
missense	O
mutation	O
in	O
exon	O
10	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
asparagine	O
residue	O
by	O
a	O
negatively	O
charged	O
aspartic	O
acid	O
.	O

Clinical	O
and	O
molecular	O
genetics	O
of	O
primary	B-Disease
dystonias	I-Disease
.	O

Primary	B-Disease
dystonias	I-Disease
are	O
movement	B-Disease
disorders	I-Disease
with	O
dystonia	B-Disease
as	O
a	O
major	O
symptom	O
.	O

They	O
are	O
frequently	O
inherited	O
as	O
Mendelian	O
traits	O
.	O

There	O
are	O
at	O
least	O
eight	O
clinically	O
distinct	O
autosomal	O
dominant	O
and	O
two	O
X	O
-	O
linked	O
recessive	O
forms	O
.	O

In	O
addition	O
,	O
pedigree	O
analyses	O
suggest	O
the	O
occurrence	O
of	O
an	O
autosomal	O
recessive	O
variant	O
.	O

The	O
clinical	O
classification	O
is	O
increasingly	O
being	O
replaced	O
by	O
a	O
genetic	O
one	O
.	O

To	O
date	O
gene	O
loci	O
have	O
been	O
identified	O
in	O
at	O
least	O
six	O
autosomal	O
dominant	O
forms	O
,	O
i	O
.	O
e	O
.	O
,	O
in	O
idiopathic	B-Disease
torsion	I-Disease
dystonia	I-Disease
(	O
9q34	O
)	O
,	O
focal	B-Disease
dystonia	I-Disease
(	O
18p	O
)	O
,	O
adult	O
-	O
onset	O
idiopathic	B-Disease
torsion	I-Disease
dystonia	I-Disease
of	O
mixed	O
type	O
(	O
8p21	O
-	O
q22	O
)	O
,	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
(	O
14q22	O
.	O
1	O
-	O
q22	O
.	O
2	O
)	O
,	O
and	O
paroxysmal	B-Disease
dystonic	I-Disease
choreoathetosis	I-Disease
(	O
2q25	O
-	O
q33	O
;	O
1p21	O
-	O
p13	O
.	O
3	O
)	O
.	O

Gene	O
loci	O
in	O
the	O
X	O
-	O
linked	O
recessive	O
forms	O
have	O
been	O
assigned	O
to	O
Xq13	O
.	O

1	O
in	O
the	O
X	B-Disease
-	I-Disease
linked	I-Disease
dystonia	I-Disease
parkinsonism	I-Disease
syndrome	I-Disease
and	O
to	O
Xq22	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
sensorineural	I-Disease
deafness	I-Disease
,	O
dystonia	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
.	O

The	O
disease	O
genes	O
have	O
been	O
identified	O
in	O
two	O
autosomal	O
dominant	O
forms	O
and	O
in	O
one	O
X	O
-	O
linked	O
recessive	O
form	O
.	O

Mutations	O
in	O
a	O
gene	O
coding	O
for	O
an	O
ATP	O
-	O
binding	O
protein	O
were	O
detected	O
in	O
idiopathic	B-Disease
torsion	I-Disease
dystonia	I-Disease
(	O
DYT1	O
)	O
,	O
and	O
the	O
GTP	O
cyclohydrolase	O
1	O
gene	O
is	O
mutated	O
in	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
(	O
DYT5	O
)	O
.	O

In	O
sensorineural	B-Disease
deafness	I-Disease
,	O
dystonia	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
,	O
mutations	O
were	O
found	O
in	O
the	O
gene	O
DDP	O
coding	O
for	O
a	O
polypeptide	O
of	O
unknown	O
function	O
.	O

This	O
article	O
reviews	O
the	O
clinical	O
and	O
molecular	O
genetics	O
of	O
primary	B-Disease
dystonias	I-Disease
,	O
critically	O
discusses	O
present	O
findings	O
,	O
and	O
proposes	O
referring	O
to	O
the	O
known	O
forms	O
,	O
most	O
of	O
which	O
can	O
be	O
distinguished	O
by	O
genetic	O
criteria	O
,	O
as	O
dystonias	B-Disease
1	I-Disease
-	I-Disease
12	I-Disease
.	O

Determination	O
of	O
30	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
mutations	O
,	O
including	O
15	O
not	O
previously	O
described	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Adrenoleukodystrophy	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
is	O
the	O
most	O
frequent	O
peroxisomal	B-Disease
disease	I-Disease
.	O

It	O
mainly	O
involves	O
the	O
nervous	O
system	O
white	O
matter	O
,	O
adrenal	O
cortex	O
and	O
testes	O
.	O

Several	O
distinct	O
clinical	O
phenotypes	O
are	O
known	O
.	O

The	O
principal	O
biochemical	O
abnormality	O
is	O
the	O
accumulation	O
of	O
saturated	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
VLCFAs	O
>	O
C22	O
0	O
,	O
mainly	O
C26	O
0	O
)	O
,	O
which	O
is	O
due	O
to	O
impaired	O
capacity	O
for	O
beta	O
-	O
oxidation	O
in	O
peroxisomes	O
.	O

Diagnosis	O
is	O
usually	O
based	O
on	O
the	O
VLCFA	O
levels	O
in	O
plasma	O
or	O
cultured	O
skin	O
fibroblasts	O
in	O
both	O
patients	O
and	O
carriers	O
.	O

In	O
0	O
.	O

1	O
%	O
of	O
affected	O
males	O
,	O
however	O
,	O
the	O
plasma	O
C26	O
0	O
level	O
is	O
borderline	O
normal	O
,	O
and	O
15	O
%	O
of	O
obligate	O
female	O
carriers	O
have	O
normal	O
results	O
.	O

Effective	O
mutation	O
detection	O
in	O
these	O
families	O
is	O
therefore	O
fundamental	O
to	O
unambiguously	O
determine	O
the	O
genetic	O
status	O
of	O
each	O
individual	O
at	O
risk	O
.	O

Of	O
particular	O
concern	O
are	O
female	O
members	O
of	O
kindreds	O
segregating	O
X	B-Disease
-	I-Disease
ALD	I-Disease
mutations	O
,	O
because	O
normal	O
VLCFA	O
levels	O
do	O
not	O
guarantee	O
lack	O
of	O
carrier	O
status	O
.	O

We	O
describe	O
a	O
fast	O
method	O
for	O
detection	O
of	O
X	B-Disease
-	I-Disease
ALD	I-Disease
mutations	O
.	O

The	O
method	O
is	O
based	O
on	O
SSCP	O
analysis	O
of	O
nested	O
PCR	O
fragments	O
followed	O
by	O
sequence	O
-	O
determination	O
reactions	O
.	O

Using	O
this	O
methodology	O
we	O
have	O
found	O
X	B-Disease
-	I-Disease
ALD	I-Disease
mutations	O
in	O
30	O
kindreds	O
,	O
including	O
15	O
not	O
previously	O
reported	O
.	O

beta	O
-	O
galactosidase	O
gene	O
mutations	O
affecting	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
elastin	O
-	O
binding	O
protein	O
in	O
GM1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
patients	O
with	O
cardiac	B-Disease
involvement	I-Disease
.	O

GM1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
is	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
acid	I-Disease
beta	I-Disease
-	I-Disease
galactosidase	I-Disease
(	O
GLB1	O
)	O
.	O

We	O
report	O
five	O
new	O
beta	O
-	O
galactosidase	O
gene	O
mutations	O
in	O
nine	O
Italian	O
patients	O
and	O
one	O
fetus	O
,	O
segregating	O
in	O
seven	O
unrelated	O
families	O
.	O

Six	O
of	O
the	O
eight	O
patients	O
with	O
the	O
infantile	O
,	O
severe	O
form	O
of	O
the	O
disease	O
presented	O
cardiac	B-Disease
involvement	I-Disease
,	O
a	O
feature	O
rarely	O
associated	O
with	O
GM1	B-Disease
-	I-Disease
gangliosidosis	I-Disease
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
RNA	O
and	O
DNA	O
identified	O
two	O
new	O
RNA	O
splicing	O
defects	O
,	O
three	O
new	O
and	O
three	O
previously	O
described	O
amino	O
acid	O
substitutions	O
.	O

Interestingly	O
,	O
all	O
patients	O
with	O
cardiac	B-Disease
involvement	I-Disease
were	O
homozygous	O
for	O
one	O
of	O
these	O
mutations	O
R59H	O
,	O
Y591C	O
,	O
Y591N	O
,	O
or	O
IVS14	O
-	O
2A	O
>	O
G	O
.	O

In	O
contrast	O
,	O
all	O
other	O
patients	O
were	O
compound	O
heterozygous	O
for	O
one	O
of	O
the	O
following	O
mutations	O
R201H	O
,	O
R482H	O
,	O
G579D	O
,	O
IVS8	O
+	O
2T	O
>	O
C	O
.	O

Although	O
we	O
could	O
not	O
directly	O
correlate	O
the	O
presence	O
of	O
cardiac	B-Disease
abnormalities	I-Disease
with	O
specific	O
genetic	B-Disease
lesions	I-Disease
,	O
the	O
mutations	O
identified	O
in	O
patients	O
with	O
cardiomyopathy	B-Disease
fell	O
in	O
the	O
GLB1	O
cDNA	O
region	O
common	O
to	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
Hbeta	O
-	O
Gal	O
-	O
related	O
protein	O
,	O
also	O
known	O
as	O
the	O
elastin	O
binding	O
protein	O
(	O
EBP	O
)	O
.	O

Consequently	O
,	O
both	O
molecules	O
are	O
affected	O
by	O
the	O
mutations	O
,	O
and	O
they	O
may	O
contribute	O
differently	O
to	O
the	O
occurrence	O
of	O
specific	O
clinical	O
manifestations	O
.	O
.	O

In	O
vivo	O
modulation	O
of	O
Hmgic	O
reduces	O
obesity	B-Disease
.	O

The	O
HMGI	O
family	O
of	O
proteins	O
consists	O
of	O
three	O
members	O
,	O
HMGIC	O
,	O
HMGI	O
and	O
HMGI	O
(	O
Y	O
)	O
,	O
that	O
function	O
as	O
architectural	O
factors	O
and	O
are	O
essential	O
components	O
of	O
the	O
enhancesome	O
.	O

HMGIC	O
is	O
predominantly	O
expressed	O
in	O
proliferating	O
,	O
undifferentiated	O
mesenchymal	O
cells	O
and	O
is	O
not	O
detected	O
in	O
adult	O
tissues	O
.	O

It	O
is	O
disrupted	O
and	O
misexpressed	O
in	O
a	O
number	O
of	O
mesenchymal	B-Disease
tumour	I-Disease
cell	O
types	O
,	O
including	O
fat	B-Disease
-	I-Disease
cell	I-Disease
tumours	I-Disease
(	O
lipomas	B-Disease
)	O
.	O

In	O
addition	O
Hmgic	O
-	O
/	O
-	O
mice	O
have	O
a	O
deficiency	O
in	O
fat	O
tissue	O
.	O

To	O
study	O
its	O
role	O
in	O
adipogenesis	O
and	O
obesity	B-Disease
,	O
we	O
examined	O
Hmgic	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
adult	O
,	O
obese	B-Disease
mice	O
.	O

Mice	O
with	O
a	O
partial	B-Disease
or	I-Disease
complete	I-Disease
deficiency	I-Disease
of	I-Disease
Hmgic	I-Disease
resisted	O
diet	O
-	O
induced	O
obesity	B-Disease
.	O

Disruption	O
of	O
Hmgic	O
caused	O
a	O
reduction	O
in	O
the	O
obesity	B-Disease
induced	O
by	O
leptin	B-Disease
deficiency	I-Disease
(	O
Lepob	O
/	O
Lepob	O
)	O
in	O
a	O
gene	O
-	O
dose	O
-	O
dependent	O
manner	O
.	O

Our	O
studies	O
implicate	O
a	O
role	O
for	O
HMGIC	O
in	O
fat	O
-	O
cell	O
proliferation	O
,	O
indicating	O
that	O
it	O
may	O
be	O
an	O
adipose	O
-	O
specific	O
target	O
for	O
the	O
treatment	O
of	O
obesity	B-Disease
.	O
.	O

Molecular	O
analysis	O
of	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
in	O
factor	B-Disease
X	I-Disease
deficiency	I-Disease
.	O

Factor	B-Disease
X	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
haemorrhagic	B-Disease
condition	I-Disease
,	O
normally	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
in	O
which	O
a	O
variable	O
clinical	O
presentation	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype	O
.	O

The	O
factor	O
X	O
(	O
F10	O
)	O
genes	O
of	O
14	O
unrelated	O
individuals	O
with	O
factor	B-Disease
X	I-Disease
deficiency	I-Disease
(	O
12	O
familial	O
and	O
two	O
sporadic	O
cases	O
)	O
were	O
sequenced	O
yielding	O
a	O
total	O
of	O
13	O
novel	O
mutations	O
.	O

Family	O
studies	O
were	O
performed	O
in	O
order	O
to	O
distinguish	O
the	O
contributions	O
of	O
individual	O
mutant	O
F10	O
alleles	O
to	O
the	O
clinical	O
and	O
laboratory	O
phenotypes	O
.	O

Missense	O
mutations	O
were	O
studied	O
by	O
means	O
of	O
molecular	O
modelling	O
,	O
whereas	O
single	O
basepair	O
substitutions	O
in	O
splice	O
sites	O
and	O
the	O
5	O
flanking	O
region	O
were	O
examined	O
by	O
in	O
vitro	O
splicing	O
assay	O
and	O
luciferase	O
reporter	O
gene	O
assay	O
respectively	O
.	O

The	O
deletion	O
allele	O
of	O
a	O
novel	O
hexanucleotide	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
F10	O
gene	O
promoter	O
region	O
was	O
shown	O
by	O
reporter	O
gene	O
assay	O
,	O
to	O
reduce	O
promoter	O
activity	O
by	O
approximately	O
20	O
%	O
.	O

One	O
family	O
manifesting	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
possessed	O
three	O
clinically	O
affected	O
members	O
who	O
were	O
heterozygous	O
for	O
a	O
splice	O
-	O
site	O
mutation	O
that	O
was	O
predicted	O
to	O
lead	O
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
product	O
.	O

A	O
model	O
which	O
accounts	O
for	O
the	O
dominant	O
negative	O
effect	O
of	O
this	O
lesion	O
is	O
presented	O
.	O

Variation	O
in	O
the	O
antigen	O
level	O
of	O
heterozygous	O
relatives	O
of	O
probands	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
between	O
families	O
than	O
within	O
families	O
,	O
consistent	O
with	O
the	O
view	O
that	O
the	O
nature	O
of	O
the	O
F10	O
lesion	O
(	O
s	O
)	O
segregating	O
in	O
a	O
given	O
family	O
is	O
a	O
prime	O
determinant	O
of	O
the	O
laboratory	O
phenotype	O
.	O

By	O
contrast	O
,	O
no	O
such	O
relationship	O
could	O
be	O
discerned	O
between	O
laboratory	O
phenotype	O
and	O
polymorphism	O
genotype	O
.	O
.	O

Transgenic	O
mice	O
expressing	O
a	O
truncated	O
form	O
of	O
the	O
high	O
mobility	O
group	O
I	O
-	O
C	O
protein	O
develop	O
adiposity	O
and	O
an	O
abnormally	O
high	O
prevalence	O
of	O
lipomas	B-Disease
.	O

Chromosomal	O
translocations	O
in	O
human	O
lipomas	B-Disease
frequently	O
create	O
fusion	O
transcripts	O
encoding	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
I	O
-	O
C	O
DNA	O
-	O
binding	O
domains	O
and	O
C	O
-	O
terminal	O
sequences	O
from	O
different	O
presumed	O
transcription	O
factors	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
HMG	O
I	O
-	O
C	O
in	O
the	O
development	O
of	O
lipomas	B-Disease
.	O

To	O
evaluate	O
the	O
role	O
of	O
the	O
HMG	O
I	O
-	O
C	O
component	O
,	O
the	O
three	O
DNA	O
-	O
binding	O
domains	O
of	O
HMG	O
I	O
-	O
C	O
have	O
now	O
been	O
expressed	O
in	O
transgenic	O
mice	O
.	O

Despite	O
the	O
ubiquitous	O
expression	O
of	O
the	O
truncated	O
HMG	O
I	O
-	O
C	O
protein	O
,	O
the	O
transgenic	O
mice	O
develop	O
a	O
selective	O
abundance	O
of	O
fat	O
tissue	O
early	O
in	O
life	O
,	O
show	O
marked	O
adipose	B-Disease
tissue	I-Disease
inflammation	I-Disease
,	O
and	O
have	O
an	O
abnormally	O
high	O
incidence	O
of	O
lipomas	B-Disease
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
DNA	O
-	O
binding	O
domains	O
of	O
HMG	O
I	O
-	O
C	O
,	O
in	O
the	O
absence	O
of	O
a	O
C	O
-	O
terminal	O
fusion	O
partner	O
,	O
are	O
sufficient	O
to	O
perturb	O
adipogenesis	O
and	O
predispose	O
to	O
lipomas	B-Disease
.	O

We	O
provide	O
data	O
supporting	O
the	O
central	O
utility	O
of	O
this	O
animal	O
model	O
as	O
a	O
tool	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
one	O
of	O
the	O
most	O
common	O
kind	O
of	O
human	O
benign	B-Disease
tumors	I-Disease
.	O
.	O

ATM	O
phosphorylates	O
p95	O
/	O
nbs1	O
in	O
an	O
S	O
-	O
phase	O
checkpoint	O
pathway	O
.	O

The	O
rare	B-Disease
diseases	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
AT	B-Disease
)	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
,	O
and	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
,	O
with	O
mutations	O
in	O
the	O
p95	O
/	O
nbs1	O
gene	O
,	O
share	O
a	O
variety	O
of	O
phenotypic	B-Disease
abnormalities	I-Disease
such	O
as	O
chromosomal	B-Disease
instability	I-Disease
,	O
radiation	O
sensitivity	O
and	O
defects	O
in	O
cell	O
-	O
cycle	O
checkpoints	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O

The	O
ATM	O
gene	O
encodes	O
a	O
protein	O
kinase	O
that	O
is	O
activated	O
by	O
ionizing	O
radiation	O
or	O
radiomimetic	O
drugs	O
,	O
whereas	O
p95	O
/	O
nbs1	O
is	O
part	O
of	O
a	O
protein	O
complex	O
that	O
is	O
involved	O
in	O
responses	O
to	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

Here	O
,	O
because	O
of	O
the	O
similarities	O
between	O
AT	B-Disease
and	O
NBS	B-Disease
,	O
we	O
evaluated	O
the	O
functional	O
interactions	O
between	O
ATM	O
and	O
p95	O
/	O
nbs1	O
.	O

Activation	O
of	O
the	O
ATM	O
kinase	O
by	O
ionizing	O
radiation	O
and	O
induction	O
of	O
ATM	O
-	O
dependent	O
responses	O
in	O
NBS	B-Disease
cells	O
indicated	O
that	O
p95	O
/	O
nbs1	O
may	O
not	O
be	O
required	O
for	O
signalling	O
to	O
ATM	O
after	O
ionizing	O
radiation	O
.	O

However	O
,	O
p95	O
/	O
nbs1	O
was	O
phosphorylated	O
on	O
serine	O
343	O
in	O
an	O
ATM	O
-	O
dependent	O
manner	O
in	O
vitro	O
and	O
in	O
vivo	O
after	O
ionizing	O
radiation	O
.	O

A	O
p95	O
/	O
nbs1	O
construct	O
mutated	O
at	O
the	O
ATM	O
phosphorylation	O
site	O
abrogated	O
an	O
S	O
-	O
phase	O
checkpoint	O
induced	O
by	O
ionizing	O
radiation	O
in	O
normal	O
cells	O
and	O
failed	O
to	O
compensate	O
for	O
this	O
functional	O
deficiency	O
in	O
NBS	B-Disease
cells	O
.	O

These	O
observations	O
link	O
ATM	O
and	O
p95	O
/	O
nbs1	O
in	O
a	O
common	O
signalling	O
pathway	O
and	O
provide	O
an	O
explanation	O
for	O
phenotypic	O
similarities	O
in	O
these	O
two	O
diseases	O
.	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
.	O

Fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
a	O
common	O
form	O
of	O
inherited	B-Disease
mental	I-Disease
retardation	I-Disease
,	O
is	O
mainly	O
caused	O
by	O
massive	O
expansion	O
of	O
CGG	O
triplet	O
repeats	O
located	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
of	O
the	O
fragile	B-Disease
X	I-Disease
mental	I-Disease
retardation	I-Disease
-	O
1	O
(	O
FMR1	O
)	O
gene	O
.	O

In	O
patients	O
with	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
the	O
expanded	O
CGG	O
triplet	O
repeats	O
are	O
hypermethylated	O
and	O
the	O
expression	O
of	O
the	O
FMR1	O
gene	O
is	O
repressed	O
,	O
which	O
leads	O
to	O
the	O
absence	O
of	O
FMR1	O
protein	O
(	O
FMRP	O
)	O
and	O
subsequent	O
mental	B-Disease
retardation	I-Disease
.	O

FMRP	O
is	O
an	O
RNA	O
-	O
binding	O
protein	O
that	O
shuttles	O
between	O
the	O
nucleus	O
and	O
cytoplasm	O
.	O

This	O
protein	O
has	O
been	O
implicated	O
in	O
protein	O
translation	O
as	O
it	O
is	O
found	O
associated	O
with	O
polyribosomes	O
and	O
the	O
rough	O
endoplasmic	O
reticulum	O
.	O

We	O
discuss	O
here	O
the	O
recent	O
progress	O
made	O
towards	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
CGG	O
repeat	O
expansion	O
and	O
physiological	O
function	O
(	O
s	O
)	O
of	O
FMRP	O
.	O

These	O
studies	O
will	O
not	O
only	O
help	O
to	O
illuminate	O
the	O
molecular	O
basis	O
of	O
the	O
general	O
class	O
of	O
human	O
diseases	O
with	O
trinucleotide	O
repeat	O
expansion	O
but	O
also	O
provide	O
an	O
avenue	O
to	O
understand	O
aspects	O
of	O
human	O
cognition	O
and	O
intelligence	O
.	O
.	O

Haploinsufficiency	B-Disease
of	I-Disease
the	I-Disease
transcription	I-Disease
factors	I-Disease
FOXC1	I-Disease
and	I-Disease
FOXC2	I-Disease
results	O
in	O
aberrant	O
ocular	O
development	O
.	O

Anterior	B-Disease
segment	I-Disease
developmental	I-Disease
disorders	I-Disease
,	O
including	O
Axenfeld	B-Disease
-	I-Disease
Rieger	I-Disease
anomaly	I-Disease
(	O
ARA	B-Disease
)	O
,	O
variably	O
associate	O
with	O
harmfully	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
which	O
causes	O
glaucoma	B-Disease
.	O

Clinically	O
observed	O
dysgenesis	O
does	O
not	O
correlate	O
with	O
IOP	O
,	O
however	O
,	O
and	O
the	O
etiology	O
of	O
glaucoma	B-Disease
development	O
is	O
not	O
understood	O
.	O

The	O
forkhead	O
transcription	O
factor	O
genes	O
Foxc1	O
(	O
formerly	O
Mf1	O
)	O
and	O
Foxc2	O
(	O
formerly	O
Mfh1	O
)	O
are	O
expressed	O
in	O
the	O
mesenchyme	O
from	O
which	O
the	O
ocular	O
drainage	O
structures	O
derive	O
.	O

Mutations	O
in	O
the	O
human	O
homolog	O
of	O
Foxc1	O
,	O
FKHL7	O
,	O
cause	O
dominant	O
anterior	B-Disease
segment	I-Disease
defects	I-Disease
and	O
glaucoma	B-Disease
in	O
various	O
families	O
.	O

We	O
show	O
that	O
Foxc1	O
(	O
+	O
/	O
-	O
)	O
mice	O
have	O
anterior	B-Disease
segment	I-Disease
abnormalities	I-Disease
similar	O
to	O
those	O
reported	O
in	O
human	O
patients	O
.	O

These	O
abnormalities	O
include	O
small	O
or	O
absent	O
Schlemms	O
canal	O
,	O
aberrantly	O
developed	O
trabecular	O
meshwork	O
,	O
iris	B-Disease
hypoplasia	I-Disease
,	O
severely	O
eccentric	O
pupils	O
and	O
displaced	O
Schwalbes	O
line	O
.	O

The	O
penetrance	O
of	O
clinically	O
obvious	O
abnormalities	O
varies	O
with	O
genetic	O
background	O
.	O

In	O
some	O
affected	O
eyes	O
,	O
collagen	O
bundles	O
were	O
half	O
normal	O
diameter	O
,	O
or	O
collagen	O
and	O
elastic	O
tissue	O
were	O
very	O
sparse	O
.	O

Thus	O
,	O
abnormalities	O
in	O
extracellular	O
matrix	O
synthesis	O
or	O
organization	O
may	O
contribute	O
to	O
development	O
of	O
the	O
ocular	O
phenotypes	O
.	O

Despite	O
the	O
abnormalities	O
in	O
ocular	O
drainage	O
structures	O
in	O
Foxc1	O
(	O
+	O
/	O
-	O
)	O
mice	O
,	O
IOP	O
was	O
normal	O
in	O
almost	O
all	O
mice	O
analyzed	O
,	O
on	O
all	O
genetic	O
backgrounds	O
and	O
at	O
all	O
ages	O
.	O

Similar	O
abnormalities	O
were	O
found	O
in	O
Foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
,	O
but	O
no	O
disease	O
-	O
associated	O
mutations	O
were	O
identified	O
in	O
the	O
human	O
homolog	O
FKHL14	O
in	O
32	O
ARA	B-Disease
patients	O
.	O

Foxc1	O
(	O
+	O
/	O
-	O
)	O
and	O
Foxc2	O
(	O
+	O
/	O
-	O
)	O
mice	O
are	O
useful	O
models	O
for	O
studying	O
anterior	O
segment	O
development	O
and	O
its	O
anomalies	O
,	O
and	O
may	O
allow	O
identification	O
of	O
genes	O
that	O
interact	O
with	O
Foxc1	O
and	O
Foxc2	O
(	O
or	O
FKHL7	O
and	O
FKHL14	O
)	O
to	O
produce	O
a	O
phenotype	O
with	O
elevated	O
IOP	O
and	O
glaucoma	B-Disease
.	O
.	O

(	O
Over	O
)	O
correction	O
of	O
FMR1	B-Disease
deficiency	I-Disease
with	O
YAC	O
transgenics	O
:	O
behavioral	O
and	O
physical	O
features	O
.	O

Fragile	B-Disease
X	I-Disease
syndrome	I-Disease
is	O
a	O
common	O
cause	O
of	O
mental	B-Disease
retardation	I-Disease
involving	O
loss	O
of	O
expression	O
of	O
the	O
FMR1	O
gene	O
.	O

The	O
role	O
of	O
FMR1	O
remains	O
undetermined	O
but	O
the	O
protein	O
appears	O
to	O
be	O
involved	O
in	O
RNA	O
metabolism	O
.	O

Fmr1	O
knockout	O
mice	O
exhibit	O
a	O
phenotype	O
with	O
some	O
similarities	O
to	O
humans	O
,	O
such	O
as	O
macroorchidism	B-Disease
and	O
behavioral	O
abnormalities	O
.	O

As	O
a	O
step	O
toward	O
understanding	O
the	O
function	O
of	O
FMR1	O
and	O
the	O
determination	O
of	O
the	O
potential	O
for	O
therapeutic	O
approaches	O
to	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
transgenic	O
mice	O
were	O
generated	O
in	O
order	O
to	O
determine	O
whether	O
the	O
Fmr1	O
knockout	O
mouse	O
phenotype	O
could	O
be	O
rescued	O
.	O

Several	O
transgenic	O
lines	O
were	O
generated	O
that	O
carried	O
the	O
entire	O
FMR1	O
locus	O
with	O
extensive	O
amounts	O
of	O
flanking	O
sequence	O
.	O

We	O
observed	O
that	O
the	O
YAC	O
transgene	O
supported	O
production	O
of	O
the	O
human	O
protein	O
(	O
FMRP	O
)	O
which	O
was	O
present	O
at	O
levels	O
10	O
to	O
15	O
times	O
that	O
of	O
endogenous	O
protein	O
and	O
was	O
expressed	O
in	O
a	O
cell	O
-	O
and	O
tissue	O
-	O
specific	O
manner	O
.	O

Macro	O
-	O
orchidism	O
was	O
absent	O
in	O
knockout	O
mice	O
carrying	O
the	O
YAC	O
transgene	O
indicating	O
functional	O
rescue	O
by	O
the	O
human	O
protein	O
.	O

Given	O
the	O
complex	O
behavioral	O
phenotype	O
in	O
fragile	B-Disease
X	I-Disease
patients	O
and	O
the	O
mild	O
phenotype	O
previously	O
reported	O
for	O
the	O
Fmr1	O
knockout	O
mouse	O
,	O
we	O
performed	O
a	O
more	O
thorough	O
evaluation	O
of	O
the	O
Fmr1	O
knockout	O
phenotype	O
using	O
additional	O
behavioral	O
assays	O
that	O
had	O
not	O
previously	O
been	O
reported	O
for	O
this	O
animal	O
model	O
.	O

The	O
mouse	O
displayed	O
reduced	O
anxiety	B-Disease
-	O
related	O
responses	O
with	O
increased	O
exploratory	O
behavior	O
.	O

FMR1	O
YAC	O
transgenic	O
mice	O
overexpressing	O
the	O
human	O
protein	O
did	O
produce	O
opposing	O
behavioral	O
responses	O
and	O
additional	O
abnormal	O
behaviors	O
were	O
also	O
observed	O
.	O

These	O
findings	O
have	O
significant	O
implications	O
for	O
gene	O
therapy	O
for	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
since	O
overexpression	O
of	O
the	O
gene	O
may	O
harbor	O
its	O
own	O
phenotype	O
.	O
.	O

Transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
expanded	O
CTG	O
repeat	O
mimic	O
closely	O
the	O
DM	B-Disease
CTG	O
repeat	O
intergenerational	O
and	O
somatic	O
instability	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
caused	O
by	O
a	O
CTG	O
repeat	O
expansion	O
in	O
the	O
3UTR	O
of	O
the	O
DM	B-Disease
protein	O
kinase	O
(	O
DMPK	O
)	O
gene	O
.	O

A	O
very	O
high	O
level	O
of	O
instability	O
is	O
observed	O
through	O
successive	O
generations	O
and	O
the	O
size	O
of	O
the	O
repeat	O
is	O
generally	O
correlated	O
with	O
the	O
severity	O
of	O
the	O
disease	O
and	O
with	O
age	O
at	O
onset	O
.	O

Furthermore	O
,	O
tissues	O
from	O
DM	B-Disease
patients	O
exhibit	O
somatic	O
mosaicism	O
that	O
increases	O
with	O
age	O
.	O

We	O
generated	O
transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
20	O
,	O
55	O
or	O
>	O
300	O
CTG	O
,	O
cloned	O
from	O
patients	O
from	O
the	O
same	O
affected	O
DM	B-Disease
family	O
.	O

Using	O
large	O
human	O
flanking	O
sequences	O
and	O
a	O
large	O
amplification	O
,	O
we	O
demonstrate	O
that	O
the	O
intergenerational	O
CTG	O
repeat	O
instability	O
is	O
reproduced	O
in	O
mice	O
,	O
with	O
a	O
strong	O
bias	O
towards	O
expansions	O
and	O
with	O
the	O
same	O
sex	O
-	O
and	O
size	O
-	O
dependent	O
characteristics	O
as	O
in	O
humans	O
.	O

Moreover	O
,	O
a	O
high	O
level	O
of	O
instability	O
,	O
increasing	O
with	O
age	O
,	O
can	O
be	O
observed	O
in	O
tissues	O
and	O
in	O
sperm	O
.	O

Although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(	O
or	O
big	O
jumps	O
over	O
several	O
hundred	O
CTG	O
repeats	O
)	O
as	O
in	O
congenital	O
forms	O
of	O
DM	B-Disease
,	O
our	O
model	O
carrying	O
>	O
300	O
CTG	O
is	O
the	O
first	O
to	O
show	O
instability	O
so	O
close	O
to	O
the	O
human	O
DM	B-Disease
situation	O
.	O

Our	O
three	O
models	O
carrying	O
different	O
sizes	O
of	O
CTG	O
repeat	O
provide	O
insight	O
on	O
the	O
different	O
factors	O
modulating	O
the	O
CTG	O
repeat	O
instability	O
.	O
.	O

Inactivation	O
of	O
the	O
Friedreich	B-Disease
ataxia	I-Disease
mouse	O
gene	O
leads	O
to	O
early	O
embryonic	B-Disease
lethality	I-Disease
without	O
iron	O
accumulation	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
the	O
most	O
common	O
autosomal	B-Disease
recessive	I-Disease
ataxia	I-Disease
,	O
is	O
caused	O
in	O
almost	O
all	O
cases	O
by	O
homozygous	O
intronic	O
expansions	O
resulting	O
in	O
the	O
loss	O
of	O
frataxin	O
,	O
a	O
mitochondrial	O
protein	O
conserved	O
through	O
evolution	O
,	O
and	O
involved	O
in	O
mitochondrial	O
iron	O
homeostasis	O
.	O

Yeast	O
knockout	O
models	O
,	O
and	O
histological	O
and	O
biochemical	O
data	O
from	O
patient	O
heart	O
biopsies	O
or	O
autopsies	O
indicate	O
that	O
the	O
frataxin	O
defect	O
causes	O
a	O
specific	O
iron	B-Disease
-	I-Disease
sulfur	I-Disease
protein	I-Disease
deficiency	I-Disease
and	O
mitochondrial	O
iron	O
accumulation	O
leading	O
to	O
the	O
pathological	O
changes	O
.	O

Affected	O
human	O
tissues	O
are	O
rarely	O
available	O
to	O
further	O
examine	O
this	O
hypothesis	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
the	O
disease	O
,	O
we	O
generated	O
a	O
mouse	O
model	O
by	O
deletion	O
of	O
exon	O
4	O
leading	O
to	O
inactivation	O
of	O
the	O
Frda	B-Disease
gene	O
product	O
.	O

We	O
show	O
that	O
homozygous	O
deletions	O
cause	O
embryonic	B-Disease
lethality	I-Disease
a	O
few	O
days	O
after	O
implantation	O
,	O
demonstrating	O
an	O
important	O
role	O
for	O
frataxin	O
during	O
early	O
development	O
.	O

These	O
results	O
suggest	O
that	O
the	O
milder	O
phenotype	O
in	O
humans	O
is	O
due	O
to	O
residual	O
frataxin	O
expression	O
associated	O
with	O
the	O
expansion	O
mutations	O
.	O

Surprisingly	O
,	O
in	O
the	O
frataxin	O
knockout	O
mouse	O
,	O
no	O
iron	O
accumulation	O
was	O
observed	O
during	O
embryonic	O
resorption	O
,	O
suggesting	O
that	O
cell	O
death	O
could	O
be	O
due	O
to	O
a	O
mechanism	O
independent	O
of	O
iron	O
accumulation	O
.	O
.	O

Gaucher	B-Disease
disease	I-Disease
:	O
the	O
origins	O
of	O
the	O
Ashkenazi	O
Jewish	O
N370S	O
and	O
84GG	O
acid	O
beta	O
-	O
glucosidase	O
mutations	O
.	O

Type	O
1	O
Gaucher	B-Disease
disease	I-Disease
(	O
GD	B-Disease
)	O
,	O
a	O
non	O
-	O
neuronopathic	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
,	O
results	O
from	O
the	O
deficient	O
activity	O
of	O
acid	O
beta	O
-	O
glucosidase	O
(	O
GBA	O
)	O
.	O

Type	O
1	O
disease	O
is	O
panethnic	O
but	O
is	O
more	O
prevalent	O
in	O
individuals	O
of	O
Ashkenazi	O
Jewish	O
(	O
AJ	O
)	O
descent	O
.	O

Of	O
the	O
causative	O
GBA	O
mutations	O
,	O
N370S	O
is	O
particularly	O
frequent	O
in	O
the	O
AJ	O
population	O
,	O
(	O
q	O
approximately	O
.	O
03	O
)	O
,	O
whereas	O
the	O
84GG	O
insertion	O
(	O
q	O
approximately	O
.	O
003	O
)	O
occurs	O
exclusively	O
in	O
the	O
Ashkenazim	O
.	O

To	O
investigate	O
the	O
genetic	O
history	O
of	O
these	O
mutations	O
in	O
the	O
AJ	O
population	O
,	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
were	O
used	O
to	O
map	O
a	O
9	O
.	O

3	O
-	O
cM	O
region	O
containing	O
the	O
GBA	O
locus	O
and	O
to	O
genotype	O
261	O
AJ	O
N370S	O
chromosomes	O
,	O
60	O
European	O
non	O
-	O
Jewish	O
N370S	O
chromosomes	O
,	O
and	O
62	O
AJ	O
84GG	O
chromosomes	O
.	O

A	O
highly	O
conserved	O
haplotype	O
at	O
four	O
markers	O
flanking	O
GBA	O
(	O
PKLR	O
,	O
D1S1595	O
,	O
D1S2721	O
,	O
and	O
D1S2777	O
)	O
was	O
observed	O
on	O
both	O
the	O
AJ	O
chromosomes	O
and	O
the	O
non	O
-	O
Jewish	O
N370S	O
chromosomes	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
founder	O
common	O
to	O
both	O
populations	O
.	O

Of	O
note	O
,	O
the	O
presence	O
of	O
different	O
divergent	O
haplotypes	O
suggested	O
the	O
occurrence	O
of	O
de	O
novo	O
,	O
recurrent	O
N370S	O
mutations	O
.	O

In	O
contrast	O
,	O
a	O
different	O
conserved	O
haplotype	O
at	O
these	O
markers	O
was	O
identified	O
on	O
the	O
84GG	O
chromosomes	O
,	O
which	O
was	O
unique	O
to	O
the	O
AJ	O
population	O
.	O

On	O
the	O
basis	O
of	O
the	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
delta	O
values	O
,	O
the	O
non	O
-	O
Jewish	O
European	O
N370S	O
chromosomes	O
had	O
greater	O
haplotype	O
diversity	O
and	O
less	O
LD	O
at	O
the	O
markers	O
flanking	O
the	O
conserved	O
haplotype	O
than	O
did	O
the	O
AJ	O
N370S	O
chromosomes	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
the	O
N370S	O
mutation	O
in	O
the	O
non	O
-	O
Jewish	O
European	O
population	O
prior	O
to	O
the	O
founding	O
of	O
the	O
AJ	O
population	O
.	O

Coalescence	O
analyses	O
for	O
the	O
N370S	O
and	O
84GG	O
mutations	O
estimated	O
similar	O
coalescence	O
times	O
,	O
of	O
48	O
and	O
55	O
.	O
5	O
generations	O
ago	O
,	O
respectively	O
.	O

The	O
results	O
of	O
these	O
studies	O
are	O
consistent	O
with	O
a	O
significant	O
bottleneck	O
occurring	O
in	O
the	O
AJ	O
population	O
during	O
the	O
first	O
millennium	O
,	O
when	O
the	O
population	O
became	O
established	O
in	O
Europe	O
.	O

HLA	O
B27	O
and	O
the	O
genetics	O
of	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O

One	O
hundred	O
and	O
twenty	O
-	O
eight	O
of	O
145	O
patients	O
with	O
ankylosing	B-Disease
spondylitis	I-Disease
(	O
AS	B-Disease
)	O
were	O
found	O
to	O
be	O
HLA	O
B27	O
positive	O
.	O

Five	O
patients	O
had	O
evidence	O
of	O
a	O
sero	O
-	O
negative	O
peripheral	B-Disease
arthritis	I-Disease
resembling	O
peripheral	B-Disease
psoriatic	I-Disease
arthritis	I-Disease
and	O
3	O
of	O
these	O
were	O
B27	O
negative	O
.	O

One	O
further	O
B27	O
negative	O
patients	O
had	O
a	O
sister	O
with	O
ankylosing	B-Disease
spondylitis	I-Disease
and	O
ulcerative	B-Disease
colitis	I-Disease
and	O
a	O
mother	O
with	O
ulcerative	B-Disease
colitis	I-Disease
.	O

There	O
was	O
evidence	O
of	O
a	O
somewhat	O
later	O
age	O
of	O
onset	O
of	O
symptoms	O
in	O
B27	O
negative	O
patients	O
.	O

These	O
findings	O
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	O
of	O
clinical	O
and	O
genetic	O
heterogeneity	O
in	O
ankylosing	B-Disease
spondylitis	I-Disease
with	O
genes	O
for	O
psoriasis	B-Disease
and	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
being	O
important	O
in	O
some	O
individuals	O
,	O
particularly	O
those	O
who	O
are	O
B27	O
negative	O
.	O

Twenty	O
-	O
five	O
first	O
-	O
degree	O
relatives	O
with	O
ankylosing	B-Disease
spondylitis	I-Disease
were	O
all	O
B27	O
positive	O
.	O

The	O
only	O
instance	O
of	O
disassociation	O
of	O
B27	O
and	O
spondylitis	B-Disease
in	O
a	O
family	O
was	O
where	O
the	O
proband	O
had	O
ulcerative	B-Disease
colitis	I-Disease
as	O
well	O
as	O
spondylitis	B-Disease
.	O

Of	O
13	O
B27	O
positive	O
fathers	O
3	O
could	O
be	O
diagnosed	O
as	O
having	O
definite	O
ankylosing	B-Disease
spondylitis	I-Disease
(	O
23	O
%	O
)	O
.	O

These	O
findings	O
are	O
thought	O
to	O
provide	O
evidence	O
against	O
the	O
concept	O
that	O
the	O
gene	O
for	O
ankylosing	B-Disease
spondylitis	I-Disease
is	O
not	O
B27	O
but	O
a	O
closely	O
linked	O
gene	O
and	O
favour	O
the	O
occurrence	O
of	O
an	O
environmental	O
event	O
affecting	O
approximately	O
one	O
-	O
fifth	O
of	O
B27	O
positive	O
males	O
to	O
result	O
in	O
disease	O
.	O
.	O

Founder	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
Polish	O
families	O
with	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	O
study	O
,	O
to	O
identify	O
possible	O
BRCA1	O
and	O
BRCA2	O
founder	O
mutations	O
in	O
the	O
Polish	O
population	O
.	O

The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	B-Disease
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
who	O
had	O
cancer	B-Disease
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O

A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
4	O
families	O
had	O
ovarian	B-Disease
cancers	I-Disease
only	O
,	O
and	O
36	O
families	O
had	O
breast	B-Disease
cancers	I-Disease
only	O
.	O

Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	O
from	O
each	O
family	O
.	O

The	O
entire	O
coding	O
region	O
of	O
BRCA1	O
and	O
BRCA2	O
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations	O
,	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
.	O

Mutations	O
were	O
found	O
in	O
35	O
(	O
53	O
%	O
)	O
of	O
the	O
66	O
families	O
studied	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	O
gene	O
.	O

BRCA1	B-Disease
abnormalities	I-Disease
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B-Disease
cancer	I-Disease
only	O
,	O
in	O
67	O
%	O
of	O
27	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
and	O
in	O
34	O
%	O
of	O
35	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
only	O
.	O

The	O
single	O
family	O
with	O
a	O
BRCA2	O
mutation	O
had	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
.	O

Seven	O
distinct	O
mutations	O
were	O
identified	O
;	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families	O
.	O

In	O
total	O
,	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(	O
94	O
%	O
)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations	O
.	O

Three	O
BRCA1	B-Disease
abnormalities	I-Disease
-	O
5382insC	O
,	O
C61G	O
,	O
and	O
4153delA	O
-	O
accounted	O
for	O
51	O
%	O
,	O
20	O
%	O
,	O
and	O
11	O
%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
.	O
.	O

Molecular	O
basis	O
of	O
very	B-Disease
long	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
CoA	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
three	O
Israeli	O
patients	O
:	O
identification	O
of	O
a	O
complex	O
mutant	O
allele	O
with	O
P65L	O
and	O
K247Q	O
mutations	O
,	O
the	O
former	O
being	O
an	O
exonic	O
mutation	O
causing	O
exon	O
3	O
skipping	O
.	O

Very	B-Disease
long	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
CoA	I-Disease
dehydrogenase	I-Disease
(	I-Disease
VLCAD	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
life	O
-	O
threatening	O
disorder	O
of	O
mitochondrial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

We	O
identified	O
four	O
novel	O
mutations	O
in	O
three	O
unrelated	O
patients	O
.	O

All	O
patients	O
had	O
the	O
severe	O
childhood	O
form	O
of	O
VLCAD	B-Disease
deficiency	I-Disease
with	O
early	O
onset	O
and	O
high	O
mortality	O
.	O

Immunoblot	O
analysis	O
revealed	O
that	O
VLCAD	O
protein	O
was	O
undetectable	O
in	O
patients	O
2	O
and	O
3	O
,	O
whereas	O
normal	O
-	O
size	O
VLCAD	O
protein	O
and	O
an	O
aberrant	O
form	O
of	O
VLCAD	O
(	O
4kDa	O
smaller	O
)	O
were	O
detected	O
in	O
patient	O
1	O
.	O

As	O
expected	O
,	O
null	O
mutations	O
were	O
found	O
in	O
patients	O
2	O
and	O
3	O
patient	O
2	O
is	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
del	O
4	O
bp	O
at	O
798	O
-	O
801	O
,	O
and	O
patient	O
3	O
is	O
homozygous	O
for	O
a	O
nonsense	O
mutation	O
65C	O
>	O
A	O
(	O
S22X	O
)	O
.	O

Patient	O
1	O
was	O
homozygous	O
for	O
a	O
complex	O
mutant	O
allele	O
containing	O
two	O
alterations	O
,	O
including	O
a	O
194C	O
>	O
T	O
transition	O
(	O
P65L	O
)	O
and	O
739A	O
>	O
C	O
transversion	O
(	O
K247Q	O
)	O
;	O
in	O
the	O
case	O
of	O
P65L	O
,	O
the	O
amino	O
acid	O
change	O
does	O
not	O
reduce	O
enzyme	O
activity	O
.	O

However	O
,	O
the	O
nucleotide	O
change	O
resulted	O
in	O
exon	O
3	O
skipping	O
,	O
whereas	O
the	O
latter	O
K247Q	O
mutation	O
had	O
a	O
drastic	O
effect	O
on	O
enzyme	O
activity	O
.	O

We	O
verified	O
these	O
events	O
by	O
in	O
vivo	O
splicing	O
experiments	O
and	O
transient	O
expression	O
analysis	O
of	O
mutant	O
cDNAs	O
.	O

The	O
P65L	O
mutation	O
locates	O
11	O
bases	O
upstream	O
of	O
a	O
splice	O
donor	O
site	O
of	O
intron	O
3	O
.	O

This	O
is	O
an	O
example	O
of	O
an	O
exonic	O
mutation	O
which	O
affects	O
exon	O
-	O
splicing	O
.	O
.	O

Submicroscopic	O
deletion	O
in	O
cousins	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
causes	O
a	O
grandmatrilineal	O
inheritance	O
pattern	O
:	O
effects	O
of	O
imprinting	O
.	O

The	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
critical	O
region	O
on	O
15q11	O
-	O
q13	O
is	O
subject	O
to	O
imprinting	O
.	O

PWS	B-Disease
becomes	O
apparent	O
when	O
genes	O
on	O
the	O
paternally	O
inherited	O
chromosome	O
are	O
not	O
expressed	O
.	O

Familial	B-Disease
PWS	I-Disease
is	O
rare	O
.	O

We	O
report	O
on	O
a	O
family	O
in	O
which	O
a	O
male	O
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
PWS	B-Disease
with	O
cytogenetically	O
normal	O
karyotypes	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
shows	O
a	O
submicroscopic	O
deletion	O
of	O
SNRPN	O
,	O
but	O
not	O
the	O
closely	O
associated	O
loci	O
D15S10	O
,	O
D15S11	O
,	O
D15S63	O
,	O
and	O
GABRB3	O
.	O

The	O
cousins	O
fathers	O
and	O
two	O
paternal	O
aunts	O
have	O
the	O
same	O
deletion	O
and	O
are	O
clinically	O
normal	O
.	O

The	O
grandmother	O
of	O
the	O
cousins	O
is	O
deceased	O
and	O
not	O
available	O
for	O
study	O
,	O
and	O
their	O
grandfather	O
is	O
not	O
deleted	O
for	O
SNRPN	O
.	O

DNA	O
methylation	O
analysis	O
of	O
D15S63	O
is	O
consistent	O
with	O
an	O
abnormality	O
of	O
the	O
imprinting	O
center	O
associated	O
with	O
PWS	B-Disease
.	O

"	O
Grandmatrilineal	O
"	O
inheritance	O
occurs	O
when	O
a	O
woman	O
with	O
deletion	O
of	O
an	O
imprinted	O
,	O
paternally	O
expressed	O
gene	O
is	O
at	O
risk	O
of	O
having	O
affected	O
grandchildren	O
through	O
her	O
sons	O
.	O

In	O
this	O
case	O
,	O
PWS	B-Disease
does	O
not	O
become	O
evident	O
as	O
long	O
as	O
the	O
deletion	O
is	O
passed	O
through	O
the	O
matrilineal	O
line	O
.	O

This	O
represents	O
a	O
unique	O
inheritance	O
pattern	O
due	O
to	O
imprinting	O
.	O
.	O

Human	O
glycine	O
decarboxylase	O
gene	O
(	O
GLDC	O
)	O
and	O
its	O
highly	O
conserved	O
processed	O
pseudogene	O
(	O
psiGLDC	O
)	O
:	O
their	O
structure	O
and	O
expression	O
,	O
and	O
the	O
identification	O
of	O
a	O
large	O
deletion	O
in	O
a	O
family	O
with	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
.	O

Mutations	O
in	O
the	O
glycine	O
decarboxylase	O
gene	O
(	O
GLDC	O
)	O
cause	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
(	O
NKH	B-Disease
)	O
,	O
an	O
in	B-Disease
-	I-Disease
born	I-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
characterized	O
by	O
severe	O
neurological	B-Disease
disturbance	I-Disease
.	O

We	O
have	O
determined	O
the	O
structure	O
of	O
GLDC	O
and	O
of	O
its	O
pseudogene	O
(	O
psiGLDC	O
)	O
and	O
studied	O
their	O
expression	O
for	O
a	O
molecular	O
analysis	O
of	O
NKH	B-Disease
.	O

The	O
GLDC	O
gene	O
spans	O
at	O
least	O
135	O
kb	O
and	O
consists	O
of	O
25	O
exons	O
.	O

All	O
donor	O
and	O
acceptor	O
sites	O
adhere	O
to	O
the	O
canonical	O
GT	O
-	O
AG	O
rule	O
,	O
except	O
for	O
the	O
donor	O
site	O
of	O
intron	O
21	O
,	O
where	O
a	O
variant	O
form	O
GC	O
is	O
used	O
instead	O
of	O
GT	O
.	O

The	O
transcription	O
initiation	O
site	O
has	O
been	O
assigned	O
to	O
a	O
residue	O
163	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
triplet	O
by	O
primer	O
extension	O
analysis	O
.	O

The	O
psiGLDC	O
gene	O
has	O
no	O
intron	O
and	O
shares	O
97	O
.	O

5	O
%	O
homology	O
with	O
the	O
coding	O
region	O
of	O
functional	O
GLDC	O
,	O
suggesting	O
that	O
psiGLDC	O
is	O
a	O
processed	O
pseudogene	O
that	O
arose	O
from	O
the	O
GLDC	O
transcript	O
about	O
4	O
-	O
8	O
million	O
years	O
ago	O
.	O

RNA	O
blotting	O
analysis	O
has	O
revealed	O
that	O
GLDC	O
is	O
expressed	O
in	O
human	O
liver	O
,	O
kidney	O
,	O
brain	O
,	O
and	O
placenta	O
.	O

We	O
have	O
also	O
examined	O
a	O
patient	O
with	O
NKH	B-Disease
with	O
no	O
detectable	O
GLDC	O
mRNA	O
in	O
his	O
lymphoblasts	O
.	O

Exons	O
1	O
-	O
3	O
of	O
the	O
functional	O
GLDC	O
gene	O
from	O
this	O
patient	O
are	O
not	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
whereas	O
those	O
from	O
control	O
subjects	O
are	O
.	O

These	O
results	O
suggest	O
a	O
large	O
homozygous	O
deletion	O
(	O
at	O
least	O
30	O
kb	O
)	O
in	O
the	O
patient	O
.	O

Furthermore	O
,	O
we	O
have	O
devised	O
a	O
semi	O
-	O
quantitative	O
PCR	O
to	O
estimate	O
the	O
number	O
of	O
GLDC	O
alleles	O
by	O
using	O
psiGLDC	O
as	O
an	O
internal	O
control	O
and	O
have	O
confirmed	O
the	O
homozygosity	O
and	O
heterozygosity	O
of	O
the	O
deletion	O
in	O
the	O
patient	O
and	O
his	O
parents	O
,	O
respectively	O
.	O

Structural	O
information	O
of	O
GLDC	O
and	O
psiGLDC	O
should	O
facilitate	O
the	O
molecular	O
analysis	O
of	O
NKH	B-Disease
.	O

De	O
novo	O
deletions	O
of	O
SNRPN	O
exon	O
1	O
in	O
early	O
human	O
and	O
mouse	O
embryos	O
result	O
in	O
a	O
paternal	O
to	O
maternal	O
imprint	O
switch	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
is	O
a	O
neurogenetic	B-Disease
disease	I-Disease
characterized	O
by	O
infantile	B-Disease
hypotonia	I-Disease
,	O
gonadal	B-Disease
hypoplasia	I-Disease
,	O
obsessive	O
behaviour	O
and	O
neonatal	O
feeding	O
difficulties	O
followed	O
by	O
hyperphagia	B-Disease
,	O
leading	O
to	O
profound	O
obesity	B-Disease
.	O

PWS	B-Disease
is	O
due	O
to	O
a	O
lack	O
of	O
paternal	O
genetic	O
information	O
at	O
15q11	O
-	O
q13	O
(	O
ref	O
.	O
2	O
)	O
.	O

Five	O
imprinted	O
,	O
paternally	O
expressed	O
genes	O
map	O
to	O
the	O
PWS	B-Disease
region	O
,	O
MKRN3	O
(	O
ref	O
.	O
3	O
)	O
,	O
NDN	O
(	O
ref	O
.	O
4	O
)	O
,	O
NDNL1	O
(	O
ref	O
.	O
5	O
)	O
,	O
SNRPN	O
(	O
refs	O
6	O
-	O
8	O
)	O
and	O
IPW	O
(	O
ref	O
.	O
9	O
)	O
,	O
as	O
well	O
as	O
two	O
poorly	O
characterized	O
framents	O
designated	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
5	O
(	O
ref	O
.	O
10	O
)	O
.	O

Imprinting	O
of	O
this	O
region	O
involves	O
a	O
bipartite	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
which	O
overlaps	O
SNRPN	O
(	O
refs	O
10	O
,	O
11	O
)	O
.	O

Deletion	O
of	O
the	O
SNRPN	O
promoter	O
/	O
exon	O
1	O
region	O
(	O
the	O
PWS	B-Disease
IC	O
element	O
)	O
appears	O
to	O
impair	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
in	O
the	O
male	O
germ	O
line	O
and	O
leads	O
to	O
PWS	B-Disease
.	O

Here	O
we	O
report	O
a	O
PWS	B-Disease
family	O
in	O
which	O
the	O
father	O
is	O
mosaic	O
for	O
an	O
IC	O
deletion	O
on	O
his	O
paternal	O
chromosome	O
.	O

The	O
deletion	O
chromosome	O
has	O
acquired	O
a	O
maternal	O
methylation	O
imprint	O
in	O
his	O
somatic	O
cells	O
.	O

We	O
have	O
made	O
identical	O
findings	O
in	O
chimaeric	O
mice	O
generated	O
from	O
two	O
independent	O
embryonic	O
stem	O
(	O
ES	O
)	O
cell	O
lines	O
harbouring	O
a	O
similar	O
deletion	O
.	O

Our	O
studies	O
demonstrate	O
that	O
the	O
PWS	B-Disease
IC	O
element	O
is	O
not	O
only	O
required	O
for	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
,	O
but	O
also	O
for	O
its	O
postzygotic	O
maintenance	O
.	O
.	O

Mice	O
deficient	B-Disease
in	I-Disease
Six5	I-Disease
develop	O
cataracts	B-Disease
:	O
implications	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
.	O

Expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
UTR	O
of	O
the	O
gene	O
DMPK	O
at	O
the	O
DM1	O
locus	O
on	O
chromosome	O
19	O
causes	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
a	O
dominantly	B-Disease
inherited	I-Disease
disease	I-Disease
characterized	O
by	O
skeletal	O
muscle	B-Disease
dystrophy	I-Disease
and	O
myotonia	B-Disease
,	O
cataracts	B-Disease
and	O
cardiac	B-Disease
conduction	I-Disease
defects	I-Disease
.	O

Targeted	O
deletion	O
of	O
Dm15	O
,	O
the	O
mouse	O
orthologue	O
of	O
human	O
DMPK	O
,	O
produced	O
mice	O
with	O
a	O
mild	O
myopathy	B-Disease
and	O
cardiac	B-Disease
conduction	I-Disease
abnormalities	I-Disease
,	O
but	O
without	O
other	O
features	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
such	O
as	O
myotonia	B-Disease
and	O
cataracts	B-Disease
.	O

We	O
,	O
and	O
others	O
,	O
have	O
demonstrated	O
that	O
repeat	O
expansion	O
decreases	O
expression	O
of	O
the	O
adjacent	O
gene	O
SIX5	O
(	O
refs	O
7	O
,	O
8	O
)	O
,	O
which	O
encodes	O
a	O
homeodomain	O
transcription	O
factor	O
.	O

To	O
determine	O
whether	O
SIX5	B-Disease
deficiency	I-Disease
contributes	O
to	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
phenotype	O
,	O
we	O
disrupted	O
mouse	O
Six5	O
by	O
replacing	O
the	O
first	O
exon	O
with	O
a	O
beta	O
-	O
galactosidase	O
reporter	O
.	O

Six5	O
-	O
mutant	O
mice	O
showed	O
reporter	O
expression	O
in	O
multiple	O
tissues	O
,	O
including	O
the	O
developing	O
lens	O
.	O

Homozygous	O
mutant	O
mice	O
had	O
no	O
apparent	O
abnormalities	B-Disease
of	I-Disease
skeletal	I-Disease
muscle	I-Disease
function	I-Disease
,	O
but	O
developed	O
lenticular	B-Disease
opacities	I-Disease
at	O
a	O
higher	O
rate	O
than	O
controls	O
.	O

Our	O
results	O
suggest	O
that	O
SIX5	B-Disease
deficiency	I-Disease
contributes	O
to	O
the	O
cataract	B-Disease
phenotype	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
and	O
that	O
myotonic	B-Disease
dystrophy	I-Disease
represents	O
a	O
multigenic	B-Disease
disorder	I-Disease
.	O
.	O

Heterozygous	O
loss	O
of	O
Six5	O
in	O
mice	O
is	O
sufficient	O
to	O
cause	O
ocular	O
cataracts	B-Disease
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
skeletal	O
muscle	B-Disease
wasting	I-Disease
,	O
myotonia	B-Disease
,	O
cardiac	B-Disease
arrhythmia	I-Disease
,	O
hyperinsulinaemia	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
and	O
ocular	O
cataracts	B-Disease
.	O

The	O
genetic	B-Disease
defect	I-Disease
in	O
DM	B-Disease
is	O
a	O
CTG	O
repeat	O
expansion	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
DMPK	O
and	O
5	O
of	O
a	O
homeodomain	O
-	O
encoding	O
gene	O
,	O
SIX5	O
(	O
formerly	O
DMAHP	O
;	O
refs	O
2	O
-	O
5	O
)	O
.	O

There	O
are	O
three	O
mechanisms	O
by	O
which	O
CTG	O
expansion	O
can	O
result	O
in	O
DM	B-Disease
.	O

First	O
,	O
repeat	O
expansion	O
may	O
alter	O
the	O
processing	O
or	O
transport	O
of	O
the	O
mutant	O
DMPK	O
mRNA	O
and	O
consequently	O
reduce	O
DMPK	O
levels	O
.	O

Second	O
,	O
CTG	O
expansion	O
may	O
establish	O
a	O
region	O
of	O
heterochromatin	O
3	O
of	O
the	O
repeat	O
sequence	O
and	O
decrease	O
SIX5	O
transcription	O
.	O

Third	O
,	O
toxic	O
effects	O
of	O
the	O
repeat	O
expansion	O
may	O
be	O
intrinsic	O
to	O
the	O
repeated	O
elements	O
at	O
the	O
level	O
of	O
DNA	O
or	O
RNA	O
(	O
refs	O
10	O
,	O
11	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
dose	O
-	O
dependent	O
loss	O
of	O
Dm15	O
(	O
the	O
mouse	O
DMPK	O
homologue	O
)	O
in	O
mice	O
produces	O
a	O
partial	O
DM	B-Disease
phenotype	O
characterized	O
by	O
decreased	O
development	O
of	O
skeletal	O
muscle	O
force	O
and	O
cardiac	B-Disease
conduction	I-Disease
disorders	I-Disease
.	O

To	O
test	O
the	O
role	O
of	O
Six5	O
loss	O
in	O
DM	B-Disease
,	O
we	O
have	O
analysed	O
a	O
strain	O
of	O
mice	O
in	O
which	O
Six5	O
was	O
deleted	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
rate	O
and	O
severity	O
of	O
cataract	B-Disease
formation	O
is	O
inversely	O
related	O
to	O
Six5	O
dosage	O
and	O
is	O
temporally	O
progressive	O
.	O

Six5	O
+	O
/	O
-	O
and	O
Six5	O
-	O
/	O
-	O
mice	O
show	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
the	O
Na	O
+	O
/	O
K	O
+	O
-	O
ATPase	O
alpha	O
-	O
1	O
subunit	O
and	O
decreased	O
Dm15	O
mRNA	O
levels	O
.	O

Thus	O
,	O
altered	O
ion	O
homeostasis	O
within	O
the	O
lens	O
may	O
contribute	O
to	O
cataract	B-Disease
formation	O
.	O

As	O
ocular	O
cataracts	B-Disease
are	O
a	O
characteristic	O
feature	O
of	O
DM	B-Disease
,	O
these	O
results	O
demonstrate	O
that	O
decreased	O
SIX5	O
transcription	O
is	O
important	O
in	O
the	O
aetiology	O
of	O
DM	B-Disease
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
DM	B-Disease
is	O
a	O
contiguous	O
gene	O
syndrome	O
associated	O
with	O
the	O
partial	O
loss	O
of	O
both	O
DMPK	O
and	O
SIX5	O
.	O
.	O

ATM	O
-	O
dependent	O
phosphorylation	O
of	O
nibrin	O
in	O
response	O
to	O
radiation	O
exposure	O
.	O

Mutations	O
in	O
the	O
gene	O
ATM	O
are	O
responsible	O
for	O
the	O
genetic	B-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
,	O
which	O
is	O
characterized	O
by	O
cerebellar	B-Disease
dysfunction	I-Disease
,	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Disease
predisposition	O
.	O

Both	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
phenotype	O
and	O
the	O
similarity	O
of	O
the	O
ATM	O
protein	O
to	O
other	O
DNA	O
-	O
damage	O
sensors	O
suggests	O
a	O
role	O
for	O
ATM	O
in	O
biochemical	O
pathways	O
involved	O
in	O
the	O
recognition	O
,	O
signalling	O
and	O
repair	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

There	O
are	O
strong	O
parallels	O
between	O
the	O
pattern	O
of	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Disease
predisposition	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
and	O
that	O
in	O
patients	O
with	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
.	O

The	O
protein	O
defective	O
in	O
NBS	B-Disease
,	O
nibrin	O
(	O
encoded	O
by	O
NBS1	O
)	O
,	O
forms	O
a	O
complex	O
with	O
MRE11	O
and	O
RAD50	O
(	O
refs	O
1	O
,	O
2	O
)	O
.	O

This	O
complex	O
localizes	O
to	O
DSBs	O
within	O
30	O
minutes	O
after	O
cellular	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
and	O
is	O
observed	O
in	O
brightly	O
staining	O
nuclear	O
foci	O
after	O
a	O
longer	O
period	O
of	O
time	O
.	O

The	O
overlap	O
between	O
clinical	O
and	O
cellular	O
phenotypes	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
and	O
NBS	B-Disease
suggests	O
that	O
ATM	O
and	O
nibrin	O
may	O
function	O
in	O
the	O
same	O
biochemical	O
pathway	O
.	O

Here	O
we	O
demonstrate	O
that	O
nibrin	O
is	O
phosphorylated	O
within	O
one	O
hour	O
of	O
treatment	O
of	O
cells	O
with	O
IR	O
.	O

This	O
response	O
is	O
abrogated	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
cells	O
that	O
either	O
do	O
not	O
express	O
ATM	O
protein	O
or	O
express	O
near	O
full	O
-	O
length	O
mutant	O
protein	O
.	O

We	O
also	O
show	O
that	O
ATM	O
physically	O
interacts	O
with	O
and	O
phosphorylates	O
nibrin	O
on	O
serine	O
343	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Phosphorylation	O
of	O
this	O
site	O
appears	O
to	O
be	O
functionally	O
important	O
because	O
mutated	O
nibrin	O
(	O
S343A	O
)	O
does	O
not	O
completely	O
complement	O
radiosensitivity	O
in	O
NBS	B-Disease
cells	O
.	O

ATM	O
phosphorylation	O
of	O
nibrin	O
does	O
not	O
affect	O
nibrin	O
-	O
MRE11	O
-	O
RAD50	O
association	O
as	O
revealed	O
by	O
radiation	O
-	O
induced	O
foci	O
formation	O
.	O

Our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
A	B-Disease
-	I-Disease
T	I-Disease
and	O
NBS	B-Disease
.	O
.	O

Clinicopathologic	O
features	O
of	O
BRCA	B-Disease
-	I-Disease
linked	I-Disease
and	I-Disease
sporadic	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

CONTEXT	O
Most	O
hereditary	B-Disease
ovarian	I-Disease
cancers	I-Disease
are	O
associated	O
with	O
germline	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O

Attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
BRCA	O
mutation	O
status	O
in	O
ovarian	B-Disease
cancer	I-Disease
have	O
produced	O
conflicting	O
results	O
,	O
especially	O
regarding	O
survival	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
hereditary	B-Disease
ovarian	I-Disease
cancers	I-Disease
have	O
distinct	O
clinical	O
and	O
pathological	O
features	O
compared	O
with	O
sporadic	B-Disease
(	I-Disease
nonhereditary	I-Disease
)	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

DESIGN	O
AND	O
SETTING	O
Retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	B-Disease
cancers	I-Disease
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B-Disease
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	B-Disease
Institute	O
,	O
over	O
a	O
12	O
-	O
year	O
period	O
(	O
December	O
1986	O
to	O
August	O
1998	O
)	O
.	O

PATIENTS	O
The	O
study	O
was	O
restricted	O
to	O
patients	O
of	O
Jewish	O
origin	O
because	O
of	O
the	O
ease	O
of	O
BRCA1	O
and	O
BRCA2	O
genotyping	O
in	O
this	O
ethnic	O
group	O
.	O

From	O
the	O
189	O
patients	O
who	O
identified	O
themselves	O
as	O
Jewish	O
,	O
88	O
hereditary	O
cases	O
were	O
identified	O
with	O
the	O
presence	O
of	O
a	O
germline	O
founder	O
mutation	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O

The	O
remaining	O
101	O
cases	O
from	O
the	O
same	O
series	O
not	O
associated	O
with	O
a	O
BRCA	O
mutation	O
and	O
2	O
additional	O
groups	O
(	O
Gynecologic	O
Oncology	O
Group	O
protocols	O
52	O
and	O
111	O
)	O
with	O
ovarian	B-Disease
cancer	I-Disease
from	O
clinical	O
trials	O
(	O
for	O
the	O
survival	O
analysis	O
)	O
were	O
included	O
for	O
comparison	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Age	O
at	O
diagnosis	O
,	O
surgical	O
stage	O
,	O
histologic	O
cell	O
type	O
and	O
grade	O
,	O
and	O
surgical	O
outcome	O
;	O
and	O
response	O
to	O
chemotherapy	O
and	O
survival	O
for	O
advanced	O
-	O
stage	O
(	O
II	O
and	O
IV	O
)	O
cases	O
.	O

RESULTS	O
Hereditary	B-Disease
cancers	I-Disease
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years	O
,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
BRCA1	O
-	O
vs	O
BRCA2	O
-	O
linked	O
patients	O
(	O
54	O
vs	O
62	O
years	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

Histology	O
,	O
grade	O
,	O
stage	O
,	O
and	O
success	O
of	O
cytoreductive	O
surgery	O
were	O
similar	O
for	O
hereditary	O
and	O
sporadic	O
cases	O
.	O

The	O
hereditary	O
group	O
had	O
a	O
longer	O
disease	O
-	O
free	O
interval	O
following	O
primary	O
chemotherapy	O
in	O
comparison	O
with	O
the	O
nonhereditary	O
group	O
,	O
with	O
a	O
median	O
time	O
to	O
recurrence	O
of	O
14	O
months	O
and	O
7	O
months	O
,	O
respectively	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Those	O
with	O
hereditary	B-Disease
cancers	I-Disease
had	O
improved	O
survival	O
compared	O
with	O
the	O
nonhereditary	O
group	O
(	O
P	O
=	O
.	O
004	O
)	O
.	O

For	O
stage	B-Disease
III	I-Disease
cancers	I-Disease
,	O
BRCA	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
Although	O
BRCA	B-Disease
-	I-Disease
associated	I-Disease
hereditary	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
this	O
population	O
have	O
surgical	O
and	O
pathological	O
characteristics	O
similar	O
to	O
those	O
of	O
sporadic	B-Disease
cancers	I-Disease
,	O
advanced	B-Disease
-	I-Disease
stage	I-Disease
hereditary	I-Disease
cancer	I-Disease
patients	O
survive	O
longer	O
than	O
nonhereditary	B-Disease
cancer	I-Disease
patients	O
.	O

Age	O
penetrance	O
is	O
greater	O
for	O
BRCA1	B-Disease
-	I-Disease
linked	I-Disease
than	I-Disease
for	I-Disease
BRCA2	I-Disease
-	I-Disease
linked	I-Disease
cancers	I-Disease
in	O
this	O
population	O
.	O

The	O
gene	O
for	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
,	O
MEFV	O
,	O
is	O
expressed	O
in	O
early	O
leukocyte	O
development	O
and	O
is	O
regulated	O
in	O
response	O
to	O
inflammatory	O
mediators	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	B-Disease
and	O
neutrophil	B-Disease
-	I-Disease
mediated	I-Disease
serosal	I-Disease
inflammation	I-Disease
.	O

We	O
recently	O
identified	O
the	O
gene	O
causing	O
FMF	B-Disease
,	O
designated	O
MEFV	O
,	O
and	O
found	O
it	O
to	O
be	O
expressed	O
in	O
mature	O
neutrophils	O
,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
inflammatory	O
regulator	O
.	O

To	O
facilitate	O
our	O
understanding	O
of	O
the	O
normal	O
function	O
of	O
MEFV	O
,	O
we	O
extended	O
our	O
previous	O
studies	O
.	O

MEFV	O
messenger	O
RNA	O
was	O
detected	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
in	O
bone	O
marrow	O
leukocytes	O
,	O
with	O
differential	O
expression	O
observed	O
among	O
cells	O
by	O
in	O
situ	O
hybridization	O
.	O

CD34	O
hematopoietic	O
stem	O
-	O
cell	O
cultures	O
induced	O
toward	O
the	O
granulocytic	O
lineage	O
expressed	O
MEFV	O
at	O
the	O
myelocyte	O
stage	O
,	O
concurrently	O
with	O
lineage	O
commitment	O
.	O

The	O
prepromyelocytic	O
cell	O
line	O
HL60	O
expressed	O
MEFV	O
only	O
at	O
granulocytic	O
and	O
monocytic	O
differentiation	O
.	O

MEFV	O
was	O
also	O
expressed	O
in	O
the	O
monocytic	O
cell	O
lines	O
U937	O
and	O
THP	O
-	O
1	O
.	O

Among	O
peripheral	O
blood	O
leukocytes	O
,	O
MEFV	O
expression	O
was	O
detected	O
in	O
neutrophils	O
,	O
eosinophils	O
,	O
and	O
to	O
varying	O
degrees	O
,	O
monocytes	O
.	O

Consistent	O
with	O
the	O
tissue	O
specificity	O
of	O
expression	O
,	O
complete	O
sequencing	O
and	O
analysis	O
of	O
upstream	O
regulatory	O
regions	O
of	O
MEFV	O
revealed	O
homology	O
to	O
myeloid	O
-	O
specific	O
promoters	O
and	O
to	O
more	O
broadly	O
expressed	O
inflammatory	O
promoter	O
elements	O
.	O

In	O
vitro	O
stimulation	O
of	O
monocytes	O
with	O
the	O
proinflammatory	O
agents	O
interferon	O
(	O
IFN	O
)	O
gamma	O
,	O
tumor	B-Disease
necrosis	O
factor	O
,	O
and	O
lipopolysaccharide	O
induced	O
MEFV	O
expression	O
,	O
whereas	O
the	O
antiinflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
4	O
,	O
IL	O
-	O
10	O
,	O
and	O
transforming	O
growth	O
factor	O
beta	O
inhibited	O
such	O
expression	O
.	O

Induction	O
by	O
IFN	O
-	O
gamma	O
occurred	O
rapidly	O
and	O
was	O
resistant	O
to	O
cycloheximide	O
.	O

IFN	O
-	O
alpha	O
also	O
induced	O
MEFV	O
expression	O
.	O

In	O
granulocytes	O
,	O
MEFV	O
was	O
up	O
-	O
regulated	O
by	O
IFN	O
-	O
gamma	O
and	O
the	O
combination	O
of	O
IFN	O
-	O
alpha	O
and	O
colchicine	O
.	O

These	O
results	O
refine	O
understanding	O
of	O
MEFV	O
by	O
placing	O
the	O
gene	O
in	O
the	O
myelomonocytic	O
-	O
specific	O
proinflammatory	O
pathway	O
and	O
identifying	O
it	O
as	O
an	O
IFN	O
-	O
gamma	O
immediate	O
early	O
gene	O
.	O
.	O

Biochemical	O
and	O
structural	O
analysis	O
of	O
missense	O
mutations	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
causing	O
mucopolysaccharidosis	B-Disease
IVA	I-Disease
phenotypes	O
.	O

Mucopolysaccharidosis	B-Disease
IVA	I-Disease
(	O
MPS	B-Disease
IVA	I-Disease
;	O
OMIM	O
#	O
253000	O
)	O
,	O
a	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
N	I-Disease
-	I-Disease
acetylgalactosamine	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
sulfate	I-Disease
sulfatase	I-Disease
(	O
GALNS	O
)	O
,	O
has	O
variable	O
clinical	O
phenotypes	O
.	O

To	O
date	O
we	O
have	O
identified	O
65	O
missense	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
MPS	B-Disease
IVA	I-Disease
patients	O
,	O
but	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
has	O
remained	O
unclear	O
.	O

We	O
studied	O
17	O
missense	O
mutations	O
using	O
biochemical	O
approaches	O
and	O
32	O
missense	O
mutations	O
,	O
using	O
structural	O
analyses	O
.	O

Fifteen	O
missense	O
mutations	O
and	O
two	O
newly	O
engineered	O
active	O
site	O
mutations	O
(	O
C79S	O
,	O
C79T	O
)	O
were	O
characterized	O
by	O
transient	O
expression	O
analysis	O
.	O

Mutant	O
proteins	O
,	O
except	O
for	O
C79S	O
and	O
C79T	O
,	O
were	O
destabilized	O
and	O
detected	O
as	O
insoluble	O
precursor	O
forms	O
while	O
the	O
C79S	O
and	O
C79T	O
mutants	O
were	O
of	O
a	O
soluble	O
mature	O
size	O
.	O

Mutants	O
found	O
in	O
the	O
severe	O
phenotype	O
had	O
no	O
activity	O
.	O

Mutants	O
found	O
in	O
the	O
mild	O
phenotype	O
had	O
a	O
considerable	O
residual	O
activity	O
(	O
1	O
.	O
3	O
-	O
13	O
.	O
3	O
%	O
of	O
wild	O
-	O
type	O
GALNS	O
activity	O
)	O
.	O

Sulfatases	O
,	O
including	O
GALNS	O
,	O
are	O
members	O
of	O
a	O
highly	O
conserved	O
gene	O
family	O
sharing	O
an	O
extensive	O
sequence	O
homology	O
.	O

Thus	O
,	O
a	O
tertiary	O
structural	O
model	O
of	O
human	O
GALNS	O
was	O
constructed	O
from	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
N	O
-	O
acetylgalacto	O
-	O
samine	O
-	O
4	O
-	O
sulfatase	O
and	O
arylsulfatase	O
A	O
,	O
using	O
homology	O
modeling	O
,	O
and	O
32	O
missense	O
mutations	O
were	O
investigated	O
.	O

Consequently	O
,	O
we	O
propose	O
that	O
there	O
are	O
at	O
least	O
three	O
different	O
reasons	O
for	O
the	O
severe	O
phenotype	O
(	O
i	O
)	O
destruction	O
of	O
the	O
hydrophobic	O
core	O
or	O
modification	O
of	O
the	O
packing	O
;	O
(	O
ii	O
)	O
removal	O
of	O
a	O
salt	O
bridge	O
to	O
destabilize	O
the	O
entire	O
conformation	O
;	O
(	O
iii	O
)	O
modification	O
of	O
the	O
active	O
site	O
.	O

In	O
contrast	O
,	O
mild	O
mutations	O
were	O
mostly	O
located	O
on	O
the	O
surface	O
of	O
the	O
GALNS	O
protein	O
.	O

These	O
studies	O
shed	O
further	O
light	O
on	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
MPS	B-Disease
IVA	I-Disease
and	O
structure	O
-	O
function	O
relationship	O
in	O
the	O
sulfatase	O
family	O
.	O

Mutations	O
at	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
locus	O
and	O
clinical	O
phenotypes	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
.	O

Mutations	O
at	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
locus	O
on	O
chromosome	O
band	O
11q22	O
cause	O
a	O
distinctive	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
in	O
homozygotes	O
and	O
predispose	O
heterozygotes	O
to	O
cancer	B-Disease
,	O
ischemic	B-Disease
heart	I-Disease
disease	I-Disease
,	O
and	O
early	O
mortality	O
.	O

PCR	O
amplification	O
from	O
genomic	O
DNA	O
and	O
automated	O
sequencing	O
of	O
the	O
entire	O
coding	O
region	O
(	O
66	O
exons	O
)	O
and	O
splice	O
junctions	O
detected	O
77	O
mutations	O
(	O
85	O
%	O
)	O
in	O
90	O
A	B-Disease
-	I-Disease
T	I-Disease
chromosomes	O
.	O

Heteroduplex	O
analysis	O
detected	O
another	O
42	O
mutations	O
at	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
locus	O
.	O

Out	O
of	O
a	O
total	O
of	O
71	O
unique	O
mutations	O
,	O
50	O
were	O
found	O
only	O
in	O
a	O
single	O
family	O
,	O
and	O
51	O
had	O
not	O
been	O
reported	O
previously	O
.	O

Most	O
(	O
58	O
/	O
71	O
,	O
82	O
%	O
)	O
mutations	O
were	O
frameshift	O
and	O
nonsense	O
mutations	O
that	O
are	O
predicted	O
to	O
cause	O
truncation	O
of	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
protein	O
;	O
the	O
less	O
common	O
mutation	O
types	O
were	O
missense	O
(	O
9	O
/	O
71	O
,	O
13	O
%	O
)	O
,	O
splicing	O
(	O
3	O
/	O
71	O
,	O
4	O
%	O
)	O
and	O
one	O
in	O
-	O
frame	O
deletion	O
,	O
2546	O
3	O
(	O
1	O
/	O
71	O
,	O
1	O
%	O
)	O
.	O

The	O
mean	O
survival	O
and	O
height	O
distribution	O
of	O
134	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
correlated	O
significantly	O
with	O
the	O
specific	O
mutations	O
present	O
in	O
the	O
patients	O
.	O

Patients	O
homozygous	O
for	O
a	O
single	O
truncating	O
mutation	O
,	O
typically	O
near	O
the	O
N	O
-	O
terminal	O
end	O
of	O
the	O
gene	O
,	O
or	O
heterozygous	O
for	O
the	O
in	O
-	O
frame	O
deletion	O
2546	O
3	O
,	O
were	O
shorter	O
and	O
had	O
significantly	O
shorter	O
survival	O
than	O
those	O
heterozygous	O
for	O
a	O
splice	O
site	O
or	O
missense	O
mutation	O
,	O
or	O
heterozygous	O
for	O
two	O
truncating	O
mutations	O
.	O

Alterations	O
of	O
the	O
length	O
or	O
amino	O
acid	O
composition	O
of	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
gene	O
product	O
affect	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
clinical	O
phenotype	O
in	O
different	O
ways	O
.	O

Mutation	O
analysis	O
at	O
the	O
A	B-Disease
-	I-Disease
T	I-Disease
locus	O
may	O
help	O
estimate	O
the	O
prognosis	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
.	O
.	O

Isolation	O
,	O
genomic	O
organization	O
,	O
and	O
expression	O
analysis	O
of	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
MEFV	O
,	O
the	O
gene	O
for	O
familial	B-Disease
mediterranean	I-Disease
fever	I-Disease
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	B-Disease
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O

Recently	O
the	O
FMF	B-Disease
gene	O
(	O
MEFV	O
)	O
was	O
cloned	O
;	O
the	O
protein	O
product	O
,	O
pyrin	O
/	O
marenostrin	O
,	O
is	O
thought	O
to	O
regulate	O
inflammation	O
in	O
myeloid	O
cells	O
.	O

In	O
this	O
manuscript	O
we	O
report	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
MEFV	O
.	O

The	O
murine	O
gene	O
contains	O
ten	O
exons	O
with	O
a	O
coding	O
sequence	O
of	O
2304	O
bp	O
,	O
while	O
the	O
rat	O
homolog	O
has	O
nine	O
exons	O
with	O
a	O
coding	O
sequence	O
of	O
2253	O
bp	O
.	O

A	O
considerable	O
amino	O
acid	O
sequence	O
homology	O
was	O
observed	O
between	O
the	O
mouse	O
and	O
human	O
(	O
47	O
.	O
6	O
%	O
identity	O
and	O
65	O
.	O
5	O
%	O
similarity	O
)	O
and	O
between	O
the	O
mouse	O
and	O
rat	O
genes	O
(	O
73	O
.	O
5	O
%	O
identity	O
and	O
82	O
.	O
1	O
%	O
similarity	O
)	O
.	O

The	O
predicted	O
rodent	O
proteins	O
have	O
several	O
important	O
domains	O
and	O
signals	O
found	O
in	O
human	O
pyrin	O
,	O
including	O
a	O
B	O
-	O
box	O
zinc	O
finger	O
domain	O
,	O
Robbins	O
-	O
Dingwall	O
nuclear	O
localization	O
signal	O
,	O
and	O
coiled	O
-	O
coil	O
domain	O
.	O

However	O
,	O
perhaps	O
because	O
of	O
an	O
ancient	O
frame	O
-	O
shift	O
mutation	O
,	O
neither	O
the	O
mouse	O
nor	O
the	O
rat	O
protein	O
has	O
an	O
intact	O
C	O
-	O
terminal	O
B30	O
.	O

2	O
domain	O
,	O
in	O
which	O
most	O
FMF	B-Disease
-	O
associated	O
mutations	O
have	O
been	O
found	O
in	O
human	O
MEFV	O
.	O

Nevertheless	O
,	O
like	O
the	O
human	O
gene	O
,	O
mouse	O
Mefv	O
is	O
expressed	O
in	O
peripheral	O
blood	O
granulocytes	O
but	O
not	O
lymphocytes	O
.	O

Consistent	O
with	O
its	O
expression	O
in	O
granulocytes	O
,	O
Mefv	O
was	O
detected	O
at	O
high	O
levels	O
in	O
the	O
primary	O
follicles	O
and	O
marginal	O
zones	O
of	O
the	O
splenic	O
white	O
pulp	O
.	O

Mefv	O
is	O
localized	O
on	O
mouse	O
Chromosome	O
(	O
Chr	O
)	O
16	O
,	O
region	O
A3	O
-	O
B1	O
,	O
extending	O
a	O
region	O
of	O
synteny	O
with	O
human	O
Chr	O
16p13	O
.	O

3	O
.	O

Development	O
of	O
knockout	O
and	O
knockin	O
mouse	O
models	O
may	O
provide	O
further	O
insights	O
into	O
the	O
functional	O
evolution	O
of	O
this	O
gene	O
.	O

Additional	O
copies	O
of	O
the	O
proteolipid	O
protein	O
gene	O
causing	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
arise	O
by	O
separate	O
integration	O
into	O
the	O
X	O
chromosome	O
.	O

The	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
is	O
normally	O
present	O
at	O
chromosome	O
Xq22	O
.	O

Mutations	O
and	O
duplications	O
of	O
this	O
gene	O
are	O
associated	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
PMD	B-Disease
)	O
.	O

Here	O
we	O
describe	O
two	O
new	O
families	O
in	O
which	O
males	O
affected	O
with	O
PMD	B-Disease
were	O
found	O
to	O
have	O
a	O
copy	O
of	O
PLP	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
in	O
addition	O
to	O
a	O
normal	O
copy	O
on	O
Xq22	O
.	O

In	O
the	O
first	O
family	O
,	O
the	O
extra	O
copy	O
was	O
first	O
detected	O
by	O
the	O
presence	O
of	O
heterozygosity	O
of	O
the	O
AhaII	O
dimorphism	O
within	O
the	O
PLP	O
gene	O
.	O

The	O
results	O
of	O
FISH	O
analysis	O
showed	O
an	O
additional	O
copy	O
of	O
PLP	O
in	O
Xp22	O
.	O

1	O
,	O
although	O
no	O
chromosomal	O
rearrangements	O
could	O
be	O
detected	O
by	O
standard	O
karyotype	O
analysis	O
.	O

Another	O
three	O
affected	O
males	O
from	O
the	O
family	O
had	O
similar	O
findings	O
.	O

In	O
a	O
second	O
unrelated	O
family	O
with	O
signs	O
of	O
PMD	B-Disease
,	O
cytogenetic	O
analysis	O
showed	O
a	O
pericentric	O
inversion	O
of	O
the	O
X	O
chromosome	O
.	O

In	O
the	O
inv	O
(	O
X	O
)	O
carried	O
by	O
several	O
affected	O
family	O
members	O
,	O
FISH	O
showed	O
PLP	O
signals	O
at	O
Xp11	O
.	O

4	O
and	O
Xq22	O
.	O

A	O
third	O
family	O
has	O
previously	O
been	O
reported	O
,	O
in	O
which	O
affected	O
members	O
had	O
an	O
extra	O
copy	O
of	O
the	O
PLP	O
gene	O
detected	O
at	O
Xq26	O
in	O
a	O
chromosome	O
with	O
an	O
otherwise	O
normal	O
banding	O
pattern	O
.	O

The	O
identification	O
of	O
three	O
separate	O
families	O
in	O
which	O
PLP	O
is	O
duplicated	O
at	O
a	O
noncontiguous	O
site	O
suggests	O
that	O
such	O
duplications	O
could	O
be	O
a	O
relatively	O
common	O
but	O
previously	O
undetected	O
cause	O
of	O
genetic	B-Disease
disorders	I-Disease
.	O

The	O
exon	O
13	O
duplication	O
in	O
the	O
BRCA1	O
gene	O
is	O
a	O
founder	O
mutation	O
present	O
in	O
geographically	O
diverse	O
populations	O
.	O

The	O
BRCA1	O
Exon	O
13	O
Duplication	O
Screening	O
Group	O
.	O

Recently	O
,	O
a	O
6	O
-	O
kb	O
duplication	O
of	O
exon	O
13	O
,	O
which	O
creates	O
a	O
frameshift	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
BRCA1	O
gene	O
,	O
has	O
been	O
described	O
in	O
three	O
unrelated	O
U	O
.	O

S	O
S	O
.	O
families	O
of	O
European	O
ancestry	O
and	O
in	O
one	O
Portuguese	O
family	O
.	O

Here	O
,	O
our	O
goal	O
was	O
to	O
estimate	O
the	O
frequency	O
and	O
geographic	O
diversity	O
of	O
carriers	O
of	O
this	O
duplication	O
.	O

To	O
do	O
this	O
,	O
a	O
collaborative	O
screening	O
study	O
was	O
set	O
up	O
that	O
involved	O
39	O
institutions	O
from	O
19	O
countries	O
and	O
included	O
3	O
,	O
580	O
unrelated	O
individuals	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
and	O
934	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
.	O

A	O
total	O
of	O
11	O
additional	O
families	O
carrying	O
this	O
mutation	O
were	O
identified	O
in	O
Australia	O
(	O
1	O
)	O
,	O
Belgium	O
(	O
1	O
)	O
,	O
Canada	O
(	O
1	O
)	O
,	O
Great	O
Britain	O
(	O
6	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
2	O
)	O
.	O

Haplotyping	O
showed	O
that	O
they	O
are	O
likely	O
to	O
derive	O
from	O
a	O
common	O
ancestor	O
,	O
possibly	O
of	O
northern	O
British	O
origin	O
.	O

Our	O
results	O
demonstrate	O
that	O
it	O
is	O
strongly	O
advisable	O
,	O
for	O
laboratories	O
carrying	O
out	O
screening	O
either	O
in	O
English	O
-	O
speaking	O
countries	O
or	O
in	O
countries	O
with	O
historical	O
links	O
with	O
Britain	O
,	O
to	O
include	O
within	O
their	O
BRCA1	O
screening	O
protocols	O
the	O
polymerase	O
chain	O
reaction	O
-	O
based	O
assay	O
described	O
in	O
this	O
report	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
families	O
with	O
deletions	O
in	O
the	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	B-Disease
)	O
gene	O
.	O

Von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
disease	I-Disease
is	O
a	O
hereditary	B-Disease
tumor	I-Disease
syndrome	I-Disease
characterized	O
by	O
predisposition	O
for	O
bilateral	B-Disease
and	I-Disease
multi	I-Disease
-	I-Disease
centric	I-Disease
hemangioblastoma	I-Disease
in	O
the	O
retina	O
and	O
central	O
nervous	O
system	O
,	O
pheochromocytoma	B-Disease
,	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
,	O
and	O
cysts	B-Disease
in	I-Disease
the	I-Disease
kidney	I-Disease
,	I-Disease
pancreas	I-Disease
,	I-Disease
and	I-Disease
epididymis	I-Disease
.	O

We	O
describe	O
five	O
families	O
for	O
which	O
direct	O
sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
VHL	B-Disease
gene	O
had	O
failed	O
to	O
identify	O
the	O
family	O
-	O
specific	O
mutation	O
.	O

Further	O
molecular	O
analysis	O
revealed	O
deletions	O
involving	O
the	O
VHL	B-Disease
gene	O
in	O
each	O
of	O
these	O
families	O
.	O

In	O
four	O
families	O
,	O
partial	O
deletions	O
of	O
one	O
or	O
more	O
exons	O
were	O
detected	O
by	O
Southern	O
blot	O
analysis	O
.	O

In	O
the	O
fifth	O
family	O
,	O
FISH	O
analysis	O
demonstrated	O
the	O
deletion	O
of	O
the	O
entire	O
VHL	B-Disease
gene	O
.	O

Our	O
results	O
show	O
that	O
(	O
quantitative	O
)	O
Southern	O
blot	O
analysis	O
is	O
a	O
sensitive	O
method	O
for	O
detecting	O
germline	O
deletions	O
of	O
the	O
VHL	B-Disease
gene	O
and	O
should	O
be	O
implemented	O
in	O
routine	O
DNA	O
diagnosis	O
for	O
VHL	B-Disease
disease	I-Disease
.	O

Our	O
data	O
support	O
the	O
previously	O
established	O
observation	O
that	O
families	O
with	O
a	O
germline	O
deletion	O
have	O
a	O
low	O
risk	O
for	O
pheochromocytoma	B-Disease
.	O

Further	O
unraveling	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
VHL	B-Disease
disease	I-Disease
has	O
revealed	O
that	O
families	O
with	O
a	O
full	O
or	O
partial	O
deletion	O
of	O
the	O
VHL	B-Disease
gene	O
exhibit	O
a	O
phenotype	O
with	O
a	O
preponderance	O
of	O
central	B-Disease
nervous	I-Disease
system	I-Disease
hemangioblastoma	I-Disease
.	O
.	O

Age	O
of	O
the	O
intronic	O
GAA	O
triplet	O
repeat	O
expansion	O
mutation	O
in	O
Friedreich	B-Disease
ataxia	I-Disease
.	O

Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
the	O
most	O
frequently	O
inherited	B-Disease
ataxia	I-Disease
,	O
is	O
due	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
to	O
a	O
large	O
expansion	O
of	O
an	O
intronic	O
GAA	O
repeat	O
.	O

Using	O
linkage	O
disequilibrium	O
analysis	O
based	O
on	O
haplotype	O
data	O
of	O
seven	O
polymorphic	O
markers	O
close	O
to	O
the	O
frataxin	O
gene	O
,	O
the	O
age	O
of	O
FRDA	B-Disease
founding	O
mutational	O
event	O
(	O
s	O
)	O
is	O
estimated	O
to	O
be	O
at	O
least	O
682	O
+	O
/	O
-	O
203	O
generations	O
(	O
95	O
%	O
confidence	O
interval	O
564	O
-	O
801	O
g	O
)	O
,	O
a	O
dating	O
which	O
is	O
consistent	O
with	O
little	O
or	O
no	O
negative	O
selection	O
and	O
provides	O
further	O
evidence	O
for	O
an	O
ancient	O
spread	O
of	O
a	O
pre	O
-	O
mutation	O
(	O
at	O
-	O
risk	O
alleles	O
)	O
in	O
western	O
Europe	O
.	O
.	O

Functional	O
link	O
between	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
and	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
gene	O
products	O
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
and	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
are	O
recessive	B-Disease
genetic	I-Disease
disorders	I-Disease
with	O
susceptibility	O
to	O
cancer	B-Disease
and	O
similar	O
cellular	O
phenotypes	O
.	O

The	O
protein	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
A	B-Disease
-	I-Disease
T	I-Disease
,	O
designated	O
ATM	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
characterized	O
by	O
a	O
carboxy	O
-	O
terminal	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
like	O
domain	O
.	O

The	O
NBS1	O
protein	O
is	O
specifically	O
mutated	O
in	O
patients	O
with	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
and	O
forms	O
a	O
complex	O
with	O
the	O
DNA	O
repair	O
proteins	O
Rad50	O
and	O
Mrel1	O
.	O

Here	O
we	O
show	O
that	O
phosphorylation	O
of	O
NBS1	O
,	O
induced	O
by	O
ionizing	O
radiation	O
,	O
requires	O
catalytically	O
active	O
ATM	O
.	O

Complexes	O
containing	O
ATM	O
and	O
NBS1	O
exist	O
in	O
vivo	O
in	O
both	O
untreated	O
cells	O
and	O
cells	O
treated	O
with	O
ionizing	O
radiation	O
.	O

We	O
have	O
identified	O
two	O
residues	O
of	O
NBS1	O
,	O
Ser	O
278	O
and	O
Ser	O
343	O
that	O
are	O
phosphorylated	O
in	O
vitro	O
by	O
ATM	O
and	O
whose	O
modification	O
in	O
vivo	O
is	O
essential	O
for	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

This	O
response	O
includes	O
S	O
-	O
phase	O
checkpoint	O
activation	O
,	O
formation	O
of	O
the	O
NBS1	O
/	O
Mrel1	O
/	O
Rad50	O
nuclear	O
foci	O
and	O
rescue	O
of	O
hypersensitivity	B-Disease
to	I-Disease
ionizing	I-Disease
radiation	I-Disease
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
a	O
biochemical	O
link	O
between	O
cell	O
-	O
cycle	O
checkpoints	O
activated	O
by	O
DNA	O
damage	O
and	O
DNA	O
repair	O
in	O
two	O
genetic	B-Disease
diseases	I-Disease
with	O
overlapping	O
phenotypes	O
.	O
.	O

Homozygosity	O
mapping	O
in	O
a	O
family	O
with	O
microcephaly	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
short	B-Disease
stature	I-Disease
to	O
a	O
Cohen	B-Disease
syndrome	I-Disease
region	O
on	O
8q21	O
.	O
3	O
-	O
8q22	O
.	O
1	O
:	O
redefining	O
a	O
clinical	O
entity	O
.	O

A	O
syndrome	O
of	O
microcephaly	B-Disease
,	O
progressive	O
postnatal	B-Disease
growth	I-Disease
deficiency	I-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
was	O
observed	O
in	O
two	O
brothers	O
and	O
their	O
cousin	O
from	O
a	O
multiply	O
consanguineous	O
kindred	O
of	O
Lebanese	O
descent	O
.	O

Hypotonia	B-Disease
,	O
chorioretinal	B-Disease
dystrophy	I-Disease
,	O
and	O
myopia	B-Disease
were	O
also	O
identified	O
.	O

The	O
severity	O
of	O
the	O
condition	O
varied	O
among	O
the	O
closely	O
related	O
patients	O
.	O

Because	O
of	O
absence	O
of	O
a	O
distinctive	O
facial	O
appearance	O
,	O
the	O
degree	O
of	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
short	B-Disease
stature	I-Disease
,	O
the	O
initially	O
considered	O
clinical	O
diagnosis	O
of	O
Cohen	B-Disease
syndrome	I-Disease
was	O
withdrawn	O
and	O
a	O
novel	O
genetic	O
entity	O
was	O
assumed	O
.	O

Homozygosity	O
mapping	O
in	O
this	O
family	O
assigned	O
the	O
gene	O
to	O
a	O
26	O
.	O

8	O
-	O
cM	O
region	O
on	O
the	O
chromosome	O
band	O
8q21	O
.	O

3	O
-	O
22	O
.	O

1	O
,	O
between	O
the	O
microsatellites	O
at	O
D8S270	O
and	O
D8S514	O
.	O

The	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
was	O
found	O
for	O
marker	O
at	O
D8S267	O
(	O
Zmax	O
=	O
3	O
.	O
.	O
237	O
at	O
Omax	O
=	O
0	O
.	O
00	O
)	O
.	O

Intriguingly	O
enough	O
,	O
the	O
identified	O
gene	O
region	O
overlaps	O
the	O
refined	O
gene	O
region	O
for	O
Cohen	B-Disease
syndrome	I-Disease
(	O
COH1	O
)	O
[	O
Kolehmainen	O
et	O
al	O
.	O
,	O
1997	O
Euro	O
J	O
Hum	O
Genet	O
5	O
206	O
-	O
213	O
]	O
.	O

This	O
fact	O
encourages	O
the	O
hypothesis	O
that	O
the	O
described	O
kindred	O
segregates	O
for	O
a	O
variant	O
of	O
Cohen	B-Disease
syndrome	I-Disease
and	O
suggests	O
a	O
redefinition	O
of	O
its	O
phenotype	O

Polymorphisms	O
of	O
the	O
CYP2D6	O
gene	O
increase	O
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O

Ankylosing	B-Disease
spondylitis	I-Disease
(	O
AS	B-Disease
)	O
is	O
a	O
common	O
and	O
highly	O
familial	O
rheumatic	B-Disease
disorder	I-Disease
.	O

The	O
sibling	O
recurrence	O
risk	O
ratio	O
for	O
the	O
disease	O
is	O
63	O
and	O
heritability	O
assessed	O
in	O
twins	O
>	O
90	O
%	O
.	O

Although	O
MHC	O
genes	O
,	O
including	O
HLA	O
-	O
B27	O
,	O
contribute	O
only	O
20	O
-	O
50	O
%	O
of	O
the	O
genetic	O
risk	O
for	O
the	O
disease	O
,	O
no	O
non	O
-	O
MHC	O
gene	O
has	O
yet	O
been	O
convincingly	O
demonstrated	O
to	O
influence	O
either	O
susceptibility	O
to	O
the	O
disease	O
or	O
its	O
phenotypic	O
expression	O
.	O

Previous	O
linkage	O
and	O
association	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	O
gene	O
for	O
AS	B-Disease
close	O
to	O
,	O
or	O
within	O
,	O
the	O
cytochrome	O
P450	O
2D6	O
gene	O
(	O
CYP2D6	O
,	O
debrisoquine	O
hydroxylase	O
)	O
located	O
at	O
chromosome	O
22q13	O
.	O
1	O
.	O

We	O
performed	O
a	O
linkage	O
study	O
of	O
chromosome	O
22	O
in	O
200	O
families	O
with	O
AS	B-Disease
affected	O
sibling	O
-	O
pairs	O
.	O

Association	O
of	O
alleles	O
of	O
the	O
CYP2D6	O
gene	O
was	O
examined	O
by	O
both	O
case	O
-	O
control	O
and	O
within	O
-	O
family	O
means	O
.	O

For	O
case	O
-	O
control	O
studies	O
,	O
617	O
unrelated	O
individuals	O
with	O
AS	B-Disease
(	O
361	O
probands	O
from	O
sibling	O
-	O
pair	O
and	O
parent	O
-	O
case	O
trio	O
families	O
and	O
256	O
unrelated	O
non	O
-	O
familial	O
sporadic	O
cases	O
)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed	O
.	O

For	O
within	O
-	O
family	O
association	O
studies	O
,	O
361	O
families	O
including	O
161	O
parent	O
-	O
case	O
trios	O
and	O
200	O
affected	O
sibling	O
-	O
pair	O
families	O
were	O
employed	O
.	O

Homozygosity	O
for	O
poor	O
metabolizer	O
alleles	O
was	O
found	O
to	O
be	O
associated	O
with	O
AS	B-Disease
.	O

Heterozygosity	O
for	O
the	O
most	O
frequent	O
poor	O
metabolizer	O
allele	O
(	O
CYP2D6	O
*	O
4	O
)	O
was	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
AS	B-Disease
.	O

Significant	O
within	O
-	O
family	O
association	O
of	O
CYP2D6	O
*	O
4	O
alleles	O
and	O
AS	B-Disease
was	O
demonstrated	O
.	O

Weak	O
linkage	O
was	O
also	O
demonstrated	O
between	O
CYP2D6	O
and	O
AS	B-Disease
.	O

We	O
postulate	O
that	O
altered	O
metabolism	O
of	O
a	O
natural	O
toxin	O
or	O
antigen	O
by	O
the	O
CYP2D6	O
gene	O
may	O
increase	O
susceptibility	O
to	O
AS	B-Disease
.	O

Functional	O
differences	O
of	O
the	O
PDS	B-Disease
gene	O
product	O
are	O
associated	O
with	O
phenotypic	O
variation	O
in	O
patients	O
with	O
Pendred	B-Disease
syndrome	I-Disease
and	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
(	O
DFNB4	B-Disease
)	O
.	O

The	O
PDS	B-Disease
gene	O
encodes	O
a	O
transmembrane	O
protein	O
,	O
known	O
as	O
pendrin	O
,	O
which	O
functions	O
as	O
a	O
transporter	O
of	O
iodide	O
and	O
chloride	O
.	O

Mutations	O
in	O
this	O
gene	O
are	O
responsible	O
for	O
Pendred	B-Disease
syndrome	I-Disease
and	O
autosomal	B-Disease
recessive	I-Disease
non	I-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
at	O
the	O
DFNB4	B-Disease
locus	O
on	O
chromosome	O
7q31	O
.	O

A	O
screen	O
of	O
20	O
individuals	O
from	O
the	O
midwestern	O
USA	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
and	O
dilated	O
vestibular	O
aqueducts	O
identified	O
three	O
people	O
(	O
15	O
%	O
)	O
with	O
PDS	B-Disease
mutations	O
.	O

To	O
determine	O
whether	O
PDS	B-Disease
mutations	O
in	O
individuals	O
with	O
Pendred	B-Disease
syndrome	I-Disease
differ	O
functionally	O
from	O
PDS	B-Disease
mutations	O
in	O
individuals	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
we	O
compared	O
three	O
common	O
Pendred	B-Disease
syndrome	I-Disease
allele	O
variants	O
(	O
L236P	O
,	O
T416P	O
and	O
E384G	O
)	O
,	O
with	O
three	O
PDS	B-Disease
mutations	O
reported	O
only	O
in	O
individuals	O
with	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
(	O
V480D	O
,	O
V653A	O
and	O
I490L	O
/	O
G497S	O
)	O
.	O

The	O
mutations	O
associated	O
with	O
Pendred	B-Disease
syndrome	I-Disease
have	O
complete	O
loss	O
of	O
pendrin	O
-	O
induced	O
chloride	O
and	O
iodide	O
transport	O
,	O
while	O
alleles	O
unique	O
to	O
people	O
with	O
DFNB4	B-Disease
are	O
able	O
to	O
transport	O
both	O
iodide	O
and	O
chloride	O
,	O
albeit	O
at	O
a	O
much	O
lower	O
level	O
than	O
wild	O
-	O
type	O
pendrin	O
.	O

We	O
hypothesize	O
that	O
this	O
residual	O
level	O
of	O
anion	O
transport	O
is	O
sufficient	O
to	O
eliminate	O
or	O
postpone	O
the	O
onset	O
of	O
goiter	B-Disease
in	O
individuals	O
with	O
DFNB4	B-Disease
.	O

We	O
propose	O
a	O
model	O
for	O
pendrin	O
function	O
in	O
the	O
thyroid	O
in	O
which	O
pendrin	O
transports	O
iodide	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
thyrocyte	O
into	O
the	O
colloid	O
space	O
.	O
.	O

The	O
human	O
factor	O
IX	O
gene	O
as	O
germline	O
mutagen	O
test	O
:	O
samples	O
from	O
Mainland	O
China	O
have	O
the	O
putatively	O
endogenous	O
pattern	O
of	O
mutation	O
.	O

Germline	O
mutations	O
are	O
the	O
major	O
source	O
of	O
genetic	O
variation	O
that	O
allows	O
a	O
species	O
to	O
evolve	O
over	O
time	O
but	O
at	O
the	O
cost	O
of	O
Mendelian	B-Disease
disease	I-Disease
and	O
genetic	O
predisposition	O
to	O
multifactorial	B-Disease
diseases	I-Disease
.	O

Previous	O
analyses	O
have	O
revealed	O
that	O
the	O
pattern	O
of	O
germline	O
mutations	O
in	O
the	O
factor	O
IX	O
gene	O
(	O
F9	O
)	O
is	O
similar	O
among	O
a	O
variety	O
of	O
ethnically	O
and	O
geographically	O
diverse	O
populations	O
and	O
compatible	O
with	O
the	O
ancient	O
pattern	O
that	O
has	O
shaped	O
the	O
mammalian	O
genome	O
.	O

Here	O
,	O
we	O
compare	O
the	O
pattern	O
of	O
germline	O
mutation	O
in	O
a	O
population	O
of	O
hemophilia	B-Disease
B	I-Disease
patients	O
from	O
Mainland	O
China	O
(	O
n	O
=	O
66	O
)	O
to	O
that	O
in	O
U	O
.	O

S	O
.	O

Caucasians	O
,	O
Blacks	O
,	O
and	O
Mexican	O
Hispanics	O
and	O
stratify	O
by	O
disease	O
severity	O
and	O
ethnicity	O
.	O

The	O
similar	O
pattern	O
of	O
germline	O
mutation	O
in	O
all	O
ethnic	O
groups	O
studied	O
to	O
date	O
provides	O
additional	O
data	O
compatible	O
with	O
the	O
inference	O
that	O
endogenous	O
processes	O
predominate	O
in	O
germline	O
mutations	O
.	O

Fas	O
preassociation	O
required	O
for	O
apoptosis	O
signaling	O
and	O
dominant	O
inhibition	O
by	O
pathogenic	O
mutations	O
.	O

Heterozygous	O
mutations	O
encoding	O
abnormal	O
forms	O
of	O
the	O
death	O
receptor	O
Fas	O
dominantly	O
interfere	O
with	O
Fas	O
-	O
induced	O
lymphocyte	O
apoptosis	O
in	O
human	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
.	O

This	O
effect	O
,	O
rather	O
than	O
depending	O
on	O
ligand	O
-	O
induced	O
receptor	O
oligomerization	O
,	O
was	O
found	O
to	O
stem	O
from	O
ligand	O
-	O
independent	O
interaction	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
Fas	O
receptors	O
through	O
a	O
specific	O
region	O
in	O
the	O
extracellular	O
domain	O
.	O

Preassociated	O
Fas	O
complexes	O
were	O
found	O
in	O
living	O
cells	O
by	O
means	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
between	O
variants	O
of	O
green	O
fluorescent	O
protein	O
.	O

These	O
results	O
show	O
that	O
formation	O
of	O
preassociated	O
receptor	O
complexes	O
is	O
necessary	O
for	O
Fas	O
signaling	O
and	O
dominant	O
interference	O
in	O
human	O
disease	O
.	O
.	O

Determination	O
of	O
carrier	O
status	O
for	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
by	O
flow	O
cytometric	O
analysis	O
of	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
protein	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

The	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
is	O
caused	O
by	O
defects	O
in	O
the	O
WAS	B-Disease
protein	O
(	O
WASP	O
)	O
gene	O
on	O
the	O
X	O
chromosome	O
.	O

Previous	O
study	O
disclosed	O
that	O
flow	O
cytometric	O
analysis	O
of	O
intracellular	O
WASP	O
expression	O
(	O
FCM	O
-	O
WASP	O
analysis	O
)	O
in	O
lymphocytes	O
was	O
useful	O
for	O
the	O
diagnosis	O
of	O
WAS	B-Disease
patients	O
.	O

Lymphocytes	O
from	O
all	O
WAS	B-Disease
patients	O
showed	O
WASPdim	O
instead	O
of	O
WASPbright	O
.	O

Here	O
we	O
report	O
that	O
FCM	O
-	O
WASP	O
analysis	O
in	O
monocytes	O
could	O
be	O
a	O
useful	O
tool	O
for	O
the	O
WAS	B-Disease
carrier	O
diagnosis	O
.	O

Monocytes	O
from	O
all	O
nine	O
WAS	B-Disease
carriers	O
showed	O
varied	O
population	O
of	O
WASPdim	O
together	O
with	O
WASPbright	O
.	O

None	O
of	O
control	O
individuals	O
possessed	O
the	O
WASPdim	O
population	O
.	O

In	O
contrast	O
,	O
lymphocytes	O
from	O
all	O
the	O
carriers	O
except	O
two	O
lacked	O
the	O
WASPdim	O
population	O
.	O

The	O
difference	O
of	O
the	O
WASPdim	O
population	O
in	O
monocytes	O
and	O
lymphocytes	O
observed	O
in	O
WAS	B-Disease
carriers	O
suggests	O
that	O
WASP	O
plays	O
a	O
more	O
critical	O
role	O
in	O
the	O
development	O
of	O
lymphocytes	O
than	O
in	O
that	O
of	O
monocytes	O
.	O

The	O
present	O
studies	O
suggest	O
that	O
a	O
skewed	O
X	O
-	O
chromosomal	O
inactivation	O
pattern	O
observed	O
in	O
WAS	B-Disease
carrier	O
peripheral	O
blood	O
cells	O
is	O
not	O
fixed	O
at	O
the	O
hemopoietic	O
stem	O
cell	O
level	O
but	O
progresses	O
after	O
the	O
lineage	O
commitment	O
.	O
.	O

Restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	B-Disease
degeneration	I-Disease
slow	O
mice	O
by	O
gene	O
therapy	O
.	O

The	O
gene	O
Prph2	O
encodes	O
a	O
photoreceptor	O
-	O
specific	O
membrane	O
glycoprotein	O
,	O
peripherin	O
-	O
2	O
(	O
also	O
known	O
as	O
peripherin	O
/	O
rds	O
)	O
,	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	O
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom	O
-	O
1	O
(	O
ref	O
.	O
2	O
)	O
.	O

The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs	O
,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life	O
,	O
and	O
which	O
contain	O
the	O
visual	O
pigments	O
necessary	O
for	O
photon	O
capture	O
.	O

Mutations	O
in	O
Prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	B-Disease
dystrophies	I-Disease
,	O
including	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
and	O
macular	B-Disease
dystrophy	I-Disease
.	O

A	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function	O
,	O
also	O
seen	O
in	O
the	O
retinal	B-Disease
degeneration	I-Disease
slow	O
(	O
rds	O
or	O
Prph2	O
Rd2	O
/	O
Rd2	O
)	O
mouse	O
,	O
which	O
is	O
homozygous	O
for	O
a	O
null	O
mutation	O
in	O
Prph2	O
.	O

It	O
is	O
characterized	O
by	O
a	O
complete	O
failure	O
to	O
develop	O
photoreceptor	O
discs	O
and	O
outer	O
segments	O
,	O
downregulation	O
of	O
rhodopsin	O
and	O
apoptotic	O
loss	O
of	O
photoreceptor	O
cells	O
.	O

The	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
Prph2Rd2	O
/	O
Rd2	O
mice	O
have	O
greatly	O
diminished	O
a	O
-	O
wave	O
and	O
b	O
-	O
wave	O
amplitudes	O
,	O
which	O
decline	O
to	O
virtually	O
undetectable	O
concentrations	O
by	O
two	O
months	O
.	O

Subretinal	O
injection	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
encoding	O
a	O
Prph2	O
transgene	O
results	O
in	O
stable	O
generation	O
of	O
outer	O
segment	O
structures	O
and	O
formation	O
of	O
new	O
stacks	O
of	O
discs	O
containing	O
both	O
perpherin	O
-	O
2	O
and	O
rhodopsin	O
,	O
which	O
in	O
many	O
cases	O
are	O
morphologically	O
similar	O
to	O
normal	O
outer	O
segments	O
.	O

Moreover	O
,	O
the	O
re	O
-	O
establishment	O
of	O
the	O
structural	O
integrity	O
of	O
the	O
photoreceptor	O
layer	O
also	O
results	O
in	O
electrophysiological	O
correction	O
.	O

These	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
complex	O
ultrastructural	O
cell	O
defect	O
can	O
be	O
corrected	O
both	O
morphologically	O
and	O
functionally	O
by	O
in	O
vivo	O
gene	O
transfer	O
.	O
.	O

Mutations	O
in	O
the	O
fibrinogen	O
aalpha	O
gene	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
congenital	B-Disease
afibrinogenemia	I-Disease
.	O

Congenital	B-Disease
afibrinogenemia	I-Disease
is	O
a	O
rare	O
,	O
autosomal	B-Disease
,	I-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
the	O
complete	O
absence	O
of	O
detectable	O
fibrinogen	O
.	O

We	O
previously	O
identified	O
the	O
first	O
causative	O
mutations	O
in	O
a	O
nonconsanguineous	O
Swiss	O
family	O
;	O
the	O
4	O
affected	O
persons	O
have	O
homozygous	O
deletions	O
of	O
approximately	O
11	O
kb	O
of	O
the	O
fibrinogen	O
alpha	O
(	O
FGA	O
)	O
gene	O
.	O

Haplotype	O
data	O
implied	O
that	O
these	O
deletions	O
occurred	O
on	O
distinct	O
ancestral	O
chromosomes	O
,	O
suggesting	O
that	O
this	O
region	O
may	O
be	O
susceptible	O
to	O
deletion	O
by	O
a	O
common	O
mechanism	O
.	O

We	O
subsequently	O
showed	O
that	O
all	O
the	O
deletions	O
were	O
identical	O
to	O
the	O
base	O
pair	O
and	O
probably	O
resulted	O
from	O
a	O
nonhomologous	O
recombination	O
mediated	O
by	O
7	O
-	O
bp	O
direct	O
repeats	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
collected	O
data	O
on	O
13	O
additional	O
unrelated	O
patients	O
to	O
identify	O
the	O
causative	O
mutations	O
and	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
11	O
-	O
kb	O
deletion	O
.	O

A	O
common	O
recurrent	O
mutation	O
,	O
at	O
the	O
donor	O
splice	O
site	O
of	O
FGA	O
intron	O
4	O
(	O
IVS4	O
+	O
1	O
G	O
>	O
T	O
)	O
,	O
accounted	O
for	O
14	O
of	O
the	O
26	O
(	O
54	O
%	O
)	O
alleles	O
.	O

One	O
patient	O
was	O
heterozygous	O
for	O
the	O
previously	O
identified	O
deletion	O
.	O

Three	O
more	O
frameshift	O
mutations	O
,	O
2	O
nonsense	O
mutations	O
,	O
and	O
a	O
second	O
splice	O
site	O
mutation	O
were	O
also	O
identified	O
.	O

Consequently	O
,	O
86	O
%	O
of	O
afibrinogenemia	B-Disease
alleles	O
analyzed	O
to	O
date	O
have	O
truncating	O
mutations	O
of	O
FGA	O
,	O
though	O
mutations	O
in	O
all	O
3	O
fibrinogen	O
genes	O
,	O
FGG	O
,	O
FGA	O
,	O
and	O
FGB	O
,	O
might	O
be	O
predicted	O
to	O
cause	O
congenital	B-Disease
afibrinogenemia	I-Disease
.	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
:	O
the	O
role	O
of	O
the	O
CUG	O
triplet	O
repeats	O
in	O
splicing	O
of	O
a	O
novel	O
DMPK	O
exon	O
and	O
altered	O
cytoplasmic	O
DMPK	O
mRNA	O
isoform	O
ratios	O
.	O

The	O
mechanism	O
by	O
which	O
(	O
CTG	O
)	O
n	O
expansion	O
in	O
the	O
3	O
UTR	O
of	O
the	O
DMPK	O
gene	O
causes	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
unknown	O
.	O

We	O
identified	O
four	O
RNA	O
splicing	O
factors	O
-	O
-	O
hnRNP	O
C	O
,	O
U2AF	O
(	O
U2	O
auxiliary	O
factor	O
)	O
,	O
PTB	O
(	O
polypyrimidine	O
tract	O
binding	O
protein	O
)	O
,	O
and	O
PSF	O
(	O
PTB	O
associated	O
splicing	O
factor	O
)	O
-	O
-	O
that	O
bind	O
to	O
two	O
short	O
regions	O
3	O
of	O
the	O
(	O
CUG	O
)	O
n	O
,	O
and	O
found	O
a	O
novel	O
3	O
DMPK	O
exon	O
resulting	O
in	O
an	O
mRNA	O
lacking	O
the	O
repeats	O
.	O

We	O
propose	O
that	O
the	O
(	O
CUG	O
)	O
n	O
is	O
an	O
essential	O
cis	O
acting	O
element	O
for	O
this	O
splicing	O
event	O
.	O

In	O
contrast	O
to	O
(	O
CUG	O
)	O
n	O
containing	O
mRNAs	O
,	O
the	O
novel	O
isoform	O
is	O
not	O
retained	O
in	O
the	O
nucleus	O
in	O
DM	B-Disease
cells	O
,	O
resulting	O
in	O
imbalances	O
in	O
relative	O
levels	O
of	O
cytoplasmic	O
DMPK	O
mRNA	O
isoforms	O
and	O
a	O
new	O
dominant	O
effect	O
of	O
the	O
mutation	O
on	O
DMPK	O
.	O
.	O

Expression	O
and	O
imprinting	O
of	O
MAGEL2	O
suggest	O
a	O
role	O
in	O
Prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
and	O
the	O
homologous	O
murine	O
imprinting	O
phenotype	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
is	O
caused	O
by	O
the	O
loss	O
of	O
expression	O
of	O
imprinted	O
genes	O
in	O
chromosome	O
15q11	O
-	O
q13	O
.	O

Affected	O
individuals	O
exhibit	O
neonatal	B-Disease
hypotonia	I-Disease
,	O
developmental	B-Disease
delay	I-Disease
and	O
childhood	B-Disease
-	I-Disease
onset	I-Disease
obesity	I-Disease
.	O

Necdin	O
,	O
a	O
protein	O
implicated	O
in	O
the	O
terminal	O
differentiation	O
of	O
neurons	O
,	O
is	O
the	O
only	O
PWS	B-Disease
candidate	O
gene	O
to	O
reduce	O
viability	O
when	O
disrupted	O
in	O
a	O
mouse	O
model	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
MAGEL2	O
(	O
also	O
known	O
as	O
NDNL1	O
)	O
,	O
a	O
gene	O
with	O
51	O
%	O
amino	O
acid	O
sequence	O
similarity	O
to	O
necdin	O
and	O
located	O
41	O
kb	O
distal	O
to	O
NDN	O
in	O
the	O
PWS	B-Disease
deletion	O
region	O
.	O

MAGEL2	O
is	O
expressed	O
predominantly	O
in	O
brain	O
,	O
the	O
primary	O
tissue	O
affected	O
in	O
PWS	B-Disease
and	O
in	O
several	O
fetal	O
tissues	O
as	O
shown	O
by	O
northern	O
blot	O
analysis	O
.	O

MAGEL2	O
is	O
imprinted	O
with	O
monoallelic	O
expression	O
in	O
control	O
brain	O
,	O
and	O
paternal	O
-	O
only	O
expression	O
in	O
the	O
central	O
nervous	O
system	O
as	O
demonstrated	O
by	O
its	O
lack	O
of	O
expression	O
in	O
brain	O
from	O
a	O
PWS	B-Disease
-	O
affected	O
individual	O
.	O

The	O
orthologous	O
mouse	O
gene	O
(	O
Magel2	O
)	O
is	O
located	O
within	O
150	O
kb	O
of	O
NDN	O
,	O
is	O
imprinted	O
with	O
paternal	O
-	O
only	O
expression	O
and	O
is	O
expressed	O
predominantly	O
in	O
late	O
developmental	O
stages	O
and	O
adult	O
brain	O
as	O
shown	O
by	O
northern	O
blotting	O
,	O
RT	O
-	O
PCR	O
and	O
whole	O
-	O
mount	O
RNA	O
in	O
situ	O
hybridization	O
.	O

Magel2	O
distribution	O
partially	O
overlaps	O
that	O
of	O
NDN	O
,	O
with	O
strong	O
expression	O
being	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
in	O
mid	O
-	O
gestation	O
mouse	O
embryos	O
by	O
in	O
situ	O
hybridization	O
.	O

We	O
hypothesize	O
that	O
,	O
although	O
loss	O
of	O
necdin	O
expression	O
may	O
be	O
important	O
in	O
the	O
neonatal	O
presentation	O
of	O
PWS	B-Disease
,	O
loss	O
of	O
MAGEL2	O
may	O
be	O
critical	O
to	O
abnormalities	B-Disease
in	I-Disease
brain	I-Disease
development	I-Disease
and	O
dysmorphic	B-Disease
features	I-Disease
in	O
individuals	O
with	O
PWS	B-Disease
.	O
.	O

Retinoschisin	O
,	O
the	O
X	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
protein	O
,	O
is	O
a	O
secreted	O
photoreceptor	O
protein	O
,	O
and	O
is	O
expressed	O
and	O
released	O
by	O
Weri	O
-	O
Rb1	O
cells	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
is	O
characterized	O
by	O
microcystic	O
-	O
like	O
changes	O
of	O
the	O
macular	O
region	O
and	O
schisis	O
within	O
the	O
inner	O
retinal	O
layers	O
,	O
leading	O
to	O
visual	B-Disease
deterioration	I-Disease
in	O
males	O
.	O

Many	O
missense	O
and	O
protein	O
-	O
truncating	O
mutations	O
of	O
the	O
causative	O
gene	O
RS1	O
have	O
now	O
been	O
identified	O
and	O
are	O
thought	O
to	O
be	O
inactivating	O
.	O

RS1	O
encodes	O
a	O
224	O
amino	O
acid	O
protein	O
,	O
retinoschisin	O
,	O
which	O
contains	O
a	O
discoidin	O
domain	O
but	O
is	O
of	O
unknown	O
function	O
.	O

We	O
have	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
a	O
peptide	O
from	O
a	O
unique	O
region	O
within	O
retinoschisin	O
,	O
which	O
detects	O
a	O
protein	O
of	O
approximately	O
28	O
kDa	O
in	O
retinal	O
samples	O
reduced	O
with	O
dithiothreitol	O
,	O
but	O
multimers	O
sized	O
>	O
40	O
kDa	O
under	O
non	O
-	O
reducing	O
conditions	O
.	O

A	O
screen	O
of	O
human	O
tissues	O
with	O
this	O
antibody	O
reveals	O
retinoschisin	O
to	O
be	O
retina	O
specific	O
and	O
the	O
antibody	O
detects	O
a	O
protein	O
of	O
similar	O
size	O
in	O
bovine	O
and	O
murine	O
retinae	O
.	O

We	O
investigated	O
the	O
expression	O
pattern	O
in	O
the	O
retina	O
of	O
both	O
RS1	O
mRNA	O
(	O
using	O
in	O
situ	O
hybridization	O
with	O
riboprobes	O
)	O
and	O
retinoschisin	O
(	O
using	O
immunohistochemistry	O
)	O
.	O

The	O
antisense	O
riboprobe	O
detected	O
RS1	O
mRNA	O
only	O
in	O
the	O
photoreceptor	O
layer	O
but	O
the	O
protein	O
product	O
of	O
the	O
gene	O
was	O
present	O
both	O
in	O
the	O
photoreceptors	O
and	O
within	O
the	O
inner	O
portions	O
of	O
the	O
retina	O
.	O

Furthermore	O
,	O
differentiated	O
retinoblastoma	B-Disease
cells	O
(	O
Weri	O
-	O
Rb1	O
cells	O
)	O
were	O
found	O
to	O
express	O
RS1	O
mRNA	O
and	O
to	O
release	O
retinoschisin	O
.	O

These	O
results	O
suggest	O
that	O
retinoschisin	O
is	O
released	O
by	O
photo	O
-	O
receptors	O
and	O
has	O
functions	O
within	O
the	O
inner	O
retinal	O
layers	O
.	O

Thus	O
,	O
X	B-Disease
-	I-Disease
linked	I-Disease
retinoschisis	I-Disease
is	O
caused	O
by	O
abnormalities	O
in	O
a	O
putative	O
secreted	O
photoreceptor	O
protein	O
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo	O
-	O
receptor	O
protein	O
associated	O
with	O
a	O
retinal	B-Disease
dystrophy	I-Disease
.	O
.	O

Study	O
of	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
beta	O
1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
in	O
the	O
benign	B-Disease
familial	I-Disease
infantile	I-Disease
convulsions	I-Disease
syndrome	I-Disease
(	O
BFIC	B-Disease
)	O
.	O

Benign	B-Disease
familial	I-Disease
infantile	I-Disease
convulsions	I-Disease
(	O
BFIC	B-Disease
)	O
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
epilepsy	I-Disease
syndrome	I-Disease
.	O

This	O
syndrome	O
has	O
been	O
recently	O
described	O
in	O
Italian	O
and	O
French	O
pedigrees	O
.	O

Patients	O
present	O
with	O
partial	O
,	O
then	O
generalized	O
seizures	O
,	O
with	O
onset	O
at	O
age	O
three	O
months	O
.	O

The	O
seizures	O
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment	O
,	O
leaving	O
no	O
neurological	B-Disease
abnormalities	I-Disease
.	O

We	O
have	O
mapped	O
BFIC	B-Disease
to	O
chromosome	O
19q	O
in	O
five	O
Italian	O
pedigrees	O
.	O

The	O
sodium	O
channel	O
beta1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
maps	O
to	O
this	O
candidate	O
region	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
one	O
Australian	O
pedigree	O
with	O
generalized	B-Disease
epilepsy	I-Disease
and	I-Disease
febrile	I-Disease
seizures	I-Disease
"	I-Disease
plus	I-Disease
"	I-Disease
(	O
GEFS	O
+	O
)	O
.	O

In	O
this	O
family	O
,	O
a	O
missense	O
mutation	O
in	O
SCN1B	O
cosegregates	O
with	O
the	O
GEFS	O
+	O
phenotype	O
.	O

BFIC	B-Disease
and	O
GEFS	O
+	O
have	O
clinical	O
features	O
in	O
common	O
,	O
therefore	O
SCN1B	O
is	O
a	O
candidate	O
gene	O
for	O
BFIC	B-Disease
.	O

We	O
studied	O
SCN1B	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
using	O
four	O
SSCP	O
methods	O
in	O
10	O
Caucasian	O
BFIC	B-Disease
probands	O
of	O
Western	O
Europe	O
.	O

We	O
found	O
no	O
exon	O
variants	O
.	O

One	O
variant	O
was	O
identified	O
in	O
intron	O
5	O
(	O
IVS5	O
-	O
10C	O
>	O
G	O
)	O
,	O
which	O
did	O
not	O
segregate	O
with	O
BFIC	B-Disease
and	O
was	O
observed	O
in	O
9	O
.	O

2	O
%	O
controls	O
.	O

A	O
second	O
variant	O
in	O
intron	O
5	O
was	O
identified	O
(	O
IVS5	O
+	O
30G	O
>	O
A	O
)	O
.	O

It	O
was	O
rare	O
,	O
as	O
not	O
observed	O
in	O
controls	O
,	O
but	O
not	O
segregating	O
with	O
the	O
BFIC	B-Disease
phenotype	O
.	O

Inactivation	O
of	O
germline	O
mutant	O
APC	B-Disease
alleles	O
by	O
attenuated	O
somatic	O
mutations	O
:	O
a	O
molecular	O
genetic	O
mechanism	O
for	O
attenuated	B-Disease
familial	I-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O

Germline	O
mutations	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
APC	I-Disease
)	I-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
result	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
.	O

Patients	O
with	O
FAP	B-Disease
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	B-Disease
colorectal	I-Disease
tumors	I-Disease
and	O
early	O
-	O
onset	O
colorectal	B-Disease
cancer	I-Disease
.	O

A	O
subset	O
of	O
germline	O
APC	B-Disease
mutations	O
results	O
in	O
an	O
attenuated	B-Disease
FAP	I-Disease
(	O
AFAP	B-Disease
)	O
phenotype	O
,	O
in	O
which	O
patients	O
develop	O
fewer	O
tumors	B-Disease
and	O
develop	O
them	O
at	O
an	O
older	O
age	O
.	O

Although	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
locations	O
of	O
APC	B-Disease
germline	O
mutations	O
and	O
the	O
development	O
of	O
AFAP	B-Disease
has	O
been	O
well	O
documented	O
,	O
the	O
mechanism	O
for	O
AFAP	B-Disease
has	O
not	O
been	O
well	O
defined	O
.	O

We	O
investigated	O
the	O
mechanism	O
for	O
AFAP	B-Disease
in	O
patients	O
carrying	O
a	O
mutant	O
APC	B-Disease
allele	O
(	O
APC	O
(	O
AS9	O
)	O
)	O
that	O
has	O
a	O
mutation	O
in	O
the	O
alternatively	O
spliced	O
region	O
of	O
exon	O
9	O
.	O

APC	O
(	O
AS9	O
)	O
was	O
found	O
to	O
down	O
-	O
regulate	O
beta	O
-	O
catenin	O
-	O
regulated	O
transcription	O
,	O
the	O
major	O
tumor	B-Disease
-	O
suppressor	O
function	O
of	O
APC	O
,	O
as	O
did	O
the	O
wild	O
-	O
type	O
APC	O
.	O

Mutation	O
analysis	O
showed	O
that	O
both	O
APC	O
(	O
AS9	O
)	O
and	O
the	O
wild	O
-	O
type	O
APC	B-Disease
alleles	O
were	O
somatically	O
mutated	O
in	O
most	O
colorectal	B-Disease
tumors	I-Disease
from	O
these	O
patients	O
.	O

Functional	O
analysis	O
showed	O
that	O
4666insA	O
,	O
a	O
common	O
somatic	O
mutation	O
in	O
APC	O
(	O
AS9	O
)	O
in	O
these	O
tumors	B-Disease
,	O
did	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
APC	O
.	O

Our	O
results	O
indicate	O
that	O
carriers	O
of	O
APC	O
(	O
AS9	O
)	O
develop	O
fewer	O
colorectal	B-Disease
tumors	I-Disease
than	O
do	O
typical	O
patients	O
with	O
FAP	B-Disease
because	O
somatic	O
inactivation	O
of	O
both	O
APC	B-Disease
alleles	O
is	O
necessary	O
for	O
colorectal	O
tumorigenesis	O
.	O

However	O
,	O
these	O
patients	O
develop	O
colorectal	B-Disease
tumors	I-Disease
more	O
frequently	O
than	O
does	O
the	O
general	O
population	O
because	O
APC	O
(	O
AS9	O
)	O
is	O
inactivated	O
by	O
mutations	O
that	O
do	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
APC	O
.	O
.	O

Iron	O
-	O
dependent	O
self	O
-	O
assembly	O
of	O
recombinant	O
yeast	O
frataxin	O
:	O
implications	O
for	O
Friedreich	B-Disease
ataxia	I-Disease
.	O

Frataxin	B-Disease
deficiency	I-Disease
is	O
the	O
primary	O
cause	O
of	O
Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
an	O
autosomal	B-Disease
recessive	I-Disease
cardiodegenerative	I-Disease
and	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
.	O

Frataxin	O
is	O
a	O
nuclear	O
-	O
encoded	O
mitochondrial	O
protein	O
that	O
is	O
widely	O
conserved	O
among	O
eukaryotes	O
.	O

Genetic	O
inactivation	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
(	O
Yfh1p	O
)	O
results	O
in	O
mitochondrial	B-Disease
iron	I-Disease
accumulation	I-Disease
and	O
hypersensitivity	B-Disease
to	I-Disease
oxidative	I-Disease
stress	I-Disease
.	O

Increased	O
iron	O
deposition	O
and	O
evidence	O
of	O
oxidative	O
damage	O
have	O
also	O
been	O
observed	O
in	O
cardiac	O
tissue	O
and	O
cultured	O
fibroblasts	O
from	O
patients	O
with	O
FRDA	B-Disease
.	O

These	O
findings	O
indicate	O
that	O
frataxin	O
is	O
essential	O
for	O
mitochondrial	O
iron	O
homeostasis	O
and	O
protection	O
from	O
iron	O
-	O
induced	O
formation	O
of	O
free	O
radicals	O
.	O

The	O
functional	O
mechanism	O
of	O
frataxin	O
,	O
however	O
,	O
is	O
still	O
unknown	O
.	O

We	O
have	O
expressed	O
the	O
mature	O
form	O
of	O
Yfh1p	O
(	O
mYfh1p	O
)	O
in	O
Escherichia	O
coli	O
and	O
have	O
analyzed	O
its	O
function	O
in	O
vitro	O
.	O

Isolated	O
mYfh1p	O
is	O
a	O
soluble	O
monomer	O
(	O
13	O
,	O
783	O
Da	O
)	O
that	O
contains	O
no	O
iron	O
and	O
shows	O
no	O
significant	O
tendency	O
to	O
self	O
-	O
associate	O
.	O

Aerobic	O
addition	O
of	O
ferrous	O
iron	O
to	O
mYfh1p	O
results	O
in	O
assembly	O
of	O
regular	O
spherical	O
multimers	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
1	O
.	O

1	O
MDa	O
(	O
megadaltons	O
)	O
and	O
a	O
diameter	O
of	O
13	O
+	O
/	O
-	O
2	O
nm	O
.	O

Each	O
multimer	O
consists	O
of	O
approximately	O
60	O
subunits	O
and	O
can	O
sequester	O
>	O
3	O
,	O
000	O
atoms	O
of	O
iron	O
.	O

Titration	O
of	O
mYfh1p	O
with	O
increasing	O
iron	O
concentrations	O
supports	O
a	O
stepwise	O
mechanism	O
of	O
multimer	O
assembly	O
.	O

Sequential	O
addition	O
of	O
an	O
iron	O
chelator	O
and	O
a	O
reducing	O
agent	O
results	O
in	O
quantitative	O
iron	O
release	O
with	O
concomitant	O
disassembly	O
of	O
the	O
multimer	O
,	O
indicating	O
that	O
mYfh1p	O
sequesters	O
iron	O
in	O
an	O
available	O
form	O
.	O

In	O
yeast	O
mitochondria	O
,	O
native	O
mYfh1p	O
exists	O
as	O
monomer	O
and	O
a	O
higher	O
-	O
order	O
species	O
with	O
a	O
molecular	O
weight	O
>	O
600	O
,	O
000	O
.	O

After	O
addition	O
of	O
(	O
55	O
)	O
Fe	O
to	O
the	O
medium	O
,	O
immunoprecipitates	O
of	O
this	O
species	O
contain	O
>	O
16	O
atoms	O
of	O
(	O
55	O
)	O
Fe	O
per	O
molecule	O
of	O
mYfh1p	O
.	O

We	O
propose	O
that	O
iron	O
-	O
dependent	O
self	O
-	O
assembly	O
of	O
recombinant	O
mYfh1p	O
reflects	O
a	O
physiological	O
role	O
for	O
frataxin	O
in	O
mitochondrial	O
iron	O
sequestration	O
and	O
bioavailability	O
.	O
.	O

A	O
mutation	O
in	O
the	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domain	O
of	O
the	O
FGD1	O
gene	O
in	O
an	O
Italian	O
family	O
with	O
faciogenital	B-Disease
dysplasia	I-Disease
(	O
Aarskog	B-Disease
-	I-Disease
Scott	I-Disease
syndrome	I-Disease
)	O
.	O

Aarskog	B-Disease
-	I-Disease
Scott	I-Disease
Syndrome	I-Disease
(	O
AAS	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
characterised	O
by	O
short	B-Disease
stature	I-Disease
and	O
multiple	O
facial	B-Disease
,	I-Disease
limb	I-Disease
and	I-Disease
genital	I-Disease
abnormalities	I-Disease
.	O

A	O
gene	O
,	O
FGD1	O
,	O
altered	O
in	O
a	O
patient	O
with	O
AAS	B-Disease
phenotype	O
,	O
has	O
been	O
identified	O
and	O
found	O
to	O
encode	O
a	O
protein	O
with	O
homology	O
to	O
Rho	O
/	O
Rac	O
guanine	O
nucleotide	O
exchange	O
factors	O
(	O
Rho	O
/	O
Rac	O
GEF	O
)	O
.	O

However	O
,	O
since	O
this	O
original	O
report	O
on	O
identification	O
of	O
a	O
mutated	O
FGD1	O
gene	O
in	O
an	O
AAS	B-Disease
patient	O
,	O
no	O
additional	O
mutations	O
in	O
the	O
FGD1	O
gene	O
have	O
been	O
described	O
.	O

We	O
analysed	O
13	O
independent	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
AAS	B-Disease
.	O

One	O
patient	O
presented	O
a	O
mutation	O
that	O
results	O
in	O
a	O
nucleotide	O
change	O
in	O
exon	O
10	O
of	O
the	O
FGD1	O
gene	O
(	O
G2559	O
>	O
A	O
)	O
substituting	O
a	O
Gln	O
for	O
Arg	O
in	O
position	O
610	O
.	O

The	O
mutation	O
was	O
found	O
to	O
segregate	O
with	O
the	O
AAS	B-Disease
phenotype	O
in	O
affected	O
males	O
and	O
carrier	O
females	O
in	O
the	O
family	O
of	O
this	O
patient	O
.	O

Interestingly	O
,	O
Arg	O
-	O
610	O
is	O
located	O
within	O
one	O
of	O
the	O
two	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domains	O
of	O
the	O
FGD1	O
gene	O
and	O
it	O
corresponds	O
to	O
a	O
highly	O
conserved	O
residue	O
which	O
has	O
been	O
involved	O
in	O
InsP	O
binding	O
in	O
PH	O
domains	O
of	O
other	O
proteins	O
.	O

The	O
same	O
residue	O
is	O
often	O
mutated	O
in	O
the	O
Brutons	O
tyrosine	O
kinase	O
(	O
Btk	O
)	O
gene	O
in	O
patients	O
with	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
agammaglobulinemia	I-Disease
.	O

The	O
Arg610Gln	O
mutation	O
represents	O
the	O
first	O
case	O
of	O
a	O
mutation	O
in	O
the	O
PH	O
domain	O
of	O
the	O
FGD1	O
gene	O
and	O
additional	O
evidence	O
that	O
mutations	O
in	O
PH	O
domains	O
can	O
be	O
associated	O
to	O
human	O
diseases	O
.	O
.	O

Amino	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
show	O
selective	O
accumulation	O
in	O
striatal	O
neurons	O
and	O
synaptic	O
toxicity	O
.	O

Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
caused	O
by	O
expansion	O
of	O
a	O
glutamine	O
repeat	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
huntingtin	O
.	O

Despite	O
its	O
widespread	O
expression	O
,	O
mutant	O
huntingtin	O
induces	O
selective	O
neuronal	O
loss	O
in	O
striatal	O
neurons	O
.	O

Here	O
we	O
report	O
that	O
,	O
in	O
mutant	O
mice	O
expressing	O
HD	B-Disease
repeats	O
,	O
the	O
production	O
and	O
aggregation	O
of	O
N	O
-	O
terminal	O
huntingtin	O
fragments	O
preferentially	O
occur	O
in	O
HD	B-Disease
-	O
affected	O
neurons	O
and	O
their	O
processes	O
and	O
axonal	O
terminals	O
.	O

N	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
form	O
aggregates	O
and	O
induce	O
neuritic	B-Disease
degeneration	I-Disease
in	O
cultured	O
striatal	O
neurons	O
.	O

N	O
-	O
terminal	O
mutant	O
huntingtin	O
also	O
binds	O
to	O
synaptic	O
vesicles	O
and	O
inhibits	O
their	O
glutamate	O
uptake	O
in	O
vitro	O
.	O

The	O
specific	O
processing	O
and	O
accumulation	O
of	O
toxic	O
fragments	O
of	O
N	O
-	O
terminal	O
huntingtin	O
in	O
HD	B-Disease
-	O
affected	O
striatal	O
neurons	O
,	O
especially	O
in	O
their	O
neuronal	O
processes	O
and	O
axonal	O
terminals	O
,	O
may	O
contribute	O
to	O
the	O
selective	O
neuropathology	O
of	O
HD	B-Disease
.	O
.	O

BRCA1	O
is	O
associated	O
with	O
a	O
human	O
SWI	O
/	O
SNF	O
-	O
related	O
complex	O
:	O
linking	O
chromatin	O
remodeling	O
to	O
breast	B-Disease
cancer	I-Disease
.	O

Germline	O
mutations	O
in	O
the	O
tumor	B-Disease
suppressor	O
gene	O
,	O
BRCA1	O
,	O
predispose	O
individuals	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

Using	O
a	O
combination	O
of	O
affinity	O
-	O
and	O
conventional	O
chromatographic	O
techniques	O
,	O
we	O
have	O
isolated	O
a	O
predominant	O
form	O
of	O
a	O
multiprotein	O
BRCA1	O
-	O
containing	O
complex	O
from	O
human	O
cells	O
displaying	O
chromatin	O
-	O
remodeling	O
activity	O
.	O

Mass	O
spectrometric	O
sequencing	O
of	O
components	O
of	O
this	O
complex	O
indicated	O
that	O
BRCA1	O
is	O
associated	O
with	O
a	O
SWI	O
/	O
SNF	O
-	O
related	O
complex	O
.	O

We	O
show	O
that	O
BRCA1	O
can	O
directly	O
interact	O
with	O
the	O
BRG1	O
subunit	O
of	O
the	O
SWI	O
/	O
SNF	O
complex	O
.	O

Moreover	O
,	O
p53	O
-	O
mediated	O
stimulation	O
of	O
transcription	O
by	O
BRCA1	O
was	O
completely	O
abrogated	O
by	O
either	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
BRG1	O
or	O
the	O
cancer	B-Disease
-	O
causing	O
deletion	O
in	O
exon	O
11	O
of	O
BRCA1	O
.	O

These	O
findings	O
reveal	O
a	O
direct	O
function	O
for	O
BRCA1	O
in	O
transcriptional	O
control	O
through	O
modulation	O
of	O
chromatin	O
structure	O
.	O
.	O

Asef	O
,	O
a	O
link	O
between	O
the	O
tumor	B-Disease
suppressor	O
APC	O
and	O
G	O
-	O
protein	O
signaling	O
.	O

The	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
gene	O
(	O
APC	O
)	O
is	O
mutated	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
and	O
in	O
sporadic	O
colorectal	B-Disease
tumors	I-Disease
.	O

Here	O
the	O
APC	B-Disease
gene	O
product	O
is	O
shown	O
to	O
bind	O
through	O
its	O
armadillo	O
repeat	O
domain	O
to	O
a	O
Rac	O
-	O
specific	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	O
GEF	O
)	O
,	O
termed	O
Asef	O
.	O

Endogenous	O
APC	O
colocalized	O
with	O
Asef	O
in	O
mouse	O
colon	O
epithelial	O
cells	O
and	O
neuronal	O
cells	O
.	O

Furthermore	O
,	O
APC	O
enhanced	O
the	O
GEF	O
activity	O
of	O
Asef	O
and	O
stimulated	O
Asef	O
-	O
mediated	O
cell	O
flattening	O
,	O
membrane	O
ruffling	O
,	O
and	O
lamellipodia	O
formation	O
in	O
MDCK	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
APC	O
-	O
Asef	O
complex	O
may	O
regulate	O
the	O
actin	O
cytoskeletal	O
network	O
,	O
cell	O
morphology	O
and	O
migration	O
,	O
and	O
neuronal	O
function	O
.	O
.	O

Function	O
of	O
an	O
axonal	O
chemoattractant	O
modulated	O
by	O
metalloprotease	O
activity	O
.	O

The	O
axonal	O
chemoattractant	O
netrin	O
-	O
1	O
guides	O
spinal	O
commissural	O
axons	O
by	O
activating	O
its	O
receptor	O
DCC	O
(	O
Deleted	O
in	O
Colorectal	B-Disease
Cancer	I-Disease
)	O
.	O

We	O
have	O
found	O
that	O
chemical	O
inhibitors	O
of	O
metalloproteases	O
potentiate	O
netrin	O
-	O
mediated	O
axon	O
outgrowth	O
in	O
vitro	O
.	O

We	O
have	O
also	O
found	O
that	O
DCC	O
is	O
a	O
substrate	O
for	O
metalloprotease	O
-	O
dependent	O
ectodomain	O
shedding	O
,	O
and	O
that	O
the	O
inhibitors	O
block	O
proteolytic	O
processing	O
of	O
DCC	O
and	O
cause	O
an	O
increase	O
in	O
DCC	O
protein	O
levels	O
on	O
axons	O
within	O
spinal	O
cord	O
explants	O
.	O

Thus	O
,	O
potentiation	O
of	O
netrin	O
activity	O
by	O
inhibitors	O
may	O
result	O
from	O
stabilization	O
of	O
DCC	O
on	O
the	O
axons	O
,	O
and	O
proteolytic	O
activity	O
may	O
regulate	O
axon	O
migration	O
by	O
controlling	O
the	O
number	O
of	O
functional	O
extracellular	O
axon	O
guidance	O
receptors	O
.	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
CUG	O
repeat	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
,	O
the	O
most	O
common	O
form	O
of	O
muscular	B-Disease
dystrophy	I-Disease
in	O
adult	O
humans	O
,	O
results	O
from	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
gene	O
.	O

The	O
mutant	O
DMPK	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
contains	O
an	O
expanded	O
CUG	O
repeat	O
and	O
is	O
retained	O
in	O
the	O
nucleus	O
.	O

We	O
have	O
expressed	O
an	O
untranslated	O
CUG	O
repeat	O
in	O
an	O
unrelated	O
mRNA	O
in	O
transgenic	O
mice	O
.	O

Mice	O
that	O
expressed	O
expanded	O
CUG	O
repeats	O
developed	O
myotonia	B-Disease
and	O
myopathy	B-Disease
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not	O
.	O

Thus	O
,	O
transcripts	O
with	O
expanded	O
CUG	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
DM	B-Disease
phenotype	O
.	O

This	O
result	O
supports	O
a	O
role	O
for	O
RNA	O
gain	O
of	O
function	O
in	O
disease	O
pathogenesis	O
.	O
.	O

Genomic	O
rearrangements	O
of	O
the	O
APC	B-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O

Germline	O
mutations	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
APC	I-Disease
)	I-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
result	O
in	O
the	O
hereditary	B-Disease
colorectal	I-Disease
cancer	I-Disease
syndrome	I-Disease
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
.	O

Almost	O
all	O
APC	B-Disease
mutations	O
that	O
have	O
been	O
identified	O
are	O
single	O
-	O
nucleotide	O
alterations	O
,	O
small	O
insertions	O
,	O
or	O
small	O
deletions	O
that	O
would	O
truncate	O
the	O
protein	O
product	O
of	O
the	O
gene	O
.	O

No	O
well	O
-	O
characterized	O
intragenic	O
rearrangement	O
of	O
APC	O
has	O
been	O
described	O
,	O
and	O
the	O
prevalence	O
of	O
this	O
type	O
of	O
mutation	O
in	O
FAP	B-Disease
patients	O
is	O
not	O
clear	O
.	O

We	O
screened	O
49	O
potential	O
FAP	B-Disease
families	O
and	O
identified	O
26	O
different	O
germline	O
APC	B-Disease
mutations	O
in	O
30	O
families	O
.	O

Four	O
of	O
these	O
mutations	O
were	O
genomic	O
rearrangements	O
resulting	O
from	O
homologous	O
and	O
nonhomologous	O
recombinations	O
mediated	O
by	O
Alu	O
elements	O
.	O

Two	O
of	O
these	O
four	O
rearrangements	O
were	O
complex	O
,	O
involving	O
deletion	O
and	O
insertion	O
of	O
nucleotides	O
.	O

Of	O
these	O
four	O
rearrangements	O
,	O
one	O
resulted	O
in	O
the	O
deletion	O
of	O
exons	O
11	O
and	O
12	O
and	O
two	O
others	O
resulted	O
in	O
either	O
complete	O
or	O
partial	O
deletion	O
of	O
exon	O
14	O
.	O

The	O
fourth	O
rearrangement	O
grossly	O
altered	O
the	O
sequence	O
within	O
intron	O
14	O
.	O

Although	O
this	O
rearrangement	O
did	O
not	O
affect	O
any	O
coding	O
sequence	O
of	O
APC	O
at	O
the	O
genomic	O
DNA	O
level	O
,	O
it	O
caused	O
inappropriate	O
splicing	O
of	O
exon	O
14	O
.	O

These	O
rearrangements	O
were	O
initially	O
revealed	O
by	O
analyzing	O
cDNAs	O
and	O
could	O
not	O
have	O
been	O
identified	O
by	O
using	O
mutation	O
detection	O
methods	O
that	O
screened	O
each	O
exon	O
individually	O
.	O

The	O
identification	O
of	O
a	O
rearrangement	O
that	O
did	O
not	O
alter	O
any	O
coding	O
exons	O
yet	O
affected	O
the	O
splicing	O
further	O
underscores	O
the	O
importance	O
of	O
using	O
cDNA	O
for	O
mutation	O
analysis	O
.	O

The	O
identification	O
of	O
four	O
genomic	O
rearrangements	O
among	O
30	O
mutations	O
suggests	O
that	O
genomic	O
rearrangements	O
are	O
frequent	O
germline	O
APC	B-Disease
mutations	O
.	O
.	O

Detection	O
of	O
a	O
novel	O
missense	O
mutation	O
and	O
second	O
recurrent	O
mutation	O
in	O
the	O
CACNA1A	O
gene	O
in	O
individuals	O
with	O
EA	B-Disease
-	I-Disease
2	I-Disease
and	O
FHM	B-Disease
.	O

Mutations	O
in	O
the	O
brain	O
specific	O
P	O
/	O
Q	O
type	O
Ca2	O
+	O
channel	O
alpha1	O
subunit	O
gene	O
,	O
CACNA1A	O
,	O
have	O
been	O
identified	O
in	O
three	O
clinically	O
distinct	O
disorders	O
,	O
viz	O
.	O
episodic	B-Disease
ataxia	I-Disease
type	I-Disease
2	I-Disease
(	O
EA	B-Disease
-	I-Disease
2	I-Disease
)	O
,	O
familial	B-Disease
hemiplegic	I-Disease
migraine	I-Disease
(	O
FHM	B-Disease
)	O
and	O
spinocerebellar	B-Disease
ataxia	I-Disease
6	I-Disease
(	O
SCA6	B-Disease
)	O
.	O

For	O
individuals	O
with	O
EA	B-Disease
-	I-Disease
2	I-Disease
,	O
the	O
mutations	O
described	O
thus	O
far	O
are	O
presumed	O
to	O
result	O
in	O
a	O
truncated	O
protein	O
product	O
.	O

Several	O
different	O
missense	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
FHM	B-Disease
.	O

At	O
least	O
two	O
of	O
these	O
mutations	O
have	O
been	O
identified	O
on	O
two	O
different	O
chromosome	O
19p13	O
haplotypes	O
and	O
thus	O
represent	O
recurrent	O
mutations	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
screened	O
several	O
individuals	O
for	O
mutations	O
in	O
all	O
47	O
exons	O
in	O
the	O
CACNA1A	O
gene	O
by	O
single	O
-	O
strand	O
conformation	O
analysis	O
.	O

We	O
have	O
characterised	O
a	O
novel	O
missense	O
mutation	O
,	O
G5260A	O
,	O
in	O
exon	O
32	O
in	O
a	O
family	O
segregating	O
for	O
EA	B-Disease
-	I-Disease
2	I-Disease
.	O

The	O
consequence	O
of	O
this	O
mutation	O
is	O
an	O
amino	O
acid	O
substitution	O
at	O
a	O
highly	O
conserved	O
position	O
within	O
the	O
CACNA1A	O
gene	O
.	O

This	O
represents	O
the	O
first	O
point	O
mutation	O
not	O
resulting	O
in	O
a	O
proposed	O
truncated	O
protein	O
.	O

Furthermore	O
,	O
this	O
mutation	O
has	O
been	O
detected	O
in	O
a	O
family	O
member	O
with	O
mild	O
clinical	O
signs	O
including	O
only	O
migraine	B-Disease
.	O

Additionally	O
,	O
a	O
second	O
previously	O
identified	O
recurrent	O
muta	O
tion	O
,	O
C2272T	O
,	O
in	O
exon	O
16	O
has	O
been	O
discovered	O
in	O
a	O
patient	O
with	O
FHM	B-Disease
.	O
.	O

Analbuminemia	B-Disease
in	O
a	O
neonate	O
.	O

A	O
small	O
-	O
for	O
-	O
gestational	O
-	O
age	O
infant	O
,	O
found	O
to	O
have	O
analbuminemia	B-Disease
in	O
the	O
neonatal	O
period	O
,	O
is	O
reported	O
and	O
the	O
twelve	O
cases	O
recorded	O
in	O
the	O
world	O
literature	O
are	O
reviewed	O
.	O

Patients	O
lacking	O
this	O
serum	O
protein	O
are	O
essentially	O
asymptomatic	O
,	O
apart	O
from	O
minimal	O
ankle	B-Disease
edema	I-Disease
and	O
ease	B-Disease
of	I-Disease
fatigue	I-Disease
.	O

Apparent	O
compensatory	O
mechanisms	O
which	O
come	O
into	O
play	O
when	O
serum	O
albumin	O
is	O
low	O
include	O
prolonged	O
half	O
-	O
life	O
of	O
albumin	O
and	O
transferrin	O
,	O
an	O
increase	O
in	O
serum	O
globulins	O
,	O
beta	O
lipoprotein	O
,	O
and	O
glycoproteins	O
,	O
arterial	B-Disease
hypotension	I-Disease
with	O
reduced	O
capillary	O
hydrostatic	O
pressure	O
,	O
and	O
the	O
ability	O
to	O
respond	O
with	O
rapid	O
sodium	O
and	O
chloride	O
diuresis	O
in	O
response	O
to	O
small	O
volume	O
changes	O
.	O

Examination	O
of	O
plasma	O
amino	O
acids	O
,	O
an	O
investigation	O
not	O
previously	O
reported	O
,	O
revealed	O
an	O
extremely	O
low	O
plasma	O
tryptophan	O
level	O
,	O
a	O
finding	O
which	O
may	O
be	O
important	O
in	O
view	O
of	O
the	O
role	O
of	O
tryptophan	O
in	O
albumin	O
synthesis	O
.	O
.	O

Histidinemia	B-Disease
.	O

Classical	O
and	O
atypical	O
form	O
in	O
siblings	O
.	O

Two	O
brothers	O
,	O
6	O
and	O
13	O
years	O
old	O
,	O
had	O
histidinemia	B-Disease
.	O

On	O
the	O
basis	O
of	O
clinical	O
and	O
biochemical	O
observations	O
,	O
the	O
younger	O
boy	O
was	O
considered	O
to	O
have	O
a	O
classical	O
type	O
of	O
the	O
disease	O
,	O
while	O
the	O
older	O
boy	O
had	O
an	O
atypical	O
form	O
characterized	O
by	O
partial	O
impairment	O
of	O
the	O
skin	O
histidase	O
activity	O
and	O
a	O
moderately	O
prolonged	O
half	O
-	O
life	O
of	O
blood	O
histidine	O
.	O

The	O
mother	O
is	O
a	O
heterozygous	O
carrier	O
,	O
while	O
the	O
father	O
and	O
sister	O
seem	O
to	O
be	O
normal	O
.	O
.	O

Carrier	O
detection	O
of	O
pyruvate	B-Disease
carboxylase	I-Disease
deficiency	I-Disease
in	O
fibroblasts	O
and	O
lymphocytes	O
.	O

Pyruvate	O
carboxylase	O
(	O
E	O
.	O
C	O
.	O
6	O
.	O
4	O
.	O
1	O
.	O
1	O
)	O
activity	O
was	O
determined	O
in	O
the	O
circulating	O
peripheral	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
family	O
of	O
a	O
patient	O
with	O
hepatic	O
,	O
cerebral	O
,	O
renal	O
cortical	O
,	O
leukocyte	O
,	O
and	O
fibroblast	O
pyruvate	B-Disease
carboxylase	I-Disease
deficiency	I-Disease
(	O
PC	B-Disease
Portland	I-Disease
deficiency	I-Disease
)	O
.	O

Lymphocyte	O
activities	O
were	O
mother	O
,	O
33	O
-	O
-	O
39	O
%	O
;	O
father	O
,	O
11	O
-	O
-	O
29	O
%	O
;	O
brother	O
,	O
82	O
-	O
-	O
103	O
%	O
;	O
and	O
sister	O
,	O
38	O
-	O
-	O
48	O
%	O
of	O
the	O
lowest	O
normal	O
.	O

Fibroblasts	O
from	O
the	O
patients	O
mother	O
and	O
father	O
had	O
42	O
and	O
34	O
%	O
,	O
respectively	O
,	O
of	O
the	O
activity	O
of	O
the	O
lowest	O
normal	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
disease	O
is	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
and	O
that	O
lymphocytes	O
and	O
fibroblasts	O
can	O
be	O
used	O
to	O
detect	O
carriers	O
.	O

Neither	O
pyruvate	O
carboxylase	O
nor	O
mitochondrial	O
PEPCK	O
activity	O
in	O
lymphocytes	O
was	O
increased	O
by	O
a	O
21	O
-	O
hr	O
fast	O
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
from	O
Italian	O
subjects	O
associated	O
with	O
severe	B-Disease
neonatal	I-Disease
jaundice	I-Disease
.	O

Screening	O
for	O
the	O
G6PD	B-Disease
deficiency	I-Disease
was	O
carried	O
out	O
at	O
the	O
Maternity	O
Division	O
of	O
the	O
Galliera	O
Hospital	O
in	O
Genoa	O
,	O
Italy	O
.	O

Two	O
groups	O
of	O
subjects	O
with	O
hyperbilirubinaemia	B-Disease
of	O
non	O
-	O
immunological	O
origin	O
were	O
examined	O
(	O
a	O
)	O
302	O
newborn	O
babies	O
of	O
Sardinian	O
extraction	O
(	O
on	O
cord	O
blood	O
)	O
and	O
(	O
b	O
)	O
201	O
newborn	O
babies	O
of	O
south	O
Italian	O
ancestry	O
(	O
on	O
peripheral	O
blood	O
)	O
.	O

Among	O
503	O
subjects	O
,	O
43	O
showed	O
an	O
enzyme	O
deficiency	O
;	O
in	O
39	O
the	O
defect	O
was	O
of	O
the	O
Mediterranean	O
type	O
.	O

In	O
one	O
case	O
,	O
previously	O
described	O
,	O
the	O
enzyme	O
was	O
of	O
the	O
A	O
-	O
type	O
.	O

In	O
the	O
remaining	O
cases	O
three	O
different	O
variants	O
were	O
identified	O
.	O

In	O
the	O
present	O
work	O
these	O
three	O
cases	O
,	O
each	O
with	O
severe	B-Disease
neonatal	I-Disease
jaundice	I-Disease
,	O
are	O
reported	O
.	O

Their	O
parents	O
originated	O
from	O
Calabria	O
,	O
from	O
Sardinia	O
and	O
from	O
Sicily	O
.	O

The	O
abnormal	O
enzymes	O
are	O
respectively	O
designated	O
as	O
GdDcbrousse	O
-	O
like	O
,	O
GdGallura	O
and	O
GdAgrigento	O
.	O
.	O

Cytogenetic	O
investigations	O
in	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O

Chromosomal	O
studies	O
were	O
performed	O
on	O
peripheral	O
blood	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
five	O
Israeli	O
-	O
Moroccan	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O

A	O
total	O
of	O
24	O
individuals	O
,	O
including	O
seven	O
propositi	O
,	O
was	O
investigated	O
.	O

Among	O
the	O
probands	O
,	O
significantly	O
elevated	O
rates	O
of	O
chromosome	O
damage	O
were	O
observed	O
in	O
both	O
blood	O
and	O
skin	O
.	O

Skin	O
fibroblasts	O
of	O
affected	O
individuals	O
showed	O
several	O
orders	O
of	O
magnitude	O
more	O
chromosome	O
breakage	O
than	O
lymphocytes	O
.	O

Increased	O
rates	O
of	O
chromosome	O
damage	O
were	O
also	O
observed	O
in	O
the	O
fibroblasts	O
of	O
some	O
phenotypically	O
normal	O
family	O
members	O
(	O
obligate	O
heterozygotes	O
and	O
sibs	O
)	O
when	O
compared	O
to	O
normal	O
controls	O
.	O

An	O
apparent	O
abnormal	O
clone	O
of	O
cells	O
,	O
possessing	O
a	O
large	O
acrocentric	O
marker	O
chromosome	O
(	O
14q	O
+	O
)	O
,	O
was	O
observed	O
in	O
varying	O
proportions	O
among	O
cells	O
of	O
all	O
the	O
propositi	O
(	O
2	O
-	O
5	O
%	O
of	O
lymphocytes	O
;	O
1	O
-	O
9	O
%	O
of	O
fibroblasts	O
)	O
.	O
.	O

Prenatal	O
diagnosis	O
of	O
Wolman	B-Disease
disease	I-Disease
.	O

Two	O
pregnancies	O
at	O
risk	O
for	O
Wolman	B-Disease
disease	I-Disease
were	O
monitored	O
by	O
assay	O
and	O
electrophoresis	O
of	O
acid	O
lipase	O
in	O
cultured	O
amniotic	O
-	O
fluid	O
cells	O
.	O

Cells	O
from	O
patient	O
1	O
had	O
5	O
%	O
of	O
control	O
levels	O
of	O
acid	O
lipase	O
,	O
using	O
14C	O
-	O
triolein	O
as	O
substrate	O
;	O
however	O
,	O
when	O
artificial	O
substrates	O
(	O
esters	O
of	O
4	O
-	O
methylumbelliferone	O
and	O
p	O
-	O
nitrophenol	O
)	O
were	O
used	O
to	O
measure	O
acid	O
lipase	O
,	O
these	O
cells	O
had	O
30	O
%	O
of	O
control	O
levels	O
.	O

Electrophoresis	O
of	O
cell	O
extracts	O
revealed	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Wolman	B-Disease
disease	I-Disease
.	O

Analysis	O
of	O
fetal	O
tissues	O
following	O
prostaglandin	O
termination	O
of	O
this	O
pregnancy	O
confirmed	O
the	O
diagnosis	O
.	O

Assay	O
of	O
fetal	O
-	O
skin	O
fibroblasts	O
with	O
14C	O
-	O
triolein	O
,	O
as	O
well	O
as	O
with	O
artificial	O
substrates	O
,	O
showed	O
marked	O
deficiency	O
of	O
acid	O
lipase	O
activity	O
.	O

Electrophoresis	O
of	O
fetal	O
-	O
tissue	O
extracts	O
also	O
demonstrated	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase	O
.	O

Amniotic	O
-	O
fluid	O
cells	O
from	O
patient	O
2	O
showed	O
normal	O
levels	O
of	O
acid	O
lipase	O
with	O
all	O
substrates	O
tested	O
;	O
the	O
electrophoretic	O
pattern	O
of	O
acid	O
lipase	O
was	O
normal	O
.	O

The	O
results	O
suggest	O
that	O
the	O
prenatal	O
diagnosis	O
of	O
Wolman	B-Disease
disease	I-Disease
be	O
made	O
using	O
the	O
radioassay	O
of	O
acid	O
lipase	O
and	O
/	O
or	O
electrophoresis	O
.	O
.	O

Malignant	B-Disease
neoplasms	I-Disease
in	O
the	O
families	O
of	O
patients	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
associated	O
with	O
a	O
greatly	O
increased	O
incidence	O
of	O
malignant	B-Disease
neoplasms	I-Disease
in	O
homozygous	O
affected	O
individuals	O
.	O

Heterozygotes	O
for	O
the	O
gene	O
for	O
A	B-Disease
-	I-Disease
T	I-Disease
are	O
thought	O
to	O
comprise	O
about	O
1	O
%	O
of	O
the	O
general	O
population	O
and	O
,	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	O
also	O
predisposes	O
the	O
heterozygous	O
carrier	O
to	O
cancers	B-Disease
.	O

Heterozygous	O
carriers	O
of	O
this	O
gene	O
are	O
common	O
among	O
the	O
close	O
relatives	O
of	O
patients	O
with	O
A	B-Disease
-	I-Disease
T	I-Disease
,	O
although	O
individual	O
carriers	O
cannot	O
be	O
identified	O
by	O
any	O
clinical	O
criterion	O
or	O
laboratory	O
test	O
.	O

For	O
this	O
reason	O
,	O
we	O
compared	O
the	O
incidence	O
of	O
death	O
from	O
malignant	B-Disease
neoplasms	I-Disease
in	O
2	O
families	O
of	O
patients	O
with	O
A	B-Disease
-	I-Disease
T	I-Disease
to	O
that	O
expected	O
in	O
a	O
random	O
sample	O
of	O
the	O
general	O
population	O
.	O

There	O
were	O
59	O
deaths	O
from	O
malignant	B-Disease
neoplasms	I-Disease
in	O
relatives	O
dying	O
before	O
age	O
75	O
,	O
compared	O
to	O
42	O
.	O

6	O
expected	O
(	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

For	O
A	B-Disease
-	I-Disease
T	I-Disease
heterozygotes	O
younger	O
than	O
age	O
45	O
,	O
the	O
risk	O
of	O
dying	O
from	O
a	O
malignant	B-Disease
neoplasm	I-Disease
was	O
estimated	O
to	O
be	O
greater	O
than	O
5	O
times	O
the	O
risk	O
for	O
the	O
general	O
population	O
.	O

A	B-Disease
-	I-Disease
T	I-Disease
heterozygotes	O
may	O
comprise	O
more	O
than	O
5	O
%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	B-Disease
before	O
age	O
45	O
.	O

The	O
incidence	O
of	O
ovarian	B-Disease
,	I-Disease
gastric	I-Disease
,	I-Disease
and	I-Disease
biliary	I-Disease
system	I-Disease
carcinomas	I-Disease
and	O
of	O
leukemia	B-Disease
and	O
lymphoma	B-Disease
was	O
increased	O
in	O
these	O
A	B-Disease
-	I-Disease
T	I-Disease
families	O
.	O

Other	O
neoplasms	B-Disease
that	O
may	O
be	O
associated	O
with	O
this	O
gene	O
in	O
heterozygotes	O
include	O
pancreatic	B-Disease
,	I-Disease
basal	I-Disease
cell	I-Disease
,	I-Disease
colonic	I-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
and	I-Disease
cervical	I-Disease
carcinomas	I-Disease
.	O

Striking	O
prevalence	O
of	O
ankylosing	B-Disease
spondylitis	I-Disease
in	O
"	O
healthy	O
"	O
w27	O
positive	O
males	O
and	O
females	O
.	O

Ankylosing	B-Disease
spondylitis	I-Disease
is	O
diagnosed	O
once	O
or	O
twice	O
in	O
each	O
1000	O
males	O
and	O
one	O
tenth	O
as	O
frequently	O
in	O
females	O
,	O
but	O
the	O
true	O
prevalence	O
is	O
unknown	O
.	O

Indentification	O
of	O
genetic	O
marker	O
,	O
HL	O
-	O
A	O
W27	O
,	O
for	O
susceptible	O
persons	O
has	O
provided	O
a	O
tool	O
facilitating	O
epidemiologic	O
studies	O
and	O
allowing	O
identification	O
of	O
"	O
control	O
"	O
populations	O
without	O
the	O
marker	O
.	O

Evaluation	O
by	O
postal	O
questionnaires	O
,	O
and	O
pelvic	O
radiography	O
of	O
78	O
HL	O
-	O
A	O
27W	O
-	O
positive	O
blood	O
donors	O
selected	O
from	O
a	O
group	O
of	O
apparently	O
healthy	O
subjects	O
revealed	O
14	O
who	O
satisfied	O
the	O
criteria	O
for	O
definite	O
ankylosing	B-Disease
spondylitis	I-Disease
.	O

The	O
prevalence	O
was	O
similar	O
in	O
both	O
sexes	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
six	O
W27	O
-	O
negative	O
controls	O
matched	O
for	O
race	O
,	O
sex	O
,	O
and	O
age	O
failed	O
to	O
yield	O
a	O
single	O
case	O
.	O

For	O
a	O
person	O
of	O
either	O
sex	O
with	O
HL	O
-	O
A	O
W27	O
,	O
there	O
appears	O
to	O
be	O
about	O
a	O
20	O
per	O
cent	O
chance	O
that	O
ankylosing	B-Disease
spondylitis	I-Disease
will	O
develop	O
,	O
suggesting	O
a	O
prevalence	O
of	O
10	O
to	O
15	O
per	O
thousand	O
.	O

Hitherto	O
accepted	O
figures	O
may	O
underestimate	O
the	O
frequency	O
by	O
a	O
factor	O
of	O
10	O
to	O
20	O
.	O
.	O

Analbuminemia	B-Disease
in	O
an	O
American	O
Indian	O
girl	O
.	O

Analbuminemia	B-Disease
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12	O
-	O
year	O
-	O
old	O
American	O
Indian	O
girl	O
with	O
atopic	B-Disease
dermatitis	I-Disease
,	O
mild	O
bronchial	B-Disease
asthma	I-Disease
,	O
a	O
mild	O
seizure	B-Disease
disorder	I-Disease
,	O
and	O
hyperlipoproteinemia	B-Disease
with	O
a	O
corneal	B-Disease
arcus	I-Disease
.	O

Immunologic	O
methods	O
revealed	O
trace	O
amounts	O
(	O
17	O
mg	O
/	O
100	O
ml	O
)	O
of	O
apparently	O
normal	O
serum	O
albumin	O
.	O

The	O
patients	O
parents	O
were	O
remotely	O
related	O
.	O

The	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	B-Disease
.	O

Heterozygotes	O
had	O
subnormal	O
levels	O
of	O
serum	O
albumin	O
.	O

The	O
Gc	O
-	O
locus	O
is	O
closely	O
linked	O
to	O
the	O
structural	O
albumin	O
locus	O
.	O

Gc	O
-	O
protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	B-Disease
.	O

Gc	O
-	O
types	O
in	O
the	O
family	O
were	O
compatible	O
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	O
of	O
analbuminemia	B-Disease
to	O
the	O
Gc	O
-	O
locus	O
.	O

These	O
findings	O
suggest	O
a	O
"	O
thalassemia	B-Disease
"	O
-	O
like	O
mutation	O
for	O
this	O
disorder	O
.	O
.	O

Deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
in	O
a	O
patient	O
with	O
piebaldism	B-Disease
.	O

We	O
have	O
previously	O
shown	O
that	O
human	O
piebaldism	B-Disease
results	O
from	O
mutations	O
of	O
the	O
KIT	O
gene	O
,	O
which	O
encodes	O
the	O
receptor	O
for	O
the	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
and	O
is	O
located	O
in	O
chromosome	O
segment	O
4q12	O
.	O

Using	O
DNA	O
of	O
a	O
patient	O
with	O
piebaldism	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
multiple	B-Disease
congenital	I-Disease
anomalies	I-Disease
associated	O
with	O
a	O
46	O
,	O
XY	O
,	O
del	O
(	O
4	O
)	O
(	O
q12q21	O
.	O
1	O
)	O
karyotype	O
,	O
we	O
carried	O
out	O
quantitative	O
Southern	O
blot	O
hybridization	O
analyses	O
of	O
the	O
KIT	O
gene	O
and	O
the	O
adjacent	O
PDGFRA	O
(	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
alpha	O
subunit	O
)	O
genes	O
.	O

The	O
patient	O
was	O
hemizygous	O
for	O
both	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
,	O
indicating	O
that	O
both	O
of	O
these	O
genes	O
are	O
included	O
within	O
the	O
deleted	O
region	O
.	O

Therefore	O
,	O
deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
may	O
account	O
for	O
the	O
piebald	B-Disease
phenotype	O
in	O
this	O
patient	O
.	O

A	O
germ	O
line	O
mutation	O
within	O
the	O
coding	O
sequence	O
for	O
the	O
putative	O
5	O
-	O
phosphoribosyl	O
-	O
1	O
-	O
pyrophosphate	O
binding	O
site	O
of	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
in	O
a	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
patient	O
:	O
missense	O
mutations	O
within	O
a	O
functionally	O
important	O
region	O
probably	O
cause	O
disease	O
.	O

Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
caused	O
by	O
a	O
complete	B-Disease
deficiency	I-Disease
of	I-Disease
hypoxanthine	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
(	O
HPRT	O
)	O
is	O
the	O
result	O
of	O
a	O
heterogeneous	O
group	O
of	O
germ	O
line	O
mutations	O
.	O

Identification	O
of	O
each	O
mutant	O
gene	O
provides	O
valuable	O
information	O
as	O
to	O
the	O
type	O
of	O
mutation	O
that	O
occurs	O
spontaneously	O
.	O

We	O
report	O
here	O
a	O
newly	O
identified	O
HPRT	O
mutation	O
in	O
a	O
Japanese	O
patient	O
with	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

This	O
gene	O
,	O
designated	O
HPRT	O
Tokyo	O
,	O
had	O
a	O
single	O
nucleotide	O
change	O
from	O
G	O
to	O
A	O
,	O
as	O
identified	O
by	O
sequencing	O
cDNA	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O

Allele	O
specific	O
oligonucleotide	O
hybridization	O
analysis	O
using	O
amplified	O
genomic	O
DNA	O
showed	O
that	O
the	O
mutant	O
gene	O
was	O
transmitted	O
from	O
the	O
maternal	O
germ	O
line	O
.	O

This	O
mutation	O
would	O
lead	O
to	O
an	O
amino	O
acid	O
substitution	O
of	O
Asp	O
for	O
Gly	O
at	O
the	O
amino	O
acid	O
position	O
140	O
located	O
within	O
the	O
putative	O
5	O
-	O
phosphoribosyl	O
-	O
1	O
-	O
pyrophosphate	O
(	O
PRPP	O
)	O
binding	O
region	O
.	O

Missense	O
mutations	O
in	O
human	O
HPRT	B-Disease
deficient	I-Disease
patients	O
thus	O
far	O
reported	O
tend	O
to	O
accumulate	O
in	O
this	O
functionally	O
active	O
region	O
.	O

However	O
,	O
a	O
comparison	O
of	O
the	O
data	O
suggested	O
that	O
both	O
missense	O
and	O
synonymous	O
mutations	O
can	O
occur	O
at	O
any	O
coding	O
sequence	O
of	O
the	O
human	O
germ	O
line	O
HPRT	O
gene	O
,	O
but	O
that	O
a	O
limited	O
percentage	O
of	O
all	O
the	O
missense	O
mutations	O
cause	O
disease	O
.	O

The	O
probability	O
that	O
a	O
mutation	O
will	O
cause	O
disease	O
tends	O
to	O
be	O
higher	O
when	O
the	O
missense	O
mutation	O
is	O
within	O
a	O
functionally	O
important	O
sequence	O
.	O
.	O

Characterisation	O
of	O
a	O
new	O
rare	O
fragile	O
site	O
easily	O
confused	O
with	O
the	O
fragile	B-Disease
X	I-Disease
.	O

A	O
new	O
fragile	O
site	O
(	O
FRAXE	O
)	O
in	O
Xq28	O
is	O
described	O
.	O

It	O
appears	O
to	O
be	O
a	O
typical	O
folate	O
sensitive	O
fragile	O
site	O
.	O

The	O
fragile	O
site	O
is	O
not	O
associated	O
with	O
mental	B-Disease
retardation	I-Disease
,	O
it	O
does	O
not	O
give	O
abnormal	O
results	O
when	O
subjected	O
to	O
Southern	O
analysis	O
with	O
probe	O
pfxa3	O
which	O
detects	O
the	O
unstable	O
DNA	O
sequence	O
characteristic	O
of	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
.	O

In	O
situ	O
hybridization	O
mapping	O
locates	O
the	O
fragile	O
site	O
between	O
150	O
kb	O
and	O
600	O
kb	O
distal	O
to	O
FRAXA	O
.	O

The	O
distinction	O
between	O
the	O
two	O
fragile	O
sites	O
is	O
important	O
clinically	O
since	O
cytogenetic	O
detection	O
of	O
FRAXE	O
,	O
without	O
molecular	O
analysis	O
,	O
could	O
result	O
in	O
misdiagnosis	O
of	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
.	O
.	O

The	O
Norrie	B-Disease
disease	I-Disease
gene	O
maps	O
to	O
a	O
150	O
kb	O
region	O
on	O
chromosome	O
Xp11	O
.	O
3	O
.	O

Norrie	B-Disease
disease	I-Disease
is	O
a	O
human	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disorder	I-Disease
of	O
unknown	O
etiology	O
characterized	O
by	O
congenital	B-Disease
blindness	I-Disease
,	O
sensory	B-Disease
neural	I-Disease
deafness	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
.	O

This	O
disease	O
gene	O
was	O
previously	O
linked	O
to	O
the	O
DXS7	O
(	O
L1	O
.	O
28	O
)	O
locus	O
and	O
the	O
MAO	O
genes	O
in	O
band	O
Xp11	O
.	O

3	O
3	O
.	O

We	O
report	O
here	O
fine	O
physical	O
mapping	O
of	O
the	O
obligate	O
region	O
containing	O
the	O
Norrie	B-Disease
disease	I-Disease
gene	O
(	O
NDP	O
)	O
defined	O
by	O
a	O
recombination	O
and	O
by	O
the	O
smallest	O
submicroscopic	O
chromosomal	O
deletion	O
associated	O
with	O
Norrie	B-Disease
disease	I-Disease
identified	O
to	O
date	O
.	O

Analysis	O
,	O
using	O
in	O
addition	O
two	O
overlapping	O
YAC	O
clones	O
from	O
this	O
region	O
,	O
allowed	O
orientation	O
of	O
the	O
MAOA	O
and	O
MAOB	O
genes	O
in	O
a	O
5	O
-	O
3	O
-	O
3	O
-	O
5	O
configuration	O
.	O

A	O
recombination	O
event	O
between	O
a	O
(	O
GT	O
)	O
n	O
polymorphism	O
in	O
intron	O
2	O
of	O
the	O
MAOB	O
gene	O
and	O
the	O
NDP	O
locus	O
,	O
in	O
a	O
family	O
previously	O
reported	O
to	O
have	O
a	O
recombination	O
between	O
DXS7	O
and	O
NDP	O
,	O
delineates	O
a	O
flanking	O
marker	O
telomeric	O
to	O
this	O
disease	O
gene	O
.	O

An	O
anonymous	O
DNA	O
probe	O
,	O
dc12	O
,	O
present	O
in	O
one	O
of	O
the	O
YACs	O
and	O
in	O
a	O
patient	O
with	O
a	O
submicroscopic	O
deletion	O
which	O
includes	O
MAOA	O
and	O
MAOB	O
but	O
not	O
L1	O
.	O

28	O
,	O
serves	O
as	O
a	O
flanking	O
marker	O
centromeric	O
to	O
the	O
disease	O
gene	O
.	O

An	O
Alu	O
-	O
PCR	O
fragment	O
from	O
the	O
right	O
arm	O
of	O
the	O
MAO	O
YAC	O
(	O
YMAO	O
.	O
AluR	O
)	O
is	O
not	O
deleted	O
in	O
this	O
patient	O
and	O
also	O
delineates	O
the	O
centromeric	O
extent	O
of	O
the	O
obligate	O
disease	O
region	O
.	O

The	O
apparent	O
order	O
of	O
these	O
loci	O
is	O
telomere	O
.	O

DXS7	O
-	O
MAOA	O
-	O
MAOB	O
-	O
NDP	O
-	O
dc12	O
-	O
YMAO	O
DXS7	O
-	O
MAOA	O
-	O
MAOB	O
-	O
NDP	O
-	O
dc12	O
-	O
YMAO	O
.	O

AluR	O
.	O
centromere	O
.	O

Together	O
these	O
data	O
define	O
the	O
obligate	O
region	O
containing	O
the	O
NDP	O
gene	O
to	O
a	O
chromosomal	O
segment	O
less	O
than	O
150	O
kb	O
.	O

Molecular	O
basis	O
of	O
phenylketonuria	B-Disease
and	O
related	O
hyperphenylalaninemias	B-Disease
:	O
mutations	O
and	O
polymorphisms	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
.	O

Mutations	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
producing	O
phenylketonuria	B-Disease
or	O
hyperphenylalaninemia	B-Disease
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O

These	O
mutations	O
all	O
exhibit	O
a	O
high	O
degree	O
of	O
association	O
with	O
specific	O
restriction	O
fragment	O
-	O
length	O
polymorphism	O
haplotypes	O
at	O
the	O
PAH	O
locus	O
.	O

About	O
50	O
of	O
these	O
mutations	O
are	O
single	O
-	O
base	O
substitutions	O
,	O
including	O
six	O
nonsense	O
mutations	O
and	O
eight	O
splicing	O
mutations	O
,	O
with	O
the	O
remainder	O
being	O
missense	O
mutations	O
.	O

One	O
splicing	O
mutation	O
results	O
in	O
a	O
3	O
amino	O
acid	O
in	O
-	O
frame	O
insertion	O
.	O

Two	O
or	O
3	O
large	O
deletions	O
,	O
2	O
single	O
codon	O
deletions	O
,	O
and	O
2	O
single	O
base	O
deletions	O
have	O
been	O
found	O
.	O

Twelve	O
of	O
the	O
missense	O
mutations	O
apparently	O
result	O
from	O
the	O
methylation	O
and	O
subsequent	O
deamination	O
of	O
highly	O
mutagenic	O
CpG	O
dinucleotides	O
.	O

Recurrent	O
mutation	O
has	O
been	O
observed	O
at	O
several	O
of	O
these	O
sites	O
,	O
producing	O
associations	O
with	O
different	O
haplotypes	O
in	O
different	O
populations	O
.	O

About	O
half	O
of	O
all	O
missense	O
mutations	O
have	O
been	O
examined	O
by	O
in	O
vitro	O
expression	O
analysis	O
,	O
and	O
a	O
significant	O
correlation	O
has	O
been	O
observed	O
between	O
residual	O
PAH	O
activity	O
and	O
disease	O
phenotype	O
.	O

Since	O
continuing	O
advances	O
in	O
molecular	O
methodologies	O
have	O
dramatically	O
accelerated	O
the	O
rate	O
in	O
which	O
new	O
mutations	O
are	O
being	O
identified	O
and	O
characterized	O
,	O
this	O
register	O
of	O
mutations	O
will	O
be	O
updated	O
periodically	O
.	O
.	O

A	O
glycine250	O
-	O
-	O
>	O
aspartate	O
substitution	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
hexosaminidase	O
A	O
causes	O
juvenile	O
-	O
onset	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
in	O
a	O
Lebanese	O
-	O
Canadian	O
family	O
.	O

The	O
mutation	O
causing	O
juvenile	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
in	O
two	O
sibs	O
of	O
Lebanese	O
-	O
Maronite	O
origin	O
is	O
described	O
.	O

An	O
mRNA	O
-	O
containing	O
extract	O
of	O
cultured	O
fibroblasts	O
obtained	O
from	O
one	O
of	O
the	O
probands	O
was	O
used	O
as	O
a	O
template	O
to	O
amplify	O
the	O
coding	O
sequence	O
of	O
the	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
alpha	O
-	O
subunit	O
.	O

Sequencing	O
of	O
amplified	O
cDNA	O
fragments	O
revealed	O
a	O
single	O
alteration	O
,	O
guanine	O
to	O
adenine	O
at	O
nt	O
749	O
creating	O
a	O
G250D	O
mutation	O
.	O

The	O
mutation	O
introduces	O
a	O
new	O
recognition	O
site	O
for	O
the	O
restriction	O
enzyme	O
Eco	O
RV	O
,	O
permitting	O
identification	O
of	O
heterozygotes	O
for	O
this	O
allele	O
following	O
PCR	O
amplification	O
and	O
Eco	O
RV	O
digestion	O
of	O
exon	O
7	O
sequences	O
from	O
genomic	O
DNA	O
templates	O
.	O

In	O
order	O
to	O
test	O
the	O
effect	O
of	O
this	O
substitution	O
,	O
an	O
in	O
vitro	O
mutagenized	O
cDNA	O
construct	O
was	O
introduced	O
into	O
a	O
mammalian	O
expression	O
vector	O
and	O
transfected	O
into	O
monkey	O
Cos	O
-	O
1	O
cells	O
separately	O
or	O
along	O
with	O
a	O
beta	O
-	O
cDNA	O
expression	O
vector	O
.	O

When	O
the	O
mutant	O
alpha	O
-	O
cDNA	O
was	O
the	O
only	O
gene	O
introduced	O
into	O
COS	O
cells	O
no	O
enzymatic	O
activity	O
above	O
endogenous	O
COS	O
cell	O
activity	O
was	O
detected	O
.	O

Cotransfection	O
of	O
normal	O
alpha	O
-	O
cDNA	O
and	O
beta	O
-	O
cDNA	O
followed	O
by	O
immunoprecipitation	O
of	O
human	O
Hex	O
A	O
resulted	O
in	O
20	O
-	O
fold	O
increase	O
in	O
the	O
ratio	O
between	O
positive	O
and	O
negative	O
(	O
mock	O
transfection	O
)	O
control	O
values	O
.	O

This	O
allowed	O
the	O
detection	O
of	O
some	O
residual	O
activity	O
(	O
12	O
%	O
of	O
the	O
positive	O
control	O
)	O
when	O
the	O
mutant	O
alpha	O
-	O
cDNA	O
replaced	O
its	O
wild	O
-	O
type	O
counterpart	O
.	O

The	O
predicted	O
protein	O
environment	O
in	O
which	O
the	O
mutation	O
occurs	O
is	O
compared	O
to	O
that	O
of	O
the	O
adult	O
-	O
onset	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
mutation	O
caused	O
by	O
a	O
Gly269	O
-	O
-	O
>	O
Ser	O
substitution	O
in	O
exon	O
7	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Novel	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
mutations	O
from	O
China	O
.	O

We	O
describe	O
three	O
HEXA	O
mutations	O
associated	O
with	O
infantile	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
in	O
three	O
unrelated	O
nonconsanguineous	O
Chinese	O
families	O
.	O

Novel	O
mutations	O
were	O
found	O
in	O
two	O
of	O
these	O
families	O
.	O

The	O
third	O
is	O
a	O
previously	O
reported	O
mutation	O
(	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nt	O
1444	O
)	O
(	O
Nakano	O
et	O
al	O
.	O
,	O
1988	O
)	O
.	O

Direct	O
sequencing	O
of	O
PCR	O
products	O
identified	O
a	O
novel	O
insertion	O
of	O
an	O
A	O
after	O
nt	O
547	O
in	O
family	O
1	O
.	O

This	O
change	O
generates	O
an	O
early	O
termination	O
codon	O
6	O
bp	O
downstream	O
from	O
the	O
insertion	O
site	O
.	O

Allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
confirmed	O
homozygosity	O
in	O
the	O
proband	O
.	O

Single	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
amplified	O
exon	O
13	O
revealed	O
a	O
T	O
-	O
-	O
>	O
C	O
transition	O
at	O
nt	O
1453	O
with	O
the	O
corresponding	O
amino	O
acid	O
substitution	O
W485R	O
in	O
the	O
second	O
family	O
.	O

This	O
mutation	O
creates	O
an	O
Fnu4HI	O
restriction	O
site	O
.	O

The	O
proband	O
is	O
homozygous	O
for	O
this	O
allele	O
.	O

When	O
the	O
site	O
-	O
specific	O
mutagenized	O
alpha	O
cDNA	O
carrying	O
the	O
T	O
-	O
-	O
>	O
C	O
transition	O
at	O
nt	O
1453	O
was	O
expressed	O
in	O
COS	O
1	O
cells	O
hexosaminidase	O
S	O
activity	O
was	O
not	O
detectable	O
above	O
background	O
.	O

A	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nt	O
1444	O
(	O
exon	O
13	O
)	O
corresponding	O
to	O
the	O
E482K	O
substitution	O
was	O
found	O
in	O
the	O
third	O
family	O
.	O

This	O
mutation	O
occurs	O
at	O
a	O
CpG	O
dinucleotide	O
.	O

It	O
has	O
been	O
reported	O
in	O
an	O
Italian	O
TSD	B-Disease
proband	O
and	O
causes	O
defective	O
intracellular	O
transport	O
of	O
the	O
alpha	O
-	O
subunit	O
from	O
the	O
rough	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Two	O
missense	O
mutations	O
causing	O
mild	O
hyperphenylalaninemia	B-Disease
associated	O
with	O
DNA	O
haplotype	O
12	O
.	O

The	O
genetic	B-Disease
defects	I-Disease
responsible	O
for	O
most	O
phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
and	O
hyperphenylalaninemia	B-Disease
(	O
HPA	B-Disease
)	O
cases	O
are	O
located	O
in	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
.	O

Approximately	O
50	O
-	O
60	O
mutations	O
have	O
been	O
reported	O
in	O
Caucasians	O
and	O
are	O
reflected	O
in	O
a	O
wide	O
range	O
of	O
clinical	O
severities	O
.	O

Most	O
mutations	O
are	O
linked	O
to	O
specific	O
haplotypes	O
,	O
as	O
defined	O
by	O
eight	O
polymorphic	O
restriction	O
sites	O
in	O
the	O
PAH	O
gene	O
.	O

We	O
hypothesized	O
that	O
there	O
is	O
at	O
least	O
one	O
mild	O
mutation	O
linked	O
to	O
haplotype	O
12	O
in	O
the	O
Swedish	O
PKU	B-Disease
/	O
HPA	B-Disease
population	O
,	O
since	O
7	O
of	O
8	O
patients	O
carrying	O
haplotype	O
12	O
had	O
mild	O
HPA	B-Disease
.	O

Sequence	O
analysis	O
revealed	O
a	O
C	O
-	O
to	O
-	O
G	O
transversion	O
at	O
the	O
second	O
base	O
of	O
codon	O
322	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
glycine	O
for	O
alanine	O
,	O
in	O
four	O
mutant	O
haplotype	O
12	O
genes	O
,	O
and	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
408	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
glutamine	O
for	O
arginine	O
,	O
in	O
another	O
three	O
mutant	O
haplotype	O
12	O
genes	O
.	O

These	O
mutations	O
segregated	O
with	O
mutant	O
haplotype	O
12	O
alleles	O
in	O
nuclear	O
families	O
but	O
were	O
not	O
present	O
on	O
normal	O
or	O
other	O
mutant	O
alleles	O
.	O

Both	O
mutations	O
were	O
tested	O
in	O
a	O
eukaryotic	O
expression	O
system	O
in	O
which	O
enzyme	O
activities	O
of	O
different	O
mutant	O
PAH	O
enzymes	O
reflect	O
the	O
relative	O
severities	O
of	O
the	O
mutations	O
,	O
although	O
these	O
in	O
vitro	O
activities	O
cannot	O
be	O
translated	O
directly	O
into	O
in	O
vivo	O
hepatic	O
activities	O
.	O

The	O
A322G	O
mutant	O
PAH	O
had	O
about	O
75	O
%	O
and	O
the	O
R408Q	O
mutant	O
PAH	O
about	O
55	O
%	O
of	O
the	O
wild	O
-	O
type	O
PAH	O
enzyme	O
activity	O
.	O

These	O
in	O
vitro	O
activities	O
are	O
the	O
highest	O
reported	O
for	O
mutant	O
PAH	O
enzymes	O
produced	O
in	O
the	O
same	O
expression	O
system	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
correlations	O
for	O
I65T	O
and	O
M1V	O
mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
locus	O
.	O

Mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
locus	O
are	O
the	O
major	O
cause	O
of	O
hyperphenylalaninemia	B-Disease
.	O

We	O
have	O
previously	O
described	O
four	O
mutations	O
(	O
M1V	O
,	O
IVS12nt1	O
,	O
R408W	O
,	O
and	O
S349P	O
)	O
at	O
the	O
PAH	O
locus	O
in	O
French	O
Canadians	O
with	O
ancestry	O
in	O
eastern	O
Quebec	O
.	O

Here	O
we	O
report	O
(	O
1	O
)	O
identification	O
of	O
another	O
mutation	O
,	O
on	O
a	O
haplotype	O
9	O
chromosome	O
,	O
which	O
converts	O
codon	O
65	O
from	O
isoleucine	O
(	O
ATT	O
)	O
to	O
threonine	O
(	O
ACT	O
)	O
,	O
(	O
2	O
)	O
expression	O
analysis	O
of	O
the	O
I65T	O
mutation	O
in	O
COS	O
cells	O
demonstrating	O
75	O
%	O
loss	O
of	O
both	O
immunoreactive	O
protein	O
and	O
enzyme	O
activity	O
,	O
and	O
(	O
3	O
)	O
expression	O
analysis	O
of	O
the	O
most	O
prevalent	O
PKU	B-Disease
allele	O
(	O
M1V	O
)	O
in	O
eastern	O
Quebec	O
,	O
showing	O
nondetectable	O
levels	O
of	O
PAH	O
protein	O
and	O
activity	O
,	O
a	O
finding	O
compatible	O
with	O
a	O
mutation	O
in	O
the	O
translation	O
initiation	O
codon	O
.	O

Homozygosity	O
for	O
M1V	O
and	O
codominant	O
inheritance	O
of	O
I65T	O
/	O
R408W	O
were	O
both	O
associated	O
with	O
classical	B-Disease
phenylketonuria	I-Disease
.	O
.	O

Molecular	O
basis	O
of	O
hexosaminidase	B-Disease
A	I-Disease
deficiency	I-Disease
and	O
pseudodeficiency	O
in	O
the	O
Berks	O
County	O
Pennsylvania	O
Dutch	O
.	O

Following	O
the	O
birth	O
of	O
two	O
infants	O
with	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
,	O
a	O
non	O
-	O
Jewish	O
,	O
Pennsylvania	O
Dutch	O
kindred	O
was	O
screened	O
for	O
TSD	B-Disease
carriers	O
using	O
the	O
biochemical	O
assay	O
.	O

A	O
high	O
frequency	O
of	O
individuals	O
who	O
appeared	O
to	O
be	O
TSD	B-Disease
heterozygotes	O
was	O
detected	O
(	O
Kelly	O
et	O
al	O
.	O
,	O
1975	O
)	O
.	O

Clinical	O
and	O
biochemical	O
evidence	O
suggested	O
that	O
the	O
increased	O
carrier	O
frequency	O
was	O
due	O
to	O
at	O
least	O
two	O
altered	O
alleles	O
for	O
the	O
hexosaminidase	O
A	O
alpha	O
-	O
subunit	O
.	O

We	O
now	O
report	O
two	O
mutant	O
alleles	O
in	O
this	O
Pennsylvania	O
Dutch	O
kindred	O
,	O
and	O
one	O
polymorphism	O
.	O

One	O
allele	O
,	O
reported	O
originally	O
in	O
a	O
French	O
TSD	B-Disease
patient	O
(	O
Akli	O
et	O
al	O
.	O
,	O
1991	O
)	O
,	O
is	O
a	O
GT	O
-	O
-	O
>	O
AT	O
transition	O
at	O
the	O
donor	O
splice	O
-	O
site	O
of	O
intron	O
9	O
.	O

The	O
second	O
,	O
a	O
C	O
-	O
-	O
>	O
T	O
transition	O
at	O
nucleotide	O
739	O
(	O
Arg247Trp	O
)	O
,	O
has	O
been	O
shown	O
by	O
Triggs	O
-	O
Raine	O
et	O
al	O
.	O

(	O
1992	O
)	O
to	O
be	O
a	O
clinically	O
benign	O
"	O
pseudodeficient	O
"	O
allele	O
associated	O
with	O
reduced	O
enzyme	O
activity	O
against	O
artificial	O
substrate	O
.	O

Finally	O
,	O
a	O
polymorphism	O
[	O
G	O
-	O
-	O
>	O
A	O
(	O
759	O
)	O
]	O
,	O
which	O
leaves	O
valine	O
at	O
codon	O
253	O
unchanged	O
,	O
is	O
described	O
.	O

A	O
mutation	O
common	O
in	O
non	O
-	O
Jewish	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
:	O
frequency	O
and	O
RNA	O
studies	O
.	O

Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
N	O
-	O
acetylhexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
.	O

We	O
have	O
discovered	O
that	O
a	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
mutation	O
,	O
IVS	O
-	O
9	O
+	O
1	O
G	O
-	O
-	O
>	O
A	O
,	O
first	O
detected	O
by	O
Akli	O
et	O
al	O
.	O

(	O
Genomics	O
11	O
124	O
-	O
134	O
,	O
1991	O
)	O
,	O
is	O
a	O
common	O
disease	O
allele	O
in	O
non	O
-	O
Jewish	O
Caucasians	O
(	O
10	O
/	O
58	O
alleles	O
examined	O
)	O
.	O

A	O
PCR	O
-	O
based	O
diagnostic	O
test	O
,	O
which	O
detects	O
an	O
NlaIII	O
site	O
generated	O
by	O
the	O
mutation	O
,	O
revealed	O
a	O
frequency	O
among	O
enzyme	O
-	O
defined	O
carriers	O
of	O
9	O
/	O
64	O
(	O
14	O
%	O
)	O
.	O

Most	O
of	O
those	O
carrying	O
the	O
allele	O
trace	O
their	O
origins	O
to	O
the	O
United	O
Kingdom	O
,	O
Ireland	O
,	O
or	O
Western	O
Europe	O
.	O

It	O
was	O
not	O
identified	O
among	O
12	O
Black	O
American	O
TSD	B-Disease
alleles	O
or	O
in	O
any	O
of	O
18	O
Ashkenazi	O
Jewish	O
,	O
enzyme	O
-	O
defined	O
carriers	O
who	O
did	O
not	O
carry	O
any	O
of	O
the	O
mutations	O
common	O
to	O
this	O
population	O
.	O

No	O
normally	O
spliced	O
RNA	O
was	O
detected	O
in	O
PCR	O
products	O
generated	O
from	O
reverse	O
transcription	O
of	O
RNA	O
carrying	O
the	O
IVS	O
-	O
9	O
mutation	O
.	O

Instead	O
,	O
the	O
low	O
levels	O
of	O
mRNA	O
from	O
this	O
allele	O
were	O
comprised	O
of	O
aberrant	O
species	O
resulting	O
from	O
the	O
use	O
of	O
either	O
of	O
two	O
cryptic	O
donor	O
sites	O
,	O
one	O
truncating	O
exon	O
9	O
and	O
the	O
other	O
within	O
IVS	O
-	O
9	O
,	O
spliced	O
to	O
exon	O
10	O
.	O

Numerous	O
additional	O
splice	O
products	O
were	O
detected	O
,	O
most	O
involving	O
skipping	O
of	O
one	O
or	O
more	O
surrounding	O
exons	O
.	O

Together	O
with	O
a	O
recently	O
identified	O
allele	O
responsible	O
for	O
Hex	O
A	O
pseudodeficiency	O
(	O
Triggs	O
-	O
Raine	O
et	O
al	O
.	O
Am	O
J	O
Hum	O
Genet	O
,	O
1992	O
)	O
,	O
these	O
two	O
alleles	O
accounted	O
for	O
almost	O
50	O
%	O
(	O
29	O
/	O
64	O
)	O
of	O
TSD	B-Disease
or	O
carrier	O
alleles	O
ascertained	O
by	O
enzyme	O
screening	O
tests	O
in	O
non	O
-	O
Jewish	O
Caucasians	O
.	O
.	O

Aberrant	O
splicing	O
of	O
the	O
CHM	B-Disease
gene	O
is	O
a	O
significant	O
cause	O
of	O
choroideremia	B-Disease
.	O

Choroideremia	B-Disease
(	O
CHM	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
progressive	I-Disease
degeneration	I-Disease
of	I-Disease
the	I-Disease
choroid	I-Disease
and	I-Disease
retina	I-Disease
.	O

12	O
%	O
of	O
unrelated	O
male	O
patients	O
carry	O
deletions	O
of	O
the	O
partially	O
cloned	O
CHM	B-Disease
gene	O
.	O

In	O
Finland	O
,	O
there	O
are	O
more	O
than	O
120	O
living	O
CHM	B-Disease
patients	O
belonging	O
to	O
eight	O
apparently	O
unrelated	O
pedigrees	O
.	O

Molecular	O
deletions	O
involving	O
the	O
CHM	B-Disease
gene	O
have	O
been	O
detected	O
in	O
three	O
families	O
.	O

We	O
have	O
screened	O
the	O
remaining	O
five	O
families	O
for	O
point	O
mutations	O
.	O

In	O
one	O
large	O
family	O
a	O
single	O
nucleotide	O
(	O
T	O
)	O
insertion	O
into	O
the	O
donor	O
splice	O
site	O
of	O
exon	O
C	O
leads	O
to	O
two	O
aberrantly	O
spliced	O
mRNAs	O
both	O
producing	O
a	O
premature	O
stop	O
codon	O
.	O

The	O
mutation	O
can	O
be	O
assayed	O
easily	O
by	O
amplification	O
and	O
digestion	O
with	O
Msel	O
.	O

Our	O
findings	O
provide	O
additional	O
evidence	O
for	O
the	O
pathogenetic	O
role	O
of	O
CHM	B-Disease
mutations	O
and	O
provide	O
a	O
diagnostic	O
tool	O
for	O
one	O
fifth	O
of	O
the	O
worlds	O
known	O
CHM	B-Disease
patients	O
.	O
.	O

Germline	O
intronic	O
and	O
exonic	O
mutations	O
in	O
the	O
Wilms	B-Disease
'	I-Disease
tumour	I-Disease
gene	O
(	O
WT1	O
)	O
affecting	O
urogenital	O
development	O
.	O

Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
human	O
developmental	B-Disease
disorder	I-Disease
affecting	O
the	O
urogenital	O
system	O
and	O
leading	O
to	O
renal	B-Disease
failure	I-Disease
,	O
intersex	B-Disease
disorders	I-Disease
and	O
Wilms	B-Disease
tumour	I-Disease
.	O

In	O
this	O
report	O
,	O
four	O
individuals	O
with	O
this	O
syndrome	O
are	O
described	O
carrying	O
germline	O
point	O
mutations	O
in	O
the	O
Wilms	B-Disease
tumour	I-Disease
suppressor	O
gene	O
,	O
WT1	O
.	O

Three	O
of	O
these	O
mutations	O
were	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
WT1	O
.	O

The	O
fourth	O
occurred	O
within	O
intron	O
9	O
,	O
preventing	O
splicing	O
at	O
one	O
of	O
the	O
alternatively	O
chosen	O
splice	O
donor	O
sites	O
of	O
exon	O
9	O
when	O
assayed	O
in	O
vitro	O
.	O

These	O
results	O
provide	O
genetic	O
evidence	O
for	O
distinct	O
functional	O
roles	O
of	O
the	O
WT1	O
isoforms	O
in	O
urogenital	O
development	O
.	O
.	O

Characterization	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
region	O
predicts	O
multiple	O
protein	O
isoform	O
-	O
encoding	O
mRNAs	O
.	O

The	O
mutation	O
underlying	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
has	O
been	O
identified	O
as	O
an	O
expansion	O
of	O
a	O
polymorphic	O
CTG	O
-	O
repeat	O
in	O
a	O
gene	O
encoding	O
protein	O
kinase	O
activity	O
.	O

Brain	O
and	O
heart	O
transcripts	O
of	O
the	O
DM	O
-	O
kinase	O
(	O
DMR	O
-	O
B15	O
)	O
gene	O
are	O
subject	O
to	O
alternative	O
RNA	O
splicing	O
in	O
both	O
human	O
and	O
mouse	O
.	O

The	O
unstable	O
[	O
CTG	O
]	O
5	O
-	O
30	O
motif	O
is	O
found	O
uniquely	O
in	O
humans	O
,	O
although	O
the	O
flanking	O
nucleotides	O
are	O
also	O
present	O
in	O
mouse	O
.	O

Characterization	O
of	O
the	O
DM	B-Disease
region	O
of	O
both	O
species	O
reveals	O
another	O
active	O
gene	O
(	O
DMR	O
-	O
N9	O
)	O
in	O
close	O
proximity	O
to	O
the	O
kinase	O
gene	O
.	O

DMR	O
-	O
N9	O
transcripts	O
,	O
mainly	O
expressed	O
in	O
brain	O
and	O
testis	O
,	O
possess	O
a	O
single	O
,	O
large	O
open	O
reading	O
frame	O
,	O
but	O
the	O
function	O
of	O
its	O
protein	O
product	O
is	O
unknown	O
.	O

Clinical	O
manifestation	O
of	O
DM	B-Disease
may	O
be	O
caused	O
by	O
the	O
expanded	O
CTG	O
-	O
repeat	O
compromising	O
the	O
(	O
alternative	O
)	O
expression	O
of	O
DM	O
-	O
kinase	O
or	O
DMR	O
-	O
N9	O
proteins	O
.	O
.	O

Fragile	B-Disease
X	I-Disease
syndrome	I-Disease
without	O
CCG	O
amplification	O
has	O
an	O
FMR1	O
deletion	O
.	O

We	O
describe	O
a	O
patient	O
with	O
typical	O
clinical	O
features	O
of	O
the	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
but	O
without	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B-Disease
X	I-Disease
or	O
an	O
amplified	O
CCG	O
trinucleotide	O
repeat	O
fragment	O
.	O

The	O
patient	O
has	O
a	O
previously	O
uncharacterized	O
submicroscopic	O
deletion	O
encompassing	O
the	O
CCG	O
repeat	O
,	O
the	O
entire	O
FMR1	O
gene	O
and	O
about	O
2	O
.	O

5	O
megabases	O
of	O
flanking	O
sequences	O
.	O

This	O
finding	O
confirms	O
that	O
the	O
fragile	B-Disease
X	I-Disease
phenotype	O
can	O
exist	O
,	O
without	O
amplification	O
of	O
the	O
CCG	O
repeat	O
or	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B-Disease
X	I-Disease
,	O
and	O
that	O
fragile	B-Disease
X	I-Disease
syndrome	I-Disease
is	O
a	O
genetically	O
homogeneous	O
disorder	O
involving	O
FMR1	O
.	O

We	O
also	O
found	O
random	O
X	O
-	O
inactivation	O
in	O
the	O
mother	O
of	O
the	O
patient	O
who	O
was	O
shown	O
to	O
be	O
a	O
carrier	O
of	O
this	O
deletion	O
.	O

Cloning	O
of	O
the	O
Huntington	B-Disease
disease	I-Disease
region	O
in	O
yeast	O
artificial	O
chromosomes	O
.	O

The	O
gene	O
responsible	O
for	O
Huntington	B-Disease
disease	I-Disease
has	O
been	O
localized	O
to	O
a	O
2	O
.	O

5	O
million	O
base	O
pair	O
(	O
Mb	O
)	O
region	O
between	O
the	O
loci	O
D4S10	O
and	O
D4S168	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
4	O
.	O

As	O
part	O
of	O
a	O
strategy	O
to	O
clone	O
the	O
HD	B-Disease
gene	O
on	O
the	O
basis	O
of	O
its	O
chromosomal	O
location	O
,	O
we	O
isolated	O
genomic	O
DNA	O
from	O
the	O
HD	B-Disease
region	O
as	O
a	O
set	O
of	O
overlapping	O
yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
clones	O
.	O

Twenty	O
-	O
eight	O
YAC	O
clones	O
were	O
identified	O
by	O
screening	O
human	O
YAC	O
libraries	O
with	O
twelve	O
PCR	O
-	O
based	O
sequence	O
-	O
tagged	O
sites	O
(	O
STSs	O
)	O
from	O
the	O
region	O
.	O

We	O
assembled	O
the	O
YAC	O
clones	O
into	O
overlapping	O
sets	O
by	O
hybridizing	O
them	O
to	O
a	O
large	O
number	O
of	O
DNA	O
probes	O
from	O
the	O
HD	B-Disease
region	O
,	O
including	O
the	O
STSs	O
.	O

In	O
addition	O
,	O
we	O
isolated	O
the	O
ends	O
of	O
the	O
human	O
DNA	O
inserts	O
of	O
most	O
of	O
the	O
YAC	O
clones	O
to	O
assist	O
in	O
the	O
construction	O
of	O
the	O
contig	O
.	O

Although	O
almost	O
half	O
of	O
the	O
YACs	O
appear	O
to	O
contain	O
chimeric	O
inserts	O
and	O
several	O
contain	O
internal	O
deletions	O
or	O
other	O
rearrangements	O
,	O
we	O
were	O
able	O
to	O
obtain	O
over	O
2	O
.	O

2	O
Mb	O
of	O
the	O
HD	B-Disease
region	O
in	O
YACs	O
,	O
including	O
one	O
continuous	O
segment	O
of	O
2	O
.	O

0	O
Mb	O
covering	O
the	O
region	O
that	O
most	O
likely	O
contains	O
the	O
HD	B-Disease
gene	O
.	O

Ten	O
of	O
the	O
twenty	O
eight	O
YAC	O
clones	O
comprise	O
a	O
minimal	O
set	O
spanning	O
the	O
2	O
.	O

2	O
Mb	O
.	O

These	O
clones	O
provide	O
reagents	O
for	O
the	O
complete	O
characterization	O
of	O
this	O
region	O
of	O
the	O
genome	O
and	O
for	O
the	O
eventual	O
isolation	O
of	O
the	O
HD	B-Disease
gene	O
.	O

Characterization	O
of	O
a	O
YAC	O
containing	O
part	O
or	O
all	O
of	O
the	O
Norrie	B-Disease
disease	I-Disease
locus	O
.	O

It	O
has	O
been	O
shown	O
from	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
that	O
the	O
monoamine	O
oxidase	O
genes	O
A	O
and	O
B	O
(	O
MAOA	O
&	O
MAOB	O
)	O
and	O
DXS7	O
loci	O
are	O
physically	O
very	O
close	O
.	O

We	O
have	O
therefore	O
extended	O
studies	O
on	O
their	O
relationship	O
through	O
the	O
characterisation	O
of	O
a	O
650	O
kb	O
YAC	O
isolated	O
using	O
L1	O
.	O

28	O
(	O
recognising	O
the	O
DXS7	O
locus	O
)	O
as	O
a	O
probe	O
.	O

Restriction	O
mapping	O
of	O
the	O
YAC	O
indicates	O
that	O
it	O
contains	O
both	O
MAOA	O
and	O
MAOB	O
genes	O
in	O
addition	O
to	O
the	O
DXS7	O
locus	O
.	O

The	O
map	O
derived	O
from	O
the	O
YL1	O
.	O

28	O
-	O
YAC	O
is	O
compatible	O
both	O
with	O
the	O
map	O
from	O
an	O
independently	O
derived	O
YAC	O
carrying	O
MAOA	O
and	O
B	O
genes	O
and	O
with	O
the	O
long	O
range	O
genomic	O
map	O
for	O
the	O
region	O
.	O

A	O
series	O
of	O
subclones	O
prepared	O
from	O
a	O
phage	O
library	O
(	O
lambda	O
DASH	O
II	O
)	O
of	O
the	O
YAC	O
have	O
been	O
characterised	O
and	O
have	O
been	O
employed	O
to	O
determine	O
the	O
end	O
point	O
of	O
the	O
deletion	O
of	O
a	O
Norrie	B-Disease
disease	I-Disease
(	O
NDP	B-Disease
)	O
patient	O
who	O
has	O
been	O
shown	O
to	O
lack	O
both	O
DXS7	O
and	O
MAO	O
coding	O
sequences	O
.	O

The	O
pattern	O
of	O
retention	O
of	O
subclones	O
in	O
the	O
deletion	O
patient	O
place	O
the	O
end	O
point	O
of	O
the	O
deletion	O
within	O
30	O
-	O
130	O
kb	O
of	O
the	O
proximal	O
end	O
of	O
the	O
YAC	O
.	O

By	O
combining	O
the	O
data	O
with	O
established	O
recombination	O
analysis	O
,	O
we	O
provide	O
evidence	O
that	O
all	O
or	O
part	O
of	O
the	O
NDP	O
lies	O
in	O
the	O
interval	O
of	O
approximately	O
250kb	O
within	O
the	O
YAC	O
.	O

Both	O
mutations	O
in	O
G6PD	O
A	O
-	O
are	O
necessary	O
to	O
produce	O
the	O
G6PD	B-Disease
deficient	I-Disease
phenotype	O
.	O

The	O
high	O
prevalence	O
of	O
glucose	B-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
African	O
populations	O
is	O
due	O
almost	O
entirely	O
to	O
the	O
enzyme	O
variant	O
A	O
-	O
,	O
which	O
differs	O
from	O
the	O
wild	O
-	O
type	O
G6PD	O
B	O
by	O
two	O
amino	O
acid	O
replacements	O
,	O
68	O
Val	O
-	O
-	O
>	O
Met	O
and	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
.	O

The	O
non	O
-	O
deficient	O
polymorphic	O
variant	O
G6PD	O
A	O
contains	O
only	O
the	O
mutation	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
.	O

The	O
frequencies	O
of	O
the	O
G6PD	O
A	O
and	O
of	O
the	O
G6PD	O
A	O
-	O
genes	O
in	O
parts	O
of	O
Africa	O
are	O
both	O
about	O
0	O
.	O

2	O
.	O

The	O
68	O
Val	O
-	O
-	O
>	O
Met	O
mutation	O
has	O
not	O
been	O
found	O
in	O
a	O
B	O
background	O
.	O

This	O
could	O
be	O
because	O
the	O
68	O
Val	O
-	O
-	O
>	O
Met	O
mutation	O
happened	O
to	O
arise	O
in	O
an	O
A	O
gene	O
in	O
the	O
first	O
instance	O
,	O
or	O
because	O
the	O
68	O
Val	O
-	O
-	O
>	O
Met	O
mutation	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
G6PD	B-Disease
deficiency	I-Disease
.	O

We	O
have	O
approached	O
this	O
question	O
by	O
producing	O
G6PD	O
B	O
,	O
A	O
,	O
A	O
-	O
,	O
and	O
G6PD	O
68	O
Val	O
-	O
-	O
>	O
Met	O
in	O
a	O
bacterial	O
expression	O
system	O
and	O
analysing	O
their	O
biochemical	O
properties	O
.	O

With	O
each	O
single	O
mutation	O
we	O
found	O
a	O
slight	O
decrease	O
in	O
both	O
the	O
specific	O
activity	O
and	O
the	O
yield	O
of	O
enzyme	O
when	O
compared	O
to	O
G6PD	O
B	O
.	O

When	O
both	O
mutations	O
were	O
introduced	O
together	O
,	O
there	O
was	O
a	O
roughly	O
additive	O
effect	O
on	O
specific	O
activity	O
,	O
but	O
a	O
much	O
more	O
drastic	O
effect	O
on	O
enzyme	O
yield	O
(	O
4	O
%	O
of	O
normal	O
)	O
.	O

This	O
synergistic	O
effect	O
was	O
also	O
demonstrated	O
on	O
thermal	O
stability	O
,	O
especially	O
at	O
low	O
NADP	O
concentrations	O
.	O

Comparable	O
results	O
were	O
produced	O
when	O
the	O
replacement	O
119	O
Gln	O
-	O
-	O
>	O
Glu	O
was	O
studied	O
instead	O
of	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
.	O

We	O
infer	O
that	O
the	O
coexistence	O
of	O
the	O
two	O
mutations	O
is	O
responsible	O
for	O
enzyme	B-Disease
deficiency	I-Disease
in	I-Disease
G6PD	I-Disease
A	O
-	O
because	O
they	O
act	O
synergistically	O
in	O
causing	O
instability	O
of	O
the	O
enzyme	O
.	O

Small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
,	O
an	O
expressed	O
gene	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
critical	O
region	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
is	O
associated	O
with	O
paternally	O
derived	O
chromosomal	O
deletions	O
in	O
region	O
15q11	O
-	O
13	O
or	O
with	O
maternal	B-Disease
disomy	I-Disease
for	I-Disease
chromosome	I-Disease
15	I-Disease
.	O

Therefore	O
,	O
loss	O
of	O
the	O
expressed	O
paternal	O
alleles	O
of	O
maternally	O
imprinted	O
genes	O
must	O
be	O
responsible	O
for	O
the	O
PWS	B-Disease
phenotype	O
.	O

We	O
have	O
mapped	O
the	O
gene	O
encoding	O
the	O
small	O
nuclear	O
RNA	O
associated	O
polypeptide	O
SmN	O
(	O
SNRPN	O
)	O
to	O
human	O
chromosome	O
15q12	O
and	O
a	O
processed	O
pseudogene	O
SNRPNP1	O
to	O
chromosome	O
region	O
6pter	O
-	O
p21	O
.	O

Furthermore	O
,	O
SNRPN	O
was	O
mapped	O
to	O
the	O
minimal	O
deletion	O
interval	O
that	O
is	O
critical	O
for	O
PWS	B-Disease
.	O

The	O
fact	O
that	O
the	O
mouse	O
Snrpn	O
gene	O
is	O
maternally	O
imprinted	O
in	O
brain	O
suggests	O
that	O
loss	O
of	O
the	O
paternally	O
derived	O
SNRPN	O
allele	O
may	O
be	O
involved	O
in	O
the	O
PWS	B-Disease
phenotype	O
.	O
.	O

The	O
presence	O
of	O
two	O
different	O
infantile	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
mutations	O
in	O
a	O
Cajun	O
population	O
.	O

A	O
study	O
was	O
undertaken	O
to	O
characterize	O
the	O
mutation	O
(	O
s	O
)	O
responsible	O
for	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
in	O
a	O
Cajun	O
population	O
in	O
southwest	O
Louisiana	O
and	O
to	O
identify	O
the	O
origins	O
of	O
these	O
mutations	O
.	O

Eleven	O
of	O
12	O
infantile	O
TSD	B-Disease
alleles	O
examined	O
in	O
six	O
families	O
had	O
the	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
alpha	O
-	O
subunit	O
exon	O
11	O
insertion	O
mutation	O
that	O
is	O
present	O
in	O
approximately	O
70	O
%	O
of	O
Ashkenazi	O
Jewish	O
TSD	B-Disease
heterozygotes	O
.	O

The	O
mutation	O
in	O
the	O
remaining	O
allele	O
was	O
a	O
single	O
-	O
base	O
transition	O
in	O
the	O
donor	O
splice	O
site	O
of	O
the	O
alpha	O
-	O
subunit	O
intron	O
9	O
.	O

To	O
determine	O
the	O
origins	O
of	O
these	O
two	O
mutations	O
in	O
the	O
Cajun	O
population	O
,	O
the	O
TSD	B-Disease
carrier	O
status	O
was	O
enzymatically	O
determined	O
for	O
90	O
members	O
of	O
four	O
of	O
the	O
six	O
families	O
,	O
and	O
extensive	O
pedigrees	O
were	O
constructed	O
for	O
all	O
carriers	O
.	O

A	O
single	O
ancestral	O
couple	O
from	O
France	O
was	O
found	O
to	O
be	O
common	O
to	O
most	O
of	O
the	O
carriers	O
of	O
the	O
exon	O
11	O
insertion	O
.	O

Pedigree	O
data	O
suggest	O
that	O
this	O
mutation	O
has	O
been	O
in	O
the	O
Cajun	O
population	O
since	O
its	O
founding	O
over	O
2	O
centuries	O
ago	O
and	O
that	O
it	O
may	O
be	O
widely	O
distributed	O
within	O
the	O
population	O
.	O

In	O
contrast	O
,	O
the	O
intron	O
9	O
mutation	O
apparently	O
was	O
introduced	O
within	O
the	O
last	O
century	O
and	O
probably	O
is	O
limited	O
to	O
a	O
few	O
Louisiana	O
families	O
.	O
.	O

Mutations	O
in	O
the	O
candidate	O
gene	O
for	O
Norrie	B-Disease
disease	I-Disease
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
isolated	O
a	O
candidate	O
gene	O
for	O
X	B-Disease
linked	I-Disease
Norrie	I-Disease
disease	I-Disease
(	O
ND	B-Disease
)	O
which	O
was	O
found	O
to	O
be	O
deleted	O
or	O
disrupted	O
in	O
several	O
patients	O
.	O

As	O
a	O
prerequisite	O
for	O
the	O
identification	O
of	O
point	O
mutations	O
in	O
the	O
ND	B-Disease
gene	O
we	O
have	O
established	O
the	O
exon	O
-	O
intron	O
structure	O
of	O
this	O
gene	O
.	O

In	O
17	O
unrelated	O
patients	O
and	O
15	O
controls	O
,	O
PCR	O
products	O
derived	O
from	O
the	O
promoter	O
region	O
,	O
exons	O
1	O
and	O
2	O
as	O
well	O
as	O
the	O
coding	O
part	O
of	O
exon	O
3	O
were	O
analysed	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
.	O

In	O
12	O
patients	O
altered	O
PCR	O
fragments	O
were	O
detected	O
which	O
were	O
studied	O
in	O
detail	O
by	O
direct	O
sequencing	O
.	O

Eleven	O
different	O
mutations	O
were	O
found	O
,	O
and	O
all	O
but	O
one	O
are	O
likely	O
to	O
give	O
rise	O
to	O
significant	O
structural	O
changes	O
in	O
the	O
predicted	O
protein	O
.	O

These	O
findings	O
,	O
and	O
the	O
absence	O
of	O
functionally	O
relevant	O
base	O
changes	O
in	O
healthy	O
controls	O
,	O
emphasize	O
the	O
causal	O
role	O
of	O
this	O
candidate	O
gene	O
in	O
Norrie	B-Disease
disease	I-Disease
and	O
pave	O
the	O
way	O
for	O
reliable	O
diagnosis	O
and	O
carrier	O
detection	O
.	O
.	O

Detection	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
dystrophin	O
gene	O
by	O
multiple	O
SSCP	O
.	O

A	O
combination	O
of	O
multiplex	O
PCR	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
was	O
employed	O
to	O
screen	O
for	O
point	O
mutations	O
in	O
the	O
human	O
dystrophin	O
gene	O
.	O

Co	O
-	O
amplification	O
of	O
11	O
exons	O
from	O
genomic	O
DNA	O
of	O
Duchenne	B-Disease
and	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
/	O
BMD	B-Disease
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
SSCP	O
analysis	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
Duchenne	B-Disease
patient	O
identified	O
by	O
this	O
approach	O
.	O

The	O
mutation	O
introduces	O
a	O
termination	O
codon	O
within	O
exon	O
8	O
of	O
the	O
dystrophin	O
gene	O
.	O

It	O
is	O
predicted	O
to	O
cause	O
a	O
very	O
premature	O
translational	O
termination	O
accounting	O
for	O
the	O
severe	O
phenotype	O
observed	O
.	O

The	O
patient	O
inherited	O
this	O
mutation	O
from	O
his	O
mother	O
.	O

In	O
addition	O
the	O
analysis	O
revealed	O
5	O
polymorphisms	O
useful	O
for	O
internal	O
control	O
.	O
.	O

Proliferation	O
-	O
related	O
expression	O
of	O
p19	O
/	O
nm23	O
nucleoside	O
diphosphate	O
kinase	O
.	O

High	O
level	O
expression	O
of	O
the	O
nm23	O
-	O
H1	O
gene	O
,	O
which	O
encodes	O
for	O
a	O
nucleoside	O
diphosphate	O
kinase	O
,	O
has	O
been	O
found	O
to	O
correlate	O
with	O
diminished	O
metastasis	O
in	O
some	O
tumors	B-Disease
but	O
not	O
in	O
others	O
.	O

We	O
have	O
previously	O
identified	O
the	O
protein	O
product	O
of	O
the	O
nm23	O
-	O
H1	O
gene	O
in	O
two	O
-	O
dimensional	O
electrophoretic	O
gels	O
and	O
have	O
designated	O
it	O
p19	O
/	O
nm23	O
.	O

In	O
neuroblastoma	B-Disease
,	O
higher	O
levels	O
of	O
p19	O
/	O
nm23	O
,	O
which	O
are	O
associated	O
with	O
amplification	O
of	O
the	O
N	O
-	O
myc	O
oncogene	O
,	O
large	O
tumor	B-Disease
mass	O
,	O
and	O
metastasis	O
,	O
were	O
observed	O
in	O
advanced	O
stage	O
tumors	B-Disease
compared	O
with	O
limited	O
stage	O
disease	O
.	O

Because	O
of	O
the	O
variable	O
expression	O
of	O
nm23	O
-	O
H1	O
in	O
different	O
tumors	B-Disease
,	O
we	O
have	O
investigated	O
the	O
relationship	O
between	O
amounts	O
of	O
the	O
protein	O
and	O
cell	O
proliferation	O
.	O

The	O
levels	O
of	O
p19	O
/	O
nm23	O
were	O
compared	O
between	O
resting	O
and	O
mitotically	O
stimulated	O
normal	O
human	O
PBLs	O
and	O
in	O
leukemia	B-Disease
cells	O
.	O

The	O
amount	O
of	O
p19	O
/	O
nm23	O
increased	O
in	O
normal	O
lymphocytes	O
in	O
response	O
to	O
mitotic	O
stimulation	O
and	O
paralleled	O
the	O
increase	O
in	O
DNA	O
synthesis	O
.	O

In	O
leukemia	B-Disease
cells	O
obtained	O
from	O
patients	O
with	O
different	O
subtypes	O
of	O
acute	B-Disease
leukemia	I-Disease
,	O
p19	O
/	O
nm23	O
levels	O
were	O
also	O
increased	O
relative	O
to	O
resting	O
normal	O
lymphocytes	O
.	O

Treatment	O
of	O
mitotically	O
stimulated	O
lymphocytes	O
with	O
cyclosporin	O
,	O
which	O
inhibits	O
proliferation	O
,	O
blocked	O
the	O
increase	O
in	O
p19	O
/	O
nm23	O
;	O
treatment	O
of	O
the	O
leukemia	B-Disease
cell	O
line	O
HL	O
-	O
60	O
with	O
dimethylsulfoxide	O
,	O
which	O
induces	O
terminal	O
differentiation	O
,	O
resulted	O
in	O
diminished	O
levels	O
of	O
p19	O
/	O
nm23	O
.	O

Our	O
data	O
therefore	O
provide	O
evidence	O
that	O
nm23	O
-	O
H1	O
expression	O
is	O
related	O
to	O
cell	O
proliferative	O
activity	O
.	O
.	O

An	O
intrachromosomal	O
insertion	O
causing	O
5q22	O
deletion	O
and	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
in	O
two	O
generations	O
.	O

We	O
report	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
FAPC	B-Disease
)	O
with	O
epidermoid	B-Disease
cysts	I-Disease
,	O
osteomata	B-Disease
,	O
and	O
areas	O
of	O
congenital	B-Disease
hypertrophy	I-Disease
of	I-Disease
the	I-Disease
retinal	I-Disease
pigment	I-Disease
epithelium	I-Disease
(	O
CHRPEs	B-Disease
)	O
in	O
a	O
male	O
patient	O
and	O
his	O
maternal	O
aunt	O
,	O
both	O
of	O
whom	O
suffered	O
a	O
mild	O
to	O
moderate	O
degree	O
of	O
mental	B-Disease
handicap	I-Disease
.	O

Both	O
had	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
(	O
del	O
(	O
5	O
)	O
(	O
q22q23	O
.	O
2	O
)	O
)	O
.	O

Two	O
other	O
normal	O
family	O
members	O
had	O
the	O
underlying	O
direct	O
insertion	O
of	O
chromosome	O
5	O
(	O
dir	O
ins	O
(	O
5	O
)	O
(	O
q31	O
.	O
3q22q23	O
3q22q23	O
.	O
2	O
)	O
)	O
.	O

Molecular	O
genetic	O
and	O
fluorescent	O
hybridisation	O
studies	O
have	O
shown	O
that	O
loci	O
D5S37	O
and	O
D5S98	O
are	O
outside	O
the	O
deletion	O
whereas	O
loci	O
detected	O
by	O
probes	O
EF5	O
.	O

44	O
and	O
YN5	O
.	O

48	O
are	O
lost	O
.	O

As	O
expected	O
,	O
the	O
molecular	O
analyses	O
indicate	O
loss	O
of	O
one	O
allele	O
at	O
the	O
MCC	O
and	O
APC	B-Disease
loci	O
.	O

The	O
APC	B-Disease
gene	O
is	O
located	O
within	O
band	O
5q22	O
.	O

Familial	O
direct	O
insertions	O
should	O
be	O
considered	O
as	O
a	O
cause	O
of	O
recurrent	O
microdeletion	O
syndromes	O
.	O

Chromosome	O
mapping	O
of	O
the	O
rod	O
photoreceptor	O
cGMP	O
phosphodiesterase	O
beta	O
-	O
subunit	O
gene	O
in	O
mouse	O
and	O
human	O
:	O
tight	O
linkage	O
to	O
the	O
Huntington	B-Disease
disease	I-Disease
region	O
(	O
4p16	O
.	O
3	O
)	O
.	O

The	O
retinal	B-Disease
degeneration	I-Disease
mouse	O
(	O
gene	O
symbol	O
,	O
rd	O
)	O
is	O
an	O
animal	O
model	O
for	O
certain	O
forms	O
of	O
human	O
hereditary	B-Disease
retinopathies	I-Disease
.	O

Recent	O
findings	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
rd	O
mouse	O
PDE	O
beta	O
-	O
subunit	O
gene	O
(	O
Pdeb	O
)	O
prompted	O
us	O
to	O
investigate	O
the	O
chromosome	O
locations	O
of	O
the	O
mouse	O
and	O
human	O
genes	O
.	O

We	O
have	O
utilized	O
backcross	O
analysis	O
in	O
mice	O
to	O
verify	O
and	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
Pdeb	O
locus	O
6	O
.	O

1	O
+	O
/	O
-	O
2	O
.	O

3	O
cM	O
distal	O
of	O
Mgsa	O
on	O
mouse	O
chromosome	O
5	O
.	O

We	O
have	O
determined	O
that	O
the	O
human	O
gene	O
(	O
PDEB	O
)	O
maps	O
to	O
4p16	O
.	O

3	O
,	O
very	O
close	O
to	O
the	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
region	O
.	O

Analysis	O
of	O
the	O
comparative	O
map	O
for	O
mice	O
and	O
humans	O
shows	O
that	O
the	O
mouse	O
homologue	O
of	O
the	O
HD	B-Disease
gene	O
will	O
reside	O
on	O
chromosome	O
5	O
.	O

Linkage	O
of	O
the	O
mouse	O
Pdeb	O
locus	O
with	O
other	O
homologues	O
in	O
the	O
human	O
4p16	O
.	O

3	O
region	O
is	O
maintained	O
but	O
gene	O
order	O
is	O
not	O
,	O
suggesting	O
at	O
least	O
three	O
possible	O
sites	O
for	O
the	O
corresponding	O
mouse	O
HD	B-Disease
gene	O
.	O

Coincident	O
Kaposi	B-Disease
sarcoma	I-Disease
and	O
T	B-Disease
-	I-Disease
cell	I-Disease
lymphoma	I-Disease
in	O
a	O
patient	O
with	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
.	O

A	O
24	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
eczema	B-Disease
,	O
recurrent	O
mild	O
infections	O
,	O
and	O
thrombocytopenia	B-Disease
consistent	O
with	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
presented	O
with	O
a	O
mediastinal	O
mass	O
,	O
generalized	O
lymphadenopathy	B-Disease
,	O
splenomegaly	B-Disease
,	O
and	O
severe	O
thrombocytopenia	B-Disease
.	O

Studies	O
of	O
immune	O
function	O
including	O
immunoglobulin	O
levels	O
and	O
T	O
-	O
cell	O
subsets	O
were	O
normal	O
.	O

Furthermore	O
,	O
his	O
T	O
lymphocytes	O
proliferated	O
normally	O
in	O
response	O
to	O
phytohemagglutinin	O
,	O
concanavalin	O
A	O
,	O
and	O
the	O
combination	O
of	O
neuraminidase	O
/	O
galactose	O
oxidase	O
.	O

However	O
,	O
their	O
proliferative	O
responses	O
to	O
anti	O
-	O
CD43	O
antibody	O
and	O
periodate	O
were	O
diminished	O
,	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
WAS	B-Disease
.	O

An	O
initial	O
inguinal	O
lymph	O
node	O
biopsy	O
surprisingly	O
revealed	O
Kaposi	B-Disease
sarcoma	I-Disease
.	O

However	O
,	O
following	O
splenectomy	O
to	O
increase	O
the	O
platelet	O
count	O
,	O
biopsy	O
of	O
the	O
mediastinal	O
mass	O
revealed	O
T	B-Disease
-	I-Disease
cell	I-Disease
large	I-Disease
cell	I-Disease
lymphoma	I-Disease
.	O

Studies	O
of	O
biopsied	O
tissue	O
for	O
the	O
presence	O
of	O
Epstein	B-Disease
-	I-Disease
Barr	I-Disease
virus	I-Disease
and	O
cytomegalovirus	B-Disease
were	O
negative	O
,	O
as	O
were	O
studies	O
of	O
blood	O
,	O
including	O
the	O
polymerase	O
chain	O
reaction	O
,	O
for	O
the	O
presence	O
of	O
the	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	O
HIV	B-Disease
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
Kaposi	B-Disease
sarcoma	I-Disease
arising	O
in	O
a	O
patient	O
with	O
a	O
congenital	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
.	O

Although	O
Kaposi	B-Disease
sarcoma	I-Disease
can	O
arise	O
in	O
the	O
face	O
of	O
the	O
severe	O
immunosuppression	O
that	O
follows	O
allograft	O
transplantation	O
and	O
in	O
patients	O
infected	O
with	O
HIV	B-Disease
,	O
we	O
postulate	O
that	O
longevity	O
in	O
the	O
face	O
of	O
mild	O
immunosuppression	O
was	O
the	O
major	O
factor	O
in	O
the	O
development	O
of	O
Kaposi	B-Disease
sarcoma	I-Disease
in	O
this	O
patient	O
.	O
.	O

The	O
APC	B-Disease
gene	O
,	O
responsible	O
for	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
,	O
is	O
mutated	O
in	O
human	O
gastric	B-Disease
cancer	I-Disease
.	O

Although	O
gastric	B-Disease
cancer	I-Disease
is	O
the	O
most	O
common	O
cancer	B-Disease
in	O
the	O
world	O
,	O
genetic	O
changes	O
during	O
its	O
carcinogenesis	O
are	O
not	O
well	O
understood	O
.	O

Since	O
some	O
gastric	B-Disease
cancers	I-Disease
are	O
considered	O
to	O
originate	O
from	O
the	O
intestinal	O
metaplasia	O
,	O
it	O
is	O
likely	O
that	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
,	O
the	O
mutation	O
of	O
which	O
causes	O
adenomatous	B-Disease
polyps	I-Disease
in	I-Disease
the	I-Disease
colon	I-Disease
,	O
is	O
associated	O
with	O
carcinogenesis	O
of	O
gastric	B-Disease
cancer	I-Disease
.	O

Based	O
on	O
this	O
idea	O
,	O
DNAs	O
isolated	O
from	O
gastric	B-Disease
cancers	I-Disease
were	O
examined	O
by	O
means	O
of	O
a	O
RNase	O
protection	O
analysis	O
coupled	O
with	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products	O
.	O

By	O
screening	O
nearly	O
one	O
-	O
half	O
of	O
the	O
coding	O
region	O
of	O
the	O
APC	B-Disease
gene	O
in	O
44	O
tumors	B-Disease
,	O
somatic	O
mutations	O
were	O
detected	O
in	O
three	O
tumors	B-Disease
a	O
missense	O
mutation	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
5	O
-	O
base	O
pair	O
deletion	O
resulting	O
in	O
a	O
frame	O
shift	O
which	O
causes	O
truncation	O
of	O
the	O
gene	O
product	O
.	O

These	O
results	O
suggest	O
that	O
the	O
mutation	O
of	O
the	O
APC	B-Disease
gene	O
also	O
plays	O
an	O
important	O
role	O
during	O
the	O
carcinogenesis	O
of	O
at	O
least	O
some	O
gastric	B-Disease
cancers	I-Disease
.	O
.	O

A	O
71	O
-	O
kilodalton	O
protein	O
is	O
a	O
major	O
product	O
of	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
.	O

The	O
known	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
products	O
,	O
the	O
muscle	O
-	O
and	O
brain	O
-	O
type	O
dystrophin	O
isoforms	O
,	O
are	O
427	O
-	O
kDa	O
proteins	O
translated	O
from	O
14	O
-	O
kilobase	O
(	O
kb	O
)	O
mRNAs	O
.	O

Recently	O
we	O
described	O
a	O
6	O
.	O

5	O
-	O
kb	O
mRNA	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
DMD	B-Disease
gene	O
.	O

Cloning	O
and	O
in	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
entire	O
coding	O
region	O
show	O
that	O
the	O
6	O
.	O

5	O
-	O
kb	O
mRNA	O
encodes	O
a	O
70	O
.	O

8	O
-	O
kDa	O
protein	O
that	O
is	O
a	O
major	O
product	O
of	O
the	O
DMD	B-Disease
gene	O
.	O

It	O
contains	O
the	O
C	O
-	O
terminal	O
and	O
the	O
cysteine	O
-	O
rich	O
domains	O
of	O
dystrophin	O
,	O
seven	O
additional	O
amino	O
acids	O
at	O
the	O
N	O
terminus	O
,	O
and	O
some	O
modifications	O
formed	O
by	O
alternative	O
splicing	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

It	O
lacks	O
the	O
entire	O
large	O
domain	O
of	O
spectrin	O
-	O
like	O
repeats	O
and	O
the	O
actin	O
-	O
binding	O
N	O
-	O
terminal	O
domain	O
of	O
dystrophin	O
.	O

This	O
protein	O
is	O
the	O
major	O
DMD	B-Disease
gene	O
product	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
but	O
is	O
undetectable	O
in	O
skeletal	O
muscle	O
extracts	O
.	O

Correlation	O
between	O
the	O
location	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
and	O
the	O
number	O
of	O
colorectal	B-Disease
polyps	I-Disease
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
.	O

Recently	O
we	O
have	O
isolated	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
which	O
causes	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
,	O
and	O
its	O
germ	O
-	O
line	O
mutations	O
in	O
a	O
substantial	O
number	O
of	O
FAP	B-Disease
patients	O
have	O
been	O
identified	O
.	O

On	O
the	O
basis	O
of	O
this	O
information	O
,	O
we	O
compared	O
the	O
location	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
in	O
22	O
unrelated	O
patients	O
(	O
12	O
of	O
whom	O
have	O
been	O
reported	O
previously	O
)	O
with	O
the	O
number	O
of	O
colorectal	B-Disease
polyps	I-Disease
developed	O
in	O
FAP	B-Disease
patients	O
;	O
17	O
were	O
sparse	O
types	O
and	O
five	O
were	O
profuse	O
types	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
considered	O
to	O
cause	O
truncation	O
of	O
the	O
gene	O
product	O
by	O
frame	O
-	O
shift	O
due	O
to	O
deletion	O
(	O
14	O
cases	O
)	O
or	O
nonsense	O
mutation	O
(	O
seven	O
cases	O
)	O
.	O

The	O
location	O
of	O
the	O
germ	O
-	O
line	O
mutations	O
seems	O
to	O
correlate	O
with	O
the	O
two	O
clinical	O
types	O
;	O
germ	O
-	O
line	O
mutations	O
in	O
five	O
FAP	B-Disease
patients	O
with	O
profuse	O
polyps	B-Disease
were	O
observed	O
between	O
codon	O
1250	O
and	O
codon	O
1464	O
,	O
whereas	O
mutations	O
in	O
17	O
FAP	B-Disease
patients	O
with	O
fewer	O
polyps	B-Disease
were	O
observed	O
in	O
the	O
other	O
regions	O
of	O
the	O
APC	B-Disease
gene	O
.	O

The	O
result	O
suggests	O
that	O
the	O
number	O
of	O
colorectal	B-Disease
polyps	I-Disease
in	O
FAP	B-Disease
patients	O
may	O
be	O
associated	O
with	O
a	O
difference	O
in	O
the	O
stability	O
or	O
biological	O
function	O
of	O
the	O
truncated	O
APC	B-Disease
protein	O
.	O
.	O

Identification	O
and	O
rapid	O
detection	O
of	O
three	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
mutations	O
in	O
the	O
Moroccan	O
Jewish	O
population	O
.	O

Infantile	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
result	O
in	O
the	O
complete	O
absence	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
activity	O
.	O

It	O
is	O
well	O
known	O
that	O
an	O
elevated	O
frequency	O
of	O
TSD	B-Disease
mutations	O
exists	O
among	O
Ashkenazi	O
Jews	O
.	O

More	O
recently	O
it	O
has	O
become	O
apparent	O
that	O
elevated	O
carrier	O
frequencies	O
for	O
TSD	B-Disease
also	O
occur	O
in	O
several	O
other	O
ethnic	O
groups	O
,	O
including	O
Moroccan	O
Jews	O
,	O
a	O
subgroup	O
of	O
Sephardic	O
Jews	O
.	O

Elsewhere	O
we	O
reported	O
an	O
in	O
-	O
frame	O
deletion	O
of	O
one	O
of	O
the	O
two	O
adjacent	O
phenylalanine	O
codons	O
at	O
position	O
304	O
or	O
305	O
(	O
delta	O
F304	O
/	O
305	O
)	O
in	O
one	O
HEXA	O
allele	O
of	O
a	O
Moroccan	O
Jewish	O
TSD	B-Disease
patient	O
and	O
in	O
three	O
obligate	O
carriers	O
from	O
six	O
unrelated	O
Moroccan	O
Jewish	O
families	O
.	O

We	O
have	O
now	O
identified	O
two	O
additional	O
mutations	O
within	O
exon	O
5	O
of	O
the	O
HEXA	O
gene	O
that	O
account	O
for	O
the	O
remaining	O
TSD	B-Disease
alleles	O
in	O
the	O
patient	O
and	O
carriers	O
.	O

One	O
of	O
the	O
mutations	O
is	O
a	O
novel	O
C	O
-	O
to	O
-	O
G	O
transversion	O
,	O
resulting	O
in	O
a	O
replacement	O
of	O
Tyr180	O
by	O
a	O
stop	O
codon	O
.	O

The	O
other	O
mutation	O
is	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
resulting	O
in	O
an	O
Arg170	O
-	O
to	O
-	O
Gln	O
substitution	O
.	O

This	O
mutation	O
is	O
at	O
a	O
CpG	O
site	O
in	O
a	O
Japanese	O
infant	O
with	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
and	O
was	O
described	O
elsewhere	O
.	O

Analysis	O
of	O
nine	O
obligate	O
carriers	O
from	O
seven	O
unrelated	O
families	O
showed	O
that	O
four	O
harbor	O
the	O
delta	O
F304	O
/	O
305	O
mutation	O
,	O
two	O
the	O
Arg170	O
-	O
-	O
-	O
-	O
Gln	O
mutation	O
,	O
and	O
one	O
the	O
Tyr180	O
-	O
-	O
-	O
-	O
Stop	O
mutation	O
.	O

We	O
also	O
have	O
developed	O
rapid	O
,	O
nonradioactive	O
assays	O
for	O
the	O
detection	O
of	O
each	O
mutation	O
,	O
which	O
should	O
be	O
helpful	O
for	O
carrier	O
screening	O
.	O
.	O

Molecular	O
characterization	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
by	O
natural	O
and	O
amplification	O
created	O
restriction	O
sites	O
:	O
five	O
mutations	O
account	O
for	O
most	O
G6PD	B-Disease
deficiency	I-Disease
cases	O
in	O
Taiwan	O
.	O

We	O
have	O
developed	O
a	O
rapid	O
and	O
simple	O
method	O
to	O
diagnose	O
the	O
molecular	O
defects	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
Chinese	O
in	O
Taiwan	O
.	O

This	O
method	O
involves	O
the	O
selective	O
amplification	O
of	O
a	O
DNA	O
fragment	O
from	O
human	O
G6PD	O
gene	O
with	O
specific	O
oligonucleotide	O
primers	O
followed	O
by	O
digestion	O
with	O
restriction	O
enzymes	O
that	O
recognize	O
artificially	O
created	O
or	O
naturally	O
occurring	O
restriction	O
sites	O
.	O

Ninety	O
-	O
four	O
Chinese	O
males	O
with	O
G6PD	B-Disease
deficiency	I-Disease
were	O
studied	O
.	O

The	O
results	O
show	O
that	O
50	O
%	O
(	O
47	O
of	O
94	O
)	O
were	O
G	O
to	O
T	O
mutation	O
at	O
nucleotide	O
(	O
nt	O
)	O
1376	O
,	O
21	O
.	O

3	O
%	O
(	O
20	O
of	O
94	O
)	O
were	O
G	O
to	O
A	O
mutation	O
at	O
nt	O
1388	O
,	O
7	O
.	O

4	O
%	O
(	O
7	O
of	O
94	O
)	O
were	O
A	O
to	O
G	O
mutation	O
at	O
nt	O
493	O
,	O
7	O
.	O

4	O
%	O
(	O
7	O
of	O
94	O
)	O
were	O
A	O
to	O
G	O
mutation	O
at	O
nt	O
95	O
,	O
4	O
.	O

2	O
%	O
(	O
4	O
of	O
94	O
)	O
were	O
C	O
to	O
T	O
mutation	O
at	O
nt	O
1024	O
,	O
1	O
.	O

1	O
%	O
(	O
1	O
of	O
94	O
)	O
was	O
G	O
to	O
T	O
mutation	O
at	O
nt	O
392	O
,	O
and	O
1	O
.	O

1	O
%	O
(	O
1	O
of	O
94	O
)	O
was	O
G	O
to	O
A	O
mutation	O
at	O
nt	O
487	O
.	O

These	O
results	O
show	O
that	O
the	O
former	O
five	O
mutations	O
account	O
for	O
more	O
than	O
90	O
%	O
of	O
G6PD	B-Disease
deficiency	I-Disease
cases	O
in	O
Taiwan	O
.	O

Aside	O
from	O
showing	O
that	O
G	O
to	O
T	O
change	O
at	O
nt	O
1376	O
is	O
the	O
most	O
common	O
mutation	O
,	O
our	O
research	O
indicates	O
that	O
nt	O
493	O
mutation	O
is	O
a	O
frequent	O
mutation	O
among	O
Chinese	O
in	O
Taiwan	O
.	O

We	O
compared	O
G6PD	O
activity	O
among	O
different	O
mutations	O
,	O
without	O
discovering	O
significant	O
differences	O
between	O
them	O
.	O

Eight	O
novel	O
inactivating	O
germ	O
line	O
mutations	O
at	O
the	O
APC	B-Disease
gene	O
identified	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
is	O
a	O
dominantly	O
inherited	O
condition	O
predisposing	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O

The	O
recent	O
isolation	O
of	O
the	O
responsible	O
gene	O
(	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
or	O
APC	B-Disease
)	O
has	O
facilitated	O
the	O
search	O
for	O
germ	O
line	O
mutations	O
in	O
affected	O
individuals	O
.	O

Previous	O
authors	O
have	O
used	O
the	O
RNase	O
protection	O
assay	O
and	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphisms	O
procedure	O
to	O
screen	O
for	O
mutations	O
.	O

In	O
this	O
study	O
we	O
used	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

DGGE	O
analysis	O
of	O
10	O
APC	B-Disease
exons	O
(	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
and	O
part	O
of	O
15	O
)	O
in	O
33	O
unrelated	O
Dutch	O
FAP	B-Disease
patients	O
has	O
led	O
to	O
the	O
identification	O
of	O
eight	O
novel	O
germ	O
line	O
mutations	O
resulting	O
in	O
stop	O
codons	O
or	O
frameshifts	O
.	O

The	O
results	O
reported	O
here	O
indicate	O
that	O
(	O
1	O
)	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
is	O
caused	O
by	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
point	O
mutations	O
;	O
(	O
2	O
)	O
all	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
chain	O
terminating	O
;	O
and	O
(	O
3	O
)	O
DGGE	O
represents	O
a	O
rapid	O
and	O
sensitive	O
technique	O
for	O
the	O
detection	O
of	O
mutations	O
in	O
the	O
unusually	O
large	O
APC	B-Disease
gene	O
.	O

An	O
extension	O
of	O
the	O
DGGE	O
analysis	O
to	O
the	O
entire	O
coding	O
region	O
in	O
a	O
sufficient	O
number	O
of	O
clinically	O
well	O
-	O
characterized	O
,	O
unrelated	O
patients	O
will	O
facilitate	O
the	O
establishment	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
occurrence	O
of	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
mutations	O
spread	O
throughout	O
the	O
entire	O
length	O
of	O
the	O
large	O
APC	B-Disease
gene	O
among	O
the	O
FAP	B-Disease
patients	O
indicates	O
that	O
this	O
approach	O
may	O
not	O
be	O
useful	O
as	O
a	O
rapid	O
presymptomatic	O
diagnostic	O
procedure	O
in	O
a	O
routine	O
laboratory	O
.	O

Nevertheless	O
,	O
the	O
above	O
DGGE	O
approach	O
has	O
incidentally	O
led	O
to	O
the	O
identification	O
of	O
a	O
common	O
polymorphism	O
in	O
exon	O
13	O
.	O

Such	O
intragenic	O
polymorphisms	O
offer	O
a	O
practical	O
approach	O
to	O
a	O
more	O
rapid	O
procedure	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	B-Disease
by	O
linkage	O
analysis	O
in	O
informative	O
families	O
.	O
.	O

Yeast	O
artificial	O
chromosomes	O
for	O
the	O
molecular	O
analysis	O
of	O
the	O
familial	B-Disease
polyposis	I-Disease
APC	I-Disease
gene	O
region	O
.	O

Two	O
yeast	O
artificial	O
chromosomes	O
(	O
YACs	O
)	O
spanning	O
a	O
total	O
distance	O
of	O
1	O
.	O

1	O
megabase	O
pairs	O
of	O
DNA	O
around	O
the	O
MCC	O
(	O
for	O
mutated	O
in	O
colorectal	B-Disease
carcinoma	I-Disease
)	O
and	O
APC	B-Disease
(	O
for	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
)	O
genes	O
at	O
5q21	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

Starting	O
from	O
the	O
MCC	O
gene	O
,	O
a	O
strategy	O
was	O
undertaken	O
to	O
identify	O
constitutional	O
submicroscopic	O
deletions	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
that	O
might	O
considerably	O
narrow	O
down	O
the	O
position	O
of	O
the	O
APC	B-Disease
gene	O
.	O

To	O
this	O
end	O
,	O
YACs	O
identified	O
by	O
the	O
MCC	O
gene	O
were	O
screened	O
across	O
a	O
chromosome	O
5	O
-	O
specific	O
cosmid	O
library	O
to	O
provide	O
a	O
source	O
of	O
DNA	O
probes	O
for	O
genomic	O
scanning	O
.	O

The	O
cosmids	O
isolated	O
from	O
these	O
experiments	O
were	O
used	O
to	O
screen	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
containing	O
chromosome	O
5	O
segregated	O
from	O
patients	O
suspected	O
to	O
carry	O
putative	O
interstitial	O
deletions	O
.	O

This	O
screening	O
approach	O
led	O
to	O
the	O
confirmation	O
of	O
a	O
small	O
heterozygous	O
deletion	O
in	O
a	O
polyposis	B-Disease
patient	O
that	O
overlaps	O
one	O
of	O
the	O
two	O
isolated	O
YACs	O
.	O

This	O
YAC	O
has	O
been	O
shown	O
to	O
contain	O
the	O
entire	O
APC	B-Disease
gene	O
,	O
in	O
addition	O
to	O
a	O
significant	O
portion	O
of	O
DNA	O
flanking	O
the	O
5	O
end	O
of	O
the	O
gene	O
,	O
and	O
should	O
therefore	O
prove	O
a	O
valuable	O
resource	O
for	O
functional	O
studies	O
by	O
transfer	O
to	O
colorectal	B-Disease
tumor	I-Disease
-	O
derived	O
cell	O
lines	O
.	O

Inherited	O
WT1	O
mutation	O
in	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
.	O

Patients	O
with	O
the	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
Wilms	B-Disease
tumor	I-Disease
,	O
genital	B-Disease
anomalies	I-Disease
,	O
and	O
nephropathy	B-Disease
)	O
have	O
been	O
demonstrated	O
to	O
carry	O
de	O
novo	O
constitutional	O
mutations	O
in	O
WT1	O
,	O
the	O
Wilms	B-Disease
tumor	I-Disease
gene	O
at	O
chromosome	O
11p13	O
.	O

We	O
report	O
three	O
new	O
cases	O
,	O
two	O
carrying	O
a	O
previously	O
described	O
WT1	O
exon	O
9	O
mutation	O
and	O
one	O
with	O
a	O
novel	O
WT1	O
exon	O
8	O
mutation	O
.	O

However	O
,	O
unlike	O
patients	O
in	O
previous	O
reports	O
,	O
one	O
of	O
our	O
three	O
patients	O
inherited	O
the	O
affected	O
allele	O
from	O
his	O
phenotypically	O
unaffected	O
father	O
.	O

This	O
observation	O
indicates	O
that	O
the	O
WT1	O
exon	O
9	O
mutation	O
affecting	O
394Arg	O
demonstrated	O
in	O
over	O
one	O
-	O
half	O
of	O
the	O
patients	O
with	O
the	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
may	O
exhibit	O
incomplete	O
penetrance	O
.	O

Consequently	O
,	O
familial	O
studies	O
in	O
patients	O
affected	O
by	O
this	O
syndrome	O
are	O
recommended	O
.	O
.	O

Submicroscopic	O
deletions	O
at	O
the	O
WAGR	B-Disease
locus	O
,	O
revealed	O
by	O
nonradioactive	O
in	O
situ	O
hybridization	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
biotin	O
-	O
labeled	O
probes	O
mapping	O
to	O
11p13	O
has	O
been	O
used	O
for	O
the	O
molecular	O
analysis	O
of	O
deletions	O
of	O
the	O
WAGR	B-Disease
(	O
Wilms	B-Disease
tumor	I-Disease
,	O
aniridia	B-Disease
,	O
genitourinary	B-Disease
abnormalities	I-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
)	O
locus	O
.	O

We	O
have	O
detected	O
a	O
submicroscopic	O
11p13	O
deletion	O
in	O
a	O
child	O
with	O
inherited	O
aniridia	B-Disease
who	O
subsequently	O
presented	O
with	O
Wilms	B-Disease
tumor	I-Disease
in	O
a	O
horseshoe	O
kidney	O
,	O
only	O
revealed	O
at	O
surgery	O
.	O

The	O
mother	O
,	O
who	O
has	O
aniridia	B-Disease
,	O
was	O
also	O
found	O
to	O
carry	O
a	O
deletion	O
including	O
both	O
the	O
aniridia	B-Disease
candidate	O
gene	O
(	O
AN2	O
)	O
and	O
the	O
Wilms	B-Disease
tumor	I-Disease
predisposition	O
gene	O
(	O
WT1	O
)	O
.	O

This	O
is	O
therefore	O
a	O
rare	O
case	O
of	O
an	O
inherited	O
WAGR	B-Disease
deletion	O
.	O

Wilms	B-Disease
tumor	I-Disease
has	O
so	O
far	O
only	O
been	O
associated	O
with	O
sporadic	O
de	O
novo	O
aniridia	B-Disease
cases	O
.	O

We	O
have	O
shown	O
that	O
a	O
cosmid	O
probe	O
for	O
a	O
candidate	O
aniridia	B-Disease
gene	O
,	O
homologous	O
to	O
the	O
mouse	O
Pax	O
-	O
6	O
gene	O
,	O
is	O
deleted	O
in	O
cell	O
lines	O
from	O
aniridia	B-Disease
patients	O
with	O
previously	O
characterized	O
deletions	O
at	O
11p13	O
,	O
while	O
another	O
cosmid	O
marker	O
mapping	O
between	O
two	O
aniridia	B-Disease
-	O
associated	O
translocation	O
breakpoints	O
(	O
and	O
hence	O
a	O
second	O
candidate	O
marker	O
)	O
is	O
present	O
on	O
both	O
chromosomes	O
.	O

These	O
results	O
support	O
the	O
Pax	O
-	O
6	O
homologue	O
as	O
a	O
strong	O
candidate	O
for	O
the	O
AN2	O
gene	O
.	O

FISH	O
with	O
cosmid	O
probes	O
has	O
proved	O
to	O
be	O
a	O
fast	O
and	O
reliable	O
technique	O
for	O
the	O
molecular	O
analysis	O
of	O
deletions	O
.	O

It	O
can	O
be	O
used	O
with	O
limited	O
amounts	O
of	O
material	O
and	O
has	O
strong	O
potential	O
for	O
clinical	O
applications	O
.	O
.	O

Linkage	O
of	O
gene	O
for	O
C2	B-Disease
deficiency	I-Disease
and	O
the	O
major	O
histocompatibility	O
complex	O
MHC	O
in	O
man	O
.	O

Family	O
study	O
of	O
a	O
further	O
case	O
.	O

Close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B-Disease
deficiency	I-Disease
was	O
first	O
reported	O
by	O
FU	O
and	O
co	O
-	O
workers	O
in	O
1974	O
.	O

We	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
C2	B-Disease
-	I-Disease
deficient	I-Disease
individual	O
with	O
clinical	O
manifestations	O
of	O
Hodgkins	B-Disease
disease	I-Disease
.	O

The	O
following	O
markers	O
were	O
tested	O
C2	O
levels	O
,	O
factor	O
B	O
polymorphism	O
,	O
blood	O
groups	O
,	O
and	O
enzyme	O
typing	O
.	O

In	O
addition	O
to	O
close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B-Disease
deficiency	I-Disease
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
Bf	O
(	O
HL	O
-	O
A	O
linked	O
,	O
electrophoretic	O
variation	O
of	O
B	O
)	O
.	O

The	O
two	O
HL	O
-	O
A	O
haplotypes	O
closely	O
linked	O
to	O
C2	B-Disease
deficiency	I-Disease
are	O
different	O
2	O
,	O
W18	O
and	O
W24	O
,	O
W18	O
.	O

They	O
share	O
,	O
however	O
,	O
the	O
SD2	O
antigen	O
W18	O
and	O
the	O
LD	O
type	O
7a	O
.	O
.	O

Screening	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
patients	O
:	O
61	O
new	O
patients	O
and	O
a	O
summary	O
of	O
150	O
unrelated	O
patients	O
.	O

We	O
report	O
here	O
the	O
result	O
of	O
a	O
screening	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
in	O
61	O
new	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
patients	O
as	O
well	O
as	O
a	O
summary	O
of	O
the	O
results	O
of	O
150	O
patients	O
.	O

Examination	O
of	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B-Disease
gene	O
,	O
based	O
on	O
a	O
ribonuclease	O
protection	O
assay	O
coupled	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
disclosed	O
mutations	O
that	O
were	O
considered	O
to	O
cause	O
significant	O
defects	O
in	O
the	O
APC	B-Disease
product	O
in	O
97	O
of	O
150	O
unrelated	O
FAP	B-Disease
patients	O
.	O

Our	O
findings	O
revealed	O
the	O
following	O
characteristics	O
of	O
the	O
germ	O
-	O
line	O
mutations	O
of	O
APC	O
1	O
)	O
the	O
great	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
to	O
truncate	O
the	O
APC	B-Disease
product	O
;	O
2	O
)	O
almost	O
all	O
of	O
the	O
mutations	O
were	O
located	O
within	O
the	O
first	O
half	O
of	O
the	O
coding	O
region	O
;	O
3	O
)	O
no	O
correlation	O
was	O
observed	O
between	O
the	O
locations	O
of	O
germ	O
-	O
line	O
mutations	O
and	O
extracolonic	O
manifestations	O
in	O
FAP	B-Disease
patients	O
;	O
4	O
)	O
more	O
than	O
80	O
%	O
of	O
base	O
substitutions	O
in	O
the	O
APC	B-Disease
gene	O
were	O
from	O
cytosine	O
to	O
other	O
nucleotides	O
,	O
nearly	O
one	O
-	O
third	O
of	O
which	O
occurred	O
at	O
the	O
GpG	O
site	O
.	O

Our	O
results	O
provide	O
information	O
helpful	O
to	O
an	O
understanding	O
of	O
the	O
APC	B-Disease
gene	O
and	O
will	O
also	O
contribute	O
to	O
presymptomatic	O
diagnosis	O
of	O
members	O
in	O
FAP	B-Disease
families	O
.	O
.	O

Somatic	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
colorectal	B-Disease
tumors	I-Disease
:	O
mutation	O
cluster	O
region	O
in	O
the	O
APC	B-Disease
gene	O
.	O

We	O
examined	O
somatic	O
mutations	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
in	O
63	O
colorectal	B-Disease
tumors	I-Disease
(	O
16	O
adenomas	B-Disease
and	O
47	O
carcinomas	B-Disease
)	O
developed	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
and	O
non	O
-	O
FAP	O
patients	O
.	O

In	O
addition	O
to	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
APC	B-Disease
locus	O
in	O
30	O
tumors	B-Disease
,	O
43	O
other	O
somatic	O
mutations	O
were	O
detected	O
.	O

Twenty	O
-	O
one	O
of	O
them	O
were	O
point	O
mutations	O
;	O
16	O
nonsense	O
and	O
two	O
missense	O
mutations	O
,	O
and	O
three	O
occurred	O
in	O
introns	O
at	O
the	O
splicing	O
site	O
.	O

Twenty	O
-	O
two	O
tumors	B-Disease
had	O
frameshift	O
mutations	O
due	O
to	O
deletion	O
or	O
insertion	O
;	O
nineteen	O
of	O
them	O
were	O
deletions	O
of	O
one	O
to	O
31	O
bp	O
and	O
three	O
were	O
a	O
1	O
-	O
bp	O
insertion	O
.	O

One	O
tumor	B-Disease
had	O
a	O
1	O
-	O
bp	O
deletion	O
in	O
an	O
intron	O
near	O
the	O
splicing	O
site	O
.	O

Hence	O
,	O
41	O
(	O
95	O
%	O
)	O
of	O
43	O
mutations	O
resulted	O
in	O
truncation	O
of	O
the	O
APC	B-Disease
protein	O
.	O

Over	O
60	O
%	O
of	O
the	O
somatic	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
were	O
clustered	O
within	O
a	O
small	O
region	O
of	O
exon	O
15	O
,	O
designated	O
as	O
MCR	O
(	O
mutation	O
cluster	O
region	O
)	O
,	O
which	O
accounted	O
for	O
less	O
than	O
10	O
%	O
of	O
the	O
coding	O
region	O
.	O

Combining	O
these	O
data	O
and	O
the	O
results	O
of	O
LOH	O
,	O
more	O
than	O
80	O
%	O
of	O
tumors	B-Disease
(	O
14	O
adenomas	B-Disease
and	O
39	O
carcinomas	B-Disease
)	O
had	O
at	O
least	O
one	O
mutation	O
in	O
the	O
APC	B-Disease
gene	O
,	O
of	O
which	O
more	O
than	O
60	O
%	O
(	O
9	O
adenomas	B-Disease
and	O
23	O
carcinomas	B-Disease
)	O
had	O
two	O
mutations	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
somatic	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
are	O
associated	O
with	O
development	O
of	O
a	O
great	O
majority	O
of	O
colorectal	B-Disease
tumors	I-Disease
.	O
.	O

Constitutional	O
mutations	O
in	O
the	O
WT1	O
gene	O
in	O
patients	O
with	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
.	O

The	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
is	O
characterised	O
by	O
a	O
typical	O
nephropathy	B-Disease
,	O
genital	B-Disease
abnormalities	I-Disease
and	O
also	O
predisposes	O
to	O
the	O
development	O
of	O
Wilms	B-Disease
tumor	I-Disease
.	O

These	O
patients	O
eventually	O
go	O
into	O
end	O
stage	O
renal	B-Disease
failure	I-Disease
.	O

A	O
candidate	O
Wilms	B-Disease
tumor	I-Disease
gene	O
,	O
WT1	O
,	O
from	O
the	O
11p13	O
chromosome	O
region	O
has	O
recently	O
been	O
cloned	O
.	O

We	O
have	O
analysed	O
the	O
DNA	O
sequence	O
in	O
constitutional	O
cells	O
from	O
eight	O
patients	O
and	O
have	O
shown	O
heterozygous	O
mutations	O
in	O
six	O
of	O
them	O
.	O

Four	O
of	O
the	O
mutations	O
were	O
in	O
exon	O
9	O
,	O
all	O
resulting	O
in	O
missense	O
mutations	O
.	O

Three	O
were	O
at	O
nucleotide	O
position	O
1180	O
resulting	O
in	O
an	O
arg	O
>	O
trp	O
amino	O
acid	O
change	O
.	O

The	O
other	O
was	O
at	O
position	O
1186	O
converting	O
an	O
asp	O
>	O
asn	O
in	O
the	O
predicted	O
resultant	O
protein	O
.	O

One	O
patient	O
had	O
a	O
missense	O
mutation	O
in	O
exon	O
8	O
,	O
converting	O
an	O
arg	O
>	O
his	O
.	O

A	O
single	O
base	O
pair	O
insertion	O
at	O
nucleotide	O
position	O
821	O
in	O
exon	O
6	O
resulted	O
in	O
the	O
generation	O
of	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
last	O
patient	O
.	O

We	O
were	O
unable	O
to	O
find	O
a	O
mutation	O
in	O
one	O
patient	O
despite	O
complete	O
sequencing	O
of	O
the	O
genomic	O
sequence	O
of	O
the	O
gene	O
.	O

The	O
last	O
patient	O
carried	O
a	O
constitutional	O
deletion	O
of	O
the	O
11p13	O
region	O
and	O
no	O
additional	O
mutation	O
was	O
found	O
.	O

There	O
was	O
no	O
obvious	O
correlation	O
between	O
the	O
type	O
of	O
mutation	O
and	O
phenotypic	O
expression	O
.	O

These	O
results	O
further	O
demonstrate	O
that	O
the	O
WT1	O
gene	O
is	O
important	O
in	O
both	O
the	O
development	O
of	O
the	O
kidney	O
and	O
the	O
genito	O
-	O
urinary	O
system	O
.	O
.	O

Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
founder	O
populations	O
:	O
diastrophic	B-Disease
dysplasia	I-Disease
in	O
Finland	O
.	O

Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
populations	O
provides	O
a	O
powerful	O
tool	O
for	O
fine	O
structure	O
localization	O
of	O
disease	O
genes	O
.	O

Here	O
,	O
Luria	O
and	O
Delbrucks	O
classical	O
methods	O
for	O
analysing	O
bacterial	O
cultures	O
are	O
adapted	O
to	O
the	O
study	O
of	O
human	O
isolated	O
founder	O
populations	O
in	O
order	O
to	O
estimate	O
(	O
i	O
)	O
the	O
recombination	O
fraction	O
between	O
a	O
disease	O
locus	O
and	O
a	O
marker	O
;	O
(	O
ii	O
)	O
the	O
expected	O
degree	O
of	O
allelic	O
homogeneity	O
in	O
a	O
population	O
;	O
and	O
(	O
iii	O
)	O
the	O
mutation	O
rate	O
of	O
marker	O
loci	O
.	O

Using	O
these	O
methods	O
,	O
we	O
report	O
striking	O
linkage	O
disequilibrium	O
for	O
diastrophic	B-Disease
dysplasia	I-Disease
(	O
DTD	B-Disease
)	O
in	O
Finland	O
indicating	O
that	O
the	O
DTD	B-Disease
gene	O
should	O
lie	O
within	O
0	O
.	O

06	O
centimorgans	O
(	O
or	O
about	O
60	O
kilobases	O
)	O
of	O
the	O
CSF1R	O
gene	O
.	O

Predictions	O
about	O
allelic	O
homogeneity	O
in	O
Finland	O
and	O
mutation	O
rates	O
in	O
simple	O
sequence	O
repeats	O
are	O
confirmed	O
by	O
independent	O
observations	O
.	O

The	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
:	O
refinement	O
of	O
the	O
localization	O
on	O
Xp	O
and	O
identification	O
of	O
another	O
closely	O
linked	O
marker	O
locus	O
,	O
OATL1	O
.	O

The	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
has	O
previously	O
been	O
mapped	O
to	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
between	O
the	O
DXS14	O
and	O
DXS7	O
loci	O
.	O

In	O
this	O
study	O
,	O
further	O
segregation	O
analysis	O
has	O
been	O
performed	O
using	O
a	O
newly	O
identified	O
WAS	B-Disease
family	O
as	O
well	O
as	O
an	O
additional	O
marker	O
probe	O
,	O
HOATL1	O
.	O

The	O
results	O
indicate	O
close	O
linkage	O
between	O
the	O
WAS	B-Disease
and	O
OATL1	O
loci	O
(	O
Z	O
=	O
6	O
.	O
08	O
at	O
theta	O
=	O
0	O
.	O
00	O
)	O
and	O
localize	O
the	O
TIMP	O
,	O
OATL1	O
,	O
DXS255	O
,	O
and	O
WAS	B-Disease
loci	O
distal	O
to	O
DXS146	O
and	O
the	O
OATL1	O
and	O
WAS	B-Disease
loci	O
proximal	O
to	O
TIMP	O
.	O

These	O
linkage	O
data	O
narrow	O
the	O
boundaries	O
within	O
which	O
the	O
WAS	B-Disease
locus	O
maps	O
to	O
the	O
chromosomal	O
region	O
bracketed	O
by	O
TIMP	O
and	O
DXS146	O
and	O
support	O
the	O
loci	O
order	O
Xpter	O
-	O
DXS7	O
-	O
TIMP	O
-	O
(	O
OATL1	O
,	O
WAS	O
,	O
DXS255	O
)	O
-	O
DXS146	O
.	O

Detection	O
of	O
an	O
unstable	O
fragment	O
of	O
DNA	O
specific	O
to	O
individuals	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
,	O
with	O
a	O
prevalence	O
of	O
2	O
-	O
14	O
per	O
100	O
,	O
000	O
individuals	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
progressive	O
muscle	B-Disease
weakness	I-Disease
and	O
sustained	B-Disease
muscle	I-Disease
contraction	I-Disease
,	O
often	O
with	O
a	O
wide	O
range	O
of	O
accompanying	O
symptoms	O
.	O

The	O
age	O
at	O
onset	O
and	O
severity	O
of	O
the	O
disease	O
show	O
extreme	O
variation	O
,	O
both	O
within	O
and	O
between	O
families	O
.	O

Despite	O
its	O
clinical	O
variability	O
,	O
this	O
dominant	O
condition	O
segregates	O
as	O
a	O
single	O
locus	O
at	O
chromosome	O
19q13	O
.	O

3	O
in	O
every	O
population	O
studied	O
.	O

It	O
is	O
flanked	O
by	O
the	O
tightly	O
linked	O
genetic	O
markers	O
ERCC1	O
proximally	O
and	O
D19S51	O
distally	O
;	O
these	O
define	O
the	O
DM	B-Disease
critical	O
region	O
.	O

We	O
report	O
the	O
isolation	O
of	O
an	O
expressed	O
sequence	O
from	O
this	O
region	O
which	O
detects	O
a	O
DNA	O
fragment	O
that	O
is	O
larger	O
in	O
affected	O
individuals	O
than	O
in	O
normal	O
siblings	O
or	O
unaffected	O
controls	O
.	O

The	O
size	O
of	O
this	O
fragment	O
varies	O
between	O
affected	O
siblings	O
,	O
and	O
increases	O
in	O
size	O
through	O
generations	O
in	O
parallel	O
with	O
increasing	O
severity	O
of	O
the	O
disease	O
.	O

We	O
postulate	O
that	O
this	O
unstable	O
DNA	O
sequence	O
is	O
the	O
molecular	O
feature	O
that	O
underlies	O
DM	B-Disease
.	O

Common	O
sequence	O
motifs	O
at	O
the	O
rearrangement	O
sites	O
of	O
a	O
constitutional	O
X	O
/	O
autosome	O
translocation	O
and	O
associated	O
deletion	O
.	O

Reciprocal	O
chromosome	O
translocations	O
are	O
common	O
de	O
novo	O
rearrangements	O
that	O
occur	O
randomly	O
throughout	O
the	O
human	O
genome	O
.	O

To	O
learn	O
about	O
causative	O
mechanisms	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
breakpoints	O
of	O
a	O
cytologically	O
balanced	O
constitutional	O
reciprocal	O
translocation	O
,	O
t	O
(	O
X	O
;	O
4	O
)	O
(	O
p21	O
.	O
2	O
;	O
q31	O
.	O
22	O
)	O
,	O
present	O
in	O
a	O
girl	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

Physical	O
mapping	O
of	O
the	O
derivative	O
chromosomes	O
,	O
after	O
their	O
separation	O
in	O
somatic	O
cell	O
hybrids	O
,	O
reveals	O
that	O
the	O
translocation	O
disrupts	O
the	O
DMD	B-Disease
gene	O
in	O
Xp21	O
within	O
the	O
18	O
-	O
kb	O
intron	O
16	O
.	O

Restriction	O
mapping	O
and	O
sequencing	O
of	O
clones	O
that	O
span	O
both	O
translocation	O
breakpoints	O
as	O
well	O
as	O
the	O
corresponding	O
normal	O
regions	O
indicate	O
the	O
loss	O
of	O
approximately	O
5	O
kb	O
in	O
the	O
formation	O
of	O
the	O
derivative	O
X	O
chromosome	O
,	O
with	O
4	O
-	O
6	O
bp	O
deleted	O
from	O
chromosome	O
4	O
.	O

RFLP	O
and	O
Southern	O
analyses	O
indicate	O
that	O
the	O
de	O
novo	O
translocation	O
is	O
a	O
paternal	O
origin	O
and	O
that	O
the	O
fathers	O
X	O
chromosome	O
contains	O
the	O
DNA	O
that	O
is	O
deleted	O
in	O
the	O
derivative	O
X	O
.	O

Most	O
likely	O
,	O
deletion	O
and	O
translation	O
arose	O
simultaneously	O
from	O
a	O
complex	O
rearrangement	O
event	O
that	O
involves	O
three	O
chromosomal	O
breakpoints	O
.	O

Short	O
regions	O
of	O
sequence	O
homology	O
were	O
present	O
at	O
the	O
three	O
sites	O
.	O

A	O
5	O
-	O
bp	O
sequence	O
,	O
GGAAT	O
,	O
found	O
exactly	O
at	O
the	O
translocation	O
breakpoints	O
on	O
both	O
normal	O
chromosomes	O
X	O
and	O
4	O
,	O
has	O
been	O
preserved	O
only	O
on	O
the	O
der	O
(	O
4	O
)	O
chromosome	O
.	O

It	O
is	O
likely	O
that	O
the	O
X	O
-	O
derived	O
sequence	O
GGAATCA	O
has	O
been	O
lost	O
in	O
the	O
formation	O
of	O
the	O
der	O
(	O
X	O
)	O
chromosome	O
,	O
as	O
it	O
matches	O
an	O
inverted	O
GAATCA	O
sequence	O
present	O
on	O
the	O
opposite	O
strand	O
exactly	O
at	O
the	O
other	O
end	O
of	O
the	O
deleted	O
5	O
-	O
kb	O
fragment	O
.	O

A	O
genetic	O
etiology	O
for	O
DiGeorge	B-Disease
syndrome	I-Disease
:	O
consistent	O
deletions	O
and	O
microdeletions	O
of	O
22q11	O
.	O

DiGeorge	B-Disease
syndrome	I-Disease
(	O
DGS	B-Disease
)	O
,	O
a	O
developmental	O
field	O
defect	O
of	O
the	O
third	O
and	O
fourth	O
pharyngeal	O
pouches	O
,	O
is	O
characterized	O
by	O
aplasia	B-Disease
or	I-Disease
hypoplasia	I-Disease
of	I-Disease
the	I-Disease
thymus	I-Disease
and	I-Disease
parathyroid	I-Disease
glands	I-Disease
and	O
by	O
conotruncal	B-Disease
cardiac	I-Disease
malformations	I-Disease
.	O

Cytogenetic	O
studies	O
support	O
the	O
presence	O
of	O
a	O
DGS	B-Disease
critical	O
region	O
in	O
band	O
22q11	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
results	O
of	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
studies	O
of	O
14	O
patients	O
with	O
DGS	B-Disease
.	O

Chromosome	O
analysis	O
,	O
utilizing	O
high	O
-	O
resolution	O
banding	O
techniques	O
,	O
detected	O
interstitial	O
deletions	O
in	O
five	O
probands	O
and	O
was	O
inconclusive	O
for	O
a	O
deletion	O
in	O
three	O
probands	O
.	O

The	O
remaining	O
six	O
patients	O
had	O
normal	O
karyotypes	O
.	O

In	O
contrast	O
,	O
molecular	O
analysis	O
detected	O
DNA	O
deletions	O
in	O
all	O
14	O
probands	O
.	O

Two	O
of	O
10	O
loci	O
tested	O
,	O
D22S75	O
and	O
D22S259	O
,	O
are	O
deleted	O
in	O
all	O
14	O
patients	O
.	O

A	O
third	O
locus	O
,	O
D22S66	O
,	O
is	O
deleted	O
in	O
the	O
eight	O
DGS	B-Disease
probands	O
tested	O
.	O

Physical	O
mapping	O
using	O
somatic	O
cell	O
hybrids	O
places	O
D22S66	O
between	O
D22S75	O
and	O
D22S259	O
,	O
suggesting	O
that	O
it	O
should	O
be	O
deleted	O
in	O
the	O
remaining	O
six	O
cases	O
.	O

Parent	O
-	O
of	O
-	O
origin	O
studies	O
were	O
performed	O
in	O
five	O
families	O
.	O

Four	O
probands	O
failed	O
to	O
inherit	O
a	O
maternal	O
allele	O
,	O
and	O
one	O
failed	O
to	O
inherit	O
a	O
paternal	O
allele	O
.	O

On	O
the	O
basis	O
of	O
these	O
families	O
,	O
and	O
of	O
six	O
maternally	O
and	O
five	O
paternally	O
derived	O
unbalanced	O
-	O
translocation	O
DGS	B-Disease
probands	O
in	O
the	O
literature	O
,	O
parent	O
of	O
origin	O
or	O
imprinting	O
does	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
DGS	B-Disease
.	O

Deletion	O
of	O
the	O
same	O
three	O
loci	O
in	O
all	O
14	O
DGS	B-Disease
probands	O
begins	O
to	O
delineate	O
the	O
region	O
of	O
chromosome	O
22	O
critical	O
for	O
DGS	B-Disease
and	O
confirms	O
the	O
hypothesis	O
that	O
submicroscopic	O
deletions	O
of	O
22q11	O
are	O
etiologic	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
.	O
.	O

Loss	O
of	O
normal	O
allele	O
of	O
the	O
APC	B-Disease
gene	O
in	O
an	O
adrenocortical	B-Disease
carcinoma	I-Disease
from	O
a	O
patient	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O

Endocrine	B-Disease
neoplasms	I-Disease
have	O
been	O
reported	O
occasionally	O
in	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
.	O

An	O
adrenocorotical	B-Disease
carcinoma	I-Disease
was	O
studied	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
FAP	B-Disease
.	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
the	O
region	O
close	O
to	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
was	O
detected	O
in	O
this	O
carcinoma	B-Disease
,	O
and	O
evidence	O
was	O
obtained	O
that	O
there	O
was	O
a	O
loss	O
of	O
the	O
normal	O
allele	O
of	O
the	O
APC	B-Disease
gene	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
LOH	O
at	O
the	O
APC	B-Disease
locus	O
in	O
adrenocortical	B-Disease
tumors	I-Disease
.	O

The	O
present	O
results	O
and	O
our	O
previous	O
data	O
on	O
LOH	O
in	O
a	O
recurring	O
desmoid	B-Disease
tumor	I-Disease
suggest	O
that	O
the	O
heterozygous	O
mutant	O
/	O
wild	O
-	O
type	O
condition	O
of	O
the	O
APC	B-Disease
gene	O
may	O
give	O
rise	O
to	O
benign	B-Disease
tumors	I-Disease
,	O
and	O
that	O
functional	O
loss	O
of	O
this	O
gene	O
leads	O
to	O
development	O
of	O
tumors	B-Disease
not	O
only	O
in	O
the	O
colon	O
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
FAP	B-Disease
patients	O
.	O
.	O

Oncogenic	O
point	O
mutations	O
in	O
exon	O
20	O
of	O
the	O
RB1	O
gene	O
in	O
families	O
showing	O
incomplete	O
penetrance	O
and	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B-Disease
phenotype	O
.	O

The	O
retinoblastoma	B-Disease
-	O
predisposition	O
gene	O
,	O
RB1	O
,	O
segregates	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
high	O
(	O
90	O
%	O
)	O
penetrance	O
.	O

Certain	O
families	O
,	O
however	O
,	O
show	O
an	O
unusual	O
low	O
-	O
penetrance	O
phenotype	O
with	O
many	O
individuals	O
being	O
unaffected	O
,	O
unilaterally	O
affected	O
,	O
or	O
with	O
evidence	O
of	O
spontaneously	O
regressed	O
tumors	B-Disease
.	O

We	O
have	O
used	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
PCR	O
sequencing	O
to	O
study	O
two	O
such	O
families	O
.	O

Mutations	O
were	O
found	O
in	O
exon	O
20	O
of	O
RB1	O
in	O
both	O
cases	O
.	O

In	O
one	O
family	O
a	O
C	O
-	O
-	O
-	O
-	O
T	O
transition	O
in	O
codon	O
661	O
converts	O
an	O
arginine	O
(	O
CGG	O
)	O
to	O
a	O
tryptophan	O
(	O
TGG	O
)	O
codon	O
.	O

In	O
this	O
family	O
,	O
incomplete	O
penetrance	O
and	O
mild	O
phenotypic	O
expression	O
were	O
observed	O
in	O
virtually	O
all	O
patients	O
,	O
possibly	O
indicating	O
that	O
single	O
amino	O
acid	O
changes	O
may	O
modify	O
protein	O
structure	O
/	O
function	O
such	O
that	O
tumorigenesis	O
is	O
not	O
inevitable	O
.	O

In	O
the	O
second	O
family	O
the	O
mutation	O
in	O
codon	O
675	O
is	O
a	O
G	O
-	O
-	O
-	O
-	O
T	O
transversion	O
that	O
converts	O
a	O
glutamine	O
(	O
GAA	O
)	O
to	O
a	O
stop	O
(	O
TAA	O
)	O
codon	O
.	O

However	O
,	O
this	O
mutation	O
also	O
occurs	O
near	O
a	O
potential	O
cryptic	O
splice	O
acceptor	O
site	O
,	O
raising	O
the	O
possibility	O
of	O
alternative	O
splicing	O
resulting	O
in	O
a	O
less	O
severely	O
disrupted	O
protein	O
.	O
.	O

Late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
.	O

In	O
that	O
allele	O
arginine84	O
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	O
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B-Disease
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	O
activity	O
.	O

A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	O
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
MLD	B-Disease
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B-Disease
.	O
.	O

Trisomy	B-Disease
15	I-Disease
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
due	O
to	O
maternal	B-Disease
disomy	I-Disease
.	O

Uniparental	B-Disease
disomy	I-Disease
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B-Disease
disomy	I-Disease
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	B-Disease
disomy	I-Disease
in	O
a	O
fetus	O
.	O

Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	B-Disease
15	I-Disease
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O

Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied	O
.	O

The	O
child	O
was	O
hypotonic	B-Disease
at	O
birth	O
,	O
and	O
high	O
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11	O
-	O
13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-	O
70	O
%	O
of	O
patients	O
with	O
PWS	B-Disease
.	O

Over	O
time	O
,	O
typical	O
features	O
of	O
PWS	B-Disease
developed	O
.	O

Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy	O
.	O

Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B-Disease
disomy	I-Disease
in	O
this	O
case	O
of	O
PWS	B-Disease
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
.	O
.	O

Genetic	O
heterogeneity	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
.	O

The	O
AMELX	O
gene	O
located	O
at	O
Xp22	O
.	O

1	O
-	O
p22	O
.	O

3	O
encodes	O
for	O
the	O
enamel	O
protein	O
amelogenin	O
and	O
has	O
been	O
implicated	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
inherited	B-Disease
dental	I-Disease
abnormality	I-Disease
X	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
(	O
XAI	B-Disease
)	O
.	O

Three	O
families	O
with	O
XAI	B-Disease
have	O
been	O
investigated	O
using	O
polymorphic	O
DNA	O
markers	O
flanking	O
the	O
position	O
of	O
AMELX	O
.	O

Using	O
two	O
-	O
point	O
linkage	O
analysis	O
,	O
linkage	O
was	O
established	O
between	O
XAI	B-Disease
and	O
several	O
of	O
these	O
markers	O
in	O
two	O
families	O
,	O
with	O
a	O
combined	O
lod	O
score	O
of	O
6	O
.	O

05	O
for	O
DXS16	O
at	O
theta	O
=	O
0	O
.	O

04	O
04	O
.	O

This	O
supports	O
the	O
involvement	O
of	O
AMELX	O
,	O
located	O
close	O
to	O
DXS16	O
,	O
in	O
the	O
XAI	B-Disease
disease	I-Disease
process	O
(	O
AIH1	O
)	O
in	O
those	O
families	O
.	O

Using	O
multipoint	O
linkage	O
analysis	O
,	O
the	O
combined	O
maximum	O
lod	O
score	O
for	O
these	O
two	O
families	O
was	O
7	O
.	O

30	O
for	O
a	O
location	O
of	O
AIH1	O
at	O
2	O
cM	O
distal	O
to	O
DXS16	O
.	O

The	O
support	O
interval	O
around	O
this	O
location	O
extended	O
about	O
8	O
cM	O
proximal	O
to	O
DXS92	O
,	O
and	O
the	O
AIH1	O
location	O
could	O
not	O
be	O
precisely	O
defined	O
by	O
multipoint	O
mapping	O
.	O

Study	O
of	O
recombination	O
events	O
indicated	O
that	O
AIH1	O
lies	O
in	O
the	O
interval	O
between	O
DXS143	O
and	O
DXS85	O
.	O

There	O
was	O
significant	O
evidence	O
against	O
linkage	O
to	O
this	O
region	O
in	O
the	O
third	O
family	O
,	O
indicating	O
locus	O
heterogeneity	O
in	O
XAI	B-Disease
.	O

Further	O
analysis	O
with	O
markers	O
on	O
the	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
showed	O
evidence	O
of	O
linkage	O
to	O
DXS144E	O
and	O
F9	O
with	O
no	O
recombination	O
with	O
either	O
of	O
these	O
markers	O
.	O

Two	O
-	O
point	O
analysis	O
gave	O
a	O
peak	O
lod	O
score	O
at	O
DXS144E	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
2	O
.	O

83	O
at	O
theta	O
=	O
0	O
,	O
with	O
a	O
peak	O
lod	O
score	O
in	O
multipoint	O
linkage	O
analysis	O
of	O
2	O
.	O

84	O
at	O
theta	O
=	O
0	O
.	O

The	O
support	O
interval	O
extended	O
9	O
cM	O
proximal	O
to	O
DXS144E	O
and	O
14	O
cM	O
distal	O
to	O
F9	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Multiple	O
origins	O
for	O
phenylketonuria	B-Disease
in	O
Europe	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
,	O
a	O
disorder	B-Disease
of	I-Disease
amino	I-Disease
acid	I-Disease
metabolism	I-Disease
prevalent	O
among	O
Caucasians	O
and	O
other	O
ethnic	O
groups	O
,	O
is	O
caused	O
primarily	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hepatic	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

PKU	B-Disease
is	O
a	O
highly	O
heterogeneous	O
disorder	O
,	O
with	O
more	O
than	O
60	O
molecular	O
lesions	O
identified	O
in	O
the	O
PAH	O
gene	O
.	O

The	O
haplotype	O
associations	O
,	O
relative	O
frequencies	O
,	O
and	O
distributions	O
of	O
five	O
prevalent	O
PAH	O
mutations	O
(	O
R158Q	O
,	O
R261Q	O
,	O
IVS10nt546	O
,	O
R408W	O
,	O
and	O
IVS12n1	O
)	O
were	O
established	O
in	O
a	O
comprehensive	O
European	O
sample	O
population	O
and	O
subsequently	O
were	O
examined	O
to	O
determine	O
the	O
potential	O
roles	O
of	O
several	O
genetic	O
mechanisms	O
in	O
explaining	O
the	O
present	O
distribution	O
of	O
the	O
major	O
PKU	B-Disease
alleles	O
.	O

Each	O
of	O
these	O
five	O
mutations	O
was	O
strongly	O
associated	O
with	O
only	O
one	O
of	O
the	O
more	O
than	O
70	O
chromosomal	O
haplotypes	O
defined	O
by	O
eight	O
RFLPs	O
in	O
or	O
near	O
the	O
PAH	O
gene	O
.	O

These	O
findings	O
suggest	O
that	O
each	O
of	O
these	O
mutations	O
arose	O
through	O
a	O
single	O
founding	O
event	O
that	O
occurred	O
within	O
time	O
periods	O
ranging	O
from	O
several	O
hundred	O
to	O
several	O
thousand	O
years	O
ago	O
.	O

From	O
the	O
significant	O
differences	O
observed	O
in	O
the	O
relative	O
frequencies	O
and	O
distributions	O
of	O
these	O
five	O
alleles	O
throughout	O
Europe	O
,	O
four	O
of	O
these	O
putative	O
founding	O
events	O
could	O
be	O
localized	O
to	O
specific	O
ethnic	O
subgroups	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
there	O
were	O
multiple	O
,	O
geographically	O
and	O
ethnically	O
distinct	O
origins	O
for	O
PKU	B-Disease
within	O
the	O
European	O
population	O
.	O
.	O

Complement	B-Disease
factor	I-Disease
2	I-Disease
deficiency	I-Disease
:	O
a	O
clinical	O
and	O
serological	O
family	O
study	O
.	O

Inherited	B-Disease
complement	I-Disease
deficiencies	I-Disease
are	O
associated	O
with	O
a	O
variety	O
of	O
connective	O
tissue	O
diseases	O
.	O

A	O
family	O
with	O
inherited	B-Disease
deficiency	I-Disease
of	I-Disease
complement	I-Disease
factor	I-Disease
2	I-Disease
(	O
C2	O
)	O
is	O
described	O
in	O
which	O
two	O
family	O
members	O
with	O
homozygous	O
C2	B-Disease
deficiency	I-Disease
developed	O
cutaneous	B-Disease
vasculitis	I-Disease
and	O
sicca	B-Disease
syndrome	I-Disease
.	O

The	O
other	O
family	O
members	O
had	O
heterozygous	O
C2	B-Disease
deficiency	I-Disease
and	O
each	O
member	O
had	O
the	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
DR2	O
(	O
w15	O
)	O
haplotype	O
.	O

The	O
mother	O
had	O
seropositive	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
.	O

Further	O
studies	O
showed	O
the	O
presence	O
of	O
cryoglobulins	O
,	O
antibodies	O
against	O
endothelial	O
cells	O
,	O
and	O
anticardiolipin	O
antibodies	O
.	O
.	O

New	O
variant	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
a	O
family	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
.	O

A	O
C	O
-	O
-	O
greater	O
than	O
G	O
transversion	O
has	O
been	O
found	O
in	O
exon	O
3	O
of	O
the	O
PLP	O
gene	O
of	O
affected	O
males	O
and	O
their	O
mother	O
in	O
a	O
single	O
sibship	O
with	O
Pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
PMD	B-Disease
)	O
.	O

The	O
transversion	O
should	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
in	O
the	O
protein	O
but	O
it	O
does	O
result	O
in	O
the	O
loss	O
of	O
a	O
HaeIII	O
restriction	O
endonuclease	O
cleavage	O
site	O
.	O

It	O
is	O
concordant	O
with	O
the	O
disease	O
in	O
this	O
family	O
.	O

One	O
-	O
hundred	O
-	O
ten	O
unrelated	O
X	O
chromosomes	O
are	O
negative	O
for	O
this	O
mutation	O
.	O

No	O
other	O
sequence	O
defect	O
was	O
found	O
in	O
the	O
PLP	O
exons	O
of	O
the	O
affected	O
males	O
.	O

The	O
cause	O
of	O
disease	O
in	O
this	O
family	O
remains	O
unknown	O
,	O
but	O
the	O
association	O
between	O
this	O
rare	O
mutation	O
and	O
PMD	B-Disease
is	O
intriguing	O
.	O

The	O
mutation	O
can	O
serve	O
as	O
a	O
marker	O
for	O
following	O
segregation	O
of	O
the	O
PLP	O
gene	O
.	O
.	O

Uncoupling	O
of	O
hypomyelination	B-Disease
and	O
glial	B-Disease
cell	I-Disease
death	I-Disease
by	O
a	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
gene	O
.	O

Proteolipid	O
protein	O
(	O
PLP	O
;	O
M	O
(	O
r	O
)	O
30	O
,	O
000	O
)	O
is	O
a	O
highly	O
conserved	O
major	O
polytopic	O
membrane	O
protein	O
in	O
myelin	O
but	O
its	O
cellular	O
function	O
remains	O
obscure	O
.	O

Neurological	O
mutant	O
mice	O
can	O
often	O
provide	O
model	O
systems	O
for	O
human	O
genetic	B-Disease
disorders	I-Disease
.	O

Mutations	O
of	O
the	O
X	O
-	O
chromosome	O
-	O
linked	O
PLP	O
gene	O
are	O
lethal	O
,	O
identified	O
first	O
in	O
the	O
jimpy	O
mouse	O
and	O
subsequently	O
in	O
patients	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
.	O

The	O
unexplained	O
phenotype	O
of	O
these	O
mutations	O
includes	O
degeneration	B-Disease
and	I-Disease
premature	I-Disease
cell	I-Disease
death	I-Disease
of	I-Disease
oligodendrocytes	I-Disease
with	O
associated	O
hypomyelination	B-Disease
.	O

Here	O
we	O
show	O
that	O
a	O
new	O
mouse	O
mutant	O
rumpshaker	O
is	O
defined	O
by	O
the	O
amino	O
-	O
acid	O
substitution	O
Ile	O
-	O
to	O
-	O
Thr	O
at	O
residue	O
186	O
in	O
a	O
membrane	O
-	O
embedded	O
domain	O
of	O
PLP	O
.	O

Surprisingly	O
,	O
rumpshaker	O
mice	O
,	O
although	O
myelin	B-Disease
-	I-Disease
deficient	I-Disease
,	O
have	O
normal	O
longevity	O
and	O
a	O
full	O
complement	O
of	O
morphologically	O
normal	O
oligodendrocytes	O
.	O

Hypomyelination	B-Disease
can	O
thus	O
be	O
genetically	O
separated	O
from	O
the	O
PLP	O
-	O
dependent	O
oligodendrocyte	B-Disease
degeneration	I-Disease
.	O

We	O
suggest	O
that	O
PLP	O
has	O
a	O
vital	O
function	O
in	O
glial	O
cell	O
development	O
,	O
distinct	O
from	O
its	O
later	O
role	O
in	O
myelin	O
assembly	O
,	O
and	O
that	O
this	O
dichotomy	O
of	O
action	O
may	O
explain	O
the	O
clinical	O
spectrum	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
.	O
.	O

A	O
pseudodeficiency	O
allele	O
common	O
in	O
non	O
-	O
Jewish	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
carriers	O
:	O
implications	O
for	O
carrier	O
screening	O
.	O

Deficiency	B-Disease
of	I-Disease
beta	I-Disease
-	I-Disease
hexosaminidase	I-Disease
A	I-Disease
(	O
Hex	O
A	O
)	O
activity	O
typically	O
results	O
in	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
.	O

However	O
,	O
healthy	O
subjects	O
found	O
to	O
be	O
deficient	B-Disease
in	I-Disease
Hex	I-Disease
A	I-Disease
activity	O
(	O
i	O
.	O
e	O
.	O
,	O
pseudodeficient	O
)	O
by	O
means	O
of	O
in	O
vitro	O
biochemical	O
tests	O
have	O
been	O
described	O
.	O

We	O
analyzed	O
the	O
HEXA	O
gene	O
of	O
one	O
pseudodeficient	O
subject	O
and	O
identified	O
both	O
a	O
C739	O
-	O
to	O
-	O
T	O
substitution	O
that	O
changes	O
Arg247	O
-	O
-	O
-	O
-	O
Trp	O
on	O
one	O
allele	O
and	O
a	O
previously	O
identified	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
mutation	O
on	O
the	O
second	O
allele	O
.	O

Six	O
additional	O
pseudodeficient	O
subjects	O
were	O
found	O
to	O
have	O
the	O
C739	O
-	O
to	O
-	O
T	O
mutation	O
.	O

This	O
allele	O
accounted	O
for	O
32	O
%	O
(	O
20	O
/	O
62	O
)	O
of	O
non	O
-	O
Jewish	O
enzyme	O
-	O
defined	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
carriers	O
but	O
for	O
none	O
of	O
36	O
Jewish	O
enzyme	O
-	O
defined	O
carriers	O
who	O
did	O
not	O
have	O
one	O
of	O
three	O
known	O
mutations	O
common	O
to	O
this	O
group	O
.	O

The	O
C739	O
-	O
to	O
-	O
T	O
allele	O
,	O
together	O
with	O
a	O
"	O
true	O
"	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
allele	O
,	O
causes	O
Hex	O
A	O
pseudodeficiency	O
.	O

Given	O
both	O
the	O
large	O
proportion	O
of	O
non	O
-	O
Jewish	O
carriers	O
with	O
this	O
allele	O
and	O
that	O
standard	O
biochemical	O
screening	O
cannot	O
differentiate	O
between	O
heterozygotes	O
for	O
the	O
C739	O
-	O
to	O
-	O
T	O
mutations	O
and	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
carriers	O
,	O
DNA	O
testing	O
for	O
this	O
mutation	O
in	O
at	O
-	O
risk	O
couples	O
is	O
essential	O
.	O

Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
:	O
detection	O
of	O
mutations	O
Thr181	O
-	O
-	O
-	O
-	O
Pro	O
and	O
Leu223	O
-	O
-	O
-	O
-	O
Pro	O
in	O
the	O
proteolipid	O
protein	O
gene	O
,	O
and	O
prenatal	O
diagnosis	O
.	O

A	O
family	O
with	O
an	O
apparent	O
history	O
of	O
X	O
-	O
linked	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
presented	O
for	O
genetic	O
counseling	O
,	O
requesting	O
carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
.	O

RFLP	O
analysis	O
using	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
probe	O
was	O
uninformative	O
in	O
this	O
family	O
.	O

A	O
prenatal	O
diagnosis	O
on	O
a	O
chorionic	O
villus	O
sample	O
(	O
CVS	O
)	O
was	O
carried	O
out	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
of	O
a	O
variant	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
.	O

The	O
fetus	O
was	O
predicted	O
to	O
be	O
unaffected	O
.	O

Sequencing	O
of	O
the	O
exon	O
from	O
the	O
CVS	O
,	O
the	O
predicted	O
-	O
carrier	O
mother	O
,	O
and	O
the	O
obligate	O
-	O
carrier	O
grandmother	O
revealed	O
an	O
A	O
-	O
to	O
-	O
C	O
change	O
at	O
nucleotide	O
541	O
in	O
the	O
two	O
women	O
but	O
not	O
in	O
the	O
fetus	O
.	O

As	O
this	O
change	O
results	O
in	O
a	O
Thr	O
-	O
to	O
-	O
Pro	O
change	O
at	O
amino	O
acid	O
181	O
in	O
a	O
region	O
of	O
the	O
gene	O
predicted	O
to	O
be	O
part	O
of	O
a	O
transmembrane	O
segment	O
,	O
it	O
was	O
concluded	O
that	O
this	O
was	O
the	O
mutation	O
causing	O
the	O
disease	O
in	O
this	O
family	O
.	O

In	O
addition	O
,	O
in	O
a	O
second	O
family	O
,	O
an	O
exon	O
5	O
variant	O
band	O
pattern	O
on	O
SSCP	O
analysis	O
was	O
shown	O
by	O
sequencing	O
to	O
be	O
due	O
to	O
a	O
T	O
-	O
to	O
-	O
C	O
change	O
at	O
nucleotide	O
668	O
.	O

This	O
results	O
in	O
a	O
Leu	O
-	O
to	O
-	O
Pro	O
change	O
in	O
a	O
carrier	O
mother	O
and	O
in	O
her	O
two	O
affected	O
sons	O
.	O

These	O
results	O
provide	O
further	O
examples	O
of	O
mutations	O
in	O
PLP	O
that	O
cause	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
and	O
illustrate	O
the	O
value	O
of	O
SSCP	O
in	O
genetic	O
analysis	O
.	O
.	O

von	B-Disease
Willebrand	I-Disease
disease	I-Disease
type	I-Disease
B	I-Disease
:	O
a	O
missense	O
mutation	O
selectively	O
abolishes	O
ristocetin	O
-	O
induced	O
von	B-Disease
Willebrand	I-Disease
factor	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib	O
.	O

von	B-Disease
Willebrand	I-Disease
factor	O
(	O
vWF	O
)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
mediates	O
the	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
by	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib	O
.	O

For	O
human	O
vWF	O
,	O
this	O
interaction	O
can	O
be	O
induced	O
in	O
vitro	O
by	O
the	O
antibiotic	O
ristocetin	O
or	O
the	O
snake	O
venom	O
protein	O
botrocetin	O
.	O

A	O
missense	O
mutation	O
,	O
Gly	O
-	O
561	O
-	O
-	O
>	O
Ser	O
,	O
was	O
identified	O
within	O
the	O
proposed	O
glycoprotein	O
Ib	O
binding	O
domain	O
of	O
vWF	O
in	O
the	O
proband	O
with	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
type	I-Disease
B	I-Disease
,	O
a	O
unique	O
variant	O
characterized	O
by	O
no	O
ristocetin	O
-	O
induced	O
,	O
but	O
normal	O
botrocetin	O
-	O
induced	O
,	O
binding	O
to	O
glycoprotein	O
Ib	O
.	O

The	O
corresponding	O
mutant	O
recombinant	O
protein	O
,	O
rvWF	O
(	O
G561S	O
)	O
,	O
formed	O
normal	O
multimers	O
and	O
exhibited	O
the	O
same	O
functional	O
defect	O
as	O
the	O
patients	O
plasma	O
vWF	O
,	O
confirming	O
that	O
this	O
mutation	O
causes	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
type	I-Disease
B	I-Disease
.	O

These	O
data	O
show	O
that	O
botrocetin	O
and	O
ristocetin	O
cofactor	O
activities	O
of	O
vWF	O
can	O
be	O
dissociated	O
by	O
a	O
point	O
mutation	O
and	O
confirm	O
that	O
these	O
mediators	O
promote	O
vWF	O
binding	O
to	O
platelets	O
by	O
different	O
mechanisms	O
.	O

The	O
normal	O
botrocetin	O
-	O
induced	O
binding	O
and	O
the	O
defective	O
ristocetin	O
-	O
induced	O
binding	O
of	O
rvWF	O
(	O
G561S	O
)	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
type	I-Disease
B	I-Disease
may	O
be	O
a	O
failure	O
of	O
normal	O
allosteric	O
regulation	O
of	O
the	O
glycoprotein	O
Ib	O
binding	O
function	O
of	O
vWF	O
.	O
.	O

Typical	O
and	O
partial	O
cat	B-Disease
eye	I-Disease
syndrome	I-Disease
:	O
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
FISH	O
.	O

Three	O
children	O
are	O
reported	O
with	O
typical	O
cat	B-Disease
eye	I-Disease
syndrome	I-Disease
(	O
CES	B-Disease
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	B-Disease
because	O
of	O
absence	O
of	O
coloboma	O
,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
FISH	O
.	O

Using	O
a	O
genomic	O
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B-Disease
was	O
shown	O
in	O
all	O
cases	O
.	O
.	O

[	O
Genetic	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
:	O
mutant	O
alleles	O
of	O
G6PD	O
in	O
the	O
Shekii	O
district	O
of	O
Azerbaijan	O
]	O

Examination	O
on	O
G6PD	B-Disease
deficiency	I-Disease
in	O
349	O
patients	O
of	O
Shekii	O
district	O
hospital	O
(	O
Azerbaijan	O
)	O
revealed	O
16	O
hemi	O
-	O
,	O
4	O
homo	O
-	O
and	O
9	O
heterozygotic	O
carriers	O
of	O
the	O
defect	O
.	O

Gd	O
-	O
frequency	O
,	O
calculated	O
from	O
the	O
data	O
obtained	O
(	O
7	O
.	O
7	O
%	O
)	O
,	O
may	O
be	O
compared	O
to	O
neighbouring	O
regions	O
frequencies	O
(	O
6	O
-	O
30	O
%	O
)	O
.	O

Carriers	O
of	O
G6PD	B-Disease
deficiency	I-Disease
are	O
residents	O
of	O
11	O
villages	O
located	O
in	O
Alasani	O
-	O
Aphtalan	O
valley	O
,	O
highly	O
endemic	O
with	O
malaria	B-Disease
in	O
the	O
past	O
;	O
nearly	O
all	O
marriages	O
are	O
endogamic	O
.	O

Physico	O
-	O
chemical	O
and	O
kinetic	O
study	O
of	O
10	O
mutant	O
forms	O
of	O
G6PD	O
,	O
according	O
to	O
WHO	O
program	O
,	O
led	O
to	O
identification	O
of	O
5	O
variants	O
of	O
the	O
II	O
class	O
(	O
Shekii	O
,	O
Bideiz	O
,	O
Shirin	O
-	O
Bulakh	O
,	O
Okhut	O
I	O
and	O
Zakataly	O
)	O
and	O
2	O
variants	O
of	O
the	O
III	O
class	O
(	O
Okhut	O
II	O
and	O
Martinique	O
-	O
like	O
)	O
.	O

Resemblance	O
of	O
the	O
majority	O
of	O
variants	O
in	O
electrophoretic	O
mobility	O
and	O
the	O
level	O
of	O
erythrocyte	O
enzyme	O
activity	O
permit	O
to	O
suggest	O
the	O
existence	O
of	O
a	O
common	O
parental	O
mutant	O
G6PD	O
allele	O
distributed	O
in	O
this	O
area	O
.	O

Craniofrontonasal	B-Disease
dysplasia	I-Disease
.	O

We	O
report	O
on	O
nine	O
patients	O
with	O
craniofrontonasal	B-Disease
dysplasia	I-Disease
(	O
CFND	B-Disease
)	O
.	O

Seven	O
classical	O
cases	O
had	O
facial	O
features	O
suggestive	O
of	O
frontonasal	B-Disease
dysplasia	I-Disease
and	O
coronal	B-Disease
craniosynostosis	I-Disease
.	O

Extracranial	B-Disease
abnormalities	I-Disease
such	O
as	O
brittle	B-Disease
nails	I-Disease
with	I-Disease
prominent	I-Disease
longitudinal	I-Disease
grooves	I-Disease
or	O
syndactyly	B-Disease
of	I-Disease
fingers	I-Disease
and	I-Disease
toes	I-Disease
were	O
observed	O
in	O
individual	O
patients	O
.	O

In	O
two	O
families	O
the	O
father	O
of	O
classical	O
cases	O
showed	O
a	O
milder	O
pattern	O
of	O
abnormalities	O
,	O
consistent	O
with	O
the	O
diagnosis	O
.	O

We	O
present	O
a	O
2	O
-	O
to	O
13	O
-	O
year	O
follow	O
-	O
up	O
on	O
our	O
patients	O
.	O

Hypotonia	B-Disease
and	O
laxity	B-Disease
of	I-Disease
joints	I-Disease
are	O
common	O
and	O
may	O
necessitate	O
supportive	O
measures	O
.	O

Mild	O
developmental	B-Disease
delay	I-Disease
was	O
noted	O
in	O
three	O
out	O
of	O
six	O
classical	O
cases	O
studied	O
in	O
detail	O
.	O

Unlike	O
almost	O
all	O
other	O
X	B-Disease
-	I-Disease
linked	I-Disease
disorders	I-Disease
,	O
clinical	O
expression	O
in	O
CFND	B-Disease
is	O
generally	O
much	O
more	O
severe	O
in	O
females	O
than	O
in	O
males	O
.	O

In	O
contrast	O
to	O
previous	O
reports	O
of	O
this	O
condition	O
,	O
one	O
of	O
our	O
severely	O
affected	O
cases	O
is	O
a	O
male	O
.	O
.	O

The	O
intron	O
7	O
donor	O
splice	O
site	O
transition	O
:	O
a	O
second	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
mutation	O
in	O
French	O
Canada	O
.	O

Mutations	O
at	O
the	O
hexosaminidase	O
A	O
(	O
HEXA	O
)	O
gene	O
which	O
cause	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
have	O
elevated	O
frequency	O
in	O
the	O
Ashkenazi	O
Jewish	O
and	O
French	O
-	O
Canadian	O
populations	O
.	O

We	O
report	O
a	O
novel	O
TSD	B-Disease
allele	O
in	O
the	O
French	O
-	O
Canadian	O
population	O
associated	O
with	O
the	O
infantile	O
form	O
of	O
the	O
disease	O
.	O

The	O
mutation	O
,	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
the	O
+	O
1	O
position	O
of	O
intron	O
7	O
,	O
abolishes	O
the	O
donor	O
splice	O
site	O
.	O

Cultured	O
human	O
fibroblasts	O
from	O
a	O
compound	O
heterozygote	O
for	O
this	O
transition	O
(	O
and	O
for	O
a	O
deletion	O
mutation	O
)	O
produce	O
no	O
detectable	O
HEXA	O
mRNA	O
.	O

The	O
intron	O
7	O
+	O
1	O
mutation	O
occurs	O
in	O
the	O
base	O
adjacent	O
to	O
the	O
site	O
of	O
the	O
adult	O
-	O
onset	O
TSD	B-Disease
mutation	O
(	O
G805A	O
)	O
.	O

In	O
both	O
mutations	O
a	O
restriction	O
site	O
for	O
the	O
endonuclease	O
EcoRII	O
is	O
abolished	O
.	O

Unambiguous	O
diagnosis	O
,	O
therefore	O
,	O
requires	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
to	O
distinguish	O
between	O
these	O
two	O
mutant	O
alleles	O
.	O

The	O
intron	O
7	O
+	O
1	O
mutation	O
has	O
been	O
detected	O
in	O
three	O
unrelated	O
families	O
.	O

Obligate	O
heterozygotes	O
for	O
the	O
intron	O
7	O
+	O
1	O
mutation	O
were	O
born	O
in	O
the	O
Saguenay	O
-	O
Lac	O
-	O
St	O
-	O
Jean	O
region	O
of	O
Quebec	O
.	O

The	O
most	O
recent	O
ancestors	O
common	O
to	O
obligate	O
carriers	O
of	O
this	O
mutation	O
were	O
from	O
the	O
Charlevoix	O
region	O
of	O
the	O
province	O
of	O
Quebec	O
.	O

This	O
mutation	O
thus	O
has	O
a	O
different	O
geographic	O
centre	O
of	O
diffusion	O
and	O
is	O
probably	O
less	O
common	O
than	O
the	O
exon	O
1	O
deletion	O
TSD	B-Disease
mutation	O
in	O
French	O
Canadians	O
.	O

Neither	O
mutation	O
has	O
been	O
detected	O
in	O
France	O
,	O
the	O
ancestral	O
homeland	O
of	O
French	O
Canada	O
.	O
.	O

Assignment	O
of	O
the	O
aspartylglucosaminidase	O
gene	O
(	O
AGA	O
)	O
to	O
4q33	O
-	O
-	O
-	O
-	O
q35	O
based	O
on	O
decreased	O
activity	O
in	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

Aspartylglucosaminuria	B-Disease
(	O
AGU	B-Disease
)	O
is	O
a	O
recessive	O
autosomally	O
inherited	O
lysosomal	B-Disease
storage	I-Disease
disorder	I-Disease
due	O
to	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
enzyme	I-Disease
aspartylglucosaminidase	I-Disease
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
this	O
human	O
enzyme	O
(	O
AGA	O
)	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21	O
-	O
-	O
-	O
-	O
qter	O
.	O

We	O
determined	O
the	O
AGA	O
activity	O
in	O
cultured	O
fibroblasts	O
of	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

The	O
results	O
indicate	O
that	O
the	O
girl	O
is	O
a	O
hemizygote	O
for	O
AGA	O
,	O
permitting	O
the	O
assignment	O
of	O
human	O
AGA	O
to	O
the	O
region	O
4q33	O
-	O
-	O
-	O
-	O
qter	O
.	O
.	O

Resolution	O
of	O
the	O
two	O
loci	O
for	O
autosomal	O
dominant	O
aniridia	B-Disease
,	O
AN1	O
and	O
AN2	O
,	O
to	O
a	O
single	O
locus	O
on	O
chromosome	O
11p13	O
.	O

Two	O
distinct	O
loci	O
have	O
been	O
proposed	O
for	O
aniridia	B-Disease
;	O
AN1	O
for	O
autosomal	O
dominant	O
aniridia	B-Disease
on	O
chromosome	O
2p	O
and	O
AN2	O
for	O
the	O
aniridia	B-Disease
in	O
the	O
WAGR	B-Disease
contiguous	I-Disease
gene	I-Disease
syndrome	I-Disease
on	O
chromosome	O
11p13	O
.	O

In	O
this	O
report	O
,	O
the	O
kindred	O
segregating	O
for	O
autosomal	O
dominant	O
aniridia	B-Disease
,	O
which	O
suggested	O
linkage	O
to	O
acid	O
phosphatase	O
-	O
1	O
(	O
ACP1	O
)	O
and	O
led	O
to	O
the	O
assignment	O
of	O
the	O
AN1	O
locus	O
on	O
chromosome	O
2p	O
,	O
has	O
been	O
updated	O
and	O
expanded	O
.	O

Linkage	O
analysis	O
between	O
the	O
aniridia	B-Disease
phenotype	O
and	O
ACP1	O
does	O
not	O
support	O
the	O
original	O
linkage	O
results	O
,	O
excluding	O
linkage	O
up	O
to	O
theta	O
=	O
0	O
.	O

17	O
with	O
Z	O
=	O
-	O
2	O
.	O

Tests	O
for	O
linkage	O
to	O
other	O
chromosome	O
2p	O
markers	O
.	O

APOB	O
,	O
D2S71	O
,	O
D2S5	O
,	O
and	O
D2S1	O
,	O
also	O
excluded	O
linkage	O
to	O
aniridia	B-Disease
.	O

Markers	O
that	O
have	O
been	O
isolated	O
from	O
the	O
chromosome	O
11p13	O
region	O
were	O
then	O
analyzed	O
in	O
this	O
aniridia	B-Disease
family	O
.	O

Two	O
RFLPs	O
at	O
the	O
D11S323	O
locus	O
give	O
significant	O
evidence	O
for	O
linkage	O
.	O

The	O
PvuII	O
polymorphism	O
detected	O
by	O
probe	O
p5S1	O
.	O

6	O
detects	O
no	O
recombinants	O
,	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
6	O
.	O

97	O
at	O
theta	O
=	O
0	O
.	O

00	O
00	O
.	O

The	O
HaeIII	O
polymorphism	O
detected	O
by	O
the	O
probe	O
p5BE1	O
.	O

2	O
gives	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
2	O
.	O

57	O
at	O
theta	O
=	O
0	O
.	O

00	O
00	O
.	O

Locus	O
D11S325	O
gives	O
a	O
lod	O
score	O
of	O
Z	O
=	O
1	O
.	O

53	O
at	O
theta	O
=	O
0	O
.	O

00	O
00	O
.	O

These	O
data	O
suggest	O
that	O
a	O
locus	O
for	O
aniridia	B-Disease
(	O
AN1	O
)	O
on	O
chromosome	O
2p	O
has	O
been	O
misassigned	O
and	O
that	O
this	O
autosomal	O
dominant	O
aniridia	B-Disease
family	O
is	O
segregating	O
for	O
an	O
aniridia	B-Disease
mutation	O
linked	O
to	O
markers	O
in	O
the	O
11p13	O
region	O
.	O

Fatal	O
pyoderma	B-Disease
gangrenosum	I-Disease
in	O
association	O
with	O
C7	B-Disease
deficiency	I-Disease
.	O

Although	O
pyoderma	B-Disease
gangrenosum	I-Disease
(	O
PG	B-Disease
)	O
is	O
often	O
associated	O
with	O
systemic	B-Disease
diseases	I-Disease
,	O
it	O
has	O
not	O
been	O
reported	O
in	O
association	O
with	O
congenital	B-Disease
complement	I-Disease
deficiencies	I-Disease
.	O

We	O
describe	O
an	O
aggressive	O
and	O
ultimately	O
fatal	O
case	O
of	O
PG	B-Disease
in	O
a	O
patient	O
with	O
a	O
congenital	O
C7	B-Disease
deficiency	I-Disease
.	O

Deficiencies	B-Disease
of	I-Disease
C7	I-Disease
can	O
be	O
associated	O
with	O
decreased	O
neutrophil	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
opsonization	O
,	O
similar	O
to	O
the	O
immunologic	B-Disease
abnormalities	I-Disease
described	O
in	O
patients	O
with	O
PG	B-Disease
.	O

Our	O
patients	O
decreased	O
complement	O
level	O
,	O
if	O
not	O
directly	O
related	O
to	O
the	O
development	O
of	O
PG	B-Disease
,	O
may	O
have	O
contributed	O
to	O
the	O
aggressive	O
nature	O
of	O
her	O
disease	O
.	O
.	O

Diverse	O
point	O
mutations	O
result	O
in	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
polymorphism	O
in	O
Taiwan	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
PHOSPHATE	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
;	I-Disease
EC	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
the	O
most	O
common	O
human	O
enzymopathy	B-Disease
,	O
affecting	O
more	O
than	O
200	O
million	O
people	O
worldwide	O
.	O

Although	O
greater	O
than	O
400	O
variants	O
have	O
been	O
described	O
based	O
on	O
clinical	O
and	O
biochemical	O
criteria	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
basis	O
of	O
these	O
G6PD	B-Disease
deficiencies	I-Disease
.	O

Recently	O
,	O
the	O
gene	O
that	O
encodes	O
human	O
G6PD	O
has	O
been	O
cloned	O
and	O
sequenced	O
,	O
which	O
enables	O
us	O
to	O
examine	O
directly	O
the	O
heterogeneity	O
of	O
G6PD	O
at	O
the	O
DNA	O
level	O
.	O

During	O
the	O
past	O
10	O
years	O
,	O
we	O
examined	O
the	O
G6PD	O
activity	O
in	O
21	O
,	O
271	O
newborn	O
Chinese	O
infants	O
(	O
11	O
,	O
400	O
males	O
and	O
9	O
,	O
871	O
females	O
)	O
and	O
identified	O
314	O
(	O
2	O
.	O
8	O
%	O
)	O
males	O
and	O
246	O
(	O
2	O
.	O
5	O
%	O
)	O
females	O
having	O
low	O
G6PD	O
activity	O
.	O

The	O
G6PD	O
gene	O
from	O
10	O
randomly	O
selected	O
affected	O
individuals	O
and	O
their	O
relatives	O
was	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
,	O
subcloned	O
,	O
and	O
sequenced	O
.	O

Our	O
results	O
indicate	O
that	O
at	O
least	O
four	O
types	O
of	O
mutation	O
are	O
responsible	O
for	O
the	O
G6PD	O
polymorphism	O
in	O
Taiwan	O
.	O

The	O
first	O
type	O
of	O
mutation	O
(	O
487	O
G	O
-	O
-	O
-	O
-	O
A	O
)	O
was	O
found	O
in	O
an	O
affected	O
Chinese	O
with	O
a	O
G	O
to	O
A	O
change	O
at	O
nucleotide	O
487	O
,	O
which	O
results	O
in	O
a	O
(	O
163	O
)	O
Gly	O
to	O
Ser	O
substitution	O
.	O

The	O
second	O
type	O
of	O
mutation	O
(	O
493	O
A	O
-	O
-	O
-	O
-	O
G	O
)	O
is	O
a	O
novel	O
mutation	O
that	O
has	O
not	O
been	O
reported	O
in	O
any	O
other	O
ethnic	O
group	O
and	O
was	O
identified	O
in	O
two	O
affected	O
Chinese	O
.	O

This	O
mutation	O
causes	O
an	O
A	O
to	O
G	O
change	O
at	O
nucleotide	O
position	O
493	O
,	O
producing	O
an	O
(	O
165	O
)	O
Asn	O
to	O
Asp	O
substitution	O
.	O

Interestingly	O
,	O
the	O
487	O
G	O
-	O
-	O
-	O
-	O
A	O
and	O
493	O
A	O
-	O
-	O
-	O
-	O
G	O
mutations	O
create	O
Alu	O
I	O
and	O
Ava	O
II	O
recognition	O
sites	O
,	O
respectively	O
,	O
which	O
enabled	O
us	O
to	O
rapidly	O
detect	O
these	O
two	O
mutations	O
by	O
PCR	O
/	O
restriction	O
enzyme	O
(	O
RE	O
)	O
digestion	O
method	O
.	O

The	O
third	O
mutation	O
(	O
1376	O
G	O
-	O
-	O
-	O
-	O
T	O
)	O
was	O
found	O
in	O
four	O
affected	O
Chinese	O
.	O

This	O
mutation	O
causes	O
a	O
G	O
to	O
T	O
change	O
at	O
nucleotide	O
position	O
1376	O
that	O
results	O
in	O
an	O
(	O
459	O
)	O
Arg	O
to	O
Leu	O
substitution	O
.	O

The	O
1376	O
G	O
-	O
-	O
-	O
-	O
T	O
mutation	O
seems	O
to	O
be	O
the	O
dominant	O
allele	O
that	O
causes	O
G6PD	B-Disease
deficiency	I-Disease
in	O
Taiwan	O
.	O

Finally	O
,	O
two	O
affected	O
Chinese	O
were	O
identified	O
as	O
having	O
the	O
fourth	O
mutation	O
(	O
1388	O
G	O
-	O
-	O
-	O
-	O
A	O
)	O
.	O

This	O
mutation	O
causes	O
a	O
G	O
to	O
A	O
change	O
at	O
nucleotide	O
1388	O
that	O
produces	O
an	O
(	O
463	O
)	O
Arg	O
to	O
His	O
substitution	O
.	O

Our	O
studies	O
provide	O
the	O
direct	O
proof	O
of	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
in	O
the	O
Chinese	O
populations	O
of	O
Taiwan	O
and	O
the	O
PCR	O
/	O
RE	O
digestion	O
method	O
is	O
suitable	O
for	O
simultaneous	O
detection	O
of	O
the	O
487	O
G	O
-	O
-	O
-	O
-	O
A	O
and	O
493	O
A	O
-	O
-	O
-	O
-	O
G	O
mutations	O
.	O

An	O
error	O
in	O
dystrophin	O
mRNA	O
processing	O
in	O
golden	B-Disease
retriever	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
an	O
animal	O
homologue	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Golden	B-Disease
retriever	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
GRMD	B-Disease
)	O
is	O
a	O
spontaneous	O
,	O
X	O
-	O
linked	O
,	O
progressively	O
fatal	O
disease	O
of	O
dogs	O
and	O
is	O
also	O
a	O
homologue	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

Two	O
-	O
thirds	O
of	O
DMD	B-Disease
patients	O
carry	O
detectable	O
deletions	O
in	O
their	O
dystrophin	O
gene	O
.	O

The	O
defect	O
underlying	O
the	O
remaining	O
one	O
-	O
third	O
of	O
DMD	B-Disease
patients	O
is	O
undetermined	O
.	O

Analysis	O
of	O
the	O
canine	O
dystrophin	O
gene	O
in	O
normal	O
and	O
GRMD	B-Disease
dogs	O
has	O
failed	O
to	O
demonstrate	O
any	O
detectable	O
loss	O
of	O
exons	O
.	O

Here	O
,	O
we	O
have	O
demonstrated	O
a	O
RNA	O
processing	O
error	O
in	O
GRMD	B-Disease
that	O
results	O
from	O
a	O
single	O
base	O
change	O
in	O
the	O
3	O
consensus	O
splice	O
site	O
of	O
intron	O
6	O
.	O

The	O
seventh	O
exon	O
is	O
then	O
skipped	O
,	O
which	O
predicts	O
a	O
termination	O
of	O
the	O
dystrophin	O
reading	O
frame	O
within	O
its	O
N	O
-	O
terminal	O
domain	O
in	O
exon	O
8	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
dystrophin	B-Disease
deficiency	I-Disease
caused	O
by	O
a	O
splice	O
-	O
site	O
mutation	O
.	O
.	O

Type	B-Disease
I	I-Disease
human	I-Disease
complement	I-Disease
C2	I-Disease
deficiency	I-Disease
.	O

A	O
28	O
-	O
base	O
pair	O
gene	O
deletion	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing	O
.	O

Two	O
variants	O
of	O
a	O
genetic	O
deficiency	B-Disease
of	I-Disease
complement	I-Disease
protein	I-Disease
C2	I-Disease
(	O
C2D	O
)	O
have	O
been	O
previously	O
identified	O
.	O

No	O
C2	O
protein	O
translation	O
is	O
detected	O
in	O
type	O
I	O
deficiency	O
,	O
while	O
type	O
II	O
deficiency	O
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

Type	B-Disease
I	I-Disease
C2	I-Disease
deficiency	I-Disease
was	O
described	O
in	O
a	O
family	O
in	O
which	O
the	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
associated	O
with	O
the	O
major	O
histocompatibility	O
haplotype	O
/	O
complotype	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
C2Q0	O
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
;	O
this	O
extended	O
haplotype	O
occurs	O
in	O
over	O
90	O
%	O
of	O
C2	B-Disease
-	I-Disease
deficient	I-Disease
individuals	O
(	O
common	O
complotype	O
/	O
haplotype	O
)	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
type	B-Disease
I	I-Disease
C2	I-Disease
deficiency	I-Disease
,	O
the	O
C2	O
gene	O
and	O
cDNA	O
were	O
characterized	O
from	O
a	O
homozygous	O
type	B-Disease
I	I-Disease
C2	I-Disease
-	I-Disease
deficient	I-Disease
individual	O
with	O
the	O
common	O
associated	O
haplotype	O
/	O
complotype	O
.	O

We	O
found	O
a	O
28	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
,	O
beginning	O
9	O
base	O
pairs	O
upstream	O
of	O
the	O
3	O
-	O
end	O
of	O
exon	O
6	O
,	O
that	O
generates	O
a	O
C2	O
transcript	O
with	O
a	O
complete	O
deletion	O
of	O
exon	O
6	O
(	O
134	O
base	O
pair	O
)	O
and	O
a	O
premature	O
termination	O
codon	O
.	O

In	O
studies	O
of	O
eight	O
kindred	O
,	O
the	O
28	O
-	O
base	O
pair	O
deletion	O
was	O
observed	O
in	O
all	O
C2Q0	O
alleles	O
associated	O
with	O
the	O
common	O
type	O
I	O
deficient	O
complotype	O
/	O
haplotype	O
;	O
this	O
deletion	O
was	O
not	O
present	O
in	O
normal	O
C2	O
nor	O
in	O
type	B-Disease
II	I-Disease
C2	I-Disease
-	I-Disease
deficient	I-Disease
genes	O
.	O

These	O
data	O
demonstrate	O
that	O
1	O
)	O
type	B-Disease
I	I-Disease
human	I-Disease
complement	I-Disease
C2	I-Disease
deficiency	I-Disease
is	O
caused	O
by	O
a	O
28	O
-	O
base	O
pair	O
genomic	O
deletion	O
that	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing	O
,	O
resulting	O
in	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
,	O
2	O
)	O
the	O
28	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
is	O
strongly	O
associated	O
with	O
the	O
HLA	O
haplotype	O
/	O
complotype	O
A25	O
,	O
B18	O
,	O
C2Q0	O
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
,	O
suggesting	O
that	O
all	O
C2	B-Disease
-	I-Disease
deficient	I-Disease
individuals	O
with	O
this	O
haplotype	O
/	O
complotype	O
will	O
harbor	O
the	O
28	O
-	O
base	O
pair	O
C2	O
gene	O
deletion	O
,	O
and	O
3	O
)	O
type	B-Disease
II	I-Disease
C2	I-Disease
deficiency	I-Disease
is	O
caused	O
by	O
a	O
different	O
,	O
as	O
yet	O
uncharacterized	O
,	O
molecular	O
genetic	B-Disease
defect	I-Disease
.	O
.	O

Molecular	O
characterization	O
of	O
two	O
galactosemia	B-Disease
mutations	O
and	O
one	O
polymorphism	O
:	O
implications	O
for	O
structure	O
-	O
function	O
analysis	O
of	O
human	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
.	O

We	O
report	O
here	O
the	O
molecular	O
characterization	O
of	O
two	O
galactosemia	B-Disease
mutations	O
,	O
L74P	O
and	O
F171S	O
,	O
and	O
one	O
polymorphism	O
,	O
S135L	O
,	O
in	O
human	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
.	O

Both	O
galactosemia	B-Disease
mutations	O
result	O
in	O
reduced	O
enzymatic	O
activity	O
when	O
reconstructed	O
in	O
the	O
cDNA	O
and	O
overexpressed	O
.	O

The	O
polymorphism	O
,	O
in	O
contrast	O
,	O
has	O
near	O
normal	O
activity	O
.	O

Both	O
mutations	O
affect	O
evolutionarily	O
conserved	O
residues	O
,	O
suggesting	O
that	O
they	O
are	O
functionally	O
important	O
,	O
while	O
the	O
polymorphism	O
occurs	O
in	O
a	O
nonconserved	O
domain	O
which	O
is	O
presumably	O
not	O
critical	O
for	O
enzymatic	O
function	O
.	O

The	O
F171S	O
mutation	O
is	O
close	O
to	O
the	O
putative	O
active	O
-	O
site	O
nucleophile	O
.	O

Our	O
data	O
further	O
support	O
the	O
notion	O
of	O
molecular	O
heterogeneity	O
of	O
galactosemia	B-Disease
and	O
suggest	O
that	O
galactosemia	B-Disease
mutations	O
and	O
GALT	O
polymorphisms	O
may	O
be	O
useful	O
tools	O
in	O
highlighting	O
different	O
functional	O
domains	O
in	O
human	O
GALT	O
.	O
.	O

Linkage	O
relationship	O
of	O
C2	B-Disease
deficiency	I-Disease
,	O
HLA	O
and	O
glyoxalase	O
I	O
loci	O
.	O

Immunogenetic	O
analysis	O
of	O
a	O
homozygous	O
C2	B-Disease
-	I-Disease
deficient	I-Disease
individual	O
and	O
family	O
members	O
demonstrated	O
linkage	O
of	O
HLA	O
-	O
A25	O
,	O
B18	O
and	O
C2o	O
.	O

HLA	O
-	O
D	O
typing	O
showed	O
that	O
5	O
members	O
typed	O
with	O
homozygous	O
Dw2	O
typing	O
cells	O
from	O
an	O
individual	O
with	O
C2	B-Disease
deficiency	I-Disease
but	O
not	O
with	O
Dw2	O
typing	O
cells	O
from	O
2	O
individuals	O
with	O
normal	O
C2	O
.	O

The	O
homozygous	O
C2	B-Disease
-	I-Disease
deficient	I-Disease
propositus	O
and	O
brother	O
were	O
HLA	O
-	O
A	O
and	O
B	O
homozygous	O
but	O
heterozygous	O
at	O
the	O
HLA	O
-	O
D	O
and	O
glyoxalase	O
I	O
loci	O
.	O

Therefore	O
,	O
in	O
this	O
family	O
,	O
the	O
C2o	O
gene	O
is	O
linked	O
with	O
two	O
distinct	O
haplotypes	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
Dw2	O
,	O
GLO1	O
and	O
HLA	O
-	O
A25	O
,	O
B18	O
,	O
D	O
unknown	O
,	O
GL02	O
.	O

These	O
results	O
could	O
be	O
explained	O
by	O
an	O
ancestral	O
recombinant	O
event	O
,	O
which	O
occurred	O
between	O
the	O
C2o	O
locus	O
and	O
HLA	O
-	O
D	O
locus	O
in	O
which	O
C2o	O
segregated	O
with	O
HLA	O
-	O
B	O
.	O

This	O
would	O
suggest	O
that	O
the	O
locus	O
for	O
the	O
C2o	O
gene	O
maps	O
between	O
HLA	O
-	O
B	O
and	O
HLA	O
-	O
D	O
on	O
the	O
sixth	O
chromosome	O
.	O
.	O

Germline	O
mutations	O
in	O
the	O
Wilms	B-Disease
'	I-Disease
tumor	I-Disease
suppressor	O
gene	O
are	O
associated	O
with	O
abnormal	O
urogenital	O
development	O
in	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
.	O

Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
human	O
condition	O
in	O
which	O
severe	O
urogenital	B-Disease
aberrations	I-Disease
result	O
in	O
renal	B-Disease
failure	I-Disease
,	O
pseudohermaphroditism	B-Disease
,	O
and	O
Wilms	B-Disease
tumor	I-Disease
(	O
nephroblastoma	B-Disease
)	O
.	O

To	O
investigate	O
its	O
possible	O
role	O
,	O
we	O
have	O
analyzed	O
the	O
coding	O
exons	O
of	O
the	O
Wilms	B-Disease
tumor	I-Disease
suppressor	O
gene	O
(	O
WT1	O
)	O
for	O
germline	O
mutations	O
.	O

In	O
ten	O
independent	O
cases	O
of	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
,	O
point	O
mutations	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
one	O
WT1	O
gene	O
copy	O
were	O
found	O
.	O

Nine	O
of	O
these	O
mutations	O
are	O
found	O
within	O
exon	O
9	O
(	O
zinc	O
finger	O
III	O
)	O
;	O
the	O
remaining	O
mutation	O
is	O
in	O
exon	O
8	O
(	O
zinc	O
finger	O
II	O
)	O
.	O

These	O
mutations	O
directly	O
affect	O
DNA	O
sequence	O
recognition	O
.	O

In	O
two	O
families	O
analyzed	O
,	O
the	O
mutations	O
were	O
shown	O
to	O
arise	O
de	O
novo	O
.	O

Wilms	B-Disease
tumors	I-Disease
from	O
three	O
individuals	O
and	O
one	O
juvenile	O
granulosa	O
cell	O
tumor	B-Disease
demonstrate	O
reduction	O
to	O
homozygosity	O
for	O
the	O
mutated	O
WT1	O
allele	O
.	O

Our	O
results	O
provide	O
evidence	O
of	O
a	O
direct	O
role	O
for	O
WT1	O
in	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
and	O
thus	O
urogenital	O
system	O
development	O
.	O
.	O

Linkage	O
analysis	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
and	O
application	O
in	O
post	O
-	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
DNA	O
markers	O
DXS52	O
and	O
the	O
clotting	O
factor	O
VIII	O
gene	O
(	O
F8C	O
)	O
,	O
in	O
several	O
large	O
families	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
.	O

The	O
tight	O
linkage	O
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	O
score	O
of	O
22	O
.	O

5	O
at	O
1	O
cM	O
.	O

F8C	O
was	O
also	O
tightly	O
linked	O
to	O
ALD	B-Disease
with	O
a	O
maximal	O
LOD	O
score	O
of	O
7	O
.	O

8	O
without	O
recombination	O
.	O

Multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
DXS304	O
,	O
DXS52	O
,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ALD	B-Disease
and	O
for	O
F8C	O
are	O
distal	O
to	O
DXS52	O
.	O

In	O
four	O
patients	O
with	O
ALD	B-Disease
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
Xqter	O
region	O
was	O
observed	O
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B-Disease
in	I-Disease
the	I-Disease
vision	I-Disease
blindness	I-Disease
genes	I-Disease
.	O

DNA	O
analysis	O
appeared	O
to	O
be	O
of	O
use	O
in	O
determination	O
of	O
the	O
carrier	O
status	O
of	O
females	O
at	O
risk	O
,	O
for	O
the	O
determination	O
of	O
the	O
origin	O
of	O
the	O
mutation	O
in	O
a	O
particular	O
family	O
,	O
and	O
for	O
prenatal	O
diagnosis	O
.	O

Two	O
distinct	O
mutations	O
at	O
a	O
single	O
BamHI	O
site	O
in	O
phenylketonuria	B-Disease
.	O

Classical	B-Disease
phenylketonuria	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	O
located	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
PAH	O
gene	O
(	O
exon	O
7	O
)	O
led	O
to	O
the	O
recognition	O
of	O
two	O
new	O
point	O
mutations	O
at	O
codon	O
272	O
and	O
273	O
(	O
272gly	O
-	O
-	O
-	O
-	O
stop	O
and	O
273ser	O
-	O
-	O
-	O
-	O
phe	O
,	O
respectively	O
)	O
.	O

Both	O
mutations	O
were	O
detected	O
in	O
north	O
eastern	O
France	O
or	O
Belgium	O
and	O
occurred	O
on	O
the	O
background	O
of	O
RFLP	O
haplotype	O
7	O
alleles	O
.	O

The	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
PKU	B-Disease
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
PAH	B-Disease
deficiencies	I-Disease
.	O
.	O

A	O
detailed	O
multipoint	O
map	O
of	O
human	O
chromosome	O
4	O
provides	O
evidence	O
for	O
linkage	O
heterogeneity	O
and	O
position	O
-	O
specific	O
recombination	O
rates	O
.	O

Utilizing	O
the	O
CEPH	O
reference	O
panel	O
and	O
genotypic	O
data	O
for	O
53	O
markers	O
,	O
we	O
have	O
constructed	O
a	O
20	O
-	O
locus	O
multipoint	O
genetic	O
map	O
of	O
human	O
chromosome	O
4	O
.	O

New	O
RFLPs	O
are	O
reported	O
for	O
four	O
loci	O
.	O

The	O
map	O
integrates	O
a	O
high	O
-	O
resolution	O
genetic	O
map	O
of	O
4p16	O
into	O
a	O
continuous	O
map	O
extending	O
to	O
4q31	O
and	O
an	O
unlinked	O
cluster	O
of	O
three	O
loci	O
at	O
4q35	O
.	O

The	O
20	O
linked	O
markers	O
form	O
a	O
continuous	O
linkage	O
group	O
of	O
152	O
cM	O
in	O
males	O
and	O
202	O
cM	O
in	O
females	O
.	O

Likely	O
genetic	O
locations	O
are	O
provided	O
for	O
25	O
polymorphic	O
anonymous	O
sequences	O
and	O
28	O
gene	O
-	O
specific	O
RFLPs	O
.	O

The	O
map	O
was	O
constructed	O
employing	O
the	O
LINKAGE	O
and	O
CRIMAP	O
computational	O
methodologies	O
to	O
build	O
the	O
multipoint	O
map	O
via	O
a	O
stepwise	O
algorithm	O
.	O

A	O
detailed	O
10	O
-	O
point	O
map	O
of	O
the	O
4p16	O
region	O
constructed	O
from	O
the	O
CEPH	O
panel	O
provides	O
evidence	O
for	O
heterogeneity	O
in	O
the	O
linkage	O
maps	O
constructed	O
from	O
families	O
segregating	O
for	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
.	O

It	O
additionally	O
provides	O
evidence	O
for	O
position	O
-	O
specific	O
recombination	O
frequencies	O
in	O
the	O
telomeric	O
region	O
of	O
4p	O
.	O
.	O

Carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
using	O
a	O
combination	O
of	O
anonymous	O
DNA	O
polymorphisms	O
and	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
cDNA	O
.	O

We	O
report	O
carrier	O
identification	O
and	O
a	O
prenatal	O
diagnosis	O
using	O
DNA	O
polymorphisms	O
in	O
2	O
families	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
Pelizaeus	I-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
PMD	B-Disease
)	O
.	O

In	O
both	O
families	O
,	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
the	O
single	O
affected	O
male	O
could	O
be	O
traced	O
back	O
to	O
his	O
unaffected	O
maternal	O
grandfather	O
.	O

Therefore	O
,	O
each	O
family	O
contains	O
a	O
new	O
mutation	O
.	O

In	O
the	O
case	O
of	O
the	O
prenatal	O
diagnosis	O
,	O
the	O
fetus	O
was	O
shown	O
by	O
cytogenetic	O
analysis	O
to	O
be	O
a	O
female	O
,	O
who	O
we	O
predict	O
will	O
be	O
a	O
noncarrier	O
of	O
PMD	B-Disease
based	O
on	O
her	O
genotype	O
with	O
the	O
PLP	O
intragenic	O
polymorphism	O
.	O
.	O

Identification	O
of	O
deletion	O
mutations	O
and	O
three	O
new	O
genes	O
at	O
the	O
familial	B-Disease
polyposis	I-Disease
locus	O
.	O

Small	O
(	O
100	O
-	O
260	O
kb	O
)	O
,	O
nested	O
deletions	O
were	O
characterized	O
in	O
DNA	O
from	O
two	O
unrelated	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
.	O

Three	O
candidate	O
genes	O
located	O
within	O
the	O
deleted	O
region	O
were	O
ascertained	O
and	O
a	O
previous	O
candidate	O
gene	O
,	O
MCC	O
,	O
was	O
shown	O
to	O
be	O
located	O
outside	O
the	O
deleted	O
region	O
.	O

One	O
of	O
the	O
new	O
genes	O
contained	O
sequence	O
identical	O
to	O
SRP19	O
,	O
the	O
gene	O
coding	O
for	O
the	O
19	O
kd	O
component	O
of	O
the	O
ribosomal	O
signal	O
recognition	O
particle	O
.	O

The	O
second	O
,	O
provisionally	O
designated	O
DP1	O
(	O
deleted	O
in	O
polyposis	O
1	O
)	O
,	O
was	O
found	O
to	O
be	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
MCC	O
.	O

Two	O
other	O
cDNAs	O
,	O
DP2	O
and	O
DP3	O
,	O
were	O
found	O
to	O
overlap	O
,	O
forming	O
a	O
single	O
gene	O
,	O
DP2	O
.	O

5	O
,	O
that	O
is	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
SRP19	O
.	O

Exclusion	O
of	O
linkage	O
between	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
and	O
the	O
human	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
gene	O
cluster	O
.	O

We	O
studied	O
the	O
relationship	O
between	O
the	O
autosomal	O
recessive	O
trait	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
and	O
the	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
genes	O
by	O
comparing	O
alleles	O
of	O
a	O
highly	O
polymorphic	O
dinucleotide	O
repeat	O
and	O
a	O
conventional	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
in	O
the	O
SAA	O
gene	O
cluster	O
in	O
Israeli	O
FMF	B-Disease
kindreds	O
.	O

By	O
haplotype	O
analysis	O
,	O
our	O
data	O
indicate	O
a	O
minimum	O
crossover	O
frequency	O
of	O
22	O
%	O
between	O
the	O
SAA	O
gene	O
marker	O
and	O
FMF	B-Disease
.	O

By	O
conventional	O
linkage	O
analysis	O
this	O
eliminates	O
a	O
minimum	O
of	O
10	O
.	O

4	O
cM	O
including	O
and	O
surrounding	O
the	O
SAA	O
gene	O
cluster	O
as	O
the	O
site	O
of	O
the	O
FMF	B-Disease
mutation	O
although	O
SAA	O
proteins	O
are	O
prominent	O
physiologic	O
markers	O
of	O
the	O
acute	O
attacks	O
.	O

PRAD1	O
,	O
a	O
candidate	O
BCL1	O
oncogene	O
:	O
mapping	O
and	O
expression	O
in	O
centrocytic	B-Disease
lymphoma	I-Disease
.	O

Rearrangement	O
of	O
the	O
BCL1	O
(	O
B	O
-	O
cell	O
lymphoma	O
1	O
)	O
region	O
on	O
chromosome	O
11q13	O
appears	O
to	O
be	O
highly	O
characteristic	O
of	O
centrocytic	B-Disease
lymphoma	I-Disease
and	O
also	O
is	O
found	O
infrequently	O
in	O
other	O
B	B-Disease
-	I-Disease
cell	I-Disease
neoplasms	I-Disease
.	O

Rearrangement	O
is	O
thought	O
to	O
deregulate	O
a	O
nearby	O
protooncogene	O
,	O
but	O
transcribed	O
sequences	O
in	O
the	O
immediate	O
vicinity	O
of	O
BCL1	O
breakpoints	O
had	O
not	O
been	O
identified	O
.	O

PRAD1	O
,	O
previously	O
designated	O
D11S287E	O
,	O
was	O
identified	O
on	O
11q13	O
as	O
a	O
chromosomal	O
breakpoint	O
region	O
rearranged	O
with	O
the	O
parathyroid	O
hormone	O
gene	O
in	O
a	O
subset	O
of	O
parathyroid	B-Disease
adenomas	I-Disease
;	O
this	O
highly	O
conserved	O
putative	O
oncogene	O
,	O
which	O
encodes	O
a	O
novel	O
cyclin	O
,	O
has	O
been	O
linked	O
to	O
BCL1	O
and	O
implicated	O
also	O
in	O
subsets	O
of	O
breast	B-Disease
and	I-Disease
squamous	I-Disease
cell	I-Disease
neoplasms	I-Disease
with	O
11q13	O
amplification	O
.	O

We	O
report	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
data	O
showing	O
BCL1	O
and	O
PRAD1	O
to	O
be	O
no	O
more	O
than	O
130	O
kilobases	O
apart	O
.	O

PRAD1	O
mRNA	O
is	O
abundantly	O
expressed	O
in	O
seven	O
of	O
seven	O
centrocytic	B-Disease
lymphomas	I-Disease
(	O
Kiel	O
classification	O
)	O
,	O
in	O
contrast	O
to	O
13	O
closely	O
related	O
but	O
noncentrocytic	B-Disease
lymphomas	I-Disease
.	O

Three	O
of	O
the	O
seven	O
centrocytic	B-Disease
lymphomas	I-Disease
had	O
detectable	O
BCL1	O
DNA	O
rearrangement	O
.	O

Also	O
,	O
two	O
unusual	O
cases	O
of	O
CLL	O
with	O
BCL1	O
rearrangement	O
overexpressed	O
PRAD1	O
,	O
in	O
contrast	O
to	O
five	O
CLL	O
controls	O
.	O

Thus	O
,	O
PRAD1	O
is	O
an	O
excellent	O
candidate	O
"	O
BCL1	O
oncogene	O
.	O

"	O
Its	O
overexpression	O
may	O
be	O
a	O
key	O
consequence	O
of	O
rearrangement	O
of	O
the	O
BCL1	O
vicinity	O
in	O
B	B-Disease
-	I-Disease
cell	I-Disease
neoplasms	I-Disease
and	O
a	O
unifying	O
pathogenetic	O
feature	O
in	O
centrocytic	B-Disease
lymphoma	I-Disease
.	O

Two	O
new	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
mutations	O
in	O
a	O
juvenile	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
patient	O
.	O

Fragments	O
of	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
gene	O
from	O
a	O
patient	O
with	O
juvenile	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
were	O
amplified	O
by	O
PCR	O
and	O
ligated	O
into	O
MP13	O
cloning	O
vectors	O
.	O

Clones	O
hybridizing	O
with	O
cDNA	O
for	O
human	O
ARSA	O
were	O
selected	O
,	O
examined	O
for	O
appropriate	O
size	O
inserts	O
,	O
and	O
used	O
to	O
prepare	O
single	O
-	O
stranded	O
phage	O
DNA	O
.	O

Examination	O
of	O
the	O
entire	O
coding	O
and	O
most	O
of	O
the	O
intronic	O
sequence	O
revealed	O
two	O
putative	O
disease	O
-	O
related	O
mutations	O
.	O

One	O
,	O
a	O
point	O
mutation	O
in	O
exon	O
3	O
,	O
resulted	O
in	O
the	O
substitution	O
of	O
isoleucine	O
by	O
serine	O
.	O

Introduction	O
of	O
this	O
alteration	O
into	O
the	O
normal	O
ARSA	O
cDNA	O
sequence	O
resulted	O
in	O
a	O
substantial	O
decrease	O
in	O
ARSA	O
activity	O
on	O
transient	O
expression	O
in	O
cultured	O
baby	O
hamster	O
kidney	O
cells	O
.	O

About	O
5	O
%	O
of	O
the	O
control	O
expression	O
was	O
observed	O
,	O
suggesting	O
a	O
small	O
residual	O
activity	O
in	O
the	O
mutated	O
ARSA	O
.	O

The	O
second	O
mutation	O
,	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	O
,	O
occurred	O
in	O
the	O
other	O
allele	O
and	O
resulted	O
in	O
an	O
altered	O
splice	O
-	O
recognition	O
sequence	O
between	O
exon	O
7	O
and	O
the	O
following	O
intron	O
.	O

The	O
mutation	O
also	O
resulted	O
in	O
the	O
loss	O
of	O
a	O
restriction	O
site	O
.	O

Apparently	O
normal	O
levels	O
of	O
mRNA	O
were	O
generated	O
from	O
this	O
allele	O
,	O
but	O
no	O
ARSA	O
activity	O
or	O
immuno	O
-	O
cross	O
-	O
reactive	O
material	O
could	O
be	O
detected	O
.	O

A	O
collection	O
of	O
DNA	O
samples	O
from	O
known	O
or	O
suspected	O
MLD	B-Disease
patients	O
,	O
members	O
of	O
their	O
families	O
,	O
and	O
normal	O
controls	O
was	O
screened	O
for	O
these	O
mutations	O
.	O

Four	O
additional	O
individuals	O
carrying	O
each	O
of	O
the	O
mutations	O
were	O
found	O
among	O
the	O
nearly	O
100	O
MLD	B-Disease
patients	O
in	O
the	O
sample	O
.	O

Gene	O
segregation	O
in	O
the	O
original	O
patients	O
family	O
was	O
consistent	O
with	O
available	O
clinical	O
and	O
biochemical	O
data	O
.	O

No	O
individuals	O
homozygous	O
for	O
either	O
of	O
these	O
two	O
mutations	O
were	O
identified	O
.	O

However	O
,	O
combinations	O
with	O
other	O
MLD	B-Disease
mutations	O
suggest	O
that	O
the	O
point	O
mutation	O
in	O
exon	O
3	O
does	O
result	O
in	O
some	O
residual	O
enzyme	O
activity	O
and	O
is	O
associated	O
with	O
late	O
-	O
onset	O
forms	O
of	O
the	O
disease	O
.	O

The	O
splice	O
-	O
site	O
mutation	O
following	O
exon	O
7	O
produces	O
late	O
-	O
infantile	O
MLD	B-Disease
when	O
combined	O
with	O
other	O
enzyme	O
-	O
null	O
mutations	O
,	O
implying	O
that	O
it	O
is	O
completely	O
silent	O
enzymatically	O
.	O
.	O

Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
and	O
presumptive	O
expression	O
of	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
gene	O
in	O
hematopoietic	O
cell	O
lineages	O
of	O
a	O
thrombocytopenic	O
carrier	O
female	O
of	O
WAS	B-Disease
.	O

We	O
report	O
on	O
a	O
thrombocytopenic	B-Disease
female	O
belonging	O
to	O
a	O
pedigree	O
with	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
with	O
probe	O
M27	O
beta	O
,	O
closely	O
linked	O
to	O
the	O
WAS	B-Disease
gene	O
,	O
demonstrated	O
that	O
she	O
is	O
a	O
carrier	O
of	O
WAS	B-Disease
.	O

Both	O
small	O
-	O
sized	O
and	O
normal	O
-	O
sized	O
platelets	O
were	O
present	O
,	O
suggesting	O
that	O
,	O
unlike	O
the	O
vast	O
majority	O
of	O
WAS	B-Disease
carriers	O
,	O
she	O
does	O
not	O
manifest	O
nonrandom	O
X	O
-	O
chromosome	O
inactivation	O
in	O
the	O
thrombopoietic	O
cell	O
lineage	O
.	O

Study	O
of	O
X	O
-	O
chromosome	O
inactivation	O
by	O
means	O
of	O
RFLP	O
and	O
methylation	O
analysis	O
demonstrated	O
that	O
the	O
pattern	O
of	O
X	O
-	O
chromosome	O
inactivation	O
was	O
nonrandom	O
in	O
T	O
lymphocytes	O
,	O
but	O
random	O
in	O
granulocytes	O
.	O

While	O
this	O
is	O
the	O
first	O
complete	O
report	O
on	O
the	O
occurrence	O
of	O
thrombocytopenia	B-Disease
in	O
a	O
carrier	O
female	O
of	O
WAS	B-Disease
as	O
the	O
result	O
of	O
atypical	O
lyonization	O
,	O
it	O
also	O
suggests	O
that	O
expression	O
of	O
the	O
WAS	B-Disease
gene	O
occurs	O
at	O
(	O
or	O
extends	O
up	O
to	O
)	O
a	O
later	O
stage	O
than	O
the	O
multipotent	O
stem	O
cell	O
along	O
the	O
hematopoietic	O
differentiation	O
pathway	O
.	O
.	O

A	O
new	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
.	O

A	O
C	O
-	O
to	O
-	O
T	O
transition	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
was	O
found	O
in	O
2	O
affected	O
males	O
and	O
two	O
obligate	O
carriers	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
.	O

The	O
mutation	O
,	O
which	O
causes	O
loss	O
of	O
an	O
HphI	O
site	O
and	O
changes	O
amino	O
acid	O
155	O
from	O
threonine	O
to	O
isoleucine	O
,	O
was	O
absent	O
from	O
108	O
normal	O
chromosomes	O
.	O

There	O
are	O
5	O
concordances	O
and	O
1	O
discrepancy	O
between	O
these	O
results	O
and	O
those	O
obtained	O
by	O
magnetic	O
resonance	O
imaging	O
in	O
this	O
family	O
.	O
.	O

A	O
3	O
-	O
base	O
pair	O
in	O
-	O
frame	O
deletion	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
results	O
in	O
a	O
kinetic	O
variant	O
of	O
phenylketonuria	B-Disease
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
due	O
to	O
deficiency	B-Disease
of	I-Disease
a	I-Disease
hepatic	I-Disease
enzyme	I-Disease
,	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

The	O
absence	O
of	O
PAH	O
activity	O
results	O
in	O
typical	O
PKU	B-Disease
while	O
persistence	O
of	O
a	O
residual	O
enzyme	O
activity	O
gives	O
rise	O
to	O
variant	O
forms	O
of	O
the	O
disease	O
.	O

We	O
report	O
here	O
a	O
3	O
-	O
base	O
pair	O
in	O
-	O
frame	O
deletion	O
of	O
the	O
PAH	O
gene	O
(	O
delta	O
194	O
)	O
in	O
a	O
mild	O
variant	O
,	O
with	O
markedly	O
reduced	O
affinity	O
of	O
the	O
enzyme	O
for	O
phenylalanine	O
(	O
Km	O
=	O
160	O
nM	O
)	O
,	O
and	O
we	O
provide	O
functional	O
evidence	O
for	O
responsibility	O
of	O
the	O
deletion	O
in	O
the	O
mutant	O
phenotype	O
.	O

Since	O
the	O
deletion	O
was	O
located	O
in	O
the	O
third	O
exon	O
of	O
the	O
gene	O
,	O
which	O
presents	O
no	O
homology	O
with	O
other	O
hydroxylases	O
,	O
we	O
suggest	O
that	O
exon	O
3	O
is	O
involved	O
in	O
the	O
specificity	O
of	O
the	O
enzyme	O
for	O
phenylalanine	O
.	O

Finally	O
,	O
since	O
none	O
of	O
the	O
98	O
PKU	B-Disease
patients	O
tested	O
were	O
found	O
to	O
carry	O
this	O
particular	O
deletion	O
,	O
our	O
study	O
suggests	O
that	O
this	O
molecular	O
event	O
probably	O
occurred	O
recently	O
on	O
the	O
background	O
of	O
a	O
haplotype	O
2	O
gene	O
in	O
Portugal	O
.	O
.	O

Mutation	O
of	O
the	O
KIT	O
(	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
receptor	O
)	O
protooncogene	O
in	O
human	O
piebaldism	B-Disease
.	O

Piebaldism	B-Disease
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
genetic	I-Disease
disorder	I-Disease
characterized	O
by	O
cogenital	O
patches	O
of	O
skin	O
and	O
hair	O
from	O
which	O
melanocytes	O
are	O
completely	O
absent	O
.	O

A	O
similar	O
disorder	O
of	O
mouse	O
,	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
,	O
results	O
from	O
mutations	O
of	O
the	O
c	O
-	O
Kit	O
protooncogene	O
,	O
which	O
encodes	O
and	O
receptor	O
for	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
.	O

We	O
identified	O
a	O
KIT	O
gene	O
mutation	O
in	O
a	O
proband	O
with	O
classic	O
autosomal	O
dominant	O
piebaldism	B-Disease
.	O

This	O
mutation	O
results	O
in	O
a	O
Gly	O
-	O
-	O
-	O
-	O
Arg	O
substitution	O
at	O
codon	O
664	O
,	O
within	O
the	O
tyrosine	O
kinase	O
domain	O
.	O

This	O
substitution	O
was	O
not	O
seen	O
in	O
any	O
normal	O
individuals	O
and	O
was	O
completely	O
linked	O
to	O
the	O
piebald	B-Disease
phenotype	O
in	O
the	O
probands	O
family	O
.	O

Piebaldism	B-Disease
in	O
this	O
family	O
thus	O
appears	O
to	O
be	O
the	O
human	O
homologue	O
to	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
of	O
the	O
mouse	O
.	O
.	O

Genetic	O
analysis	O
of	O
a	O
Japanese	O
family	O
with	O
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
indicates	O
a	O
lack	O
of	O
linkage	O
to	O
the	O
apolipoprotein	O
B	O
gene	O
.	O

Normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
is	O
a	O
rare	O
familial	B-Disease
disorder	I-Disease
characterized	O
by	O
an	O
isolated	O
deficiency	B-Disease
of	I-Disease
apoB	I-Disease
-	I-Disease
100	I-Disease
.	O

We	O
have	O
previously	O
reported	O
a	O
patient	O
with	O
this	O
disease	O
,	O
who	O
had	O
normal	O
apoB	O
-	O
48	O
but	O
no	O
apoB	O
-	O
100	O
.	O

To	O
elucidate	O
the	O
genetic	B-Disease
abnormalities	I-Disease
in	O
this	O
family	O
,	O
we	O
studied	O
the	O
linkage	O
of	O
apoB	O
gene	O
using	O
three	O
genetic	O
markers	O
.	O

The	O
proband	O
and	O
her	O
affected	O
brother	O
showed	O
completely	O
different	O
apoB	O
gene	O
alleles	O
,	O
suggesting	O
that	O
the	O
apoB	O
gene	O
itself	O
is	O
not	O
related	O
to	O
this	O
disorder	O
in	O
this	O
family	O
.	O

By	O
contrast	O
,	O
an	O
American	O
case	O
had	O
a	O
point	O
substitution	O
in	O
the	O
apoB	O
gene	O
generating	O
an	O
in	O
-	O
frame	O
stop	O
codon	O
.	O

These	O
results	O
indicate	O
that	O
this	O
disorder	O
can	O
be	O
caused	O
by	O
defect	O
(	O
s	O
)	O
of	O
either	O
an	O
apoB	O
gene	O
or	O
other	O
genes	O
.	O
.	O

Localisation	O
of	O
the	O
gene	O
for	O
Norrie	B-Disease
disease	I-Disease
to	O
between	O
DXS7	O
and	O
DXS426	O
on	O
Xp	O
.	O

A	O
highly	O
informative	O
microsatellite	O
marker	O
,	O
DXS426	O
,	O
which	O
maps	O
proximal	O
to	O
DXS7	O
in	O
the	O
interval	O
Xp11	O
.	O

4	O
-	O
Xp11	O
4	O
-	O
Xp11	O
.	O

23	O
,	O
has	O
been	O
used	O
to	O
refine	O
further	O
the	O
localisation	O
of	O
the	O
gene	O
for	O
Norrie	B-Disease
disease	I-Disease
(	O
NDP	B-Disease
)	O
.	O

The	O
results	O
from	O
a	O
multiply	O
informative	O
crossover	O
localize	O
the	O
NDP	B-Disease
gene	O
proximal	O
to	O
DXS7	O
.	O

In	O
conjunction	O
with	O
information	O
from	O
2	O
NDP	B-Disease
patients	O
who	O
have	O
a	O
deletion	O
for	O
DXS7	O
but	O
not	O
for	O
DSX426	O
,	O
our	O
data	O
indicate	O
that	O
the	O
NDP	B-Disease
gene	O
lies	O
between	O
DXS7	O
and	O
DXS426	O
on	O
proximal	O
Xp	O
.	O

Aberrant	O
splicing	O
of	O
phenylalanine	O
hydroxylase	O
mRNA	O
:	O
the	O
major	O
cause	O
for	O
phenylketonuria	B-Disease
in	O
parts	O
of	O
southern	O
Europe	O
.	O

We	O
report	O
a	O
mutation	O
within	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
that	O
causes	O
aberrant	O
splicing	O
of	O
the	O
mRNA	O
and	O
that	O
is	O
in	O
tight	O
association	O
with	O
chromosomal	O
haplotypes	O
6	O
,	O
10	O
,	O
and	O
36	O
.	O

Because	O
of	O
the	O
high	O
frequency	O
of	O
these	O
particular	O
haplotypes	O
in	O
Bulgaria	O
,	O
Italy	O
,	O
and	O
Turkey	O
,	O
it	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequent	O
defects	O
in	O
the	O
PAH	O
gene	O
causing	O
classical	O
phenylketonuria	B-Disease
in	O
this	O
part	O
of	O
Europe	O
.	O

The	O
mutation	O
is	O
a	O
G	O
to	O
A	O
transition	O
at	O
position	O
546	O
in	O
intron	O
10	O
of	O
the	O
PAH	O
gene	O
,	O
11	O
bp	O
upstream	O
from	O
the	O
intron	O
10	O
/	O
exon	O
11	O
boundary	O
.	O

It	O
activates	O
a	O
cryptic	O
splice	O
site	O
and	O
results	O
in	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
9	O
nucleotides	O
between	O
exon	O
10	O
and	O
exon	O
11	O
of	O
the	O
processed	O
mRNA	O
.	O

Normal	O
amounts	O
of	O
liver	O
PAH	O
protein	O
are	O
present	O
in	O
homozygous	O
patients	O
,	O
but	O
no	O
catalytic	O
activity	O
can	O
be	O
detected	O
.	O

This	O
loss	O
of	O
enzyme	O
activity	O
is	O
probably	O
caused	O
by	O
conformational	O
changes	O
resulting	O
from	O
the	O
insertion	O
of	O
three	O
additional	O
amino	O
acids	O
(	O
Gly	O
-	O
Leu	O
-	O
Gln	O
)	O
between	O
the	O
normal	O
sequences	O
encoded	O
by	O
exon	O
10	O
and	O
exon	O
11	O
.	O
.	O

Gardner	B-Disease
syndrome	I-Disease
in	O
a	O
boy	O
with	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

We	O
described	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
Gardner	B-Disease
syndrome	I-Disease
(	O
GS	B-Disease
)	O
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
craniofacial	B-Disease
abnormalities	I-Disease
.	O

High	O
-	O
resolution	O
banding	O
analysis	O
showed	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
(	O
q22	O
.	O
1	O
-	O
-	O
-	O
-	O
q31	O
1	O
-	O
-	O
-	O
-	O
q31	O
.	O
1	O
)	O
.	O

The	O
breakpoints	O
in	O
the	O
present	O
case	O
and	O
in	O
3	O
previously	O
reported	O
5q	O
-	O
patients	O
with	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
suggest	O
that	O
the	O
gene	O
responsible	O
for	O
GS	B-Disease
/	O
or	O
familial	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
FPC	B-Disease
)	O
is	O
in	O
the	O
5q22	O
region	O
,	O
a	O
result	O
consistent	O
with	O
the	O
findings	O
of	O
linkage	O
studies	O

Huntington	B-Disease
disease	I-Disease
and	O
childhood	O
-	O
onset	O
Tourette	B-Disease
syndrome	I-Disease
.	O

A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
childhood	O
-	O
onset	O
Tourette	B-Disease
syndrome	I-Disease
(	O
TS	B-Disease
)	O
developed	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
.	O

We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood	O
-	O
onset	O
TS	B-Disease
with	O
adult	O
onset	O
HD	B-Disease
.	O

Discovery	O
of	O
other	O
cases	O
with	O
both	O
disorders	O
may	O
provide	O
clues	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
.	O
.	O

Sequence	O
of	O
DNA	O
flanking	O
the	O
exons	O
of	O
the	O
HEXA	O
gene	O
,	O
and	O
identification	O
of	O
mutations	O
in	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
.	O

The	O
rapid	O
identification	O
of	O
mutations	O
causing	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
requires	O
the	O
capacity	O
to	O
readily	O
screen	O
the	O
regions	O
of	O
the	O
HEXA	O
gene	O
most	O
likely	O
to	O
be	O
affected	O
by	O
mutation	O
.	O

We	O
have	O
sequenced	O
the	O
portions	O
of	O
the	O
introns	O
flanking	O
each	O
of	O
the	O
14	O
HEXA	O
exons	O
in	O
order	O
to	O
specify	O
oligonucleotide	O
primers	O
for	O
the	O
PCR	O
-	O
dependent	O
amplification	O
of	O
each	O
exon	O
and	O
splice	O
-	O
junction	O
sequence	O
.	O

The	O
amplified	O
products	O
were	O
analyzed	O
,	O
by	O
electrophoresis	O
in	O
nondenaturing	O
polyacrylamide	O
gels	O
,	O
for	O
the	O
presence	O
of	O
either	O
heteroduplexes	O
,	O
derived	O
from	O
the	O
annealing	O
of	O
normal	O
and	O
mutant	O
DNA	O
strands	O
,	O
or	O
single	O
-	O
strand	O
conformational	O
polymorphisms	O
(	O
SSCP	O
)	O
,	O
derived	O
from	O
the	O
renaturation	O
of	O
single	O
-	O
stranded	O
DNA	O
.	O

Five	O
novel	O
mutations	O
from	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
patients	O
were	O
detected	O
a	O
5	O
-	O
bp	O
deletion	O
of	O
TCTCC	O
in	O
IVS	O
-	O
9	O
;	O
a	O
2	O
-	O
bp	O
deletion	O
of	O
TG	O
in	O
exon	O
5	O
;	O
G78	O
to	O
A	O
,	O
giving	O
a	O
stop	O
codon	O
in	O
exon	O
1	O
;	O
G533	O
to	O
T	O
in	O
exon	O
5	O
,	O
producing	O
the	O
third	O
amino	O
acid	O
substitution	O
detected	O
at	O
this	O
site	O
;	O
and	O
G	O
to	O
C	O
at	O
position	O
1	O
of	O
IVS	O
-	O
2	O
,	O
expected	O
to	O
produce	O
abnormal	O
splicing	O
.	O

In	O
addition	O
,	O
two	O
mutations	O
,	O
(	O
G1496	O
to	O
A	O
in	O
exon	O
13	O
and	O
a	O
4	O
-	O
bp	O
insertion	O
in	O
exon	O
11	O
)	O
that	O
have	O
previously	O
been	O
reported	O
were	O
identified	O
.	O
.	O

Molecular	O
characterization	O
of	O
two	O
galactosemia	B-Disease
mutations	O
:	O
correlation	O
of	O
mutations	O
with	O
highly	O
conserved	O
domains	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyl	O
transferase	O
.	O

Galactosemia	B-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	I-Disease
human	I-Disease
galactose	I-Disease
metabolism	I-Disease
caused	O
by	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
enzyme	I-Disease
galactose	I-Disease
-	I-Disease
1	I-Disease
-	I-Disease
phosphate	I-Disease
uridyl	I-Disease
transferase	I-Disease
(	O
GALT	O
)	O
.	O

The	O
molecular	O
basis	O
of	O
this	O
disorder	O
is	O
at	O
present	O
not	O
well	O
understood	O
.	O

We	O
report	O
here	O
two	O
missense	O
mutations	O
which	O
result	O
in	O
low	O
or	O
undetectable	O
enzymatic	O
activity	O
.	O

First	O
,	O
we	O
identified	O
at	O
nucleotide	O
591	O
a	O
transition	O
which	O
substitutes	O
glutamine	O
188	O
by	O
arginine	O
.	O

The	O
mutated	O
glutamine	O
is	O
not	O
only	O
highly	O
conserved	O
in	O
evolution	O
(	O
conserved	O
also	O
in	O
Escherichia	O
coli	O
and	O
Saccharomyces	O
cerevisiae	O
)	O
,	O
but	O
is	O
also	O
two	O
amino	O
acid	O
residues	O
downstream	O
from	O
the	O
active	O
site	O
histidine	O
-	O
proline	O
-	O
histidine	O
triad	O
and	O
results	O
in	O
about	O
10	O
%	O
of	O
normal	O
enzymatic	O
activity	O
.	O

The	O
arginine	O
188	O
mutation	O
is	O
the	O
most	O
common	O
galactosemia	B-Disease
mutation	O
characterized	O
to	O
date	O
.	O

It	O
accounts	O
for	O
one	O
-	O
fourth	O
of	O
the	O
galactosemia	B-Disease
alleles	O
studied	O
.	O

Second	O
,	O
we	O
report	O
the	O
substitution	O
of	O
arginine	O
333	O
by	O
tryptophan	O
,	O
caused	O
by	O
a	O
transition	O
at	O
nucleotide	O
1025	O
.	O

The	O
area	O
surrounding	O
this	O
missense	O
mutation	O
is	O
the	O
most	O
highly	O
conserved	O
domain	O
in	O
the	O
homologous	O
enzymes	O
from	O
E	O
.	O
coli	O
,	O
yeast	O
,	O
and	O
humans	O
,	O
and	O
this	O
mutation	O
results	O
in	O
undetectable	O
enzymatic	O
activity	O
,	O
suggesting	O
that	O
this	O
is	O
a	O
severe	O
mutation	O
.	O

This	O
second	O
mutation	O
appears	O
to	O
be	O
rare	O
,	O
since	O
it	O
was	O
found	O
only	O
in	O
the	O
patient	O
we	O
sequenced	O
.	O

Our	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
heterogeneity	O
of	O
galactosemia	B-Disease
at	O
the	O
molecular	O
level	O
,	O
heterogeneity	O
which	O
might	O
be	O
related	O
to	O
the	O
variable	O
clinical	O
outcome	O
observed	O
in	O
this	O
disorder	O
.	O
.	O

Hypoxanthine	B-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
deficiency	I-Disease
:	O
analysis	O
of	O
HPRT	O
mutations	O
by	O
direct	O
sequencing	O
and	O
allele	O
-	O
specific	O
amplification	O
.	O

The	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
is	O
a	O
severe	O
X	B-Disease
chromosome	I-Disease
-	I-Disease
linked	I-Disease
human	I-Disease
disease	I-Disease
caused	O
by	O
a	O
virtual	O
absence	B-Disease
of	I-Disease
hypoxanthine	I-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
(	I-Disease
HPRT	I-Disease
)	I-Disease
activity	I-Disease
.	O

A	O
partial	O
deficiency	O
in	O
the	O
activity	O
of	O
this	O
enzyme	O
can	O
result	O
in	O
gouty	B-Disease
arthritis	I-Disease
.	O

To	O
determine	O
the	O
genetic	O
basis	O
for	O
reduction	O
or	O
loss	O
of	O
enzyme	O
activity	O
,	O
we	O
have	O
amplified	O
and	O
sequenced	O
the	O
coding	O
region	O
of	O
HPRT	O
cDNA	O
from	O
four	O
patients	O
one	O
with	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
(	O
HPRTPerth	O
)	O
and	O
three	O
with	O
partial	B-Disease
deficiencies	I-Disease
of	I-Disease
HPRT	I-Disease
activity	I-Disease
,	O
which	O
have	O
been	O
designated	O
HPRTUrangan	O
,	O
HPRTSwan	O
and	O
HPRTToowong	O
.	O

In	O
all	O
four	O
patients	O
,	O
the	O
only	O
mutation	O
identified	O
was	O
a	O
single	O
base	O
substitution	O
in	O
exons	O
2	O
or	O
3	O
of	O
the	O
coding	O
region	O
,	O
which	O
in	O
each	O
case	O
predicts	O
a	O
single	O
amino	O
acid	O
substitution	O
in	O
the	O
translated	O
protein	O
.	O

Each	O
base	O
change	O
was	O
confirmed	O
by	O
allele	O
-	O
specific	O
amplification	O
of	O
the	O
patients	O
genomic	O
DNA	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
mutation	O
found	O
for	O
HPRTPerth	O
is	O
identical	O
to	O
that	O
reported	O
for	O
HPRTFlint	O
.	O

It	O
appears	O
that	O
the	O
two	O
mutations	O
are	O
de	O
novo	O
events	O
.	O
.	O

Molecular	O
and	O
metabolic	O
basis	O
for	O
the	O
metabolic	B-Disease
disorder	I-Disease
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
.	O

We	O
have	O
previously	O
described	O
a	O
disorder	O
,	O
normotriglyceridemic	B-Disease
abetalipoproteinemia	I-Disease
,	O
that	O
is	O
characterized	O
by	O
the	O
virtual	O
absence	O
of	O
plasma	O
low	O
density	O
lipoproteins	O
and	O
complete	O
absence	O
of	O
apoB	O
-	O
100	O
,	O
but	O
with	O
apparently	O
normal	O
secretion	O
of	O
triglyceride	O
-	O
rich	O
lipoproteins	O
containing	O
apoB	O
-	O
48	O
.	O

The	O
patients	O
plasma	O
lipoproteins	O
were	O
shown	O
on	O
polyacrylamide	O
gels	O
and	O
by	O
antibody	O
mapping	O
to	O
have	O
a	O
new	O
truncated	O
apoB	O
variant	O
,	O
apoB	O
-	O
50	O
,	O
circulating	O
along	O
with	O
her	O
apoB	O
-	O
48	O
.	O

We	O
have	O
found	O
this	O
individual	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
C	O
-	O
to	O
-	O
T	O
nucleotide	O
substitution	O
at	O
apoB	O
codon	O
2252	O
,	O
which	O
produces	O
a	O
premature	O
in	O
-	O
frame	O
stop	O
codon	O
.	O

Thus	O
,	O
this	O
is	O
a	O
rare	O
example	O
of	O
homozygous	B-Disease
hypobetalipoproteinemia	I-Disease
.	O

Electron	O
photomicrographs	O
revealed	O
that	O
the	O
diameters	O
of	O
particles	O
in	O
the	O
d	O
less	O
than	O
1	O
.	O

006	O
g	O
/	O
ml	O
lipoprotein	O
fraction	O
,	O
in	O
both	O
the	O
postprandial	O
and	O
postabsorptive	O
state	O
,	O
are	O
bimodally	O
distributed	O
.	O

The	O
molar	O
ratio	O
of	O
apoE	O
to	O
apoB	O
in	O
these	O
particles	O
is	O
3	O
.	O

5	O
1	O
,	O
similar	O
to	O
normal	O
VLDL	O
.	O

The	O
plasma	O
LDL	O
interval	O
contains	O
both	O
spherical	O
and	O
cuboidal	O
particles	O
.	O

Autologous	O
reinfusion	O
of	O
labeled	O
d	O
less	O
than	O
1	O
.	O

006	O
g	O
/	O
ml	O
lipoproteins	O
showed	O
exponential	O
disappearance	O
from	O
plasma	O
,	O
with	O
an	O
apparent	O
half	O
-	O
removal	O
time	O
of	O
50	O
min	O
,	O
somewhat	O
slower	O
than	O
for	O
normal	O
chylomicrons	O
but	O
within	O
the	O
normal	O
range	O
for	O
VLDL	O
.	O

The	O
calculated	O
production	O
rate	O
for	O
apoB	O
was	O
within	O
the	O
normal	O
range	O
in	O
this	O
subject	O
.	O

A	O
single	O
origin	O
of	O
phenylketonuria	B-Disease
in	O
Yemenite	O
Jews	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
a	O
metabolic	B-Disease
disease	I-Disease
caused	O
by	O
recessive	O
mutations	O
of	O
the	O
gene	O
encoding	O
the	O
hepatic	O
enzyme	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

The	O
incidence	O
of	O
PKU	B-Disease
varies	O
widely	O
across	O
different	O
geographic	O
areas	O
,	O
and	O
is	O
highest	O
(	O
about	O
1	O
in	O
5	O
,	O
000	O
live	O
births	O
)	O
in	O
Ireland	O
and	O
western	O
Scotland	O
,	O
and	O
among	O
Yemenite	O
Jews	O
.	O

A	O
limited	O
number	O
of	O
point	O
mutations	O
account	O
for	O
most	O
of	O
the	O
PKU	B-Disease
cases	O
in	O
the	O
European	O
population	O
.	O

Here	O
we	O
report	O
that	O
a	O
single	O
molecular	O
defect	O
-	O
-	O
a	O
deletion	O
spanning	O
the	O
third	O
exon	O
of	O
the	O
PAH	O
gene	O
-	O
-	O
is	O
responsible	O
for	O
all	O
the	O
PKU	B-Disease
cases	O
among	O
the	O
Yemenite	O
Jews	O
.	O

Examination	O
of	O
a	O
random	O
sample	O
of	O
Yemenite	O
Jews	O
using	O
a	O
molecular	O
probe	O
that	O
detects	O
the	O
carriers	O
of	O
this	O
deletion	O
indicated	O
a	O
high	O
frequency	O
of	O
the	O
defective	O
gene	O
in	O
this	O
community	O
.	O

Although	O
the	O
deleted	O
PAH	O
gene	O
was	O
traced	O
to	O
25	O
different	O
locations	O
throughout	O
Yemen	O
,	O
family	O
histories	O
and	O
official	O
documents	O
of	O
the	O
Yemenite	O
Jewish	O
community	O
showed	O
that	O
the	O
common	O
ancestor	O
of	O
all	O
the	O
carriers	O
of	O
this	O
genetic	B-Disease
defect	I-Disease
lived	O
in	O
Sana	O
,	O
the	O
capital	O
of	O
Yemen	O
,	O
before	O
the	O
eighteenth	O
century	O
.	O
.	O

Linkage	O
of	O
aspartylglucosaminuria	B-Disease
(	O
AGU	B-Disease
)	O
to	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
.	O

Aspartylglucosaminuria	B-Disease
(	O
AGU	B-Disease
)	O
is	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
enzyme	O
aspartylglucosaminidase	O
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
AGA	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21	O
-	O
qter	O
of	O
chromosome	O
4	O
.	O

We	O
have	O
studied	O
the	O
map	O
position	O
of	O
the	O
AGU	O
locus	O
in	O
relation	O
to	O
other	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
using	O
linkage	O
analyses	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
alleles	O
for	O
the	O
ADH2	O
,	O
ADH3	O
,	O
EGF	O
,	O
FG	O
alpha	O
and	O
FG	O
beta	O
loci	O
and	O
blood	O
group	O
antigens	O
for	O
the	O
MNS	O
locus	O
were	O
determined	O
in	O
a	O
panel	O
of	O
12	O
Finnish	O
AGU	B-Disease
families	O
.	O

The	O
heterozygous	O
family	O
members	O
were	O
identified	O
by	O
reduced	O
activity	O
of	O
AGA	O
in	O
lymphocytes	O
.	O

Linkage	O
studies	O
were	O
performed	O
using	O
both	O
pairwise	O
and	O
multipoint	O
analyses	O
.	O

Loose	O
linkage	O
of	O
the	O
AGU	B-Disease
locus	O
to	O
the	O
FG	O
and	O
MNS	O
loci	O
was	O
observed	O
(	O
z	O
=	O
1	O
.	O
16	O
,	O
z	O
=	O
1	O
.	O
39	O
,	O
respectively	O
)	O
.	O

Multipoint	O
analysis	O
to	O
the	O
fixed	O
map	O
[	O
ADH	O
-	O
(	O
0	O
.	O
03	O
)	O
-	O
EGF	O
-	O
(	O
0	O
.	O
35	O
)	O
-	O
FG	O
-	O
(	O
0	O
.	O
11	O
)	O
-	O
MNS	O
]	O
suggests	O
that	O
the	O
location	O
of	O
the	O
AGU	O
locus	O
is	O
0	O
.	O

05	O
-	O
0	O
.	O

30	O
recombination	O
units	O
distal	O
to	O
MNS	O
(	O
z	O
=	O
3	O
.	O
03	O
)	O
.	O

The	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
FG	O
-	O
MNS	O
-	O
AGU	O
is	O
35	O
times	O
more	O
likely	O
than	O
the	O
next	O
best	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
AGU	O
-	O
FG	O
-	O
MNS	O
.	O

Linkage	O
relationships	O
of	O
the	O
apolipoprotein	O
C1	O
gene	O
and	O
a	O
cytochrome	O
P450	O
gene	O
(	O
CYP2A	O
)	O
to	O
myotonic	B-Disease
dystrophy	I-Disease
.	O

We	O
have	O
studied	O
the	O
genetic	O
linkage	O
of	O
two	O
markers	O
,	O
the	O
apolipoprotein	O
C1	O
(	O
APOC1	O
)	O
gene	O
and	O
a	O
cytochrome	O
P450	O
(	O
CYP2A	O
)	O
gene	O
,	O
in	O
relation	O
to	O
the	O
gene	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
.	O

A	O
peak	O
lod	O
score	O
of	O
9	O
.	O

29	O
at	O
2	O
cM	O
was	O
observed	O
for	O
APOC1	O
-	O
DM	O
,	O
with	O
a	O
lod	O
score	O
of	O
8	O
.	O

55	O
at	O
4	O
cM	O
for	O
CYP2A	O
-	O
DM	O
.	O

These	O
two	O
markers	O
also	O
show	O
close	O
linkage	O
to	O
each	O
other	O
(	O
theta	O
max	O
=	O
0	O
.	O
05	O
,	O
Zmax	O
=	O
9	O
.	O
09	O
)	O
.	O

From	O
examination	O
of	O
the	O
genotypes	O
of	O
the	O
recombinant	O
individuals	O
,	O
CYP2A	O
appears	O
to	O
map	O
proximal	O
to	O
DM	O
because	O
in	O
one	O
recombinant	O
individual	O
CYP2A	O
,	O
APOC2	O
and	O
CKMM	O
had	O
all	O
recombined	O
with	O
DM	O
.	O

Evidence	O
from	O
another	O
CYP2A	O
-	O
DM	O
recombinant	O
individual	O
places	O
CYP2A	O
proximal	O
to	O
APOC2	O
and	O
CKMM	O
.	O

Localisation	O
of	O
CYP2A	O
on	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
also	O
suggests	O
that	O
it	O
is	O
proximal	O
to	O
DM	O
and	O
APOC2	O
/	O
C1	O
/	O
E	O
gene	O
cluster	O
.	O

Genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
around	O
the	O
gene	O
for	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
on	O
chromosome	O
5	O
.	O

A	O
genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
close	O
to	O
the	O
gene	O
(	O
APC	O
)	O
for	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
on	O
chromosome	O
5q	O
is	O
reported	O
.	O

One	O
hundred	O
fifty	O
-	O
five	O
typed	O
members	O
of	O
nine	O
FAP	B-Disease
kindred	O
provided	O
more	O
than	O
90	O
meioses	O
for	O
linkage	O
analysis	O
.	O

A	O
number	O
of	O
crucial	O
recombination	O
events	O
have	O
been	O
identified	O
which	O
are	O
informative	O
at	O
three	O
or	O
more	O
loci	O
,	O
allowing	O
confident	O
ordering	O
of	O
parts	O
of	O
the	O
map	O
.	O

There	O
was	O
no	O
evidence	O
of	O
genetic	O
heterogeneity	O
,	O
with	O
all	O
families	O
showing	O
linkage	O
of	O
at	O
least	O
one	O
chromosome	O
5	O
marker	O
to	O
the	O
gene	O
.	O

Recombination	O
data	O
and	O
two	O
-	O
point	O
linkage	O
analysis	O
support	O
a	O
locus	O
order	O
of	O
centromere	O
-	O
pi	O
227	O
-	O
C11P11	O
-	O
ECB27	O
-	O
L5	O
.	O

62	O
-	O
APC	O
-	O
EF5	O
62	O
-	O
APC	O
-	O
EF5	O
.	O

44	O
-	O
YN5	O
44	O
-	O
YN5	O
.	O

48	O
-	O
telomer	O
e	O
,	O
although	O
EF5	O
.	O

44	O
could	O
lie	O
in	O
the	O
interval	O
L5	O
.	O

62	O
-	O
APC	O
or	O
ECB27	O
-	O
L5	O
.	O

62	O
.	O

No	O
recombinants	O
were	O
identified	O
between	O
APC	O
and	O
either	O
EF5	O
.	O

44	O
or	O
YN5	O
.	O

48	O
,	O
but	O
published	O
deletion	O
mapping	O
in	O
colorectal	B-Disease
carcinomas	I-Disease
and	O
linkage	O
analysis	O
in	O
FAP	B-Disease
suggest	O
that	O
YN5	O
.	O

48	O
is	O
1	O
-	O
3	O
cM	O
from	O
APC	O
.	O

The	O
present	O
study	O
suggests	O
that	O
YN5	O
.	O

48	O
and	O
L5	O
.	O

62	O
delineate	O
a	O
small	O
region	O
of	O
chromosome	O
5	O
within	O
which	O
the	O
EF5	O
.	O

44	O
locus	O
lies	O
very	O
close	O
to	O
the	O
APC	B-Disease
gene	O
.	O

These	O
data	O
not	O
only	O
allow	O
use	O
of	O
flanking	O
markers	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	B-Disease
but	O
also	O
provide	O
a	O
high	O
-	O
density	O
map	O
of	O
the	O
region	O
for	O
isolation	O
of	O
the	O
APC	B-Disease
gene	O
itself	O
and	O
for	O
further	O
assessment	O
of	O
the	O
role	O
of	O
chromosome	O
5	O
deletions	O
in	O
the	O
biology	O
of	O
sporadic	O
colorectal	B-Disease
cancer	I-Disease
.	O

Serum	O
amyloid	O
A	O
and	O
P	O
protein	O
genes	O
in	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
.	O

Two	O
recent	O
studies	O
have	O
suggested	O
the	O
involvement	O
of	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
and	O
P	O
(	O
APCS	O
)	O
genes	O
in	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
MEF	B-Disease
)	O
.	O

To	O
test	O
the	O
role	O
of	O
SAA	O
and	O
APCS	O
in	O
MEF	B-Disease
and	O
MEF	B-Disease
-	I-Disease
amyloidosis	I-Disease
,	O
we	O
studied	O
17	O
informative	O
families	O
(	O
15	O
Armenians	O
,	O
2	O
non	O
-	O
Ashkenazi	O
Jews	O
)	O
and	O
8	O
MEF	B-Disease
patients	O
with	O
amyloidosis	B-Disease
using	O
a	O
candidate	O
gene	O
approach	O
.	O

No	O
evidence	O
for	O
any	O
MEF	B-Disease
-	O
associated	O
polymorphism	O
was	O
found	O
in	O
any	O
of	O
the	O
41	O
Armenian	O
and	O
Jewish	O
MEF	B-Disease
patients	O
tested	O
.	O

Our	O
family	O
studies	O
allowed	O
us	O
to	O
rule	O
out	O
tight	O
linkage	O
between	O
SAA	O
and	O
MEF	B-Disease
(	O
lod	O
score	O
=	O
-	O
2	O
.	O
16	O
,	O
theta	O
less	O
than	O
or	O
equal	O
to	O
0	O
.	O
06	O
)	O
.	O

For	O
APCS	O
we	O
found	O
that	O
the	O
allele	O
frequency	O
in	O
the	O
MEF	B-Disease
-	I-Disease
amyloidosis	I-Disease
patients	O
was	O
similar	O
to	O
that	O
in	O
18	O
unrelated	O
MEF	B-Disease
patients	O
without	O
amyloidosis	B-Disease
and	O
their	O
33	O
healthy	O
parents	O
.	O

Some	O
Mexican	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
revisited	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
appears	O
to	O
be	O
fairly	O
common	O
in	O
Mexico	O
.	O

We	O
have	O
now	O
examined	O
the	O
DNA	O
of	O
three	O
previously	O
reported	O
electrophoretically	O
fast	O
Mexican	O
G6PD	O
variants	O
,	O
-	O
G6PD	O
Distrito	O
Federal	O
,	O
G6PD	O
Tepic	O
,	O
and	O
G6PD	O
Castilla	O
.	O

All	O
three	O
of	O
these	O
variants	O
,	O
believed	O
on	O
the	O
basis	O
of	O
biochemical	O
characterization	O
and	O
population	O
origin	O
to	O
be	O
unique	O
,	O
have	O
the	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
at	O
nucleotide	O
202	O
and	O
the	O
A	O
-	O
-	O
-	O
-	O
G	O
transition	O
at	O
nucleotide	O
376	O
,	O
mutations	O
that	O
we	O
now	O
recognize	O
to	O
be	O
characteristic	O
of	O
G6PD	O
A	O
-	O
.	O

Two	O
other	O
Mexican	O
males	O
with	O
G6PD	B-Disease
deficiency	I-Disease
were	O
found	O
to	O
have	O
the	O
same	O
mutation	O
.	O

All	O
five	O
have	O
the	O
(	O
NlaIII	O
/	O
FokI	O
/	O
PvuII	O
/	O
PstI	O
)	O
haplotype	O
characteristic	O
of	O
G6PD	O
A	O
-	O
in	O
Africa	O
.	O

Since	O
the	O
PvuII	O
+	O
genotype	O
seems	O
to	O
be	O
rare	O
in	O
Europe	O
,	O
we	O
conclude	O
that	O
all	O
of	O
these	O
G6PD	O
A	O
-	O
genes	O
had	O
their	O
ancient	O
origin	O
in	O
Africa	O
,	O
although	O
in	O
many	O
of	O
the	O
Mexican	O
patients	O
with	O
G6PD	O
A	O
-	O
202A	O
/	O
376G	O
the	O
gene	O
may	O
have	O
been	O
imported	O
more	O
recently	O
from	O
Spain	O
,	O
where	O
this	O
variant	O
,	O
formerly	O
known	O
as	O
G6PD	O
Betica	O
,	O
is	O
also	O
prevalent	O
.	O
.	O

Hereditary	O
deficiency	B-Disease
of	I-Disease
C5	I-Disease
in	O
association	O
with	O
discoid	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O

A	O
29	O
-	O
year	O
-	O
old	O
woman	O
with	O
discoid	B-Disease
lupus	I-Disease
erythematosus	I-Disease
had	O
undetectable	O
classic	O
pathway	O
complement	O
activity	O
.	O

Hypocomplementemia	B-Disease
was	O
due	O
to	O
selective	O
deficiency	B-Disease
of	I-Disease
C5	I-Disease
.	O

One	O
of	O
her	O
children	O
was	O
also	O
deficient	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
documented	O
case	O
of	O
an	O
association	O
between	O
discoid	B-Disease
lupus	I-Disease
erythematosus	I-Disease
and	O
C5	B-Disease
deficiency	I-Disease
.	O
.	O

Founder	O
effect	O
of	O
a	O
prevalent	O
phenylketonuria	B-Disease
mutation	O
in	O
the	O
Oriental	O
population	O
.	O

A	O
missense	O
mutation	O
has	O
been	O
identified	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
[	O
PAH	O
;	O
phenylalanine	O
4	O
-	O
monooxygenase	O
;	O
L	O
-	O
phenylalanine	O
,	O
tetrahydrobiopterin	O
oxygen	O
oxidoreductase	O
(	O
4	O
-	O
hydroxylating	O
)	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
]	O
gene	O
in	O
a	O
Chinese	O
patient	O
with	O
classic	O
phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
.	O

A	O
G	O
-	O
to	O
-	O
C	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
413	O
in	O
exon	O
12	O
of	O
the	O
gene	O
results	O
in	O
the	O
substitution	O
of	O
Pro413	O
for	O
Arg413	O
in	O
the	O
mutant	O
protein	O
.	O

This	O
mutation	O
(	O
R413P	O
)	O
results	O
in	O
negligible	O
enzymatic	O
activity	O
when	O
expressed	O
in	O
heterologous	O
mammalian	O
cells	O
and	O
is	O
compatible	O
with	O
a	O
classic	O
PKU	B-Disease
phenotype	O
in	O
the	O
patient	O
.	O

Population	O
genetic	O
studies	O
reveal	O
that	O
this	O
mutation	O
is	O
tightly	O
linked	O
to	O
restriction	O
fragment	O
length	O
polymorphism	O
haplotype	O
4	O
,	O
which	O
is	O
the	O
predominant	O
haplotype	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
Oriental	O
population	O
.	O

It	O
accounts	O
for	O
13	O
.	O

8	O
%	O
of	O
northern	O
Chinese	O
and	O
27	O
%	O
of	O
Japanese	O
PKU	B-Disease
alleles	O
,	O
but	O
it	O
is	O
rare	O
in	O
southern	O
Chinese	O
(	O
2	O
.	O
2	O
%	O
)	O
and	O
is	O
absent	O
in	O
the	O
Caucasian	O
population	O
.	O

The	O
data	O
demonstrate	O
unambiguously	O
that	O
the	O
mutation	O
occurred	O
after	O
racial	O
divergence	O
of	O
Orientals	O
and	O
Caucasians	O
and	O
suggest	O
that	O
the	O
allele	O
has	O
spread	O
throughout	O
the	O
Orient	O
by	O
a	O
founder	O
effect	O
.	O

Previous	O
protein	O
polymorphism	O
studies	O
in	O
eastern	O
Asia	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
"	O
northern	O
Mongoloids	O
"	O
represented	O
a	O
founding	O
population	O
in	O
Asia	O
.	O

Our	O
results	O
are	O
compatible	O
with	O
this	O
hypothesis	O
in	O
that	O
the	O
PKU	B-Disease
mutation	O
might	O
have	O
occurred	O
in	O
northern	O
Mongoloids	O
and	O
subsequently	O
spread	O
to	O
the	O
Chinese	O
and	O
Japanese	O
populations	O
.	O

Glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
caused	O
by	O
a	O
defect	O
in	O
the	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
.	O

Glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
(	O
GGM	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
manifesting	O
within	O
the	O
first	O
weeks	O
of	O
life	O
and	O
characterized	O
by	O
a	O
selective	O
failure	O
to	O
absorb	O
dietary	O
glucose	O
and	O
galactose	O
from	O
the	O
intestine	O
.	O

The	O
consequent	O
severe	O
diarrhoea	B-Disease
and	O
dehydration	B-Disease
are	O
usually	O
fatal	O
unless	O
these	O
sugars	O
are	O
eliminated	O
from	O
the	O
diet	O
.	O

Intestinal	O
biopsies	O
of	O
GGM	B-Disease
patients	O
have	O
revealed	O
a	O
specific	O
defect	O
in	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
absorption	O
of	O
glucose	O
in	O
the	O
brush	O
border	O
.	O

Normal	O
glucose	O
absorption	O
is	O
mediated	O
by	O
the	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
in	O
the	O
brush	O
border	O
membrane	O
of	O
the	O
intestinal	O
epithelium	O
.	O

Cellular	O
influx	O
is	O
driven	O
by	O
the	O
transmembrane	O
Na	O
+	O
electrochemical	O
potential	O
gradient	O
;	O
thereafter	O
the	O
sugar	O
moves	O
to	O
the	O
blood	O
across	O
the	O
basolateral	O
membrane	O
via	O
the	O
facilitated	O
glucose	O
carrier	O
.	O

We	O
have	O
previously	O
cloned	O
and	O
sequenced	O
a	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
from	O
normal	O
human	O
ileum	O
and	O
shown	O
that	O
this	O
gene	O
,	O
SGLT1	O
,	O
resides	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
.	O

We	O
have	O
now	O
amplified	O
SGLT1	O
complementary	O
DNA	O
and	O
genomic	O
DNA	O
from	O
members	O
of	O
a	O
family	O
affected	O
with	O
GGM	B-Disease
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O

Sequence	O
analysis	O
of	O
the	O
amplified	O
products	O
has	O
revealed	O
a	O
single	O
missense	O
mutation	O
in	O
SGLT1	O
which	O
cosegregates	O
with	O
the	O
GGM	B-Disease
phenotype	O
and	O
results	O
in	O
a	O
complete	O
loss	O
of	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
glucose	O
transport	O
in	O
Xenopus	O
oocytes	O
injected	O
with	O
this	O
complementary	O
RNA	O
.	O
.	O

A	O
de	O
novo	O
unbalanced	O
reciprocal	O
translocation	O
identified	O
as	O
paternal	O
in	O
origin	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

Interstitial	O
cytogenetic	O
deletions	O
involving	O
the	O
paternally	O
derived	O
chromosome	O
15q11	O
-	O
13	O
have	O
been	O
described	O
in	O
patients	O
with	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

We	O
report	O
a	O
child	O
with	O
PWS	B-Disease
and	O
a	O
de	O
novo	O
unbalanced	O
karyotype	O
-	O
45	O
,	O
XY	O
,	O
-	O
9	O
,	O
-	O
15	O
,	O
+	O
der	O
(	O
9	O
)	O
t	O
(	O
9	O
;	O
15	O
)	O
(	O
q34	O
;	O
q13	O
)	O
.	O

Molecular	O
studies	O
with	O
the	O
DNA	O
probe	O
pML34	O
confirmed	O
that	O
only	O
a	O
single	O
Prader	B-Disease
Willi	I-Disease
critical	O
region	O
(	O
PWCR	O
15q11	O
.	O
2	O
-	O
q12	O
)	O
copy	O
was	O
present	O
.	O

Hybridisation	O
of	O
patient	O
and	O
parental	O
DNA	O
with	O
the	O
multi	O
-	O
allelic	O
probe	O
CMW1	O
,	O
which	O
maps	O
to	O
pter	O
-	O
15q13	O
,	O
showed	O
that	O
the	O
chromosome	O
involved	O
in	O
the	O
translocation	O
was	O
paternal	O
in	O
origin	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
paternally	O
-	O
derived	O
PWCR	O
allele	O
loss	O
caused	O
by	O
an	O
unbalanced	O
translocation	O
that	O
has	O
arisen	O
de	O
novo	O
.	O

Localisation	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
to	O
19q13	O
.	O
2	O
-	O
19q13	O
.	O
3	O
and	O
its	O
relationship	O
to	O
twelve	O
polymorphic	O
loci	O
on	O
19q	O
.	O

The	O
order	O
of	O
fourteen	O
polymorphic	O
markers	O
localised	O
to	O
the	O
long	O
arm	O
of	O
human	O
chromosome	O
19	O
has	O
been	O
established	O
by	O
multipoint	O
mapping	O
in	O
a	O
set	O
of	O
40	O
CEPH	O
(	O
Centre	O
dEtude	O
de	O
Polymorphisme	O
Humain	O
,	O
Paris	O
)	O
reference	O
families	O
.	O

We	O
report	O
here	O
the	O
linkage	O
relationship	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
locus	O
to	O
twelve	O
of	O
these	O
markers	O
as	O
studied	O
in	O
45	O
families	O
with	O
DM	B-Disease
.	O

The	O
resulting	O
genetic	O
map	O
is	O
supported	O
by	O
the	O
localisation	O
of	O
the	O
DNA	O
markers	O
in	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
.	O

Ten	O
of	O
the	O
twelve	O
markers	O
have	O
been	O
shown	O
to	O
be	O
proximal	O
to	O
the	O
DM	B-Disease
gene	O
and	O
two	O
,	O
PRKCG	O
and	O
D19S22	O
,	O
distal	O
but	O
at	O
distances	O
of	O
approximately	O
25	O
cM	O
and	O
15	O
cM	O
,	O
respectively	O
.	O

The	O
closest	O
proximal	O
markers	O
are	O
APOC2	O
(	O
apolipoprotein	O
C	O
-	O
II	O
)	O
and	O
CKM	O
(	O
creatine	O
kinase	O
,	O
muscle	O
)	O
approximately	O
3	O
cM	O
and	O
2	O
cM	O
from	O
the	O
DM	B-Disease
gene	O
respectively	O
,	O
in	O
the	O
order	O
APOC2	O
-	O
CKM	O
-	O
DM	O
.	O

The	O
distance	O
between	O
APOC2	O
,	O
CKM	O
and	O
DM	B-Disease
(	O
of	O
the	O
order	O
of	O
2	O
million	O
base	O
pairs	O
)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	O
walking	O
and	O
jumping	O
.	O

The	O
data	O
presented	O
here	O
should	O
enable	O
us	O
to	O
determine	O
whether	O
or	O
not	O
new	O
markers	O
are	O
distal	O
to	O
APOC2	O
/	O
CKM	O
and	O
thus	O
potentially	O
flank	O
the	O
DM	B-Disease
gene	O
.	O
.	O

Localization	O
of	O
histidase	O
to	O
human	O
chromosome	O
region	O
12q22	O
-	O
-	O
-	O
-	O
q24	O
.	O
1	O
and	O
mouse	O
chromosome	O
region	O
10C2	O
-	O
-	O
-	O
-	O
D1	O
.	O

The	O
human	O
gene	O
for	O
histidase	O
(	O
histidine	O
ammonia	O
-	O
lyase	O
;	O
HAL	O
)	O
,	O
the	O
enzyme	O
deficient	O
in	O
histidinemia	B-Disease
,	O
was	O
assigned	O
to	O
human	O
chromosome	O
12	O
by	O
Southern	O
blot	O
analysis	O
of	O
human	O
X	O
mouse	O
somatic	O
cell	O
hybrid	O
DNA	O
.	O

The	O
gene	O
was	O
sublocalized	O
to	O
region	O
12q22	O
-	O
-	O
-	O
-	O
q24	O
.	O

1	O
by	O
in	O
situ	O
hybridization	O
,	O
using	O
a	O
human	O
histidase	O
cDNA	O
.	O

The	O
homologous	O
locus	O
in	O
the	O
mouse	O
(	O
Hal	O
)	O
was	O
mapped	O
to	O
region	O
10C2	O
-	O
-	O
-	O
-	O
D1	O
by	O
in	O
situ	O
hybridization	O
,	O
using	O
a	O
cell	O
line	O
from	O
a	O
mouse	O
homozygous	O
for	O
a	O
1	O
.	O

10	O
Robertsonian	O
translocation	O
.	O

These	O
assignments	O
extend	O
the	O
conserved	O
syntenic	O
region	O
between	O
human	O
chromosome	O
12	O
and	O
mouse	O
chromosome	O
10	O
that	O
includes	O
the	O
genes	O
for	O
phenylalanine	O
hydroxylase	O
,	O
gamma	O
interferon	O
,	O
peptidase	O
,	O
and	O
citrate	O
synthase	O
.	O

The	O
localization	O
of	O
histidase	O
to	O
mouse	O
chromosome	O
10	O
suggests	O
that	O
the	O
histidase	O
regulatory	O
locus	O
(	O
Hsd	O
)	O
and	O
the	O
histidinemia	O
mutation	O
(	O
his	O
)	O
,	O
which	O
are	O
both	O
known	O
to	O
be	O
on	O
chromosome	O
10	O
,	O
may	O
be	O
alleles	O
of	O
the	O
histidase	O
structural	O
gene	O
locus	O
.	O

Determination	O
of	O
the	O
mutations	O
responsible	O
for	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
in	O
17	O
subjects	O
.	O

Hypoxanthine	O
-	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
is	O
a	O
purine	O
salvage	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
hypoxanthine	O
to	O
inosine	O
monophosphate	O
and	O
guanine	O
to	O
guanosine	O
monophosphate	O
.	O

Previous	O
studies	O
of	O
mutant	O
HPRT	O
proteins	O
analyzed	O
at	O
the	O
molecular	O
level	O
have	O
shown	O
a	O
significant	O
heterogeneity	O
.	O

This	O
investigation	O
further	O
verifies	O
this	O
heterogeneity	O
and	O
identifies	O
insertions	O
,	O
deletions	O
,	O
and	O
point	O
mutations	O
.	O

The	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
product	O
of	O
reverse	O
-	O
transcribed	O
HPRT	O
mRNA	O
enabled	O
the	O
rapid	O
identification	O
of	O
the	O
mutations	O
found	O
in	O
17	O
previously	O
uncharacterized	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O
.	O

Linkage	O
of	O
DNA	O
markers	O
at	O
Xq28	O
to	O
adrenoleukodystrophy	B-Disease
and	O
adrenomyeloneuropathy	B-Disease
present	O
within	O
the	O
same	O
family	O
.	O

We	O
present	O
a	O
large	O
kindred	O
that	O
contained	O
patients	O
with	O
either	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
or	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
.	O

The	O
pedigree	O
clearly	O
supported	O
the	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
of	O
the	O
nonneonatal	O
form	O
of	O
ALD	B-Disease
/	O
AMN	B-Disease
.	O

Analysis	O
with	O
DNA	O
markers	O
at	O
Xq28	O
suggested	O
segregation	O
of	O
both	O
ALD	B-Disease
and	O
AMN	B-Disease
with	O
an	O
identical	O
haplotype	O
.	O

This	O
indicated	O
that	O
nonneonatal	O
ALD	B-Disease
and	O
AMN	B-Disease
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
same	O
gene	O
at	O
Xq28	O
.	O

It	O
showed	O
,	O
furthermore	O
,	O
that	O
phenotypic	O
differences	O
between	O
ALD	B-Disease
and	O
AMN	B-Disease
are	O
not	O
necessarily	O
the	O
consequence	O
of	O
allelic	O
heterogeneity	O
due	O
to	O
different	O
mutations	O
within	O
the	O
same	O
gene	O
.	O

The	O
maximal	O
lod	O
score	O
for	O
linkage	O
of	O
the	O
ALD	B-Disease
/	O
AMN	B-Disease
gene	O
and	O
the	O
multiallelic	O
anonymous	O
DNA	O
marker	O
at	O
DXS52	O
was	O
3	O
.	O

0	O
at	O
a	O
recombination	O
fraction	O
of	O
0	O
.	O

00	O
.	O

This	O
made	O
a	O
prenatal	O
or	O
presymptomatic	O
diagnosis	O
and	O
heterozygote	O
detection	O
by	O
DNA	O
analysis	O
with	O
this	O
marker	O
reliable	O
.	O

Skewed	O
X	O
inactivation	O
in	O
a	O
female	O
MZ	O
twin	O
results	O
in	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

One	O
of	O
female	O
MZ	O
twins	O
presented	O
with	O
muscular	B-Disease
dystrophy	I-Disease
.	O

Physical	O
examination	O
,	O
creatine	O
phosphokinase	O
levels	O
,	O
and	O
muscle	O
biopsy	O
were	O
consistent	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

However	O
,	O
because	O
of	O
her	O
sex	O
she	O
was	O
diagnosed	O
as	O
having	O
limb	B-Disease
-	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

With	O
cDNA	O
probes	O
to	O
the	O
DMD	B-Disease
gene	O
,	O
a	O
gene	O
deletion	O
was	O
detected	O
in	O
the	O
twins	O
and	O
their	O
mother	O
.	O

The	O
de	O
novo	O
mutation	O
which	O
arose	O
in	O
the	O
mother	O
was	O
shown	O
by	O
novel	O
junction	O
fragments	O
generated	O
by	O
HindIII	O
,	O
PstI	O
,	O
or	O
TaqI	O
when	O
probed	O
with	O
cDNA8	O
.	O

Additional	O
evidence	O
of	O
a	O
large	O
gene	O
deletion	O
was	O
given	O
by	O
novel	O
SfiI	O
junction	O
fragments	O
detected	O
by	O
probes	O
p20	O
,	O
J	O
-	O
Bir	O
,	O
and	O
J	O
-	O
66	O
on	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
.	O

Immunoblot	O
analysis	O
of	O
muscle	O
from	O
the	O
affected	O
twin	O
showed	O
dystrophin	O
of	O
normal	O
size	O
but	O
of	O
reduced	O
amount	O
.	O

Immunofluorescent	O
visualization	O
of	O
dystrophin	O
revealed	O
foci	O
of	O
dystrophin	O
-	O
positive	O
fibers	O
adjacent	O
to	O
foci	O
of	O
dystrophin	O
-	O
negative	O
fibers	O
.	O

These	O
data	O
indicate	O
that	O
the	O
affected	O
twin	O
is	O
a	O
manifesting	O
carrier	O
of	O
an	O
abnormal	O
DMD	B-Disease
gene	O
,	O
her	O
myopathy	B-Disease
being	O
a	O
direct	O
result	O
of	O
underexpression	O
of	O
dystrophin	O
.	O

Cytogenetic	O
analysis	O
revealed	O
normal	O
karyotypes	O
,	O
eliminating	O
the	O
possibility	O
of	O
a	O
translocation	O
affecting	O
DMD	B-Disease
gene	O
function	O
.	O

Both	O
linkage	O
analysis	O
and	O
DNA	O
fingerprint	O
analysis	O
revealed	O
that	O
each	O
twin	O
has	O
two	O
different	O
X	O
chromosomes	O
,	O
eliminating	O
the	O
possibility	O
of	O
uniparental	B-Disease
disomy	I-Disease
as	O
a	O
mechanism	O
for	O
DMD	B-Disease
expression	O
.	O

On	O
the	O
basis	O
of	O
methylation	O
differences	O
of	O
the	O
paternal	O
and	O
maternal	O
X	O
chromosomes	O
in	O
these	O
MZ	O
twins	O
,	O
we	O
propose	O
uneven	O
lyonization	O
(	O
X	O
chromosome	O
inactivation	O
)	O
as	O
the	O
underlying	O
mechanism	O
for	O
disease	O
expression	O
in	O
the	O
affected	O
female	O
.	O
.	O

Adrenoleukodystrophy	B-Disease
and	O
adrenomyeloneuropathy	B-Disease
associated	O
with	O
partial	O
adrenal	B-Disease
insufficiency	I-Disease
in	O
three	O
generations	O
of	O
a	O
kindred	O
.	O

Four	O
cases	O
of	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
and	O
one	O
case	O
of	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
have	O
developed	O
in	O
a	O
kindred	O
over	O
three	O
generations	O
demonstrating	O
that	O
AMN	B-Disease
is	O
a	O
clinical	O
variant	O
of	O
ALD	B-Disease
.	O

Pituitary	O
-	O
adrenal	O
function	O
studies	O
were	O
performed	O
in	O
10	O
family	O
members	O
,	O
including	O
two	O
affected	O
males	O
and	O
four	O
females	O
identified	O
as	O
carriers	O
of	O
ALD	B-Disease
/	O
AMN	B-Disease
.	O

No	O
pituitary	B-Disease
-	I-Disease
adrenal	I-Disease
abnormality	I-Disease
was	O
found	O
in	O
the	O
carriers	O
.	O

However	O
,	O
basal	O
morning	O
plasma	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
levels	O
were	O
markedly	O
elevated	O
in	O
the	O
two	O
males	O
with	O
ALD	B-Disease
and	O
AMN	B-Disease
,	O
despite	O
the	O
fact	O
that	O
they	O
had	O
no	O
clinical	O
signs	O
of	O
adrenal	B-Disease
insufficiency	I-Disease
and	O
that	O
morning	O
plasma	O
cortisol	O
levels	O
and	O
their	O
response	O
to	O
maximal	O
exogenous	O
ACTH	O
stimulation	O
appeared	O
to	O
be	O
normal	O
.	O

In	O
addition	O
,	O
the	O
integrated	O
24	O
-	O
hour	O
response	O
to	O
the	O
administration	O
were	O
also	O
subnormal	O
in	O
these	O
two	O
cases	O
.	O

Thus	O
,	O
people	O
with	O
ALD	B-Disease
and	O
AMN	B-Disease
may	O
have	O
subclinical	O
partial	O
adrenocrotical	B-Disease
insufficiency	I-Disease
.	O

No	O
other	O
endocrinologic	B-Disease
dysfunction	I-Disease
was	O
identified	O
.	O
.	O

Regional	O
localisation	O
of	O
the	O
Friedreich	B-Disease
ataxia	I-Disease
locus	O
to	O
human	O
chromosome	O
9q13	O
-	O
-	O
-	O
-	O
q21	O
.	O
1	O
.	O

We	O
have	O
previously	O
assigned	O
the	O
Friedreich	B-Disease
ataxia	I-Disease
locus	O
(	O
FRDA	O
)	O
to	O
chromosome	O
9	O
;	O
the	O
current	O
maximal	O
lod	O
score	O
between	O
FRDA	O
and	O
MCT112	O
(	O
D9S15	O
)	O
is	O
greater	O
than	O
50	O
at	O
a	O
recombination	O
fraction	O
of	O
theta	O
=	O
0	O
.	O

The	O
physical	O
assignment	O
of	O
the	O
locus	O
defined	O
by	O
MCT112	O
,	O
and	O
hence	O
FRDA	O
,	O
has	O
not	O
been	O
determined	O
,	O
although	O
linkage	O
analysis	O
of	O
MCT112	O
with	O
other	O
chromosome	O
9	O
markers	O
inferred	O
a	O
location	O
close	O
to	O
the	O
centromere	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridisation	O
with	O
MCT112	O
,	O
a	O
corresponding	O
cosmid	O
MJ1	O
,	O
and	O
DR47	O
(	O
D9S5	O
)	O
,	O
coupled	O
with	O
mapping	O
studies	O
on	O
hybrid	O
cell	O
panels	O
,	O
to	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
disease	O
locus	O
.	O

The	O
in	O
situ	O
location	O
of	O
all	O
three	O
probes	O
is	O
9q13	O
-	O
-	O
-	O
-	O
q21	O
.	O

1	O
,	O
distal	O
to	O
the	O
variable	O
heterochromatin	O
region	O
.	O

Physical	O
assignment	O
of	O
FRDA	O
will	O
allow	O
us	O
to	O
identify	O
hybrid	O
cell	O
lines	O
containing	O
the	O
mutated	O
gene	O
.	O

Increased	O
high	O
-	O
density	O
lipoprotein	O
levels	O
caused	O
by	O
a	O
common	O
cholesteryl	O
-	O
ester	O
transfer	O
protein	O
gene	O
mutation	O
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
plasma	O
cholesteryl	O
-	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
catalyzes	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
to	O
other	O
lipoproteins	O
.	O

We	O
recently	O
described	O
a	O
Japanese	O
family	O
with	O
increased	O
HDL	O
levels	O
and	O
CETP	B-Disease
deficiency	I-Disease
due	O
to	O
a	O
splicing	O
defect	O
of	O
the	O
CETP	O
gene	O
.	O

To	O
assess	O
the	O
frequency	O
and	O
phenotype	O
of	O
this	O
condition	O
,	O
we	O
screened	O
11	O
additional	O
families	O
with	O
high	O
HDL	O
levels	O
by	O
means	O
of	O
a	O
radioimmunoassay	O
for	O
CETP	O
and	O
DNA	O
analysis	O
.	O

RESULTS	O
.	O

We	O
found	O
the	O
same	O
CETP	O
gene	O
mutation	O
in	O
four	O
families	O
from	O
three	O
different	O
regions	O
of	O
Japan	O
.	O

Analysis	O
of	O
restriction	O
-	O
fragment	O
-	O
length	O
polymorphisms	O
of	O
the	O
mutant	O
CETP	O
allele	O
showed	O
that	O
all	O
probands	O
were	O
homozygous	O
for	O
the	O
identical	O
haplotype	O
.	O

Family	O
members	O
homozygous	O
for	O
CETP	B-Disease
deficiency	I-Disease
(	O
n	O
=	O
10	O
)	O
had	O
moderate	O
hypercholesterolemia	B-Disease
(	O
mean	O
total	O
cholesterol	O
level	O
[	O
+	O
/	O
-	O
SD	O
]	O
,	O
7	O
.	O
01	O
+	O
/	O
-	O
0	O
.	O
83	O
mmol	O
per	O
liter	O
)	O
,	O
markedly	O
increased	O
levels	O
of	O
HDL	O
cholesterol	O
(	O
4	O
.	O
24	O
+	O
/	O
-	O
1	O
.	O
01	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	O
A	O
-	O
I	O
,	O
and	O
decreased	O
levels	O
of	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
80	O
mmol	O
per	O
liter	O
)	O
and	O
apolipoprotein	O
B	O
.	O

Members	O
heterozygous	O
for	O
the	O
deficiency	O
(	O
n	O
=	O
20	O
)	O
,	O
whose	O
CETP	O
levels	O
were	O
in	O
the	O
lower	O
part	O
of	O
the	O
normal	O
range	O
,	O
had	O
moderately	O
increased	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
apolipoprotein	O
A	O
-	O
I	O
and	O
an	O
increased	O
ratio	O
of	O
HDL	O
subclass	O
2	O
to	O
HDL	O
subclass	O
3	O
,	O
as	O
compared	O
with	O
unaffected	O
family	O
members	O
(	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
.	O

CETP	B-Disease
deficiency	I-Disease
was	O
not	O
found	O
in	O
six	O
unrelated	O
subjects	O
with	O
elevated	O
HDL	O
cholesterol	O
levels	O
who	O
were	O
from	O
different	O
parts	O
of	O
the	O
United	O
States	O
.	O

CONCLUSIONS	O
.	O

CETP	B-Disease
deficiency	I-Disease
appears	O
to	O
be	O
a	O
frequent	O
cause	O
of	O
increased	O
HDL	O
levels	O
in	O
the	O
population	O
of	O
Japan	O
,	O
possibly	O
because	O
of	O
a	O
founder	O
effect	O
.	O

The	O
results	O
that	O
we	O
observed	O
in	O
heterozygotes	O
suggest	O
that	O
CETP	O
normally	O
plays	O
a	O
part	O
in	O
the	O
regulation	O
of	O
levels	O
of	O
HDL	O
subclass	O
2	O
.	O

There	O
was	O
no	O
evidence	O
of	O
premature	B-Disease
atherosclerosis	I-Disease
in	O
the	O
families	O
with	O
CETP	B-Disease
deficiency	I-Disease
.	O

In	O
fact	O
,	O
the	O
lipoprotein	O
profile	O
of	O
persons	O
with	O
CETP	B-Disease
deficiency	I-Disease
is	O
potentially	O
antiatherogenic	O
and	O
may	O
be	O
associated	O
with	O
an	O
increased	O
life	O
span	O
.	O

Further	O
mapping	O
of	O
an	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
locus	O
to	O
the	O
chromosome	O
11q23	O
region	O
.	O

We	O
recently	O
mapped	O
the	O
gene	O
for	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
group	O
A	O
(	O
ATA	O
)	O
to	O
chromosome	O
11q22	O
-	O
23	O
by	O
linkage	O
analysis	O
,	O
using	O
the	O
genetic	O
markers	O
THY1	O
and	O
pYNB3	O
.	O

12	O
(	O
D11S144	O
)	O
.	O

The	O
most	O
likely	O
order	O
was	O
cent	O
-	O
AT	O
-	O
S144	O
-	O
THY1	O
.	O

The	O
present	O
paper	O
describes	O
further	O
mapping	O
of	O
the	O
AT	B-Disease
locus	O
by	O
means	O
of	O
a	O
panel	O
of	O
10	O
markers	O
that	O
span	O
approximately	O
60	O
cM	O
in	O
the	O
11q22	O
-	O
23	O
region	O
centered	O
around	O
S144	O
and	O
THY1	O
.	O

Location	O
scores	O
indicate	O
that	O
three	O
contiguous	O
subsegments	O
within	O
the	O
[	O
S144	O
-	O
THY1	O
]	O
segment	O
,	O
as	O
well	O
as	O
three	O
contiguous	O
segments	O
telomeric	O
to	O
THY1	O
,	O
are	O
each	O
unlikely	O
to	O
contain	O
the	O
AT	B-Disease
locus	O
,	O
while	O
the	O
more	O
centromeric	O
[	O
STMY	O
-	O
S144	O
]	O
segment	O
is	O
most	O
likely	O
to	O
contain	O
the	O
AT	B-Disease
locus	O
.	O

These	O
data	O
,	O
together	O
with	O
recent	O
refinements	O
in	O
the	O
linkage	O
and	O
physical	O
maps	O
of	O
11q22	O
-	O
23	O
,	O
place	O
the	O
AT	B-Disease
locus	O
at	O
11q23	O
.	O

Recurrent	O
meningitis	B-Disease
in	O
a	O
patient	O
with	O
congenital	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
C9	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
.	O

First	O
case	O
of	O
C9	B-Disease
deficiency	I-Disease
in	O
Europe	O
.	O

We	O
describe	O
the	O
first	O
cases	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
C9	B-Disease
deficiency	I-Disease
in	O
Europe	O
that	O
were	O
detected	O
in	O
a	O
Swiss	O
family	O
,	O
of	O
which	O
two	O
members	O
-	O
-	O
one	O
with	O
a	O
complete	O
deficiency	O
and	O
the	O
other	O
with	O
approximately	O
half	O
-	O
normal	O
C9	O
levels	O
-	O
-	O
experienced	O
bacterial	B-Disease
meningitis	I-Disease
.	O

The	O
index	O
patient	O
,	O
a	O
56	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
a	O
history	O
of	O
purulent	B-Disease
meningitis	I-Disease
at	O
the	O
age	O
of	O
23	O
years	O
,	O
presented	O
with	O
an	O
acute	B-Disease
meningococcal	I-Disease
meningitis	I-Disease
.	O

No	O
impairment	B-Disease
of	I-Disease
cellular	I-Disease
immunity	I-Disease
or	O
immunoglobulin	B-Disease
deficiency	I-Disease
could	O
be	O
found	O
.	O

Complement	O
assays	O
showed	O
a	O
complete	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
C9	I-Disease
component	I-Disease
,	O
while	O
the	O
other	O
individual	O
component	O
levels	O
were	O
normal	O
and	O
the	O
hemolytic	O
activity	O
(	O
measured	O
using	O
the	O
CH50	O
assay	O
)	O
was	O
only	O
slightly	O
reduced	O
.	O

A	O
family	O
study	O
revealed	O
complete	B-Disease
C9	I-Disease
deficiency	I-Disease
in	O
the	O
patients	O
healthy	O
brother	O
and	O
half	O
-	O
normal	O
C9	O
concentrations	O
in	O
his	O
sister	O
,	O
his	O
son	O
(	O
who	O
also	O
had	O
experienced	O
an	O
episode	O
of	O
bacterial	B-Disease
meningitis	I-Disease
)	O
,	O
and	O
his	O
niece	O
,	O
consistent	O
with	O
an	O
inherited	O
C9	B-Disease
deficiency	I-Disease
.	O

This	O
first	O
case	O
of	O
recurrent	B-Disease
meningitis	I-Disease
in	O
a	O
white	O
patient	O
with	O
complete	B-Disease
C9	I-Disease
deficiency	I-Disease
suggests	O
that	O
this	O
complement	B-Disease
defect	I-Disease
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
bacterial	B-Disease
,	I-Disease
especially	I-Disease
neisserial	I-Disease
,	I-Disease
infections	I-Disease
.	O
.	O

Detection	O
of	O
98	O
%	O
of	O
DMD	B-Disease
/	O
BMD	B-Disease
gene	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
.	O

We	O
describe	O
oligonucleotide	O
primer	O
sequences	O
that	O
can	O
be	O
used	O
to	O
amplify	O
eight	O
exons	O
plus	O
the	O
muscle	O
promoter	O
of	O
the	O
dystrophin	O
gene	O
in	O
a	O
single	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

When	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set	O
,	O
these	O
two	O
multiplex	O
reactions	O
detect	O
about	O
98	O
%	O
of	O
deletions	O
in	O
patients	O
with	O
Duchenne	B-Disease
or	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
,	O
BMD	B-Disease
)	O
.	O

Furthermore	O
,	O
these	O
primers	O
amplify	O
most	O
of	O
the	O
exons	O
in	O
the	O
deletion	O
prone	O
"	O
hot	O
spot	O
"	O
region	O
around	O
exons	O
44	O
to	O
53	O
,	O
allowing	O
determination	O
of	O
deletion	O
endpoints	O
and	O
prediction	O
of	O
mutational	O
effects	O
on	O
the	O
translational	O
reading	O
frame	O
.	O

Thus	O
,	O
use	O
of	O
these	O
PCR	O
-	O
based	O
assays	O
will	O
allow	O
deletion	O
detection	O
and	O
prenatal	O
diagnosis	O
for	O
most	O
DMD	B-Disease
/	O
BMD	B-Disease
patients	O
in	O
a	O
fraction	O
of	O
the	O
time	O
required	O
for	O
Southern	O
blot	O
analysis	O
.	O
.	O

Genetic	O
heterogeneity	O
at	O
the	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
locus	O
in	O
southern	O
Italy	O
:	O
a	O
study	O
on	O
a	O
population	O
from	O
the	O
Matera	O
district	O
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
has	O
been	O
analyzed	O
by	O
gel	O
electrophoresis	O
and	O
by	O
quantitative	O
assay	O
in	O
an	O
unselected	O
sample	O
of	O
1524	O
schoolboys	O
from	O
the	O
province	O
of	O
Matera	O
(	O
Lucania	O
)	O
in	O
southern	O
Italy	O
.	O

We	O
have	O
identified	O
43	O
subjects	O
with	O
a	O
G6PD	O
variant	O
.	O

Of	O
these	O
,	O
31	O
had	O
severe	O
G6PD	B-Disease
deficiency	I-Disease
,	O
nine	O
had	O
mild	O
to	O
moderate	O
deficiency	O
,	O
and	O
three	O
had	O
a	O
non	O
-	O
deficient	O
electrophoretic	O
variant	O
.	O

The	O
overall	O
rate	O
of	O
G6PD	B-Disease
deficiency	I-Disease
was	O
2	O
.	O

6	O
%	O
.	O

The	O
frequency	O
of	O
G6PD	B-Disease
deficiency	I-Disease
,	O
ranging	O
from	O
7	O
.	O

2	O
%	O
on	O
the	O
Ionian	O
Coast	O
to	O
zero	O
on	O
the	O
eastern	O
side	O
of	O
the	O
Lucanian	O
Apennines	O
,	O
appears	O
to	O
be	O
inversely	O
related	O
to	O
the	O
distance	O
of	O
each	O
town	O
examined	O
from	O
the	O
Ionian	O
Coast	O
,	O
suggesting	O
that	O
this	O
geographic	O
distribution	O
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
gene	O
flow	O
from	O
Greek	O
settlers	O
.	O

Biochemical	O
characterization	O
has	O
shown	O
that	O
most	O
of	O
the	O
G6PD	B-Disease
deficiency	I-Disease
in	O
this	O
population	O
is	O
accounted	O
for	O
by	O
G6PD	O
Mediterranean	O
.	O

In	O
addition	O
,	O
we	O
have	O
found	O
several	O
examples	O
of	O
two	O
other	O
known	O
polymorphic	O
variants	O
(	O
G6PD	O
Cagliari	O
and	O
G6PD	O
A	O
-	O
)	O
;	O
three	O
new	O
polymorphic	O
variants	O
,	O
G6PD	O
Metaponto	O
(	O
class	O
III	O
)	O
,	O
G6PD	O
Montalbano	O
(	O
class	O
III	O
)	O
,	O
and	O
G6PD	O
Pisticci	O
(	O
class	O
IV	O
)	O
;	O
and	O
two	O
sporadic	O
variants	O
,	O
G6PD	O
Tursi	O
(	O
class	O
III	O
)	O
and	O
G6PD	O
Ferrandina	O
(	O
class	O
II	O
)	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
marked	O
genetic	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
within	O
a	O
relatively	O
narrow	O
geographic	O
area	O
and	O
they	O
prove	O
the	O
presence	O
in	O
the	O
Italian	O
peninsula	O
of	O
a	O
gene	O
(	O
GdA	O
-	O
)	O
regarded	O
as	O
characteristically	O
African	O
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
murine	I-Disease
fifth	I-Disease
complement	I-Disease
component	I-Disease
(	I-Disease
C5	I-Disease
)	I-Disease
.	O

A	O
2	O
-	O
base	O
pair	O
gene	O
deletion	O
in	O
a	O
5	O
'	O
-	O
exon	O
.	O

To	O
ascertain	O
the	O
molecular	O
mechanism	O
that	O
causes	O
murine	O
C5	B-Disease
deficiency	I-Disease
,	O
genomic	O
and	O
cDNA	O
libraries	O
were	O
constructed	O
from	O
mouse	O
liver	O
DNA	O
and	O
mRNA	O
employing	O
the	O
congenic	O
strains	O
B10	O
.	O

D2	O
/	O
nSnJ	O
and	O
B10	O
.	O

D2	O
/	O
oSnJ	O
that	O
are	O
sufficient	O
and	O
deficient	B-Disease
for	I-Disease
C5	I-Disease
,	O
respectively	O
.	O

Genomic	O
fragments	O
were	O
isolated	O
which	O
correspond	O
to	O
PvuII	O
and	O
HindIII	O
restriction	O
fragment	O
length	O
polymorphisms	O
associated	O
with	O
C5	B-Disease
deficiency	I-Disease
.	O

Sequence	O
analyses	O
demonstrated	O
that	O
each	O
of	O
these	O
polymorphisms	O
resulted	O
from	O
single	O
base	O
pair	O
substitutions	O
and	O
that	O
neither	O
substitution	O
would	O
probably	O
cause	O
or	O
contribute	O
to	O
the	O
C5	B-Disease
deficiency	I-Disease
.	O

Sequence	O
analyses	O
of	O
C5	O
sufficient	O
and	O
deficient	O
cDNAs	O
revealed	O
a	O
2	O
base	O
-	O
pair	O
deletion	O
in	O
the	O
deficient	O
cDNAs	O
.	O

The	O
"	O
TA	O
"	O
deletion	O
was	O
located	O
near	O
the	O
5	O
end	O
of	O
the	O
cDNA	O
.	O

This	O
deletion	O
shifts	O
the	O
reading	O
frame	O
of	O
the	O
C5	O
mRNA	O
so	O
that	O
the	O
termination	O
codon	O
UGA	O
is	O
present	O
4	O
base	O
pairs	O
downstream	O
from	O
the	O
deletion	O
.	O

Genomic	O
DNA	O
was	O
amplified	O
and	O
sequenced	O
corresponding	O
to	O
the	O
area	O
surrounding	O
the	O
2	O
-	O
base	O
pair	O
deletion	O
.	O

Six	O
C5	B-Disease
-	I-Disease
deficient	I-Disease
strains	O
,	O
A	O
/	O
HeJ	O
,	O
AKR	O
/	O
J	O
,	O
DBA	O
/	O
2J	O
,	O
NZB	O
/	O
B1NJ	O
,	O
SWR	O
/	O
J	O
,	O
and	O
B10	O
.	O

D2	O
/	O
oSnJ	O
,	O
and	O
four	O
C5	O
-	O
sufficient	O
strains	O
,	O
Balb	O
/	O
CJ	O
,	O
C57Bl	O
/	O
6J	O
,	O
DBA	O
/	O
1J	O
,	O
and	O
B10	O
.	O

D2	O
/	O
nSnJ	O
,	O
were	O
analyzed	O
.	O

The	O
sequencing	O
data	O
revealed	O
that	O
the	O
2	O
base	O
pairs	O
were	O
deleted	O
from	O
the	O
C5	O
gene	O
of	O
each	O
deficient	O
mouse	O
tested	O
but	O
not	O
from	O
the	O
C5	O
gene	O
of	O
any	O
sufficient	O
mouse	O
.	O

These	O
data	O
demonstrate	O
that	O
1	O
)	O
there	O
is	O
an	O
identical	O
2	O
-	O
base	O
pair	O
deletion	O
in	O
an	O
exon	O
of	O
the	O
C5	O
gene	O
in	O
several	O
different	O
C5	B-Disease
-	I-Disease
deficient	I-Disease
mouse	O
strains	O
;	O
2	O
)	O
the	O
mRNA	O
transcribed	O
from	O
the	O
C5D	O
gene	O
retains	O
this	O
deletion	O
;	O
and	O
3	O
)	O
this	O
mutation	O
should	O
result	O
in	O
C5	B-Disease
protein	I-Disease
deficiency	I-Disease
.	O

Molecular	O
genetics	O
of	O
PKU	B-Disease
in	O
eastern	O
Europe	O
:	O
a	O
nonsense	O
mutation	O
associated	O
with	O
haplotype	O
4	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
a	O
genetic	B-Disease
disorder	I-Disease
secondary	O
to	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

Several	O
mutations	O
in	O
the	O
PAH	O
gene	O
have	O
recently	O
been	O
reported	O
,	O
and	O
linkage	O
disequilibrium	O
was	O
observed	O
between	O
RFLP	O
haplotypes	O
and	O
specific	O
mutations	O
.	O

A	O
new	O
molecular	B-Disease
lesion	I-Disease
has	O
been	O
identified	O
in	O
exon	O
7	O
of	O
the	O
PAH	O
gene	O
in	O
a	O
Hungarian	O
PKU	B-Disease
patient	O
by	O
direct	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
DNA	O
.	O

The	O
C	O
-	O
to	O
-	O
T	O
transition	O
causes	O
the	O
substitution	O
of	O
Arg243	O
to	O
a	O
termination	O
codon	O
,	O
and	O
the	O
mutant	O
allele	O
is	O
associated	O
with	O
haplotype	O
4	O
of	O
the	O
PAH	O
gene	O
.	O

The	O
mutation	O
is	O
present	O
in	O
two	O
of	O
nine	O
mutant	O
haplotype	O
4	O
alleles	O
among	O
Eastern	O
Europeans	O
and	O
is	O
not	O
present	O
among	O
Western	O
Europeans	O
and	O
Asians	O
.	O

The	O
rarity	O
of	O
this	O
mutant	O
allele	O
and	O
its	O
restricted	O
geographic	O
distribution	O
suggest	O
that	O
the	O
mutational	O
event	O
occurred	O
recently	O
on	O
a	O
normal	O
haplotype	O
4	O
background	O
in	O
Eastern	O
Europe	O
.	O
.	O

The	O
red	O
-	O
green	O
visual	O
pigment	O
gene	O
region	O
in	O
adrenoleukodystrophy	B-Disease
.	O

Although	O
recent	O
data	O
established	O
that	O
a	O
specific	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acyl	O
-	O
CoA	O
synthetase	O
is	O
defective	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
,	O
the	O
ALD	B-Disease
gene	O
is	O
still	O
unidentified	O
.	O

The	O
ALD	B-Disease
locus	O
has	O
been	O
mapped	O
to	O
Xq28	O
,	O
like	O
the	O
red	O
and	O
green	O
color	O
pigment	O
genes	O
.	O

Abnormal	B-Disease
color	I-Disease
vision	I-Disease
has	O
been	O
observed	O
in	O
12	O
of	O
27	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
,	O
a	O
milder	O
form	O
of	O
ALD	B-Disease
.	O

Furthermore	O
,	O
rearrangements	O
of	O
the	O
color	O
vision	O
gene	O
cluster	O
were	O
found	O
in	O
four	O
of	O
eight	O
ALD	B-Disease
kindreds	O
.	O

This	O
led	O
us	O
to	O
propose	O
that	O
a	O
single	O
DNA	O
rearrangement	O
could	O
underlie	O
both	O
ALD	B-Disease
and	O
abnormal	B-Disease
color	I-Disease
vision	I-Disease
in	O
these	O
patients	O
.	O

Study	O
of	O
34	O
French	O
ALD	B-Disease
patients	O
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	O
of	O
green	O
/	O
red	O
visual	O
pigment	O
rearrangements	O
3	O
to	O
the	O
red	O
/	O
green	O
color	O
vision	O
gene	O
complex	O
.	O

The	O
previous	O
report	O
of	O
such	O
rearrangements	O
was	O
based	O
on	O
small	O
numbers	O
and	O
lack	O
of	O
knowledge	O
that	O
the	O
frequency	O
of	O
"	O
abnormal	O
"	O
color	O
vision	O
arrays	O
on	O
molecular	O
analysis	O
was	O
twice	O
as	O
high	O
as	O
expected	O
on	O
the	O
basis	O
of	O
the	O
frequency	O
of	O
phenotypic	B-Disease
color	I-Disease
vision	I-Disease
defects	I-Disease
.	O

The	O
red	O
/	O
green	O
color	O
pigment	O
(	O
R	O
/	O
GCP	O
)	O
region	O
was	O
studied	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
in	O
14	O
of	O
these	O
patients	O
,	O
and	O
we	O
did	O
not	O
find	O
any	O
fragment	O
size	O
difference	O
between	O
the	O
patients	O
and	O
normal	O
individuals	O
who	O
have	O
the	O
same	O
number	O
of	O
pigment	O
genes	O
.	O

The	O
R	O
/	O
GCP	O
region	O
was	O
also	O
analyzed	O
in	O
29	O
French	O
and	O
seven	O
North	O
American	O
ALD	B-Disease
patients	O
by	O
using	O
six	O
genomic	O
DNA	O
probes	O
,	O
isolated	O
from	O
a	O
cosmid	O
walk	O
,	O
that	O
flank	O
the	O
color	O
vision	O
genes	O
.	O

No	O
deletions	O
were	O
found	O
with	O
probes	O
that	O
lie	O
3	O
of	O
the	O
green	O
pigment	O
genes	O
.	O

One	O
of	O
the	O
eight	O
previously	O
reported	O
ALD	B-Disease
individuals	O
has	O
a	O
long	O
deletion	O
5	O
of	O
the	O
red	O
pigment	O
gene	O
,	O
a	O
deletion	O
causing	O
blue	O
cone	O
monochromacy	O
.	O

This	O
finding	O
and	O
the	O
previous	O
findings	O
of	O
a	O
45	O
%	O
frequency	O
of	O
phenotypic	O
color	O
vision	O
defects	O
in	O
patients	O
with	O
AMN	B-Disease
may	O
suggest	O
that	O
the	O
ALD	B-Disease
/	O
AMN	B-Disease
gene	O
lies	O
5	O
to	O
the	O
red	O
pigment	O
gene	O
and	O
that	O
the	O
frequent	O
phenotypic	O
color	B-Disease
vision	I-Disease
anomalies	I-Disease
owe	O
their	O
origin	O
to	O
deleted	O
DNA	O
that	O
includes	O
regulatory	O
genes	O
for	O
color	O
vision	O
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
phenotypic	O
color	B-Disease
vision	I-Disease
anomalies	I-Disease
in	O
AMN	B-Disease
may	O
be	O
phenocopies	O
secondary	O
to	O
retinal	O
or	O
neural	O
involvement	O
by	O
the	O
disease	O
.	O

The	O
single	O
case	O
of	O
blue	O
cone	O
monochromacy	O
may	O
therefore	O
be	O
a	O
fortuitous	O
coincidence	O
of	O
two	O
diseases	O
.	O
.	O

Paroxysmal	B-Disease
nocturnal	I-Disease
haemoglobinuria	I-Disease
with	O
coexisting	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
:	O
lack	O
of	O
massive	O
haemolytic	B-Disease
attack	I-Disease
.	O

A	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
haemoglobinuria	I-Disease
(	O
PNH	B-Disease
)	O
was	O
found	O
to	O
have	O
an	O
inherited	B-Disease
deficiency	I-Disease
in	I-Disease
the	I-Disease
ninth	I-Disease
complement	I-Disease
component	I-Disease
(	O
C9	O
)	O
.	O

In	O
complement	O
-	O
sensitivity	O
lysis	O
tests	O
,	O
80	O
%	O
of	O
her	O
erythrocytes	O
were	O
markedly	O
complement	O
-	O
sensitive	O
(	O
PNH	O
-	O
III	O
)	O
.	O

Laser	O
cytofluorimetry	O
with	O
a	O
monoclonal	O
antibody	O
against	O
decay	O
-	O
accelerating	O
factor	O
(	O
DAF	O
)	O
revealed	O
that	O
95	O
%	O
of	O
her	O
erythrocytes	O
were	O
DAF	O
-	O
negative	O
.	O

Surprisingly	O
,	O
she	O
has	O
suffered	O
only	O
mild	O
haemolysis	B-Disease
and	O
has	O
never	O
experienced	O
massive	O
spontaneous	O
haemolysis	B-Disease
.	O

Gross	O
haemoglobinuria	B-Disease
and	O
jaundice	B-Disease
occurred	O
only	O
after	O
receiving	O
postoperative	O
transfusion	O
of	O
whole	O
blood	O
.	O

In	O
her	O
serum	O
,	O
C9	O
was	O
not	O
detectable	O
either	O
by	O
immunological	O
or	O
by	O
functional	O
assays	O
.	O

Both	O
the	O
Ham	O
test	O
and	O
the	O
sugar	O
water	O
test	O
using	O
normal	O
human	O
serum	O
or	O
plasma	O
yielded	O
marked	O
haemolysis	O
of	O
the	O
patients	O
erythrocytes	O
.	O

When	O
the	O
patients	O
serum	O
or	O
plasma	O
was	O
used	O
,	O
only	O
a	O
trace	O
of	O
lysis	O
was	O
detected	O
.	O

Addition	O
of	O
purified	O
human	O
C9	O
to	O
her	O
plasma	O
fully	O
restored	O
haemolysis	O
.	O

These	O
observations	O
indicated	O
that	O
C9	O
may	O
play	O
a	O
critical	O
role	O
in	O
haemolytic	B-Disease
attacks	I-Disease
in	O
patients	O
with	O
PNH	B-Disease
and	O
that	O
characteristic	O
haemolysis	B-Disease
in	O
PNH	B-Disease
may	O
be	O
tempered	O
by	O
coexisting	O
C9	B-Disease
deficiency	I-Disease
.	O
.	O

Duplicational	O
mutation	O
at	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
locus	O
:	O
its	O
frequency	O
,	O
distribution	O
,	O
origin	O
,	O
and	O
phenotypegenotype	O
correlation	O
.	O

Partial	O
gene	O
deletion	O
is	O
the	O
major	O
cause	O
of	O
mutation	O
leading	O
to	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
and	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
.	O

Partial	O
gene	O
duplication	O
has	O
also	O
been	O
recognized	O
in	O
a	O
few	O
cases	O
.	O

We	O
have	O
conducted	O
a	O
survey	O
for	O
duplication	O
in	O
72	O
unrelated	O
nondeletion	O
patients	O
,	O
analyzed	O
by	O
Southern	O
blot	O
hybridization	O
with	O
clones	O
representing	O
the	O
entire	O
DMD	B-Disease
cDNA	O
.	O

With	O
careful	O
quantitative	O
analysis	O
of	O
hybridization	O
band	O
intensity	O
,	O
10	O
cases	O
were	O
found	O
to	O
carry	O
a	O
duplication	O
of	O
part	O
of	O
the	O
gene	O
,	O
a	O
frequency	O
of	O
14	O
%	O
for	O
nondeletion	O
cases	O
(	O
10	O
/	O
72	O
)	O
,	O
or	O
6	O
%	O
for	O
all	O
cases	O
(	O
10	O
/	O
181	O
)	O
.	O

The	O
extent	O
of	O
these	O
duplications	O
has	O
been	O
characterized	O
according	O
to	O
the	O
published	O
exon	O
-	O
containing	O
HindIII	O
fragment	O
map	O
,	O
and	O
in	O
six	O
of	O
the	O
10	O
duplications	O
a	O
novel	O
restriction	O
fragment	O
that	O
spanned	O
the	O
duplication	O
junction	O
was	O
detected	O
.	O

The	O
resulting	O
translational	O
reading	O
frame	O
of	O
mRNA	O
has	O
been	O
predicted	O
for	O
nine	O
duplications	O
.	O

A	O
shift	O
of	O
the	O
reading	O
frame	O
was	O
predicted	O
in	O
four	O
of	O
the	O
six	O
DMD	B-Disease
cases	O
and	O
in	O
one	O
of	O
the	O
two	O
intermediate	O
cases	O
,	O
while	O
the	O
reading	O
frame	O
remained	O
uninterrupted	O
in	O
both	O
BMD	B-Disease
cases	O
.	O

RFLP	O
and	O
quantitative	O
Southern	O
blot	O
analyses	O
revealed	O
a	O
grandpaternal	O
origin	O
of	O
duplication	O
in	O
four	O
families	O
and	O
grandmaternal	O
origin	O
in	O
one	O
family	O
.	O

In	O
all	O
five	O
families	O
,	O
the	O
duplication	O
was	O
found	O
to	O
originate	O
from	O
a	O
single	O
X	O
chromosome	O
.	O

Unequal	O
sister	O
-	O
chromatid	O
exchange	O
is	O
proposed	O
to	O
be	O
the	O
mechanism	O
for	O
the	O
formation	O
of	O
these	O
duplications	O
.	O
.	O

Glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
:	O
Gd	O
(	O
+	O
)	O
Alexandra	O
associated	O
with	O
neonatal	B-Disease
jaundice	I-Disease
and	O
Gd	O
(	O
-	O
)	O
Camperdown	O
in	O
a	O
young	O
man	O
with	O
lamellar	B-Disease
cataracts	I-Disease
.	O

Two	O
male	O
subjects	O
are	O
described	O
,	O
with	O
unusual	O
clinical	O
presentations	O
and	O
with	O
hitherto	O
undescribed	O
G6PD	O
variants	O
.	O

The	O
first	O
,	O
of	O
Italian	O
extraction	O
,	O
suffered	O
from	O
severe	O
neonatal	B-Disease
jaundice	I-Disease
following	O
maternal	O
ingestion	O
of	O
fresh	O
broad	O
beans	O
(	O
Vicia	O
fava	O
)	O
both	O
prenatally	O
and	O
postnatally	O
the	O
expression	O
of	O
the	O
enzymatic	O
defect	O
was	O
much	O
more	O
severe	O
in	O
the	O
neonatal	O
period	O
than	O
on	O
retesting	O
in	O
adolescence	O
,	O
when	O
biochemical	O
characterization	O
showed	O
unique	O
features	O
which	O
justify	O
designation	O
as	O
a	O
new	O
variant	O
Gd	O
(	O
+	O
)	O
Alexandra	O
.	O

The	O
second	O
patient	O
,	O
a	O
boy	O
of	O
Maltese	O
extraction	O
who	O
was	O
found	O
to	O
have	O
bilateral	B-Disease
lamellar	I-Disease
cataracts	I-Disease
at	O
the	O
age	O
of	O
4	O
years	O
,	O
was	O
identified	O
as	O
G6PD	B-Disease
deficient	I-Disease
only	O
as	O
a	O
result	O
of	O
a	O
survey	O
of	O
children	O
of	O
Mediterranean	O
origin	O
with	O
unexplained	O
cataract	B-Disease
formation	O
;	O
he	O
has	O
approximately	O
15	O
%	O
of	O
normal	O
enzyme	O
activity	O
,	O
with	O
another	O
unique	O
combination	O
of	O
biochemical	O
characteristics	O
which	O
has	O
led	O
to	O
its	O
designation	O
as	O
Gd	O
(	O
-	O
)	O
Camperdown	O
.	O

Although	O
this	O
association	O
may	O
be	O
coincidental	O
,	O
it	O
prompts	O
further	O
attention	O
to	O
the	O
possibility	O
that	O
under	O
certain	O
circumstances	O
G6PD	B-Disease
deficiency	I-Disease
may	O
favor	O
cataract	B-Disease
formation	O
.	O

The	O
two	O
cases	O
illustrate	O
the	O
value	O
of	O
characterization	O
of	O
the	O
mutant	O
enzyme	O
whenever	O
unexpected	O
clinical	O
or	O
laboratory	O
results	O
are	O
obtained	O
.	O
.	O

Statistical	O
analysis	O
of	O
the	O
two	O
stage	O
mutation	O
model	O
in	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
disease	I-Disease
,	O
and	O
in	O
sporadic	B-Disease
cerebellar	I-Disease
haemangioblastoma	I-Disease
and	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Analysis	O
of	O
the	O
age	O
incidence	O
curves	O
for	O
unilateral	B-Disease
and	I-Disease
bilateral	I-Disease
retinoblastoma	I-Disease
led	O
Knudson	O
to	O
propose	O
that	O
hereditary	B-Disease
tumours	I-Disease
may	O
arise	O
by	O
a	O
single	O
event	O
and	O
sporadic	B-Disease
tumours	I-Disease
by	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

It	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
may	O
arise	O
from	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

We	O
analysed	O
the	O
age	O
incidence	O
curves	O
for	O
symptomatic	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
n	O
=	O
26	O
)	O
and	O
cerebellar	B-Disease
haemangioblastoma	I-Disease
(	O
n	O
=	O
68	O
)	O
in	O
109	O
patients	O
with	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
disease	I-Disease
,	O
and	O
compared	O
them	O
to	O
104	O
patients	O
with	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
43	O
patients	O
with	O
sporadic	B-Disease
cerebellar	I-Disease
haemangioblastoma	I-Disease
.	O

The	O
age	O
incidence	O
curves	O
for	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
cerebellar	B-Disease
haemangioblastoma	I-Disease
in	O
VHL	B-Disease
disease	I-Disease
were	O
compatible	O
with	O
a	O
single	O
mutation	O
model	O
,	O
whereas	O
the	O
age	O
incidence	O
curves	O
for	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
cerebellar	B-Disease
haemangioblastoma	I-Disease
suggested	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

These	O
data	O
are	O
compatible	O
with	O
the	O
VHL	B-Disease
gene	O
functioning	O
as	O
a	O
recessive	O
tumour	B-Disease
suppressor	O
gene	O
.	O

Sporadic	B-Disease
cerebellar	I-Disease
haemangioblastoma	I-Disease
and	O
some	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
may	O
arise	O
from	O
somatic	O
mutations	O
inactivating	O
both	O
alleles	O
at	O
the	O
VHL	B-Disease
locus	O
.	O
.	O

Screening	O
for	O
carriers	O
of	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
among	O
Ashkenazi	O
Jews	O
.	O

A	O
comparison	O
of	O
DNA	O
-	O
based	O
and	O
enzyme	O
-	O
based	O
tests	O
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
prevention	O
of	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
GM2	B-Disease
gangliosidosis	I-Disease
,	I-Disease
type	I-Disease
1	I-Disease
)	O
depends	O
on	O
the	O
identification	O
of	O
carriers	O
of	O
the	O
gene	O
for	O
this	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
.	O

We	O
compared	O
the	O
enzyme	O
-	O
based	O
test	O
widely	O
used	O
in	O
screening	O
for	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
with	O
a	O
test	O
based	O
on	O
analysis	O
of	O
DNA	O
.	O

We	O
developed	O
methods	O
to	O
detect	O
the	O
three	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
occur	O
with	O
high	O
frequency	O
among	O
Ashkenazi	O
Jews	O
two	O
mutations	O
cause	O
infantile	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
,	O
and	O
the	O
third	O
causes	O
the	O
adult	O
-	O
onset	O
form	O
of	O
the	O
disease	O
.	O

DNA	O
segments	O
containing	O
these	O
mutation	O
sites	O
were	O
amplified	O
with	O
the	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
mutations	O
.	O

RESULTS	O
.	O

Among	O
62	O
Ashkenazi	O
obligate	O
carriers	O
of	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
,	O
the	O
three	O
specific	O
mutations	O
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	O
alleles	O
(	O
98	O
percent	O
)	O
.	O

In	O
216	O
Ashkenazi	O
carriers	O
identified	O
by	O
the	O
enzyme	O
test	O
,	O
DNA	O
analysis	O
showed	O
that	O
177	O
(	O
82	O
percent	O
)	O
had	O
one	O
of	O
the	O
identified	O
mutations	O
.	O

Of	O
the	O
177	O
,	O
79	O
percent	O
had	O
the	O
exon	O
11	O
insertion	O
mutation	O
,	O
18	O
percent	O
had	O
the	O
intron	O
12	O
splice	O
-	O
junction	O
mutation	O
,	O
and	O
3	O
percent	O
had	O
the	O
less	O
severe	O
exon	O
7	O
mutation	O
associated	O
with	O
adult	O
-	O
onset	O
disease	O
.	O

The	O
results	O
of	O
the	O
enzyme	O
tests	O
in	O
the	O
39	O
subjects	O
(	O
18	O
percent	O
)	O
who	O
were	O
defined	O
as	O
carriers	O
but	O
in	O
whom	O
DNA	O
analysis	O
did	O
not	O
identify	O
a	O
mutant	O
allele	O
were	O
probably	O
false	O
positive	O
(	O
although	O
there	O
remains	O
some	O
possibility	O
of	O
unidentified	O
mutations	O
)	O
.	O

In	O
addition	O
,	O
of	O
152	O
persons	O
defined	O
as	O
noncarriers	O
by	O
the	O
enzyme	O
-	O
based	O
test	O
,	O
1	O
was	O
identified	O
as	O
a	O
carrier	O
by	O
DNA	O
analysis	O
(	O
i	O
.	O
e	O
e	O
.	O
,	O
a	O
false	O
negative	O
enzyme	O
-	O
test	O
result	O
)	O
.	O

CONCLUSIONS	O
.	O

The	O
increased	O
specificity	O
and	O
predictive	O
value	O
of	O
the	O
DNA	O
-	O
based	O
test	O
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	O
tests	O
currently	O
used	O
to	O
screen	O
for	O
carriers	O
of	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
.	O

Total	B-Disease
deficiency	I-Disease
of	I-Disease
plasma	I-Disease
cholesteryl	I-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
in	O
subjects	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
intron	O
14	O
splicing	O
defect	O
.	O

The	O
molecular	O
basis	O
of	O
cholesteryl	B-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
(	I-Disease
CETP	I-Disease
)	I-Disease
deficiency	I-Disease
was	O
investigated	O
in	O
4	O
unrelated	O
CETP	B-Disease
-	I-Disease
deficient	I-Disease
families	O
.	O

The	O
high	O
density	O
lipoprotein	O
-	O
cholesterol	O
levels	O
of	O
the	O
probands	O
exceeded	O
150	O
mg	O
/	O
dl	O
.	O

The	O
plasma	O
of	O
the	O
probands	O
was	O
totally	O
deficient	O
in	O
CETP	O
activity	O
and	O
mass	O
.	O

The	O
genomic	O
DNA	O
of	O
the	O
patients	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
,	O
using	O
two	O
oligonucleotide	O
primers	O
located	O
in	O
the	O
intron	O
12	O
and	O
14	O
of	O
the	O
CETP	O
gene	O
,	O
and	O
the	O
amplified	O
products	O
were	O
directly	O
sequenced	O
.	O

Two	O
patients	O
were	O
homozygous	O
for	O
a	O
G	O
-	O
to	O
-	O
A	O
change	O
at	O
the	O
5	O
-	O
splice	O
donor	O
site	O
of	O
the	O
intron	O
14	O
.	O

The	O
G	O
-	O
to	O
-	O
A	O
change	O
would	O
cause	O
impaired	O
splicing	O
of	O
pre	O
-	O
messenger	O
RNA	O
.	O

The	O
other	O
two	O
probands	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
but	O
totally	O
lacked	O
CETP	O
.	O

Their	O
lipoprotein	O
patterns	O
were	O
also	O
similar	O
to	O
those	O
of	O
the	O
two	O
homozygotes	O
.	O

Thus	O
,	O
other	O
genetic	B-Disease
defects	I-Disease
or	O
metabolic	O
factors	O
influencing	O
CETP	O
expression	O
are	O
implicated	O
.	O

The	O
data	O
suggest	O
that	O
the	O
G	O
-	O
to	O
-	O
A	O
mutation	O
may	O
be	O
common	O
in	O
human	O
plasma	O
CETP	B-Disease
deficiency	I-Disease
.	O

Furthermore	O
,	O
there	O
could	O
be	O
compound	O
heterozygotes	O
who	O
totally	O
lack	O
plasma	O
CETP	O
and	O
have	O
lipoprotein	O
profiles	O
similar	O
to	O
those	O
of	O
homozygotes	O
.	O
.	O

Molecular	O
genetics	O
of	O
the	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
Mediterranean	O
variant	O
and	O
description	O
of	O
a	O
new	O
G6PD	O
mutant	O
,	O
G6PD	O
Andalus1361A	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
;	I-Disease
E	I-Disease
.	I-Disease
C	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
the	O
most	O
common	O
human	O
enzymopathy	B-Disease
;	O
more	O
than	O
300	O
different	O
biochemical	O
variants	O
of	O
the	O
enzyme	O
have	O
been	O
described	O
.	O

In	O
many	O
parts	O
of	O
the	O
world	O
the	O
Mediterranean	O
type	O
of	O
G6PD	B-Disease
deficiency	I-Disease
is	O
prevalent	O
.	O

However	O
,	O
G6PD	O
Mediterranean	O
has	O
come	O
to	O
be	O
regarded	O
as	O
a	O
generic	O
term	O
applied	O
to	O
similar	O
G6PD	O
mutations	O
thought	O
,	O
however	O
,	O
to	O
represent	O
a	O
somewhat	O
heterogeneous	O
group	O
.	O

A	O
C	O
-	O
-	O
-	O
-	O
T	O
mutation	O
at	O
nucleotide	O
563	O
of	O
G6PD	O
Mediterranean	O
has	O
been	O
identified	O
by	O
Vulliamy	O
et	O
al	O
.	O
,	O
and	O
the	O
same	O
mutation	O
has	O
been	O
found	O
by	O
De	O
Vita	O
et	O
al	O
.	O
in	O
G6PD	O
Mediterranean	O
,	O
G6PD	O
Sassari	O
,	O
and	O
G6PD	O
Cagliari	O
.	O

The	O
latter	O
subjects	O
had	O
an	O
additional	O
mutation	O
,	O
at	O
nucleotide	O
1311	O
,	O
that	O
did	O
not	O
produce	O
a	O
coding	O
change	O
.	O

We	O
have	O
examined	O
genomic	O
DNA	O
of	O
five	O
patients	O
-	O
-	O
four	O
of	O
Spanish	O
origin	O
and	O
one	O
of	O
Jewish	O
origin	O
-	O
-	O
having	O
enzymatically	O
documented	O
G6PD	O
Mediterranean	O
.	O

All	O
had	O
both	O
the	O
mutation	O
at	O
nucleotide	O
563	O
and	O
that	O
at	O
nucleotide	O
1311	O
.	O

A	O
sixth	O
sample	O
,	O
resembling	O
G6PD	O
Mediterranean	O
kinetically	O
but	O
with	O
a	O
slightly	O
rapid	O
electrophoretic	O
mobility	O
,	O
was	O
designated	O
G6PD	O
Andalus	O
and	O
was	O
found	O
to	O
have	O
a	O
different	O
mutation	O
,	O
a	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
at	O
nucleotide	O
1361	O
,	O
producing	O
an	O
arginine	O
-	O
to	O
-	O
histidine	O
substitution	O
.	O

These	O
studies	O
suggest	O
that	O
G6PD	O
Mediterranean	O
is	O
,	O
after	O
all	O
,	O
relatively	O
homogeneous	O
.	O

A	O
normal	O
male	O
with	O
an	O
inherited	O
deletion	O
of	O
one	O
exon	O
within	O
the	O
DMD	B-Disease
gene	O
.	O

We	O
describe	O
two	O
brothers	O
with	O
identical	O
inherited	O
deletions	O
of	O
one	O
single	O
exon	O
within	O
the	O
middle	O
of	O
the	O
DMD	B-Disease
gene	O
;	O
one	O
brother	O
has	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
diagnosed	O
at	O
11	O
years	O
of	O
age	O
,	O
whereas	O
the	O
older	O
brother	O
is	O
normal	O
at	O
18	O
.	O

These	O
results	O
have	O
implications	O
for	O
genetic	O
counselling	O
and	O
prenatal	O
diagnosis	O
in	O
families	O
with	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
.	O

Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
expression	O
in	O
normal	O
and	O
diseased	O
human	O
muscle	O
.	O

A	O
probe	O
for	O
the	O
5	O
end	O
of	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
was	O
used	O
to	O
study	O
expression	O
of	O
the	O
gene	O
in	O
normal	O
human	O
muscle	O
,	O
myogenic	O
cell	O
cultures	O
,	O
and	O
muscle	O
from	O
patients	O
with	O
DMD	B-Disease
.	O

Expression	O
was	O
found	O
in	O
RNA	O
from	O
normal	O
fetal	O
muscle	O
,	O
adult	O
cardiac	O
and	O
skeletal	O
muscle	O
,	O
and	O
cultured	O
muscle	O
after	O
myoblast	O
fusion	O
.	O

In	O
DMD	B-Disease
muscle	O
,	O
expression	O
of	O
this	O
portion	O
of	O
the	O
gene	O
was	O
also	O
revealed	O
by	O
in	O
situ	O
RNA	O
hybridization	O
,	O
particularly	O
in	O
regenerating	O
muscle	O
fibers	O
.	O
.	O

Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
.	O

Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
or	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
DMD	B-Disease
locus	O
.	O

This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b	O
-	O
7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O

These	O
80	O
individuals	O
account	O
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al	O
.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
)	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O

Thirty	O
-	O
eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B-Disease
,	O
BMD	B-Disease
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B-Disease
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B-Disease
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
BMD	B-Disease
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in	O
-	O
frame	O
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al	O
.	O
and	O
Koenig	O
et	O
al	O
.	O
but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al	O
.	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

Cloning	O
of	O
breakpoints	O
of	O
a	O
chromosome	O
translocation	O
identifies	O
the	O
AN2	O
locus	O
.	O

Chromosome	O
translocations	O
involving	O
11p13	O
have	O
been	O
associated	O
with	O
familial	B-Disease
aniridia	I-Disease
in	O
two	O
kindreds	O
highlighting	O
the	O
chromosomal	O
localization	O
of	O
the	O
AN2	O
locus	O
.	O

This	O
locus	O
is	O
also	O
part	O
of	O
the	O
WAGR	B-Disease
complex	O
(	O
Wilms	B-Disease
tumor	I-Disease
,	O
aniridia	B-Disease
,	O
genitourinary	B-Disease
abnormalities	I-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
)	O
.	O

In	O
one	O
kindred	O
,	O
the	O
translocation	O
is	O
associated	O
with	O
a	O
deletion	O
,	O
and	O
probes	O
for	O
this	O
region	O
were	O
used	O
to	O
identify	O
and	O
clone	O
the	O
breakpoints	O
of	O
the	O
translocation	O
in	O
the	O
second	O
kindred	O
.	O

Comparison	O
of	O
phage	O
restriction	O
maps	O
exclude	O
the	O
presence	O
of	O
any	O
sizable	O
deletion	O
in	O
this	O
case	O
.	O

Sequences	O
at	O
the	O
chromosome	O
11	O
breakpoint	O
are	O
conserved	O
in	O
multiple	O
species	O
,	O
suggesting	O
that	O
the	O
translocation	O
falls	O
within	O
the	O
AN2	O
gene	O
.	O
.	O

Linkage	O
analysis	O
of	O
the	O
apolipoprotein	O
C2	O
gene	O
and	O
myotonic	B-Disease
dystrophy	I-Disease
on	O
human	O
chromosome	O
19	O
reveals	O
linkage	O
disequilibrium	O
in	O
a	O
French	O
-	O
Canadian	O
population	O
.	O

The	O
gene	O
for	O
human	O
apolipoprotein	O
C2	O
(	O
APOC2	O
)	O
,	O
situated	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
19	O
,	O
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
,	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
.	O

Six	O
APOC2	O
RFLPs	O
(	O
TaqI	O
,	O
BglI	O
,	O
BanI	O
,	O
BamHI	O
,	O
NcoI	O
,	O
and	O
AvaII	O
)	O
have	O
been	O
identified	O
to	O
date	O
.	O

We	O
have	O
conducted	O
a	O
comprehensive	O
DM	B-Disease
linkage	O
study	O
utilizing	O
all	O
six	O
RFLPs	O
and	O
involving	O
50	O
families	O
and	O
372	O
individuals	O
.	O

The	O
most	O
informative	O
RFLPs	O
are	O
,	O
in	O
descending	O
order	O
,	O
NcoI	O
(	O
lod	O
=	O
6	O
.	O
64	O
,	O
theta	O
=	O
0	O
.	O
05	O
)	O
,	O
BglI	O
(	O
lod	O
=	O
6	O
.	O
12	O
,	O
theta	O
=	O
0	O
.	O
05	O
)	O
,	O
AvaII	O
(	O
lod	O
=	O
6	O
.	O
02	O
,	O
theta	O
=	O
0	O
.	O
03	O
)	O
,	O
BanI	O
(	O
lod	O
=	O
5	O
.	O
76	O
,	O
theta	O
=	O
0	O
.	O
04	O
)	O
,	O
TaqI	O
(	O
lod	O
=	O
4	O
.	O
29	O
,	O
theta	O
=	O
0	O
.	O
06	O
)	O
,	O
and	O
BamHI	O
(	O
lod	O
=	O
1	O
.	O
75	O
,	O
theta	O
=	O
0	O
.	O
01	O
)	O
.	O

A	O
substantial	O
increase	O
in	O
the	O
lod	O
scores	O
over	O
those	O
seen	O
with	O
the	O
individual	O
RFLPs	O
was	O
obtained	O
when	O
the	O
linkage	O
of	O
the	O
entire	O
APOC2	O
haplotype	O
(	O
composed	O
of	O
the	O
six	O
RFLPs	O
)	O
was	O
studied	O
(	O
lod	O
=	O
17	O
.	O
87	O
,	O
theta	O
=	O
0	O
.	O
04	O
)	O
.	O

We	O
have	O
observed	O
significant	O
inter	O
-	O
APOC2	O
RFLP	O
linkage	O
disequilibrium	O
.	O

Consequently	O
,	O
the	O
three	O
most	O
informative	O
RFLPs	O
have	O
been	O
found	O
to	O
be	O
BanI	O
,	O
TaqI	O
,	O
and	O
either	O
BglI	O
,	O
AvaII	O
,	O
or	O
NcoI	O
polymorphisms	O
.	O

We	O
also	O
demonstrate	O
linkage	O
disequilibrium	O
between	O
DM	O
and	O
APOC2	O
in	O
our	O
French	O
-	O
Canadian	O
population	O
(	O
standardized	O
disequilibrium	O
constant	O
phi	O
=	O
.	O
22	O
,	O
chi	O
2	O
=	O
5	O
.	O
12	O
,	O
df	O
=	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
04	O
)	O
.	O

This	O
represents	O
the	O
first	O
evidence	O
of	O
linkage	O
disequilibrium	O
between	O
APOC2	O
and	O
the	O
DM	B-Disease
locus	O
.	O

Phenylalanine	O
hydroxylase	O
gene	O
haplotypes	O
in	O
Polynesians	O
:	O
evolutionary	O
origins	O
and	O
absence	O
of	O
alleles	O
associated	O
with	O
severe	O
phenylketonuria	B-Disease
.	O

A	O
total	O
of	O
630	O
haplotypes	O
for	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
locus	O
were	O
established	O
in	O
five	O
groups	O
of	O
Polynesians	O
comprising	O
Samoans	O
,	O
Tongans	O
,	O
Cook	O
Islanders	O
,	O
Maori	O
,	O
and	O
Niueans	O
.	O

Considerable	O
genetic	O
continuity	O
was	O
demonstrated	O
between	O
these	O
widely	O
dispersed	O
populations	O
,	O
since	O
three	O
common	O
haplotypes	O
(	O
4	O
,	O
1	O
,	O
and	O
7	O
)	O
constituted	O
over	O
95	O
%	O
of	O
alleles	O
.	O

A	O
control	O
group	O
of	O
individuals	O
from	O
Southeast	O
Asia	O
shared	O
the	O
same	O
major	O
haplotypes	O
,	O
4	O
,	O
1	O
,	O
and	O
7	O
,	O
with	O
Polynesians	O
.	O

These	O
data	O
provide	O
further	O
support	O
for	O
the	O
theories	O
of	O
genetic	O
homogeneity	O
and	O
of	O
Asian	O
affinities	O
of	O
the	O
Polynesian	O
precursor	O
populations	O
.	O

The	O
absence	O
of	O
severe	O
phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
in	O
both	O
Polynesians	O
and	O
Southeast	O
Asians	O
is	O
consistent	O
with	O
the	O
lack	O
of	O
PAH	O
haplotypes	O
2	O
and	O
3	O
,	O
on	O
which	O
the	O
severe	O
PKU	B-Disease
mutants	O
have	O
arisen	O
among	O
Caucasians	O
.	O
.	O

Preferential	O
germline	O
mutation	O
of	O
the	O
paternal	O
allele	O
in	O
retinoblastoma	B-Disease
.	O

The	O
event	O
triggering	O
malignant	O
proliferation	O
in	O
70	O
%	O
of	O
retinoblastoma	B-Disease
tumours	I-Disease
is	O
loss	O
of	O
heterozygosity	O
for	O
chromosome	O
13q14	O
,	O
whereby	O
the	O
normal	O
retinoblastoma	B-Disease
gene	O
(	O
RB1	O
)	O
allele	O
is	O
lost	O
and	O
an	O
already	O
mutated	O
RB1	O
allele	O
remains	O
in	O
the	O
tumour	B-Disease
.	O

The	O
first	O
allele	O
suffers	O
a	O
mutational	O
event	O
-	O
-	O
deletion	O
,	O
duplication	O
or	O
point	O
mutation	O
(	O
manuscript	O
in	O
preparation	O
)	O
-	O
-	O
either	O
in	O
the	O
germ	O
line	O
(	O
all	O
bilateral	O
patients	O
)	O
or	O
in	O
a	O
somatic	O
retinal	O
cell	O
(	O
most	O
unilateral	O
patients	O
)	O
.	O

Most	O
bilateral	O
patients	O
have	O
no	O
family	O
history	O
of	O
retinoblastoma	B-Disease
and	O
are	O
presumed	O
to	O
have	O
new	O
germline	O
mutations	O
which	O
arose	O
in	O
the	O
egg	O
,	O
sperm	O
or	O
early	O
embryo	O
.	O

We	O
have	O
determined	O
the	O
parental	O
origin	O
of	O
the	O
retained	O
allele	O
in	O
nine	O
retinoblastoma	B-Disease
tumours	I-Disease
from	O
eight	O
unrelated	O
non	O
-	O
familial	O
cases	O
by	O
using	O
RB1	O
-	O
linked	O
genetic	O
markers	O
.	O

Six	O
tumours	B-Disease
retained	O
the	O
paternal	O
allele	O
and	O
three	O
retained	O
the	O
maternal	O
allele	O
.	O

Of	O
the	O
three	O
unilateral	B-Disease
tumours	I-Disease
,	O
only	O
one	O
retained	O
the	O
paternal	O
RB1	O
allele	O
.	O

Thus	O
,	O
there	O
is	O
no	O
evidence	O
that	O
the	O
paternal	O
RB1	O
allele	O
is	O
preferentially	O
retained	O
in	O
retinoblastoma	B-Disease
,	O
as	O
has	O
been	O
suggested	O
to	O
be	O
the	O
case	O
in	O
osteosarcoma	B-Disease
.	O

By	O
contrast	O
,	O
tumours	B-Disease
from	O
four	O
of	O
the	O
five	O
bilateral	O
patients	O
retained	O
the	O
paternal	O
RB1	O
allele	O
.	O

This	O
suggests	O
either	O
that	O
new	O
germline	O
RB1	O
mutations	O
arise	O
more	O
frequently	O
during	O
spermatogenesis	O
than	O
during	O
oogenesis	O
,	O
or	O
that	O
imprinting	O
in	O
the	O
early	O
embryo	O
affects	O
chromosomal	O
susceptibility	O
to	O
mutation	O
.	O
.	O

Haplotype	O
analysis	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
Turkish	O
phenylketonuria	B-Disease
families	O
.	O

We	O
have	O
estimated	O
the	O
haplotype	O
distribution	O
of	O
mutant	O
and	O
normal	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
alleles	O
for	O
17	O
Turkish	O
phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
families	O
20	O
normal	O
and	O
27	O
mutated	O
PAH	O
alleles	O
could	O
be	O
identified	O
.	O

Of	O
the	O
latter	O
,	O
the	O
most	O
prevalent	O
were	O
associated	O
with	O
haplotype	O
6	O
(	O
29	O
.	O
6	O
%	O
)	O
,	O
1	O
(	O
18	O
.	O
5	O
%	O
)	O
and	O
36	O
(	O
11	O
.	O
1	O
%	O
)	O
,	O
while	O
the	O
normal	O
alleles	O
were	O
preferentially	O
associated	O
with	O
haplotype	O
1	O
(	O
20	O
%	O
)	O
.	O

Of	O
the	O
19	O
different	O
haplotypes	O
observed	O
,	O
5	O
have	O
not	O
been	O
described	O
previously	O
.	O

The	O
haplotype	O
distribution	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
Northern	O
European	O
population	O
.	O

Two	O
of	O
the	O
eight	O
polymorphic	O
sites	O
were	O
in	O
association	O
with	O
PKU	B-Disease
.	O

No	O
deletions	O
of	O
exon	O
sequences	O
were	O
found	O
in	O
the	O
families	O
analysed	O
.	O

Huntington	B-Disease
disease	I-Disease
:	O
no	O
evidence	O
for	O
locus	O
heterogeneity	O
.	O

A	O
total	O
of	O
63	O
families	O
with	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
were	O
examined	O
for	O
linkage	O
between	O
HD	B-Disease
and	O
G8	O
(	O
D4S10	O
)	O
.	O

The	O
families	O
included	O
57	O
Caucasian	O
,	O
four	O
Black	O
American	O
,	O
and	O
two	O
Japanese	O
.	O

The	O
combined	O
maximum	O
lod	O
score	O
was	O
87	O
.	O

69	O
at	O
theta	O
=	O
0	O
.	O

04	O
(	O
99	O
%	O
confidence	O
interval	O
0	O
.	O
018	O
-	O
0	O
.	O
071	O
)	O
.	O

The	O
maximum	O
frequency	O
of	O
recombination	O
was	O
0	O
.	O

03	O
in	O
males	O
and	O
0	O
.	O

05	O
in	O
females	O
.	O

Fifty	O
-	O
seven	O
families	O
gave	O
positive	O
lod	O
scores	O
;	O
five	O
small	O
families	O
gave	O
mildly	O
negative	O
lod	O
scores	O
.	O

The	O
maximum	O
likelihood	O
estimate	O
of	O
alpha	O
,	O
the	O
proportion	O
of	O
linked	O
loci	O
,	O
was	O
1	O
.	O

0	O
with	O
a	O
lower	O
99	O
%	O
confidence	O
interval	O
of	O
0	O
.	O

88	O
.	O

These	O
data	O
suggest	O
that	O
there	O
is	O
only	O
one	O
HD	B-Disease
locus	O
,	O
although	O
a	O
second	O
rare	O
locus	O
cannot	O
be	O
ruled	O
out	O
.	O

Haplotype	O
and	O
multipoint	O
linkage	O
analysis	O
in	O
Finnish	O
choroideremia	B-Disease
families	O
.	O

Multipoint	O
linkage	O
analysis	O
of	O
choroideremia	B-Disease
(	O
TCD	B-Disease
)	O
and	O
seven	O
X	O
chromosomal	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
was	O
carried	O
out	O
in	O
18	O
Finnish	O
TCD	B-Disease
families	O
.	O

The	O
data	O
place	O
TCD	B-Disease
distal	O
to	O
PGK	O
and	O
DXS72	O
,	O
very	O
close	O
to	O
DXYS1	O
and	O
DXYS5	O
(	O
Zmax	O
=	O
24	O
at	O
theta	O
=	O
0	O
)	O
and	O
proximal	O
to	O
DXYS4	O
and	O
DXYS12	O
.	O

This	O
agrees	O
with	O
the	O
data	O
obtained	O
from	O
other	O
linkage	O
studies	O
and	O
from	O
physical	O
mapping	O
.	O

All	O
the	O
TCD	B-Disease
males	O
and	O
carrier	O
females	O
studied	O
have	O
the	O
same	O
DXYS1	O
allele	O
in	O
coupling	O
with	O
TCD	B-Disease
.	O

In	O
Northeastern	O
Finland	O
,	O
66	O
/	O
69	O
chromosomes	O
carrying	O
TCD	B-Disease
had	O
the	O
same	O
haplotype	O
at	O
loci	O
DXS72	O
,	O
DXYS1	O
,	O
DXYS4	O
,	O
and	O
DXYS12	O
.	O

The	O
same	O
haplotype	O
is	O
seen	O
in	O
only	O
15	O
/	O
99	O
chromosomes	O
not	O
carrying	O
TCD	B-Disease
.	O

Moreover	O
,	O
in	O
71	O
/	O
104	O
non	O
-	O
TCD	O
chromosomes	O
,	O
the	O
haplotype	O
at	O
six	O
marker	O
loci	O
is	O
different	O
from	O
those	O
seen	O
in	O
any	O
of	O
the	O
76	O
TCD	B-Disease
chromosomes	O
.	O

This	O
supports	O
the	O
previously	O
described	O
hypothesis	O
that	O
the	O
large	O
Northern	O
Finnish	O
choroideremia	B-Disease
pedigrees	O
,	O
comprising	O
a	O
total	O
of	O
over	O
80	O
living	O
patients	O
representing	O
more	O
than	O
a	O
fifth	O
of	O
all	O
TCD	B-Disease
patients	O
described	O
worldwide	O
,	O
carry	O
the	O
same	O
mutation	O
.	O

These	O
linkage	O
and	O
haplotype	O
data	O
provide	O
improved	O
opportunities	O
for	O
prenatal	O
diagnosis	O
based	O
on	O
RFLP	O
studies	O
.	O
.	O

Autosomal	O
dominant	O
aniridia	B-Disease
linked	O
to	O
the	O
chromosome	O
11p13	O
markers	O
catalase	O
and	O
D11S151	O
in	O
a	O
large	O
Dutch	O
family	O
.	O

In	O
a	O
large	O
pedigree	O
with	O
autosomal	O
dominant	O
aniridia	B-Disease
,	O
we	O
found	O
close	O
linkage	O
between	O
the	O
aniridia	B-Disease
locus	O
AN2	O
and	O
the	O
markers	O
catalase	O
(	O
CAT	O
)	O
(	O
zeta	O
=	O
7	O
.	O
27	O
at	O
theta	O
=	O
0	O
.	O
00	O
)	O
and	O
D11S151	O
(	O
zeta	O
=	O
3	O
.	O
86	O
at	O
theta	O
=	O
0	O
.	O
10	O
)	O
flanking	O
the	O
AN2	O
locus	O
on	O
11p13	O
.	O

Positive	O
lod	O
scores	O
were	O
also	O
obtained	O
for	O
the	O
11p13	O
-	O
-	O
-	O
-	O
11p14	O
markers	O
D11S16	O
and	O
FSHB	O
with	O
the	O
linkage	O
group	O
CAT	O
/	O
AN2	O
/	O
D11S151	O
.	O

We	O
conclude	O
that	O
the	O
autosomal	O
dominant	O
aniridia	B-Disease
in	O
this	O
family	O
is	O
due	O
to	O
a	O
mutation	O
at	O
the	O
AN2	O
locus	O
on	O
11p13	O
.	O

We	O
have	O
excluded	O
linkage	O
(	O
zeta	O
less	O
than	O
-	O
2	O
at	O
theta	O
less	O
than	O
0	O
.	O
18	O
)	O
between	O
the	O
aniridia	B-Disease
and	O
the	O
chromosome	O
2p25	O
marker	O
D2S1	O
(	O
linked	O
to	O
ACP1	O
)	O
.	O

Recombination	O
events	O
that	O
locate	O
myotonic	B-Disease
dystrophy	I-Disease
distal	O
to	O
APOC2	O
on	O
19q	O
.	O

We	O
previously	O
reported	O
a	O
recombination	O
in	O
an	O
individual	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
which	O
placed	O
the	O
markers	O
D19S19	O
and	O
APOC2	O
on	O
the	O
same	O
side	O
of	O
the	O
DM	B-Disease
locus	O
.	O

Haplotyping	O
of	O
this	O
family	O
with	O
more	O
recently	O
characterized	O
probes	O
which	O
are	O
either	O
tightly	O
linked	O
to	O
DM	B-Disease
or	O
distal	O
to	O
the	O
linkage	O
group	O
at	O
q13	O
.	O

2	O
shows	O
that	O
the	O
DM	B-Disease
locus	O
is	O
distal	O
to	O
APOC2	O
.	O

This	O
is	O
confirmed	O
by	O
other	O
recombinants	O
where	O
DM	B-Disease
segregates	O
with	O
distal	O
probes	O
.	O

Additional	O
marker	O
to	O
marker	O
recombinations	O
in	O
unaffected	O
individuals	O
are	O
reported	O
and	O
support	O
the	O
order	O
and	O
orientation	O
of	O
the	O
DM	B-Disease
linkage	O
group	O
as	O
pter	O
-	O
(	O
INSR	O
,	O
LDLR	O
,	O
S9	O
)	O
-	O
(	O
S19	O
,	O
BCL3	O
,	O
APOC2	O
)	O
-	O
(	O
CKMM	O
,	O
DM	O
)	O
-	O
(	O
S22	O
,	O
+	O
+	O
+	O
PRKCG	O
)	O
-	O
qter	O
.	O

The	O
data	O
presented	O
here	O
cannot	O
determine	O
whether	O
DM	B-Disease
is	O
proximal	O
or	O
distal	O
to	O
CKMM	O
.	O

The	O
consequences	O
of	O
this	O
probe	O
order	O
for	O
antenatal	O
diagnosis	O
and	O
future	O
research	O
aiming	O
to	O
isolate	O
the	O
gene	O
which	O
is	O
affected	O
in	O
DM	B-Disease
are	O
discussed	O
.	O

Mutations	O
in	O
the	O
RB1	O
gene	O
and	O
their	O
effects	O
on	O
transcription	O
.	O

Inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
during	O
normal	O
retinal	O
development	O
initiates	O
the	O
formation	O
of	O
a	O
retinoblastoma	B-Disease
(	I-Disease
RB	I-Disease
)	I-Disease
tumor	I-Disease
.	O

To	O
identify	O
the	O
mutations	O
which	O
inactivate	O
RB1	O
,	O
21	O
RB	B-Disease
tumors	I-Disease
isolated	O
from	O
19	O
patients	O
were	O
analyzed	O
with	O
the	O
polymerase	O
chain	O
reaction	O
or	O
an	O
RNase	O
protection	O
assay	O
or	O
both	O
.	O

Mutations	O
were	O
identified	O
in	O
13	O
of	O
21	O
RB	B-Disease
tumors	I-Disease
;	O
in	O
8	O
tumors	B-Disease
,	O
the	O
precise	O
errors	O
in	O
nucleotide	O
sequence	O
were	O
characterized	O
.	O

Each	O
of	O
four	O
germ	O
line	O
mutations	O
involved	O
a	O
small	O
deletion	O
or	O
duplication	O
,	O
while	O
three	O
somatic	O
mutations	O
were	O
point	O
mutations	O
leading	O
to	O
splice	O
alterations	O
and	O
loss	O
of	O
an	O
exon	O
from	O
the	O
mature	O
RB1	O
mRNA	O
.	O

We	O
were	O
unable	O
to	O
detect	O
expression	O
of	O
the	O
mutant	O
allele	O
in	O
lymphoblasts	O
of	O
three	O
bilaterally	O
affected	O
patients	O
,	O
although	O
the	O
mutation	O
was	O
present	O
in	O
the	O
genomic	O
DNA	O
and	O
transcripts	O
containing	O
the	O
mutations	O
were	O
obvious	O
in	O
the	O
RB	B-Disease
tumors	I-Disease
in	O
the	O
absence	O
of	O
a	O
normal	O
RB1	O
allele	O
.	O

The	O
variations	O
in	O
the	O
level	O
of	O
expression	O
of	O
mutant	O
transcripts	O
suggest	O
deregulation	O
of	O
RB1	O
transcription	O
in	O
the	O
absence	O
of	O
a	O
functional	O
RB1	O
gene	O
product	O
.	O
.	O

Partial	O
deletion	O
8q	O
without	O
Langer	B-Disease
-	I-Disease
Giedion	I-Disease
syndrome	I-Disease
:	O
a	O
recognisable	O
syndrome	O
.	O

We	O
report	O
two	O
de	O
novo	O
cases	O
of	O
del	O
(	O
8	O
)	O
(	O
pter	O
-	O
-	O
-	O
-	O
q24	O
.	O
1	O
)	O
with	O
breakpoints	O
involving	O
the	O
distal	O
part	O
of	O
band	O
8q24	O
.	O

1	O
1	O
.	O

The	O
clinical	O
features	O
were	O
similar	O
and	O
there	O
were	O
no	O
obvious	O
stigmata	O
of	O
Langer	B-Disease
-	I-Disease
Giedion	I-Disease
syndrome	I-Disease
(	O
LGS	B-Disease
)	O
.	O

There	O
are	O
three	O
other	O
cases	O
reported	O
with	O
a	O
deletion	O
of	O
chromosome	O
8	O
at	O
approximately	O
the	O
same	O
breakpoint	O
,	O
one	O
without	O
LGS	B-Disease
and	O
some	O
similarities	O
to	O
our	O
cases	O
,	O
the	O
other	O
two	O
with	O
LGS	B-Disease
.	O

Our	O
findings	O
would	O
support	O
the	O
observation	O
that	O
the	O
critical	O
segment	O
for	O
the	O
assignment	O
of	O
LGS	B-Disease
is	O
proximal	O
to	O
or	O
involves	O
the	O
proximal	O
part	O
of	O
8q24	O
.	O

1	O
,	O
but	O
a	O
review	O
of	O
published	O
reports	O
suggests	O
that	O
the	O
aetiology	O
of	O
LGS	B-Disease
may	O
be	O
a	O
more	O
complex	O
issue	O

Myotonic	B-Disease
dystrophy	I-Disease
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
muscle	O
-	O
type	O
creatine	O
kinase	O
(	O
CKMM	O
)	O
.	O

We	O
have	O
studied	O
genetic	O
linkage	O
between	O
the	O
gene	O
for	O
creatine	O
kinase	O
muscle	O
type	O
(	O
CKMM	O
)	O
and	O
the	O
gene	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
.	O

In	O
a	O
panel	O
of	O
65	O
myotonic	B-Disease
dystrophy	I-Disease
families	O
from	O
Canada	O
and	O
the	O
Netherlands	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
Zmax	O
)	O
of	O
22	O
.	O

8	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O

03	O
was	O
obtained	O
.	O

Tight	O
linkage	O
was	O
also	O
demonstrated	O
for	O
CKMM	O
and	O
the	O
gene	O
for	O
apolipoprotein	O
C2	O
(	O
ApoC2	O
)	O
.	O

This	O
establishes	O
CKMM	O
as	O
a	O
useful	O
marker	O
for	O
myotonic	B-Disease
dystrophy	I-Disease

Color	B-Disease
vision	I-Disease
defects	I-Disease
in	O
adrenomyeloneuropathy	B-Disease
.	O

The	O
relationship	O
between	O
abnormal	B-Disease
color	I-Disease
vision	I-Disease
and	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
was	O
investigated	O
in	O
27	O
AMN	B-Disease
patients	O
and	O
31	O
age	O
-	O
matched	O
controls	O
by	O
using	O
the	O
Farnsworth	O
-	O
Munsell	O
100	O
Hue	O
test	O
.	O

Twelve	O
(	O
44	O
%	O
)	O
of	O
27	O
patients	O
showed	O
test	O
scores	O
significantly	O
above	O
normal	O
.	O

The	O
axes	O
of	O
bipolarity	O
determined	O
by	O
the	O
testing	O
differed	O
widely	O
between	O
the	O
patients	O
with	O
abnormal	O
scores	O
,	O
compatible	O
with	O
the	O
notion	O
that	O
different	O
alterations	O
in	O
visual	O
pigment	O
genes	O
occur	O
in	O
different	O
AMN	B-Disease
kindreds	O
.	O

These	O
observations	O
confirm	O
our	O
earlier	O
impression	O
that	O
the	O
frequency	O
of	O
abnormal	B-Disease
color	I-Disease
vision	I-Disease
is	O
increased	O
in	O
these	O
kindreds	O
,	O
and	O
it	O
supports	O
our	O
contentions	O
that	O
(	O
1	O
)	O
AMN	B-Disease
(	O
and	O
its	O
companion	O
,	O
adrenoleukodystrophy	B-Disease
)	O
are	O
very	O
closely	O
linked	O
to	O
the	O
visual	O
pigment	O
loci	O
at	O
Xq28	O
and	O
(	O
2	O
)	O
this	O
proximity	O
might	O
provide	O
the	O
opportunity	O
to	O
observe	O
contiguous	B-Disease
gene	I-Disease
defects	I-Disease
.	O
.	O

Molecular	O
analysis	O
of	O
a	O
female	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
patient	O
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
female	O
patient	O
with	O
the	O
X	O
-	O
linked	O
recessive	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
(	O
hypoxanthine	B-Disease
phosphoribosyltransferase	I-Disease
[	I-Disease
HPRT	I-Disease
]	I-Disease
deficiency	I-Disease
)	O
.	O

Cytogenetic	O
and	O
carrier	O
studies	O
revealed	O
structurally	O
normal	O
chromosomes	O
for	O
this	O
patient	O
and	O
her	O
parents	O
and	O
demonstrated	O
that	O
this	O
mutation	O
arose	O
through	O
a	O
de	O
novo	O
gametic	O
event	O
.	O

Comparison	O
of	O
this	O
patients	O
DNA	O
with	O
the	O
DNA	O
of	O
her	O
parents	O
revealed	O
that	O
a	O
microdeletion	O
,	O
which	O
occurred	O
within	O
a	O
maternal	O
gamete	O
and	O
involved	O
the	O
entire	O
HPRT	O
gene	O
,	O
was	O
partially	O
responsible	O
for	O
the	O
disease	O
in	O
this	O
patient	O
.	O

Somatic	O
cell	O
hybrids	O
,	O
generated	O
to	O
separate	O
maternal	O
and	O
paternal	O
X	O
chromosomes	O
,	O
showed	O
that	O
expression	O
of	O
two	O
additional	O
X	O
-	O
linked	O
enzymes	O
,	O
phosphoglycerate	O
kinase	O
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
,	O
were	O
expressed	O
only	O
in	O
cells	O
that	O
contained	O
the	O
maternal	O
X	O
chromosome	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
functionally	O
inactive	O
paternal	O
X	O
chromosome	O
.	O

Furthermore	O
,	O
comparison	O
of	O
methylation	O
patterns	O
within	O
a	O
region	O
of	O
the	O
HPRT	O
gene	O
known	O
to	O
be	O
important	O
in	O
gene	O
regulation	O
revealed	O
differences	O
between	O
DNA	O
from	O
the	O
father	O
and	O
the	O
patient	O
,	O
in	O
keeping	O
with	O
an	O
active	O
HPRT	O
locus	O
in	O
the	O
father	O
and	O
an	O
inactive	O
HPRT	O
locus	O
in	O
the	O
patient	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
nonrandom	O
inactivation	O
of	O
the	O
cytogenetically	O
normal	O
paternal	O
X	O
chromosome	O
and	O
a	O
microdeletion	O
of	O
the	O
HPRT	O
gene	O
on	O
an	O
active	O
maternal	O
X	O
chromosome	O
were	O
responsible	O
for	O
the	O
absence	O
of	O
HPRT	O
in	O
this	O
patient	O
.	O
.	O

Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
:	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
neurologic	I-Disease
disorder	I-Disease
of	I-Disease
myelin	I-Disease
metabolism	I-Disease
with	O
a	O
novel	O
mutation	O
in	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
.	O

The	O
nosology	O
of	O
the	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
myelin	I-Disease
metabolism	I-Disease
has	O
been	O
stymied	O
by	O
the	O
lack	O
of	O
molecular	O
genetic	O
analysis	O
.	O

Historically	O
,	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
has	O
encompassed	O
a	O
host	O
of	O
neurologic	B-Disease
disorders	I-Disease
that	O
present	O
with	O
a	O
deficit	B-Disease
of	I-Disease
myelin	I-Disease
,	O
the	O
membrane	O
elaborated	O
by	O
glial	O
cells	O
that	O
encircles	O
and	O
successively	O
enwraps	O
axons	O
.	O

We	O
describe	O
here	O
a	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
pedigree	O
of	O
the	O
classical	O
type	O
,	O
with	O
X	O
-	O
linked	O
inheritance	O
,	O
a	O
typical	O
clinical	O
progression	O
,	O
and	O
a	O
pathologic	O
loss	O
of	O
myelinating	O
cells	O
and	O
myelin	O
in	O
the	O
central	O
nervous	O
system	O
.	O

To	O
discriminate	O
variants	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
,	O
a	O
set	O
of	O
oligonucleotide	O
primers	O
was	O
constructed	O
to	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
PCR	O
)	O
amplify	O
and	O
sequence	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
,	O
a	O
structural	O
protein	O
that	O
comprises	O
half	O
of	O
the	O
protein	O
of	O
the	O
myelin	O
sheath	O
.	O

The	O
PLP	O
gene	O
in	O
one	O
of	O
two	O
affected	O
males	O
and	O
the	O
carrier	O
mother	O
of	O
this	O
family	O
exhibited	O
a	O
single	O
base	O
difference	O
in	O
the	O
more	O
than	O
2	O
kb	O
of	O
the	O
PLP	O
gene	O
sequenced	O
,	O
a	O
C	O
-	O
-	O
-	O
-	O
T	O
transition	O
that	O
would	O
create	O
a	O
serine	O
substitution	O
for	O
proline	O
at	O
the	O
carboxy	O
end	O
of	O
the	O
protein	O
.	O

Our	O
results	O
delineate	O
the	O
clinical	O
features	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
,	O
define	O
the	O
possible	O
molecular	O
pathology	O
of	O
this	O
dysmyelinating	B-Disease
disorder	I-Disease
,	O
and	O
address	O
the	O
molecular	O
classification	O
of	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
myelin	I-Disease
metabolism	I-Disease
.	O

Patients	O
with	O
the	O
classical	O
form	O
(	O
type	O
I	O
)	O
and	O
the	O
more	O
severely	O
affected	O
,	O
connatal	O
variant	O
of	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	I-Disease
type	I-Disease
II	I-Disease
)	I-Disease
would	O
be	O
predicted	O
to	O
display	O
mutation	O
at	O
the	O
PLP	O
locus	O
.	O

The	O
other	O
variants	O
(	O
types	O
III	O
-	O
VI	O
)	O
,	O
which	O
have	O
sometimes	O
been	O
categorized	O
as	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
,	O
may	O
represent	O
mutations	O
in	O
genes	O
encoding	O
other	O
structural	O
myelin	O
proteins	O
or	O
proteins	O
critical	O
to	O
myelination	O
.	O
.	O

Molecular	O
basis	O
of	O
human	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
:	O
analysis	O
of	O
platelet	O
von	B-Disease
Willebrand	I-Disease
factor	O
mRNA	O
.	O

von	B-Disease
Willebrand	I-Disease
disease	I-Disease
(	O
vWD	B-Disease
)	O
,	O
the	O
most	O
common	O
inherited	B-Disease
bleeding	I-Disease
disorder	I-Disease
in	O
humans	O
,	O
can	O
result	O
from	O
either	O
a	O
quantitative	O
or	O
a	O
qualitative	O
defect	O
in	O
the	O
adhesive	O
glycoprotein	O
,	O
von	B-Disease
Willebrand	I-Disease
factor	O
(	O
vWF	O
)	O
.	O

Molecular	O
studies	O
of	O
vWD	B-Disease
have	O
been	O
limited	O
by	O
the	O
large	O
size	O
of	O
the	O
vWF	O
gene	O
and	O
difficulty	O
in	O
obtaining	O
the	O
vWF	O
mRNA	O
from	O
patients	O
.	O

By	O
use	O
of	O
an	O
adaptation	O
of	O
the	O
polymerase	O
chain	O
reaction	O
,	O
vWF	O
mRNA	O
was	O
amplified	O
and	O
sequenced	O
from	O
peripheral	O
blood	O
platelets	O
.	O

A	O
silent	O
vWF	O
allele	O
was	O
identified	O
,	O
resulting	O
from	O
a	O
cis	O
defect	O
in	O
vWF	O
mRNA	O
transcription	O
or	O
processing	O
.	O

In	O
two	O
type	B-Disease
IIA	I-Disease
vWD	I-Disease
patients	O
,	O
two	O
different	O
but	O
adjacent	O
missense	O
mutations	O
were	O
identified	O
,	O
the	O
locations	O
of	O
which	O
may	O
identify	O
an	O
important	O
vWF	O
functional	O
domain	O
.	O

Expression	O
in	O
heterologous	O
cells	O
of	O
recombinant	O
vWF	O
containing	O
one	O
of	O
these	O
latter	O
mutations	O
reproduced	O
the	O
characteristic	O
structural	O
abnormality	O
seen	O
in	O
type	B-Disease
IIA	I-Disease
vWD	I-Disease
plasma	O
.	O
.	O

Familial	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
associated	O
with	O
recurrent	O
meningococcal	B-Disease
infections	I-Disease
.	O

We	O
describe	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
suffering	O
from	O
recurrent	B-Disease
meningitis	I-Disease
with	O
a	O
complete	O
absence	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C7	O
)	O
.	O

Diagnosis	O
was	O
established	O
by	O
haemolytic	O
titration	O
and	O
western	O
blotting	O
.	O

The	O
patients	O
serum	O
lacked	O
the	O
85	O
kDa	O
C7	O
chain	O
.	O

Haemolytic	O
activity	O
of	O
serum	O
was	O
reconstituted	O
with	O
either	O
pooled	O
normal	O
human	O
serum	O
or	O
with	O
purified	O
C7	O
.	O

The	O
relatives	O
(	O
parents	O
and	O
one	O
sister	O
)	O
had	O
half	O
-	O
normal	O
levels	O
of	O
both	O
immunochemically	O
and	O
functionally	O
determined	O
C7	O
,	O
indicating	O
a	O
heterozygous	O
state	O
for	O
C7	B-Disease
deficiency	I-Disease
.	O
.	O

Translocation	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
1	O
;	O
p13	O
)	O
associated	O
with	O
familial	O
isolated	B-Disease
aniridia	I-Disease
.	O

A	O
father	O
and	O
daughter	O
with	O
isolated	B-Disease
aniridia	I-Disease
were	O
observed	O
to	O
have	O
an	O
apparently	O
balanced	O
,	O
reciprocal	O
translocation	O
involving	O
chromosomes	O
5	O
and	O
11	O
[	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
1	O
;	O
p13	O
)	O
]	O
.	O

No	O
other	O
clinical	O
characteristics	O
often	O
associated	O
with	O
the	O
deletion	O
of	O
11p13	O
were	O
observed	O
in	O
this	O
family	O
.	O

This	O
finding	O
,	O
in	O
association	O
with	O
3	O
other	O
instances	O
of	O
single	O
breaks	O
at	O
11p13	O
and	O
aniridia	B-Disease
,	O
supports	O
the	O
assignment	O
of	O
AN2	O
to	O
11p13	O
.	O

Homozygous	B-Disease
hypobetalipoproteinemia	I-Disease
:	O
a	O
disease	O
distinct	O
from	O
abetalipoproproteinemia	B-Disease
at	O
the	O
molecular	O
level	O
.	O

apoB	O
DNA	O
,	O
RNA	O
,	O
and	O
protein	O
from	O
two	O
patients	O
with	O
homozygous	B-Disease
hypobetalipoproteinemia	I-Disease
(	O
HBL	B-Disease
)	O
were	O
evaluated	O
and	O
compared	O
with	O
normal	O
individuals	O
.	O

Southern	O
blot	O
analysis	O
with	O
10	O
different	O
cDNA	O
probes	O
revealed	O
a	O
normal	O
gene	O
without	O
major	O
insertions	O
,	O
deletions	O
,	O
or	O
rearrangements	O
.	O

Northern	O
and	O
slot	O
blot	O
analyses	O
of	O
total	O
liver	O
mRNA	O
from	O
HBL	B-Disease
patients	O
documented	O
a	O
normal	O
size	O
apoB	O
mRNA	O
that	O
was	O
present	O
in	O
greatly	O
reduced	O
quantities	O
.	O

ApoB	O
protein	O
was	O
detected	O
within	O
HBL	B-Disease
hepatocytes	O
utilizing	O
immunohistochemical	O
techniques	O
;	O
however	O
,	O
it	O
was	O
markedly	O
reduced	O
in	O
quantity	O
when	O
compared	O
with	O
control	O
samples	O
.	O

No	O
apoB	O
was	O
detectable	O
in	O
the	O
plasma	O
of	O
HBL	B-Disease
individuals	O
with	O
an	O
ELISA	O
assay	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
a	O
mutation	O
in	O
the	O
coding	O
portion	O
of	O
the	O
apoB	O
gene	O
in	O
HBL	B-Disease
patients	O
,	O
leading	O
to	O
an	O
abnormal	O
apoB	O
protein	O
and	O
apoB	O
mRNA	O
instability	O
.	O

These	O
results	O
are	O
distinct	O
from	O
those	O
previously	O
noted	O
in	O
abetalipoproteinemia	B-Disease
,	O
which	O
was	O
characterized	O
by	O
an	O
elevated	O
level	O
of	O
hepatic	O
apoB	O
mRNA	O
and	O
accumulation	O
of	O
intracellular	O
hepatic	O
apoB	O
protein	O
.	O
.	O

Spontaneous	O
reversion	O
of	O
novel	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
mutation	O
by	O
HPRT	O
gene	O
rearrangement	O
.	O

Molecular	O
analysis	O
of	O
an	O
unusual	O
patient	O
with	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
has	O
suggested	O
that	O
the	O
mutation	O
is	O
due	O
to	O
a	O
partial	O
HPRT	O
gene	O
duplication	O
.	O

We	O
now	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
mutant	O
HPRT	O
cDNA	O
which	O
shows	O
the	O
precise	O
duplication	O
of	O
exons	O
2	O
and	O
3	O
.	O

This	O
mutation	O
is	O
the	O
result	O
of	O
an	O
internal	O
duplication	O
of	O
16	O
-	O
20	O
kilobases	O
of	O
the	O
gene	O
.	O

The	O
structure	O
of	O
the	O
mutant	O
gene	O
suggests	O
that	O
the	O
duplication	O
was	O
not	O
generated	O
by	O
a	O
single	O
unequal	O
crossing	O
-	O
over	O
event	O
between	O
two	O
normal	O
HPRT	O
alleles	O
.	O

Growth	O
of	O
Epstein	B-Disease
-	I-Disease
Barr	I-Disease
virus	O
-	O
transformed	O
lymphoblasts	O
from	O
this	O
patient	O
in	O
selective	O
medium	O
has	O
permitted	O
isolation	O
of	O
spontaneous	O
HPRT	O
+	O
revertants	O
of	O
this	O
mutation	O
.	O

The	O
reversion	O
event	O
involves	O
a	O
second	O
major	O
HPRT	O
gene	O
rearrangement	O
where	O
most	O
or	O
all	O
of	O
the	O
duplicated	O
portion	O
of	O
the	O
mutant	O
gene	O
is	O
deleted	O
.	O

The	O
original	O
mutation	O
therefore	O
has	O
the	O
potential	O
for	O
spontaneous	O
somatic	O
reversion	O
.	O

This	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	O
of	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
exhibited	O
by	O
this	O
patient	O
.	O
.	O

Complex	B-Disease
glycerol	I-Disease
kinase	I-Disease
deficiency	I-Disease
:	O
molecular	O
-	O
genetic	O
,	O
cytogenetic	O
,	O
and	O
clinical	O
studies	O
of	O
five	O
Japanese	O
patients	O
.	O

Five	O
male	O
Japanese	O
patients	O
with	O
complex	B-Disease
glycerol	I-Disease
kinase	I-Disease
deficiency	I-Disease
(	O
CGKD	B-Disease
)	O
and	O
their	O
relatives	O
were	O
studied	O
clinically	O
,	O
cytogenetically	O
,	O
and	O
molecular	O
-	O
genetically	O
.	O

All	O
patients	O
had	O
muscular	B-Disease
dystrophy	I-Disease
or	O
muscle	B-Disease
weakness	I-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
congenital	B-Disease
adrenal	I-Disease
hypoplasia	I-Disease
,	O
and	O
glycerol	B-Disease
kinase	I-Disease
deficiency	I-Disease
.	O

High	O
-	O
resolution	O
GTG	O
-	O
banded	O
chromosomes	O
showed	O
a	O
microdeletion	O
in	O
the	O
Xp21	O
region	O
in	O
all	O
four	O
patients	O
examined	O
and	O
in	O
all	O
five	O
mothers	O
.	O

Southern	O
hybridizations	O
,	O
after	O
digestions	O
by	O
restriction	O
endonucleases	O
,	O
with	O
various	O
cloned	O
DNAs	O
(	O
D2	O
,	O
99	O
-	O
6	O
,	O
B24	O
,	O
C7	O
,	O
L1	O
-	O
4	O
,	O
cDMD13	O
-	O
14	O
,	O
J66	O
-	O
HI	O
,	O
P20	O
,	O
J	O
-	O
Bir	O
,	O
ERT87	O
-	O
30	O
,	O
ERT87	O
-	O
15	O
,	O
ERT87	O
-	O
8	O
,	O
ERT87	O
-	O
1	O
,	O
XJ	O
-	O
1	O
.	O
1	O
,	O
754	O
,	O
cx5	O
.	O
7	O
,	O
and	O
OTC	O
-	O
1	O
)	O
that	O
are	O
located	O
around	O
Xp21	O
also	O
showed	O
a	O
deletion	O
in	O
the	O
genome	O
of	O
all	O
patients	O
and	O
mothers	O
.	O

Although	O
the	O
deletion	O
differed	O
in	O
size	O
among	O
patients	O
,	O
a	O
segment	O
commonly	O
absent	O
was	O
located	O
between	O
the	O
genomic	O
sequences	O
corresponding	O
to	O
L1	O
-	O
4	O
and	O
cDMD13	O
-	O
14	O
.	O

This	O
finding	O
indicated	O
that	O
the	O
gene	O
coding	O
for	O
glycerol	O
kinase	O
(	O
GK	O
)	O
is	O
located	O
within	O
this	O
segment	O
.	O

A	O
comparison	O
of	O
the	O
clinical	O
manifestations	O
of	O
the	O
present	O
five	O
patients	O
and	O
reported	O
CGKD	B-Disease
or	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
patients	O
with	O
DNA	O
deletion	O
suggests	O
the	O
existence	O
of	O
a	O
certain	O
gene	O
responsible	O
for	O
gonadotropin	B-Disease
deficiency	I-Disease
(	O
GTD	B-Disease
)	O
.	O

The	O
result	O
of	O
the	O
present	O
study	O
and	O
results	O
of	O
previous	O
studies	O
suggest	O
that	O
genes	O
for	O
ornithine	O
transcarbamylase	O
(	O
OTC	O
)	O
,	O
DMD	B-Disease
,	O
and	O
GK	O
and	O
putative	O
genes	O
responsible	O
for	O
congenital	B-Disease
adrenal	I-Disease
hypoplasia	I-Disease
(	O
AHC	B-Disease
)	O
and	O
GTD	B-Disease
are	O
arranged	O
from	O
telomere	O
to	O
centromere	O
as	O
pter	O
-	O
-	O
GTD	O
-	O
-	O
AHC	O
-	O
-	O
GK	O
-	O
-	O
DMD	O
-	O
-	O
OTC	O
-	O
-	O
cen	O

Genetically	O
determined	O
low	O
C4	O
:	O
a	O
predisposing	O
factor	O
to	O
autoimmune	B-Disease
chronic	I-Disease
active	I-Disease
hepatitis	I-Disease
.	O

Of	O
26	O
patients	O
with	O
autoimmune	B-Disease
chronic	I-Disease
active	I-Disease
hepatitis	I-Disease
(	O
CAH	B-Disease
)	O
starting	O
in	O
childhood	O
18	O
(	O
69	O
%	O
)	O
had	O
low	O
C4	O
and	O
5	O
(	O
19	O
%	O
)	O
had	O
low	O
C3	O
serum	O
levels	O
.	O

Impaired	O
hepatic	O
synthesis	O
and	O
immune	O
-	O
consumption	O
were	O
unlikely	O
since	O
transferrin	O
levels	O
were	O
normal	O
in	O
all	O
patients	O
,	O
albumin	O
levels	O
were	O
persistently	O
low	O
in	O
only	O
3	O
,	O
and	O
only	O
3	O
had	O
raised	O
levels	O
of	O
activation	O
fragment	O
C3d	O
.	O

C4d	O
was	O
normal	O
in	O
all	O
patients	O
studied	O
.	O

In	O
the	O
families	O
of	O
12	O
probands	O
with	O
low	O
C4	O
,	O
7	O
parents	O
had	O
low	O
C4	O
and	O
2	O
had	O
levels	O
which	O
were	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O

5	O
of	O
10	O
siblings	O
from	O
5	O
families	O
had	O
low	O
C4	O
.	O

These	O
results	O
suggest	O
that	O
low	O
C4	O
levels	O
in	O
CAH	B-Disease
are	O
genetically	O
determined	O
.	O

C4	O
phenotyping	O
in	O
20	O
patients	O
and	O
in	O
26	O
parents	O
showed	O
that	O
90	O
%	O
and	O
81	O
%	O
,	O
respectively	O
,	O
had	O
null	O
allotypes	O
at	O
either	O
the	O
C4A	O
or	O
C4B	O
locus	O
compared	O
with	O
59	O
%	O
in	O
controls	O
,	O
indicating	O
that	O
defective	O
expression	O
of	O
structural	O
genes	O
may	O
contribute	O
to	O
the	O
observed	O
C4	B-Disease
deficiency	I-Disease
.	O
.	O

An	O
amino	O
-	O
acid	O
substitution	O
involved	O
in	O
phenylketonuria	B-Disease
is	O
in	O
linkage	O
disequilibrium	O
with	O
DNA	O
haplotype	O
2	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
human	I-Disease
genetic	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
,	O
phenylalanine	O
4	O
-	O
monooxygenase	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O

PKU	B-Disease
is	O
a	O
common	O
inborn	B-Disease
error	I-Disease
of	I-Disease
amino	I-Disease
-	I-Disease
acid	I-Disease
metabolism	I-Disease
in	O
caucasian	O
populations	O
and	O
approximately	O
1	O
in	O
50	O
individuals	O
are	O
carriers	O
of	O
a	O
PKU	B-Disease
allele	O
.	O

To	O
define	O
the	O
molecular	O
basis	O
of	O
PKU	B-Disease
,	O
we	O
characterized	O
twelve	O
restriction	O
fragment	O
-	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
haplotypes	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
northern	O
European	O
population	O
and	O
observed	O
that	O
90	O
%	O
of	O
the	O
PKU	B-Disease
alleles	O
in	O
this	O
population	O
are	O
confined	O
to	O
four	O
common	O
RFLP	O
haplotypes	O
.	O

We	O
have	O
recently	O
reported	O
a	O
splicing	O
mutation	O
in	O
the	O
PAH	O
gene	O
that	O
is	O
associated	O
with	O
RFLP	O
haplotype	O
3	O
which	O
is	O
present	O
at	O
about	O
40	O
%	O
of	O
mutant	O
alleles	O
.	O

We	O
now	O
report	O
the	O
molecular	B-Disease
lesion	I-Disease
associated	O
with	O
the	O
RFLP	O
haplotype	O
2	O
mutant	O
allele	O
.	O

This	O
defect	O
is	O
caused	O
by	O
a	O
C	O
-	O
to	O
-	O
T	O
transition	O
in	O
exon	O
12	O
resulting	O
in	O
an	O
amino	O
-	O
acid	O
substitution	O
(	O
Arg	O
to	O
Trp	O
)	O
at	O
residue	O
408	O
of	O
PAH	O
.	O

Direct	O
hybridization	O
analysis	O
of	O
the	O
point	O
mutation	O
using	O
a	O
specific	O
oligonucleotide	O
probe	O
demonstrated	O
that	O
this	O
mutation	O
is	O
also	O
in	O
linkage	O
disequilibrium	O
with	O
RFLP	O
haplotype	O
2	O
alleles	O
that	O
make	O
up	O
about	O
20	O
%	O
of	O
mutant	O
PAH	O
genes	O

Choroideremia	B-Disease
:	O
close	O
linkage	O
to	O
DXYS1	O
and	O
DXYS12	O
demonstrated	O
by	O
segregation	O
analysis	O
and	O
historical	O
-	O
genealogical	O
evidence	O
.	O

Linkage	O
studies	O
using	O
restriction	O
fragment	O
length	O
polymorphisms	O
were	O
conducted	O
in	O
the	O
X	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
,	O
choroideremia	B-Disease
,	O
designated	O
TCD	B-Disease
for	O
Progressive	B-Disease
Tapeto	I-Disease
-	I-Disease
Choroidal	I-Disease
Dystrophy	I-Disease
.	O

Previously	O
demonstrated	O
close	O
linkage	O
with	O
locus	O
DXYS1	O
was	O
confirmed	O
(	O
lod	O
11	O
.	O
44	O
at	O
0	O
recombination	O
distance	O
)	O
.	O

In	O
addition	O
,	O
locus	O
DXYS12	O
was	O
found	O
to	O
be	O
closely	O
linked	O
with	O
TCD	B-Disease
(	O
lod	O
3	O
.	O
31	O
at	O
0	O
recombination	O
distance	O
)	O
.	O

The	O
disease	O
mainly	O
occurs	O
in	O
three	O
large	O
kindreds	O
in	O
remote	O
Northern	O
Finland	O
.	O

While	O
formal	O
genealogical	O
proof	O
is	O
lacking	O
,	O
all	O
presently	O
living	O
(	O
more	O
than	O
80	O
affected	O
males	O
and	O
120	O
carrier	O
females	O
)	O
probably	O
originate	O
from	O
a	O
common	O
founder	O
couple	O
born	O
in	O
1644	O
and	O
1646	O
,	O
twelve	O
generations	O
ago	O
.	O

All	O
36	O
patients	O
and	O
48	O
carriers	O
tested	O
from	O
the	O
three	O
kindreds	O
had	O
the	O
same	O
haplotype	O
(	O
TCD	B-Disease
/	O
DXYS1	O
,	O
11kb	O
/	O
DXYS12	O
,	O
1	O
.	O
6kb	O
)	O
.	O

Given	O
that	O
at	O
least	O
105	O
female	O
meioses	O
transmitting	O
TCD	B-Disease
have	O
occurred	O
since	O
1650	O
in	O
these	O
kindreds	O
,	O
extremely	O
close	O
linkage	O
between	O
TCD	B-Disease
,	O
DXYS1	O
and	O
DXYS12	O
is	O
suggested	O
.	O

The	O
above	O
haplotype	O
is	O
a	O
very	O
useful	O
diagnostic	O
tool	O
in	O
these	O
TCD	B-Disease
families	O
.	O

We	O
suggest	O
that	O
our	O
historical	O
-	O
genealogical	O
approach	O
to	O
linkage	O
analysis	O
may	O
be	O
possible	O
elsewhere	O
in	O
similar	O
isolated	O
populations	O

Von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
disease	I-Disease
maps	O
to	O
the	O
region	O
of	O
chromosome	O
3	O
associated	O
with	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
disease	I-Disease
(	O
VHL	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
with	O
inherited	O
susceptibility	O
to	O
various	O
forms	O
of	O
cancer	B-Disease
,	O
including	O
hemangioblastomas	B-Disease
of	O
the	O
central	O
nervous	O
system	O
,	O
phaeochromocytomas	B-Disease
,	O
pancreatic	B-Disease
malignancies	I-Disease
,	O
and	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O

Renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
constitute	O
a	O
particularly	O
frequent	O
cause	O
of	O
death	O
in	O
this	O
disorder	O
,	O
occurring	O
as	O
bilateral	B-Disease
and	I-Disease
multifocal	I-Disease
tumours	I-Disease
,	O
and	O
presenting	O
at	O
an	O
earlier	O
age	O
than	O
in	O
sporadic	O
,	O
non	O
-	O
familial	O
cases	O
of	O
this	O
tumour	B-Disease
type	O
.	O

We	O
report	O
here	O
that	O
the	O
VHL	B-Disease
gene	O
is	O
linked	O
to	O
the	O
locus	O
encoding	O
the	O
human	O
homologoue	O
of	O
the	O
RAF1	O
oncogene	O
,	O
which	O
maps	O
to	O
chromosome	O
3p25	O
(	O
ref	O
.	O
4	O
)	O
.	O

Crossovers	O
with	O
the	O
VHL	B-Disease
locus	O
suggest	O
that	O
the	O
defect	O
responsible	O
for	O
the	O
VHL	B-Disease
phenotype	O
is	O
not	O
a	O
mutation	O
in	O
the	O
RAF1	O
gene	O
itself	O
.	O

An	O
alternative	O
or	O
prior	O
event	O
to	O
oncogene	O
activation	O
in	O
tumour	B-Disease
formation	O
may	O
be	O
the	O
inactivation	O
of	O
a	O
putative	O
tumour	B-Disease
suppressor	O
which	O
can	O
be	O
associated	O
with	O
both	O
the	O
inherited	B-Disease
and	I-Disease
sporadic	I-Disease
forms	I-Disease
of	I-Disease
the	I-Disease
cancer	I-Disease
.	O

Sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
have	O
previously	O
been	O
associated	O
with	O
the	O
loss	O
of	O
regions	O
on	O
chromosome	O
3p	O
(	O
refs	O
5	O
,	O
6	O
)	O
.	O

Consequently	O
,	O
sporadic	O
and	O
VHL	O
-	O
associated	O
forms	O
of	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
might	O
both	O
result	O
from	O
alterations	O
causing	O
loss	O
of	O
function	O
of	O
the	O
same	O
tumour	B-Disease
suppressor	O
gene	O
on	O
this	O
chromosome	O
.	O
.	O

Tightly	O
linked	O
flanking	O
markers	O
for	O
the	O
Lowe	B-Disease
oculocerebrorenal	I-Disease
syndrome	I-Disease
,	O
with	O
application	O
to	O
carrier	O
assessment	O
.	O

The	O
Lowe	B-Disease
oculocerebrorenal	I-Disease
syndrome	I-Disease
(	O
OCRL	B-Disease
)	O
is	O
characterized	O
by	O
congenital	O
cataract	B-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
defective	B-Disease
renal	I-Disease
tubular	I-Disease
function	I-Disease
.	O

A	O
map	O
assignment	O
of	O
OCRL	B-Disease
to	O
Xq24	O
-	O
q26	O
has	O
been	O
made	O
previously	O
by	O
linkage	O
analysis	O
with	O
DXS42	O
at	O
Xq24	O
-	O
q26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
5	O
.	O
09	O
)	O
and	O
with	O
DXS10	O
at	O
Xq26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
6	O
.	O
45	O
)	O
.	O

Two	O
additional	O
families	O
were	O
studied	O
and	O
three	O
additional	O
polymorphisms	O
were	O
identified	O
at	O
DXS42	O
by	O
using	O
a	O
35	O
-	O
kb	O
sequence	O
isolated	O
with	O
the	O
probe	O
detecting	O
the	O
original	O
polymorphism	O
at	O
DXS42	O
.	O

With	O
additional	O
OCRL	B-Disease
families	O
made	O
informative	O
for	O
DXS42	O
,	O
theta	O
remained	O
0	O
with	O
z	O
=	O
6	O
.	O

63	O
;	O
and	O
for	O
DXS10	O
theta	O
=	O
0	O
.	O

03	O
and	O
z	O
=	O
7	O
.	O

07	O
.	O

Evidence	O
for	O
placing	O
OCRL	O
at	O
Xq25	O
also	O
comes	O
from	O
a	O
female	O
with	O
Lowe	B-Disease
syndrome	I-Disease
and	O
an	O
X	O
;	O
3	O
translocation	O
.	O

We	O
have	O
used	O
the	O
Xq25	O
breakpoint	O
in	O
this	O
patient	O
to	O
determine	O
the	O
position	O
of	O
OCRL	O
relative	O
to	O
the	O
two	O
linked	O
markers	O
.	O

Each	O
derivative	O
chromosome	O
was	O
isolated	O
away	O
from	O
its	O
normal	O
counterpart	O
in	O
somatic	O
cell	O
hybrids	O
.	O

DXS42	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
X	O
containing	O
Xpterq25	O
,	O
and	O
DXS10	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
3	O
containing	O
Xq25	O
-	O
qter	O
.	O

The	O
markers	O
DXS10	O
and	O
DXS42	O
therefore	O
show	O
tight	O
linkage	O
with	O
OCRL	B-Disease
in	O
six	O
families	O
and	O
flank	O
the	O
Xq25	O
breakpoint	O
in	O
a	O
female	O
patient	O
with	O
an	O
X	O
;	O
3	O
translocation	O
.	O

Linkage	O
analysis	O
with	O
flanking	O
markers	O
was	O
used	O
to	O
assess	O
OCRL	B-Disease
carrier	O
status	O
in	O
women	O
at	O
risk	O
.	O

Results	O
,	O
when	O
compared	O
with	O
carrier	O
determination	O
by	O
ophthalmologic	O
examination	O
,	O
indicated	O
that	O
the	O
slit	O
-	O
lamp	O
exam	O
can	O
be	O
a	O
sensitive	O
and	O
specific	O
method	O
of	O
carrier	O
determination	O
in	O
many	O
cases	O

Identification	O
of	O
a	O
single	O
nucleotide	O
change	O
in	O
the	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
gene	O
(	O
HPRTYale	O
)	O
responsible	O
for	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

Complete	O
deficiency	B-Disease
of	I-Disease
hypoxanthine	I-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyltransferase	I-Disease
(	O
HPRT	O
)	O
causes	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

Previous	O
characterization	O
of	O
a	O
mutant	O
form	O
of	O
HPRT	O
,	O
HPRTYale	O
,	O
from	O
a	O
subject	O
with	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
revealed	O
normal	O
mRNA	O
and	O
protein	O
concentrations	O
,	O
no	O
residual	O
catalytic	O
activity	O
,	O
and	O
cathodal	O
migration	O
upon	O
PAGE	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
HPRTYale	O
cDNA	O
.	O

The	O
nucleotide	O
sequence	O
of	O
full	O
-	O
length	O
HPRTYale	O
cDNA	O
revealed	O
a	O
single	O
nucleotide	O
substitution	O
compared	O
with	O
normal	O
HPRT	O
cDNA	O
G	O
-	O
-	O
-	O
-	O
C	O
at	O
nucleotide	O
position	O
211	O
.	O

This	O
transversion	O
predicts	O
substitution	O
of	O
arginine	O
for	O
glycine	O
at	O
amino	O
acid	O
position	O
71	O
,	O
explaining	O
the	O
cathodal	O
migration	O
of	O
HPRTYale	O
.	O

Chou	O
-	O
Fasman	O
secondary	O
structure	O
analysis	O
predicts	O
a	O
change	O
in	O
the	O
probability	O
of	O
beta	O
-	O
turn	O
formation	O
in	O
the	O
region	O
containing	O
the	O
mutation	O
.	O

Inclusion	O
of	O
the	O
bulky	O
arginine	O
side	O
chain	O
in	O
place	O
of	O
glycine	O
probably	O
disrupts	O
protein	O
folding	O
as	O
well	O
.	O

Cloning	O
mutant	O
forms	O
of	O
cDNA	O
allows	O
identification	O
of	O
specific	O
mutations	O
,	O
provides	O
insight	O
into	O
mutational	O
mechanisms	O
,	O
and	O
facilitates	O
structure	O
-	O
function	O
analysis	O
of	O
mutant	O
proteins	O
.	O
.	O

Two	O
point	O
mutations	O
are	O
responsible	O
for	O
G6PD	O
polymorphism	O
in	O
Sardinia	O
.	O

The	O
human	O
X	O
-	O
linked	O
gene	O
encoding	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
is	O
highly	O
polymorphic	O
;	O
more	O
than	O
300	O
G6PD	O
variants	O
have	O
been	O
identified	O
.	O

G6PD	B-Disease
deficiency	I-Disease
in	O
different	O
geographical	O
areas	O
appears	O
to	O
have	O
arisen	O
through	O
independent	O
mutational	O
events	O
,	O
but	O
within	O
the	O
same	O
population	O
it	O
may	O
also	O
be	O
heterogeneous	O
.	O

One	O
example	O
is	O
the	O
island	O
of	O
Sardinia	O
,	O
where	O
careful	O
clinical	O
and	O
biochemical	O
studies	O
have	O
identified	O
four	O
different	O
G6PD	O
variants	O
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
four	O
G6PD	O
variants	O
from	O
Sardinia	O
and	O
found	O
that	O
only	O
two	O
mutations	O
are	O
responsible	O
for	O
G6PD	B-Disease
deficiency	I-Disease
in	O
this	O
area	O
one	O
mutation	O
is	O
the	O
cause	O
of	O
the	O
G6PD	B-Disease
Seattle	I-Disease
-	I-Disease
like	I-Disease
phenotype	I-Disease
,	O
a	O
milder	O
form	O
of	O
G6PD	B-Disease
deficiency	I-Disease
;	O
the	O
other	O
mutation	O
is	O
responsible	O
for	O
all	O
forms	O
of	O
very	O
severe	O
G6PD	B-Disease
deficiency	I-Disease
in	O
Sardinia	O
and	O
,	O
possibly	O
,	O
in	O
the	O
Mediterranean	O
.	O
.	O

Chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
CNSHA	B-Disease
)	O
and	O
glucose	B-Disease
6	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
a	O
patient	O
with	O
familial	B-Disease
amyloidotic	I-Disease
polyneuropathy	I-Disease
(	O
FAP	B-Disease
)	O
.	O

Molecular	O
study	O
of	O
a	O
new	O
variant	O
(	O
G6PD	O
Clinic	O
)	O
with	O
markedly	O
acidic	O
pH	O
optimum	O
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
variant	O
with	O
severe	O
erythrocytic	B-Disease
G6PD	I-Disease
deficiency	I-Disease
and	O
a	O
unique	O
pH	O
optimum	O
is	O
described	O
in	O
a	O
young	O
patient	O
with	O
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
CNSHA	B-Disease
)	O
and	O
familial	B-Disease
amyloidotic	I-Disease
polyneuropathy	I-Disease
(	O
FAP	B-Disease
)	O
.	O

Chronic	B-Disease
hemolysis	I-Disease
was	O
present	O
in	O
the	O
absence	O
of	O
infections	O
,	O
oxidant	O
drugs	O
or	O
ingestion	O
of	O
faba	O
beans	O
.	O

Residual	O
enzyme	O
activity	O
was	O
about	O
2	O
.	O

6	O
%	O
and	O
63	O
%	O
of	O
normal	O
activity	O
in	O
erythrocytes	O
and	O
leucocytes	O
,	O
respectively	O
.	O

A	O
molecular	O
study	O
using	O
standard	O
methods	O
showed	O
G6PD	O
in	O
the	O
patient	O
to	O
have	O
normal	O
electrophoretic	O
mobility	O
(	O
at	O
pH	O
7	O
.	O
0	O
,	O
8	O
.	O
0	O
and	O
8	O
.	O
8	O
)	O
,	O
normal	O
apparent	O
affinity	O
for	O
substrates	O
(	O
Km	O
,	O
G6P	O
and	O
NADP	O
)	O
and	O
a	O
slightly	O
abnormal	O
utilization	O
of	O
substrate	O
analogues	O
(	O
decreased	O
deamino	O
-	O
NADP	O
and	O
increased	O
2	O
-	O
deoxyglucose	O
-	O
6	O
-	O
phosphate	O
utilization	O
)	O
.	O

Heat	O
stability	O
was	O
found	O
to	O
be	O
markedly	O
decreased	O
(	O
8	O
%	O
of	O
residual	O
activity	O
after	O
20	O
min	O
of	O
incubation	O
at	O
46	O
degrees	O
C	O
)	O
and	O
a	O
particular	O
characteristic	O
of	O
this	O
enzyme	O
was	O
a	O
biphasic	O
pH	O
curve	O
with	O
a	O
greatly	O
increased	O
activity	O
at	O
low	O
pH	O
.	O

Although	O
molecular	O
characteristics	O
of	O
this	O
variant	O
closely	O
resemble	O
those	O
of	O
G6PD	O
Bangkok	O
and	O
G6PD	O
Duarte	O
,	O
it	O
can	O
be	O
distinguished	O
from	O
these	O
and	O
all	O
other	O
previously	O
reported	O
variants	O
by	O
virtue	O
of	O
its	O
unusual	O
pH	O
curve	O
.	O

Therefore	O
the	O
present	O
variant	O
has	O
been	O
designated	O
G6PD	O
Clinic	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	O
variants	O
previously	O
described	O

Molecular	O
detection	O
of	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
putative	O
retinoblastoma	B-Disease
susceptibility	O
locus	O
.	O

A	O
candidate	O
DNA	O
sequence	O
with	O
many	O
of	O
the	O
properties	O
predicted	O
for	O
the	O
retinoblastoma	B-Disease
susceptibility	O
(	O
RB1	O
)	O
locus	O
has	O
been	O
cloned	O
(	O
S	O
.	O
H	O
.	O
Friend	O
,	O
R	O
.	O
Bernards	O
,	O
S	O
.	O
Rogelj	O
,	O
R	O
.	O
A	O
.	O
Weinberg	O
,	O
J	O
.	O
M	O
.	O
Rapaport	O
,	O
D	O
.	O
M	O
.	O
Albert	O
,	O
and	O
T	O
.	O
P	O
.	O
Dryja	O
,	O
Nature	O
[	O
London	O
]	O
323	O
643	O
-	O
645	O
,	O
1986	O
)	O
.	O

The	O
large	O
size	O
of	O
this	O
gene	O
(	O
ca	O
.	O
200	O
kilobases	O
[	O
kb	O
]	O
)	O
and	O
its	O
multiple	O
dispersed	O
exons	O
(	O
Wiggs	O
et	O
al	O
.	O
,	O
N	O
.	O
Engl	O
.	O
J	O
.	O
Med	O
.	O
318	O
151	O
-	O
157	O
,	O
1988	O
)	O
complicate	O
molecular	O
screening	O
strategies	O
important	O
in	O
prenatal	O
and	O
presymptomatic	O
diagnosis	O
and	O
in	O
carrier	O
detection	O
.	O

Here	O
we	O
used	O
field	O
inversion	O
gel	O
electrophoresis	O
(	O
FIGE	O
)	O
to	O
construct	O
a	O
restriction	O
map	O
of	O
approximately	O
1	O
,	O
000	O
kb	O
of	O
DNA	O
surrounding	O
the	O
RB1	O
locus	O
and	O
to	O
detect	O
the	O
translocation	O
breakpoints	O
in	O
three	O
retinoblastoma	B-Disease
patients	O
.	O

DNA	O
probes	O
from	O
either	O
the	O
5	O
or	O
3	O
end	O
of	O
the	O
gene	O
were	O
used	O
to	O
detect	O
a	O
250	O
-	O
kb	O
EagI	O
restriction	O
fragment	O
in	O
DNA	O
from	O
unaffected	O
individuals	O
.	O

Both	O
probes	O
identified	O
an	O
additional	O
hybridizing	O
fragment	O
in	O
the	O
DNA	O
from	O
each	O
patient	O
,	O
permitting	O
the	O
breakpoints	O
in	O
all	O
three	O
to	O
be	O
mapped	O
within	O
the	O
cloned	O
RB1	O
gene	O
.	O

Analysis	O
of	O
the	O
breakpoint	O
in	O
one	O
translocation	O
cell	O
line	O
allowed	O
the	O
RB1	O
gene	O
to	O
be	O
oriented	O
with	O
its	O
5	O
end	O
toward	O
the	O
centromere	O
.	O

The	O
5	O
end	O
of	O
the	O
gene	O
also	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
clustering	O
of	O
sites	O
for	O
several	O
infrequently	O
cleaving	O
restriction	O
enzymes	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
HpaII	O
tiny	O
fragment	O
island	O
.	O

The	O
detection	O
and	O
mapping	O
of	O
the	O
translocation	O
breakpoints	O
of	O
all	O
three	O
retinoblastoma	B-Disease
patients	O
to	O
within	O
the	O
putative	O
RB1	O
gene	O
substantiated	O
the	O
authenticity	O
of	O
this	O
candidate	O
sequence	O
and	O
demonstrated	O
the	O
utility	O
of	O
FIGE	O
in	O
detecting	O
chromosomal	O
rearrangements	O
affecting	O
this	O
locus	O
.	O

Inherited	O
C3	B-Disease
deficiency	I-Disease
with	O
recurrent	O
infections	O
and	O
glomerulonephritis	B-Disease
.	O

A	O
10	O
-	O
year	O
-	O
old	O
Laotian	O
boy	O
had	O
homozygous	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
third	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
and	O
recurrent	O
bacterial	B-Disease
infections	I-Disease
beginning	O
at	O
age	O
5	O
months	O
.	O

Cellular	O
and	O
humoral	O
immunity	O
were	O
normal	O
,	O
as	O
were	O
polymorphonuclear	O
leukocyte	O
chemotaxis	O
and	O
bactericidal	O
activities	O
.	O

Serum	O
complement	O
-	O
mediated	O
hemolytic	O
,	O
chemotactic	O
,	O
and	O
opsonic	O
activities	O
were	O
deficient	O
.	O

In	O
vitro	O
addition	O
of	O
purified	O
C3	O
to	O
patient	O
serum	O
restored	O
hemolytic	O
complement	O
to	O
normal	O
levels	O
,	O
and	O
plasma	O
infusion	O
during	O
each	O
of	O
four	O
episodes	O
of	O
pneumonia	B-Disease
significantly	O
enhanced	O
serum	O
opsonic	O
activity	O
for	O
as	O
long	O
as	O
36	O
hours	O
.	O

A	O
renal	O
biopsy	O
specimen	O
revealed	O
mesangiopathic	B-Disease
glomerulonephritis	I-Disease
,	O
although	O
significant	O
levels	O
of	O
circulating	O
IgG	O
immune	O
complexes	O
were	O
not	O
detected	O
.	O

These	O
findings	O
further	O
support	O
the	O
association	O
of	O
C3	B-Disease
deficiency	I-Disease
with	O
immune	B-Disease
-	I-Disease
complex	I-Disease
disease	I-Disease
and	O
suggest	O
that	O
plasma	O
infusion	O
may	O
be	O
an	O
adjunct	O
to	O
antibiotic	O
therapy	O
in	O
the	O
management	O
of	O
severe	O
pyogenic	B-Disease
infections	I-Disease
in	O
patients	O
with	O
C3	B-Disease
deficiency	I-Disease
.	O
.	O

DNA	O
restriction	O
fragments	O
associated	O
with	O
alpha	O
1	O
-	O
antitrypsin	O
indicate	O
a	O
single	O
origin	O
for	O
deficiency	O
allele	O
PI	O
Z	O
.	O

The	O
alpha	O
1	O
-	O
protease	O
inhibitor	O
,	O
or	O
alpha	O
-	O
antitrypsin	O
(	O
AAT	O
)	O
,	O
a	O
major	O
plasma	O
inhibitor	O
of	O
leukocyte	O
elastase	O
and	O
bacterial	O
proteases	O
,	O
is	O
encoded	O
at	O
the	O
PI	O
locus	O
on	O
chromosome	O
14	O
(	O
14q24	O
.	O
3	O
-	O
q32	O
.	O
1	O
)	O
.	O

A	O
deficiency	B-Disease
of	I-Disease
AAT	I-Disease
in	O
individuals	O
homozygous	O
for	O
the	O
PI	O
Z	O
allele	O
occurs	O
in	O
about	O
1	O
in	O
2	O
,	O
000	O
-	O
8	O
,	O
000	O
caucasians	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
early	O
adult	O
onset	O
emphysema	B-Disease
and	O
liver	B-Disease
disease	I-Disease
in	O
childhood	O
.	O

We	O
have	O
now	O
used	O
DNA	O
polymorphisms	O
associated	O
with	O
the	O
AAT	O
gene	O
to	O
investigate	O
the	O
origin	O
of	O
the	O
PI	O
Z	O
allele	O
.	O

Using	O
two	O
genomic	O
probes	O
extending	O
into	O
the	O
5	O
and	O
3	O
flanking	O
regions	O
,	O
respectively	O
,	O
we	O
have	O
identified	O
eight	O
polymorphic	O
restriction	O
sites	O
.	O

Extensive	O
linkage	O
disequilibrium	O
occurs	O
throughout	O
the	O
probed	O
region	O
with	O
the	O
PI	O
Z	O
allele	O
,	O
but	O
not	O
with	O
normal	O
PI	O
M	O
alleles	O
.	O

The	O
Z	O
allele	O
occurs	O
mainly	O
with	O
one	O
haplotype	O
,	O
indicating	O
a	O
single	O
,	O
relatively	O
recent	O
,	O
origin	O
in	O
caucasians	O

Segregation	O
analysis	O
of	O
a	O
marker	O
localised	O
Xp21	O
.	O
2	O
-	O
Xp21	O
.	O
3	O
in	O
Duchenne	B-Disease
and	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
families	O
.	O

A	O
DNA	O
marker	O
C7	O
,	O
localised	O
Xp21	O
.	O

1	O
-	O
Xp21	O
.	O

3	O
,	O
has	O
been	O
studied	O
in	O
kindreds	O
segregating	O
for	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
and	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
.	O

In	O
DMD	B-Disease
families	O
four	O
crossovers	O
were	O
observed	O
in	O
38	O
informative	O
meioses	O
between	O
C7	O
and	O
the	O
DMD	B-Disease
locus	O
(	O
theta	O
=	O
0	O
.	O
12	O
,	O
z	O
max	O
=	O
+	O
2	O
.	O
72	O
)	O
.	O

In	O
BMD	B-Disease
families	O
no	O
recombinants	O
were	O
observed	O
in	O
the	O
16	O
informative	O
meioses	O
studied	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
localisation	O
of	O
the	O
mutations	O
in	O
these	O
disorders	O
being	O
in	O
the	O
same	O
region	O
of	O
Xp21	O
.	O

Studies	O
in	O
families	O
also	O
segregating	O
for	O
the	O
DNA	O
marker	O
754	O
support	O
the	O
previously	O
reported	O
physical	O
order	O
of	O
these	O
loci	O
as	O
X	O
centromere	O
-	O
754	O
-	O
DMD	O
-	O
BMD	O
-	O
C7	O
-	O
X	O
telomere	O
.	O

A	O
recombination	O
fraction	O
of	O
0	O
.	O

11	O
(	O
z	O
max	O
=	O
+	O
5	O
.	O
58	O
)	O
was	O
found	O
between	O
DMD	O
-	O
754	O
by	O
combining	O
our	O
previously	O
published	O
data	O
with	O
the	O
data	O
presented	O
here	O
.	O

C7	O
and	O
754	O
thus	O
provide	O
good	O
bridging	O
markers	O
for	O
the	O
diagnosis	O
of	O
DMD	B-Disease
and	O
BMD	B-Disease

Isolation	O
of	O
molecular	O
probes	O
associated	O
with	O
the	O
chromosome	O
15	O
instability	O
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

Flow	O
cytometry	O
and	O
recombinant	O
DNA	O
techniques	O
have	O
been	O
used	O
to	O
obtain	O
reagents	O
for	O
a	O
molecular	O
analysis	O
of	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

HindIII	O
total	O
-	O
digest	O
libraries	O
were	O
prepared	O
in	O
lambda	O
phage	O
Charon	O
21A	O
from	O
flow	O
-	O
sorted	O
inverted	O
duplicated	O
no	O
.	O
15	O
human	O
chromosomes	O
and	O
propagated	O
on	O
recombination	O
-	O
proficient	O
(	O
LE392	O
)	O
and	O
recBC	O
-	O
,	O
sbcB	O
-	O
(	O
DB1257	O
)	O
bacteria	O
.	O

Twelve	O
distinct	O
chromosome	O
15	O
-	O
specific	O
probes	O
have	O
been	O
isolated	O
.	O

Eight	O
localized	O
to	O
the	O
region	O
15q11	O
-	O
-	O
-	O
-	O
13	O
.	O

Four	O
of	O
these	O
eight	O
sublocalized	O
to	O
band	O
15q11	O
.	O

2	O
and	O
are	O
shown	O
to	O
be	O
deleted	O
in	O
DNA	O
of	O
one	O
of	O
two	O
patients	O
examined	O
with	O
the	O
PWS	B-Disease
.	O

Heteroduplex	O
analysis	O
of	O
two	O
of	O
these	O
clones	O
,	O
which	O
grew	O
on	O
DB1257	O
but	O
not	O
on	O
LE392	O
,	O
revealed	O
stem	O
-	O
loop	O
structures	O
in	O
the	O
inserts	O
,	O
indicative	O
of	O
inverted	O
,	O
repeated	O
DNA	O
elements	O
.	O

Such	O
DNA	O
repeats	O
might	O
account	O
for	O
some	O
of	O
the	O
cloning	O
instability	O
of	O
DNA	O
segments	O
from	O
proximal	O
15q	O
.	O

Analysis	O
of	O
the	O
genetic	O
and	O
physical	O
instability	O
associated	O
with	O
the	O
repeated	O
sequences	O
we	O
have	O
isolated	O
from	O
band	O
15q11	O
.	O

2	O
may	O
elucidate	O
the	O
molecular	O
basis	O
for	O
the	O
instability	O
of	O
this	O
chromosomal	O
region	O
in	O
patients	O
with	O
the	O
PWS	B-Disease
or	O
other	O
diseases	O
associated	O
with	O
chromosomal	B-Disease
abnormalities	I-Disease
in	O
the	O
proximal	O
long	O
arm	O
of	O
human	O
chromosome	O
15	O

Analysis	O
of	O
deletions	O
in	O
DNA	O
from	O
patients	O
with	O
Becker	B-Disease
and	I-Disease
Duchenne	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
for	O
which	O
the	O
biochemical	O
defect	O
is	O
as	O
yet	O
unknown	O
.	O

Recently	O
,	O
two	O
cloned	O
segments	O
of	O
human	O
X	O
-	O
chromosome	O
DNA	O
have	O
been	O
described	O
which	O
detect	O
structural	O
alterations	O
within	O
or	O
near	O
the	O
genetic	O
locus	O
responsible	O
for	O
the	O
disorder	O
.	O

Both	O
of	O
these	O
cloned	O
segments	O
were	O
described	O
as	O
tightly	O
linked	O
to	O
the	O
locus	O
and	O
were	O
capable	O
of	O
detecting	O
deletions	O
in	O
the	O
DNA	O
of	O
boys	O
affected	O
with	O
DMD	B-Disease
.	O

In	O
an	O
attempt	O
to	O
determine	O
more	O
precisely	O
the	O
occurrence	O
of	O
these	O
deletions	O
within	O
a	O
large	O
population	O
of	O
DMD	B-Disease
patients	O
and	O
the	O
accuracy	O
of	O
one	O
of	O
the	O
segments	O
,	O
DXS164	O
(	O
pERT87	O
)	O
,	O
in	O
determining	O
the	O
inheritance	O
of	O
the	O
DMD	B-Disease
X	O
chromosome	O
,	O
the	O
subclones	O
1	O
,	O
8	O
and	O
15	O
were	O
made	O
available	O
to	O
many	O
investigators	O
throughout	O
the	O
world	O
.	O

Here	O
we	O
describe	O
the	O
combined	O
results	O
of	O
more	O
than	O
20	O
research	O
laboratories	O
with	O
respect	O
to	O
the	O
occurrence	O
of	O
deletions	O
at	O
the	O
DXS164	O
locus	O
in	O
DNA	O
samples	O
isolated	O
from	O
patients	O
with	O
DMD	B-Disease
and	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
.	O

The	O
results	O
indicate	O
that	O
the	O
DXS164	O
locus	O
apparently	O
recombines	O
with	O
DMD	B-Disease
5	O
%	O
of	O
the	O
time	O
,	O
but	O
is	O
probably	O
located	O
between	O
independent	O
sites	O
of	O
mutation	O
which	O
yield	O
DMD	B-Disease
.	O

The	O
breakpoints	O
of	O
some	O
deletions	O
are	O
delineated	O
within	O
the	O
DXS164	O
locus	O
,	O
and	O
it	O
is	O
evident	O
that	O
the	O
deletions	O
at	O
the	O
DMD	B-Disease
locus	O
are	O
frequent	O
and	O
extremely	O
large	O
.	O
.	O

A	O
potential	O
animal	O
model	O
for	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
through	O
introduction	O
of	O
HPRT	O
mutations	O
into	O
mice	O
.	O

The	O
human	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
neurological	B-Disease
and	I-Disease
behavioural	I-Disease
disorder	I-Disease
,	O
affecting	O
only	O
males	O
,	O
which	O
is	O
caused	O
by	O
an	O
inherited	B-Disease
deficiency	I-Disease
in	O
the	O
level	O
of	O
activity	O
of	O
the	O
purine	O
salvage	O
enzyme	O
hypoxanthine	O
-	O
guanosine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
)	O
.	O

How	O
the	O
resulting	O
alterations	O
in	O
purine	O
metabolism	O
lead	O
to	O
the	O
severe	O
symptoms	O
characteristic	O
of	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
patients	O
is	O
still	O
not	O
understood	O
.	O

No	O
mutations	O
at	O
the	O
Hprt	O
locus	O
leading	O
to	O
loss	O
of	O
activity	O
have	O
been	O
described	O
in	O
laboratory	O
animals	O
.	O

To	O
derive	O
an	O
animal	O
model	O
for	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
,	O
we	O
have	O
used	O
cultured	O
mouse	O
embryonic	O
stem	O
cells	O
,	O
mutagenized	O
by	O
retroviral	O
insertion	O
and	O
selected	O
for	O
loss	O
of	O
HPRT	O
activity	O
,	O
to	O
construct	O
chimaeric	O
mice	O
.	O

Two	O
clonal	O
lines	O
carrying	O
different	O
mutant	O
Hprt	O
alleles	O
have	O
given	O
rise	O
to	O
germ	O
cells	O
in	O
chimaeras	O
,	O
allowing	O
the	O
derivation	O
of	O
strains	O
of	O
mutant	O
mice	O
having	O
the	O
same	O
biochemical	O
defect	O
as	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
patients	O
.	O

Male	O
mice	O
carrying	O
the	O
mutant	O
alleles	O
are	O
viable	O
and	O
analysis	O
of	O
their	O
cells	O
shows	O
a	O
total	O
lack	O
of	O
HPRT	O
activity	O
.	O
.	O

Re	O
-	O
evaluation	O
of	O
the	O
sublocalization	O
of	O
esterase	O
D	O
and	O
its	O
relation	O
to	O
the	O
retinoblastoma	B-Disease
locus	O
by	O
in	O
situ	O
hybridization	O
.	O

In	O
situ	O
hybridization	O
of	O
a	O
cDNA	O
probe	O
for	O
the	O
esterase	O
D	O
gene	O
(	O
ESD	O
)	O
was	O
carried	O
out	O
on	O
human	O
chromosomes	O
.	O

The	O
probe	O
hybridized	O
most	O
strongly	O
to	O
13q14	O
.	O

2	O
and	O
13q14	O
.	O

3	O
.	O

This	O
observation	O
raises	O
doubts	O
concerning	O
the	O
most	O
recently	O
published	O
assignment	O
of	O
ESD	O
to	O
13q14	O
.	O

1	O
.	O

A	O
deletion	O
in	O
an	O
individual	O
with	O
retinoblastoma	B-Disease
was	O
reported	O
to	O
separate	O
the	O
closely	O
linked	O
ESD	O
and	O
retinoblastoma	B-Disease
(	O
RB1	O
)	O
loci	O
,	O
placing	O
ESD	O
proximal	O
to	O
RB1	O
.	O

Quantitative	O
in	O
situ	O
hybridization	O
studies	O
of	O
this	O
deletion	O
do	O
not	O
confirm	O
this	O
interpretation	O
.	O

Rather	O
,	O
they	O
suggest	O
that	O
ESD	O
is	O
missing	O
from	O
the	O
deleted	O
chromosome	O
13	O
and	O
duplicated	O
on	O
the	O
normal	O
homolog	O
.	O

From	O
these	O
findings	O
,	O
we	O
conclude	O
that	O
the	O
deletion	O
in	O
this	O
individual	O
cannot	O
be	O
used	O
to	O
determine	O
the	O
orientation	O
nor	O
the	O
sublocalization	O
of	O
ESD	O
and	O
RB1	O
within	O
the	O
13q14	O
region	O
.	O

Hereditary	B-Disease
C2	I-Disease
deficiency	I-Disease
associated	O
with	O
common	O
variable	O
immunodeficiency	B-Disease
.	O

Homozygous	O
C2	B-Disease
deficiency	I-Disease
in	O
a	O
19	O
-	O
year	O
-	O
old	O
boy	O
was	O
associated	O
with	O
variable	O
immunodeficiency	B-Disease
manifested	O
by	O
marked	O
hypoimmunoglobulinemia	B-Disease
and	O
impaired	O
antibody	O
responses	O
,	O
normal	O
circulating	O
B	O
lymphocytes	O
,	O
and	O
subnormal	O
T	O
-	O
cell	O
functions	O
.	O

Neither	O
antilymphocytic	O
autoantibodies	O
nor	O
chromosomal	B-Disease
abnormalities	I-Disease
were	O
found	O
.	O

Serum	O
immunoglobulin	O
levels	O
were	O
within	O
normal	O
limits	O
in	O
his	O
parents	O
and	O
brother	O
who	O
were	O
heterozygous	O
for	O
C2	B-Disease
deficiency	I-Disease
.	O

The	O
patients	O
lymphocytes	O
were	O
homozygous	O
at	O
the	O
HLA	O
-	O
D	O
locus	O
but	O
expressed	O
an	O
antigen	O
different	O
from	O
DW2	O
.	O
.	O

Mild	O
and	O
severe	O
muscular	B-Disease
dystrophy	I-Disease
associated	O
with	O
deletions	O
in	O
Xp21	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

We	O
have	O
analysed	O
over	O
300	O
patients	O
suffering	O
from	O
Duchenne	B-Disease
or	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
or	O
BMD	B-Disease
)	O
.	O

Deletions	O
have	O
been	O
characterised	O
which	O
encompass	O
either	O
the	O
pERT87	O
(	O
DXS164	O
)	O
locus	O
only	O
,	O
the	O
XJ1	O
.	O

1	O
(	O
DXS206	O
)	O
and	O
HIP25	O
loci	O
only	O
,	O
or	O
all	O
three	O
loci	O
.	O

These	O
loci	O
have	O
been	O
shown	O
to	O
lie	O
within	O
the	O
DMD	B-Disease
region	O
covering	O
several	O
hundred	O
kilobases	O
(	O
kb	O
)	O
of	O
DNA	O
.	O

One	O
mildly	O
affected	O
BMD	B-Disease
patient	O
possesses	O
a	O
deletion	O
of	O
at	O
least	O
110	O
kb	O
including	O
exons	O
of	O
the	O
DMD	B-Disease
gene	O
.	O

Other	O
patients	O
with	O
similar	O
exon	O
deletions	O
,	O
or	O
smaller	O
deletions	O
,	O
show	O
the	O
more	O
severe	O
phenotype	O
typical	O
of	O
DMD	B-Disease
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
severity	O
of	O
the	O
clinical	O
phenotype	O
cannot	O
be	O
explained	O
on	O
the	O
basis	O
of	O
the	O
size	O
of	O
the	O
deletion	O
.	O

We	O
discuss	O
this	O
in	O
the	O
context	O
of	O
candidate	O
gene	O
sequences	O
.	O

Patterns	O
of	O
exon	O
deletions	O
in	O
Duchenne	B-Disease
and	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

A	O
panel	O
of	O
patients	O
with	O
Duchenne	B-Disease
and	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
and	O
BMD	B-Disease
)	O
has	O
been	O
screened	O
with	O
the	O
cDNA	O
probes	O
Cf56a	O
and	O
Cf23a	O
,	O
which	O
detect	O
exons	O
in	O
the	O
central	O
part	O
of	O
the	O
DMD	B-Disease
gene	O
.	O

One	O
or	O
more	O
exons	O
were	O
deleted	O
in	O
60	O
%	O
of	O
patients	O
.	O

The	O
deletions	O
were	O
mapped	O
and	O
prove	O
to	O
be	O
heterogeneous	O
in	O
size	O
and	O
extent	O
,	O
particularly	O
in	O
DMD	B-Disease
.	O

Deletions	O
specific	O
to	O
DMD	B-Disease
and	O
to	O
BMD	B-Disease
are	O
described	O
.	O

Half	O
of	O
all	O
BMD	B-Disease
patients	O
have	O
a	O
deletion	O
of	O
one	O
particular	O
small	O
group	O
of	O
exons	O
;	O
smaller	O
deletions	O
within	O
this	O
same	O
group	O
produce	O
the	O
more	O
severe	O
DMD	B-Disease
.	O
.	O

Hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
third	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
a	O
child	O
with	O
fever	B-Disease
,	O
skin	B-Disease
rash	I-Disease
,	O
and	O
arthralgias	B-Disease
:	O
response	O
to	O
transfusion	O
of	O
whole	O
blood	O
.	O

A	O
previously	O
well	O
34	O
-	O
month	O
-	O
old	O
male	O
presenting	O
with	O
fever	B-Disease
,	O
skin	B-Disease
rash	I-Disease
,	O
and	O
arthralgias	B-Disease
was	O
found	O
to	O
lack	O
C3	O
by	O
immunochemical	O
(	O
undetectable	O
)	O
and	O
hemolytic	O
(	O
1	O
%	O
normal	O
)	O
assays	O
.	O

No	O
infectious	O
agent	O
could	O
be	O
demonstrated	O
.	O

Protein	O
levels	O
of	O
Clq	O
.	O

C4	O
,	O
C5	O
,	O
properdin	O
,	O
and	O
C3b	O
-	O
INA	O
and	O
hemolytic	O
activities	O
of	O
complement	O
components	O
C1	O
to	O
C9	O
except	O
C3	O
were	O
normal	O
or	O
elevated	O
;	O
total	O
hemolytic	O
complement	O
activity	O
was	O
13	O
%	O
of	O
normal	O
and	O
was	O
reconstituted	O
by	O
purified	O
C3	O
.	O

Properdin	O
factor	O
B	O
was	O
702	O
(	O
normal	O
175	O
to	O
275	O
)	O
mug	O
/	O
ml	O
,	O
and	O
was	O
not	O
cleaver	O
upon	O
addition	O
of	O
zymosan	O
or	O
cobra	O
venom	O
factor	O
.	O

The	O
serum	O
had	O
normal	O
immune	O
adherence	O
activity	O
,	O
but	O
was	O
deficient	O
in	O
ability	O
to	O
opsonize	O
Candida	O
albicans	O
for	O
uptake	O
and	O
Escherichia	O
coli	O
for	O
killing	O
by	O
neurophils	O
,	O
generate	O
neutrophil	O
chemotactic	O
factors	O
and	O
inhibit	O
the	O
growth	O
of	O
E	O
.	O
coli	O
;	O
these	O
activities	O
were	O
restored	O
by	O
purified	O
C3	O
.	O

A	O
transfusion	O
of	O
320	O
ml	O
1	O
-	O
hour	O
-	O
old	O
normal	O
whole	O
blood	O
on	O
the	O
fifty	O
-	O
second	O
day	O
resulted	O
in	O
transitory	O
elevation	O
of	O
the	O
C3	O
level	O
to	O
25	O
mg	O
/	O
dl	O
with	O
a	O
fall	O
-	O
off	O
(	O
approximately	O
2	O
1	O
/	O
2	O
%	O
per	O
hour	O
)	O
to	O
undetectable	O
levels	O
by	O
69	O
hours	O
;	O
it	O
was	O
followed	O
by	O
disappearance	O
of	O
the	O
skin	B-Disease
rash	I-Disease
and	O
arthralgias	B-Disease
and	O
return	O
to	O
normal	O
of	O
the	O
previously	O
elevated	O
temperature	O
and	O
CRP	O
levels	O
.	O

C3	O
levels	O
in	O
family	O
members	O
(	O
seven	O
of	O
24	O
half	O
-	O
normal	O
)	O
,	O
lack	O
of	O
anti	O
-	O
C3	O
activity	O
,	O
normal	O
C3b	O
-	O
INA	O
levels	O
and	O
a	O
normal	O
rate	O
of	O
catabolism	O
of	O
transfused	O
C3	O
indicated	O
that	O
the	O
deficiency	O
was	O
inherited	O
with	O
autosomal	O
codominance	O
and	O
involved	O
decreased	B-Disease
synthesis	I-Disease
of	I-Disease
C3	I-Disease
.	O

Thus	O
,	O
this	O
child	O
is	O
a	O
unique	O
individual	O
with	O
inherited	B-Disease
C3	I-Disease
deficiency	I-Disease
presenting	O
with	O
absence	O
of	O
repeated	O
infections	O
,	O
whose	O
symptoms	O
of	O
fever	B-Disease
,	O
skin	B-Disease
rash	I-Disease
,	O
and	O
arthralgia	B-Disease
were	O
abated	O
by	O
whole	O
blood	O
transfusion	O
.	O
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
and	O
their	O
frequency	O
in	O
Guangdong	O
,	O
China	O
.	O

Erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
was	O
characterized	O
in	O
blood	O
samples	O
obtained	O
from	O
97	O
randomly	O
selected	O
males	O
with	O
enzyme	B-Disease
deficiency	I-Disease
from	O
various	O
regions	O
of	O
Guangdong	O
Province	O
,	O
China	O
.	O

Nine	O
new	O
variants	O
(	O
Gd	O
Kaiping	O
,	O
Gd	O
Boluo	O
,	O
Gd	O
Huiyang	O
,	O
Gd	O
Gaomin	O
,	O
Gd	O
Qing	O
-	O
Baijiang	O
,	O
Gd	O
Gaozhou	O
,	O
Gd	O
Huazhou	O
,	O
Gd	O
Nanhai	O
,	O
and	O
Gd	O
Guangzhou	O
)	O
were	O
identified	O
.	O

Of	O
the	O
31	O
variants	O
found	O
in	O
this	O
province	O
,	O
Gd	O
Kaiping	O
,	O
Gd	O
Taiwan	O
-	O
Hakka	O
,	O
Gd	O
Haad	O
Yai	O
,	O
Gd	O
Haad	O
Yai	O
-	O
like	O
and	O
Gd	O
Huiyang	O
occurred	O
most	O
frequently	O
.	O

The	O
frequency	O
of	O
each	O
variant	O
was	O
calculated	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
was	O
high	O
in	O
this	O
area	O
.	O
.	O

Homozygous	O
and	O
heterozygous	O
deletions	O
of	O
the	O
von	B-Disease
Willebrand	I-Disease
factor	O
gene	O
in	O
patients	O
and	O
carriers	O
of	O
severe	B-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
.	O

Severe	B-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
is	O
characterized	O
by	O
undetectable	O
or	O
trace	O
quantities	O
of	O
von	B-Disease
Willebrand	I-Disease
factor	O
in	O
plasma	O
and	O
tissue	O
stores	O
.	O

We	O
have	O
studied	O
the	O
genomic	O
DNA	O
of	O
10	O
affected	O
individuals	O
from	O
six	O
families	O
with	O
this	O
disorder	O
using	O
probes	O
from	O
the	O
5	O
and	O
3	O
ends	O
of	O
the	O
vWF	O
cDNA	O
and	O
with	O
a	O
probe	O
extending	O
from	O
the	O
5	O
end	O
into	O
the	O
central	O
region	O
.	O

Southern	O
blots	O
of	O
restriction	O
endonuclease	O
digests	O
and	O
gene	O
dosage	O
analysis	O
measurements	O
carried	O
out	O
with	O
quantitative	O
slot	O
blots	O
of	O
undigested	O
genomic	O
DNA	O
separated	O
these	O
patients	O
into	O
three	O
groups	O
.	O

The	O
first	O
group	O
consisted	O
of	O
a	O
family	O
with	O
complete	O
homozygous	O
deletions	O
of	O
the	O
vWF	O
gene	O
in	O
the	O
four	O
probands	O
.	O

Gene	O
dosage	O
analysis	O
was	O
consistent	O
with	O
heterozygous	O
deletions	O
in	O
both	O
of	O
the	O
asymptomatic	O
parents	O
and	O
four	O
asymptomatic	O
siblings	O
of	O
this	O
kindred	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
second	O
group	O
was	O
comprised	O
of	O
a	O
family	O
in	O
which	O
there	O
was	O
a	O
complete	O
heterozygous	O
deletion	O
of	O
the	O
vWF	O
gene	O
in	O
the	O
proband	O
and	O
one	O
asymptomatic	O
parent	O
,	O
suggesting	O
that	O
a	O
different	O
type	O
of	O
genetic	B-Disease
abnormality	I-Disease
was	O
inherited	O
from	O
the	O
other	O
parent	O
.	O

Thus	O
,	O
the	O
patient	O
appeared	O
to	O
be	O
doubly	O
heterozygous	O
for	O
interacting	O
genetic	B-Disease
abnormalities	I-Disease
affecting	O
vWF	O
expression	O
.	O

In	O
the	O
third	O
group	O
,	O
no	O
gene	O
deletions	O
could	O
be	O
detected	O
.	O

Alloantibodies	O
developed	O
only	O
in	O
the	O
kindred	O
with	O
homozygous	O
deletions	O
.	O

These	O
techniques	O
should	O
prove	O
useful	O
in	O
identifying	O
carriers	O
of	O
severe	B-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
and	O
also	O
in	O
defining	O
patients	O
predictably	O
at	O
risk	O
of	O
developing	O
alloantibodies	O
to	O
vWF	O
.	O

Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
.	O

Impaired	O
fatty	O
alcohol	O
oxidation	O
in	O
cultured	O
fibroblasts	O
due	O
to	O
deficient	O
fatty	O
alcohol	O
:	O
nicotinamide	O
adenine	O
dinucleotide	O
oxidoreductase	O
activity	O
.	O

Lipid	O
metabolism	O
was	O
studied	O
in	O
cultured	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
the	O
inherited	B-Disease
disorder	I-Disease
,	O
Sjogren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
(	O
SLS	B-Disease
)	O
.	O

Intact	O
SLS	B-Disease
fibroblasts	O
incubated	O
in	O
the	O
presence	O
of	O
[	O
1	O
-	O
14C	O
]	O
palmitate	O
accumulated	O
more	O
radioactive	O
hexadecanol	O
than	O
did	O
normal	O
cells	O
,	O
whereas	O
incorporation	O
of	O
radioactivity	O
into	O
other	O
cellular	O
lipids	O
was	O
unaltered	O
.	O

The	O
hexadecanol	O
content	O
of	O
SLS	B-Disease
fibroblasts	O
was	O
abnormally	O
elevated	O
.	O

Hexadecanol	O
accumulation	O
was	O
not	O
due	O
to	O
increased	O
fatty	O
alcohol	O
synthesis	O
nor	O
its	O
deficient	O
utilization	O
for	O
glycerol	O
ether	O
synthesis	O
.	O

The	O
half	O
-	O
life	O
of	O
intracellular	O
hexadecanol	O
loaded	O
into	O
SLS	B-Disease
fibroblasts	O
was	O
increased	O
(	O
70	O
min	O
)	O
compared	O
with	O
normal	O
(	O
15	O
min	O
)	O
,	O
and	O
intact	O
SLS	B-Disease
fibroblasts	O
showed	O
impaired	O
oxidation	O
of	O
[	O
14C	O
]	O
-	O
hexadecanol	O
to	O
fatty	O
acid	O
.	O

Fatty	O
alcohol	O
NAD	O
+	O
oxidoreductase	O
,	O
the	O
enzyme	O
catalyzing	O
this	O
reaction	O
,	O
was	O
deficient	O
in	O
SLS	B-Disease
fibroblasts	O
.	O

Mean	O
total	O
activity	O
in	O
SLS	B-Disease
fibroblasts	O
(	O
n	O
=	O
5	O
)	O
was	O
13	O
%	O
of	O
that	O
in	O
normal	O
fibroblasts	O
,	O
and	O
palmitoyl	O
CoA	O
-	O
inhibitable	O
activity	O
was	O
1	O
%	O
of	O
normal	O
.	O

Fibroblasts	O
from	O
two	O
obligate	O
SLS	B-Disease
heterozygotes	O
had	O
enzyme	O
activities	O
intermediate	O
between	O
that	O
in	O
normal	O
fibroblasts	O
and	O
individuals	O
with	O
SLS	B-Disease
.	O

These	O
results	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
SLS	B-Disease
is	O
deficiency	B-Disease
of	I-Disease
fatty	I-Disease
alcohol	I-Disease
NAD	I-Disease
+	I-Disease
oxidoreductase	I-Disease
.	O

SLS	B-Disease
represents	O
the	O
first	O
inherited	B-Disease
disorder	I-Disease
in	O
man	O
associated	O
with	O
an	O
isolated	O
abnormality	B-Disease
in	I-Disease
fatty	I-Disease
alcohol	I-Disease
metabolism	I-Disease
.	O
.	O

Germinal	O
mosaicism	O
in	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

We	O
have	O
identified	O
a	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
pedigree	O
where	O
the	O
disease	O
is	O
associated	O
with	O
a	O
molecular	O
deletion	O
within	O
the	O
DMD	B-Disease
locus	O
.	O

We	O
have	O
examined	O
the	O
meiotic	O
segregation	O
products	O
of	O
the	O
common	O
female	O
ancestor	O
using	O
marker	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
detected	O
by	O
probes	O
that	O
lie	O
within	O
this	O
deletion	O
.	O

These	O
studies	O
show	O
that	O
this	O
female	O
has	O
transmitted	O
three	O
distinct	O
types	O
of	O
X	O
chromosome	O
to	O
her	O
offspring	O
.	O

This	O
observation	O
may	O
be	O
explained	O
by	O
postulating	O
that	O
the	O
mutation	O
arose	O
as	O
a	O
postzygotic	O
deletion	O
within	O
this	O
common	O
ancestor	O
,	O
who	O
was	O
consequently	O
germinally	O
mosaic	O
.	O
.	O

Nebulin	O
seen	O
in	O
DMD	B-Disease
males	O
including	O
one	O
patient	O
with	O
a	O
large	O
DNA	O
deletion	O
encompassing	O
the	O
DMD	B-Disease
gene	O
.	O

The	O
presence	O
of	O
nebulin	O
in	O
a	O
muscle	O
specimen	O
from	O
a	O
patient	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
due	O
to	O
a	O
large	O
deletion	O
precludes	O
the	O
possibility	O
that	O
this	O
protein	O
is	O
the	O
DMD	B-Disease
gene	O
product	O
.	O
.	O

Expression	O
of	O
the	O
murine	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
in	O
muscle	O
and	O
brain	O
.	O

Complementary	O
DNA	O
clones	O
were	O
isolated	O
that	O
represent	O
the	O
5	O
terminal	O
2	O
.	O

5	O
kilobases	O
of	O
the	O
murine	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
Dmd	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
.	O

Mouse	O
Dmd	O
mRNA	O
was	O
detectable	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
and	O
at	O
a	O
level	O
approximately	O
90	O
percent	O
lower	O
in	O
brain	O
.	O

Dmd	O
mRNA	O
is	O
also	O
present	O
,	O
but	O
at	O
much	O
lower	O
than	O
normal	O
levels	O
,	O
in	O
both	O
the	O
muscle	O
and	O
brain	O
of	O
three	O
different	O
strains	O
of	O
dystrophic	B-Disease
mdx	O
mice	O
.	O

The	O
identification	O
of	O
Dmd	O
mRNA	O
in	O
brain	O
raises	O
the	O
possibility	O
of	O
a	O
relation	O
between	O
human	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
expression	O
and	O
the	O
mental	B-Disease
retardation	I-Disease
found	O
in	O
some	O
DMD	B-Disease
males	O
.	O

These	O
results	O
also	O
provide	O
evidence	O
that	O
the	O
mdx	O
mutations	O
are	O
allelic	O
variants	O
of	O
mouse	O
Dmd	O
gene	O
mutations	O
.	O

Glucose	B-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
and	O
incidence	O
of	O
hematologic	B-Disease
malignancy	I-Disease
.	O

We	O
have	O
evaluated	O
the	O
hypothesis	O
of	O
a	O
negative	O
association	O
between	O
glucose	B-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
and	O
cancer	B-Disease
in	O
a	O
cohort	O
of	O
481	O
Sardinian	O
males	O
with	O
hematological	B-Disease
malignancies	I-Disease
.	O

The	O
frequency	O
of	O
G6PD	B-Disease
deficiency	I-Disease
in	O
the	O
patients	O
was	O
not	O
different	O
from	O
the	O
incidence	O
in	O
a	O
group	O
of	O
16	O
,	O
219	O
controls	O
.	O

The	O
same	O
conclusion	O
resulted	O
from	O
the	O
comparison	O
of	O
the	O
frequency	O
of	O
expression	O
of	O
the	O
GdB	O
gene	O
in	O
23	O
heterozygous	O
women	O
having	O
a	O
clonal	O
hematologic	B-Disease
disease	I-Disease
and	O
a	O
control	O
group	O
of	O
37	O
healthy	O
heterozygotes	O
.	O

Therefore	O
at	O
present	O
there	O
is	O
no	O
evidence	O
that	O
G6PD	B-Disease
deficiency	I-Disease
has	O
a	O
protective	O
effect	O
against	O
development	O
of	O
hematologic	B-Disease
neoplasms	I-Disease
.	O
.	O

Hepatoblastoma	B-Disease
,	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
and	O
jaw	B-Disease
lesions	I-Disease
in	O
Gardner	B-Disease
syndrome	I-Disease
.	O

Hepatoblastoma	B-Disease
is	O
a	O
rare	O
neoplasm	B-Disease
of	O
infants	O
and	O
children	O
only	O
recently	O
documented	O
in	O
association	O
with	O
hereditary	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
of	I-Disease
the	I-Disease
colon	I-Disease
[	O
Kingston	O
et	O
al	O
.	O
,	O
1983	O
]	O
.	O

We	O
report	O
four	O
children	O
with	O
hepatoblastoma	B-Disease
from	O
four	O
unrelated	O
families	O
with	O
Gardner	B-Disease
syndrome	I-Disease
(	O
GS	B-Disease
)	O
.	O

One	O
child	O
,	O
now	O
19	O
years	O
old	O
,	O
survived	O
after	O
a	O
resection	O
of	O
a	O
hepatoblastoma	B-Disease
in	O
infancy	O
and	O
recently	O
was	O
found	O
to	O
have	O
GS	B-Disease
.	O

He	O
has	O
an	O
associated	O
odontoma	B-Disease
and	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
,	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
be	O
clinical	O
markers	O
of	O
GS	B-Disease
.	O

Many	O
individuals	O
in	O
these	O
four	O
GS	B-Disease
families	O
,	O
both	O
affected	O
and	O
at	O
risk	O
,	O
have	O
osteomatous	B-Disease
jaw	I-Disease
lesions	I-Disease
and	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
.	O

A	O
search	O
for	O
colonic	B-Disease
polyps	I-Disease
should	O
be	O
made	O
in	O
families	O
of	O
infants	O
and	O
children	O
with	O
hepatoblastoma	B-Disease
.	O

If	O
the	O
child	O
survives	O
,	O
he	O
or	O
she	O
should	O
be	O
monitored	O
for	O
the	O
later	O
appearance	O
of	O
colonic	B-Disease
polyps	I-Disease
.	O

The	O
finding	O
of	O
jaw	B-Disease
lesions	I-Disease
and	O
/	O
or	O
pigmented	B-Disease
ocular	I-Disease
fundus	I-Disease
lesions	I-Disease
in	O
relatives	O
at	O
risk	O
are	O
indications	O
of	O
the	O
possible	O
presence	O
of	O
the	O
GS	B-Disease
gene	O
.	O

Identification	O
of	O
an	O
altered	O
splice	O
site	O
in	O
Ashkenazi	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
.	O

Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
N	O
-	O
acetylhexosaminidase	O
A	O
(	O
ref	O
.	O
1	O
)	O
.	O

A	O
relatively	O
high	O
frequency	O
of	O
carriers	O
(	O
1	O
/	O
27	O
)	O
of	O
a	O
lethal	O
,	O
infantile	O
form	O
of	O
the	O
disease	O
is	O
found	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
it	O
is	O
not	O
yet	O
evident	O
whether	O
this	O
has	O
resulted	O
from	O
a	O
founder	O
effect	O
and	O
random	O
genetic	O
drift	O
or	O
from	O
a	O
selective	O
advantage	O
of	O
heterozygotes	O
.	O

We	O
have	O
identified	O
a	O
single	O
-	O
base	O
mutation	O
in	O
a	O
cloned	O
fragment	O
of	O
the	O
HEXA	O
gene	O
from	O
an	O
Ashkenazi	O
Jewish	O
patient	O
.	O

This	O
change	O
,	O
the	O
substitution	O
of	O
a	O
C	O
for	O
G	O
in	O
the	O
first	O
nucleotide	O
of	O
intron	O
12	O
is	O
expected	O
to	O
result	O
in	O
defective	O
splicing	O
of	O
the	O
messenger	O
RNA	O
.	O

A	O
test	O
for	O
the	O
mutant	O
allele	O
based	O
on	O
amplification	O
of	O
DNA	O
by	O
the	O
polymerase	O
chain	O
rection	O
and	O
cleavage	O
of	O
a	O
DdeI	O
restriction	O
site	O
generated	O
by	O
the	O
mutation	O
revealed	O
that	O
this	O
case	O
and	O
two	O
other	O
cases	O
of	O
the	O
Ashkenazi	O
,	O
infantile	O
form	O
of	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
are	O
heterozygous	O
for	O
two	O
different	O
mutations	O
.	O

The	O
occurrence	O
of	O
multiple	O
mutant	O
alleles	O
warrants	O
further	O
examination	O
of	O
the	O
selective	O
advantage	O
hypothesis	O
.	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
Mus	O
musculus	O
.	O

A	O
mouse	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1	O
-	O
ethyl	O
-	O
1	O
-	O
nitrosourea	O
-	O
treated	O
male	O
mice	O
.	O

The	O
activity	O
alteration	O
was	O
detected	O
in	O
blood	O
but	O
can	O
also	O
be	O
observed	O
in	O
other	O
tissue	O
extracts	O
.	O

Hemizygous	O
,	O
heterozygous	O
,	O
and	O
homozygous	O
mutants	O
have	O
,	O
respectively	O
,	O
about	O
15	O
,	O
60	O
,	O
and	O
15	O
%	O
G6PD	O
remaining	O
activity	O
in	O
the	O
blood	O
as	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Erythrocyte	O
indices	O
did	O
not	O
show	O
differences	O
between	O
mutants	O
and	O
wild	O
types	O
.	O

The	O
mutation	O
does	O
not	O
affect	O
the	O
electrophoretic	O
migration	O
,	O
the	O
isoelectric	O
point	O
,	O
or	O
the	O
thermal	O
stability	O
.	O

Kinetic	O
properties	O
,	O
such	O
as	O
the	O
Km	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	O
utilization	O
of	O
substrate	O
analogues	O
,	O
showed	O
no	O
differences	O
between	O
wild	O
types	O
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	O
utilization	O
of	O
deamino	O
-	O
NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants	O
.	O

This	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
X	B-Disease
-	I-Disease
linked	I-Disease
G6PD	I-Disease
deficiency	I-Disease
in	O
humans	O
.	O
.	O

Diverse	O
point	O
mutations	O
in	O
the	O
human	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
cause	O
enzyme	B-Disease
deficiency	I-Disease
and	O
mild	O
or	O
severe	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
;	I-Disease
EC	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
common	O
genetic	B-Disease
abnormality	I-Disease
affecting	O
an	O
estimated	O
400	O
million	O
people	O
worldwide	O
.	O

Clinical	O
and	O
biochemical	O
analyses	O
have	O
identified	O
many	O
variants	O
exhibiting	O
a	O
range	O
of	O
phenotypes	O
,	O
which	O
have	O
been	O
well	O
characterized	O
from	O
the	O
hematological	O
point	O
of	O
view	O
.	O

However	O
,	O
until	O
now	O
,	O
their	O
precise	O
molecular	O
basis	O
has	O
remained	O
unknown	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
seven	O
mutant	O
G6PD	O
alleles	O
.	O

In	O
the	O
nondeficient	O
polymorphic	O
African	O
variant	O
G6PD	O
A	O
we	O
have	O
found	O
a	O
single	O
point	O
mutation	O
.	O

The	O
other	O
six	O
mutants	O
investigated	O
were	O
all	O
associated	O
with	O
enzyme	B-Disease
deficiency	I-Disease
.	O

In	O
one	O
of	O
the	O
commonest	O
,	O
G6PD	O
Mediterranean	O
,	O
which	O
is	O
associated	O
with	O
favism	B-Disease
among	O
other	O
clinical	O
manifestations	O
,	O
a	O
single	O
amino	O
acid	O
replacement	O
was	O
found	O
(	O
serine	O
-	O
-	O
-	O
-	O
phenylalanine	O
)	O
it	O
must	O
be	O
responsible	O
for	O
the	O
decreased	O
stability	O
and	O
the	O
reduced	O
catalytic	O
efficiency	O
of	O
this	O
enzyme	O
.	O

Single	O
point	O
mutations	O
were	O
also	O
found	O
in	O
G6PD	O
Metaponto	O
(	O
Southern	O
Italy	O
)	O
and	O
in	O
G6PD	O
Ilesha	O
(	O
Nigeria	O
)	O
,	O
which	O
are	O
asymptomatic	O
,	O
and	O
in	O
G6PD	O
Chatham	O
,	O
which	O
was	O
observed	O
in	O
an	O
Indian	O
boy	O
with	O
neonatal	B-Disease
jaundice	I-Disease
.	O

In	O
G6PD	O
"	O
Matera	O
,	O
"	O
which	O
is	O
now	O
known	O
to	O
be	O
the	O
same	O
as	O
G6PD	O
A	O
-	O
,	O
two	O
separate	O
point	O
mutations	O
were	O
found	O
,	O
one	O
of	O
which	O
is	O
the	O
same	O
as	O
in	O
G6PD	O
A	O
.	O

In	O
G6PD	O
Santiago	O
,	O
a	O
de	O
novo	O
mutation	O
(	O
glycine	O
-	O
-	O
-	O
-	O
arginine	O
)	O
is	O
associated	O
with	O
severe	O
chronic	O
hemolytic	B-Disease
anemia	I-Disease
.	O

The	O
mutations	O
observed	O
show	O
a	O
striking	O
predominance	O
of	O
C	O
-	O
-	O
-	O
-	O
T	O
transitions	O
,	O
with	O
CG	O
doublets	O
involved	O
in	O
four	O
of	O
seven	O
cases	O
.	O

Thus	O
,	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
.	O

Tight	O
linkage	O
between	O
myotonic	B-Disease
dystrophy	I-Disease
and	O
apolipoprotein	O
E	O
genes	O
revealed	O
with	O
allele	O
-	O
specific	O
oligonucleotides	O
.	O

In	O
16	O
families	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
a	O
novel	O
approach	O
based	O
on	O
use	O
of	O
allele	O
-	O
specific	O
oligonucleotides	O
has	O
been	O
employed	O
to	O
study	O
the	O
linkage	O
relationship	O
between	O
the	O
apolipoprotein	O
E	O
(	O
APOE	O
)	O
gene	O
and	O
DM	B-Disease
.	O

Synthetic	O
oligonucleotides	O
,	O
designed	O
to	O
discriminate	O
between	O
APOE	O
alleles	O
epsilon	O
3	O
and	O
epsilon	O
4	O
,	O
enabled	O
us	O
to	O
distinguish	O
heterozygous	O
carriers	O
in	O
a	O
hybridization	O
assay	O
.	O

In	O
a	O
subset	O
of	O
families	O
,	O
the	O
relevant	O
segment	O
of	O
the	O
APOE	O
gene	O
was	O
enzymatically	O
amplified	O
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
method	O
.	O

For	O
DM	O
and	O
APOE	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
zmax	O
of	O
7	O
.	O

47	O
was	O
obtained	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O

047	O
(	O
male	O
theta	O
=	O
female	O
theta	O
)	O
.	O

No	O
recombination	O
(	O
maximum	O
lod	O
score	O
of	O
5	O
.	O
61	O
at	O
theta	O
=	O
0	O
.	O
0	O
)	O
was	O
found	O
between	O
APOE	O
and	O
the	O
apolipoprotein	O
CII	O
(	O
APOC2	O
)	O
gene	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
APOC2	O
,	O
APOE	O
is	O
a	O
useful	O
marker	O
for	O
presymptomatic	O
DM	B-Disease
diagnosis	O
.	O

Regional	O
localization	O
of	O
polymorphic	O
DNA	O
loci	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
using	O
deletions	O
associated	O
with	O
choroideremia	B-Disease
.	O

In	O
two	O
unrelated	O
families	O
,	O
males	O
have	O
been	O
identified	O
who	O
suffer	O
from	O
choroideremia	B-Disease
and	O
at	O
the	O
same	O
time	O
have	O
an	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
.	O

By	O
high	O
-	O
resolution	O
banding	O
we	O
have	O
characterized	O
the	O
deletion	O
chromosomes	O
as	O
del	O
(	O
X	O
)	O
(	O
q21	O
.	O
1	O
-	O
q21	O
1	O
-	O
q21	O
.	O
33	O
)	O
and	O
del	O
(	O
X	O
)	O
(	O
q21	O
.	O
2	O
-	O
q21	O
2	O
-	O
q21	O
.	O
31	O
)	O
respectively	O
.	O

By	O
Southern	O
blot	O
analysis	O
we	O
have	O
mapped	O
ten	O
different	O
polymorphic	O
DNA	O
loci	O
relative	O
to	O
the	O
position	O
of	O
the	O
deletion	O
and	O
the	O
choroideremia	B-Disease
locus	O
TCD	O
.	O

One	O
probe	O
,	O
p31	O
,	O
was	O
shown	O
to	O
cover	O
one	O
of	O
the	O
breakpoints	O
of	O
the	O
smallest	O
deletion	O
.	O

The	O
following	O
order	O
of	O
the	O
loci	O
was	O
suggested	O
by	O
deletion	O
mapping	O
cen	O
-	O
DXS106	O
-	O
DXS72	O
-	O
TCD	O
-	O
(	O
DXYS1	O
/	O
DXYS23	O
/	O
DXYS5	O
)	O
-	O
DXYS2	O
-	O
(	O
DXYS12	O
/	O
DXS3	O
)	O
-	O
(	O
DXS17	O
/	O
DXS101	O
)	O
-	O
Xqter	O
.	O

Retroviral	O
-	O
mediated	O
gene	O
transfer	O
of	O
human	O
phenylalanine	O
hydroxylase	O
into	O
NIH	O
3T3	O
and	O
hepatoma	B-Disease
cells	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
caused	O
by	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hepatic	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

A	O
full	O
-	O
length	O
human	O
PAH	O
cDNA	O
sequence	O
has	O
been	O
inserted	O
into	O
pzip	O
-	O
neoSV	O
(	O
X	O
)	O
,	O
which	O
is	O
a	O
retroviral	O
vector	O
containing	O
the	O
bacterial	O
neo	O
gene	O
.	O

The	O
recombinant	O
has	O
been	O
transfected	O
into	O
psi	O
2	O
cells	O
,	O
which	O
provide	O
synthesis	O
of	O
the	O
retroviral	O
capsid	O
.	O

Recombinant	O
virus	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
of	O
the	O
transfected	O
psi	O
2	O
cells	O
,	O
which	O
is	O
capable	O
of	O
transmitting	O
the	O
human	O
PAH	O
gene	O
into	O
mouse	O
NIH	O
3T3	O
cells	O
by	O
infection	O
leading	O
to	O
stable	O
incorporation	O
of	O
the	O
recombinant	O
provirus	O
.	O

Infected	O
cells	O
express	O
PAH	O
mRNA	O
,	O
immunoreactive	O
PAH	O
protein	O
,	O
and	O
exhibit	O
pterin	O
-	O
dependent	O
phenylalanine	O
hydroxylase	O
activity	O
.	O

The	O
recombinant	O
virus	O
is	O
also	O
capable	O
of	O
infecting	O
a	O
mouse	O
hepatoma	B-Disease
cell	O
line	O
that	O
does	O
not	O
normally	O
synthesize	O
PAH	O
.	O

PAH	O
activity	O
is	O
present	O
in	O
the	O
cellular	O
extracts	O
and	O
the	O
entire	O
hydroxylation	O
system	O
is	O
reconstituted	O
in	O
the	O
hepatoma	B-Disease
cells	O
infected	O
with	O
the	O
recombinant	O
viruses	O
.	O

Thus	O
,	O
recombinant	O
viruses	O
containing	O
human	O
PAH	O
cDNA	O
provide	O
a	O
means	O
for	O
introducing	O
functional	O
PAH	O
into	O
mammalian	O
cells	O
of	O
hepatic	O
origin	O
and	O
can	O
potentially	O
be	O
introduced	O
into	O
whole	O
animals	O
as	O
a	O
model	O
for	O
somatic	O
gene	O
therapy	O
for	O
PKU	B-Disease
.	O
.	O

Estimation	O
of	O
the	O
male	O
to	O
female	O
ratio	O
of	O
mutation	O
rates	O
from	O
the	O
segregation	O
of	O
X	O
-	O
chromosomal	O
DNA	O
haplotypes	O
in	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
families	O
.	O

A	O
novel	O
procedure	O
is	O
presented	O
to	O
estimate	O
the	O
ratio	O
of	O
male	O
to	O
female	O
mutation	O
rates	O
for	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

X	O
-	O
specific	O
restriction	O
fragment	O
length	O
polymorphisms	O
are	O
used	O
to	O
establish	O
DNA	O
haplotypes	O
in	O
three	O
-	O
generation	O
DMD	B-Disease
families	O
.	O

From	O
the	O
proportion	O
of	O
DMD	B-Disease
patients	O
who	O
have	O
inherited	O
their	O
maternal	O
grandfathers	O
X	O
chromosome	O
,	O
the	O
ratio	O
of	O
mutation	O
rates	O
can	O
be	O
calculated	O
.	O

In	O
contrast	O
to	O
classical	O
methods	O
,	O
the	O
proposed	O
procedure	O
is	O
not	O
restricted	O
to	O
sporadic	O
or	O
familiar	O
cases	O
nor	O
is	O
any	O
information	O
on	O
the	O
carrier	O
status	O
of	O
female	O
relatives	O
required	O
.	O
.	O

Deletions	O
of	O
a	O
DNA	O
sequence	O
in	O
retinoblastomas	B-Disease
and	O
mesenchymal	B-Disease
tumors	I-Disease
:	O
organization	O
of	O
the	O
sequence	O
and	O
its	O
encoded	O
protein	O
.	O

Retinoblastoma	B-Disease
is	O
a	O
childhood	B-Disease
tumor	I-Disease
that	O
can	O
arise	O
because	O
of	O
mutant	O
alleles	O
acquired	O
as	O
somatic	O
or	O
germinal	O
mutations	O
.	O

The	O
mutant	O
allele	O
can	O
be	O
carried	O
in	O
the	O
germ	O
line	O
.	O

The	O
mutations	O
creating	O
these	O
alleles	O
act	O
by	O
inactivating	O
copies	O
of	O
a	O
recessive	O
oncogene	O
located	O
within	O
band	O
q14	O
of	O
chromosome	O
13	O
and	O
termed	O
the	O
RB1	O
locus	O
.	O

We	O
have	O
reported	O
isolation	O
of	O
a	O
cDNA	O
fragment	O
that	O
recognizes	O
chromosomal	O
sequences	O
possessing	O
many	O
of	O
the	O
attributes	O
of	O
the	O
retinoblastoma	B-Disease
gene	O
associated	O
with	O
the	O
RB1	O
locus	O
.	O

We	O
now	O
report	O
that	O
this	O
segment	O
is	O
additionally	O
the	O
target	O
of	O
somatic	O
mutations	O
in	O
mesenchymal	B-Disease
tumors	I-Disease
among	O
patients	O
having	O
no	O
apparent	O
predisposition	O
to	O
retinoblastoma	B-Disease
and	O
no	O
previous	O
evidence	O
of	O
retinoblastoma	B-Disease
.	O

These	O
tumors	B-Disease
provide	O
additional	O
evidence	O
that	O
the	O
cloned	O
sequences	O
are	O
representative	O
of	O
a	O
gene	O
that	O
is	O
a	O
frequent	O
target	O
of	O
inactivation	O
during	O
tumorigenesis	O
.	O

Sequence	O
analysis	O
of	O
this	O
cDNA	O
provides	O
little	O
insight	O
into	O
its	O
normal	O
functional	O
role	O
.	O
.	O

Treatment	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
with	O
growth	O
hormone	O
inhibitors	O
.	O

A	O
controlled	O
,	O
double	O
-	O
blind	O
therapeutic	O
trial	O
with	O
the	O
drug	O
mazindol	O
,	O
a	O
growth	O
hormone	O
inhibitor	O
,	O
was	O
performed	O
in	O
a	O
pair	O
of	O
7	O
1	O
/	O
2	O
year	O
-	O
old	O
monozygotic	O
twins	O
,	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

The	O
rationale	O
for	O
this	O
trial	O
was	O
based	O
on	O
a	O
patient	O
(	O
reported	O
previously	O
)	O
affected	O
simultaneously	O
with	O
DMD	B-Disease
and	O
growth	B-Disease
hormone	I-Disease
(	I-Disease
GH	I-Disease
)	I-Disease
deficiency	I-Disease
,	O
who	O
is	O
showing	O
a	O
benign	O
course	O
of	O
the	O
dystrophic	B-Disease
process	I-Disease
and	O
is	O
still	O
walking	O
at	O
18	O
years	O
.	O

One	O
of	O
the	O
twins	O
received	O
2	O
mg	O
of	O
mazindol	O
daily	O
,	O
while	O
the	O
other	O
received	O
a	O
placebo	O
.	O

The	O
assessment	O
,	O
repeated	O
every	O
2	O
months	O
,	O
included	O
weight	O
and	O
height	O
measurements	O
,	O
functional	O
and	O
motor	O
ability	O
tests	O
,	O
ergometry	O
and	O
determinations	O
of	O
serum	O
enzymes	O
and	O
GH	O
levels	O
.	O

After	O
one	O
year	O
of	O
trial	O
the	O
code	O
was	O
broken	O
and	O
it	O
was	O
seen	O
that	O
the	O
twin	O
under	O
placebo	O
treatment	O
was	O
strikingly	O
worse	O
than	O
his	O
brother	O
,	O
the	O
progression	O
of	O
whose	O
condition	O
was	O
practically	O
arrested	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
treatment	O
with	O
a	O
GH	O
inhibitor	O
is	O
beneficial	O
for	O
DMD	B-Disease
patients	O
.	O
.	O

Identification	O
and	O
localization	O
of	O
mutations	O
at	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
locus	O
by	O
ribonuclease	O
A	O
cleavage	O
.	O

Many	O
mutations	O
leading	O
to	O
human	O
disease	O
are	O
the	O
result	O
of	O
single	O
DNA	O
base	O
pair	O
changes	O
that	O
cannot	O
be	O
identified	O
by	O
Southern	O
analysis	O
.	O

This	O
has	O
prompted	O
the	O
development	O
of	O
alternative	O
assays	O
for	O
point	O
mutation	O
detection	O
.	O

The	O
recently	O
described	O
ribonuclease	O
A	O
cleavage	O
procedure	O
,	O
with	O
a	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
chromatography	O
step	O
,	O
has	O
been	O
used	O
to	O
identify	O
the	O
mutational	O
lesions	O
in	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
messenger	O
RNAs	O
of	O
patients	O
with	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

Distinctive	O
ribonuclease	O
A	O
cleavage	O
patterns	O
were	O
identified	O
in	O
messenger	O
RNA	O
from	O
5	O
of	O
14	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
patients	O
who	O
were	O
chosen	O
because	O
no	O
HPRT	O
Southern	O
or	O
Northern	O
blotting	O
pattern	O
changes	O
had	O
been	O
found	O
.	O

This	O
approach	O
now	O
allows	O
HPRT	O
mutation	O
detection	O
in	O
50	O
percent	O
of	O
the	O
cases	O
of	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

The	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
procedure	O
provides	O
a	O
general	O
method	O
for	O
analysis	O
of	O
low	O
abundance	O
messenger	O
RNAs	O
.	O
.	O

Two	O
new	O
variants	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
associated	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
spherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
:	O
G6PD	O
Wayne	O
and	O
G6PD	O
Huron	O
.	O

Two	O
new	O
deficient	O
variants	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
causing	O
hereditary	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
HNSHA	B-Disease
)	O
are	O
described	O
.	O

Both	O
of	O
these	O
are	O
unique	O
and	O
they	O
have	O
been	O
named	O
G6PD	O
Wayne	O
and	O
G6PD	O
Huron	O
.	O

Patients	O
with	O
G6PD	O
Wayne	O
underwent	O
splenectomy	O
and	O
no	O
objective	O
improvement	O
was	O
noted	O
.	O

The	O
patients	O
with	O
G6PD	O
Huron	O
were	O
under	O
medical	O
observation	O
for	O
a	O
considerable	O
period	O
of	O
time	O
without	O
the	O
diagnosis	O
of	O
G6PD	B-Disease
deficiency	I-Disease
being	O
entertained	O
because	O
the	O
family	O
was	O
of	O
Northern	O
European	O
origin	O
.	O

Since	O
sporadic	O
variants	O
of	O
G6PD	O
causing	O
HNSHA	B-Disease
show	O
no	O
special	O
racial	O
predilection	O
,	O
the	O
diagnosis	O
of	O
G6PD	B-Disease
deficiency	I-Disease
should	O
always	O
be	O
considered	O
in	O
patients	O
with	O
this	O
syndrome	O
.	O
.	O

Sialophorin	O
,	O
a	O
surface	O
sialoglycoprotein	O
defective	O
in	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
,	O
is	O
involved	O
in	O
human	O
T	O
lymphocyte	O
proliferation	O
.	O

The	O
mAb	O
L10	O
was	O
used	O
to	O
determine	O
the	O
distribution	O
and	O
the	O
function	O
of	O
sialophorin	O
,	O
the	O
heavily	O
glycosylated	O
surface	O
molecule	O
that	O
is	O
deficient	O
/	O
defective	O
in	O
lymphocytes	O
of	O
patients	O
with	O
the	O
X	B-Disease
-	I-Disease
linked	I-Disease
immunodeficiency	I-Disease
Wiskott	I-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
.	O

Dual	O
-	O
parameter	O
FACS	O
analysis	O
indicated	O
that	O
sialophorin	O
is	O
expressed	O
on	O
CD4	O
+	O
and	O
CD8	O
+	O
lymphocytes	O
,	O
on	O
a	O
subpopulation	O
of	O
peripheral	O
blood	O
B	O
lymphocytes	O
,	O
on	O
all	O
thymocytes	O
,	O
and	O
on	O
a	O
subpopulation	O
of	O
bone	O
marrow	O
cells	O
.	O

Functional	O
studies	O
demonstrated	O
that	O
L10	O
mAb	O
stimulates	O
the	O
proliferation	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
as	O
measured	O
by	O
stimulation	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
.	O

The	O
time	O
course	O
and	O
magnitude	O
of	O
increased	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
by	O
T	O
lymphocytes	O
in	O
response	O
to	O
L10	O
mAb	O
paralleled	O
that	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
.	O

Effective	O
stimulation	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
monocytes	O
and	O
the	O
Fc	O
portion	O
of	O
L10	O
mAb	O
.	O

Stimulation	O
of	O
lymphocytes	O
by	O
L10	O
,	O
like	O
stimulation	O
by	O
anti	O
-	O
CD3	O
mAb	O
,	O
involves	O
increased	O
expression	O
of	O
4F2	O
,	O
HLA	O
-	O
DR	O
,	O
and	O
IL	O
-	O
2	O
-	O
R	O
.	O

These	O
observations	O
suggest	O
that	O
sialophorin	O
functions	O
in	O
T	O
cell	O
activation	O
.	O
.	O

Hypopigmentation	B-Disease
in	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

Cutaneous	B-Disease
and	I-Disease
ocular	I-Disease
pigmentation	I-Disease
were	O
evaluated	O
in	O
29	O
individuals	O
with	O
the	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

Criteria	O
for	O
hypopigmentation	B-Disease
included	O
the	O
presence	O
of	O
type	O
I	O
or	O
II	O
skin	O
,	O
the	O
lightest	O
skin	O
type	O
in	O
the	O
family	O
by	O
history	O
,	O
and	O
iris	O
translucency	O
on	O
globe	O
transillumination	O
.	O

On	O
the	O
basis	O
of	O
these	O
criteria	O
,	O
48	O
%	O
of	O
the	O
PWS	B-Disease
individuals	O
were	O
hypopigmented	B-Disease
.	O

The	O
presence	O
of	O
hypopigmentation	B-Disease
correlated	O
with	O
a	O
small	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
;	O
however	O
,	O
this	O
deletion	O
was	O
also	O
found	O
in	O
individuals	O
who	O
did	O
not	O
meet	O
the	O
full	O
criteria	O
for	O
hypopigmentation	B-Disease
.	O

Hairbulb	O
tyrosinase	O
activity	O
and	O
glutathione	O
content	O
,	O
as	O
well	O
as	O
urine	O
cysteinyldopa	O
excretion	O
,	O
were	O
low	O
in	O
PWS	B-Disease
individuals	O
with	O
and	O
without	O
hypopigmentation	B-Disease
and	O
did	O
not	O
separate	O
these	O
two	O
groups	O
.	O

We	O
conclude	O
that	O
hypopigmentation	B-Disease
is	O
found	O
in	O
a	O
significant	O
proportion	O
of	O
individuals	O
with	O
PWS	B-Disease
and	O
that	O
the	O
hypopigmentation	B-Disease
may	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
15	O
.	O

The	O
mechanism	O
for	O
the	O
hypopigmentation	B-Disease
is	O
unknown	O
.	O
.	O

Phenotype	O
heterogeneity	O
among	O
hemizygotes	O
in	O
a	O
family	O
biochemically	O
screened	O
for	O
adrenoleukodystrophy	B-Disease
.	O

We	O
report	O
on	O
two	O
clinically	O
,	O
neurologically	O
normal	O
relatives	O
of	O
a	O
boy	O
affected	O
by	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
;	O
they	O
were	O
found	O
repeatedly	O
to	O
have	O
the	O
biochemical	O
defect	O
of	O
an	O
ALD	B-Disease
hemizygote	O
.	O

The	O
assay	O
consisted	O
in	O
the	O
determination	O
of	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
in	O
lyophilized	O
and	O
reconstituted	O
plasma	O
.	O

While	O
no	O
evidence	O
of	O
neurologic	B-Disease
disease	I-Disease
(	O
leukodystrophy	B-Disease
or	O
myeloneuropathy	B-Disease
)	O
was	O
present	O
in	O
these	O
hemizygotes	O
,	O
adrenocortical	B-Disease
insufficiency	I-Disease
provoking	O
compensatory	O
high	O
ACTH	O
release	O
was	O
found	O
in	O
both	O
.	O

These	O
findings	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
counseling	O
families	O
in	O
which	O
cases	O
with	O
clinically	O
expressed	O
ALD	B-Disease
are	O
represented	O
in	O
several	O
generations	O
.	O
.	O

The	O
mapping	O
of	O
a	O
cDNA	O
from	O
the	O
human	O
X	B-Disease
-	I-Disease
linked	I-Disease
Duchenne	I-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
to	O
the	O
mouse	O
X	O
chromosome	O
.	O

The	O
recent	O
discovery	O
of	O
sequences	O
at	O
the	O
site	O
of	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
in	O
humans	O
has	O
opened	O
up	O
the	O
possibility	O
of	O
a	O
detailed	O
molecular	O
analysis	O
of	O
the	O
genes	O
in	O
humans	O
and	O
in	O
related	O
mammalian	O
species	O
.	O

Until	O
relatively	O
recently	O
,	O
there	O
was	O
no	O
obvious	O
mouse	O
model	O
of	O
this	O
genetic	B-Disease
disease	I-Disease
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
.	O

The	O
identification	O
of	O
a	O
mouse	O
X	O
-	O
linked	O
mutant	O
showing	O
muscular	B-Disease
dystrophy	I-Disease
,	O
mdx	O
,	O
has	O
provided	O
a	O
candidate	O
mouse	O
genetic	O
homologue	O
to	O
the	O
DMD	B-Disease
locus	O
;	O
the	O
relatively	O
mild	O
pathological	O
features	O
of	O
mdx	O
suggest	O
it	O
may	O
have	O
more	O
in	O
common	O
with	O
mutations	O
of	O
the	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
type	O
at	O
the	O
same	O
human	O
locus	O
,	O
however	O
.	O

But	O
the	O
close	O
genetic	O
linkage	O
of	O
mdx	O
to	O
G6PD	O
and	O
Hprt	O
on	O
the	O
mouse	O
X	O
chromosome	O
,	O
coupled	O
with	O
its	O
comparatively	O
mild	O
pathology	O
,	O
have	O
suggested	O
that	O
the	O
mdx	O
mutation	O
may	O
instead	O
correspond	O
to	O
Emery	B-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
which	O
itself	O
is	O
closely	O
linked	O
to	O
DNA	O
markers	O
at	O
Xq28	O
-	O
qter	O
in	O
the	O
region	O
of	O
G6PD	O
on	O
the	O
human	O
X	O
chromosome	O
.	O

Using	O
an	O
interspecific	O
mouse	O
domesticus	O
/	O
spretus	O
cross	O
,	O
segregating	O
for	O
a	O
variety	O
of	O
markers	O
on	O
the	O
mouse	O
X	O
chromosome	O
,	O
we	O
have	O
positioned	O
on	O
the	O
mouse	O
X	O
chromosome	O
sequences	O
homologous	O
to	O
a	O
DMD	B-Disease
cDNA	O
clone	O
.	O

These	O
sequences	O
map	O
provocatively	O
close	O
to	O
the	O
mdx	O
mutation	O
and	O
unexpectedly	O
distant	O
from	O
sparse	O
fur	O
,	O
spf	O
,	O
the	O
mouse	O
homologue	O
of	O
OTC	O
(	O
ornithine	O
transcarbamylase	O
)	O
which	O
is	O
closely	O
linked	O
to	O
DMD	B-Disease
on	O
the	O
human	O
X	O
chromosome	O
.	O
.	O

Localization	O
of	O
the	O
region	O
homologous	O
to	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
locus	O
on	O
the	O
mouse	O
X	O
chromosome	O
.	O

Recent	O
progress	O
has	O
resulted	O
in	O
part	O
of	O
the	O
gene	O
mutated	O
in	O
Duchenne	B-Disease
and	I-Disease
the	I-Disease
milder	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophies	I-Disease
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	O
itself	O
extends	O
over	O
1	O
,	O
000	O
to	O
2	O
,	O
000	O
kilobases	O
(	O
kb	O
)	O
.	O

To	O
study	O
how	O
mutations	O
in	O
this	O
gene	O
affect	O
muscle	O
development	O
and	O
integrity	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
have	O
available	O
a	O
mouse	O
model	O
of	O
the	O
human	O
disease	O
.	O

The	O
mouse	O
mdx	O
mutation	O
affects	O
muscle	O
and	O
confers	O
a	O
mild	O
dystrophic	B-Disease
syndrome	I-Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	O
is	O
equivalent	O
to	O
Duchenne	B-Disease
/	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
man	O
.	O

Here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
that	O
cross	O
-	O
hybridize	O
to	O
mouse	O
X	O
-	O
linked	O
sequences	O
to	O
localize	O
the	O
gene	O
homologous	O
to	O
DMD	B-Disease
in	O
the	O
mouse	O
.	O

Both	O
sequences	O
map	O
to	O
the	O
region	O
of	O
10	O
centimorgan	O
lying	O
between	O
the	O
Tabby	O
(	O
Ta	O
)	O
and	O
St14	O
-	O
1	O
(	O
DxPas8	O
)	O
loci	O
,	O
close	O
to	O
the	O
phosphorylase	O
b	O
kinase	O
locus	O
(	O
Phk	O
)	O
.	O

By	O
analogy	O
with	O
the	O
human	O
X	O
-	O
chromosome	O
,	O
we	O
conclude	O
that	O
the	O
region	O
in	O
the	O
mouse	O
around	O
the	O
G6pd	O
and	O
St14	O
-	O
1	O
loci	O
may	O
contain	O
two	O
genes	O
corresponding	O
to	O
distinct	O
human	O
myopathies	B-Disease
Emery	B-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
which	O
is	O
known	O
to	O
be	O
closely	O
linked	O
to	O
St14	O
-	O
1	O
in	O
man	O
and	O
the	O
DMD	B-Disease
homologue	O
described	O
here	O
.	O
.	O

GT	O
to	O
AT	O
transition	O
at	O
a	O
splice	O
donor	O
site	O
causes	O
skipping	O
of	O
the	O
preceding	O
exon	O
in	O
phenylketonuria	B-Disease
.	O

Classical	B-Disease
Phenylketonuria	I-Disease
(	O
PKU	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
human	I-Disease
genetic	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

We	O
isolated	O
several	O
mutant	O
PAH	O
cDNA	O
clones	O
from	O
a	O
PKU	B-Disease
carrier	O
individual	O
and	O
showed	O
that	O
they	O
contained	O
an	O
internal	O
116	O
base	O
pair	O
deletion	O
,	O
corresponding	O
precisely	O
to	O
exon	O
12	O
of	O
the	O
human	O
chromosomal	O
PAH	O
gene	O
.	O

The	O
deletion	O
causes	O
the	O
synthesis	O
of	O
a	O
truncated	O
protein	O
lacking	O
the	O
C	O
-	O
terminal	O
52	O
amino	O
acids	O
.	O

Gene	O
transfer	O
and	O
expression	O
studies	O
using	O
the	O
mutant	O
PAH	O
cDNA	O
indicated	O
that	O
the	O
deletion	O
abolishes	O
PAH	O
activity	O
in	O
the	O
cell	O
as	O
a	O
result	O
of	O
protein	O
instability	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
the	O
deletion	O
,	O
the	O
mutant	O
chromosomal	O
PAH	O
gene	O
was	O
isolated	O
from	O
this	O
individual	O
and	O
shown	O
to	O
contain	O
a	O
GT	O
-	O
-	O
greater	O
than	O
AT	O
substitution	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
12	O
.	O

Thus	O
,	O
the	O
consequence	O
of	O
the	O
splice	O
donor	O
site	O
mutation	O
in	O
the	O
human	O
liver	O
is	O
the	O
skipping	O
of	O
the	O
preceding	O
exon	O
during	O
RNA	O
splicing	O
.	O
.	O

Conservation	O
of	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
in	O
mice	O
and	O
humans	O
.	O

A	O
portion	O
of	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
gene	O
transcript	O
from	O
human	O
fetal	O
skeletal	O
muscle	O
and	O
mouse	O
adult	O
heart	O
was	O
sequenced	O
,	O
representing	O
approximately	O
25	O
percent	O
of	O
the	O
total	O
,	O
14	O
-	O
kb	O
DMD	B-Disease
transcript	O
.	O

The	O
nucleic	O
acid	O
and	O
predicted	O
amino	O
acid	O
sequences	O
from	O
the	O
two	O
species	O
are	O
nearly	O
90	O
percent	O
homologous	O
.	O

The	O
amino	O
acid	O
sequence	O
that	O
is	O
predicted	O
from	O
this	O
portion	O
of	O
the	O
DMD	B-Disease
gene	O
indicates	O
that	O
the	O
protein	O
product	O
might	O
serve	O
a	O
structural	O
role	O
in	O
muscle	O
,	O
but	O
the	O
abundance	O
and	O
tissue	O
distribution	O
of	O
the	O
messenger	O
RNA	O
suggests	O
that	O
the	O
DMD	B-Disease
protein	O
is	O
not	O
nebulin	O
.	O
.	O

Familial	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
with	O
apparently	O
normal	O
chromosomes	O
.	O

We	O
report	O
on	O
4	O
sibs	O
(	O
2F	O
,	O
2M	O
)	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

Diagnosis	O
was	O
made	O
clinically	O
on	O
the	O
basis	O
of	O
history	O
,	O
behavior	O
,	O
and	O
physical	O
findings	O
in	O
3	O
of	O
the	O
sibs	O
.	O

The	O
other	O
child	O
had	O
died	O
at	O
age	O
10	O
months	O
with	O
a	O
history	O
and	O
clinical	O
findings	O
typical	O
of	O
first	O
phase	O
of	O
PWS	B-Disease
.	O

Results	O
of	O
chromosome	O
studies	O
on	O
the	O
parents	O
and	O
surviving	O
sibs	O
were	O
normal	O
.	O

The	O
implications	O
of	O
this	O
unusual	O
familial	O
occurrence	O
for	O
our	O
understanding	O
of	O
PWS	B-Disease
are	O
discussed	O
.	O
.	O

Nebulin	O
and	O
titin	O
expression	O
in	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
appears	O
normal	O
.	O

Monoclonal	O
antibodies	O
which	O
recognize	O
different	O
epitopes	O
on	O
either	O
titin	O
or	O
nebulin	O
show	O
normal	O
staining	O
patterns	O
on	O
frozen	O
sections	O
of	O
three	O
muscle	O
biopsies	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

Gel	O
electrophoresis	O
and	O
immunoblotting	O
performed	O
on	O
two	O
of	O
these	O
muscle	O
biopsies	O
show	O
the	O
normal	O
pattern	O
of	O
titin	O
and	O
nebulin	O
polypeptides	O
.	O

Since	O
the	O
donor	O
of	O
one	O
of	O
these	O
biopsies	O
has	O
a	O
large	O
deletion	O
of	O
the	O
5	O
-	O
region	O
of	O
the	O
DMD	B-Disease
gene	O
,	O
our	O
results	O
argue	O
against	O
the	O
recent	O
proposal	O
that	O
nebulin	O
is	O
the	O
gene	O
mutated	O
in	O
DMD	B-Disease
.	O
.	O

Heterozygous	B-Disease
C2	I-Disease
deficiency	I-Disease
associated	O
with	O
angioedema	B-Disease
,	O
myasthenia	B-Disease
gravis	I-Disease
,	O
and	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O

We	O
describe	O
a	O
patient	O
with	O
myasthenia	B-Disease
gravis	I-Disease
,	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
,	O
and	O
angioedema	B-Disease
associated	O
with	O
heterozygous	O
complement	B-Disease
factor	I-Disease
2	I-Disease
(	I-Disease
C2	I-Disease
)	I-Disease
deficiency	I-Disease
.	O

The	O
significance	O
of	O
this	O
association	O
is	O
controversial	O
,	O
though	O
the	O
association	O
of	O
C2	B-Disease
deficiency	I-Disease
with	O
certain	O
histocompatibility	O
antigens	O
suggests	O
possible	O
linkage	O
to	O
immune	O
response	O
genes	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
heterozygous	O
C2	B-Disease
deficiency	I-Disease
in	O
association	O
with	O
this	O
combination	O
of	O
autoimmune	B-Disease
disorders	I-Disease
,	O
and	O
we	O
discuss	O
the	O
aetiological	O
implications	O
.	O
.	O

Genetic	O
analysis	O
of	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
third	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
Brittany	O
spaniel	O
dogs	O
.	O

Genetically	O
determined	O
C3	B-Disease
deficiency	I-Disease
in	O
Brittany	O
spaniel	O
dogs	O
shares	O
a	O
number	O
of	O
biochemical	O
and	O
clinical	O
characteristics	O
with	O
the	O
human	O
disorder	O
.	O

In	O
humans	O
,	O
the	O
gene	O
for	O
C3	B-Disease
deficiency	I-Disease
is	O
a	O
null	O
gene	O
that	O
is	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
C3	O
and	O
is	O
not	O
linked	O
to	O
the	O
major	O
histocompatibility	O
locus	O
.	O

The	O
current	O
study	O
used	O
allotype	O
analysis	O
of	O
canine	O
C3	O
in	O
order	O
to	O
demonstrate	O
that	O
the	O
gene	O
for	O
C3	B-Disease
deficiency	I-Disease
in	O
these	O
dogs	O
is	O
also	O
a	O
null	O
gene	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
C3	O
.	O

In	O
addition	O
,	O
preliminary	O
pedigree	O
analysis	O
suggests	O
that	O
the	O
gene	O
for	O
canine	O
C3	B-Disease
deficiency	I-Disease
is	O
apparently	O
not	O
closely	O
linked	O
to	O
the	O
major	O
histocompatibility	O
complex	O
of	O
the	O
dog	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
C3	B-Disease
deficiency	I-Disease
in	O
Brittany	O
spaniel	O
dogs	O
not	O
only	O
shares	O
biochemical	O
and	O
clinical	O
features	O
with	O
C3	B-Disease
deficiency	I-Disease
in	O
humans	O
,	O
but	O
also	O
shares	O
some	O
genetic	O
characteristics	O
with	O
the	O
human	O
disorder	O
.	O
.	O

Gene	O
transfer	O
and	O
expression	O
of	O
human	O
phenylalanine	O
hydroxylase	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
caused	O
by	O
a	O
genetic	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
)	O
.	O

A	O
full	O
-	O
length	O
complementary	O
DNA	O
clone	O
of	O
human	O
PAH	O
was	O
inserted	O
into	O
a	O
eukaryotic	O
expression	O
vector	O
and	O
transferred	O
into	O
mouse	O
NIH3T3	O
cells	O
which	O
do	O
not	O
normally	O
express	O
PAH	O
.	O

The	O
transformed	O
mouse	O
cells	O
expressed	O
PAH	O
messenger	O
RNA	O
,	O
immunoreactive	O
protein	O
,	O
and	O
enzymatic	O
activity	O
that	O
are	O
characteristic	O
of	O
the	O
normal	O
human	O
liver	O
products	O
,	O
demonstrating	O
that	O
a	O
single	O
gene	O
contains	O
all	O
of	O
the	O
necessary	O
genetic	O
information	O
to	O
code	O
for	O
functional	O
PAH	O
.	O

These	O
results	O
support	O
the	O
use	O
of	O
the	O
human	O
PAH	O
probe	O
in	O
prenatal	O
diagnosis	O
and	O
detection	O
of	O
carriers	O
,	O
to	O
provide	O
new	O
opportunities	O
for	O
the	O
biochemical	O
characterization	O
of	O
normal	O
and	O
mutant	O
enzymes	O
,	O
and	O
in	O
the	O
investigation	O
of	O
alternative	O
genetic	O
therapies	O
for	O
PKU	B-Disease
.	O
.	O

Regional	O
mapping	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
and	O
the	O
phenylketonuria	B-Disease
locus	O
in	O
the	O
human	O
genome	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	O
amino	O
acid	O
metabolism	O
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
hepatic	I-Disease
enzyme	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
;	O
phenylalanine	O
4	O
-	O
monooxygenase	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O

A	O
cDNA	O
clone	O
for	O
human	O
PAH	O
has	O
previously	O
been	O
used	O
to	O
assign	O
the	O
corresponding	O
gene	O
to	O
human	O
chromosome	O
12	O
.	O

To	O
define	O
the	O
regional	O
map	O
position	O
of	O
the	O
disease	O
locus	O
and	O
the	O
PAH	O
gene	O
on	O
human	O
chromosome	O
12	O
,	O
DNA	O
was	O
isolated	O
from	O
human	O
-	O
hamster	O
somatic	O
cell	O
hybrids	O
with	O
various	O
deletions	O
of	O
human	O
chromosome	O
12	O
and	O
was	O
analyzed	O
by	O
Southern	O
blot	O
analysis	O
using	O
the	O
human	O
cDNA	O
PAH	O
clone	O
as	O
a	O
hybridization	O
probe	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
detailed	O
biochemical	O
and	O
cytogenetic	O
characterization	O
of	O
the	O
hybrid	O
cells	O
,	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
human	O
PAH	O
gene	O
has	O
been	O
defined	O
as	O
12q14	O
.	O

3	O
-	O
-	O
-	O
-	O
qter	O
3	O
-	O
-	O
-	O
-	O
qter	O
.	O

The	O
PAH	O
map	O
position	O
on	O
chromosome	O
12	O
was	O
further	O
localized	O
by	O
in	O
situ	O
hybridization	O
of	O
125I	O
-	O
labeled	O
human	O
PAH	O
cDNA	O
to	O
chromosomes	O
prepared	O
from	O
a	O
human	O
lymphoblastoid	O
cell	O
line	O
.	O

Results	O
of	O
these	O
experiments	O
demonstrated	O
that	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
PAH	O
gene	O
and	O
the	O
PKU	B-Disease
locus	O
in	O
man	O
is	O
12q22	O
-	O
-	O
-	O
-	O
12q24	O
.	O

1	O
.	O

These	O
results	O
not	O
only	O
provide	O
a	O
regionalized	O
map	O
position	O
for	O
a	O
major	O
human	O
disease	O
locus	O
but	O
also	O
can	O
serve	O
as	O
a	O
reference	O
point	O
for	O
linkage	O
analysis	O
with	O
other	O
DNA	O
markers	O
on	O
human	O
chromosome	O
12	O

Heterogeneity	O
of	O
type	B-Disease
I	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
:	O
evidence	O
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	B-Disease
Willebrand	I-Disease
factor	O
.	O

Type	B-Disease
I	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
(	O
vWD	B-Disease
)	O
is	O
characterized	O
by	O
equally	O
low	O
plasma	O
concentrations	O
of	O
von	B-Disease
Willebrand	I-Disease
factor	O
antigen	O
(	O
vWF	O
Ag	O
)	O
and	O
ristocetin	O
cofactor	O
(	O
RiCof	O
)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vWF	O
multimers	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
agarose	O
gel	O
electrophoresis	O
.	O

For	O
17	O
patients	O
(	O
13	O
kindreds	O
)	O
diagnosed	O
with	O
these	O
criteria	O
,	O
we	O
have	O
studied	O
the	O
platelet	O
contents	O
of	O
vWF	O
Ag	O
and	O
RiCof	O
and	O
the	O
changes	O
of	O
these	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
.	O

Platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
normal	O
in	O
four	O
kindreds	O
(	O
called	O
"	O
platelet	O
normal	O
"	O
subgroup	O
)	O
;	O
following	O
1	O
-	O
deamino	O
-	O
8	O
-	O
D	O
-	O
arginine	O
vasopressin	O
;	O
plasma	O
vWF	O
Ag	O
,	O
RiCof	O
and	O
the	O
bleeding	O
time	O
(	O
BT	O
)	O
became	O
normal	O
.	O

In	O
six	O
kindreds	O
,	O
platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
equally	O
low	O
(	O
platelet	O
low	O
)	O
;	O
after	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
and	O
RiCof	O
remained	O
low	O
,	O
and	O
the	O
BT	O
was	O
prolonged	O
.	O

In	O
three	O
additional	O
kindreds	O
,	O
platelets	O
contained	O
normal	O
concentrations	O
of	O
vWF	O
Ag	O
,	O
but	O
RiCof	O
was	O
very	O
low	O
(	O
platelet	O
discordant	O
)	O
;	O
even	O
though	O
a	O
complete	O
set	O
of	O
multimers	O
was	O
found	O
in	O
plasma	O
and	O
platelets	O
,	O
there	O
was	O
a	O
relatively	O
small	O
amount	O
of	O
large	O
multimers	O
.	O

After	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
became	O
normal	O
,	O
but	O
RiCof	O
remained	O
low	O
and	O
the	O
BT	O
was	O
very	O
prolonged	O
.	O

These	O
findings	O
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vWF	O
(	O
RiCof	O
less	O
than	O
vWF	O
Ag	O
)	O
even	O
in	O
type	B-Disease
I	I-Disease
vWD	I-Disease
,	O
coexisting	O
with	O
a	O
complete	O
set	O
of	O
vWF	O
multimers	O
(	O
platelet	O
discordant	O
)	O
;	O
that	O
the	O
abnormal	O
vWF	O
can	O
be	O
shown	O
more	O
clearly	O
in	O
platelets	O
than	O
in	O
plasma	O
or	O
else	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
;	O
and	O
that	O
DDAVP	O
normalizes	O
the	O
BT	O
only	O
in	O
those	O
patients	O
with	O
normal	O
platelet	O
levels	O
of	O
both	O
vWF	O
Ag	O
and	O
RiCof	O
(	O
platelet	O
normal	O
)	O
.	O
.	O

Genetic	O
analysis	O
in	O
families	O
with	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
.	O

We	O
have	O
brought	O
together	O
information	O
on	O
864	O
affected	O
individuals	O
in	O
164	O
families	O
(	O
including	O
three	O
new	O
pedigrees	O
)	O
reported	O
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
Demarquay	O
first	O
described	O
a	O
family	O
with	O
what	O
was	O
later	O
called	O
van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
.	O

Both	O
types	O
of	O
oral	B-Disease
cleft	I-Disease
,	O
cleft	B-Disease
palate	I-Disease
(	O
CP	B-Disease
)	O
and	O
cleft	B-Disease
lip	I-Disease
with	O
or	O
without	O
CP	B-Disease
(	O
CLP	B-Disease
)	O
,	O
segregate	O
in	O
these	O
families	O
together	O
with	O
lower	O
lip	B-Disease
pits	I-Disease
or	O
fistulae	B-Disease
in	O
an	O
autosomal	O
dominant	O
mode	O
with	O
high	O
penetrance	O
estimated	O
to	O
be	O
K	O
=	O
.	O

89	O
and	O
.	O

99	O
by	O
different	O
methods	O
.	O

Cleft	O
types	O
(	O
CLP	B-Disease
and	O
CP	B-Disease
)	O
occur	O
in	O
VWS	B-Disease
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	O
non	O
-	O
VWS	O
population	O
,	O
ie	O
,	O
about	O
twice	O
as	O
many	O
cleft	O
-	O
bearing	O
individuals	O
have	O
CLP	B-Disease
as	O
have	O
CP	B-Disease
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	O
excess	O
of	O
females	O
with	O
CP	B-Disease
and	O
excess	O
of	O
males	O
with	O
CLP	B-Disease
;	O
in	O
VWS	B-Disease
the	O
sex	O
ratios	O
are	O
more	O
nearly	O
equal	O
.	O

Lip	B-Disease
pits	I-Disease
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes	O
.	O

Affected	O
males	O
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
VWS	B-Disease
.	O

However	O
,	O
there	O
is	O
an	O
excess	O
of	O
less	O
severely	O
affected	O
individuals	O
among	O
transmitters	O
and	O
a	O
deficiency	O
of	O
more	O
severely	O
affected	O
,	O
brought	O
about	O
by	O
a	O
proband	O
bias	O
and	O
differential	O
fecundity	O
.	O

The	O
expression	O
of	O
VWS	B-Disease
is	O
significantly	O
modified	O
by	O
the	O
genetic	O
background	O
More	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	O
more	O
extreme	O
expression	O
in	O
their	O
children	O
.	O

For	O
a	O
VWS	B-Disease
gene	O
carrier	O
the	O
relative	O
risk	O
of	O
transmitting	O
a	O
cleft	O
is	O
26	O
.	O

45	O
%	O
;	O
that	O
of	O
transmitting	O
lower	O
lip	B-Disease
pits	I-Disease
is	O
23	O
.	O

55	O
%	O
.	O

Three	O
pedigrees	O
of	O
lip	B-Disease
pits	I-Disease
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	O
number	O
of	O
affected	O
individuals	O
.	O

Control	O
of	O
gene	O
expression	O
in	O
VWS	B-Disease
in	O
the	O
three	O
target	O
tissues	O
appears	O
to	O
be	O
independent	O
and	O
separately	O
designated	O
.	O

Mutation	O
rate	O
of	O
the	O
VWS	B-Disease
gene	O
is	O
calculated	O
to	O
be	O
1	O
.	O

8	O
X	O
10	O
(	O
-	O
5	O
)	O

Hereditary	B-Disease
C7	I-Disease
deficiency	I-Disease
.	O

Diagnosis	O
and	O
HLA	O
studies	O
in	O
a	O
French	O
-	O
Canadian	O
family	O
.	O

The	O
serum	O
of	O
a	O
44	O
-	O
yr	O
-	O
old	O
woman	O
of	O
French	O
-	O
Canadian	O
descent	O
having	O
a	O
B	O
-	O
27	O
positive	O
ankylosing	B-Disease
spondylitis	I-Disease
was	O
deficient	B-Disease
in	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C7	O
)	O
as	O
determined	O
by	O
hemolytic	O
and	O
immunochemical	O
methods	O
.	O

No	O
inhibitor	O
against	O
C7	O
was	O
detected	O
,	O
and	O
the	O
levels	O
of	O
all	O
other	O
complement	O
components	O
were	O
normal	O
.	O

No	O
deficiency	O
in	O
the	O
opsonic	O
activity	O
of	O
the	O
serum	O
was	O
found	O
,	O
and	O
the	O
results	O
of	O
basic	O
coagulation	O
studies	O
of	O
the	O
plasma	O
were	O
normal	O
.	O

On	O
investigation	O
of	O
the	O
patients	O
family	O
,	O
two	O
sisters	O
were	O
found	O
to	O
have	O
the	O
same	O
deficiency	O
but	O
were	O
otherwise	O
in	O
good	O
health	O
.	O

The	O
seven	O
other	O
siblings	O
were	O
heterozygous	O
for	O
C7	B-Disease
deficiency	I-Disease
,	O
while	O
the	O
paternal	O
aunt	O
had	O
a	O
normal	O
C7	O
level	O
.	O

In	O
the	O
third	O
generation	O
,	O
six	O
children	O
of	O
the	O
three	O
homozygous	O
sisters	O
and	O
five	O
children	O
of	O
heterozygotes	O
were	O
available	O
for	O
testing	O
.	O

Studies	O
of	O
the	O
HLA	O
antigens	O
in	O
all	O
the	O
22	O
subjects	O
and	O
in	O
three	O
spouses	O
indicated	O
no	O
close	O
linkage	O
between	O
the	O
CM	B-Disease
deficienty	I-Disease
and	O
the	O
HLA	O
system	O
.	O

In	O
addition	O
,	O
the	O
simultaneous	O
occurrence	O
of	O
two	O
hereditary	O
complement	B-Disease
deficiencies	I-Disease
(	I-Disease
C2	I-Disease
and	I-Disease
C7	I-Disease
)	I-Disease
was	O
discovered	O
in	O
one	O
family	O
of	O
this	O
remarkable	O
kindred	O
.	O
.	O

Genetic	O
defect	B-Disease
in	I-Disease
secretion	I-Disease
of	I-Disease
complement	I-Disease
C5	I-Disease
in	O
mice	O
.	O

A	O
genetic	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
(	I-Disease
C5	I-Disease
)	I-Disease
component	I-Disease
of	I-Disease
complement1	I-Disease
-	I-Disease
3	I-Disease
,	O
a	O
serum	O
glycoprotein	O
of	O
molecular	O
weight	O
(	O
MW	O
)	O
220	O
,	O
000	O
(	O
ref	O
.	O
4	O
)	O
,	O
has	O
been	O
found	O
in	O
39	O
%	O
of	O
inbred	O
strains	O
of	O
mice3	O
.	O

Sera	O
of	O
deficient	O
mice	O
lack	O
detectable	O
C5	O
activity	O
and	O
protein2	O
,	O
3	O
.	O

In	O
addition	O
deficient	O
mice	O
produce	O
antibody	O
to	O
mouse	O
C5	O
when	O
injected	O
with	O
sera	O
from	O
C5	O
sufficient	O
(	O
normal	O
)	O
strains	O
.	O

Levy	O
et	O
al	O
.	O

5	O
showed	O
that	O
somatic	O
cell	O
hybrids	O
between	O
C5	O
deficient	O
(	O
B10	O
.	O
D2	O
/	O
old	O
line	O
)	O
macrophages	O
and	O
either	O
C5	O
sufficient	O
(	O
B10	O
.	O
D2	O
/	O
new	O
line	O
)	O
mouse	O
kidney	O
or	O
chicken	O
erythroblasts	O
secreted	O
haemolytically	O
active	O
mouse	O
C5	O
in	O
vitro	O
.	O

Several	O
possible	O
molecular	O
mechanisms	O
to	O
account	O
for	O
the	O
findings	O
were	O
considered	O
,	O
but	O
insufficient	O
direct	O
data	O
were	O
available	O
to	O
choose	O
among	O
them	O
.	O

We	O
recently	O
reported	O
that	O
mouse	O
(	O
CD	O
.	O
1	O
strain	O
)	O
peritoneal	O
cells	O
in	O
culture	O
synthesise	O
and	O
secrete	O
a	O
single	O
chain	O
precursor	O
,	O
pro	O
-	O
C5	O
(	O
MW	O
approximately	O
210	O
,	O
000	O
)	O
,	O
of	O
the	O
two	O
-	O
chain	O
(	O
alpha	O
chain	O
,	O
125	O
,	O
000	O
and	O
beta	O
chain	O
83	O
,	O
000	O
MW	O
)	O
C5	O
protein6	O
.	O

Radiolabelled	O
precursor	O
C5	O
was	O
contained	O
within	O
the	O
cells	O
and	O
was	O
secreted	O
into	O
the	O
tissue	O
culture	O
media	O
.	O

Using	O
similar	O
methods	O
,	O
we	O
now	O
find	O
that	O
C5	B-Disease
deficiency	I-Disease
in	O
each	O
of	O
five	O
different	O
mouse	O
strains	O
(	O
AKR	O
,	O
SWR	O
,	O
DBA	O
/	O
2J8	O
A	O
/	O
HeJ	O
and	O
B10	O
.	O
D2	O
/	O
old	O
line	O
)	O
is	O
due	O
to	O
a	O
failure	O
in	O
secretion	O
of	O
C5	O
protein	O
and	O
not	O
to	O
a	O
failure	O
in	O
biosynthesis	O
of	O
pro	O
-	O
C5	O

Recurrent	O
meningococcal	B-Disease
meningitis	I-Disease
with	O
absence	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
:	O
an	O
evaluation	O
of	O
underlying	O
immunologic	O
mechanisms	O
.	O

A	O
51	O
/	O
2	O
-	O
year	O
-	O
old	O
black	O
girl	O
with	O
recurrent	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
absence	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C6	O
)	O
is	O
reported	O
.	O

To	O
explore	O
the	O
pathogenesis	O
of	O
recurrent	O
neisserial	B-Disease
infections	I-Disease
in	O
C6	B-Disease
deficiency	I-Disease
,	O
a	O
detailed	O
analysis	O
of	O
her	O
immune	O
competence	O
was	O
conducted	O
.	O

Her	O
serum	O
had	O
normal	O
chemotactic	O
,	O
opsonic	O
,	O
alternative	O
complement	O
pathway	O
,	O
and	O
specific	O
antibody	O
activity	O
,	O
but	O
lacked	O
complement	O
-	O
mediated	O
bacteriolytic	O
activity	O
.	O

In	O
addition	O
,	O
her	O
C6	B-Disease
-	I-Disease
deficient	I-Disease
serum	O
was	O
indistinguishable	O
from	O
normal	O
serum	O
in	O
a	O
complement	O
-	O
dependent	O
assay	O
of	O
phagocyte	O
bactericidal	O
activity	O
.	O

Absent	O
bacteriolysis	O
remains	O
the	O
only	O
consistent	O
defect	O
associated	O
with	O
recurrent	O
neisserial	B-Disease
infections	I-Disease
and	O
absence	O
of	O
one	O
of	O
the	O
late	O
-	O
acting	O
complement	O
components	O
.	O
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
human	O
subjects	O
.	O

Clinical	O
,	O
genetic	O
and	O
immunologic	O
studies	O
in	O
a	O
large	O
kindred	O
.	O

The	O
discovery	O
of	O
a	O
large	O
kindred	O
with	O
a	O
heritable	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C5	O
)	O
has	O
permitted	O
the	O
accumulation	O
of	O
new	O
clinical	O
,	O
genetic	O
and	O
immunologic	O
data	O
concerning	O
the	O
role	O
of	O
C5	O
in	O
human	O
subjects	O
.	O

The	O
proband	O
,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	B-Disease
infection	I-Disease
,	O
has	O
a	O
hemolytic	O
C5	O
level	O
of	O
approximately	O
0	O
.	O

5	O
per	O
cent	O
of	O
normal	O
.	O

No	O
C5	O
protein	O
was	O
detectable	O
,	O
but	O
low	O
levels	O
of	O
functional	O
C5	O
activity	O
could	O
be	O
found	O
using	O
a	O
sensitive	O
bactericidal	O
assay	O
.	O

The	O
probands	O
twin	O
as	O
well	O
as	O
another	O
sister	O
also	O
had	O
extremely	O
low	O
levels	O
of	O
hemolytic	O
C5	O
(	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
normal	O
)	O
,	O
but	O
both	O
these	O
subjects	O
have	O
been	O
healthy	O
.	O

Hemolytic	O
complement	O
and	O
bacteriolytic	O
activity	O
could	O
be	O
restored	O
by	O
the	O
addition	O
of	O
purified	O
C5	O
.	O

No	O
chemotactic	O
activity	O
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
C5	B-Disease
-	I-Disease
deficient	I-Disease
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	O
or	O
alternative	O
pathways	O
,	O
again	O
demonstrating	O
the	O
importance	O
of	O
C5	O
in	O
human	O
subjects	O
for	O
the	O
production	O
of	O
chemotactic	O
factors	O
.	O

The	O
chemotactic	O
responsiveness	O
of	O
the	O
patients	O
polymorphonuclear	O
leukocytes	O
and	O
monocytes	O
to	O
preformed	O
chemotactic	O
factors	O
was	O
not	O
depressed	O
.	O

Twenty	O
-	O
two	O
of	O
32	O
other	O
family	O
members	O
from	O
three	O
generations	O
had	O
depressed	O
whole	O
hemolytic	O
complement	O
levels	O
.	O

In	O
19	O
of	O
30	O
family	O
members	O
,	O
levels	O
of	O
hemolytic	O
C5	O
ranged	O
from	O
13	O
to	O
64	O
per	O
cent	O
of	O
normal	O
.	O

No	O
linkage	O
for	O
C5	B-Disease
deficiency	I-Disease
and	O
the	O
A	O
or	O
B	O
loci	O
of	O
the	O
major	O
histocompatibility	O
complex	O
could	O
be	O
found	O
.	O

These	O
data	O
suggest	O
an	O
autosomal	O
codominant	O
mode	O
of	O
inheritance	O
of	O
C5	B-Disease
deficiency	I-Disease
.	O

Deficiency	B-Disease
of	I-Disease
C5	I-Disease
is	O
compatible	O
with	O
good	O
health	O
,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	B-Disease
infection	I-Disease

Incidence	O
and	O
characteristics	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variants	O
in	O
Japan	O
.	O

A	O
total	O
of	O
3000	O
men	O
living	O
in	O
Yamaguchi	O
were	O
screened	O
for	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
using	O
Beutlers	O
spot	O
test	O
and	O
three	O
types	O
of	O
starch	O
gel	O
electrophoresis	O
.	O

These	O
electrophoresis	O
used	O
a	O
phosphate	O
buffer	O
system	O
at	O
pH	O
7	O
.	O

0	O
,	O
a	O
TRIS	O
-	O
EDTA	O
-	O
borate	O
buffer	O
system	O
at	O
pH	O
8	O
.	O

6	O
,	O
and	O
a	O
TRIS	O
-	O
hydrochloride	O
buffer	O
system	O
at	O
pH	O
8	O
.	O
.	O

Fifteen	O
G6PD	B-Disease
-	I-Disease
deficient	I-Disease
variants	O
were	O
found	O
at	O
the	O
rate	O
of	O
0	O
.	O

5	O
%	O
and	O
classified	O
into	O
four	O
groups	O
.	O

As	O
new	O
variants	O
,	O
G6PD	O
Konan	O
,	O
Kamiube	O
,	O
and	O
Kiwa	O
were	O
identified	O
.	O

These	O
three	O
variants	O
had	O
a	O
mild	O
to	O
moderate	O
G6PD	B-Disease
deficiency	I-Disease
and	O
were	O
not	O
associated	O
with	O
any	O
clinical	O
signs	O
.	O

G6PD	O
Konan	O
had	O
fast	O
electrophoretic	O
mobility	O
as	O
compared	O
with	O
normal	O
levels	O
,	O
G6PD	O
Kiwa	O
had	O
slightly	O
elevated	O
electrophoretic	O
mobility	O
,	O
and	O
G6PD	O
Kamiube	O
had	O
normal	O
electrophoretic	O
mobility	O
.	O

These	O
three	O
variants	O
had	O
normal	O
levels	O
of	O
Km	O
G6P	O
,	O
Km	O
NADP	O
,	O
and	O
Ki	O
NADPH	O
,	O
normal	O
utilizations	O
of	O
both	O
2	O
-	O
deoxy	O
-	O
G6P	O
and	O
deamino	O
-	O
NAPD	O
,	O
normal	O
heat	O
stability	O
,	O
and	O
a	O
normal	O
pH	O
curve	O
.	O

The	O
other	O
variant	O
was	O
G6PD	O
Ube	O
,	O
which	O
we	O
had	O
previously	O
found	O
in	O
Yamaguchi	O
(	O
Nakashima	O
et	O
al	O
.	O
,	O
1977	O
)	O
.	O

One	O
boy	O
with	O
G6PD	O
Ube	O
was	O
Korean	O

Utilization	O
of	O
purines	O
by	O
an	O
HPRT	O
variant	O
in	O
an	O
intelligent	O
,	O
nonmutilative	O
patient	O
with	O
features	O
of	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

The	O
patient	O
,	O
H	O
.	O

Chr	O
.	O

B	O
.	O
,	O
was	O
among	O
the	O
first	O
reported	O
with	O
hyperuricemia	B-Disease
and	O
central	B-Disease
nervous	I-Disease
system	I-Disease
symptoms	I-Disease
.	O

He	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
;	O
E	O
.	O
C	O
.	O
2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
distinct	O
from	O
the	O
enzyme	O
present	O
in	O
patients	O
with	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

The	O
patient	O
had	O
chroeoathetosis	B-Disease
,	O
spasticity	B-Disease
,	O
dysarthric	B-Disease
speech	I-Disease
,	O
and	O
hyperuricemia	B-Disease
.	O

However	O
,	O
his	O
intelligence	O
was	O
normal	O
and	O
he	O
had	O
no	O
evidence	O
of	O
self	O
-	O
mutilation	O
.	O

There	O
was	O
no	O
activity	O
of	O
HPRT	O
in	O
the	O
lysates	O
of	O
erythrocytes	O
and	O
cultured	O
fibroblasts	O
when	O
analyzed	O
in	O
the	O
usual	O
manner	O
.	O

Using	O
a	O
newly	O
developed	O
method	O
for	O
the	O
study	O
of	O
purine	O
metabolism	O
in	O
intact	O
cultured	O
cells	O
,	O
this	O
patient	O
was	O
found	O
to	O
metabolize	O
some	O
9	O
%	O
of	O
8	O
-	O
14C	O
-	O
hypoxanthine	O
,	O
and	O
90	O
%	O
of	O
the	O
isotope	O
utilized	O
was	O
converted	O
to	O
adenine	O
and	O
guanine	O
nucleotides	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
patients	O
with	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	O
to	O
nucleotides	O
.	O

The	O
patients	O
fibroblasts	O
were	O
even	O
more	O
efficient	O
in	O
the	O
metabolism	O
of	O
8	O
-	O
14C	O
-	O
guanine	O
,	O
which	O
was	O
utilized	O
to	O
the	O
extent	O
of	O
27	O
%	O
,	O
over	O
80	O
%	O
of	O
which	O
was	O
converted	O
to	O
guanine	O
and	O
adenine	O
nucleotides	O
.	O

The	O
growth	O
of	O
the	O
cultured	O
fibroblasts	O
of	O
this	O
patient	O
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	O
aminopterin	O
thymidine	O
(	O
HAT	O
)	O
,	O
whereas	O
the	O
growth	O
of	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
cells	O
was	O
inhibited	O
and	O
normal	O
cells	O
grew	O
normally	O
.	O

Similarly	O
in	O
8	O
-	O
azaguanine	O
,	O
6	O
-	O
thioguanine	O
,	O
and	O
8	O
-	O
azahypoxanthine	O
,	O
the	O
growth	O
of	O
the	O
patients	O
cells	O
was	O
intermediate	O
between	O
normal	O
and	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
cells	O
.	O

These	O
observations	O
provide	O
further	O
evidence	O
for	O
genetic	O
heterogeneity	O
among	O
patients	O
with	O
disorders	O
in	O
purine	O
metabolism	O
involving	O
the	O
HPRT	O
gene	O
.	O

They	O
document	O
that	O
this	O
famous	O
patient	O
did	O
not	O
have	O
the	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease

Localisation	O
of	O
the	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
DNA	O
sequences	O
.	O

A	O
linkage	O
study	O
in	O
30	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	O
sequences	O
from	O
the	O
X	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
,	O
suggests	O
that	O
the	O
BMD	B-Disease
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
in	O
the	O
p21	O
region	O
.	O

The	O
genes	O
for	O
Becker	B-Disease
and	I-Disease
Duchenne	I-Disease
dystrophies	I-Disease
must	O
therefore	O
be	O
closely	O
linked	O
,	O
if	O
not	O
allelic	O
,	O
and	O
any	O
future	O
DNA	O
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	O
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O

The	O
linkage	O
analysis	O
also	O
provides	O
data	O
on	O
the	O
frequency	O
of	O
recombination	O
along	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
and	O
across	O
the	O
centromeric	O
region	O
.	O
.	O

Molecular	O
evidence	O
for	O
new	O
mutation	O
at	O
the	O
hprt	O
locus	O
in	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
patients	O
.	O

Hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
;	O
EC2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
,	O
which	O
functions	O
in	O
the	O
metabolic	O
salvage	O
of	O
purines	O
,	O
is	O
encoded	O
by	O
an	O
X	O
-	O
linked	O
gene	O
in	O
man	O
.	O

Partial	O
HPRT	B-Disease
deficiencies	I-Disease
are	O
associated	O
with	O
gouty	B-Disease
arthritis	I-Disease
,	O
while	O
absence	O
of	O
activity	O
results	O
in	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
(	O
L	B-Disease
-	I-Disease
N	I-Disease
)	O
.	O

L	B-Disease
-	I-Disease
N	I-Disease
patients	O
fail	O
to	O
reproduce	O
and	O
the	O
heterozygous	O
state	O
appears	O
to	O
confer	O
no	O
selective	O
advantage	O
.	O

Thus	O
,	O
Haldanes	O
principle	O
predicts	O
that	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
must	O
occur	O
frequently	O
in	O
order	O
for	O
L	B-Disease
-	I-Disease
N	I-Disease
syndrome	I-Disease
to	O
be	O
maintained	O
in	O
the	O
population	O
.	O

This	O
constant	O
introduction	O
of	O
new	O
mutations	O
would	O
be	O
expected	O
to	O
result	O
in	O
a	O
heterogeneous	O
collection	O
of	O
genetic	B-Disease
lesions	I-Disease
,	O
some	O
of	O
which	O
may	O
be	O
novel	O
.	O

As	O
we	O
report	O
here	O
,	O
the	O
mutations	O
in	O
the	O
hprt	O
gene	O
of	O
seven	O
L	B-Disease
-	I-Disease
N	I-Disease
patients	O
,	O
selected	O
from	O
an	O
initial	O
survey	O
of	O
28	O
patients	O
,	O
have	O
been	O
characterized	O
and	O
all	O
were	O
found	O
to	O
be	O
distinctly	O
different	O
,	O
as	O
predicted	O
.	O

The	O
origin	O
of	O
one	O
unusual	O
mutation	O
has	O
been	O
identified	O
by	O
analysis	O
of	O
DNA	O
from	O
four	O
generations	O
of	O
family	O
members	O
.	O

Further	O
molecular	O
analysis	O
of	O
the	O
origin	O
of	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
should	O
aid	O
in	O
resolving	O
the	O
issue	O
of	O
an	O
apparent	O
difference	O
in	O
the	O
frequency	O
of	O
hprt	O
mutations	O
in	O
males	O
and	O
females	O

Allelic	O
exclusion	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
T	O
lymphocytes	O
from	O
a	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
carrier	O
.	O

An	O
obligate	O
carrier	O
of	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
who	O
was	O
also	O
heterozygous	O
for	O
the	O
A	O
and	O
B	O
types	O
of	O
X	O
-	O
linked	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
was	O
found	O
.	O

With	O
her	O
it	O
became	O
possible	O
to	O
determine	O
whether	O
allelic	O
exclusion	O
occurs	O
in	O
particular	O
cell	O
-	O
types	O
of	O
the	O
WAS	B-Disease
carrier	O
.	O

If	O
so	O
,	O
the	O
remaining	O
cells	O
of	O
a	O
particular	O
cell	O
-	O
type	O
would	O
express	O
only	O
the	O
normal	O
X	O
chromosome	O
and	O
only	O
one	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
isoenzyme	O
would	O
be	O
demonstrable	O
.	O

This	O
carrier	O
had	O
only	O
the	O
B	O
isoenzyme	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
T	O
lymphocytes	O
,	O
although	O
both	O
isoenzymes	O
A	O
and	O
B	O
were	O
present	O
in	O
erythrocytes	O
and	O
neutrophils	O
.	O

These	O
findings	O
suggest	O
that	O
selection	O
against	O
the	O
WAS	B-Disease
gene	O
occurs	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
T	O
lymphocytes	O
and	O
that	O
the	O
defects	O
associated	O
with	O
WAS	B-Disease
expressed	O
in	O
these	O
cell	O
-	O
types	O
may	O
be	O
implicated	O
in	O
the	O
genesis	O
of	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
.	O
.	O

Complement	B-Disease
deficiency	I-Disease
and	O
nephritis	B-Disease
.	O

A	O
report	O
of	O
a	O
family	O
.	O

A	O
family	O
is	O
described	O
in	O
which	O
three	O
children	O
had	O
homozygous	O
deficiency	B-Disease
of	I-Disease
C3	I-Disease
and	O
in	O
which	O
both	O
parents	O
and	O
two	O
other	O
children	O
were	O
heterozygous	O
for	O
the	O
C3	O
null	O
gene	O
.	O

One	O
child	O
with	O
heterozygous	O
C3	B-Disease
deficiency	I-Disease
was	O
found	O
to	O
have	O
membranoproliferative	O
glomerulonephritis	B-Disease
;	O
proteinuria	B-Disease
and	O
/	O
or	O
microscopical	O
haematuria	B-Disease
was	O
present	O
in	O
all	O
three	O
homozygous	O
C3	B-Disease
-	I-Disease
deficient	I-Disease
children	O
.	O

All	O
children	O
with	O
homozygous	O
or	O
heterozygous	O
C3	B-Disease
deficiency	I-Disease
were	O
,	O
to	O
a	O
varying	O
degree	O
,	O
susceptible	O
to	O
infection	O
.	O

The	O
only	O
child	O
of	O
the	O
family	O
with	O
normal	O
complement	O
had	O
no	O
increased	O
risk	O
of	O
infection	O
and	O
no	O
renal	B-Disease
disease	I-Disease
.	O

This	O
family	O
study	O
provides	O
further	O
support	O
for	O
the	O
proposal	O
that	O
C3	B-Disease
deficiency	I-Disease
predisposes	O
to	O
nephritis	B-Disease
.	O
.	O

Heterogeneity	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
Algeria	O
.	O

Study	O
in	O
Northern	O
Algeria	O
with	O
description	O
of	O
five	O
new	O
variants	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
was	O
found	O
in	O
3	O
.	O

2	O
%	O
of	O
the	O
male	O
population	O
living	O
in	O
the	O
urban	O
area	O
of	O
Algiers	O
.	O

The	O
deficient	O
subjects	O
originated	O
from	O
multiple	O
geographic	O
regions	O
of	O
Northern	O
Algeria	O
,	O
with	O
prevalence	O
of	O
individuals	O
of	O
Berber	O
-	O
Kabyle	O
origin	O
.	O

Red	O
blood	O
cell	O
G6PD	O
was	O
partially	O
purified	O
and	O
characterized	O
in	O
deficient	O
males	O
from	O
17	O
families	O
,	O
and	O
six	O
different	O
variants	O
were	O
found	O
.	O

Among	O
them	O
,	O
only	O
one	O
,	O
the	O
Gd	O
(	O
-	O
)	O
Kabyle	O
variant	O
,	O
had	O
been	O
previously	O
described	O
.	O

It	O
was	O
detected	O
in	O
nine	O
families	O
.	O

The	O
other	O
five	O
variants	O
were	O
new	O
Gd	O
(	O
-	O
)	O
Laghouat	O
(	O
four	O
cases	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Blida	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Thenia	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Titteri	O
(	O
one	O
case	O
)	O
,	O
and	O
Gd	O
(	O
-	O
)	O
Alger	O
(	O
two	O
brothers	O
)	O
.	O

Strikingly	O
,	O
the	O
common	O
Mediterranean	O
variant	O
was	O
not	O
found	O
.	O

G6PD	B-Disease
deficiency	I-Disease
is	O
heterogeneous	O
in	O
northern	O
Algeria	O
where	O
autochtonous	O
variants	O
seem	O
to	O
prevail	O
.	O

The	O
Kabyle	O
variant	O
may	O
be	O
common	O
in	O
this	O
country	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
inhibits	O
in	O
vitro	O
growth	O
of	O
Plasmodium	O
falciparum	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
;	I-Disease
EC	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
1	I-Disease
.	I-Disease
49	I-Disease
)	I-Disease
-	I-Disease
deficient	I-Disease
red	O
blood	O
cells	O
from	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
from	O
the	O
island	O
of	O
Sardinia	O
were	O
studied	O
for	O
their	O
ability	O
to	O
support	O
growth	O
in	O
vitro	O
of	O
the	O
malaria	B-Disease
-	O
causing	O
organism	O
Plasmodium	O
falciparum	O
.	O

Parasite	O
growth	O
was	O
approximately	O
one	O
-	O
third	O
of	O
normal	O
in	O
both	O
hemi	O
-	O
and	O
heterozygotes	O
for	O
G6PD	B-Disease
deficiency	I-Disease
.	O

In	O
Sardinians	O
with	O
the	O
beta	O
0	O
-	O
thalassemia	O
trait	O
,	O
parasite	O
growth	O
was	O
normal	O
except	O
when	O
G6PD	B-Disease
deficiency	I-Disease
occurred	O
together	O
with	O
the	O
thalassemia	B-Disease
trait	O
.	O

The	O
data	O
support	O
the	O
hypothesis	O
that	O
G6PD	B-Disease
deficiency	I-Disease
may	O
confer	O
a	O
selective	O
advantage	O
in	O
a	O
malarious	B-Disease
area	O
;	O
the	O
female	O
heterozygote	O
may	O
be	O
at	O
a	O
particular	O
advantage	O
because	O
resistance	O
to	O
malaria	B-Disease
equals	O
that	O
of	O
male	O
hemizygotes	O
,	O
but	O
the	O
risk	O
of	O
fatal	B-Disease
hemolysis	I-Disease
may	O
be	O
less	O
.	O

However	O
,	O
more	O
female	O
heterozygotes	O
must	O
be	O
studied	O
to	O
confirm	O
this	O
hypothesis	O
.	O

No	O
protective	O
effect	O
of	O
beta	O
0	O
-	O
thalassemia	O
trait	O
could	O
be	O
demonstrated	O
in	O
vitro	O
.	O

Bone	O
marrow	O
transplant	O
in	O
adrenoleukodystrophy	B-Disease
.	O

An	O
allogeneic	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
from	O
a	O
normal	O
HLA	O
identical	O
sibling	O
donor	O
was	O
performed	O
in	O
a	O
13	O
-	O
year	O
-	O
old	O
boy	O
with	O
rapidly	O
progressive	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
.	O

Engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	O
within	O
4	O
weeks	O
,	O
but	O
neurologic	B-Disease
deterioration	I-Disease
continued	O
.	O

The	O
patient	O
died	O
of	O
an	O
adenovirus	B-Disease
infection	I-Disease
141	O
days	O
after	O
BMT	O
.	O

ALD	B-Disease
is	O
characterized	O
by	O
abnormally	O
high	O
plasma	O
levels	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
as	O
a	O
result	O
of	O
impaired	O
capacity	O
to	O
degrade	O
them	O
.	O

Ten	O
days	O
after	O
BMT	O
,	O
the	O
white	O
blood	O
cell	O
VLCFA	O
levels	O
and	O
enzyme	O
activity	O
became	O
normal	O
;	O
after	O
3	O
months	O
,	O
there	O
was	O
progressive	O
reduction	O
of	O
plasma	O
VLCFA	O
to	O
levels	O
only	O
slightly	O
above	O
normal	O
.	O
.	O

[	O
Gd	O
-	O
allele	O
distribution	O
patterns	O
in	O
Azerbaijan	O
.	O
III	O
.	O
The	O
identification	O
of	O
mutant	O
forms	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
]	O

In	O
28	O
families	O
with	O
G6PD	B-Disease
deficiency	I-Disease
living	O
in	O
3	O
settlements	O
of	O
Shekii	O
district	O
of	O
Azerbaijan	O
11	O
G6PD	O
variants	O
of	O
II	O
and	O
III	O
classes	O
differing	O
by	O
kinetic	O
properties	O
were	O
identified	O
according	O
WHO	O
program	O
.	O

9	O
of	O
them	O
are	O
characterized	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
.	O

Comparison	O
of	O
G6PD	O
spectra	O
in	O
two	O
subpopulations	O
and	O
in	O
a	O
mixed	O
group	O
permits	O
to	O
make	O
a	O
conclusion	O
about	O
existence	O
of	O
common	O
and	O
rare	O
G6PD	O
alleles	O
in	O
examined	O
population	O
.	O

They	O
distribute	O
by	O
gene	O
drift	O
supported	O
by	O
natural	O
selection	O
.	O

Among	O
7	O
samples	O
of	O
G6PD	O
with	O
normal	O
and	O
increased	O
activity	O
two	O
new	O
variants	O
of	O
IV	O
class	O
-	O
-	O
Nukha	O
and	O
Bash	O
-	O
Kungut	O
-	O
-	O
were	O
found	O
.	O
.	O

Adrenoleukodystrophy	B-Disease
:	O
survey	O
of	O
303	O
cases	O
:	O
biochemistry	O
,	O
diagnosis	O
,	O
and	O
therapy	O
.	O

Adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
is	O
a	O
genetically	O
determined	O
disorder	O
associated	O
with	O
progressive	B-Disease
central	I-Disease
demyelination	I-Disease
and	O
adrenal	B-Disease
cortical	I-Disease
insufficiency	I-Disease
.	O

All	O
affected	O
persons	O
show	O
increased	O
levels	O
of	O
saturated	O
unbranched	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
particularly	O
hexacosanoate	O
(	O
C26	O
0	O
)	O
,	O
because	O
of	O
impaired	O
capacity	O
to	O
degrade	O
these	O
acids	O
.	O

This	O
degradation	O
normally	O
takes	O
place	O
in	O
a	O
subcellular	O
organelle	O
called	O
the	O
peroxisome	O
,	O
and	O
ALD	B-Disease
,	O
together	O
with	O
Zellwegers	B-Disease
cerebrohepatorenal	I-Disease
syndrome	I-Disease
,	O
is	O
now	O
considered	O
to	O
belong	O
to	O
the	O
newly	O
formed	O
category	O
of	O
peroxisomal	B-Disease
disorders	I-Disease
.	O

Biochemical	O
assays	O
permit	O
prenatal	O
diagnosis	O
,	O
as	O
well	O
as	O
identification	O
of	O
most	O
heterozygotes	O
.	O

We	O
have	O
identified	O
303	O
patients	O
with	O
ALD	B-Disease
in	O
217	O
kindreds	O
.	O

These	O
patients	O
show	O
a	O
wide	O
phenotypic	O
variation	O
.	O

Sixty	O
percent	O
of	O
patients	O
had	O
childhood	O
ALD	B-Disease
and	O
17	O
%	O
adrenomyeloneuropathy	B-Disease
,	O
both	O
of	O
which	O
are	O
X	O
-	O
linked	O
,	O
with	O
the	O
gene	O
mapped	O
to	O
Xq28	O
.	O

Neonatal	B-Disease
ALD	I-Disease
,	O
a	O
distinct	O
entity	O
with	O
autosomal	O
recessive	O
inheritance	O
and	O
points	O
of	O
resemblance	O
to	O
Zellwegers	B-Disease
syndrome	I-Disease
,	O
accounted	O
for	O
7	O
%	O
of	O
the	O
cases	O
.	O

Although	O
excess	O
C26	O
0	O
in	O
the	O
brain	O
of	O
patients	O
with	O
ALD	B-Disease
is	O
partially	O
of	O
dietary	O
origin	O
,	O
dietary	O
C26	O
0	O
restriction	O
did	O
not	O
produce	O
clear	O
benefit	O
.	O

Bone	O
marrow	O
transplant	O
lowered	O
the	O
plasma	O
C26	O
0	O
level	O
but	O
failed	O
to	O
arrest	O
neurological	O
progression	O
.	O
.	O

Genetic	O
polymorphism	O
of	O
G6PD	O
in	O
a	O
Bulgarian	O
population	O
.	O

Considerable	O
genetic	O
heterogeneity	O
in	O
G6PD	O
was	O
found	O
in	O
the	O
Bulgarian	O
population	O
-	O
14	O
G6PD	O
variants	O
isolated	O
from	O
117	O
hemizygous	O
carriers	O
of	O
G6PD	B-Disease
deficiency	I-Disease
.	O

Of	O
these	O
,	O
G6PD	O
Mediterranean	O
type	O
was	O
a	O
polymorphic	O
variant	O
and	O
G6PD	O
Corinth	O
occurred	O
with	O
high	O
frequency	O
.	O

Two	O
new	O
variants	O
were	O
identified	O
-	O
G6PD	O
Rudosem	O
and	O
G6PD	O
Nedelino	O
.	O

In	O
a	O
selected	O
group	O
of	O
78	O
subjects	O
with	O
clinical	O
manifestations	O
,	O
four	O
variants	O
were	O
established	O
G6PD	O
Mediterranian	O
,	O
G6PD	O
Corinth	O
,	O
G6PD	O
Seattle	O
and	O
G6PD	O
Ohut	O
II	O
.	O
.	O

Clinical	O
use	O
of	O
DNA	O
markers	O
linked	O
to	O
the	O
gene	O
for	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Seventy	O
families	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
known	O
to	O
the	O
Institute	O
of	O
Child	O
Health	O
fall	O
into	O
three	O
categories	O
with	O
respect	O
to	O
potential	O
linkage	O
analysis	O
with	O
the	O
X	O
chromosome	O
DNA	O
markers	O
RC8	O
and	O
L1	O
.	O

28	O
that	O
bridge	O
the	O
DMD	B-Disease
gene	O
.	O

Families	O
in	O
which	O
there	O
is	O
at	O
least	O
one	O
obligatory	O
female	O
heterozygote	O
(	O
n	O
=	O
13	O
)	O
.	O

Here	O
prediction	O
and	O
exclusion	O
of	O
DMD	B-Disease
gene	O
transmission	O
may	O
be	O
possible	O
,	O
the	O
accuracy	O
being	O
dependent	O
on	O
the	O
closeness	O
of	O
the	O
linkage	O
of	O
the	O
DNA	O
marker	O
(	O
s	O
)	O
to	O
the	O
DMD	B-Disease
gene	O
;	O
an	O
illustrative	O
case	O
is	O
reported	O
.	O

Families	O
in	O
which	O
there	O
is	O
a	O
single	O
affected	O
boy	O
,	O
who	O
also	O
has	O
one	O
or	O
more	O
healthy	O
brothers	O
(	O
n	O
=	O
26	O
)	O
.	O

Given	O
an	O
informative	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
,	O
the	O
probability	O
that	O
the	O
boy	O
represents	O
a	O
new	O
mutation	O
can	O
be	O
reassessed	O
;	O
it	O
is	O
also	O
possible	O
to	O
exclude	O
the	O
DMD	B-Disease
gene	O
in	O
a	O
sister	O
.	O

Families	O
with	O
a	O
single	O
affected	O
boy	O
with	O
no	O
brother	O
(	O
n	O
=	O
30	O
)	O
.	O

Here	O
exclusion	O
of	O
the	O
DMD	B-Disease
gene	O
in	O
a	O
sister	O
may	O
be	O
possible	O
.	O

Only	O
in	O
one	O
family	O
was	O
there	O
no	O
possibility	O
of	O
useful	O
linkage	O
analysis	O
.	O

The	O
linkage	O
analysis	O
required	O
is	O
described	O
,	O
and	O
the	O
need	O
to	O
check	O
DMD	B-Disease
families	O
for	O
informative	O
RFLPs	O
is	O
stressed	O
.	O

Family	O
studies	O
in	O
Bechterew	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
(	O
ankylosing	B-Disease
spondylitis	I-Disease
)	O
III	O
.	O

Genetics	O
.	O

The	O
results	O
of	O
segregation	O
analyses	O
in	O
75	O
families	O
where	O
the	O
proband	O
had	O
ankylosing	B-Disease
spondylitis	I-Disease
,	O
are	O
presented	O
.	O

Of	O
the	O
278	O
adult	O
,	O
living	O
first	O
degree	O
relatives	O
,	O
approximately	O
85	O
%	O
cooperated	O
in	O
the	O
study	O
.	O

Clinical	O
and	O
radiographical	O
examinations	O
were	O
performed	O
and	O
HLA	O
typing	O
was	O
conducted	O
.	O

The	O
results	O
were	O
in	O
agreement	O
with	O
our	O
hypothesis	O
that	O
ankylosing	B-Disease
spondylitis	I-Disease
is	O
part	O
of	O
a	O
syndrome	O
where	O
different	O
genetic	O
factors	O
interact	O
.	O

Such	O
known	O
factors	O
are	O
HLA	O
B27	O
associated	O
disease	O
susceptibility	O
,	O
susceptibility	O
to	O
psoriatic	B-Disease
arthropathy	I-Disease
and	O
susceptibility	O
to	O
entero	B-Disease
-	I-Disease
arthropathy	I-Disease
.	O

Radiographical	O
sacro	B-Disease
-	I-Disease
iliitis	I-Disease
was	O
restricted	O
to	O
HLA	O
B27	O
positive	O
relatives	O
,	O
and	O
was	O
more	O
frequently	O
found	O
in	O
relatives	O
to	O
probands	O
with	O
psoriasis	B-Disease
than	O
in	O
relatives	O
to	O
probands	O
without	O
psoriasis	B-Disease
.	O

Environmental	O
factors	O
(	O
intestinal	O
bacteria	O
)	O
are	O
known	O
to	O
trigger	O
the	O
disease	O
at	O
least	O
in	O
some	O
persons	O
,	O
and	O
we	O
have	O
postulated	O
that	O
all	O
or	O
most	O
of	O
them	O
have	O
the	O
predisposition	O
to	O
develop	O
disease	O
.	O

Thus	O
,	O
the	O
syndrome	O
has	O
a	O
multifactorial	O
etiology	O
.	O

The	O
phenotypic	O
expressions	O
of	O
the	O
different	O
genetic	O
predispositions	O
involved	O
,	O
include	O
sacro	B-Disease
-	I-Disease
iliitis	I-Disease
,	O
psoriasis	B-Disease
,	O
acute	B-Disease
anterior	I-Disease
uveitis	I-Disease
,	O
peripheral	O
arthropathy	B-Disease
and	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
.	O

We	O
suggest	O
the	O
descriptive	O
name	O
HEREDITARY	B-Disease
MULTIFOCAL	I-Disease
RELAPSING	I-Disease
INFLAMMATION	I-Disease
(	O
HEMRI	B-Disease
)	O
for	O
this	O
syndrome	O
.	O

Ankylosing	B-Disease
spondylitis	I-Disease
,	O
psoriatic	B-Disease
arthropathy	I-Disease
and	O
entero	B-Disease
-	I-Disease
arthropathy	I-Disease
may	O
be	O
regarded	O
as	O
clinical	O
sub	O
-	O
types	O
of	O
the	O
syndrome	O
.	O
.	O

Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
and	O
chromosome	O
15	O
.	O

A	O
clinical	O
discussion	O
of	O
20	O
cases	O
.	O

A	O
chromosome	B-Disease
15	I-Disease
anomaly	I-Disease
was	O
observed	O
in	O
12	O
of	O
20	O
patients	O
,	O
17	O
of	O
whom	O
were	O
clinically	O
suspected	O
of	O
having	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

The	O
clinical	O
features	O
of	O
eight	O
cases	O
with	O
15q11	O
-	O
12	O
deletion	O
were	O
very	O
similar	O
to	O
those	O
originally	O
described	O
in	O
PWS	B-Disease
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
group	O
of	O
normal	O
karyotype	O
patients	O
is	O
heterogeneous	O
,	O
and	O
their	O
features	O
do	O
not	O
strictly	O
correspond	O
to	O
the	O
clinical	O
definition	O
of	O
PWS	B-Disease
.	O

However	O
,	O
the	O
hypothesis	O
that	O
PWS	B-Disease
is	O
associated	O
with	O
deletion	O
of	O
15q11	O
-	O
12	O
can	O
neither	O
explain	O
the	O
apparently	O
balanced	O
translocations	O
of	O
chromosome	O
15	O
nor	O
account	O
for	O
the	O
small	O
supernumerary	O
metacentric	O
chromosomes	O
corresponding	O
to	O
an	O
isochromosome	O
15	O
for	O
band	O
15q11	O
observed	O
in	O
some	O
cases	O
.	O
.	O

The	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
gene	O
in	O
North	O
American	O
Jewish	O
populations	O
:	O
geographic	O
variations	O
and	O
origin	O
.	O

From	O
data	O
collected	O
in	O
a	O
North	O
American	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
heterozygote	O
screening	O
program	O
,	O
the	O
TSD	B-Disease
carrier	O
frequency	O
among	O
46	O
,	O
304	O
Jewish	O
individuals	O
was	O
found	O
to	O
be	O
.	O

0324	O
(	O
1	O
in	O
31	O
individuals	O
)	O
.	O

This	O
frequency	O
is	O
consistent	O
with	O
earlier	O
estimates	O
based	O
on	O
TSD	B-Disease
incidence	O
data	O
.	O

TSD	B-Disease
carrier	O
frequencies	O
were	O
then	O
examined	O
by	O
single	O
country	O
and	O
single	O
region	O
of	O
origin	O
in	O
28	O
,	O
029	O
Jews	O
within	O
this	O
sample	O
for	O
whom	O
such	O
data	O
were	O
available	O
for	O
analysis	O
.	O

Jews	O
with	O
Polish	O
and	O
/	O
or	O
Russian	O
ancestry	O
constituted	O
88	O
%	O
of	O
this	O
sample	O
and	O
had	O
a	O
TSD	B-Disease
carrier	O
frequency	O
of	O
.	O

0327	O
.	O

No	O
TSD	B-Disease
carriers	O
were	O
observed	O
among	O
the	O
166	O
Jews	O
of	O
Near	O
Eastern	O
origins	O
.	O

Relative	O
to	O
Jews	O
of	O
Polish	O
and	O
Russian	O
origins	O
,	O
there	O
was	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
the	O
TSD	B-Disease
carrier	O
frequency	O
in	O
Jews	O
of	O
Austrian	O
,	O
Hungarian	O
,	O
and	O
Czechoslovakian	O
origins	O
(	O
P	O
less	O
than	O
.	O
005	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
TSD	B-Disease
gene	O
proliferated	O
among	O
the	O
antecedents	O
of	O
modern	O
Ashkenazi	O
Jewry	O
after	O
the	O
Second	O
Diaspora	O
(	O
70	O
A	O
.	O
D	O
.	O
)	O
and	O
before	O
their	O
major	O
migrations	O
to	O
regions	O
of	O
Poland	O
and	O
Russia	O
(	O
before	O
1100	O
A	O
.	O
D	O
.	O
)	O
.	O

Human	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
a	O
patient	O
with	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
no	O
haemostasis	B-Disease
abnormality	I-Disease
.	O

A	O
case	O
of	O
human	O
complete	O
C6	B-Disease
deficiency	I-Disease
is	O
reported	O
.	O

The	O
patient	O
,	O
a	O
31	O
year	O
old	O
white	O
male	O
,	O
was	O
seen	O
on	O
the	O
occasion	O
of	O
an	O
isolated	O
episode	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
.	O

Serum	O
complement	O
hemolytic	O
and	O
bactericidal	O
activities	O
were	O
lacking	O
and	O
could	O
be	O
restored	O
to	O
normal	O
by	O
addition	O
of	O
appropriate	O
amounts	O
of	O
purified	O
C6	O
.	O

No	O
hemostatic	B-Disease
abnormalities	I-Disease
were	O
observed	O
.	O
.	O

Absence	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
a	O
patient	O
with	O
chronic	B-Disease
meningococcemia	I-Disease
presenting	O
as	O
vasculitis	B-Disease
.	O

A	O
previously	O
healthy	O
40	O
-	O
year	O
-	O
old	O
man	O
presenting	O
with	O
fever	B-Disease
,	O
arthritis	B-Disease
,	O
and	O
cutaneous	B-Disease
vasculitis	I-Disease
was	O
found	O
to	O
have	O
chronic	B-Disease
meningococcemia	I-Disease
.	O

Evaluation	O
of	O
his	O
complement	O
system	O
showed	O
an	O
absence	O
of	O
functional	O
and	O
antigenic	O
C7	O
,	O
compatible	O
with	O
a	O
complete	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
.	O

Study	O
of	O
the	O
patients	O
family	O
spanning	O
four	O
generations	O
showed	O
heterozygous	O
deficiency	B-Disease
of	I-Disease
C7	I-Disease
in	O
five	O
members	O
.	O

Chronic	B-Disease
neisserial	I-Disease
infection	I-Disease
can	O
be	O
associated	O
with	O
C7	B-Disease
deficiency	I-Disease
and	O
must	O
be	O
distinguished	O
from	O
other	O
causes	O
of	O
cutaneous	B-Disease
vasculitis	I-Disease
.	O
.	O

Familial	B-Disease
discoid	I-Disease
lupus	I-Disease
erythematosus	I-Disease
associated	O
with	O
heterozygote	O
C2	B-Disease
deficiency	I-Disease
.	O

Two	O
siblings	O
with	O
chronic	B-Disease
discoid	I-Disease
lupus	I-Disease
erythematosus	I-Disease
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
C2	B-Disease
deficiency	I-Disease
.	O

An	O
association	O
with	O
histocompatibility	O
markers	O
HLA	O
-	O
B18	O
and	O
HLA	O
-	O
Dw2	O
was	O
demonstrated	O
,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	O
B	O
was	O
present	O
.	O

Linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
C2	B-Disease
deficiency	I-Disease
gene	O
and	O
genes	O
coding	O
for	O
B18	O
,	O
Dw2	O
,	O
and	O
BfS	O
antigens	O
.	O

One	O
HLA	O
-	O
ACB	O
/	O
DBf	O
recombinant	O
was	O
observed	O
showing	O
closer	O
linkage	O
between	O
HLA	O
-	O
D	O
and	O
Bf	O
than	O
between	O
HLA	O
-	O
B	O
and	O
Bf	O
.	O
.	O

Severe	B-Disease
-	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
associated	O
with	O
chronic	O
hemolytic	B-Disease
anemia	I-Disease
,	O
granulocyte	B-Disease
dysfunction	I-Disease
,	O
and	O
increased	O
susceptibility	O
to	O
infections	O
:	O
description	O
of	O
a	O
new	O
molecular	O
variant	O
(	O
G6PD	O
Barcelona	O
)	O
.	O

Molecular	O
,	O
kinetic	O
,	O
and	O
functional	O
studies	O
were	O
carried	O
out	O
on	O
erythrocytes	O
and	O
leukocytes	O
in	O
a	O
Spanish	O
male	O
with	O
G6PD	B-Disease
deficiency	I-Disease
,	O
congenital	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
CNSHA	B-Disease
)	O
,	O
and	O
increased	O
susceptibility	O
to	O
infections	O
.	O

G6PD	O
activity	O
was	O
absent	O
in	O
patients	O
red	O
cells	O
and	O
was	O
about	O
2	O
%	O
of	O
normal	O
in	O
leukocytes	O
.	O

Molecular	O
studies	O
using	O
standard	O
methods	O
(	O
WHO	O
,	O
1967	O
)	O
showed	O
G6PD	O
in	O
the	O
patient	O
to	O
have	O
a	O
slightly	O
fast	O
electrophoretic	O
mobility	O
at	O
pH	O
8	O
.	O

0	O
with	O
otherwise	O
normal	O
properties	O
(	O
heat	O
stability	O
at	O
46	O
degrees	O
C	O
,	O
apparent	O
affinity	O
for	O
substrates	O
,	O
optimum	O
pH	O
,	O
and	O
utilization	O
of	O
substrate	O
analogues	O
)	O
.	O

Other	O
tests	O
showed	O
the	O
patients	O
granulocytes	O
to	O
engulf	O
latex	O
particles	O
normally	O
,	O
but	O
to	O
have	O
impaired	O
reduction	O
of	O
nitroblue	O
tetrazolium	O
and	O
ferricytochrome	O
-	O
c	O
as	O
well	O
as	O
reduced	O
iodination	O
.	O

Chemotaxis	O
and	O
random	O
migration	O
of	O
the	O
patients	O
granulocytes	O
were	O
normal	O
as	O
were	O
myeloperoxidase	O
,	O
leukocyte	O
alkaline	O
phosphatase	O
(	O
LAP	O
)	O
,	O
and	O
ultrastructural	O
features	O
.	O

The	O
molecular	O
characteristics	O
of	O
G6PD	O
in	O
the	O
patient	O
differed	O
from	O
those	O
of	O
all	O
previously	O
reported	O
variants	O
associated	O
with	O
CNSHA	B-Disease
,	O
so	O
the	O
present	O
variant	O
was	O
provisionally	O
called	O
G6PD	O
Barcelona	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	O
variants	O
previously	O
described	O
.	O

Possible	O
mechanisms	O
for	O
the	O
severe	O
deficiency	B-Disease
of	I-Disease
G6PD	I-Disease
in	O
erythrocytes	O
and	O
granulocytes	O
was	O
investigated	O
by	O
studies	O
on	O
the	O
immunologic	O
specific	O
activity	O
of	O
the	O
mutant	O
enzyme	O
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
Papua	O
New	O
Guinea	O
.	O

The	O
description	O
of	O
13	O
new	O
variants	O
.	O

A	O
total	O
of	O
362	O
males	O
from	O
various	O
regions	O
of	O
Papua	O
New	O
Guinea	O
were	O
screened	O
for	O
red	O
cell	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
activity	O
.	O

Twenty	O
-	O
six	O
G6PD	B-Disease
deficient	I-Disease
individuals	O
were	O
identified	O
.	O

Biochemical	O
characterization	O
of	O
G6PD	O
purified	O
from	O
these	O
subjects	O
has	O
revealed	O
13	O
new	O
variants	O
and	O
several	O
copies	O
of	O
previously	O
described	O
forms	O
of	O
G6PD	O
.	O

This	O
study	O
illustrates	O
the	O
extreme	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
among	O
the	O
people	O
of	O
Papua	O
New	O
Guinea	O
.	O
.	O

Heterogeneity	O
of	O
"	O
Mediterranean	O
type	O
"	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
Spain	O
and	O
description	O
of	O
two	O
new	O
variants	O
associated	O
with	O
favism	B-Disease
.	O

Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
;	O
EC	O
1	O
.	O

1	O
.	O

1	O
.	O

49	O
from	O
thirty	O
-	O
six	O
unrelated	O
Spanish	O
males	O
was	O
partially	O
purified	O
from	O
blood	O
,	O
and	O
the	O
variants	O
were	O
characterized	O
biochemically	O
and	O
electrophoretically	O
according	O
to	O
the	O
methods	O
recommended	O
by	O
the	O
world	O
Health	O
Organization	O
.	O

Subjects	O
were	O
from	O
multiple	O
geographic	O
regions	O
within	O
Spain	O
,	O
and	O
all	O
suffered	O
from	O
hemolytic	B-Disease
anemia	I-Disease
,	O
either	O
acute	O
(	O
34	O
cases	O
)	O
or	O
chronic	O
nonspherocytic	O
(	O
2	O
cases	O
)	O
.	O

Almost	O
all	O
the	O
variants	O
studied	O
presented	O
residual	O
erythrocyte	O
G6PD	O
activity	O
ranging	O
from	O
0	O
to	O
10	O
%	O
of	O
normal	O
,	O
and	O
five	O
different	O
mutants	O
were	O
responsible	O
for	O
the	O
deficient	O
phenotype	O
.	O

Three	O
variants	O
were	O
similar	O
to	O
others	O
previously	O
described	O
G6PD	O
Mediterranean	O
(	O
11	O
cases	O
)	O
,	O
G6PD	O
Athens	O
-	O
like	O
(	O
3	O
cases	O
)	O
,	O
and	O
G6PD	O
Union	O
(	O
2	O
cases	O
)	O
.	O

The	O
remaining	O
variants	O
were	O
different	O
from	O
the	O
numerous	O
variants	O
already	O
reported	O
and	O
have	O
been	O
considered	O
as	O
new	O
mutants	O
.	O

Provisionally	O
they	O
are	O
called	O
G6PD	O
Betica	O
(	O
19	O
cases	O
)	O
and	O
G6PD	O
Menorca	O
(	O
1	O
case	O
)	O
.	O

The	O
present	O
study	O
constitutes	O
the	O
first	O
attempt	O
to	O
characterize	O
the	O
deficient	B-Disease
G6PD	I-Disease
variants	O
found	O
in	O
Spain	O
and	O
supplies	O
new	O
data	O
on	O
the	O
relationship	O
between	O
molecular	O
characteristics	O
of	O
deficient	O
variants	O
and	O
their	O
clinical	O
manifestations	O
.	O

The	O
most	O
important	O
findings	O
can	O
be	O
summarized	O
as	O
follows	O
(	O
1	O
)	O
The	O
Spanish	O
population	O
is	O
characterized	O
by	O
an	O
important	O
heterogeneity	O
in	O
G6PD	B-Disease
deficiency	I-Disease
.	O

(	O
2	O
)	O
Although	O
G6PD	O
Mediterranean	O
is	O
very	O
frequent	O
,	O
it	O
presents	O
a	O
relatively	O
high	O
degree	O
of	O
polymorphism	O
.	O

(	O
3	O
)	O
Favism	B-Disease
has	O
been	O
observed	O
associated	O
with	O
all	O
kinds	O
of	O
variants	O
described	O
here	O
.	O

(	O
4	O
)	O
G6PD	O
Betica	O
,	O
which	O
is	O
the	O
most	O
frequent	O
variant	O
found	O
in	O
subjects	O
of	O
Southern	O
Spanish	O
origin	O
,	O
has	O
been	O
observed	O
associated	O
with	O
favism	B-Disease
in	O
all	O
cases	O
except	O
one	O
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variant	O
(	O
G6PD	O
Nagano	O
)	O
associated	O
with	O
congenital	B-Disease
hemolytic	I-Disease
anemia	I-Disease
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
variant	O
associated	O
with	O
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
was	O
reported	O
.	O

The	O
patient	O
,	O
a	O
6	O
-	O
year	O
-	O
old	O
Japanese	O
male	O
,	O
was	O
noticed	O
to	O
have	O
hemolytic	B-Disease
anemia	I-Disease
soon	O
after	O
birth	O
,	O
and	O
a	O
diagnosis	O
of	O
G6PD	B-Disease
deficiency	I-Disease
was	O
made	O
at	O
the	O
age	O
of	O
2	O
.	O

He	O
had	O
episodes	O
of	O
hemolytic	B-Disease
crisis	I-Disease
several	O
times	O
after	O
upper	B-Disease
respiratory	I-Disease
infection	I-Disease
.	O

G6PD	O
activity	O
of	O
the	O
patient	O
was	O
5	O
.	O

5	O
%	O
of	O
normal	O
.	O

The	O
enzymatic	O
characteristics	O
were	O
examined	O
when	O
he	O
was	O
5	O
years	O
old	O
,	O
and	O
his	O
G6PD	O
showed	O
faster	O
-	O
than	O
-	O
normal	O
electrophoretic	O
mobility	O
,	O
low	O
Km	O
G6P	O
,	O
high	O
Km	O
NADP	O
,	O
low	O
Ki	O
NADPH	O
,	O
normal	O
utilization	O
of	O
substrate	O
analogues	O
,	O
heat	O
instability	O
,	O
and	O
a	O
normal	O
pH	O
optimum	O
curve	O
.	O

From	O
these	O
results	O
,	O
this	O
was	O
considered	O
to	O
be	O
a	O
new	O
variant	O
and	O
was	O
designated	O
G6PD	O
Nagano	O
.	O

Infection	O
-	O
induced	O
hemolysis	B-Disease
and	O
chronic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
seem	O
to	O
be	O
due	O
to	O
markedly	O
impaired	O
enzyme	O
activity	O
and	O
thermal	O
instability	O
.	O

Heterozygous	O
C2	B-Disease
-	I-Disease
deficiency	I-Disease
and	O
myasthenia	B-Disease
gravis	I-Disease
.	O

Complement	B-Disease
deficiency	I-Disease
states	O
in	O
myasthenia	B-Disease
gravis	I-Disease
(	O
MG	B-Disease
)	O
have	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
a	O
19	O
-	O
year	O
-	O
old	O
woman	O
with	O
typical	O
MG	B-Disease
and	O
heterozygous	O
C2	B-Disease
deficiency	I-Disease
,	O
along	O
with	O
HLA	O
typing	O
of	O
the	O
patient	O
and	O
her	O
immediate	O
family	O
.	O
.	O

Adrenoleukodystrophy	B-Disease
:	O
increased	O
plasma	O
content	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
.	O

With	O
a	O
new	O
method	O
we	O
measured	O
the	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
the	O
plasma	O
of	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
hemizygotes	O
,	O
ALD	B-Disease
heterozygotes	O
,	O
and	O
controls	O
.	O

ALD	B-Disease
hemizygotes	O
showed	O
increased	O
levels	O
of	O
hexacosanoate	O
(	O
C26	O
fatty	O
acid	O
)	O
which	O
represented	O
0	O
.	O

081	O
+	O
/	O
-	O
0	O
.	O

0066	O
%	O
(	O
SEM	O
)	O
of	O
total	O
fatty	O
acids	O
,	O
compared	O
to	O
0	O
.	O

015	O
+	O
/	O
-	O
0	O
.	O

0032	O
%	O
in	O
the	O
controls	O
.	O

C25	O
,	O
C24	O
,	O
and	O
C23	O
fatty	O
acids	O
were	O
also	O
increased	O
,	O
but	O
the	O
C22	O
and	O
C20	O
fatty	O
acids	O
were	O
normal	O
.	O

C26	O
levels	O
were	O
also	O
increased	O
in	O
most	O
ALD	B-Disease
heterozygotes	O
,	O
with	O
a	O
mean	O
level	O
0	O
.	O

057	O
+	O
/	O
-	O
0	O
.	O

0063	O
%	O
of	O
total	O
fatty	O
acids	O
.	O

The	O
technique	O
can	O
be	O
used	O
for	O
diagnosis	O
and	O
carrier	O
identification	O
,	O
and	O
in	O
the	O
evaluation	O
of	O
therapy	O
.	O

Abnormal	O
high	O
density	O
lipoproteins	O
in	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
.	O

The	O
plasma	O
lipoprotein	O
profiles	O
and	O
high	O
density	O
lipoproteins	O
(	O
HDL	O
)	O
were	O
characterized	O
in	O
patients	O
with	O
the	O
genetic	B-Disease
disease	I-Disease
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

Abnormalities	B-Disease
in	I-Disease
the	I-Disease
HDL	I-Disease
may	O
contribute	O
to	O
their	O
increased	O
atherogenesis	O
and	O
excessive	O
deposits	O
of	O
tissue	O
sterols	O
in	O
the	O
presence	O
of	O
low	O
or	O
low	O
-	O
normal	O
concentrations	O
of	O
plasma	O
cholesterol	O
(	O
165	O
+	O
/	O
-	O
25	O
mg	O
/	O
dl	O
)	O
and	O
low	O
density	O
lipoproteins	O
(	O
LDL	O
)	O
.	O

The	O
mean	O
HDL	O
-	O
cholesterol	O
concentration	O
in	O
the	O
CTX	B-Disease
plasmas	O
was	O
14	O
.	O

5	O
+	O
/	O
-	O
3	O
.	O

2	O
mg	O
/	O
dl	O
,	O
about	O
one	O
-	O
third	O
the	O
normal	O
value	O
.	O

The	O
low	O
HDL	O
-	O
cholesterol	O
reflects	O
a	O
low	O
concentration	O
and	O
an	O
abnormal	O
lipid	O
composition	O
of	O
the	O
plasma	O
HDL	O
.	O

Relative	O
to	O
normal	O
HDL	O
,	O
the	O
cholesteryl	O
esters	O
are	O
low	O
,	O
free	O
cholesterol	O
and	O
phospholipids	O
essentially	O
normal	O
,	O
and	O
triglycerides	O
increased	O
.	O

The	O
ratio	O
of	O
apoprotein	O
(	O
apo	O
)	O
to	O
total	O
cholesterol	O
in	O
the	O
HDL	O
of	O
CTX	B-Disease
was	O
two	O
to	O
three	O
times	O
greater	O
than	O
normal	O
.	O

In	O
the	O
CTX	B-Disease
HDL	O
,	O
the	O
ratio	O
of	O
apoAI	O
to	O
apoAII	O
was	O
high	O
,	O
the	O
proportion	O
of	O
apoC	O
low	O
,	O
and	O
a	O
normally	O
minor	O
form	O
of	O
apoAI	O
increased	O
relative	O
to	O
other	O
forms	O
.	O

The	O
HDL	O
in	O
electron	O
micrographs	O
appeared	O
normal	O
morphologically	O
and	O
in	O
particle	O
size	O
.	O

The	O
abnormalities	O
in	O
lipoprotein	O
distribution	O
profile	O
and	O
composition	O
of	O
the	O
plasma	O
HDL	O
result	O
from	O
metabolic	O
defects	O
that	O
are	O
not	O
understood	O
but	O
may	O
be	O
linked	O
to	O
the	O
genetic	B-Disease
defect	I-Disease
in	O
bile	O
acid	O
synthesis	O
in	O
CTX	B-Disease
.	O

As	O
a	O
consequence	O
,	O
it	O
is	O
probable	O
that	O
the	O
normal	O
functions	O
of	O
the	O
HDL	O
,	O
possibly	O
including	O
modulation	O
of	O
LDL	O
-	O
cholesterol	O
uptake	O
and	O
the	O
removal	O
of	O
excess	O
cholesterol	O
from	O
peripheral	O
tissues	O
,	O
are	O
perturbed	O
significantly	O
in	O
this	O
disease	O
.	O

Genetics	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
:	O
an	O
autosomal	O
recessive	O
trait	O
with	O
high	O
gene	O
frequency	O
in	O
Sephardim	O
of	O
Moroccan	O
origin	O
.	O

We	O
described	O
6	O
patients	O
(	O
from	O
3	O
families	O
)	O
affected	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

All	O
are	O
Sephardic	O
Jews	O
of	O
Moroccan	O
extraction	O
.	O

In	O
view	O
of	O
the	O
small	O
number	O
of	O
CTX	B-Disease
patients	O
diagnosed	O
in	O
the	O
world	O
(	O
a	O
total	O
of	O
50	O
including	O
our	O
6	O
patients	O
)	O
,	O
we	O
are	O
probably	O
dealing	O
with	O
an	O
ethnic	O
subgroup	O
with	O
a	O
high	O
CTX	O
gene	O
frequency	O
,	O
which	O
we	O
have	O
estimated	O
to	O
be	O
1	O
/	O
108	O
.	O

Since	O
there	O
are	O
differences	O
in	O
expression	O
in	O
this	O
disease	O
,	O
we	O
recommend	O
cholestanol	O
study	O
in	O
cases	O
of	O
undiagnosed	O
cataract	B-Disease
or	O
tendinous	B-Disease
xanthomas	I-Disease
in	O
childhood	O
or	O
early	O
adolescence	O
.	O

The	O
diagnosis	O
in	O
CTX	B-Disease
is	O
important	O
not	O
only	O
for	O
genetic	O
counseling	O
,	O
but	O
also	O
in	O
veiw	O
of	O
possible	O
treatment	O
.	O
.	O

New	O
genetic	O
variants	O
of	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
in	O
Italy	O
.	O

Six	O
new	O
variants	O
of	O
human	O
erythrocyte	O
G6PD	O
have	O
been	O
characterized	O
.	O

All	O
of	O
them	O
were	O
found	O
in	O
Italian	O
males	O
and	O
all	O
were	O
associated	O
with	O
enzyme	B-Disease
deficiency	I-Disease
,	O
but	O
only	O
two	O
with	O
signs	O
of	O
haemolysis	B-Disease
.	O

These	O
and	O
other	O
variants	O
reported	O
in	O
the	O
literature	O
,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic	O
,	O
are	O
found	O
to	O
map	O
in	O
parts	O
of	O
Italy	O
where	O
common	O
types	O
of	O
G6PD	B-Disease
deficiency	I-Disease
are	O
also	O
prevalent	O
.	O
.	O

Variants	O
of	O
erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
in	O
Bulgarian	O
populations	O
.	O

Ten	O
variants	O
of	O
erythrocyte	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
were	O
identified	O
in	O
22	O
patients	O
with	O
G6PD	B-Disease
deficiency	I-Disease
from	O
three	O
districts	O
of	O
Bulgaria	O
.	O

Corinth	O
-	O
like	O
and	O
Fayoum	O
-	O
like	O
variants	O
were	O
the	O
most	O
frequent	O
;	O
Mediterranean	O
,	O
Ohut	O
II	O
,	O
Kilgore	O
,	O
Boston	O
,	O
Poznan	O
,	O
and	O
Panay	O
variants	O
and	O
two	O
new	O
variants	O
,	O
Petrich	O
and	O
Gotze	O
Delchev	O
,	O
were	O
each	O
found	O
in	O
one	O
or	O
two	O
carriers	O
.	O

No	O
correlation	O
was	O
revealed	O
between	O
clinical	O
and	O
biochemical	O
polymorphism	O
.	O
.	O

Nephropathy	B-Disease
in	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
.	O

Nephropathy	B-Disease
was	O
detected	O
in	O
five	O
of	O
32	O
patients	O
with	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
who	O
were	O
participating	O
in	O
a	O
study	O
of	O
transfer	O
factor	O
(	O
TF	O
)	O
therapy	O
.	O

In	O
two	O
patients	O
,	O
nephropathy	B-Disease
was	O
present	O
before	O
TF	O
and	O
did	O
not	O
appear	O
changed	O
by	O
TF	O
therapy	O
.	O

One	O
of	O
these	O
patients	O
subsequently	O
developed	O
progressive	O
renal	B-Disease
failure	I-Disease
requiring	O
dialysis	O
beginning	O
5	O
1	O
/	O
2	O
years	O
after	O
TF	O
therapy	O
.	O

In	O
two	O
patients	O
,	O
decreased	O
renal	O
function	O
appeared	O
very	O
soon	O
after	O
the	O
administration	O
of	O
TF	O
.	O

One	O
patient	O
showed	O
gradually	O
decreasing	O
renal	O
function	O
beginning	O
after	O
two	O
years	O
of	O
TF	O
therapy	O
.	O

An	O
additional	O
patient	O
was	O
identified	O
who	O
died	O
with	O
renal	B-Disease
failure	I-Disease
without	O
having	O
received	O
TF	O
.	O

The	O
results	O
suggest	O
that	O
renal	B-Disease
failure	I-Disease
occurs	O
in	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
TF	O
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	B-Disease
disease	I-Disease
in	O
patients	O
with	O
this	O
syndrome	O
.	O
.	O

Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
:	O
cellular	O
impairments	O
and	O
their	O
implication	O
for	O
carrier	O
detection	O
.	O

A	O
family	O
in	O
which	O
two	O
male	O
siblings	O
were	O
affected	O
with	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
was	O
studied	O
using	O
G	O
-	O
6	O
-	O
PD	O
isoenzymes	O
as	O
an	O
X	O
-	O
linked	O
marker	O
in	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
cellular	O
abnormalities	O
.	O

Isolated	O
peripheral	O
blood	O
cell	O
types	O
from	O
the	O
doubly	O
heterozygous	O
mother	O
of	O
the	O
affected	O
males	O
seemingly	O
failed	O
to	O
express	O
the	O
G	O
-	O
6	O
-	O
PD	O
allele	O
in	O
cis	O
position	O
with	O
the	O
WAS	B-Disease
allele	O
while	O
her	O
cultured	O
skin	O
fibroblasts	O
expressed	O
both	O
G	O
-	O
6	O
-	O
PD	O
alleles	O
.	O

Additionally	O
,	O
a	O
histogram	O
analysis	O
of	O
platelet	O
size	O
revealed	O
a	O
single	O
population	O
of	O
abnormally	O
small	O
platelets	O
in	O
the	O
affected	O
propositus	O
,	O
whereas	O
the	O
heterozygous	O
mother	O
had	O
no	O
appreciable	O
small	O
platelet	O
subpopulation	O
.	O

In	O
vitro	O
culture	O
of	O
hemopoietic	O
progenitor	O
cells	O
of	O
the	O
heterozygous	O
mother	O
showed	O
that	O
the	O
majority	O
of	O
progenitor	O
cells	O
did	O
not	O
express	O
the	O
WAS	B-Disease
allele	O
.	O

However	O
,	O
a	O
small	O
number	O
of	O
cells	O
expressing	O
the	O
G	O
-	O
6	O
-	O
PD	O
type	O
linked	O
with	O
the	O
WAS	B-Disease
allele	O
were	O
detected	O
.	O

The	O
proportion	O
of	O
the	O
latter	O
progenitors	O
was	O
significantly	O
higher	O
among	O
more	O
primitive	O
progenitors	O
(	O
those	O
giving	O
rise	O
to	O
later	O
appearing	O
colonies	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
selection	O
against	O
cells	O
expressing	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
defect	I-Disease
takes	O
place	O
in	O
the	O
hemopoietic	O
system	O
of	O
the	O
heterozygous	O
female	O
and	O
offers	O
a	O
possible	O
means	O
of	O
carrier	O
detection	O
in	O
some	O
women	O
.	O

Linkage	O
studies	O
in	O
this	O
family	O
revealed	O
one	O
example	O
of	O
probable	O
recombination	O
between	O
the	O
loci	O
for	O
WAS	B-Disease
and	O
G	O
-	O
6	O
-	O
PD	O
among	O
three	O
informative	O
subjects	O
,	O
suggesting	O
that	O
these	O
two	O
loci	O
may	O
not	O
be	O
closely	O
linked	O
on	O
the	O
X	O
-	O
chromosome	O
.	O
.	O

A	O
new	O
CT	O
pattern	O
in	O
adrenoleukodystrophy	B-Disease
.	O

A	O
new	O
CT	O
pattern	O
was	O
observed	O
in	O
2	O
patients	O
with	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
.	O

This	O
pattern	O
,	O
which	O
the	O
authors	O
call	O
Type	O
II	O
,	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
posterior	O
periventricular	O
areas	O
of	O
decreased	O
attenuation	O
around	O
the	O
trigone	O
on	O
non	O
-	O
contrast	O
scans	O
after	O
contrast	O
infusion	O
,	O
however	O
,	O
there	O
is	O
striking	O
enhancement	O
of	O
various	O
white	O
-	O
matter	O
structures	O
(	O
tracts	O
or	O
fiber	O
systems	O
)	O
such	O
as	O
the	O
internal	O
capsules	O
,	O
corpus	O
callosum	O
,	O
corona	O
radiata	O
,	O
forceps	O
major	O
,	O
and	O
cerebral	O
peduncles	O
.	O

This	O
is	O
different	O
from	O
numerous	O
previous	O
descriptions	O
of	O
the	O
CT	O
pattern	O
in	O
ALD	B-Disease
.	O

Type	B-Disease
II	I-Disease
ALD	I-Disease
does	O
not	O
appear	O
to	O
have	O
been	O
seen	O
in	O
any	O
other	O
leukoencephalopathy	B-Disease
and	O
is	O
probably	O
specific	O
for	O
a	O
phenotypic	O
variant	O
or	O
an	O
evolving	O
stage	O
of	O
ALD	B-Disease
.	O
.	O

Further	O
evidence	O
for	O
heterogeneity	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
Papua	O
New	O
Guinea	O
.	O

Four	O
new	O
G6PD	O
variants	O
have	O
been	O
characterized	O
in	O
individuals	O
from	O
Papua	O
New	O
Guinea	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
previously	O
reported	O
Markham	O
variant	O
and	O
the	O
newly	O
characterized	O
Salata	O
variant	O
may	O
be	O
widely	O
distributed	O
in	O
Papua	O
New	O
Guinea	O
.	O

Th	O
data	O
presented	O
here	O
together	O
with	O
those	O
of	O
previously	O
published	O
studies	O
demonstrate	O
a	O
degree	O
of	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
that	O
is	O
much	O
higher	O
than	O
that	O
in	O
other	O
regions	O
of	O
the	O
world	O
where	O
G6PD	B-Disease
deficiency	I-Disease
is	O
common	O
.	O
.	O

Increased	O
incidence	O
of	O
cataracts	B-Disease
in	O
male	O
subjects	O
deficient	B-Disease
in	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
RBCs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	O
cataractous	B-Disease
patients	O
than	O
in	O
672	O
control	O
subjects	O
of	O
Sardinian	O
origin	O
.	O

The	O
frequency	O
of	O
the	O
deficiency	O
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	B-Disease
.	O

In	O
the	O
G6PD	B-Disease
-	I-Disease
deficient	I-Disease
group	O
,	O
the	O
incidence	O
of	O
cortical	B-Disease
and	I-Disease
total	I-Disease
cataracts	I-Disease
was	O
also	O
increased	O
.	O

It	O
is	O
suggested	O
that	O
decrease	O
of	O
the	O
G6PD	O
activity	O
in	O
the	O
lens	O
,	O
which	O
accompanies	O
its	O
deficiency	O
in	O
the	O
erythrocyte	O
,	O
might	O
play	O
a	O
role	O
in	O
the	O
cataracto	O
-	O
genesis	O
of	O
these	O
patients	O
.	O

Moreover	O
,	O
G6PD	B-Disease
deficiency	I-Disease
should	O
be	O
added	O
to	O
other	O
conditions	O
,	O
such	O
as	O
the	O
galactosemic	B-Disease
states	O
and	O
riboflavin	B-Disease
deficiency	I-Disease
,	O
where	O
cataracts	B-Disease
represent	O
a	O
sensitive	O
indicator	O
of	O
metabolic	B-Disease
abnormalities	I-Disease
of	O
the	O
RBC	O
.	O
.	O

Molecular	O
basis	O
of	O
human	O
mitochondrial	O
very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
CoA	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
causing	O
cardiomyopathy	B-Disease
and	O
sudden	B-Disease
death	I-Disease
in	O
childhood	O
.	O

beta	O
-	O
Oxidation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
provides	O
the	O
major	O
source	O
of	O
energy	O
in	O
the	O
heart	O
.	O

Defects	O
in	O
enzymes	O
of	O
the	O
beta	O
-	O
oxidation	O
pathway	O
cause	O
sudden	B-Disease
,	I-Disease
unexplained	I-Disease
death	I-Disease
in	O
childhood	O
,	O
acute	O
hepatic	B-Disease
encephalopathy	I-Disease
or	O
liver	B-Disease
failure	I-Disease
,	O
skeletal	B-Disease
myopathy	I-Disease
,	O
and	O
cardiomyopathy	B-Disease
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
[	O
VLCAD	O
;	O
very	O
-	O
long	O
-	O
chain	O
-	O
acyl	O
-	O
CoA	O
(	O
acceptor	O
)	O
2	O
,	O
3	O
-	O
oxidoreductase	O
,	O
EC	O
1	O
.	O
3	O
3	O
.	O
99	O
99	O
.	O
13	O
]	O
catalyzes	O
the	O
first	O
step	O
in	O
beta	O
-	O
oxidation	O
.	O

We	O
have	O
isolated	O
the	O
human	O
VLCAD	O
cDNA	O
and	O
gene	O
and	O
determined	O
the	O
complete	O
nucleotide	O
sequences	O
.	O

Polymerase	O
chain	O
reaction	O
amplification	O
of	O
VLCAD	O
mRNA	O
and	O
genomic	O
exons	O
defined	O
the	O
molecular	O
defects	O
in	O
two	O
patients	O
with	O
VLCAD	B-Disease
deficiency	I-Disease
who	O
presented	O
with	O
unexplained	O
cardiac	B-Disease
arrest	I-Disease
and	O
cardiomyopathy	B-Disease
.	O

In	O
one	O
,	O
a	O
homozygous	O
mutation	O
in	O
the	O
consensus	O
dinucleotide	O
of	O
the	O
donor	O
splice	O
site	O
(	O
g	O
+	O
1	O
-	O
-	O
>	O
a	O
)	O
was	O
associated	O
with	O
universal	O
skipping	O
of	O
the	O
prior	O
exon	O
(	O
exon	O
11	O
)	O
.	O

The	O
second	O
patient	O
was	O
a	O
compound	O
heterozygote	O
,	O
with	O
a	O
missense	O
mutation	O
,	O
C1837	O
-	O
-	O
>	O
T	O
,	O
changing	O
the	O
arginine	O
at	O
residue	O
613	O
to	O
tryptophan	O
on	O
one	O
allele	O
and	O
a	O
single	O
base	O
deletion	O
at	O
the	O
intron	O
-	O
exon	O
6	O
boundary	O
as	O
the	O
second	O
mutation	O
.	O

This	O
initial	O
delineation	O
of	O
human	O
mutations	O
in	O
VLCAD	O
suggests	O
that	O
VLCAD	B-Disease
deficiency	I-Disease
reduces	O
myocardial	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
and	O
energy	O
production	O
and	O
is	O
associated	O
with	O
cardiomyopathy	B-Disease
and	O
sudden	B-Disease
death	I-Disease
in	O
childhood	O
.	O

Aberrant	O
subcellular	O
localization	O
of	O
BRCA1	O
in	O
breast	B-Disease
cancer	I-Disease
.	O

The	O
BRCA1	O
gene	O
product	O
was	O
identified	O
as	O
a	O
220	O
-	O
kilodalton	O
nuclear	O
phosphoprotein	O
in	O
normal	O
cells	O
,	O
including	O
breast	O
ductal	O
epithelial	O
cells	O
,	O
and	O
in	O
18	O
of	O
20	O
tumor	B-Disease
cell	O
lines	O
derived	O
from	O
tissues	O
other	O
than	O
breast	O
and	O
ovary	O
.	O

In	O
16	O
of	O
17	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
lines	O
and	O
17	O
of	O
17	O
samples	O
of	O
cells	O
obtained	O
from	O
malignant	O
effusions	O
,	O
however	O
,	O
BRCA1	O
localized	O
mainly	O
in	O
cytoplasm	O
.	O

Absence	O
of	O
BRCA1	O
or	O
aberrant	O
subcellular	O
location	O
was	O
also	O
observed	O
to	O
a	O
variable	O
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	B-Disease
cancer	I-Disease
biopsies	O
.	O

These	O
findings	O
suggest	O
that	O
BRCA1	B-Disease
abnormalities	I-Disease
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
breast	B-Disease
cancers	I-Disease
,	O
sporadic	O
as	O
well	O
as	O
familial	O
.	O
.	O

Mapping	O
of	O
the	O
mouse	O
homologue	O
of	O
the	O
Wilson	B-Disease
disease	I-Disease
gene	O
to	O
mouse	O
chromosome	O
8	O
.	O

ATP7B	O
,	O
the	O
gene	O
altered	O
in	O
Wilson	B-Disease
disease	I-Disease
(	O
WD	B-Disease
)	O
patients	O
,	O
lies	O
in	O
a	O
block	O
of	O
homology	O
shared	O
between	O
human	O
chromosome	O
13q14	O
and	O
the	O
central	O
region	O
of	O
mouse	O
chromosome	O
14	O
.	O

However	O
,	O
we	O
have	O
mapped	O
the	O
murine	O
homologue	O
of	O
ATP7B	O
(	O
Atp7b	O
)	O
to	O
mouse	O
chromosome	O
8	O
by	O
somatic	O
cell	O
hybrid	O
analysis	O
.	O

Analysis	O
of	O
80	O
interspecific	O
backcross	O
offspring	O
was	O
used	O
to	O
position	O
Atp7b	O
close	O
to	O
D8Mit3	O
and	O
another	O
ATPase	O
locus	O
,	O
Atp4b	O
,	O
on	O
mouse	O
chromosome	O
8	O
.	O

ATP4B	O
lies	O
in	O
13q34	O
and	O
is	O
separated	O
from	O
ATP7B	O
by	O
several	O
loci	O
whose	O
mouse	O
homologues	O
map	O
to	O
mouse	O
chromosome	O
14	O
.	O

The	O
assignment	O
of	O
Atp7b	O
to	O
mouse	O
chromosome	O
8	O
identifies	O
a	O
previously	O
unrecognized	O
region	O
of	O
homology	O
between	O
this	O
chromosome	O
and	O
human	O
chromosome	O
13	O
.	O

This	O
assignment	O
suggests	O
a	O
possible	O
location	O
for	O
the	O
toxic	O
milk	O
mutation	O
in	O
the	O
mouse	O
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
homologue	O
of	O
WD	B-Disease
.	O
.	O

Germline	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
in	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
provide	O
evidence	O
for	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Mutations	O
in	O
the	O
BRCA1	O
gene	O
,	O
discovered	O
in	O
1994	O
,	O
are	O
associated	O
with	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
.	O

We	O
have	O
analysed	O
60	O
families	O
with	O
a	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
for	O
germline	O
mutations	O
in	O
BRCA1	O
.	O

Twenty	O
-	O
two	O
different	O
mutations	O
were	O
detected	O
in	O
32	O
families	O
(	O
53	O
%	O
)	O
,	O
of	O
which	O
14	O
are	O
previously	O
unreported	O
.	O

We	O
observed	O
a	O
significant	O
correlation	O
between	O
the	O
location	O
of	O
the	O
mutation	O
in	O
the	O
gene	O
and	O
the	O
ratio	O
of	O
breast	B-Disease
to	I-Disease
ovarian	I-Disease
cancer	I-Disease
incidence	O
within	O
each	O
family	O
.	O

Our	O
data	O
suggest	O
a	O
transition	O
in	O
risk	O
such	O
that	O
mutations	O
in	O
the	O
3	O
third	O
of	O
the	O
gene	O
are	O
associated	O
with	O
a	O
lower	O
proportion	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O

Haplotype	O
analysis	O
supports	O
previous	O
data	O
which	O
suggest	O
some	O
BRCA1	O
mutation	O
carriers	O
have	O
common	O
ancestors	O
;	O
however	O
,	O
we	O
have	O
found	O
at	O
least	O
two	O
examples	O
where	O
recurrent	O
mutations	O
appear	O
to	O
have	O
arisen	O
independently	O
.	O
.	O

Hereditary	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
and	O
recurrent	O
meningococcal	B-Disease
infection	I-Disease
:	O
investigations	O
of	O
an	O
Irish	O
family	O
using	O
a	O
novel	O
haemolytic	O
screening	O
assay	O
for	O
complement	O
activity	O
and	O
C7	O
M	O
/	O
N	O
allotyping	O
.	O

Terminal	B-Disease
complement	I-Disease
component	I-Disease
deficiency	I-Disease
predisposes	O
to	O
meningococcal	B-Disease
infection	I-Disease
and	O
is	O
inherited	O
in	O
an	O
autosomal	O
co	O
-	O
dominant	O
manner	O
.	O

An	O
Irish	O
family	O
is	O
described	O
,	O
in	O
which	O
2	O
of	O
3	O
brothers	O
had	O
recurrent	O
meningococcal	B-Disease
infection	I-Disease
.	O

A	O
novel	O
screening	O
assay	O
was	O
used	O
to	O
investigate	O
for	O
terminal	B-Disease
complement	I-Disease
deficiency	I-Disease
and	O
the	O
2	O
affected	O
brothers	O
were	O
found	O
to	O
be	O
completely	B-Disease
deficient	I-Disease
in	I-Disease
the	I-Disease
seventh	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C7	O
)	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
C7	O
revealed	O
lower	O
than	O
normal	O
levels	O
in	O
the	O
remaining	O
brother	O
and	O
parents	O
.	O

C7	O
M	O
/	O
N	O
protein	O
polymorphism	O
allotyping	O
,	O
used	O
to	O
investigate	O
the	O
segregation	O
of	O
the	O
C7	B-Disease
deficiency	I-Disease
genes	O
,	O
showed	O
that	O
the	O
apparently	O
complement	O
sufficient	O
brother	O
was	O
heterozygous	O
C7	B-Disease
deficient	I-Disease
and	O
a	O
carrier	O
of	O
one	O
of	O
the	O
deficiency	O
genes	O
.	O

Complement	O
screening	O
should	O
be	O
carried	O
out	O
in	O
any	O
individual	O
suffering	O
recurrent	O
meningococcal	B-Disease
infection	I-Disease
or	O
infection	O
with	O
an	O
uncommon	O
meningococcal	B-Disease
serogroup	O
.	O

Identification	O
of	O
complement	B-Disease
deficient	I-Disease
patients	O
allows	O
the	O
implementation	O
of	O
strategies	O
to	O
prevent	O
recurrent	O
infection	O
.	O
.	O

Molecular	O
basis	O
of	O
subtotal	B-Disease
complement	I-Disease
C6	I-Disease
deficiency	I-Disease
.	O

A	O
carboxy	O
-	O
terminally	O
truncated	O
but	O
functionally	O
active	O
C6	O
.	O

Individuals	O
with	O
subtotal	B-Disease
complement	I-Disease
C6	I-Disease
deficiency	I-Disease
possess	O
a	O
C6	O
molecule	O
that	O
is	O
14	O
%	O
shorter	O
than	O
normal	O
C6	O
and	O
present	O
in	O
low	O
but	O
detectable	O
concentrations	O
(	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
mean	O
)	O
.	O

We	O
now	O
show	O
that	O
this	O
dysmorphic	O
C6	O
is	O
bactericidally	O
active	O
and	O
lacks	O
an	O
epitope	O
that	O
was	O
mapped	O
to	O
the	O
most	O
carboxy	O
-	O
terminal	O
part	O
of	O
C6	O
using	O
C6	O
cDNA	O
fragments	O
expressed	O
as	O
fusion	O
proteins	O
in	O
the	O
pUEX	O
expression	O
system	O
.	O

We	O
thus	O
predicted	O
that	O
the	O
abnormal	O
C6	O
molecule	O
might	O
be	O
carboxy	O
-	O
terminally	O
truncated	O
and	O
sought	O
a	O
mutation	O
in	O
an	O
area	O
approximately	O
14	O
%	O
from	O
the	O
carboxy	O
-	O
terminal	O
end	O
of	O
the	O
coding	O
sequence	O
.	O

By	O
sequencing	O
PCR	O
-	O
amplified	O
products	O
from	O
this	O
region	O
,	O
we	O
found	O
,	O
in	O
three	O
individuals	O
from	O
two	O
families	O
,	O
a	O
mutation	O
that	O
might	O
plausibly	O
be	O
responsible	O
for	O
the	O
defect	O
.	O

All	O
three	O
have	O
an	O
abnormal	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
,	O
which	O
would	O
probably	O
prevent	O
splicing	O
.	O

An	O
in	O
-	O
frame	O
stop	O
codon	O
is	O
found	O
17	O
codons	O
downstream	O
from	O
the	O
intron	O
boundary	O
,	O
which	O
would	O
lead	O
to	O
a	O
truncated	O
polypeptide	O
13	O
.	O

5	O
%	O
smaller	O
than	O
normal	O
C6	O
.	O

This	O
result	O
was	O
unexpected	O
,	O
as	O
earlier	O
studies	O
mapped	O
the	O
C5b	O
binding	O
site	O
,	O
or	O
a	O
putative	O
enzymatic	O
region	O
,	O
to	O
this	O
part	O
of	O
C6	O
.	O

Interestingly	O
,	O
all	O
three	O
subjects	O
were	O
probably	O
heterozygous	O
for	O
both	O
subtotal	B-Disease
C6	I-Disease
and	I-Disease
complete	I-Disease
C6	I-Disease
deficiency	I-Disease
.	O

Myotonic	B-Disease
dystrophy	I-Disease
:	O
evidence	O
for	O
a	O
possible	O
dominant	O
-	O
negative	O
RNA	O
mutation	O
.	O

The	O
trinucleotide	O
expansion	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
is	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
gene	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
the	O
expanded	O
repeat	O
causes	O
the	O
clinically	O
variable	O
and	O
multisystemic	B-Disease
disease	I-Disease
,	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
are	O
not	O
understood	O
.	O

It	O
has	O
been	O
particularly	O
difficult	O
to	O
rationalize	O
the	O
dominant	O
inheritance	O
with	O
the	O
fact	O
that	O
the	O
expansion	O
mutation	O
lies	O
outside	O
of	O
the	O
protein	O
-	O
encoding	O
gene	O
elements	O
,	O
and	O
should	O
not	O
be	O
translated	O
into	O
protein	O
.	O

Here	O
we	O
use	O
muscle	O
biopsies	O
from	O
classical	O
adult	O
-	O
onset	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
to	O
study	O
the	O
accumulation	O
of	O
transcripts	O
from	O
both	O
the	O
normal	O
and	O
expanded	O
DM	B-Disease
kinase	O
genes	O
in	O
patient	O
muscle	O
,	O
and	O
compare	O
the	O
results	O
to	O
normal	O
and	O
myopathic	B-Disease
controls	O
.	O

We	O
found	O
relatively	O
small	O
decreases	O
of	O
DM	B-Disease
kinase	O
RNA	O
in	O
the	O
total	O
RNA	O
pool	O
from	O
muscle	O
;	O
however	O
,	O
these	O
reductions	O
were	O
not	O
disease	O
specific	O
.	O

Analysis	O
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
showed	O
dramatic	O
decreases	O
of	O
both	O
the	O
mutant	O
and	O
normal	O
DM	B-Disease
kinase	O
RNAs	O
,	O
and	O
these	O
changes	O
were	O
disease	O
-	O
specific	O
.	O

Our	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
molecular	O
pathogenetic	O
mechanism	O
for	O
myotonic	B-Disease
dystrophy	I-Disease
both	O
the	O
normal	O
and	O
expanded	O
DM	B-Disease
kinase	O
genes	O
are	O
transcribed	O
in	O
patient	O
muscle	O
,	O
but	O
the	O
abnormal	O
expansion	O
-	O
containing	O
RNA	O
has	O
a	O
dominant	O
effect	O
on	O
RNA	O
metabolism	O
by	O
preventing	O
the	O
accumulation	O
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
.	O

The	O
ability	O
of	O
the	O
expansion	O
mutation	O
to	O
alter	O
accumulation	O
of	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
in	O
trans	O
suggests	O
that	O
myotonic	B-Disease
dystrophy	I-Disease
may	O
be	O
the	O
first	O
example	O
of	O
a	O
dominant	O
-	O
negative	O
mutation	O
manifested	O
at	O
the	O
RNA	O
level	O
.	O
.	O

A	O
strong	O
candidate	O
for	O
the	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
BRCA1	O
.	O

A	O
strong	O
candidate	O
for	O
the	O
17q	O
-	O
linked	O
BRCA1	O
gene	O
,	O
which	O
influences	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
has	O
been	O
identified	O
by	O
positional	O
cloning	O
methods	O
.	O

Probable	O
predisposing	O
mutations	O
have	O
been	O
detected	O
in	O
five	O
of	O
eight	O
kindreds	O
presumed	O
to	O
segregate	O
BRCA1	O
susceptibility	O
alleles	O
.	O

The	O
mutations	O
include	O
an	O
11	O
-	O
base	O
pair	O
deletion	O
,	O
a	O
1	O
-	O
base	O
pair	O
insertion	O
,	O
a	O
stop	O
codon	O
,	O
a	O
missense	O
substitution	O
,	O
and	O
an	O
inferred	O
regulatory	O
mutation	O
.	O

The	O
BRCA1	O
gene	O
is	O
expressed	O
in	O
numerous	O
tissues	O
,	O
including	O
breast	O
and	O
ovary	O
,	O
and	O
encodes	O
a	O
predicted	O
protein	O
of	O
1863	O
amino	O
acids	O
.	O

This	O
protein	O
contains	O
a	O
zinc	O
finger	O
domain	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
,	O
but	O
is	O
otherwise	O
unrelated	O
to	O
previously	O
described	O
proteins	O
.	O

Identification	O
of	O
BRCA1	O
should	O
facilitate	O
early	O
diagnosis	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
in	O
some	O
individuals	O
as	O
well	O
as	O
a	O
better	O
understanding	O
of	O
breast	B-Disease
cancer	I-Disease
biology	O
.	O
.	O

Molecular	O
characterization	O
of	O
galactosemia	B-Disease
(	O
type	O
1	O
)	O
mutations	O
in	O
Japanese	O
.	O

We	O
characterized	O
two	O
novel	O
mutations	O
of	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
in	O
two	O
Japanese	O
patients	O
with	O
GALT	B-Disease
deficiency	I-Disease
and	O
identified	O
N314D	O
and	O
R333W	O
mutations	O
,	O
previously	O
found	O
in	O
Caucasians	O
.	O

One	O
novel	O
missense	O
mutation	O
was	O
an	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
by	O
histidine	O
at	O
the	O
codon	O
231	O
(	O
R231H	O
)	O
.	O

GALT	O
activity	O
of	O
the	O
R231H	O
mutant	O
construct	O
was	O
reduced	O
to	O
15	O
%	O
of	O
normal	O
controls	O
in	O
a	O
COS	O
cell	O
expression	O
system	O
.	O

The	O
other	O
was	O
a	O
splicing	O
mutation	O
,	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	O
at	O
the	O
38th	O
nucleotide	O
in	O
exon	O
3	O
(	O
318A	O
-	O
-	O
>	O
G	O
)	O
,	O
resulting	O
in	O
a	O
38	O
-	O
bp	O
deletion	O
in	O
the	O
GALT	O
cDNA	O
by	O
activating	O
a	O
cryptic	O
splice	O
acceptor	O
site	O
.	O

In	O
seven	O
Japanese	O
families	O
(	O
14	O
alleles	O
for	O
classic	O
form	O
and	O
one	O
allele	O
for	O
Duarte	O
variant	O
)	O
with	O
GALT	B-Disease
deficiency	I-Disease
,	O
the	O
R231H	O
and	O
318A	O
-	O
-	O
>	O
G	O
mutations	O
were	O
found	O
only	O
on	O
both	O
alleles	O
of	O
the	O
proband	O
.	O

The	O
N314D	O
and	O
R333W	O
mutations	O
were	O
found	O
on	O
one	O
allele	O
each	O
.	O

The	O
Q188R	O
was	O
prevalent	O
in	O
the	O
United	O
States	O
but	O
not	O
in	O
Japanese	O
patients	O
.	O

The	O
N314D	O
mutation	O
was	O
associated	O
with	O
the	O
Duarte	O
variant	O
in	O
Japanese	O
persons	O
,	O
as	O
well	O
as	O
in	O
the	O
United	O
States	O
.	O

We	O
speculate	O
that	O
classic	B-Disease
galactosemia	I-Disease
mutations	O
appear	O
to	O
differ	O
between	O
Japanese	O
and	O
Caucasian	O
patients	O
.	O

Our	O
limited	O
data	O
set	O
on	O
galactosemia	B-Disease
mutations	O
in	O
Japanese	O
suggests	O
that	O
the	O
N314D	O
GALT	O
mutation	O
encoding	O
the	O
Duarte	O
variant	O
arose	O
before	O
Asian	O
and	O
Caucasian	O
people	O
diverged	O
and	O
that	O
classic	B-Disease
galactosemia	I-Disease
mutations	O
arose	O
and	O
/	O
or	O
accumulated	O
after	O
the	O
divergence	O
of	O
Asian	O
and	O
Caucasian	O
populations	O
.	O
.	O

Three	O
novel	O
aniridia	B-Disease
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

Aniridia	B-Disease
(	O
iris	B-Disease
hypoplasia	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
congenital	I-Disease
disorder	I-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
.	O

Mutations	O
in	O
the	O
human	O
aniridia	B-Disease
(	O
PAX6	O
)	O
gene	O
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O

In	O
the	O
study	O
reported	O
here	O
we	O
describe	O
PAX6	O
mutations	O
in	O
one	O
sporadic	O
and	O
five	O
familial	O
cases	O
with	O
aniridia	B-Disease
.	O

Of	O
the	O
four	O
different	O
mutations	O
identified	O
,	O
one	O
was	O
identical	O
to	O
a	O
previously	O
reported	O
mutation	O
(	O
C	O
-	O
-	O
>	O
T	O
transition	O
at	O
codon	O
240	O
)	O
,	O
and	O
three	O
were	O
novel	O
two	O
in	O
the	O
glycine	O
-	O
rich	O
region	O
and	O
one	O
in	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
(	O
PST	O
)	O
region	O
.	O

One	O
PAX6	O
mutation	O
found	O
in	O
the	O
PST	O
region	O
was	O
associated	O
with	O
cataracts	B-Disease
in	O
an	O
aniridia	B-Disease
family	O
.	O

Another	O
splice	O
mutation	O
in	O
the	O
PST	O
domain	O
occurred	O
in	O
an	O
aniridia	B-Disease
patient	O
with	O
anosmia	B-Disease
(	O
inability	O
to	O
smell	O
)	O
.	O

The	O
six	O
new	O
aniridia	B-Disease
cases	O
reported	O
here	O
have	O
mutations	O
predicted	O
to	O
generate	O
incomplete	O
PAX6	O
proteins	O
.	O

These	O
results	O
support	O
the	O
theory	O
that	O
human	O
aniridia	B-Disease
is	O
caused	O
by	O
haploinsufficiency	B-Disease
of	I-Disease
PAX6	I-Disease
.	O
.	O

The	O
carrier	O
frequency	O
of	O
the	O
BRCA1	O
185delAG	O
mutation	O
is	O
approximately	O
1	O
percent	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
.	O

Since	O
BRCA1	O
,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

In	O
high	O
-	O
risk	O
pedigrees	O
,	O
female	O
carriers	O
of	O
BRCA1	O
mutations	O
have	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
and	O
a	O
40	O
-	O
50	O
%	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O

However	O
,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
has	O
not	O
been	O
determined	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	B-Disease
as	O
in	O
individuals	O
from	O
the	O
high	O
-	O
risk	O
families	O
studied	O
so	O
far	O
.	O

Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	O
mutation	O
in	O
several	O
Ashkenazi	O
Jewish	O
breast	O
/	O
ovarian	O
families	O
,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
Ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	B-Disease
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin	O
.	O

We	O
observed	O
the	O
185delAG	O
mutation	O
in	O
0	O
.	O

9	O
%	O
of	O
Ashkenazim	O
(	O
95	O
%	O
confidence	O
limit	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
8	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples	O
.	O

Our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
Ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

Identification	O
and	O
localization	O
of	O
huntingtin	O
in	O
brain	O
and	O
human	O
lymphoblastoid	O
cell	O
lines	O
with	O
anti	O
-	O
fusion	O
protein	O
antibodies	O
.	O

The	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
phenotype	O
is	O
associated	O
with	O
expansion	O
of	O
a	O
trinucleotide	O
repeat	O
in	O
the	O
IT15	O
gene	O
,	O
which	O
is	O
predicted	O
to	O
encode	O
a	O
348	O
-	O
kDa	O
protein	O
named	O
huntington	O
.	O

We	O
used	O
polyclonal	O
and	O
monoclonal	O
anti	O
-	O
fusion	O
protein	O
antibodies	O
to	O
identify	O
native	O
huntingtin	O
in	O
rat	O
,	O
monkey	O
,	O
and	O
human	O
.	O

Western	O
blots	O
revealed	O
a	O
protein	O
with	O
the	O
expected	O
molecular	O
weight	O
which	O
is	O
present	O
in	O
the	O
soluble	O
fraction	O
of	O
rat	O
and	O
monkey	O
brain	O
tissues	O
and	O
lymphoblastoid	O
cells	O
from	O
control	O
cases	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
from	O
juvenile	O
-	O
onset	O
heterozygote	O
HD	B-Disease
cases	O
,	O
both	O
normal	O
and	O
mutant	O
huntingtin	O
are	O
expressed	O
,	O
and	O
increasing	O
repeat	O
expansion	O
leads	O
to	O
lower	O
levels	O
of	O
the	O
mutant	O
protein	O
.	O

Immunocytochemistry	O
indicates	O
that	O
huntingtin	O
is	O
located	O
in	O
neurons	O
throughout	O
the	O
brain	O
,	O
with	O
the	O
highest	O
levels	O
evident	O
in	O
larger	O
neurons	O
.	O

In	O
the	O
human	O
striatum	O
,	O
huntingtin	O
is	O
enriched	O
in	O
a	O
patch	O
-	O
like	O
distribution	O
,	O
potentially	O
corresponding	O
to	O
the	O
first	O
areas	O
affected	O
in	O
HD	B-Disease
.	O

Subcellular	O
localization	O
of	O
huntingtin	O
is	O
consistent	O
with	O
a	O
cytosolic	O
protein	O
primarily	O
found	O
in	O
somatodendritic	O
regions	O
.	O

Huntingtin	O
appears	O
to	O
particularly	O
associate	O
with	O
microtubules	O
,	O
although	O
some	O
is	O
also	O
associated	O
with	O
synaptic	O
vesicles	O
.	O

On	O
the	O
basis	O
of	O
the	O
localization	O
of	O
huntingtin	O
in	O
association	O
with	O
microtubules	O
,	O
we	O
speculate	O
that	O
the	O
mutation	O
impairs	O
the	O
cytoskeletal	O
anchoring	O
or	O
transport	O
of	O
mitochondria	O
,	O
vesicles	O
,	O
or	O
other	O
organelles	O
or	O
molecules	O
.	O
.	O

Marked	O
phenotypic	O
heterogeneity	O
associated	O
with	O
expansion	O
of	O
a	O
CAG	O
repeat	O
sequence	O
at	O
the	O
spinocerebellar	B-Disease
ataxia	I-Disease
3	I-Disease
/	I-Disease
Machado	I-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
locus	O
.	O

The	O
spinocerebellar	B-Disease
ataxia	I-Disease
3	I-Disease
locus	O
(	O
SCA3	B-Disease
)	O
for	O
type	B-Disease
I	I-Disease
autosomal	I-Disease
dominant	I-Disease
cerebellar	I-Disease
ataxia	I-Disease
(	O
ADCA	B-Disease
type	I-Disease
I	I-Disease
)	O
,	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	B-Disease
disorders	I-Disease
,	O
has	O
been	O
mapped	O
to	O
chromosome	O
14q32	O
.	O

1	O
1	O
.	O

ADCA	B-Disease
type	I-Disease
I	I-Disease
patients	O
from	O
families	O
segregating	O
SCA3	B-Disease
share	O
clinical	O
features	O
in	O
common	O
with	O
those	O
with	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
,	O
the	O
gene	O
of	O
which	O
maps	O
to	O
the	O
same	O
region	O
.	O

We	O
show	O
here	O
that	O
the	O
disease	O
gene	O
segregating	O
in	O
each	O
of	O
three	O
French	O
ADCA	B-Disease
type	I-Disease
I	I-Disease
kindreds	O
and	O
in	O
a	O
French	O
family	O
with	O
neuropathological	O
findings	O
suggesting	O
the	O
ataxochoreic	O
form	O
of	O
dentatorubropallidoluysian	B-Disease
atrophy	I-Disease
carries	O
an	O
expanded	O
CAG	O
repeat	O
sequence	O
located	O
at	O
the	O
same	O
locus	O
as	O
that	O
for	O
MJD	B-Disease
.	O

Analysis	O
of	O
the	O
mutation	O
in	O
these	O
families	O
shows	O
a	O
strong	O
negative	O
correlation	O
between	O
size	O
of	O
the	O
expanded	O
CAG	O
repeat	O
and	O
age	O
at	O
onset	O
of	O
clinical	O
disease	O
.	O

Instability	O
of	O
the	O
expanded	O
triplet	O
repeat	O
was	O
not	O
found	O
to	O
be	O
affected	O
by	O
sex	O
of	O
the	O
parent	O
transmitting	O
the	O
mutation	O
.	O

Evidence	O
was	O
found	O
for	O
somatic	O
and	O
gonadal	O
mosaicism	O
for	O
alleles	O
carrying	O
expanded	O
trinucleotide	O
repeats	O
.	O

Overexpression	O
of	O
DM20	O
messenger	O
RNA	O
in	O
two	O
brothers	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
.	O

Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
is	O
a	O
rare	B-Disease
,	I-Disease
sex	I-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
,	I-Disease
dysmyelinating	I-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
that	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
myelin	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
.	O

Only	O
25	O
%	O
of	O
patients	O
studied	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
have	O
exonic	O
mutations	O
in	O
this	O
gene	O
,	O
the	O
underlying	O
cause	O
of	O
the	O
disease	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O

The	O
PLP	O
gene	O
encodes	O
two	O
major	O
alternatively	O
spliced	O
transcripts	O
called	O
PLP	O
and	O
DM20	O
.	O

PLP	O
messenger	O
RNA	O
is	O
specifically	O
expressed	O
in	O
central	O
nervous	O
system	O
tissue	O
,	O
whereas	O
DM20	O
messenger	O
RNA	O
is	O
found	O
in	O
central	O
nervous	O
system	O
,	O
cardiac	O
,	O
and	O
other	O
tissues	O
.	O

We	O
studied	O
cultured	O
skin	O
fibroblasts	O
from	O
2	O
brothers	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
who	O
exhibited	O
no	O
detectable	O
exonic	O
mutation	O
of	O
the	O
PLP	O
gene	O
.	O

Examination	O
of	O
RNA	O
from	O
these	O
cells	O
showed	O
that	O
the	O
level	O
of	O
DM20	O
messenger	O
RNA	O
is	O
elevated	O
sixfold	O
relative	O
to	O
male	O
control	O
skin	O
fibroblasts	O
.	O

An	O
unrelated	O
female	O
carrier	O
,	O
also	O
with	O
no	O
detectable	O
exonic	O
mutation	O
,	O
showed	O
a	O
threefold	O
increase	O
in	O
DM20	O
messenger	O
RNA	O
in	O
cultured	O
skin	O
fibroblasts	O
.	O

Our	O
findings	O
suggest	O
that	O
in	O
some	O
patients	O
,	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
is	O
caused	O
by	O
overexpression	O
of	O
PLP	O
gene	O
transcripts	O
,	O
and	O
that	O
in	O
these	O
families	O
a	O
50	O
%	O
increase	O
of	O
DM20	O
messenger	O
RNA	O
in	O
females	O
,	O
relative	O
to	O
the	O
increase	O
in	O
affected	O
males	O
,	O
can	O
identify	O
a	O
female	O
carrier	O
.	O
.	O

The	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
and	O
X	B-Disease
-	I-Disease
linked	I-Disease
congenital	I-Disease
thrombocytopenia	I-Disease
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene	O
.	O

The	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
thrombocytopenia	B-Disease
,	O
small	O
platelets	O
,	O
eczema	B-Disease
,	O
recurrent	O
infections	O
,	O
and	O
immunodeficiency	B-Disease
.	O

Besides	O
the	O
classic	O
WAS	B-Disease
phenotype	O
,	O
there	O
is	O
a	O
group	O
of	O
patients	O
with	O
congenital	B-Disease
X	I-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
(	O
XLT	B-Disease
)	O
who	O
have	O
small	O
platelets	O
but	O
only	O
transient	O
eczema	B-Disease
,	O
if	O
any	O
,	O
and	O
minimal	O
immune	B-Disease
deficiency	I-Disease
.	O

Because	O
the	O
gene	O
responsible	O
for	O
WAS	B-Disease
has	O
been	O
sequenced	O
,	O
it	O
was	O
possible	O
to	O
correlate	O
the	O
WAS	B-Disease
phenotypes	O
with	O
WAS	B-Disease
gene	O
mutations	O
.	O

Using	O
a	O
fingerprinting	O
screening	O
technique	O
,	O
we	O
determined	O
the	O
approximate	O
location	O
of	O
the	O
mutation	O
in	O
13	O
unrelated	O
WAS	B-Disease
patients	O
with	O
mild	O
to	O
severe	O
clinical	O
symptoms	O
.	O

Direct	O
sequence	O
analysis	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
obtained	O
from	O
patient	O
-	O
derived	O
cell	O
lines	O
showed	O
12	O
unique	O
mutations	O
distributed	O
throughout	O
the	O
WAS	B-Disease
gene	O
,	O
including	O
insertions	O
,	O
deletions	O
,	O
and	O
point	O
mutations	O
resulting	O
in	O
amino	O
acid	O
substitutions	O
,	O
termination	O
,	O
exon	O
skipping	O
,	O
or	O
splicing	O
defects	O
.	O

Of	O
4	O
unrelated	O
patients	O
with	O
the	O
XLT	B-Disease
phenotype	O
,	O
3	O
had	O
missense	O
mutations	O
affecting	O
exon	O
2	O
and	O
1	O
had	O
a	O
splice	O
-	O
site	O
mutation	O
affecting	O
exon	O
9	O
.	O

Patients	O
with	O
classic	O
WAS	B-Disease
had	O
more	O
complex	O
mutations	O
,	O
resulting	O
in	O
termination	O
codons	O
,	O
frameshift	O
,	O
and	O
early	O
termination	O
.	O

These	O
findings	O
provide	O
direct	O
evidence	O
that	O
XLT	B-Disease
and	O
WAS	B-Disease
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene	O
and	O
suggest	O
that	O
severe	O
clinical	O
phenotypes	O
are	O
associated	O
with	O
complex	O
mutations	O
.	O
.	O

Myotonia	B-Disease
levior	I-Disease
is	O
a	O
chloride	B-Disease
channel	I-Disease
disorder	I-Disease
.	O

The	O
group	O
of	O
dominant	B-Disease
non	I-Disease
-	I-Disease
dystrophic	I-Disease
myotonias	I-Disease
,	O
comprising	O
disorders	O
characterized	O
by	O
clinically	O
similar	O
forms	O
of	O
myogenic	O
muscle	O
stiffness	O
,	O
is	O
genetically	O
inhomogeneous	O
.	O

Dominant	B-Disease
myotonia	I-Disease
congenita	I-Disease
(	O
Thomsens	B-Disease
disease	I-Disease
)	O
is	O
linked	O
to	O
CLCN1	O
,	O
the	O
gene	O
encoding	O
the	O
major	O
muscle	O
chloride	O
channel	O
,	O
localized	O
on	O
chromosome	O
7q35	O
.	O

In	O
contrast	O
,	O
dominant	B-Disease
myotonias	I-Disease
sensitive	O
to	O
potassium	O
are	O
caused	O
by	O
point	O
mutations	O
in	O
SCN4A	O
on	O
chromosome	O
17q	O
,	O
the	O
gene	O
for	O
the	O
alpha	O
subunit	O
of	O
the	O
adult	O
skeletal	O
muscle	O
sodium	O
channel	O
.	O

No	O
linkage	O
or	O
molecular	O
genetic	O
data	O
are	O
as	O
yet	O
available	O
on	O
myotonia	B-Disease
levior	I-Disease
characterized	O
by	O
milder	O
symptoms	O
and	O
later	O
onset	O
of	O
myotonia	B-Disease
than	O
in	O
Thomsens	B-Disease
disease	I-Disease
,	O
and	O
absence	O
of	O
muscle	B-Disease
hypertrophy	I-Disease
.	O

We	O
report	O
a	O
CLCN1	O
Gln	O
-	O
552	O
-	O
Arg	O
substitution	O
for	O
a	O
family	O
with	O
dominant	O
inheritance	O
previously	O
diagnosed	O
to	O
have	O
myotonia	B-Disease
levior	I-Disease
.	O

Thus	O
,	O
this	O
disorder	O
appears	O
as	O
a	O
variant	O
of	O
Thomsens	B-Disease
disease	I-Disease
due	O
to	O
mutations	O
leading	O
to	O
low	O
clinical	O
expressivity	O
.	O

In	O
addition	O
,	O
we	O
report	O
a	O
novel	O
Ile	O
-	O
290	O
-	O
Met	O
CLCN1	O
mutation	O
for	O
a	O
typical	O
Thomsen	O
pedigree	O
.	O

In	O
another	O
family	O
previously	O
diagnosed	O
as	O
having	O
Thomsens	B-Disease
disease	I-Disease
,	O
we	O
unexpectedly	O
found	O
a	O
CLCN1	O
14	O
bp	O
deletion	O
known	O
to	O
cause	O
recessive	B-Disease
myotonia	I-Disease
,	O
and	O
a	O
rare	O
Trp	O
-	O
118	O
-	O
Gly	O
polymorphism	O
.	O
.	O

Southern	O
analysis	O
reveals	O
a	O
large	O
deletion	O
at	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
locus	O
in	O
a	O
patient	O
with	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

Whole	O
genomic	O
hprt	O
clones	O
were	O
used	O
in	O
Southern	O
analysis	O
to	O
screen	O
the	O
integrity	O
of	O
the	O
hprt	O
gene	O
in	O
a	O
family	O
that	O
includes	O
a	O
patient	O
with	O
HPRT	B-Disease
enzyme	I-Disease
deficiency	I-Disease
causal	O
to	O
Lesch	B-Disease
-	I-Disease
Nyhan	I-Disease
syndrome	I-Disease
.	O

A	O
5	O
kb	O
DNA	O
sequence	O
deletion	O
was	O
found	O
to	O
have	O
its	O
endpoints	O
in	O
the	O
first	O
and	O
third	O
introns	O
.	O

The	O
probes	O
identified	O
the	O
carrier	O
status	O
of	O
female	O
family	O
members	O
,	O
aided	O
by	O
an	O
RFLP	O
carried	O
by	O
the	O
mothers	O
normal	O
X	O
-	O
chromosome	O
.	O
.	O

Characterisation	O
of	O
molecular	O
defects	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
(	O
AIH1	O
)	O
.	O

Amelogenins	O
are	O
an	O
heterogenous	O
family	O
of	O
proteins	O
produced	O
by	O
ameloblasts	O
of	O
the	O
enamel	O
organ	O
during	O
tooth	O
development	O
.	O

Disturbances	O
of	O
enamel	O
formation	O
occur	O
in	O
amelogenesis	B-Disease
imperfecta	I-Disease
,	O
a	O
clinically	O
heterogenous	O
group	O
of	O
inherited	B-Disease
disorders	I-Disease
characterised	O
by	O
defective	O
enamel	O
biomineralisation	O
.	O

An	O
amelogenin	O
gene	O
,	O
AMGX	O
,	O
has	O
been	O
mapped	O
to	O
the	O
short	O
of	O
the	O
X	O
chromosome	O
(	O
Xp22	O
.	O
1	O
-	O
p22	O
.	O
3	O
)	O
and	O
has	O
been	O
implicated	O
in	O
the	O
molecular	O
pathology	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
amelogenesis	I-Disease
imperfecta	I-Disease
(	O
AIH1	B-Disease
)	O
.	O

We	O
have	O
identified	O
three	O
families	O
exhibiting	O
AIH1	B-Disease
and	O
screened	O
the	O
AMGX	O
gene	O
for	O
mutations	O
using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
DNA	O
sequencing	O
.	O

Three	O
novel	O
mutations	O
were	O
identified	O
a	O
C	O
-	O
T	O
substitution	O
in	O
exon	O
5	O
,	O
and	O
a	O
G	O
-	O
T	O
substitution	O
and	O
single	O
cytosine	O
deletion	O
in	O
exon	O
6	O
,	O
confirming	O
the	O
existence	O
of	O
extensive	O
allelic	O
heterogeneity	O
in	O
this	O
condition	O
.	O

The	O
identification	O
of	O
family	O
-	O
specific	O
mutations	O
will	O
enable	O
early	O
identification	O
of	O
affected	O
individuals	O
and	O
correlation	O
of	O
clinical	O
phenotype	O
with	O
genotype	O
will	O
facilitate	O
an	O
objective	O
system	O
of	O
disease	O
classification	O
.	O

Frequency	O
of	O
exon	O
15	O
missense	O
mutation	O
(	O
442D	O
:	O
G	O
)	O
in	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
in	O
hyperalphalipoproteinemic	B-Disease
Japanese	O
subjects	O
.	O

Cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
transfers	O
cholesteryl	O
ester	O
from	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
to	O
apo	O
B	O
-	O
containing	O
lipoproteins	O
.	O

The	O
hyperalphalipoproteinemia	B-Disease
caused	O
by	O
CETP	B-Disease
deficiency	I-Disease
is	O
fairly	O
common	O
in	O
Japan	O
and	O
one	O
of	O
the	O
most	O
common	O
mutations	O
in	O
the	O
CETP	O
gene	O
is	O
the	O
splicing	O
defect	O
of	O
the	O
intron	O
14	O
,	O
the	O
allelic	O
frequency	O
of	O
which	O
has	O
been	O
shown	O
to	O
be	O
0	O
.	O

0049	O
in	O
the	O
Japanese	O
general	O
population	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
a	O
missense	O
mutation	O
in	O
exon	O
15	O
of	O
the	O
CETP	O
gene	O
(	O
442D	O
G	O
)	O
,	O
showing	O
a	O
dominant	O
effect	O
on	O
the	O
CETP	O
activity	O
and	O
HDL	O
-	O
cholesterol	O
level	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
determined	O
the	O
frequency	O
of	O
this	O
new	O
mutation	O
in	O
Japanese	O
hyperalphalipoproteinemic	B-Disease
(	O
HDL	O
-	O
cholesterol	O
>	O
or	O
=	O
100	O
mg	O
/	O
dl	O
)	O
subjects	O
.	O

A	O
rapid	O
and	O
easy	O
screening	O
method	O
for	O
this	O
new	O
mutation	O
was	O
developed	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
mediated	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Among	O
117	O
Japanese	O
hyperalphalipoproteinemic	B-Disease
subjects	O
(	O
HDL	O
-	O
cholesterol	O
;	O
116	O
.	O
7	O
+	O
/	O
-	O
16	O
.	O
5	O
mg	O
/	O
dl	O
,	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
)	O
without	O
the	O
intron	O
14	O
splice	O
defect	O
,	O
three	O
homozygotes	O
(	O
2	O
.	O
5	O
%	O
)	O
and	O
34	O
heterozygotes	O
(	O
29	O
.	O
1	O
%	O
)	O
were	O
found	O
to	O
have	O
the	O
442D	O
G	O
mutation	O
.	O

The	O
relative	O
allelic	O
frequency	O
of	O
this	O
mutation	O
was	O
calculated	O
to	O
be	O
0	O
.	O

17	O
.	O

One	O
of	O
the	O
homozygotes	O
for	O
the	O
442D	O
G	O
mutation	O
was	O
the	O
patient	O
previously	O
described	O
by	O
us	O
as	O
having	O
hyperalphalipoproteinemia	B-Disease
with	O
corneal	B-Disease
opacity	I-Disease
and	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O

This	O
was	O
the	O
first	O
reported	O
subject	O
homozygous	O
for	O
the	O
CETP	B-Disease
deficiency	I-Disease
who	O
also	O
demonstrated	O
atherosclerotic	B-Disease
symptoms	I-Disease
.	O

In	O
homozygous	O
subjects	O
,	O
CETP	O
activity	O
ranged	O
from	O
37	O
%	O
to	O
62	O
%	O
of	O
the	O
normal	O
value	O
,	O
which	O
was	O
consistent	O
with	O
the	O
results	O
obtained	O
from	O
the	O
transient	O
expression	O
experiment	O
previously	O
reported	O
;	O
however	O
,	O
the	O
specific	O
activity	O
of	O
CETP	O
was	O
not	O
as	O
low	O
as	O
expected	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mucopolysaccharidosis	B-Disease
type	I-Disease
IVA	I-Disease
:	O
common	O
double	O
deletion	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfatase	O
gene	O
(	O
GALNS	O
)	O
.	O

Mucopolysaccharidosis	B-Disease
IVA	I-Disease
(	O
MPS	B-Disease
IVA	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
in	I-Disease
N	I-Disease
-	I-Disease
acetylgalactosamine	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
sulfatase	I-Disease
(	O
GALNS	O
)	O
.	O

We	O
found	O
two	O
separate	O
deletions	O
of	O
nearly	O
8	O
.	O

0	O
and	O
6	O
.	O

0	O
kb	O
in	O
the	O
GALNS	O
gene	O
,	O
including	O
some	O
exons	O
.	O

There	O
are	O
Alu	O
repetitive	O
elements	O
near	O
the	O
breakpoints	O
of	O
the	O
8	O
.	O

0	O
-	O
kb	O
deletion	O
,	O
and	O
this	O
deletion	O
resulted	O
from	O
an	O
Alu	O
-	O
Alu	O
recombination	O
.	O

The	O
other	O
6	O
.	O

0	O
-	O
kb	O
deletion	O
involved	O
illegitimate	O
recombinational	O
events	O
between	O
incomplete	O
short	O
direct	O
repeats	O
of	O
8	O
bp	O
at	O
deletion	O
breakpoints	O
.	O

The	O
same	O
rearrangement	O
has	O
been	O
observed	O
in	O
a	O
heteroallelic	O
state	O
in	O
four	O
unrelated	O
patients	O
.	O

This	O
is	O
the	O
first	O
documentation	O
of	O
a	O
common	O
double	O
deletion	O
a	O
gene	O
that	O
is	O
not	O
a	O
member	O
of	O
a	O
gene	O
cluster	O
.	O

Detection	O
of	O
eight	O
BRCA1	O
mutations	O
in	O
10	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
,	O
including	O
1	O
family	O
with	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
.	O

Genetic	O
epidemiological	O
evidence	O
suggests	O
that	O
mutations	O
in	O
BRCA1	O
may	O
be	O
responsible	O
for	O
approximately	O
one	O
half	O
of	O
early	O
onset	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
and	O
the	O
majority	O
of	O
familial	B-Disease
breast	I-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

The	O
recent	O
cloning	O
of	O
BRCA1	O
allows	O
for	O
the	O
direct	O
detection	O
of	O
mutations	O
,	O
but	O
the	O
feasibility	O
of	O
presymptomatic	O
screening	O
for	O
cancer	B-Disease
susceptibility	O
is	O
unknown	O
.	O

We	O
analyzed	O
genomic	O
DNA	O
from	O
one	O
affected	O
individual	O
from	O
each	O
of	O
24	O
families	O
with	O
at	O
least	O
three	O
cases	O
of	O
ovarian	B-Disease
or	I-Disease
breast	I-Disease
cancer	I-Disease
,	O
using	O
SSCP	O
assays	O
.	O

Variant	O
SSCP	O
bands	O
were	O
subcloned	O
and	O
sequenced	O
.	O

Allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
was	O
used	O
to	O
verify	O
sequence	O
changes	O
and	O
to	O
screen	O
DNA	O
from	O
control	O
individuals	O
.	O

Six	O
frameshift	O
and	O
two	O
missense	O
mutations	O
were	O
detected	O
in	O
10	O
different	O
families	O
.	O

A	O
frameshift	O
mutation	O
was	O
detected	O
in	O
a	O
male	O
proband	O
affected	O
with	O
both	O
breast	B-Disease
and	I-Disease
prostate	I-Disease
cancer	I-Disease
.	O

A	O
40	O
-	O
bp	O
deletion	O
was	O
detected	O
in	O
a	O
patient	O
who	O
developed	O
intra	B-Disease
-	I-Disease
abdominal	I-Disease
carcinomatosis	I-Disease
1	O
year	O
after	O
prophylactic	O
oophorectomy	O
.	O

Mutations	O
were	O
detected	O
throughout	O
the	O
gene	O
,	O
and	O
only	O
one	O
was	O
detected	O
in	O
more	O
than	O
a	O
single	O
family	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
that	O
inherited	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
can	O
occur	O
as	O
a	O
consequence	O
of	O
a	O
wide	O
array	O
of	O
BRCA1	O
mutations	O
.	O

These	O
results	O
suggests	O
that	O
development	O
of	O
a	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
will	O
be	O
technically	O
challenging	O
.	O

The	O
finding	O
of	O
a	O
mutation	O
in	O
a	O
family	O
with	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
not	O
previously	O
thought	O
to	O
be	O
related	O
to	O
BRCA1	O
,	O
also	O
illustrates	O
the	O
potential	O
difficulties	O
of	O
genetic	O
counseling	O
for	O
individuals	O
known	O
to	O
carry	O
mutations	O
.	O
.	O

Natural	O
selection	O
of	O
hemi	O
-	O
and	O
heterozygotes	O
for	O
G6PD	B-Disease
deficiency	I-Disease
in	O
Africa	O
by	O
resistance	O
to	O
severe	O
malaria	B-Disease
.	O

Glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
,	O
the	O
most	O
common	O
enzymopathy	B-Disease
of	O
humans	O
,	O
affects	O
over	O
400	O
million	O
people	O
.	O

The	O
geographical	O
correlation	O
of	O
its	O
distribution	O
with	O
the	O
historical	O
endemicity	O
of	O
malaria	B-Disease
suggests	O
that	O
this	O
disorder	O
has	O
risen	O
in	O
frequency	O
through	O
natural	O
selection	O
by	O
malaria	B-Disease
.	O

However	O
,	O
attempts	O
to	O
confirm	O
that	O
G6PD	B-Disease
deficiency	I-Disease
is	O
protective	O
in	O
case	O
-	O
control	O
studies	O
of	O
malaria	B-Disease
have	O
yielded	O
conflicting	O
results	O
.	O

Hence	O
,	O
for	O
this	O
X	B-Disease
-	I-Disease
linked	I-Disease
disorder	I-Disease
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
are	O
protected	O
or	O
,	O
as	O
frequently	O
suggested	O
,	O
only	O
females	O
.	O

Furthermore	O
,	O
how	O
much	O
protection	O
may	O
be	O
afforded	O
is	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
,	O
in	O
two	O
large	O
case	O
-	O
control	O
studies	O
of	O
over	O
2	O
,	O
000	O
African	O
children	O
,	O
the	O
common	O
African	O
form	O
of	O
G6PD	B-Disease
deficiency	I-Disease
(	O
G6PD	B-Disease
A	I-Disease
-	I-Disease
)	O
is	O
associated	O
with	O
a	O
46	O
-	O
58	O
%	O
reduction	O
in	O
risk	O
of	O
severe	O
malaria	B-Disease
for	O
both	O
female	O
heterozygotes	O
and	O
male	O
hemizygotes	O
.	O

A	O
mathematical	O
model	O
incorporating	O
the	O
measured	O
selective	O
advantage	O
against	O
malaria	B-Disease
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage	O
,	O
associated	O
with	O
this	O
enzyme	B-Disease
deficiency	I-Disease
,	O
has	O
retarded	O
its	O
rise	O
in	O
frequency	O
in	O
malaria	B-Disease
-	O
endemic	O
regions	O
.	O

Although	O
G6PD	B-Disease
deficiency	I-Disease
is	O
now	O
regarded	O
as	O
a	O
generally	O
benign	O
disorder	O
,	O
in	O
earlier	O
environmental	O
conditions	O
it	O
could	O
have	O
been	O
significantly	O
disadvantageous	O
.	O
.	O

The	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
PAX3	O
/	O
FKHR	O
fusion	O
protein	O
is	O
a	O
transcriptional	O
activator	O
.	O

Chimeric	O
transcription	O
factors	O
,	O
created	O
by	O
gene	O
fusions	O
as	O
the	O
result	O
of	O
chromosomal	O
translocations	O
,	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
pathologically	O
disparate	O
solid	B-Disease
tumors	I-Disease
.	O

The	O
PAX3	O
/	O
FKHR	O
fusion	O
gene	O
,	O
formed	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
,	O
encodes	O
a	O
hybrid	O
protein	O
that	O
contains	O
both	O
PAX3	O
DNA	O
binding	O
domains	O
,	O
the	O
paired	O
box	O
and	O
homeodomain	O
,	O
linked	O
to	O
the	O
bisected	O
DNA	O
binding	O
domain	O
of	O
FKHR	O
,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors	O
.	O

Here	O
we	O
report	O
that	O
PAX3	O
and	O
PAX3	O
/	O
FKHR	O
display	O
similar	O
,	O
but	O
not	O
identical	O
transactivation	O
activities	O
when	O
tested	O
with	O
model	O
Pax	O
recognition	O
sequences	O
.	O

No	O
functional	O
role	O
could	O
be	O
ascribed	O
solely	O
to	O
the	O
residual	O
FKHR	O
binding	O
domain	O
present	O
in	O
the	O
fusion	O
protein	O
,	O
but	O
FKHR	O
was	O
found	O
to	O
contribute	O
a	O
strong	O
carboxyl	O
terminal	O
activation	O
domain	O
replacing	O
the	O
one	O
located	O
in	O
the	O
unrearranged	O
PAX3	O
gene	O
.	O

We	O
show	O
that	O
the	O
native	O
PAX3	O
/	O
FKHR	O
protein	O
present	O
in	O
tumor	B-Disease
cells	O
with	O
this	O
translocation	O
has	O
transcriptional	O
characteristics	O
similar	O
to	O
the	O
in	O
vitro	O
expressed	O
protein	O
.	O

The	O
ability	O
of	O
the	O
PAX3	O
/	O
FKHR	O
hybrid	O
protein	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
specific	O
manner	O
and	O
to	O
transactivate	O
the	O
expression	O
of	O
artificial	O
reporter	O
genes	O
suggests	O
that	O
its	O
aberrant	O
expression	O
could	O
subvert	O
the	O
transcriptional	O
programs	O
that	O
normally	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
survival	O
of	O
primitive	O
myogenic	O
precursors	O
in	O
vivo	O
.	O
.	O

A	O
p16INK4a	O
-	O
insensitive	O
CDK4	O
mutant	O
targeted	O
by	O
cytolytic	O
T	O
lymphocytes	O
in	O
a	O
human	O
melanoma	B-Disease
.	O

A	O
mutated	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
(	O
CDK4	O
)	O
was	O
identified	O
as	O
a	O
tumor	B-Disease
-	O
specific	O
antigen	O
recognized	O
by	O
HLA	O
-	O
A2	O
.	O

1	O
-	O
restricted	O
autologous	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
in	O
a	O
human	O
melanoma	B-Disease
.	O

The	O
mutated	O
CDK4	O
allele	O
was	O
present	O
in	O
autologous	O
cultured	O
melanoma	B-Disease
cells	O
and	O
metastasis	O
tissue	O
,	O
but	O
not	O
in	O
the	O
patients	O
lymphocytes	O
.	O

The	O
mutation	O
,	O
an	O
arginine	O
-	O
to	O
-	O
cysteine	O
exchange	O
at	O
residue	O
24	O
,	O
was	O
part	O
of	O
the	O
CDK4	O
peptide	O
recognized	O
by	O
CTLs	O
and	O
prevented	O
binding	O
of	O
the	O
CDK4	O
inhibitor	O
p16INK4a	O
,	O
but	O
not	O
of	O
p21	O
or	O
of	O
p27KIP1	O
.	O

The	O
same	O
mutation	O
was	O
found	O
in	O
one	O
additional	O
melanoma	B-Disease
among	O
28	O
melanomas	B-Disease
analyzed	O
.	O

These	O
results	O
suggest	O
that	O
mutation	O
of	O
CDK4	O
can	O
create	O
a	O
tumor	B-Disease
-	O
specific	O
antigen	O
and	O
can	O
disrupt	O
the	O
cell	O
-	O
cycle	O
regulation	O
exerted	O
by	O
the	O
tumor	B-Disease
suppressor	O
p16INK4a	O
.	O
.	O

Rapid	O
detection	O
of	O
BRCA1	O
mutations	O
by	O
the	O
protein	O
truncation	O
test	O
.	O

More	O
than	O
75	O
%	O
of	O
the	O
reported	O
mutations	O
in	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
,	O
BRCA1	O
,	O
result	O
in	O
truncated	O
proteins	O
.	O

We	O
have	O
used	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
11	O
,	O
which	O
encodes	O
61	O
%	O
of	O
BRCA1	O
.	O

In	O
45	O
patients	O
from	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
we	O
found	O
six	O
novel	O
mutations	O
two	O
single	O
nucleotide	O
insertions	O
,	O
three	O
small	O
deletions	O
(	O
1	O
-	O
5	O
bp	O
)	O
and	O
a	O
nonsense	O
mutation	O
identified	O
two	O
unrelated	O
families	O
.	O

Furthermore	O
,	O
we	O
were	O
able	O
to	O
amplify	O
the	O
remaining	O
coding	O
region	O
by	O
RT	O
-	O
PCR	O
using	O
lymphocyte	O
RNA	O
.	O

Combined	O
with	O
PTT	O
,	O
we	O
detected	O
aberrantly	O
spliced	O
products	O
affecting	O
exons	O
5	O
and	O
6	O
in	O
one	O
of	O
two	O
BRCA1	O
-	O
linked	O
families	O
examined	O
.	O

The	O
protein	O
truncation	O
test	O
promises	O
to	O
become	O
a	O
valuable	O
technique	O
in	O
detecting	O
BRCA1	O
mutations	O
.	O
.	O

Cloning	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients	O
.	O

Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	O
and	O
736	O
bp	O
,	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	O
mitochondrial	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
VLCAD	O
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
,	O
including	O
a	O
40	O
-	O
amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615	O
-	O
amino	O
acid	O
mature	O
polypeptide	O
.	O

PCR	O
-	O
amplified	O
VLCAD	O
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD	B-Disease
-	I-Disease
deficient	I-Disease
patients	O
.	O

In	O
both	O
patients	O
,	O
a	O
105	O
-	O
bp	O
deletion	O
encompassing	O
bases	O
1078	O
-	O
1182	O
in	O
VLCAD	O
cDNA	O
was	O
identified	O
.	O

The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	O
pre	O
-	O
mRNA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	B-Disease
deficiency	I-Disease
.	O

Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	O
VLCAD	O
was	O
performed	O
in	O
the	O
patients	O
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
normal	I-Disease
VLCAD	I-Disease
protein	I-Disease
causes	O
impaired	O
long	O
-	O
chain	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	O
fibroblasts	O
.	O

In	O
patient	O
fibroblasts	O
,	O
raising	O
VLCAD	O
activity	O
to	O
approximately	O
20	O
%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	O
acid	O
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	B-Disease
deficiency	I-Disease
.	O
.	O

Brain	B-Disease
disease	I-Disease
and	O
molecular	O
analysis	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O

Abnormal	O
amplification	O
of	O
a	O
CTG	O
repeat	O
on	O
chromosome	O
19	O
is	O
the	O
molecular	O
basis	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
.	O

Expansion	O
of	O
the	O
repeat	O
has	O
been	O
correlated	O
with	O
severity	O
of	O
several	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

We	O
performed	O
extensive	O
cognitive	O
testing	O
,	O
cerebral	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
a	O
molecular	O
analysis	O
in	O
28	O
cases	O
of	O
DM	B-Disease
to	O
determine	O
the	O
relationship	O
between	O
the	O
molecular	O
defect	O
and	O
brain	B-Disease
disease	I-Disease
.	O

Performance	O
in	O
two	O
or	O
more	O
cognitive	O
tests	O
was	O
pathological	O
in	O
10	O
cases	O
.	O

Fourteen	O
patients	O
had	O
subcortical	O
white	B-Disease
matter	I-Disease
lesions	I-Disease
on	O
MRI	O
,	O
14	O
had	O
cerebral	B-Disease
atrophy	I-Disease
.	O

Amplification	O
of	O
the	O
CTG	O
repeat	O
showed	O
a	O
strong	O
correlation	O
with	O
cognitive	O
test	O
deficits	O
when	O
exceeding	O
a	O
length	O
of	O
over	O
1000	O
trinucleotides	O
.	O

MRI	O
lesions	O
were	O
associated	O
with	O
impaired	O
psychometric	O
performance	O
,	O
but	O
MRI	O
and	O
molecular	O
findings	O
were	O
only	O
weakly	O
related	O
.	O

Disease	O
duration	O
influenced	O
the	O
appearance	O
and	O
amount	O
of	O
white	B-Disease
matter	I-Disease
lesions	I-Disease
on	O
MRI	O
.	O

Quantification	O
of	O
CTG	O
repeat	O
size	O
may	O
allow	O
an	O
early	O
estimate	O
on	O
the	O
probability	O
of	O
brain	O
involvement	O
in	O
DM	B-Disease
;	O
cognitive	B-Disease
dysfunction	I-Disease
is	O
associated	O
with	O
white	B-Disease
matter	I-Disease
lesions	I-Disease
and	O
cerebral	B-Disease
atrophy	I-Disease
later	O
on	O
in	O
the	O
course	O
.	O
.	O

Mutations	O
in	O
the	O
gene	O
for	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
in	O
patients	O
with	O
different	O
clinical	O
phenotypes	O
.	O

Recently	O
,	O
the	O
gene	O
for	O
the	O
most	O
common	O
peroxisomal	B-Disease
disorder	I-Disease
,	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
,	O
has	O
been	O
described	O
encoding	O
a	O
peroxisomal	O
membrane	O
transporter	O
protein	O
.	O

We	O
analyzed	O
the	O
entire	O
protein	O
-	O
coding	O
sequence	O
of	O
this	O
gene	O
by	O
reverse	O
-	O
transcription	O
PCR	O
,	O
SSCP	O
,	O
and	O
DNA	O
sequencing	O
in	O
five	O
patients	O
with	O
different	O
clinical	O
expression	O
of	O
X	B-Disease
-	I-Disease
ALD	I-Disease
and	O
in	O
their	O
female	O
relatives	O
;	O
these	O
clinical	O
expressions	O
were	O
cerebral	O
childhood	O
ALD	B-Disease
,	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
,	O
and	O
"	O
Addison	B-Disease
disease	I-Disease
only	I-Disease
"	O
(	O
ADO	B-Disease
)	O
phenotype	O
.	O

In	O
the	O
three	O
patients	O
exhibiting	O
the	O
classical	O
picture	O
of	O
severe	O
childhood	O
ALD	B-Disease
we	O
identified	O
in	O
the	O
5	O
portion	O
of	O
the	O
X	B-Disease
-	I-Disease
ALD	I-Disease
gene	O
a	O
38	O
-	O
bp	O
deletion	O
that	O
causes	O
a	O
frameshift	O
mutation	O
,	O
a	O
3	O
-	O
bp	O
deletion	O
leading	O
to	O
a	O
deletion	O
of	O
an	O
amino	O
acid	O
in	O
the	O
ATP	O
-	O
binding	O
domain	O
of	O
the	O
ALD	B-Disease
protein	O
,	O
and	O
a	O
missense	O
mutation	O
.	O

In	O
the	O
patient	O
with	O
the	O
clinical	O
phenotype	O
of	O
AMN	B-Disease
,	O
a	O
nonsense	O
mutation	O
in	O
codon	O
212	O
,	O
along	O
with	O
a	O
second	O
site	O
mutation	O
at	O
codon	O
178	O
,	O
was	O
observed	O
.	O

Analysis	O
of	O
the	O
patient	O
with	O
the	O
ADO	B-Disease
phenotype	O
revealed	O
a	O
further	O
missense	O
mutation	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
ALDP	O
/	O
PMP70	O
comparison	O
.	O

The	O
disruptive	O
nature	O
of	O
two	O
mutations	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
frameshift	O
and	O
the	O
nonsense	O
mutation	O
)	O
in	O
patients	O
with	O
biochemically	O
proved	O
childhood	O
ALD	B-Disease
and	O
AMN	B-Disease
further	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
alterations	O
in	O
this	O
gene	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
X	B-Disease
-	I-Disease
ALD	I-Disease
.	O

Since	O
the	O
current	O
biochemical	O
techniques	O
for	O
X	B-Disease
-	I-Disease
ALD	I-Disease
carrier	O
detection	O
in	O
affected	O
families	O
lack	O
sufficient	O
reliability	O
,	O
our	O
procedure	O
described	O
for	O
systematic	O
mutation	O
scanning	O
is	O
also	O
capable	O
of	O
improving	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O

Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
myotonic	B-Disease
dystrophy	I-Disease
in	O
the	O
same	O
patient	O
.	O

We	O
report	O
on	O
the	O
first	O
patient	O
identified	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
and	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

The	O
family	O
of	O
the	O
propositus	O
had	O
a	O
strong	O
history	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
and	O
there	O
was	O
an	O
intrafamilial	O
pathological	O
expansion	O
of	O
the	O
responsible	O
CTG	O
repeat	O
between	O
the	O
mildly	O
affected	O
mother	O
(	O
160	O
repeats	O
;	O
normal	O
27	O
repeats	O
)	O
and	O
her	O
more	O
severely	O
affected	O
son	O
(	O
650	O
repeats	O
)	O
,	O
and	O
his	O
sister	O
(	O
650	O
repeats	O
)	O
.	O

The	O
propositus	O
was	O
an	O
isolated	O
case	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
with	O
marked	O
dystrophin	B-Disease
deficiency	I-Disease
in	O
muscle	O
biopsy	O
.	O

The	O
patient	O
was	O
still	O
ambulatory	O
post	O
age	O
16	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
could	O
interfere	O
to	O
some	O
extent	O
with	O
the	O
progression	O
of	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

However	O
,	O
other	O
interpretations	O
are	O
possible	O
.	O

Twelve	O
percent	O
of	O
dystrophin	O
revertant	O
fibers	O
as	O
observed	O
by	O
immunohistochemistry	O
could	O
be	O
sufficient	O
to	O
ameliorate	O
typical	O
DMD	B-Disease
clinical	O
severity	O
,	O
or	O
the	O
patient	O
may	O
present	O
a	O
somatic	O
mosaic	O
.	O

The	O
pathophysiological	O
interactions	O
of	O
these	O
two	O
unlinked	O
disorders	O
are	O
discussed	O
at	O
the	O
clinical	O
and	O
histopathological	O
levels	O
.	O
.	O

Age	O
at	O
diagnosis	O
as	O
an	O
indicator	O
of	O
eligibility	O
for	O
BRCA1	O
DNA	O
testing	O
in	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
.	O

We	O
searched	O
for	O
criteria	O
that	O
could	O
indicate	O
breast	B-Disease
cancer	I-Disease
families	O
with	O
a	O
high	O
prior	O
probability	O
of	O
being	O
caused	O
by	O
the	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
locus	O
BRCA1	O
on	O
chromosome	O
17	O
.	O

To	O
this	O
end	O
,	O
we	O
performed	O
a	O
linkage	O
study	O
with	O
59	O
consecutively	O
collected	O
Dutch	O
breast	B-Disease
cancer	I-Disease
families	O
,	O
including	O
16	O
with	O
at	O
least	O
one	O
case	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O

We	O
used	O
an	O
intake	O
cut	O
-	O
off	O
of	O
at	O
least	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
at	O
any	O
age	O
.	O

Significant	O
evidence	O
for	O
linkage	O
was	O
found	O
only	O
among	O
the	O
13	O
breast	B-Disease
cancer	I-Disease
families	O
with	O
a	O
mean	O
age	O
at	O
diagnosis	O
of	O
less	O
than	O
45	O
years	O
.	O

An	O
unexpectedly	O
low	O
proportion	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1	O
,	O
which	O
could	O
be	O
due	O
to	O
a	O
founder	O
effect	O
in	O
the	O
Dutch	O
population	O
.	O

Given	O
the	O
expected	O
logistical	O
problems	O
in	O
clinical	O
management	O
now	O
that	O
BRCA1	O
has	O
been	O
identified	O
,	O
we	O
propose	O
an	O
interim	O
period	O
in	O
which	O
only	O
families	O
with	O
a	O
strong	O
positive	O
family	O
history	O
for	O
early	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
will	O
be	O
offered	O
BRCA1	O
mutation	O
testing	O
.	O
.	O

Linkage	O
analysis	O
of	O
26	O
Canadian	O
breast	B-Disease
and	I-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O

We	O
have	O
examined	O
26	O
Canadian	O
families	O
with	O
hereditary	B-Disease
breast	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
for	O
linkage	O
to	O
markers	O
flanking	O
the	O
BRCA1	O
gene	O
on	O
chromosome	O
17q12	O
-	O
q21	O
.	O

Of	O
the	O
15	O
families	O
that	O
contain	O
cases	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
94	O
%	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
overall	O
evidence	O
of	O
linkage	O
in	O
the	O
group	O
of	O
10	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
without	O
ovarian	B-Disease
cancer	I-Disease
.	O

A	O
genetic	O
recombinant	O
in	O
a	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
family	O
indicates	O
a	O
placement	O
of	O
BRCA1	O
telomeric	O
to	O
D17S776	O
,	O
and	O
helps	O
to	O
define	O
the	O
region	O
of	O
assignment	O
of	O
the	O
cancer	B-Disease
susceptibility	O
gene	O
.	O

Other	O
cancers	B-Disease
of	O
interest	O
that	O
appeared	O
in	O
the	O
BRCA1	O
-	O
linked	O
families	O
included	O
primary	B-Disease
peritoneal	I-Disease
cancer	I-Disease
,	O
cancer	B-Disease
of	I-Disease
the	I-Disease
fallopian	I-Disease
tube	I-Disease
,	O
and	O
malignant	B-Disease
melanoma	I-Disease
.	O
.	O

Structural	O
analysis	O
of	O
the	O
5	O
'	O
region	O
of	O
mouse	O
and	O
human	O
Huntington	B-Disease
disease	I-Disease
genes	O
reveals	O
conservation	O
of	O
putative	O
promoter	O
region	O
and	O
di	O
-	O
and	O
trinucleotide	O
polymorphisms	O
.	O

We	O
have	O
previously	O
cloned	O
and	O
characterized	O
the	O
murine	O
homologue	O
of	O
the	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
gene	O
and	O
shown	O
that	O
it	O
maps	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O

3	O
3	O
.	O

Here	O
we	O
present	O
a	O
detailed	O
comparison	O
of	O
the	O
sequence	O
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	O
of	O
the	O
5	O
genomic	O
region	O
of	O
the	O
murine	O
(	O
Hdh	O
)	O
and	O
human	O
HD	B-Disease
genes	O
encompassing	O
the	O
first	O
five	O
exons	O
.	O

We	O
show	O
that	O
in	O
this	O
region	O
these	O
two	O
genes	O
share	O
identical	O
exon	O
boundaries	O
,	O
but	O
have	O
different	O
-	O
size	O
introns	O
.	O

Two	O
dinucleotide	O
(	O
CT	O
)	O
and	O
one	O
trinucleotide	O
intronic	O
polymorphism	O
in	O
Hdh	O
and	O
an	O
intronic	O
CA	O
polymorphism	O
in	O
the	O
HD	B-Disease
gene	O
were	O
identified	O
.	O

Comparison	O
of	O
940	O
-	O
bp	O
sequence	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
reveals	O
a	O
highly	O
conserved	O
region	O
(	O
78	O
.	O
8	O
%	O
nucleotide	O
identity	O
)	O
between	O
Hdh	O
and	O
the	O
HD	B-Disease
gene	O
from	O
nucleotide	O
-	O
56	O
to	O
-	O
206	O
(	O
of	O
Hdh	O
)	O
.	O

Neither	O
Hdh	O
nor	O
the	O
HD	B-Disease
gene	O
have	O
typical	O
TATA	O
or	O
CCAAT	O
elements	O
,	O
but	O
both	O
show	O
one	O
putative	O
AP2	O
binding	O
site	O
and	O
numerous	O
potential	O
Sp1	O
binding	O
sites	O
.	O

The	O
high	O
sequence	O
identity	O
between	O
Hdh	O
and	O
the	O
HD	B-Disease
gene	O
for	O
approximately	O
200	O
bp	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
the	O
Huntington	B-Disease
disease	I-Disease
gene	O

The	O
protein	O
deficient	O
in	O
Lowe	B-Disease
syndrome	I-Disease
is	O
a	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
5	O
-	O
phosphatase	O
.	O

Lowe	B-Disease
syndrome	I-Disease
,	O
also	O
known	O
as	O
oculocerebrorenal	B-Disease
syndrome	I-Disease
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
X	O
chromosome	O
-	O
encoded	O
OCRL	O
gene	O
.	O

The	O
OCRL	O
protein	O
is	O
51	O
%	O
identical	O
to	O
inositol	O
polyphosphate	O
5	O
-	O
phosphatase	O
II	O
(	O
5	O
-	O
phosphatase	O
II	O
)	O
from	O
human	O
platelets	O
over	O
a	O
span	O
of	O
744	O
aa	O
,	O
suggesting	O
that	O
OCRL	O
may	O
be	O
a	O
similar	O
enzyme	O
.	O

We	O
engineered	O
a	O
construct	O
of	O
the	O
OCRL	O
cDNA	O
that	O
encodes	O
amino	O
acids	O
homologous	O
to	O
the	O
platelet	O
5	O
-	O
phosphatase	O
for	O
expression	O
in	O
baculovirus	O
-	O
infected	O
Sf9	O
insect	O
cells	O
.	O

This	O
cDNA	O
encodes	O
aa	O
264	O
-	O
968	O
of	O
the	O
OCRL	O
protein	O
.	O

The	O
recombinant	O
protein	O
was	O
found	O
to	O
catalyze	O
the	O
reactions	O
also	O
carried	O
out	O
by	O
platelet	O
5	O
-	O
phosphatase	O
II	O
.	O

Thus	O
OCRL	O
converts	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
to	O
inositol	O
1	O
,	O
4	O
-	O
bisphosphate	O
,	O
and	O
it	O
converts	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrakisphosphate	O
to	O
inositol	O
1	O
,	O
3	O
,	O
4	O
-	O
trisphosphate	O
.	O

Most	O
important	O
,	O
the	O
enzyme	O
converts	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
to	O
phosphatidylinositol	O
4	O
-	O
phosphate	O
.	O

The	O
relative	O
ability	O
of	O
OCRL	O
to	O
catalyze	O
the	O
three	O
reactions	O
is	O
different	O
from	O
that	O
of	O
5	O
-	O
phosphatase	O
II	O
and	O
from	O
that	O
of	O
another	O
5	O
-	O
phosphatase	O
isoenzyme	O
from	O
platelets	O
,	O
5	O
-	O
phosphatase	O
I	O
.	O

The	O
recombinant	O
OCRL	O
protein	O
hydrolyzes	O
the	O
phospholipid	O
substrate	O
10	O
-	O
to	O
30	O
-	O
fold	O
better	O
than	O
5	O
-	O
phosphatase	O
II	O
,	O
and	O
5	O
-	O
phosphatase	O
I	O
does	O
not	O
cleave	O
the	O
lipid	O
at	O
all	O
.	O

We	O
also	O
show	O
that	O
OCRL	O
functions	O
as	O
a	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
5	O
-	O
phosphatase	O
in	O
OCRL	O
-	O
expressing	O
Sf9	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
OCRL	O
is	O
mainly	O
a	O
lipid	O
phosphatase	O
that	O
may	O
control	O
cellular	O
levels	O
of	O
a	O
critical	O
metabolite	O
,	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
.	O

Deficiency	O
of	O
this	O
enzyme	O
apparently	O
causes	O
the	O
protean	O
manifestations	O
of	O
Lowe	B-Disease
syndrome	I-Disease
.	O
.	O

New	O
founder	O
haplotypes	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
in	O
southern	O
Africa	O
.	O

The	O
association	O
between	O
normal	O
alleles	O
at	O
the	O
CTG	O
repeat	O
and	O
two	O
nearby	O
polymorphisms	O
in	O
the	O
myotonin	O
protein	O
kinase	O
gene	O
,	O
the	O
Alu	O
insertion	O
/	O
deletion	O
polymorphism	O
and	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
kinase	O
(	O
DMK	O
)	O
(	O
G	O
/	O
T	O
)	O
intron	O
9	O
/	O
HinfI	O
polymorphism	O
,	O
has	O
been	O
analyzed	O
in	O
South	O
African	O
Negroids	O
,	O
a	O
population	O
in	O
which	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
has	O
not	O
been	O
described	O
.	O

South	O
African	O
Negroids	O
have	O
a	O
CTG	O
allelic	O
distribution	O
that	O
is	O
significantly	O
different	O
from	O
that	O
in	O
Caucasoids	O
and	O
Japanese	O
the	O
CTG	O
repeat	O
lengths	O
of	O
>	O
or	O
=	O
19	O
are	O
very	O
rare	O
.	O

The	O
striking	O
linkage	O
disequilibrium	O
between	O
specific	O
alleles	O
at	O
the	O
Alu	O
polymorphism	O
(	O
Alu	O
(	O
ins	O
)	O
and	O
Alu	O
(	O
del	O
)	O
)	O
,	O
the	O
HinfI	O
polymorphism	O
(	O
HinfI	O
-	O
1	O
and	O
HinfI	O
-	O
2	O
)	O
,	O
and	O
the	O
CTG	O
repeat	O
polymorphism	O
seen	O
in	O
Caucasoid	O
(	O
Europeans	O
and	O
Canadians	O
)	O
populations	O
was	O
also	O
found	O
in	O
the	O
South	O
African	O
Negroid	O
population	O
.	O

Numerous	O
haplotypes	O
,	O
not	O
previously	O
described	O
in	O
Europeans	O
,	O
were	O
,	O
however	O
,	O
found	O
.	O

It	O
thus	O
seems	O
likely	O
that	O
only	O
a	O
small	O
number	O
of	O
these	O
"	O
African	O
"	O
chromosomes	O
were	O
present	O
in	O
the	O
progenitors	O
of	O
all	O
non	O
-	O
African	O
peoples	O
.	O

These	O
data	O
provide	O
support	O
for	O
the	O
"	O
out	O
of	O
Africa	O
"	O
model	O
for	O
the	O
origin	O
of	O
modern	O
humans	O
and	O
suggest	O
that	O
the	O
rare	O
ancestral	O
DM	B-Disease
mutation	O
event	O
may	O
have	O
occurred	O
after	O
the	O
migration	O
from	O
Africa	O
,	O
hence	O
the	O
absence	O
of	O
DM	B-Disease
in	O
sub	O
-	O
Saharan	O
Negroid	O
peoples	O
.	O
.	O

Discordant	O
clinical	O
outcome	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
relatives	O
showing	O
(	O
CTG	O
)	O
n	O
>	O
700	O
repeats	O
.	O

A	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
family	O
is	O
described	O
in	O
which	O
discordant	O
DM	B-Disease
phenotypes	O
were	O
found	O
in	O
the	O
children	O
of	O
two	O
affected	O
sisters	O
with	O
similar	O
CTG	O
expansion	O
and	O
clinical	O
manifestations	O
.	O

In	O
this	O
family	O
,	O
congenital	O
as	O
well	O
as	O
early	O
severe	O
childhood	O
and	O
later	O
childhood	O
onset	O
DM	B-Disease
coexist	O
.	O

This	O
observation	O
strengthens	O
the	O
limited	O
ability	O
of	O
lymphocytes	O
CTG	O
repeat	O
number	O
analysis	O
in	O
predicting	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
DM	B-Disease
patients	O
.	O
.	O

Purification	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
and	O
characterization	O
of	O
its	O
deficiency	O
in	O
seven	O
patients	O
.	O

Mitochondrial	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
VLCAD	O
)	O
was	O
purified	O
from	O
human	O
liver	O
.	O

The	O
molecular	O
masses	O
of	O
the	O
native	O
enzyme	O
and	O
the	O
subunit	O
were	O
estimated	O
to	O
be	O
154	O
and	O
70	O
kD	O
,	O
respectively	O
.	O

The	O
enzyme	O
was	O
found	O
to	O
catalyze	O
the	O
major	O
part	O
of	O
mitochondrial	O
palmitoylcoenzyme	O
A	O
dehydrogenation	O
in	O
liver	O
,	O
heart	O
,	O
skeletal	O
muscle	O
,	O
and	O
skin	O
fibroblasts	O
(	O
89	O
-	O
97	O
,	O
86	O
-	O
99	O
,	O
96	O
-	O
99	O
,	O
and	O
78	O
-	O
87	O
%	O
,	O
respectively	O
)	O
.	O

Skin	O
fibroblasts	O
from	O
26	O
patients	O
suspected	O
of	O
having	O
a	O
disorder	O
of	O
mitochondrial	O
beta	O
-	O
oxidation	O
were	O
analyzed	O
for	O
VLCAD	O
protein	O
using	O
immunoblotting	O
,	O
and	O
7	O
of	O
them	O
contained	O
undetectable	O
or	O
trace	O
levels	O
of	O
the	O
enzyme	O
.	O

The	O
seven	O
deficient	O
fibroblast	O
lines	O
were	O
characterized	O
by	O
measuring	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenation	O
activities	O
,	O
overall	O
palmitic	O
acid	O
oxidation	O
,	O
and	O
VLCAD	O
protein	O
synthesis	O
using	O
pulse	O
-	O
chase	O
,	O
further	O
confirming	O
the	O
diagnosis	O
of	O
VLCAD	B-Disease
deficiency	I-Disease
.	O

These	O
results	O
suggested	O
the	O
heterogenous	O
nature	O
of	O
the	O
mutations	O
causing	O
the	O
deficiency	O
in	O
the	O
seven	O
patients	O
.	O

Clinically	O
,	O
all	O
patients	O
with	O
VLCAD	B-Disease
deficiency	I-Disease
exhibited	O
cardiac	B-Disease
disease	I-Disease
.	O

At	O
least	O
four	O
of	O
them	O
presented	O
with	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
.	O

This	O
frequency	O
(	O
>	O
57	O
%	O
)	O
was	O
much	O
higher	O
than	O
that	O
observed	O
in	O
patients	O
with	O
other	O
disorders	O
of	O
mitochondrial	O
long	O
-	O
chain	O
fatty	O
acid	O
oxidation	O
that	O
may	O
be	O
accompanied	O
by	O
cardiac	B-Disease
disease	I-Disease
in	O
infants	O
.	O
.	O

Hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
man	O
.	O

II	O
.	O

Biological	O
properties	O
of	O
C5	B-Disease
-	I-Disease
deficient	I-Disease
human	O
serum	O
.	O

The	O
first	O
known	O
human	O
kindred	O
with	O
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C5	O
)	O
was	O
documented	O
in	O
the	O
accompanying	O
report	O
.	O

This	O
study	O
examines	O
several	O
biological	O
properties	O
of	O
C5	B-Disease
-	I-Disease
deficient	I-Disease
(	O
C5D	B-Disease
)	O
human	O
serum	O
,	O
particularly	O
sera	O
obtained	O
from	O
two	O
C5D	B-Disease
homozygotes	O
.	O

The	O
proband	O
,	O
who	O
has	O
inactive	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
is	O
completely	O
lacking	O
C5	O
,	O
while	O
her	O
healthy	O
half	O
-	O
sister	O
has	O
1	O
-	O
2	O
%	O
of	O
normal	O
levels	O
.	O

Both	O
sera	O
were	O
severely	O
impaired	O
in	O
their	O
ability	O
to	O
generate	O
chemotactic	O
activity	O
for	O
normal	O
human	O
neutrophils	O
upon	O
incubation	O
with	O
aggregated	O
human	O
gamma	O
-	O
globulin	O
or	O
Escherichia	O
coli	O
endotoxin	O
.	O

This	O
function	O
was	O
fully	O
restored	O
in	O
the	O
siblings	O
serum	O
,	O
and	O
substantially	O
improved	O
in	O
the	O
probands	O
serum	O
,	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
to	O
normal	O
serum	O
concentrations	O
.	O

Sera	O
from	O
eight	O
family	O
members	O
who	O
were	O
apparently	O
heterozygous	O
for	O
C5	B-Disease
deficiency	I-Disease
gave	O
normal	O
chemotactic	O
scores	O
.	O

The	O
ability	O
of	O
C5D	B-Disease
serum	O
to	O
opsonize	O
Saccharomyces	O
cerevisiae	O
(	O
bakers	O
yeast	O
)	O
or	O
Candida	O
albicans	O
for	O
ingestion	O
by	O
normal	O
neutrophils	O
was	O
completely	O
normal	O
.	O

In	O
addition	O
,	O
C5D	B-Disease
serum	O
was	O
capable	O
of	O
promoting	O
normal	O
phagocytosis	O
and	O
intracellular	O
killing	O
of	O
Staphylococcus	O
aureus	O
.	O

The	O
probands	O
serum	O
was	O
incapable	O
of	O
mediating	O
lysis	O
of	O
erythrocytes	O
from	O
a	O
patient	O
with	O
paroxysmal	B-Disease
nocturnal	I-Disease
hemoglobinuria	I-Disease
in	O
both	O
the	O
sucrose	O
hemolysia	O
and	O
acid	O
hemolysis	O
tests	O
,	O
and	O
also	O
lacked	O
bactericidal	O
activity	O
against	O
sensitized	O
or	O
unsensitized	O
Salmonella	O
typhi	O
.	O

The	O
siblings	O
serum	O
,	O
containing	O
only	O
1	O
-	O
2	O
%	O
of	O
normal	O
C5	O
,	O
effectively	O
lysed	O
S	O
.	O
typhi	O
,	O
but	O
only	O
at	O
eightfold	O
lower	O
serum	O
dilutions	O
as	O
compared	O
to	O
normals	O
.	O

These	O
findings	O
underscore	O
the	O
critical	O
role	O
of	O
C5	O
in	O
the	O
generation	O
of	O
chemotactic	O
activity	O
and	O
in	O
cytolytic	O
reactions	O
,	O
as	O
opposed	O
to	O
a	O
nonobligatory	O
or	O
minimal	O
role	O
in	O
opsonization	O
,	O
at	O
least	O
for	O
the	O
organisms	O
under	O
study	O
.	O
.	O

Human	O
peroxisomal	O
targeting	O
signal	O
-	O
1	O
receptor	O
restores	O
peroxisomal	O
protein	O
import	O
in	O
cells	O
from	O
patients	O
with	O
fatal	O
peroxisomal	B-Disease
disorders	I-Disease
.	O

Two	O
peroxisomal	O
targeting	O
signals	O
,	O
PTS1	O
and	O
PTS2	O
,	O
are	O
involved	O
in	O
the	O
import	O
of	O
proteins	O
into	O
the	O
peroxisome	O
matrix	O
.	O

Human	O
patients	O
with	O
fatal	O
generalized	O
peroxisomal	B-Disease
deficiency	I-Disease
disorders	I-Disease
fall	O
into	O
at	O
least	O
nine	O
genetic	O
complementation	O
groups	O
.	O

Cells	O
from	O
many	O
of	O
these	O
patients	O
are	O
deficient	O
in	O
the	O
import	O
of	O
PTS1	O
-	O
containing	O
proteins	O
,	O
but	O
the	O
causes	O
of	O
the	O
protein	O
-	O
import	O
defect	O
in	O
these	O
patients	O
are	O
unknown	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	O
cDNA	O
homologue	O
(	O
PTS1R	O
)	O
of	O
the	O
Pichia	O
pastoris	O
PAS8	O
gene	O
,	O
the	O
PTS1	O
receptor	O
(	O
McCollum	O
,	O
D	O
.	O
,	O
E	O
.	O
Monosov	O
,	O
and	O
S	O
.	O
Subramani	O
.	O
1993	O
.	O
J	O
.	O
Cell	O
Biol	O
.	O
121	O
761	O
-	O
774	O
)	O
.	O

The	O
PTS1R	O
mRNA	O
is	O
expressed	O
in	O
all	O
human	O
tissues	O
examined	O
.	O

Antibodies	O
to	O
the	O
human	O
PTS1R	O
recognize	O
this	O
protein	O
in	O
human	O
,	O
monkey	O
,	O
rat	O
,	O
and	O
hamster	O
cells	O
.	O

The	O
protein	O
is	O
localized	O
mainly	O
in	O
the	O
cytosol	O
but	O
is	O
also	O
found	O
to	O
be	O
associated	O
with	O
peroxisomes	O
.	O

Part	O
of	O
the	O
peroxisomal	O
PTS1R	O
protein	O
is	O
tightly	O
bound	O
to	O
the	O
peroxisomal	O
membrane	O
.	O

Antibodies	O
to	O
PTS1R	O
inhibit	O
peroxisomal	O
protein	O
-	O
import	O
of	O
PTS1	O
-	O
containing	O
proteins	O
in	O
a	O
permeabilized	O
CHO	O
cell	O
system	O
.	O

In	O
vitro	O
-	O
translated	O
PTS1R	O
protein	O
specifically	O
binds	O
a	O
serine	O
-	O
lysine	O
-	O
leucine	O
-	O
peptide	O
.	O

A	O
PAS8	O
-	O
PTS1R	O
fusion	O
protein	O
complements	O
the	O
P	O
.	O
pastoris	O
pas8	O
mutant	O
.	O

The	O
PTS1R	O
cDNA	O
also	O
complements	O
the	O
PTS1	B-Disease
protein	I-Disease
-	I-Disease
import	I-Disease
defect	I-Disease
in	O
skin	O
fibroblasts	O
from	O
patients	O
-	O
-	O
belonging	O
to	O
complementation	O
group	O
two	O
-	O
-	O
diagnosed	O
as	O
having	O
neonatal	B-Disease
adrenoleukodystrophy	I-Disease
or	O
Zellweger	B-Disease
syndrome	I-Disease
.	O

The	O
PTS1R	O
gene	O
has	O
been	O
localized	O
to	O
a	O
chromosomal	O
location	O
where	O
no	O
other	O
peroxisomal	B-Disease
disorder	I-Disease
genes	O
are	O
known	O
to	O
map	O
.	O

Our	O
findings	O
represent	O
the	O
only	O
case	O
in	O
which	O
the	O
molecular	O
basis	O
of	O
the	O
protein	B-Disease
-	I-Disease
import	I-Disease
deficiency	I-Disease
in	O
human	O
peroxisomal	B-Disease
disorders	I-Disease
is	O
understood	O
.	O

Spectrum	O
of	O
germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
:	O
a	O
study	O
of	O
232	O
patients	O
with	O
hereditary	B-Disease
and	I-Disease
non	I-Disease
hereditary	I-Disease
retinoblastoma	I-Disease
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
confer	O
hereditary	O
predisposition	O
to	O
retinoblastoma	B-Disease
.	O

We	O
have	O
performed	O
a	O
mutation	O
survey	O
of	O
the	O
RB1	O
gene	O
in	O
232	O
patients	O
with	O
hereditary	B-Disease
or	I-Disease
non	I-Disease
hereditary	I-Disease
retinoblastoma	I-Disease
.	O

We	O
systematically	O
explored	O
all	O
27	O
exons	O
and	O
flanking	O
sequences	O
as	O
well	O
as	O
the	O
promotor	O
.	O

All	O
types	O
of	O
point	O
mutations	O
are	O
represented	O
and	O
are	O
found	O
unequally	O
distributed	O
along	O
the	O
RB1	O
gene	O
sequence	O
.	O

In	O
the	O
population	O
we	O
studied	O
,	O
exons	O
3	O
,	O
8	O
,	O
18	O
and	O
19	O
are	O
preferentially	O
altered	O
.	O

The	O
range	O
of	O
frequency	O
of	O
detection	O
of	O
germline	O
mutations	O
is	O
about	O
20	O
%	O
,	O
indicating	O
that	O
other	O
mechanisms	O
of	O
inactivation	O
of	O
RB1	O
should	O
be	O
involved	O
.	O

The	O
spectrum	O
of	O
mutations	O
presented	O
here	O
should	O
help	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
retinoblastoma	B-Disease
and	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
leading	O
to	O
tumorigenesis	O
.	O
.	O

Aniridia	B-Disease
-	O
associated	O
cytogenetic	O
rearrangements	O
suggest	O
that	O
a	O
position	O
effect	O
may	O
cause	O
the	O
mutant	O
phenotype	O
.	O

Current	O
evidence	O
suggests	O
that	O
aniridia	B-Disease
(	O
absence	B-Disease
of	I-Disease
iris	I-Disease
)	O
is	O
caused	O
by	O
loss	O
of	O
function	O
of	O
one	O
copy	O
of	O
the	O
PAX6	O
gene	O
,	O
which	O
maps	O
to	O
11p13	O
.	O

We	O
present	O
the	O
further	O
characterisation	O
of	O
two	O
aniridia	B-Disease
pedigrees	O
in	O
which	O
the	O
disease	O
segregates	O
with	O
chromosomal	O
rearrangements	O
which	O
involve	O
11p13	O
but	O
do	O
not	O
disrupt	O
the	O
PAX6	O
gene	O
.	O

We	O
have	O
isolated	O
three	O
human	O
YAC	O
clones	O
which	O
encompass	O
the	O
PAX6	O
locus	O
and	O
we	O
have	O
used	O
these	O
to	O
show	O
that	O
in	O
both	O
cases	O
the	O
chromosomal	O
breakpoint	O
is	O
at	O
least	O
85	O
kb	O
distal	O
of	O
the	O
3	O
end	O
of	O
PAX6	O
.	O

In	O
addition	O
,	O
the	O
open	O
reading	O
frame	O
of	O
PAX6	O
is	O
apparently	O
free	O
of	O
mutations	O
.	O

We	O
propose	O
that	O
the	O
PAX6	O
gene	O
on	O
the	O
rearranged	O
chromosome	O
11	O
is	O
in	O
an	O
inappropriate	O
chromatin	O
environment	O
for	O
normal	O
expression	O
and	O
therefore	O
that	O
a	O
position	O
effect	O
is	O
the	O
underlying	O
mechanism	O
of	O
disease	O
in	O
these	O
families	O
.	O
.	O

Somatic	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
sporadic	B-Disease
ovarian	I-Disease
tumours	I-Disease
.	O

The	O
BRCA1	O
gene	O
on	O
chromosome	O
17q21	O
is	O
responsible	O
for	O
an	O
autosomal	B-Disease
dominant	I-Disease
syndrome	I-Disease
of	O
increased	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
but	O
no	O
somatic	O
mutations	O
in	O
tumours	B-Disease
have	O
yet	O
been	O
described	O
.	O

To	O
study	O
the	O
potential	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
carcinogenesis	O
,	O
we	O
analysed	O
the	O
genomic	O
DNA	O
of	O
tumour	B-Disease
and	O
normal	O
fractions	O
of	O
47	O
ovarian	B-Disease
cancers	I-Disease
for	O
mutations	O
in	O
BRCA1	O
using	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O

We	O
now	O
describe	O
somatic	O
mutations	O
in	O
the	O
DNA	O
of	O
four	O
tumours	B-Disease
which	O
also	O
had	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
a	O
BRCA1	O
intragenic	O
marker	O
.	O

Our	O
data	O
support	O
a	O
tumour	B-Disease
suppressor	O
mechanism	O
for	O
BRCA1	O
;	O
somatic	O
mutations	O
and	O
LOH	O
may	O
result	O
in	O
inactivation	O
of	O
BRCA1	O
in	O
at	O
least	O
a	O
small	O
number	O
of	O
ovarian	B-Disease
cancers	I-Disease
.	O
.	O

Decreased	O
expression	O
of	O
BRCA1	O
accelerates	O
growth	O
and	O
is	O
often	O
present	O
during	O
sporadic	B-Disease
breast	I-Disease
cancer	I-Disease
progression	O
.	O

We	O
have	O
characterized	O
expression	O
of	O
the	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
,	O
BRCA1	O
,	O
in	O
cases	O
of	O
non	B-Disease
-	I-Disease
hereditary	I-Disease
(	I-Disease
sporadic	I-Disease
)	I-Disease
breast	I-Disease
cancer	I-Disease
and	O
analyzed	O
the	O
effect	O
of	O
antisense	O
inhibition	O
of	O
BRCA1	O
on	O
the	O
proliferative	O
rate	O
of	O
mammary	O
epithelial	O
cells	O
.	O

BRCA1	O
mRNA	O
levels	O
are	O
markedly	O
decreased	O
during	O
the	O
transition	O
from	O
carcinoma	B-Disease
in	I-Disease
situ	I-Disease
to	O
invasive	B-Disease
cancer	I-Disease
.	O

Experimental	O
inhibition	O
of	O
BRCA1	O
expression	O
with	O
antisense	O
oligonucleotides	O
produced	O
accelerated	O
growth	O
of	O
normal	O
and	O
malignant	O
mammary	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
non	O
-	O
mammary	O
epithelial	O
cells	O
.	O

These	O
studies	O
suggest	O
that	O
BRCA1	O
may	O
normally	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
mammary	O
epithelial	O
cell	O
growth	O
whose	O
function	O
is	O
compromised	O
in	O
breast	B-Disease
cancer	I-Disease
either	O
by	O
direct	O
mutation	O
or	O
alterations	O
in	O
gene	O
expression	O
.	O
.	O

Additional	O
case	O
of	O
female	O
monozygotic	O
twins	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
due	O
to	O
opposite	O
X	O
-	O
chromosome	O
inactivation	O
.	O

A	O
pair	O
of	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
,	O
heterozygous	O
carriers	O
for	O
a	O
deletion	O
in	O
the	O
DMD	B-Disease
gene	O
and	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
were	O
analyzed	O
by	O
molecular	O
studies	O
,	O
in	O
situ	O
hybridization	O
,	O
and	O
methylation	O
pattern	O
of	O
X	O
chromosomes	O
to	O
search	O
for	O
opposite	O
X	O
inactivation	O
as	O
an	O
explanation	O
of	O
their	O
clinical	O
discordance	O
.	O

Results	O
in	O
lymphocytes	O
and	O
skin	O
fibroblast	O
cell	O
lines	O
suggest	O
a	O
partial	O
mirror	O
inactivation	O
with	O
the	O
normal	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
unaffected	O
twin	O
,	O
and	O
the	O
maternal	O
deleted	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
affected	O
twin	O
.	O

A	O
review	O
shows	O
that	O
MZ	O
female	O
twins	O
discordant	O
for	O
X	B-Disease
-	I-Disease
linked	I-Disease
diseases	I-Disease
are	O
not	O
uncommon	O
.	O

Twinning	O
and	O
X	O
inactivation	O
may	O
be	O
interrelated	O
and	O
could	O
explain	O
the	O
female	O
twins	O
discordant	O
for	O
X	O
-	O
linked	O
traits	O
.	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
:	O
a	O
novel	O
mutation	O
of	O
the	O
ALD	B-Disease
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes	O
.	O

Fragments	O
of	O
the	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
cDNA	O
from	O
a	O
patient	O
with	O
adolescent	B-Disease
ALD	I-Disease
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned	O
.	O

Bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ALD	B-Disease
gene	O
disclosed	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
at	O
nucleotide	O
1451	O
in	O
exon	O
five	O
,	O
resulting	O
in	O
substitution	O
of	O
proline	O
484	O
by	O
arginine	O
.	O

Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	O
,	O
comprising	O
two	O
cerebral	B-Disease
ALD	I-Disease
,	O
one	O
adrenomyeloneuropathy	B-Disease
,	O
one	O
Addison	B-Disease
only	I-Disease
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	O
long	O
chain	O
fatty	O
acids	O
)	O
carried	O
this	O
mutation	O
,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
,	O
in	O
five	O
unrelated	O
ALD	B-Disease
patients	O
,	O
and	O
in	O
twenty	O
controls	O
.	O

We	O
propose	O
that	O
this	O
missense	O
mutation	O
generated	O
the	O
disease	O
per	O
se	O
as	O
well	O
as	O
the	O
metabolic	O
defect	O
;	O
the	O
different	O
phenotypes	O
,	O
however	O
,	O
must	O
have	O
originated	O
by	O
means	O
of	O
additional	O
pathogenetic	O
factors	O
.	O
.	O

Novel	O
mutation	O
at	O
the	O
initiation	O
codon	O
in	O
the	O
Norrie	B-Disease
disease	I-Disease
gene	O
in	O
two	O
Japanese	O
families	O
.	O

We	O
have	O
identified	O
a	O
new	O
mutation	O
of	O
Norrie	B-Disease
disease	I-Disease
(	O
ND	B-Disease
)	O
gene	O
in	O
two	O
Japanese	O
males	O
from	O
unrelated	O
families	O
;	O
they	O
showed	O
typical	O
ocular	O
features	O
of	O
ND	B-Disease
but	O
no	O
mental	B-Disease
retardation	I-Disease
or	O
hearing	B-Disease
impairment	I-Disease
.	O

A	O
mutation	O
was	O
found	O
in	O
both	O
patients	O
at	O
the	O
initiation	O
codon	O
of	O
exon	O
2	O
of	O
the	O
ND	B-Disease
gene	O
(	O
ATG	O
to	O
GTG	O
)	O
,	O
with	O
otherwise	O
normal	O
nucleotide	O
sequences	O
.	O

Their	O
mothers	O
had	O
the	O
normal	O
and	O
mutant	O
types	O
of	O
the	O
gene	O
,	O
which	O
was	O
expected	O
for	O
heterozygotes	O
of	O
the	O
disease	O
.	O

The	O
mutation	O
of	O
the	O
initiation	O
codon	O
would	O
cause	O
the	O
failure	O
of	O
ND	B-Disease
gene	O
expression	O
or	O
a	O
defect	O
in	O
translation	O
thereby	O
truncating	O
the	O
amino	O
terminus	O
of	O
ND	B-Disease
protein	O
.	O

In	O
view	O
of	O
the	O
rarity	O
and	O
marked	O
heterogeneity	O
of	O
mutations	O
in	O
the	O
ND	B-Disease
gene	O
,	O
the	O
present	O
apparently	O
unrelated	O
Japanese	O
families	O
who	O
have	O
lived	O
in	O
the	O
same	O
area	O
for	O
over	O
two	O
centuries	O
presumably	O
share	O
the	O
origin	O
of	O
the	O
mutation	O
.	O
.	O

Anticipation	O
resulting	O
in	O
elimination	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
gene	O
:	O
a	O
follow	O
up	O
study	O
of	O
one	O
extended	O
family	O
.	O

We	O
have	O
re	O
-	O
examined	O
an	O
extended	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
family	O
,	O
previously	O
described	O
in	O
1955	O
,	O
in	O
order	O
to	O
study	O
the	O
long	O
term	O
effects	O
of	O
anticipation	O
in	O
DM	B-Disease
and	O
in	O
particular	O
the	O
implications	O
for	O
families	O
affected	O
by	O
this	O
disease	O
.	O

This	O
follow	O
up	O
study	O
provides	O
data	O
on	O
35	O
gene	O
carriers	O
and	O
46	O
asymptomatic	O
at	O
risk	O
family	O
members	O
in	O
five	O
generations	O
.	O

Clinical	O
anticipation	O
,	O
defined	O
as	O
the	O
cascade	O
of	O
mild	O
,	O
adult	O
,	O
childhood	O
,	O
or	O
congenital	B-Disease
disease	I-Disease
in	O
subsequent	O
generations	O
,	O
appeared	O
to	O
be	O
a	O
relentless	O
process	O
,	O
occurring	O
in	O
all	O
affected	O
branches	O
of	O
the	O
family	O
.	O

The	O
cascade	O
was	O
found	O
to	O
proceed	O
asynchronously	O
in	O
the	O
different	O
branches	O
,	O
mainly	O
because	O
of	O
an	O
unequal	O
number	O
of	O
generations	O
with	O
mild	O
disease	O
.	O

The	O
transition	O
from	O
the	O
mild	O
to	O
the	O
adult	O
type	O
was	O
associated	O
with	O
transmission	O
through	O
a	O
male	O
parent	O
.	O

Stable	O
transmission	O
of	O
the	O
asymptomatic	O
/	O
mild	O
phenotype	O
showed	O
a	O
female	O
transmission	O
bias	O
.	O

We	O
further	O
examined	O
the	O
extent	O
and	O
causes	O
of	O
gene	O
loss	O
in	O
this	O
pedigree	O
.	O

Gene	O
loss	O
in	O
the	O
patient	O
group	O
was	O
complete	O
,	O
owing	O
to	O
infertility	B-Disease
of	O
the	O
male	O
patients	O
with	O
adult	O
onset	O
disease	O
and	O
the	O
fact	O
that	O
mentally	B-Disease
retarded	I-Disease
patients	O
did	O
not	O
procreate	O
.	O

Out	O
of	O
the	O
46	O
at	O
risk	O
subjects	O
in	O
the	O
two	O
youngest	O
generations	O
,	O
only	O
one	O
was	O
found	O
to	O
have	O
a	O
full	O
mutation	O
.	O

This	O
is	O
the	O
only	O
subject	O
who	O
may	O
transmit	O
the	O
gene	O
to	O
the	O
sixth	O
generation	O
.	O

No	O
protomutation	O
carriers	O
were	O
found	O
in	O
the	O
fourth	O
and	O
fifth	O
generations	O
.	O

Therefore	O
it	O
is	O
highly	O
probable	O
that	O
the	O
DM	B-Disease
gene	O
will	O
be	O
eliminated	O
from	O
this	O
pedigree	O
within	O
one	O
generation	O
.	O

The	O
high	O
population	O
frequency	O
of	O
DM	B-Disease
can	O
at	O
present	O
not	O
be	O
explained	O
by	O
the	O
contribution	O
of	O
asymptomatic	O
cases	O
in	O
the	O
younger	O
generations	O
of	O
known	O
families	O
,	O
but	O
is	O
probably	O
caused	O
by	O
the	O
events	O
in	O
the	O
ancestral	O
generations	O
.	O
.	O

The	O
gene	O
for	O
spinal	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
3	O
(	O
SCA3	O
)	O
is	O
located	O
in	O
a	O
region	O
of	O
approximately	O
3	O
cM	O
on	O
chromosome	O
14q24	O
.	O
3	O
-	O
q32	O
.	O
2	O
.	O

SCA3	O
,	O
the	O
gene	O
for	O
spinal	B-Disease
cerebellar	I-Disease
ataxia	I-Disease
3	O
,	O
was	O
recently	O
mapped	O
to	O
a	O
15	O
-	O
cM	O
interval	O
between	O
D14S67	O
and	O
D14S81	O
on	O
chromosome	O
14q	O
,	O
by	O
linkage	O
analysis	O
in	O
two	O
families	O
of	O
French	O
ancestry	O
.	O

The	O
SCA3	O
candidate	O
region	O
has	O
now	O
been	O
refined	O
by	O
linkage	O
analysis	O
with	O
four	O
new	O
microsatellite	O
markers	O
(	O
D14S256	O
,	O
D14S291	O
,	O
D14S280	O
,	O
and	O
AFM343vf1	O
)	O
in	O
the	O
same	O
two	O
families	O
,	O
in	O
which	O
19	O
additional	O
individuals	O
were	O
genotyped	O
,	O
and	O
in	O
a	O
third	O
French	O
family	O
.	O

Combined	O
two	O
-	O
point	O
linkage	O
analyses	O
show	O
that	O
the	O
new	O
markers	O
,	O
D14S280	O
and	O
AFM343vf1	O
,	O
are	O
tightly	O
linked	O
to	O
the	O
SCA3	O
locus	O
,	O
with	O
maximal	O
lod	O
scores	O
,	O
at	O
recombination	O
fraction	O
,	O
(	O
theta	O
)	O
=	O
.	O

00	O
,	O
of	O
7	O
.	O

05	O
and	O
13	O
.	O

70	O
,	O
respectively	O
.	O

Combined	O
multipoint	O
and	O
recombinant	O
haplotype	O
analyses	O
localize	O
the	O
SCA3	O
locus	O
to	O
a	O
3	O
-	O
cM	O
interval	O
flanked	O
by	O
D14S291	O
and	O
D14S81	O
.	O

The	O
same	O
allele	O
for	O
D14S280	O
segregates	O
with	O
the	O
disease	O
locus	O
in	O
the	O
three	O
kindreds	O
.	O

This	O
allele	O
is	O
frequent	O
in	O
the	O
French	O
population	O
,	O
however	O
,	O
and	O
linkage	O
disequilibrium	O
is	O
not	O
clearly	O
established	O
.	O

The	O
SCA3	O
locus	O
remains	O
within	O
the	O
29	O
-	O
cM	O
region	O
on	O
14q24	O
.	O

3	O
-	O
q32	O
.	O

2	O
containing	O
the	O
gene	O
for	O
the	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
,	O
which	O
is	O
clinically	O
related	O
to	O
the	O
phenotype	O
determined	O
by	O
SCA3	O
,	O
but	O
it	O
cannot	O
yet	O
be	O
concluded	O
that	O
both	O
diseases	O
result	O
from	O
alterations	O
of	O
the	O
same	O
gene	O

An	O
evaluation	O
of	O
genetic	O
heterogeneity	O
in	O
145	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O

Breast	B-Disease
Cancer	I-Disease
Linkage	O
Consortium	O
.	O

The	O
breast	B-Disease
-	I-Disease
ovary	I-Disease
cancer	I-Disease
-	I-Disease
family	I-Disease
syndrome	I-Disease
is	O
a	O
dominant	O
predisposition	O
to	O
cancer	B-Disease
of	I-Disease
the	I-Disease
breast	I-Disease
and	I-Disease
ovaries	I-Disease
which	O
has	O
been	O
mapped	O
to	O
chromosome	O
region	O
17q12	O
-	O
q21	O
.	O

The	O
majority	O
,	O
but	O
not	O
all	O
,	O
of	O
breast	B-Disease
-	I-Disease
ovary	I-Disease
cancer	I-Disease
families	O
show	O
linkage	O
to	O
this	O
susceptibility	O
locus	O
,	O
designated	O
BRCA1	O
.	O

We	O
report	O
here	O
the	O
results	O
of	O
a	O
linkage	O
analysis	O
of	O
145	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

These	O
families	O
contain	O
either	O
a	O
total	O
of	O
three	O
or	O
more	O
cases	O
of	O
early	O
-	O
onset	O
(	O
before	O
age	O
60	O
years	O
)	O
breast	B-Disease
cancer	I-Disease
or	O
ovarian	B-Disease
cancer	I-Disease
.	O

All	O
families	O
contained	O
at	O
least	O
one	O
case	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O

Overall	O
,	O
an	O
estimated	O
76	O
%	O
of	O
the	O
145	O
families	O
are	O
linked	O
to	O
the	O
BRCA1	O
locus	O
.	O

None	O
of	O
the	O
13	O
families	O
with	O
cases	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
appear	O
to	O
be	O
linked	O
,	O
but	O
it	O
is	O
estimated	O
that	O
92	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
76	O
%	O
-	O
100	O
%	O
)	O
of	O
families	O
with	O
no	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
and	O
with	O
two	O
or	O
more	O
ovarian	B-Disease
cancers	I-Disease
are	O
linked	O
to	O
BRCA1	O
.	O

These	O
data	O
suggest	O
that	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
-	I-Disease
family	I-Disease
syndrome	I-Disease
is	O
genetically	O
heterogeneous	O
.	O

However	O
,	O
the	O
large	O
majority	O
of	O
families	O
with	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
and	O
with	O
two	O
or	O
more	O
cases	O
of	O
ovarian	B-Disease
cancer	I-Disease
are	O
likely	O
to	O
be	O
due	O
to	O
BRCA1	O
mutations	O
.	O
.	O

Molecular	O
basis	O
of	O
essential	B-Disease
fructosuria	I-Disease
:	O
molecular	O
cloning	O
and	O
mutational	O
analysis	O
of	O
human	O
ketohexokinase	O
(	O
fructokinase	O
)	O
.	O

Essential	B-Disease
fructosuria	I-Disease
is	O
one	O
of	O
the	O
oldest	O
known	O
inborn	B-Disease
errors	I-Disease
of	I-Disease
metabolism	I-Disease
.	O

It	O
is	O
a	O
benign	O
condition	O
which	O
is	O
believed	O
to	O
result	O
from	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
fructokinase	I-Disease
(	O
ketohexokinase	O
,	O
KHK	O
,	O
E	O
.	O
C	O
.	O
2	O
.	O
7	O
.	O
1	O
.	O
3	O
)	O
.	O

This	O
enzyme	O
catalyses	O
the	O
first	O
step	O
of	O
metabolism	O
of	O
dietary	O
fructose	O
,	O
conversion	O
of	O
fructose	O
to	O
fructose	O
-	O
1	O
-	O
phosphate	O
.	O

Despite	O
the	O
early	O
recognition	O
of	O
this	O
disorder	O
,	O
the	O
primary	O
structure	O
of	O
human	O
KHK	O
and	O
the	O
molecular	O
basis	O
of	O
essential	B-Disease
fructosuria	I-Disease
have	O
not	O
been	O
previously	O
defined	O
.	O

In	O
this	O
report	O
,	O
the	O
isolation	O
and	O
sequencing	O
of	O
full	O
-	O
length	O
cDNA	O
clones	O
encoding	O
human	O
ketohexokinase	O
are	O
described	O
.	O

Alternative	O
mRNA	O
species	O
and	O
alternative	O
KHK	O
isozymes	O
are	O
produced	O
by	O
alternative	O
polyadenylation	O
and	O
splicing	O
of	O
the	O
KHK	O
gene	O
.	O

The	O
KHK	O
proteins	O
show	O
a	O
high	O
level	O
of	O
sequence	O
conservation	O
relative	O
to	O
rat	O
KHK	O
.	O

Direct	O
evidence	O
that	O
mutation	O
of	O
the	O
KHK	O
structural	O
gene	O
is	O
the	O
cause	O
of	O
essential	B-Disease
fructosuria	I-Disease
was	O
also	O
obtained	O
.	O

In	O
a	O
well	O
-	O
characterized	O
family	O
,	O
in	O
which	O
three	O
of	O
eight	O
siblings	O
have	O
fructosuria	B-Disease
,	O
all	O
affected	O
individuals	O
are	O
compound	O
heterozygotes	O
for	O
two	O
mutations	O
Gly40Arg	O
and	O
Ala43Thr	O
.	O

Both	O
mutations	O
result	O
from	O
G	O
-	O
-	O
>	O
A	O
transitions	O
,	O
and	O
each	O
alters	O
the	O
same	O
conserved	O
region	O
of	O
the	O
KHK	O
protein	O
.	O

Neither	O
mutation	O
was	O
seen	O
in	O
a	O
sample	O
of	O
52	O
unrelated	O
control	O
individuals	O
.	O

An	O
additional	O
conservative	O
amino	O
acid	O
change	O
(	O
Val49IIe	O
)	O
was	O
present	O
on	O
the	O
KHK	O
allele	O
bearing	O
Ala43Thr	O

Homozygous	O
presence	O
of	O
the	O
crossover	O
(	O
fusion	O
gene	O
)	O
mutation	O
identified	O
in	O
a	O
type	B-Disease
II	I-Disease
Gaucher	I-Disease
disease	I-Disease
fetus	O
:	O
is	O
this	O
analogous	O
to	O
the	O
Gaucher	O
knock	O
-	O
out	O
mouse	O
model	O
?	O

Gaucher	B-Disease
disease	I-Disease
(	O
GD	B-Disease
)	O
is	O
an	O
inherited	O
deficiency	B-Disease
of	I-Disease
beta	I-Disease
-	I-Disease
glucocerebrosidase	I-Disease
(	O
EC	O
3	O
.	O
1	O
.	O
2	O
.	O
45	O
,	O
gene	O
symbol	O
GBA	O
)	O
.	O

In	O
type	B-Disease
I	I-Disease
GD	I-Disease
,	O
the	O
CNS	O
is	O
not	O
involved	O
(	O
nonneuronopathic	O
)	O
,	O
whereas	O
in	O
type	B-Disease
II	I-Disease
GD	I-Disease
(	O
acute	O
neuronopathic	O
)	O
CNS	O
involvement	O
is	O
early	O
and	O
rapidly	O
progressive	O
,	O
while	O
in	O
type	B-Disease
III	I-Disease
GD	I-Disease
(	O
subacute	O
neuronopathic	O
)	O
CNS	O
involvement	O
occurs	O
later	O
and	O
is	O
slowly	O
progressive	O
.	O

The	O
T6433C	O
(	O
L444P	O
)	O
substitution	O
is	O
prevalent	O
in	O
type	B-Disease
GD	I-Disease
II	I-Disease
.	O

It	O
may	O
occur	O
alone	O
as	O
a	O
single	O
base	O
-	O
pair	O
mutation	O
but	O
often	O
is	O
found	O
as	O
part	O
of	O
a	O
complex	O
allele	O
containing	O
additional	O
GBA	O
nucleotide	O
substitutions	O
,	O
G6468C	O
(	O
A456P	O
)	O
and	O
G6482C	O
(	O
V460V	O
)	O
,	O
without	O
(	O
recNciI	O
)	O
or	O
with	O
(	O
recTL	O
)	O
G5957C	O
(	O
D409H	O
)	O
.	O

This	O
complex	O
allele	O
is	O
presumed	O
to	O
have	O
formed	O
by	O
recombination	O
(	O
crossover	O
,	O
fusion	O
)	O
of	O
the	O
structural	O
gene	O
with	O
the	O
pseudogene	O
,	O
which	O
contains	O
the	O
mutated	O
sequences	O
.	O

Two	O
complex	O
alleles	O
have	O
never	O
been	O
demonstrated	O
to	O
coexist	O
in	O
any	O
individual	O
.	O

We	O
devised	O
a	O
selective	O
PCR	O
method	O
for	O
the	O
specific	O
amplification	O
of	O
the	O
normal	O
and	O
/	O
or	O
fusion	O
gene	O
.	O

Using	O
this	O
procedure	O
we	O
demonstrated	O
the	O
fusion	O
gene	O
in	O
homozygous	O
form	O
for	O
the	O
first	O
time	O
,	O
in	O
a	O
Macedonian	O
/	O
Ashkenazi	O
Jewish	O
GD	B-Disease
type	I-Disease
II	I-Disease
fetus	O
.	O

Both	O
parents	O
were	O
carriers	O
of	O
the	O
recombination	O
.	O

This	O
was	O
confirmed	O
by	O
direct	O
sequence	O
analysis	O
.	O

A	O
previous	O
conceptus	O
in	O
this	O
family	O
was	O
stillborn	B-Disease
at	O
36	O
weeks	O
,	O
with	O
features	O
of	O
severe	O
type	B-Disease
II	I-Disease
GD	I-Disease
.	O

Neonates	O
showing	O
a	O
severe	O
clinical	O
phenotype	O
,	O
analogous	O
to	O
the	O
early	O
neonatal	O
lethal	O
disease	O
occurring	O
in	O
mice	O
homozygous	O
for	O
a	O
null	O
allele	O
produced	O
by	O
targeted	O
disruption	O
of	O
GBA	O
,	O
have	O
been	O
described	O
elsewhere	O
,	O
but	O
the	O
specific	O
mutations	O
in	O
these	O
cases	O
have	O
not	O
yet	O
been	O
characterized	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Late	O
infantile	O
metachromatic	B-Disease
leukodystrophy	I-Disease
in	O
Israel	O
.	O

Metachromatic	B-Disease
Leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
is	O
a	O
neurodegenerative	B-Disease
disease	I-Disease
in	O
which	O
the	O
lysosomal	O
enzyme	O
,	O
Aryl	O
sulfatase	O
A	O
(	O
ARSA	O
)	O
is	O
deficient	O
.	O

The	O
disease	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
its	O
frequency	O
is	O
estimated	O
to	O
be	O
1	O
/	O
40	O
,	O
000	O
live	O
births	O
.	O

The	O
gene	O
of	O
ARSA	O
has	O
been	O
cloned	O
and	O
up	O
to	O
now	O
eight	O
mutations	O
causing	O
MLD	B-Disease
have	O
been	O
reported	O
.	O

Another	O
mutation	O
,	O
PD	O
,	O
leads	O
to	O
the	O
deficiency	O
of	O
the	O
enzyme	O
in	O
vitro	O
(	O
pseudodeficiency	O
)	O
without	O
any	O
known	O
clinical	O
effect	O
.	O

The	O
PD	O
mutation	O
is	O
frequent	O
in	O
all	O
populations	O
.	O

In	O
Israel	O
,	O
late	O
infantile	O
MLD	B-Disease
was	O
found	O
to	O
be	O
very	O
frequent	O
in	O
a	O
small	O
Jewish	O
isolate	O
,	O
the	O
Habbanite	O
Jews	O
(	O
1	O
/	O
75	O
live	O
births	O
)	O
.	O

The	O
molecular	O
analysis	O
demonstrated	O
that	O
in	O
the	O
Habbanite	O
population	O
,	O
the	O
mutation	O
occurred	O
on	O
an	O
allele	O
with	O
the	O
PD	O
mutation	O
.	O

The	O
loss	O
of	O
ARSA	O
activity	O
is	O
due	O
to	O
a	O
point	O
mutation	O
C	O
>	O
T	O
leading	O
to	O
a	O
change	O
of	O
proline	O
to	O
leucine	O
.	O

MLD	B-Disease
is	O
also	O
frequent	O
among	O
Moslem	O
Arabs	O
in	O
Jerusalem	O
.	O

The	O
mutation	O
is	O
a	O
transition	O
G	O
>	O
A	O
destroying	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
2	O
.	O

This	O
mutation	O
has	O
been	O
reported	O
in	O
patients	O
with	O
the	O
late	O
infantile	O
MLD	B-Disease
from	O
different	O
ethnic	O
groups	O
.	O

The	O
Christian	O
Arabs	O
in	O
Israel	O
also	O
have	O
a	O
high	O
incidence	O
of	O
the	O
disease	O
(	O
1	O
/	O
10	O
,	O
000	O
live	O
births	O
)	O
;	O
the	O
mutation	O
in	O
this	O
population	O
is	O
still	O
unknown	O
.	O

Knowledge	O
of	O
the	O
different	O
mutations	O
causing	O
MLD	B-Disease
in	O
these	O
defined	O
populations	O
will	O
allow	O
a	O
carrier	O
screening	O
program	O
to	O
be	O
carried	O
out	O
and	O
prevent	O
the	O
birth	O
of	O
additional	O
affected	O
children	O
.	O
.	O

A	O
single	O
amino	O
acid	O
substitution	O
(	O
G103D	O
)	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produces	O
Kniest	B-Disease
dysplasia	I-Disease
.	O

Kniest	B-Disease
dysplasia	I-Disease
is	O
a	O
moderately	O
severe	O
chondrodysplasia	B-Disease
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
II	O
collagen	O
,	O
COL2A1	O
.	O

Characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	B-Disease
trunk	I-Disease
and	I-Disease
extremities	I-Disease
,	O
mid	B-Disease
-	I-Disease
face	I-Disease
hypoplasia	I-Disease
,	O
cleft	B-Disease
palate	I-Disease
,	O
myopia	B-Disease
,	O
retinal	B-Disease
detachment	I-Disease
,	O
and	O
hearing	B-Disease
loss	I-Disease
.	O

Recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
Kniest	B-Disease
dysplasia	I-Disease
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
Kniest	B-Disease
dysplasia	I-Disease
phenotype	O
.	O

We	O
used	O
SSCP	O
to	O
analyze	O
an	O
amplified	O
genomic	O
DNA	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
Kniest	B-Disease
dysplasia	I-Disease
.	O

An	O
abnormality	O
was	O
identified	O
in	O
one	O
patient	O
.	O

DNA	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
patient	O
was	O
heterozygous	O
for	O
a	O
G	O
to	O
A	O
transition	O
that	O
implied	O
substitution	O
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	O
by	O
aspartate	O
.	O

The	O
mutation	O
was	O
not	O
observed	O
in	O
DNA	O
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband	O
.	O

Protein	O
microsequencing	O
demonstrated	O
expression	O
of	O
the	O
abnormal	O
allele	O
in	O
cartilage	O
.	O

These	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
Kniest	B-Disease
dysplasia	I-Disease
and	O
further	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
domain	O
,	O
which	O
includes	O
the	O
region	O
encoded	O
by	O
exon	O
12	O
,	O
in	O
the	O
type	O
II	O
collagen	O
protein	O
leads	O
to	O
this	O
disorder	O
.	O
.	O

CAG	O
expansions	O
in	O
a	O
novel	O
gene	O
for	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
at	O
chromosome	O
14q32	O
.	O
1	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
containing	O
CAG	O
repeats	O
and	O
mapped	O
it	O
to	O
chromosome	O
14q32	O
.	O

1	O
,	O
the	O
genetic	O
locus	O
for	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
.	O

In	O
normal	O
individuals	O
the	O
gene	O
contains	O
between	O
13	O
and	O
36	O
CAG	O
repeats	O
,	O
whereas	O
most	O
of	O
the	O
clinically	O
diagnosed	O
patients	O
and	O
all	O
of	O
the	O
affected	O
members	O
of	O
a	O
family	O
with	O
the	O
clinical	O
and	O
pathological	O
diagnosis	O
of	O
MJD	B-Disease
show	O
expansion	O
of	O
the	O
repeat	O
-	O
number	O
(	O
from	O
68	O
-	O
79	O
)	O
.	O

Southern	O
blot	O
analyses	O
and	O
genomic	O
cloning	O
demonstrates	O
the	O
existence	O
of	O
related	O
genes	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
similar	O
abnormalities	O
in	O
related	O
genes	O
may	O
give	O
rise	O
to	O
diseases	O
similar	O
to	O
MJD	B-Disease
.	O

Mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
families	O
with	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

We	O
analysed	O
50	O
probands	O
with	O
a	O
family	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
for	O
germline	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
BRCA1	O
candidate	O
gene	O
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
on	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O

A	O
total	O
of	O
eight	O
putative	O
disease	O
-	O
causing	O
alterations	O
were	O
identified	O
four	O
of	O
these	O
are	O
frameshifts	O
and	O
two	O
are	O
nonsense	O
mutations	O
.	O

In	O
addition	O
,	O
we	O
found	O
two	O
missense	O
mutations	O
,	O
one	O
of	O
which	O
changes	O
the	O
final	O
cysteine	O
of	O
the	O
BRCA1	O
zinc	O
finger	O
motif	O
to	O
glycine	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
tumour	B-Disease
suppressor	O
model	O
,	O
and	O
support	O
the	O
notion	O
that	O
this	O
candidate	O
gene	O
is	O
in	O
fact	O
BRCA1	O
.	O

The	O
heterogeneity	O
of	O
mutations	O
,	O
coupled	O
with	O
the	O
large	O
size	O
of	O
the	O
gene	O
,	O
indicates	O
that	O
clinical	O
application	O
of	O
BRCA1	O
mutation	O
testing	O
will	O
be	O
technically	O
challenging	O
.	O
.	O

Confirmation	O
of	O
BRCA1	O
by	O
analysis	O
of	O
germline	O
mutations	O
linked	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
ten	O
families	O
.	O

We	O
provide	O
genetic	O
evidence	O
supporting	O
the	O
identity	O
of	O
the	O
candidate	O
gene	O
for	O
BRCA1	O
through	O
the	O
characterization	O
of	O
germline	O
mutations	O
in	O
63	O
breast	B-Disease
cancer	I-Disease
patients	O
and	O
10	O
ovarian	B-Disease
cancer	I-Disease
patients	O
in	O
ten	O
families	O
with	O
cancer	B-Disease
linked	O
to	O
chromosome	O
17q21	O
.	O

Nine	O
different	O
mutations	O
were	O
detected	O
by	O
screening	O
BRCA1	O
DNA	O
and	O
RNA	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Seven	O
mutations	O
lead	O
to	O
protein	O
truncations	O
at	O
sites	O
throughout	O
the	O
gene	O
.	O

One	O
missense	O
mutation	O
(	O
which	O
occurred	O
independently	O
in	O
two	O
families	O
)	O
leads	O
to	O
loss	O
of	O
a	O
cysteine	O
in	O
the	O
zinc	O
binding	O
domain	O
.	O

An	O
intronic	O
single	O
basepair	O
substitution	O
destroys	O
an	O
acceptor	O
site	O
and	O
activates	O
a	O
cryptic	O
splice	O
site	O
,	O
leading	O
to	O
a	O
59	O
basepair	O
insertion	O
and	O
chain	O
termination	O
.	O

The	O
four	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
had	O
chain	O
termination	O
mutations	O
in	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
.	O
.	O

High	O
resolution	O
genetic	O
analysis	O
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	O
for	O
the	O
origin	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
mutation	O
.	O

The	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
has	O
been	O
identified	O
as	O
an	O
amplification	O
of	O
an	O
unstable	O
trinucleotide	O
(	O
CTG	O
)	O
n	O
repeat	O
in	O
over	O
99	O
%	O
of	O
the	O
global	O
DM	B-Disease
population	O
.	O

It	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
an	O
Alu	O
element	O
polymorphism	O
within	O
the	O
DM	B-Disease
kinase	O
gene	O
,	O
suggesting	O
that	O
DM	B-Disease
is	O
a	O
consequence	O
of	O
one	O
or	O
few	O
ancestral	O
mutations	O
.	O

A	O
recent	O
analysis	O
utilizing	O
this	O
polymorphism	O
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	O
marker	O
,	O
suggested	O
that	O
similar	O
to	O
Fragile	B-Disease
X	I-Disease
syndrome	I-Disease
,	O
DM	B-Disease
exhibited	O
a	O
founder	O
effect	O
(	O
Imbert	O
et	O
al	O
.	O
,	O
1993	O
Nature	O
Genet	O
.	O
4	O
,	O
72	O
-	O
76	O
)	O
.	O

In	O
contrast	O
,	O
the	O
low	O
reproductive	O
fitness	O
of	O
individuals	O
with	O
congenital	O
DM	B-Disease
(	O
the	O
endpoint	O
of	O
genetic	O
anticipation	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
)	O
suggests	O
a	O
higher	O
rate	O
of	O
new	O
mutations	O
.	O

We	O
present	O
a	O
high	O
resolution	O
genetic	O
analysis	O
of	O
the	O
DM	B-Disease
locus	O
using	O
PCR	O
based	O
assays	O
of	O
nine	O
polymorphisms	O
,	O
spanning	O
a	O
physical	O
distance	O
of	O
30	O
kb	O
,	O
within	O
and	O
immediately	O
flanking	O
the	O
DM	B-Disease
kinase	O
gene	O
.	O

The	O
persistent	O
complete	O
allelic	O
association	O
of	O
the	O
DM	B-Disease
mutation	O
with	O
all	O
these	O
polymorphisms	O
provides	O
further	O
support	O
to	O
previous	O
observations	O
and	O
suggests	O
more	O
strongly	O
that	O
the	O
DM	B-Disease
mutation	O
occurred	O
on	O
the	O
background	O
of	O
a	O
particular	O
haplotype	O
in	O
which	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
became	O
inherently	O
unstable	O
and	O
therefore	O
predisposed	O
to	O
amplification	O
.	O

Genetic	O
instability	O
in	O
human	O
ovarian	B-Disease
cancer	I-Disease
cell	O
lines	O
.	O

We	O
have	O
analyzed	O
the	O
stability	O
of	O
microsatellites	O
in	O
cell	O
lines	O
derived	O
from	O
human	O
ovarian	B-Disease
cancers	I-Disease
and	O
found	O
that	O
5	O
out	O
of	O
10	O
of	O
the	O
ovarian	B-Disease
tumor	I-Disease
cell	O
lines	O
are	O
genetically	O
unstable	O
at	O
the	O
majority	O
of	O
the	O
loci	O
analyzed	O
.	O

In	O
clones	O
and	O
subclones	O
derived	O
serially	O
from	O
one	O
of	O
these	O
cell	O
lines	O
(	O
2774	O
;	O
serous	B-Disease
cystadenocarcinoma	I-Disease
)	O
,	O
a	O
very	O
high	O
proportion	O
of	O
microsatellites	O
distributed	O
in	O
many	O
different	O
regions	O
of	O
the	O
genome	O
change	O
their	O
size	O
in	O
a	O
mercurial	O
fashion	O
.	O

We	O
conclude	O
that	O
genomic	O
instability	O
in	O
ovarian	B-Disease
tumors	I-Disease
is	O
a	O
dynamic	O
and	O
ongoing	O
process	O
whose	O
high	O
frequency	O
may	O
have	O
been	O
previously	O
underestimated	O
by	O
PCR	O
-	O
based	O
allelotyping	O
of	O
bulk	O
tumor	B-Disease
tissue	O
.	O

We	O
have	O
identified	O
the	O
source	O
of	O
the	O
genetic	O
instability	O
in	O
one	O
ovarian	B-Disease
tumor	I-Disease
as	O
a	O
point	O
mutation	O
(	O
R524P	O
)	O
in	O
the	O
human	O
mismatch	O
-	O
repair	O
gene	O
MSH2	O
(	O
Salmonella	O
MutS	O
homologue	O
)	O
,	O
which	O
has	O
recently	O
been	O
shown	O
to	O
be	O
involved	O
in	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O

Patient	O
2774	O
was	O
a	O
38	O
-	O
year	O
-	O
old	O
heterozygote	O
,	O
and	O
her	O
normal	O
tissue	O
carried	O
both	O
mutant	O
and	O
wild	O
-	O
type	O
alleles	O
of	O
the	O
human	O
MSH2	O
gene	O
.	O

However	O
the	O
wild	O
-	O
type	O
allele	O
was	O
lost	O
at	O
some	O
point	O
early	O
during	O
tumorigenesis	O
so	O
that	O
DNA	O
isolated	O
either	O
from	O
the	O
patients	O
ovarian	B-Disease
tumor	I-Disease
or	O
from	O
the	O
2774	O
cell	O
line	O
carries	O
only	O
the	O
mutant	O
allele	O
of	O
the	O
human	O
MSH2	O
gene	O
.	O

The	O
genetic	O
instability	O
observed	O
in	O
the	O
tumor	B-Disease
and	O
cell	O
line	O
DNA	O
,	O
together	O
with	O
the	O
germ	O
-	O
line	O
mutation	O
in	O
a	O
mismatch	O
-	O
repair	O
gene	O
,	O
suggest	O
that	O
the	O
MSH2	O
gene	O
is	O
involved	O
in	O
the	O
onset	O
and	O
/	O
or	O
progression	O
in	O
a	O
subset	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
.	O

BRCA1	O
mutations	O
in	O
primary	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
carcinomas	I-Disease
.	O

Loss	O
of	O
heterozygosity	O
data	O
from	O
familial	B-Disease
tumors	I-Disease
suggest	O
that	O
BRCA1	O
,	O
a	O
gene	O
that	O
confers	O
susceptibility	O
to	O
ovarian	B-Disease
and	I-Disease
early	I-Disease
-	I-Disease
onset	I-Disease
breast	B-Disease
cancer	I-Disease
,	O
encodes	O
a	O
tumor	B-Disease
suppressor	O
.	O

The	O
BRCA1	O
region	O
is	O
also	O
subject	O
to	O
allelic	O
loss	O
in	O
sporadic	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
an	O
indication	O
that	O
BRCA1	O
mutations	O
may	O
occur	O
somatically	O
in	O
these	O
tumors	B-Disease
.	O

The	O
BRCA1	O
coding	O
region	O
was	O
examined	O
for	O
mutations	O
in	O
primary	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
tumors	I-Disease
that	O
show	O
allele	O
loss	O
at	O
the	O
BRCA1	O
locus	O
.	O

Mutations	O
were	O
detected	O
in	O
3	O
of	O
32	O
breast	O
and	O
1	O
of	O
12	O
ovarian	B-Disease
carcinomas	I-Disease
;	O
all	O
four	O
mutations	O
were	O
germline	O
alterations	O
and	O
occurred	O
in	O
early	O
-	O
onset	O
cancers	B-Disease
.	O

These	O
results	O
suggest	O
that	O
mutation	O
of	O
BRCA1	O
may	O
not	O
be	O
critical	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
that	O
arise	O
in	O
the	O
absence	O
of	O
a	O
mutant	O
germline	O
allele	O
.	O
.	O

PAX6	O
gene	O
dosage	O
effect	O
in	O
a	O
family	O
with	O
congenital	B-Disease
cataracts	I-Disease
,	O
aniridia	B-Disease
,	O
anophthalmia	B-Disease
and	O
central	B-Disease
nervous	I-Disease
system	I-Disease
defects	I-Disease
.	O

The	O
human	O
eye	O
malformation	O
aniridia	B-Disease
results	O
from	O
haploinsufficiency	B-Disease
of	I-Disease
PAX6	I-Disease
,	O
a	O
paired	O
box	O
DNA	O
-	O
binding	O
protein	O
.	O

To	O
study	O
this	O
dosage	O
effect	O
,	O
we	O
characterized	O
two	O
PAX6	O
mutations	O
in	O
a	O
family	O
segregating	O
aniridia	B-Disease
and	O
a	O
milder	O
syndrome	O
consisting	O
of	O
congenital	B-Disease
cataracts	I-Disease
and	O
late	O
onset	O
corneal	B-Disease
dystrophy	I-Disease
.	O

The	O
nonsense	O
mutations	O
,	O
at	O
codons	O
103	O
and	O
353	O
,	O
truncate	O
PAX6	O
within	O
the	O
N	O
-	O
terminal	O
paired	O
and	O
C	O
-	O
terminal	O
PST	O
domains	O
,	O
respectively	O
.	O

The	O
wild	O
-	O
type	O
PST	O
domain	O
activates	O
transcription	O
autonomously	O
and	O
the	O
mutant	O
form	O
has	O
partial	O
activity	O
.	O

A	O
compound	O
heterozygote	O
had	O
severe	O
craniofacial	B-Disease
and	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
defects	I-Disease
and	O
no	B-Disease
eyes	I-Disease
.	O

The	O
pattern	O
of	O
malformations	O
is	O
similar	O
to	O
that	O
in	O
homozygous	O
Sey	O
mice	O
and	O
suggests	O
a	O
critical	O
role	O
for	O
PAX6	O
in	O
controlling	O
the	O
migration	O
and	O
differentiation	O
of	O
specific	O
neuronal	O
progenitor	O
cells	O
in	O
the	O
brain	O
.	O
.	O

A	O
physical	O
map	O
and	O
candidate	O
genes	O
in	O
the	O
BRCA1	O
region	O
on	O
chromosome	O
17q12	O
-	O
21	O
.	O

We	O
have	O
constructed	O
a	O
physical	O
map	O
of	O
a	O
4	O
cM	O
region	O
on	O
chromosome	O
17q12	O
-	O
21	O
that	O
contains	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
BRCA1	O
.	O

The	O
map	O
comprises	O
a	O
contig	O
of	O
137	O
overlapping	O
yeast	O
artificial	O
chromosomes	O
and	O
P1	O
clones	O
,	O
onto	O
which	O
we	O
have	O
placed	O
112	O
PCR	O
markers	O
.	O

We	O
have	O
localized	O
more	O
than	O
20	O
genes	O
on	O
this	O
map	O
,	O
ten	O
of	O
which	O
had	O
not	O
been	O
mapped	O
to	O
the	O
region	O
previously	O
,	O
and	O
have	O
isolated	O
30	O
cDNA	O
clones	O
representing	O
partial	O
sequences	O
of	O
as	O
yet	O
unidentified	O
genes	O
.	O

Two	O
genes	O
that	O
lie	O
within	O
a	O
narrow	O
region	O
defined	O
by	O
meiotic	O
breakpoints	O
in	O
BRCA1	O
patients	O
have	O
been	O
sequenced	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
without	O
revealing	O
any	O
deleterious	O
mutations	O
.	O

These	O
new	O
reagents	O
should	O
facilitate	O
the	O
identification	O
of	O
BRCA1	O
.	O
.	O

The	O
LEC	O
rat	O
has	O
a	O
deletion	O
in	O
the	O
copper	O
transporting	O
ATPase	O
gene	O
homologous	O
to	O
the	O
Wilson	B-Disease
disease	I-Disease
gene	O
.	O

The	O
Long	O
-	O
Evans	O
Cinnamon	O
(	O
LEC	O
)	O
rat	O
shows	O
similarity	O
to	O
Wilson	B-Disease
disease	I-Disease
in	O
many	O
clinical	O
and	O
biochemical	O
features	O
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
the	O
rat	O
gene	O
(	O
Atp7b	O
)	O
homologous	O
to	O
the	O
human	O
Wilson	B-Disease
disease	I-Disease
gene	O
(	O
ATP7B	O
)	O
and	O
have	O
used	O
them	O
to	O
identify	O
a	O
partial	O
deletion	O
in	O
the	O
Atp7b	O
gene	O
in	O
the	O
LEC	O
rat	O
.	O

The	O
deletion	O
removes	O
at	O
least	O
900	O
bp	O
of	O
the	O
coding	O
region	O
at	O
the	O
3	O
end	O
,	O
includes	O
the	O
crucial	O
ATP	O
binding	O
domain	O
and	O
extends	O
downstream	O
of	O
the	O
gene	O
.	O

Our	O
results	O
provide	O
convincing	O
evidence	O
for	O
defining	O
the	O
LEC	O
rat	O
as	O
an	O
animal	O
model	O
for	O
Wilson	B-Disease
disease	I-Disease
.	O

This	O
model	O
will	O
be	O
important	O
for	O
studying	O
liver	O
pathophysiology	O
,	O
for	O
developing	O
therapy	O
for	O
Wilson	B-Disease
disease	I-Disease
and	O
for	O
studying	O
the	O
pathway	O
of	O
copper	O
transport	O
and	O
its	O
possible	O
interaction	O
with	O
other	O
heavy	O
metals	O
.	O
.	O

Genomic	O
organization	O
of	O
the	O
adrenoleukodystrophy	B-Disease
gene	O
.	O

Adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
,	O
the	O
most	O
frequent	O
peroxisomal	B-Disease
disorder	I-Disease
,	O
is	O
a	O
severe	O
neurodegenerative	B-Disease
disease	I-Disease
associated	O
with	O
an	O
impairment	B-Disease
of	I-Disease
very	I-Disease
long	I-Disease
chain	I-Disease
fatty	I-Disease
acids	I-Disease
beta	I-Disease
-	I-Disease
oxidation	I-Disease
.	O

We	O
have	O
recently	O
identified	O
by	O
positional	O
cloning	O
the	O
gene	O
responsible	O
for	O
ALD	B-Disease
,	O
located	O
in	O
Xq28	O
.	O

It	O
encodes	O
a	O
new	O
member	O
of	O
the	O
"	O
ABC	O
"	O
superfamily	O
of	O
membrane	O
-	O
associated	O
transporters	O
that	O
shows	O
,	O
in	O
particular	O
,	O
significant	O
homology	O
to	O
the	O
70	O
-	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
.	O

We	O
report	O
here	O
a	O
detailed	O
characterization	O
of	O
the	O
ALD	B-Disease
gene	O
structure	O
.	O

It	O
extends	O
over	O
21	O
kb	O
and	O
consists	O
of	O
10	O
exons	O
.	O

To	O
facilitate	O
the	O
detection	O
of	O
mutations	O
in	O
ALD	B-Disease
patients	O
,	O
we	O
have	O
determined	O
the	O
intronic	O
sequences	O
flanking	O
the	O
exons	O
as	O
well	O
as	O
the	O
sequence	O
of	O
the	O
3	O
untranslated	O
region	O
and	O
of	O
the	O
immediate	O
5	O
promoter	O
region	O
.	O

Sequences	O
present	O
in	O
distal	O
exons	O
cross	O
-	O
hybridize	O
strongly	O
to	O
additional	O
sequences	O
in	O
the	O
human	O
genome	O
.	O

The	O
ALD	B-Disease
gene	O
has	O
been	O
positioned	O
on	O
a	O
pulsed	O
-	O
field	O
map	O
between	O
DXS15	O
and	O
the	O
L1CAM	O
gene	O
,	O
about	O
650	O
kb	O
upstream	O
from	O
the	O
color	O
pigment	O
genes	O
.	O

The	O
frequent	O
occurrence	O
of	O
color	O
vision	O
anomalies	O
observed	O
in	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
(	O
the	O
adult	O
onset	O
form	O
of	O
ALD	B-Disease
)	O
thus	O
does	O
not	O
represent	O
a	O
contiguous	B-Disease
gene	I-Disease
syndrome	I-Disease
but	O
a	O
secondary	O
manifestation	O
of	O
ALD	B-Disease
.	O
.	O

The	O
murine	O
homologues	O
of	O
the	O
Huntington	B-Disease
disease	I-Disease
gene	O
(	O
Hdh	O
)	O
and	O
the	O
alpha	O
-	O
adducin	O
gene	O
(	O
Add1	O
)	O
map	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O
3	O
.	O

Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
a	O
severe	O
autosomal	B-Disease
dominant	I-Disease
neurodegenerative	I-Disease
disorder	I-Disease
associated	O
with	O
a	O
novel	O
gene	O
(	O
IT15	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
the	O
cloning	O
of	O
Hdh	O
,	O
the	O
murine	O
homologue	O
of	O
IT15	O
.	O

Here	O
,	O
using	O
an	O
interspecific	O
backcross	O
,	O
we	O
have	O
mapped	O
both	O
Hdh	O
and	O
the	O
mouse	O
homologue	O
of	O
human	O
alpha	O
-	O
adducin	O
(	O
Add1	O
)	O
,	O
a	O
membrane	O
-	O
associated	O
cytoskeletal	O
protein	O
gene	O
.	O

Both	O
of	O
these	O
genes	O
map	O
in	O
the	O
same	O
position	O
on	O
mouse	O
chromosome	O
5	O
in	O
a	O
region	O
associated	O
with	O
ancestral	O
chromosomal	O
rearrangements	O
and	O
show	O
no	O
recombination	O
with	O
D5H4S43	O
,	O
D5H4S115	O
,	O
and	O
D5H4S62	O
,	O
the	O
murine	O
homologues	O
of	O
D4S43	O
,	O
D4S115	O
,	O
and	O
D4S62	O
,	O
respectively	O
.	O

Further	O
mapping	O
studies	O
of	O
humans	O
,	O
mice	O
,	O
and	O
other	O
mammalian	O
species	O
should	O
reveal	O
the	O
nature	O
of	O
the	O
rearrangements	O
affecting	O
this	O
chromosomal	O
segment	O
during	O
mammalian	O
evolution	O
.	O
.	O

Genetic	O
cholesteryl	B-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
deficiency	I-Disease
caused	O
by	O
two	O
prevalent	O
mutations	O
as	O
a	O
major	O
determinant	O
of	O
increased	O
levels	O
of	O
high	O
density	O
lipoprotein	O
cholesterol	O
.	O

Genetic	O
determinants	O
of	O
HDL	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
levels	O
in	O
the	O
general	O
population	O
are	O
poorly	O
understood	O
.	O

We	O
previously	O
described	O
plasma	O
cholesteryl	B-Disease
ester	I-Disease
transfer	I-Disease
protein	I-Disease
(	I-Disease
CETP	I-Disease
)	I-Disease
deficiency	I-Disease
due	O
to	O
an	O
intron	O
14	O
G	O
(	O
+	O
1	O
)	O
-	O
to	O
-	O
A	O
mutation	O
(	O
Int14	O
A	O
)	O
in	O
several	O
families	O
with	O
very	O
high	O
HDL	O
-	O
C	O
levels	O
in	O
Japan	O
.	O

Subjects	O
with	O
HDL	O
-	O
C	O
>	O
or	O
=	O
100	O
mg	O
/	O
dl	O
(	O
n	O
=	O
130	O
)	O
were	O
screened	O
by	O
PCR	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
the	O
CETP	O
gene	O
.	O

Two	O
other	O
mutations	O
were	O
identified	O
by	O
DNA	O
sequencing	O
or	O
primer	O
-	O
mediated	O
restriction	O
map	O
modification	O
of	O
PCR	O
products	O
a	O
novel	O
intron	O
14	O
splice	O
donor	O
site	O
mutation	O
caused	O
by	O
a	O
T	O
insertion	O
at	O
position	O
+	O
3	O
from	O
the	O
exon14	O
/	O
intron14	O
boundary	O
(	O
Int14	O
T	O
)	O
and	O
a	O
missense	O
mutation	O
(	O
Asp442	O
to	O
Gly	O
)	O
within	O
exon	O
15	O
(	O
D442G	O
)	O
.	O

The	O
Int14	O
T	O
mutation	O
was	O
only	O
found	O
in	O
one	O
family	O
.	O

However	O
,	O
the	O
D442G	O
and	O
Int14	O
A	O
mutations	O
were	O
highly	O
prevalent	O
in	O
subjects	O
with	O
HDL	O
-	O
C	O
>	O
or	O
=	O
60	O
mg	O
/	O
dl	O
,	O
with	O
combined	O
allele	O
frequencies	O
of	O
9	O
%	O
,	O
12	O
%	O
,	O
21	O
%	O
and	O
43	O
%	O
for	O
HDL	O
-	O
C	O
60	O
-	O
79	O
,	O
80	O
-	O
99	O
,	O
100	O
-	O
119	O
,	O
and	O
>	O
or	O
=	O
120	O
mg	O
/	O
dl	O
,	O
respectively	O
.	O

Furthermore	O
,	O
prevalences	O
of	O
the	O
D442G	O
and	O
Int14	O
A	O
mutations	O
were	O
extremely	O
high	O
in	O
a	O
general	O
sample	O
of	O
Japanese	O
men	O
(	O
n	O
=	O
236	O
)	O
,	O
with	O
heterozygote	O
frequencies	O
of	O
7	O
%	O
and	O
2	O
%	O
,	O
respectively	O
.	O

These	O
two	O
mutations	O
accounted	O
for	O
about	O
10	O
%	O
of	O
the	O
total	O
variance	O
of	O
HDL	O
-	O
C	O
in	O
this	O
population	O
.	O

The	O
phenotype	O
in	O
a	O
genetic	O
compound	O
heterozygote	O
(	O
Int14	O
T	O
and	O
Int14	O
A	O
)	O
was	O
similar	O
to	O
that	O
of	O
Int14	O
A	O
homozygotes	O
(	O
no	O
detectable	O
CETP	O
and	O
markedly	O
increased	O
HDL	O
-	O
C	O
)	O
,	O
indicating	O
that	O
the	O
Int14	O
T	O
produces	O
a	O
null	O
allele	O
.	O

In	O
four	O
D442G	O
homozygotes	O
,	O
mean	O
HDL	O
-	O
C	O
levels	O
(	O
86	O
+	O
/	O
-	O
26	O
mg	O
/	O
dl	O
)	O
were	O
lower	O
than	O
in	O
Int14	O
A	O
homozygotes	O
(	O
158	O
+	O
/	O
-	O
35	O
mg	O
/	O
dl	O
)	O
,	O
reflecting	O
residual	O
CETP	O
activity	O
in	O
plasma	O
.	O

In	O
47	O
D442G	O
heterozygotes	O
,	O
mean	O
HDL	O
-	O
C	O
levels	O
were	O
91	O
+	O
/	O
-	O
23	O
mg	O
/	O
dl	O
,	O
similar	O
to	O
the	O
level	O
in	O
D442G	O
homozygotes	O
,	O
and	O
significantly	O
greater	O
than	O
mean	O
HDL	O
-	O
C	O
levels	O
in	O
Int14	O
A	O
heterozygotes	O
(	O
69	O
+	O
/	O
-	O
15	O
mg	O
/	O
dl	O
)	O
.	O

Thus	O
,	O
the	O
D442G	O
mutation	O
acts	O
differently	O
to	O
the	O
null	O
mutations	O
with	O
weaker	O
effects	O
on	O
HDL	O
in	O
the	O
homozygous	O
state	O
and	O
stronger	O
effects	O
in	O
the	O
heterozygotes	O
,	O
suggesting	O
dominant	O
expression	O
of	O
a	O
partially	O
defective	O
allele	O
.	O

CETP	B-Disease
deficiency	I-Disease
,	O
reflecting	O
two	O
prevalent	O
mutations	O
(	O
D442G	O
and	O
Int14	O
A	O
)	O
,	O
is	O
the	O
first	O
example	O
of	O
a	O
genetic	B-Disease
deficiency	I-Disease
state	O
which	O
is	O
sufficiently	O
common	O
to	O
explain	O
a	O
significant	O
fraction	O
of	O
the	O
variation	O
in	O
HDL	O
-	O
C	O
in	O
the	O
general	O
population	O
.	O
.	O

Treatment	O
of	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
:	O
effects	O
of	O
chenodeoxycholic	O
acid	O
,	O
pravastatin	O
,	O
and	O
combined	O
use	O
.	O

Treatments	O
by	O
oral	O
administration	O
of	O
chenodeoxycholic	O
acid	O
(	O
CDCA	O
)	O
alone	O
,	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
(	O
HMG	O
)	O
CoA	O
reductase	O
inhibitor	O
(	O
pravastatin	O
)	O
alone	O
,	O
and	O
combination	O
of	O
the	O
two	O
drugs	O
were	O
attempted	O
for	O
7	O
patients	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

CDCA	O
treatment	O
at	O
a	O
dose	O
of	O
300	O
mg	O
/	O
day	O
reduced	O
serum	O
cholestanol	O
(	O
67	O
.	O
3	O
%	O
reduction	O
)	O
,	O
lathosterol	O
(	O
50	O
.	O
8	O
%	O
)	O
,	O
campesterol	O
(	O
61	O
.	O
7	O
%	O
)	O
and	O
sitosterol	O
(	O
12	O
.	O
7	O
%	O
)	O
.	O

However	O
,	O
the	O
sera	O
of	O
the	O
patients	O
changed	O
to	O
be	O
"	O
atherogenic	O
"	O
;	O
total	O
cholesterol	O
,	O
triglyceride	O
and	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-	O
cholesterol	O
were	O
increased	O
,	O
while	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
cholesterol	O
was	O
decreased	O
.	O

Contrarily	O
,	O
pravastatin	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
day	O
improved	O
the	O
sera	O
of	O
the	O
patients	O
to	O
be	O
markedly	O
"	O
anti	O
-	O
atherogenic	O
"	O
,	O
but	O
the	O
reductions	O
of	O
cholestanol	O
(	O
30	O
.	O
4	O
%	O
)	O
,	O
lathosterol	O
(	O
44	O
.	O
0	O
%	O
)	O
,	O
campesterol	O
(	O
22	O
.	O
9	O
%	O
)	O
and	O
sitosterol	O
(	O
9	O
.	O
6	O
%	O
)	O
were	O
inadequate	O
.	O

Combined	O
treatment	O
with	O
CDCA	O
and	O
pravastatin	O
showed	O
good	O
overlapping	O
of	O
the	O
effects	O
of	O
each	O
drug	O
alone	O
.	O

The	O
sera	O
of	O
the	O
patients	O
were	O
apparently	O
more	O
"	O
anti	O
-	O
atherogenic	O
"	O
than	O
those	O
after	O
CDCA	O
treatment	O
.	O

Serum	O
cholestanol	O
concentration	O
was	O
still	O
2	O
.	O

7	O
times	O
higher	O
than	O
in	O
controls	O
,	O
but	O
the	O
serum	O
lathosterol	O
level	O
was	O
within	O
the	O
normal	O
range	O
,	O
indicating	O
that	O
the	O
enhancement	O
of	O
overall	O
cholesterol	O
synthesis	O
in	O
the	O
patients	O
was	O
sufficiently	O
suppressed	O
.	O

Plant	O
sterol	O
levels	O
were	O
also	O
within	O
the	O
normal	O
range	O
.	O

The	O
combination	O
of	O
CDCA	O
and	O
pravastatin	O
was	O
a	O
good	O
treatment	O
for	O
CTX	B-Disease
,	O
based	O
on	O
the	O
improvement	O
of	O
serum	O
lipoprotein	O
metabolism	O
,	O
the	O
suppression	O
of	O
cholesterol	O
synthesis	O
,	O
and	O
reductions	O
of	O
cholestanol	O
and	O
plant	O
sterol	O
levels	O
.	O

In	O
all	O
of	O
7	O
patients	O
,	O
the	O
progression	O
of	O
disease	O
was	O
arrested	O
,	O
but	O
dramatic	O
effects	O
on	O
clinical	O
manifestations	O
,	O
xanthoma	B-Disease
,	O
and	O
electrophysiological	O
findings	O
could	O
not	O
be	O
found	O
after	O
the	O
treatment	O
of	O
these	O
drugs	O

Mutation	O
spectrum	O
in	O
the	O
CHM	B-Disease
gene	O
of	O
Danish	O
and	O
Swedish	O
choroideremia	B-Disease
patients	O
.	O

The	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	B-Disease
(	O
CHM	B-Disease
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	B-Disease
.	O

We	O
have	O
performed	O
mutation	O
screening	O
in	O
patients	O
from	O
15	O
Danish	O
and	O
Swedish	O
families	O
by	O
using	O
Southern	O
blot	O
hybridization	O
and	O
the	O
polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
technique	O
.	O

Causative	O
mutations	O
in	O
the	O
CHM	B-Disease
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families	O
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach	O
.	O

In	O
four	O
of	O
these	O
families	O
deletions	O
of	O
different	O
sizes	O
were	O
found	O
.	O

Thus	O
,	O
in	O
one	O
patient	O
,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon	O
,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
CHM	B-Disease
gene	O
.	O

Mapping	O
of	O
the	O
deletion	O
endpoints	O
in	O
these	O
four	O
patients	O
and	O
in	O
another	O
11	O
male	O
patients	O
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	O
map	O
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21	O
.	O

In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	O
at	O
least	O
8	O
causative	O
mutations	O
were	O
found	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Interestingly	O
,	O
all	O
CHM	B-Disease
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	B-Disease
patients	O
give	O
rise	O
to	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
codon	O
.	O
.	O

Predominance	O
of	O
the	O
adrenomyeloneuropathy	B-Disease
phenotype	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
in	O
The	O
Netherlands	O
:	O
a	O
survey	O
of	O
30	O
kindreds	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
is	O
an	O
inherited	B-Disease
disorder	I-Disease
of	O
peroxisomal	O
beta	O
-	O
oxidation	O
associated	O
with	O
accumulation	O
of	O
saturated	O
very	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
results	O
in	O
central	O
and	O
peripheral	O
demyelination	B-Disease
and	O
in	O
impaired	B-Disease
function	I-Disease
of	I-Disease
adrenal	I-Disease
cortex	I-Disease
and	I-Disease
testes	I-Disease
.	O

The	O
phenotypic	O
expression	O
is	O
highly	O
variable	O
,	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
(	O
CCALD	B-Disease
)	O
and	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
being	O
the	O
main	O
variants	O
.	O

We	O
explored	O
the	O
30	O
Dutch	O
kindreds	O
well	O
known	O
to	O
the	O
Dutch	O
X	B-Disease
-	I-Disease
ALD	I-Disease
/	O
AMN	B-Disease
Study	O
Group	O
and	O
phenotyped	O
77	O
male	O
patients	O
35	O
(	O
46	O
%	O
)	O
had	O
AMN	B-Disease
and	O
24	O
(	O
31	O
%	O
)	O
CCALD	B-Disease
or	O
adolescent	B-Disease
cerebral	I-Disease
ALD	I-Disease
(	O
AdolCALD	B-Disease
)	O
.	O

These	O
percentages	O
differ	O
significantly	O
from	O
previous	O
reports	O
,	O
in	O
which	O
25	O
to	O
28	O
%	O
of	O
the	O
patients	O
developed	O
AMN	B-Disease
and	O
53	O
to	O
57	O
%	O
CCALD	B-Disease
or	O
AdolCALD	B-Disease
.	O

Our	O
findings	O
indicate	O
that	O
-	O
-	O
at	O
least	O
in	O
the	O
Netherlands	O
-	O
-	O
AMN	B-Disease
may	O
be	O
the	O
most	O
frequent	O
phenotype	O
of	O
X	B-Disease
-	I-Disease
ALD	I-Disease
.	O
.	O

Adrenoleukodystrophy	B-Disease
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O

An	O
antibody	O
against	O
the	O
synthetic	O
C	O
-	O
terminal	O
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	O
responsible	O
for	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ALD	B-Disease
gene	O
.	O

The	O
antibody	O
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	O
in	O
control	O
fibroblasts	O
,	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	O
with	O
ALD	B-Disease
(	O
#	O
163	O
)	O
,	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	B-Disease
gene	O
was	O
undetectable	O
based	O
on	O
Northern	O
blot	O
analysis	O
.	O

The	O
293T	O
cells	O
transfected	O
with	O
the	O
full	O
-	O
coding	O
cDNA	O
inserted	O
in	O
the	O
expression	O
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein	O
,	O
as	O
detected	O
by	O
Western	O
blot	O
.	O

In	O
an	O
immunocytological	O
study	O
,	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern	O
,	O
in	O
the	O
normal	O
fibroblasts	O
.	O

However	O
,	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells	O
.	O

These	O
data	O
thus	O
indicate	O
that	O
the	O
ALD	B-Disease
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O
.	O

Isolation	O
of	O
the	O
gene	O
for	O
McLeod	B-Disease
syndrome	I-Disease
that	O
encodes	O
a	O
novel	O
membrane	O
transport	O
protein	O
.	O

McLeod	B-Disease
syndrome	I-Disease
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
multisystem	I-Disease
disorder	I-Disease
characterized	O
by	O
abnormalities	O
in	O
the	O
neuromuscular	O
and	O
hematopoietic	O
systems	O
.	O

We	O
have	O
assembled	O
a	O
cosmid	O
contig	O
of	O
360	O
kb	O
that	O
encompasses	O
the	O
McLeod	B-Disease
gene	O
locus	O
.	O

A	O
50	O
kb	O
deletion	O
was	O
detected	O
by	O
screening	O
DNA	O
from	O
patients	O
with	O
radiolabeled	O
whole	O
cosmids	O
,	O
and	O
two	O
transcription	O
units	O
were	O
identified	O
within	O
this	O
deletion	O
.	O

The	O
mRNA	O
expression	O
pattern	O
of	O
one	O
of	O
them	O
,	O
designated	O
as	O
XK	O
,	O
correlates	O
closely	O
to	O
the	O
McLeod	B-Disease
phenotype	O
.	O

XK	O
encodes	O
a	O
novel	O
protein	O
with	O
structural	O
characteristics	O
of	O
prokaryotic	O
and	O
eukaryotic	O
membrane	O
transport	O
proteins	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
XK	O
from	O
two	O
unrelated	O
McLeod	B-Disease
patients	O
has	O
identified	O
point	O
mutations	O
at	O
conserved	O
splice	O
donor	O
and	O
acceptor	O
sites	O
.	O

These	O
findings	O
provide	O
direct	O
evidence	O
that	O
XK	O
is	O
responsible	O
for	O
McLeod	B-Disease
syndrome	I-Disease
.	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
spastic	I-Disease
paraplegia	I-Disease
and	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
are	O
allelic	B-Disease
disorders	I-Disease
at	O
the	O
proteolipid	O
protein	O
locus	O
.	O

Three	O
forms	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
spastic	I-Disease
paraplegia	I-Disease
(	O
SPG	B-Disease
)	O
have	O
been	O
defined	O
.	O

One	O
locus	O
(	O
SPG	O
1	O
)	O
maps	O
to	O
Xq28	O
while	O
two	O
clinically	O
distinct	O
forms	O
map	O
to	O
Xq22	O
(	O
SPG2	O
)	O
.	O

A	O
rare	O
X	B-Disease
-	I-Disease
linked	I-Disease
dysmyelinating	I-Disease
disorder	I-Disease
of	O
the	O
central	O
nervous	O
system	O
,	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
(	O
PMD	B-Disease
)	O
,	O
has	O
also	O
been	O
mapped	O
to	O
Xq21	O
-	O
q22	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
which	O
encodes	O
two	O
myelin	O
proteins	O
,	O
PLP	O
and	O
DM20	O
.	O

While	O
narrowing	O
the	O
genetic	O
interval	O
containing	O
SPG2	O
in	O
a	O
large	O
pedigree	O
,	O
we	O
found	O
that	O
PLP	O
was	O
the	O
closest	O
marker	O
to	O
the	O
disease	O
locus	O
,	O
implicating	O
PLP	O
as	O
a	O
possible	O
candidate	O
gene	O
.	O

We	O
have	O
found	O
that	O
a	O
point	O
mutation	O
(	O
His139Tyr	O
)	O
in	O
exon	O
3B	O
of	O
an	O
affected	O
male	O
produces	O
a	O
mutant	O
PLP	O
but	O
a	O
normal	O
DM20	O
,	O
and	O
segregates	O
with	O
the	O
disease	O
(	O
Zmax	O
=	O
6	O
.	O
63	O
,	O
theta	O
=	O
0	O
.	O
00	O
)	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
SPG2	O
and	O
PMD	B-Disease
are	O
allelic	B-Disease
disorders	I-Disease

Canavan	B-Disease
disease	I-Disease
:	O
mutations	O
among	O
Jewish	O
and	O
non	O
-	O
Jewish	O
patients	O
.	O

Canavan	B-Disease
disease	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
leukodystrophy	I-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
aspartoacylase	I-Disease
(	O
ASPA	O
)	O
.	O

Sixty	O
-	O
four	O
probands	O
were	O
analyzed	O
for	O
mutations	O
in	O
the	O
ASPA	O
gene	O
.	O

Three	O
point	O
mutations	O
-	O
-	O
693C	O
-	O
-	O
>	O
A	O
,	O
854A	O
-	O
-	O
>	O
C	O
,	O
and	O
914C	O
-	O
-	O
>	O
A	O
-	O
-	O
were	O
identified	O
in	O
the	O
coding	O
sequence	O
.	O

The	O
693C	O
-	O
-	O
>	O
A	O
and	O
914C	O
-	O
-	O
>	O
A	O
base	O
changes	O
,	O
resulting	O
in	O
nonsense	O
tyr231	O
-	O
-	O
>	O
ter	O
and	O
missense	O
ala305	O
-	O
-	O
>	O
glu	O
mutations	O
,	O
respectively	O
,	O
lead	O
to	O
complete	O
loss	O
of	O
ASPA	O
activity	O
in	O
in	O
vitro	O
expression	O
studies	O
.	O

The	O
854A	O
-	O
-	O
>	O
C	O
transversion	O
converted	O
glu	O
to	O
ala	O
in	O
codon	O
285	O
.	O

The	O
glu285	O
-	O
-	O
>	O
ala	O
mutant	O
ASPA	O
has	O
2	O
.	O

5	O
%	O
of	O
the	O
activity	O
expressed	O
by	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

A	O
fourth	O
mutation	O
,	O
433	O
-	O
-	O
2	O
(	O
A	O
-	O
-	O
>	O
G	O
)	O
transition	O
,	O
was	O
identified	O
at	O
the	O
splice	O
-	O
acceptor	O
site	O
in	O
intron	O
2	O
.	O

The	O
splice	O
-	O
site	O
mutation	O
would	O
lead	O
to	O
skipping	O
of	O
exon	O
3	O
,	O
accompanied	O
by	O
a	O
frameshift	O
,	O
and	O
thus	O
would	O
produce	O
aberrant	O
ASPA	O
.	O

Of	O
the	O
128	O
unrelated	O
Canavan	B-Disease
chromosomes	O
analyzed	O
,	O
88	O
were	O
from	O
probands	O
of	O
Ashkenazi	O
Jewish	O
descent	O
.	O

The	O
glu285	O
-	O
-	O
>	O
ala	O
mutation	O
was	O
predominant	O
(	O
82	O
.	O
9	O
%	O
)	O
in	O
this	O
population	O
,	O
followed	O
by	O
the	O
tyr231	O
-	O
-	O
>	O
ter	O
(	O
14	O
.	O
8	O
%	O
)	O
and	O
433	O
-	O
-	O
2	O
(	O
A	O
-	O
-	O
>	O
G	O
)	O
(	O
1	O
.	O
1	O
%	O
)	O
mutations	O
.	O

The	O
three	O
mutations	O
account	O
for	O
98	O
.	O

8	O
%	O
of	O
the	O
Canavan	B-Disease
chromosomes	O
of	O
Ashkenazi	O
Jewish	O
origin	O
.	O

The	O
ala305	O
-	O
-	O
>	O
glu	O
mutation	O
was	O
found	O
exclusively	O
in	O
non	O
-	O
Jewish	O
probands	O
of	O
European	O
descent	O
and	O
constituted	O
60	O
%	O
of	O
the	O
40	O
mutant	O
chromosomes	O
.	O

Predominant	O
occurrence	O
of	O
certain	O
mutations	O
among	O
Ashkenazi	O
Jewish	O
and	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B-Disease
disease	I-Disease
would	O
suggest	O
a	O
founding	O
-	O
father	O
effect	O
in	O
propagation	O
of	O
these	O
mutant	O
chromosomes	O

Intelligence	O
quotient	O
profile	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
intergenerational	O
deficit	O
,	O
and	O
correlation	O
with	O
CTG	O
amplification	O
.	O

An	O
abbreviated	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
Revised	O
(	O
WAIS	O
-	O
R	O
)	O
was	O
used	O
to	O
assess	O
verbal	O
and	O
arithmetical	O
cognitive	O
performance	O
in	O
55	O
subjects	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
,	O
covering	O
all	O
grades	O
of	O
disease	O
severity	O
,	O
and	O
31	O
controls	O
at	O
50	O
%	O
risk	O
of	O
inheriting	O
DM	B-Disease
.	O

Scaled	O
scores	O
from	O
the	O
assessment	O
were	O
converted	O
into	O
an	O
intelligence	O
quotient	O
(	O
IQ	O
)	O
estimation	O
on	O
each	O
person	O
.	O

Significant	O
IQ	O
differences	O
were	O
found	O
between	O
(	O
1	O
)	O
all	O
55	O
DM	B-Disease
subjects	O
(	O
mean	O
90	O
.	O
2	O
,	O
SD	O
16	O
.	O
1	O
)	O
and	O
31	O
controls	O
(	O
102	O
.	O
6	O
,	O
SD	O
9	O
.	O
4	O
)	O
,	O
with	O
no	O
sex	O
differences	O
in	O
either	O
group	O
;	O
(	O
2	O
)	O
15	O
affected	O
parents	O
(	O
99	O
.	O
3	O
,	O
SD	O
12	O
.	O
2	O
)	O
and	O
their	O
affected	O
children	O
(	O
88	O
.	O
1	O
,	O
SD	O
17	O
.	O
2	O
)	O
,	O
where	O
significance	O
was	O
dependent	O
on	O
parental	O
sex	O
being	O
female	O
;	O
and	O
(	O
3	O
)	O
15	O
pairs	O
of	O
affected	O
sibs	O
(	O
89	O
.	O
6	O
,	O
SD	O
13	O
.	O
2	O
)	O
and	O
their	O
normal	O
sibs	O
(	O
100	O
.	O
2	O
,	O
SD	O
7	O
.	O
6	O
)	O
.	O

IQ	O
steadily	O
declined	O
as	O
(	O
1	O
)	O
the	O
age	O
of	O
onset	O
of	O
signs	O
and	O
symptoms	O
decreased	O
,	O
and	O
(	O
2	O
)	O
the	O
CTG	O
expansion	O
size	O
increased	O
.	O

The	O
correlation	O
appeared	O
to	O
be	O
more	O
linear	O
with	O
age	O
of	O
onset	O
.	O

The	O
correlation	O
of	O
IQ	O
difference	O
and	O
CTG	O
expansion	O
difference	O
in	O
both	O
the	O
DM	B-Disease
parent	O
-	O
child	O
pairs	O
and	O
normal	O
sib	O
-	O
affected	O
sib	O
pairs	O
was	O
poor	O
,	O
indicating	O
that	O
CTG	O
expansion	O
is	O
not	O
a	O
reliable	O
predictor	O
of	O
IQ	O
either	O
in	O
individual	O
persons	O
or	O
families	O
.	O

Further	O
analysis	O
of	O
cognitive	O
function	O
in	O
DM	B-Disease
is	O
required	O
to	O
clarify	O
specific	O
deficits	O
characteristic	O
of	O
this	O
patient	O
group	O

Adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
and	O
a	O
cytogenetic	O
deletion	O
of	O
chromosome	O
5	O
resulting	O
from	O
a	O
maternal	O
intrachromosomal	O
insertion	O
.	O

We	O
present	O
the	O
clinical	O
and	O
laboratory	O
findings	O
in	O
an	O
institutionalised	O
adult	O
patient	O
originally	O
referred	O
for	O
autism	B-Disease
.	O

A	O
high	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
predicted	O
when	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
,	O
del	O
(	O
5	O
)	O
(	O
q15q22	O
.	O
3	O
)	O
,	O
was	O
detected	O
in	O
her	O
lymphocytes	O
and	O
deletion	O
of	O
the	O
MCC	O
and	O
APC	B-Disease
genes	O
confirmed	O
by	O
molecular	O
analysis	O
.	O

Adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
and	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
rectum	I-Disease
were	O
subsequently	O
diagnosed	O
in	O
the	O
patient	O
.	O

She	O
was	O
profoundly	O
mentally	B-Disease
retarded	I-Disease
,	O
autistic	B-Disease
,	O
and	O
had	O
minor	O
dysmorphic	B-Disease
features	I-Disease
consistent	O
with	O
those	O
of	O
previous	O
patients	O
with	O
similar	O
deletions	O
.	O

The	O
deletion	O
arose	O
as	O
a	O
result	O
of	O
recombination	O
within	O
the	O
small	O
insertion	O
loop	O
formed	O
at	O
meiosis	O
by	O
the	O
direct	O
insertion	O
(	O
dir	O
ins	O
(	O
5	O
)	O
(	O
q22	O
.	O
3q14	O
.	O
2q15	O
)	O
)	O
found	O
in	O
the	O
patients	O
mother	O
.	O

This	O
family	O
further	O
confirms	O
the	O
cytogenetic	O
mapping	O
of	O
both	O
MCC	O
and	O
APC	B-Disease
genes	O
to	O
5q22	O
and	O
comparison	O
with	O
other	O
recent	O
cases	O
suggests	O
that	O
both	O
genes	O
and	O
their	O
closely	O
linked	O
markers	O
lie	O
within	O
the	O
5q22	O
.	O

1	O
subband	O

Familial	B-Disease
male	I-Disease
breast	I-Disease
cancer	I-Disease
is	O
not	O
linked	O
to	O
the	O
BRCA1	O
locus	O
on	O
chromosome	O
17q	O
.	O

Breast	B-Disease
cancer	I-Disease
in	O
men	O
is	O
about	O
a	O
hundredfold	O
less	O
common	O
than	O
in	O
women	O
and	O
this	O
has	O
hindered	O
research	O
into	O
its	O
genetic	O
basis	O
.	O

We	O
have	O
examined	O
22	O
families	O
with	O
at	O
least	O
one	O
case	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
for	O
linkage	O
to	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
locus	O
,	O
BRCA1	O
,	O
on	O
chromosome	O
17q	O
.	O

We	O
found	O
strong	O
evidence	O
against	O
linkage	O
to	O
BRCA1	O
(	O
lod	O
score	O
-	O
16	O
.	O
63	O
)	O
and	O
the	O
best	O
estimate	O
of	O
the	O
proportion	O
of	O
linked	O
families	O
was	O
0	O
%	O
(	O
95	O
%	O
CI	O
0	O
-	O
18	O
%	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
there	O
is	O
a	O
gene	O
(	O
s	O
)	O
other	O
than	O
BRCA1	O
which	O
predisposes	O
to	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
in	O
women	O
and	O
which	O
confers	O
a	O
higher	O
risk	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
.	O

Identification	O
of	O
additional	O
pedigrees	O
that	O
include	O
cases	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
may	O
therefore	O
facilitate	O
the	O
mapping	O
and	O
isolation	O
of	O
this	O
gene	O
.	O

The	O
EWS	O
gene	O
,	O
involved	O
in	O
Ewing	B-Disease
family	I-Disease
of	I-Disease
tumors	I-Disease
,	O
malignant	B-Disease
melanoma	I-Disease
of	I-Disease
soft	I-Disease
parts	I-Disease
and	O
desmoplastic	B-Disease
small	I-Disease
round	I-Disease
cell	I-Disease
tumors	I-Disease
,	O
codes	O
for	O
an	O
RNA	O
binding	O
protein	O
with	O
novel	O
regulatory	O
domains	O
.	O

The	O
EWS	O
gene	O
,	O
which	O
maps	O
to	O
band	O
q12	O
of	O
human	O
chromosome	O
22	O
,	O
is	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
human	O
solid	B-Disease
tumors	I-Disease
including	O
Ewing	B-Disease
sarcoma	I-Disease
,	O
related	O
primitive	O
neuroectodermal	B-Disease
tumors	I-Disease
,	O
malignant	B-Disease
melanoma	I-Disease
of	I-Disease
soft	I-Disease
parts	I-Disease
and	O
desmoplastic	B-Disease
small	I-Disease
round	I-Disease
cell	I-Disease
tumors	I-Disease
.	O

In	O
these	O
tumors	B-Disease
,	O
the	O
EWS	O
is	O
fused	O
to	O
genes	O
encoding	O
transcriptional	O
activators	O
/	O
repressors	O
,	O
like	O
Fli	O
-	O
1	O
or	O
erg	O
or	O
ATF	O
1	O
or	O
wt1	O
.	O

To	O
better	O
understand	O
the	O
function	O
of	O
the	O
EWS	O
protein	O
,	O
we	O
cloned	O
the	O
EWS	O
cDNA	O
.	O

Sequence	O
analysis	O
of	O
this	O
cDNA	O
revealed	O
differential	O
splicing	O
involving	O
two	O
exons	O
encoding	O
72	O
amino	O
acids	O
.	O

Both	O
alternatively	O
spliced	O
transcripts	O
,	O
EWS	O
and	O
EWS	O
-	O
b	O
,	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cells	O
.	O

Because	O
EWS	O
proteins	O
contain	O
putative	O
conserved	O
RNA	O
binding	O
motifs	O
,	O
we	O
studied	O
the	O
RNA	O
binding	O
properties	O
of	O
the	O
EWS	O
protein	O
.	O

The	O
EWS	O
-	O
b	O
protein	O
binds	O
to	O
RNA	O
in	O
vitro	O
and	O
,	O
specifically	O
,	O
to	O
poly	O
G	O
and	O
poly	O
U	O
.	O

The	O
RNA	O
binding	O
activity	O
was	O
localized	O
to	O
the	O
carboxy	O
terminal	O
86	O
amino	O
acids	O
,	O
which	O
constitute	O
RGG	O
box	O
.	O

Thus	O
the	O
amino	O
terminal	O
domain	O
of	O
EWS	O
(	O
NTD	O
-	O
EWS	O
)	O
,	O
which	O
is	O
involved	O
in	O
chromosome	O
translocation	O
may	O
regulate	O
the	O
specificity	O
of	O
RNA	O
binding	O
activity	O
of	O
EWS	O
.	O

An	O
EWS	O
-	O
erg	O
chimeric	O
protein	O
,	O
which	O
is	O
found	O
in	O
Ewings	B-Disease
sarcoma	I-Disease
cells	O
,	O
functions	O
as	O
a	O
transcriptional	O
activator	O
.	O

Mutational	O
analysis	O
of	O
EWS	O
-	O
erg	O
chimeric	O
protein	O
revealed	O
that	O
NTD	O
-	O
EWS	O
functions	O
as	O
a	O
regulatory	O
domain	O
for	O
the	O
transcriptional	O
activation	O
properties	O
of	O
EWS	O
-	O
erg	O
chimeric	O
protein	O
.	O
.	O

Canavan	B-Disease
disease	I-Disease
:	O
genomic	O
organization	O
and	O
localization	O
of	O
human	O
ASPA	O
to	O
17p13	O
-	O
ter	O
and	O
conservation	O
of	O
the	O
ASPA	O
gene	O
during	O
evolution	O
.	O

Canavan	B-Disease
disease	I-Disease
,	O
or	O
spongy	B-Disease
degeneration	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
,	O
is	O
a	O
severe	O
leukodystrophy	B-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
aspartoacylase	I-Disease
(	O
ASPA	O
)	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
was	O
identified	O
in	O
human	O
ASPA	O
coding	O
sequence	O
from	O
patients	O
with	O
Canavan	B-Disease
disease	I-Disease
.	O

The	O
human	O
ASPA	O
gene	O
has	O
been	O
cloned	O
and	O
found	O
to	O
span	O
29	O
kb	O
of	O
the	O
genome	O
.	O

Human	O
aspartoacylase	O
is	O
coded	O
by	O
six	O
exons	O
intervened	O
by	O
five	O
introns	O
.	O

The	O
exons	O
vary	O
from	O
94	O
(	O
exon	O
III	O
)	O
to	O
514	O
(	O
exon	O
VI	O
)	O
bases	O
.	O

The	O
exon	O
/	O
intron	O
splice	O
junction	O
sites	O
follow	O
the	O
gt	O
/	O
ag	O
consensus	O
sequence	O
rule	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
human	O
/	O
mouse	O
somatic	O
cell	O
hybrid	O
cell	O
lines	O
localized	O
ASPA	O
to	O
human	O
chromosome	O
17	O
.	O

The	O
human	O
ASPA	O
locus	O
was	O
further	O
mapped	O
in	O
the	O
17p13	O
-	O
ter	O
region	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
bovine	O
aspa	O
gene	O
has	O
also	O
been	O
cloned	O
,	O
and	O
its	O
exon	O
/	O
intron	O
organization	O
is	O
identical	O
to	O
that	O
of	O
the	O
human	O
gene	O
.	O

The	O
500	O
-	O
base	O
sequence	O
upstream	O
of	O
the	O
initiator	O
ATG	O
codon	O
in	O
the	O
human	O
gene	O
and	O
that	O
in	O
the	O
bovine	O
gene	O
are	O
77	O
%	O
identical	O
.	O

Human	O
ASPA	O
coding	O
sequences	O
cross	O
-	O
hybridize	O
with	O
genomic	O
DNA	O
from	O
yeast	O
,	O
chicken	O
,	O
rabbit	O
,	O
cow	O
,	O
dog	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
monkey	O
.	O

The	O
specificity	O
of	O
cross	O
-	O
species	O
hybridization	O
of	O
coding	O
sequences	O
suggests	O
that	O
aspartoacylase	O
has	O
been	O
conserved	O
during	O
evolution	O
.	O

It	O
should	O
now	O
be	O
possible	O
to	O
identify	O
mutations	O
in	O
the	O
noncoding	O
genomic	O
sequences	O
that	O
lead	O
to	O
Canavan	B-Disease
disease	I-Disease
and	O
to	O
study	O
the	O
regulation	O
of	O
ASPA	O
.	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
:	O
size	O
-	O
and	O
sex	O
-	O
dependent	O
dynamics	O
of	O
CTG	O
meiotic	O
instability	O
,	O
and	O
somatic	O
mosaicism	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
a	O
progressive	O
neuromuscular	B-Disease
disorder	I-Disease
which	O
results	O
from	O
elongations	O
of	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B-Disease
gene	O
.	O

A	O
correlation	O
has	O
been	O
demonstrated	O
between	O
the	O
increase	O
in	O
the	O
repeat	O
number	O
of	O
this	O
sequence	O
and	O
the	O
severity	O
of	O
the	O
disease	O
.	O

However	O
,	O
the	O
clinical	O
status	O
of	O
patients	O
cannot	O
be	O
unambiguously	O
ascertained	O
solely	O
on	O
the	O
basis	O
of	O
the	O
number	O
of	O
CTG	O
repeats	O
.	O

Moreover	O
,	O
the	O
exclusive	O
maternal	O
inheritance	O
of	O
the	O
congenital	O
form	O
remains	O
unexplained	O
.	O

Our	O
observation	O
of	O
differently	O
sized	O
repeats	O
in	O
various	O
DM	B-Disease
tissues	O
from	O
the	O
same	O
individual	O
may	O
explain	O
why	O
the	O
size	O
of	O
the	O
mutation	O
observed	O
in	O
lymphocytes	O
does	O
not	O
necessarily	O
correlate	O
with	O
the	O
severity	O
and	O
nature	O
of	O
symptoms	O
.	O

Through	O
a	O
molecular	O
and	O
genetic	O
study	O
of	O
142	O
families	O
including	O
418	O
DM	B-Disease
patients	O
,	O
we	O
have	O
investigated	O
the	O
dynamics	O
of	O
the	O
CTG	O
repeat	O
meiotic	O
instability	O
.	O

A	O
positive	O
correlation	O
between	O
the	O
size	O
of	O
the	O
repeat	O
and	O
the	O
intergenerational	O
enlargement	O
was	O
observed	O
similarly	O
through	O
male	O
and	O
female	O
meioses	O
for	O
<	O
or	O
=	O
0	O
.	O

5	O
-	O
kb	O
CTG	O
sequences	O
.	O

Beyond	O
0	O
.	O

5	O
kb	O
,	O
the	O
intergenerational	O
variation	O
was	O
more	O
important	O
through	O
female	O
meioses	O
,	O
whereas	O
a	O
tendency	O
to	O
compression	O
was	O
observed	O
almost	O
exclusively	O
in	O
male	O
meioses	O
,	O
for	O
>	O
or	O
=	O
1	O
.	O

5	O
-	O
kb	O
fragments	O
.	O

This	O
implies	O
a	O
size	O
-	O
and	O
sex	O
-	O
dependent	O
meiotic	O
instability	O
.	O

Moreover	O
,	O
segregation	O
analysis	O
supports	O
the	O
hypothesis	O
of	O
a	O
maternal	O
as	O
well	O
as	O
a	O
familial	O
predisposition	O
for	O
the	O
occurrence	O
of	O
the	O
congenital	O
form	O
.	O

Finally	O
,	O
this	O
analysis	O
reveals	O
a	O
significant	O
excess	O
of	O
transmitting	O
grandfathers	O
partially	O
accounted	O
for	O
by	O
increased	O
fertility	O
in	O
affected	O
males	O

Illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
lymphocytes	O
for	O
identification	O
of	O
mutations	O
in	O
phenylketonuria	B-Disease
.	O

Taking	O
advantage	O
of	O
the	O
illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
,	O
we	O
have	O
been	O
able	O
to	O
analyse	O
the	O
PAH	O
cDNA	O
sequence	O
of	O
hyperphenylalaninemic	B-Disease
children	O
in	O
circulating	O
lymphocytes	O
.	O

Using	O
this	O
approach	O
,	O
we	O
have	O
also	O
identified	O
3	O
novel	O
mutations	O
in	O
cDNA	O
from	O
liver	O
and	O
lymphocytes	O
of	O
two	O
patients	O
.	O

One	O
mutation	O
,	O
detected	O
by	O
the	O
abnormal	O
pattern	O
of	O
migration	O
of	O
an	O
amplified	O
fragment	O
,	O
is	O
a	O
C	O
to	O
T	O
transition	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
10	O
,	O
which	O
resulted	O
in	O
the	O
skipping	O
of	O
exon	O
11	O
with	O
the	O
premature	O
termination	O
of	O
RNA	O
translation	O
downstream	O
from	O
exon	O
12	O
(	O
-	O
3	O
IVS10	O
)	O
.	O

The	O
other	O
two	O
mutations	O
are	O
missense	O
mutations	O
in	O
exons	O
10	O
and	O
11	O
(	O
respectively	O
,	O
L333F	O
and	O
E390G	O
)	O
.	O

The	O
present	O
study	O
supports	O
the	O
view	O
that	O
circulating	O
lymphocytes	O
give	O
easy	O
access	O
to	O
PAH	O
gene	O
transcripts	O
whose	O
nucleotide	O
sequence	O
is	O
identical	O
to	O
that	O
reported	O
in	O
liver	O
and	O
therefore	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	O
genetic	O
studies	O
in	O
phenylketonuria	B-Disease
.	O
.	O

High	O
residual	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
in	O
a	O
patient	O
with	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
.	O

We	O
identified	O
a	O
patient	O
suffering	O
from	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
who	O
has	O
a	O
residual	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
of	O
about	O
10	O
%	O
.	O

Fibroblasts	O
of	O
the	O
patient	O
show	O
significant	O
sulfatide	O
degradation	O
activity	O
exceeding	O
that	O
of	O
adult	B-Disease
MLD	I-Disease
patients	O
.	O

Analysis	O
of	O
the	O
ARSA	O
gene	O
in	O
this	O
patient	O
revealed	O
heterozygosity	O
for	O
two	O
new	O
mutant	O
alleles	O
in	O
one	O
allele	O
,	O
deletion	O
of	O
C	O
447	O
in	O
exon	O
2	O
leads	O
to	O
a	O
frameshift	O
and	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
position	O
105	O
;	O
in	O
the	O
second	O
allele	O
,	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
in	O
exon	O
5	O
causes	O
a	O
Gly309	O
-	O
-	O
>	O
Ser	O
substitution	O
.	O

Transient	O
expression	O
of	O
the	O
mutant	O
Ser309	O
-	O
ARSA	O
resulted	O
in	O
only	O
13	O
%	O
enzyme	O
activity	O
of	O
that	O
observed	O
in	O
cells	O
expressing	O
normal	O
ARSA	O
.	O

The	O
mutant	O
ARSA	O
is	O
correctly	O
targeted	O
to	O
the	O
lysosomes	O
but	O
is	O
unstable	O
.	O

These	O
findings	O
are	O
in	O
contrast	O
to	O
previous	O
results	O
showing	O
that	O
the	O
late	B-Disease
-	I-Disease
infantile	I-Disease
type	I-Disease
of	I-Disease
MLD	I-Disease
is	O
always	O
associated	O
with	O
the	O
complete	O
absence	O
of	O
ARSA	O
activity	O
.	O

The	O
expression	O
of	O
the	O
mutant	O
ARSA	O
protein	O
may	O
be	O
influenced	O
by	O
particular	O
features	O
of	O
oligodendrocytes	O
,	O
such	O
that	O
the	O
level	O
of	O
mutant	O
enzyme	O
is	O
lower	O
in	O
these	O
cells	O
than	O
in	O
others	O
.	O
.	O

An	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
missense	O
mutation	O
(	O
T274M	O
)	O
causing	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
.	O

Metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
arylsulfatase	I-Disease
A	I-Disease
(	O
ARSA	O
;	O
EC	O
3	O
.	O
1	O
.	O
6	O
.	O
8	O
)	O
.	O

The	O
8	O
ARSA	O
exons	O
and	O
adjacent	O
intron	O
boundaries	O
from	O
a	O
patient	O
with	O
late	B-Disease
-	I-Disease
infantile	I-Disease
metachromatic	I-Disease
leukodystrophy	I-Disease
were	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
in	O
seven	O
discrete	O
reactions	O
.	O

Amplified	O
ARSA	O
exons	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
sequence	O
alterations	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
followed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
products	O
.	O

The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
C	O
-	O
-	O
>	O
T	O
transition	O
in	O
exon	O
IV	O
that	O
results	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
threonine	O
residue	O
at	O
amino	O
acid	O
274	O
with	O
a	O
methionine	O
(	O
T274M	O
)	O
.	O

Analysis	O
of	O
a	O
further	O
29	O
MLD	B-Disease
patients	O
revealed	O
the	O
presence	O
of	O
five	O
additional	O
homozygotes	O
for	O
T274M	O
.	O

All	O
6	O
T274M	O
homozygotes	O
(	O
representing	O
four	O
families	O
)	O
were	O
of	O
Lebanese	O
descent	O
,	O
and	O
all	O
were	O
known	O
to	O
be	O
the	O
result	O
of	O
consanguineous	O
marriages	O
.	O

The	O
altered	O
amino	O
acid	O
is	O
rigidly	O
conserved	O
among	O
10	O
sulfatases	O
from	O
Escherichia	O
coli	O
to	O
humans	O
;	O
therefore	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
resultant	O
mutant	O
protein	O
will	O
have	O
little	O
or	O
no	O
enzyme	O
activity	O
.	O

This	O
is	O
consistent	O
with	O
the	O
very	O
low	O
ARSA	O
activity	O
measured	O
in	O
these	O
patients	O
and	O
their	O
uniformly	O
severe	O
clinical	O
presentation	O

Mutations	O
in	O
the	O
PAX6	O
gene	O
in	O
patients	O
with	O
hereditary	O
aniridia	B-Disease
.	O

The	O
14	O
exons	O
of	O
the	O
PAX6	O
gene	O
have	O
been	O
analysed	O
exon	O
-	O
by	O
-	O
exon	O
using	O
SSCP	O
in	O
6	O
aniridia	B-Disease
families	O
.	O

In	O
each	O
family	O
band	O
shifts	O
were	O
observed	O
on	O
the	O
SSCP	O
gels	O
for	O
only	O
one	O
exon	O
and	O
direct	O
PCR	O
-	O
sequencing	O
revealed	O
mutations	O
in	O
each	O
case	O
.	O

Two	O
mutations	O
involved	O
C	O
-	O
-	O
>	O
T	O
transitions	O
in	O
CGAarg	O
codons	O
in	O
exons	O
9	O
and	O
11	O
.	O

Another	O
C	O
-	O
-	O
>	O
T	O
transition	O
converted	O
a	O
CAG	O
-	O
glutamine	O
to	O
a	O
TAG	O
-	O
stop	O
in	O
exon	O
7	O
.	O

Small	O
insertions	O
created	O
frameshifts	O
which	O
produced	O
downstream	O
stop	O
codons	O
in	O
another	O
two	O
patients	O
and	O
an	O
A	O
-	O
-	O
>	O
T	O
mutation	O
disrupted	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
5	O
in	O
the	O
remaining	O
family	O
.	O

Thus	O
,	O
complete	O
inactivation	O
of	O
the	O
PAX6	O
gene	O
is	O
predicted	O
in	O
all	O
cases	O
.	O

Analysis	O
of	O
other	O
affected	O
members	O
of	O
the	O
families	O
showed	O
that	O
,	O
in	O
each	O
case	O
,	O
all	O
affected	O
individuals	O
carried	O
the	O
same	O
family	O
-	O
specific	O
mutation	O
.	O

One	O
polymorphism	O
was	O
found	O
in	O
exon	O
7	O
.	O

This	O
data	O
strongly	O
supports	O
the	O
candidature	O
of	O
PAX6	O
as	O
the	O
gene	O
responsible	O
for	O
hereditary	O
aniridia	B-Disease
.	O
.	O

Three	O
novel	O
mutations	O
in	O
five	O
unrelated	O
subjects	O
with	O
hereditary	O
protein	B-Disease
S	I-Disease
deficiency	I-Disease
type	I-Disease
I	I-Disease
.	O

A	O
panel	O
of	O
eight	O
unrelated	O
subjects	O
with	O
inherited	O
type	B-Disease
I	I-Disease
protein	I-Disease
S	I-Disease
deficiency	I-Disease
was	O
screened	O
for	O
mutations	O
in	O
the	O
PROS1	O
gene	O
.	O

In	O
five	O
subjects	O
an	O
abnormality	O
was	O
found	O
but	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
remaining	O
three	O
subjects	O
.	O

Two	O
subjects	O
shared	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
position	O
+	O
5	O
of	O
the	O
donor	O
splice	O
site	O
consensus	O
sequence	O
of	O
intron	O
10	O
.	O

Also	O
in	O
two	O
subjects	O
an	O
A	O
-	O
-	O
>	O
T	O
transversion	O
was	O
detected	O
in	O
the	O
stopcodon	O
of	O
the	O
PROS1	O
gene	O
;	O
this	O
transversion	O
predicts	O
a	O
protein	O
S	O
molecule	O
that	O
is	O
extended	O
by	O
14	O
amino	O
acids	O
.	O

The	O
fifth	O
subject	O
was	O
found	O
to	O
possess	O
two	O
sequence	O
abnormalities	O
.	O

One	O
allele	O
carried	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
near	O
the	O
donor	O
splice	O
junction	O
of	O
intron	O
2	O
,	O
but	O
this	O
abnormality	O
is	O
probably	O
neutral	O
,	O
since	O
it	O
was	O
inherited	O
from	O
the	O
parent	O
with	O
normal	O
protein	O
S	O
antigen	O
levels	O
.	O

In	O
the	O
other	O
allele	O
a	O
single	O
T	O
insertion	O
in	O
codon	O
-	O
25	O
was	O
found	O
.	O

Analysis	O
of	O
platelet	O
RNA	O
showed	O
that	O
only	O
the	O
mRNA	O
with	O
the	O
A	O
-	O
-	O
>	O
T	O
mutation	O
in	O
the	O
stopcodon	O
is	O
present	O
in	O
amounts	O
comparable	O
to	O
wildtype	O
RNA	O
.	O

mRNA	O
from	O
the	O
alleles	O
with	O
the	O
other	O
two	O
mutations	O
was	O
either	O
undetectable	O
or	O
present	O
in	O
greatly	O
reduced	O
amounts	O
.	O

The	O
latter	O
indicates	O
that	O
a	O
mRNA	O
based	O
approach	O
is	O
not	O
feasible	O
for	O
the	O
genetic	O
analysis	O
of	O
protein	B-Disease
S	I-Disease
deficiency	I-Disease
type	I-Disease
I	I-Disease
.	O
.	O

Characteristics	O
of	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O

In	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
,	O
the	O
size	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
DM	B-Disease
kinase	O
gene	O
generally	O
increases	O
in	O
successive	O
generations	O
with	O
clinical	O
evidence	O
of	O
anticipation	O
.	O

However	O
,	O
there	O
have	O
also	O
been	O
cases	O
with	O
an	O
intergenerational	O
contraction	O
of	O
the	O
repeat	O
.	O

We	O
examined	O
1	O
,	O
489	O
DM	B-Disease
parent	O
-	O
offspring	O
pairs	O
,	O
of	O
which	O
95	O
(	O
6	O
.	O
4	O
%	O
)	O
showed	O
such	O
contractions	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
PBL	O
)	O
.	O

In	O
56	O
of	O
the	O
95	O
pairs	O
,	O
clinical	O
data	O
allowed	O
an	O
analysis	O
of	O
their	O
anticipation	O
status	O
.	O

It	O
is	O
surprising	O
that	O
anticipation	O
occurred	O
in	O
27	O
(	O
48	O
%	O
)	O
of	O
these	O
56	O
pairs	O
,	O
while	O
none	O
clearly	O
showed	O
a	O
later	O
onset	O
of	O
DM	B-Disease
in	O
the	O
symptomatic	O
offspring	O
.	O

The	O
contraction	O
occurred	O
in	O
76	O
(	O
10	O
%	O
)	O
of	O
753	O
paternal	O
transmissions	O
and	O
in	O
19	O
(	O
3	O
%	O
)	O
of	O
736	O
maternal	O
transmissions	O
.	O

Anticipation	O
was	O
observed	O
more	O
frequently	O
in	O
maternal	O
(	O
85	O
%	O
)	O
than	O
in	O
paternal	O
(	O
37	O
%	O
)	O
transmissions	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
parental	O
repeat	O
size	O
correlated	O
with	O
the	O
size	O
of	O
intergenerational	O
contraction	O
(	O
r2	O
=	O
.	O
50	O
,	O
P	O
<	O
<	O
.	O
001	O
)	O
,	O
and	O
the	O
slope	O
of	O
linear	O
regression	O
was	O
steeper	O
in	O
paternal	O
(	O
-	O
.	O
62	O
)	O
than	O
in	O
maternal	O
(	O
-	O
.	O
30	O
)	O
transmissions	O
(	O
P	O
<	O
<	O
.	O
001	O
)	O
.	O

Sixteen	O
DM	B-Disease
parents	O
had	O
multiple	O
DM	B-Disease
offspring	O
with	O
the	O
CTG	O
repeat	O
contractions	O
.	O

This	O
frequency	O
was	O
higher	O
than	O
the	O
frequency	O
expected	O
from	O
the	O
probability	O
of	O
the	O
repeat	O
contractions	O
(	O
6	O
.	O
4	O
%	O
)	O
and	O
the	O
size	O
of	O
DM	B-Disease
sib	O
population	O
(	O
1	O
.	O
54	O
DM	B-Disease
offspring	O
per	O
DM	B-Disease
parent	O
,	O
in	O
968	O
DM	B-Disease
parents	O
)	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
leukocyte	O
DNA	O
frequently	O
accompanies	O
apparent	O
anticipation	O
,	O
especially	O
when	O
DM	B-Disease
is	O
maternally	O
transmitted	O
,	O
and	O
(	O
2	O
)	O
the	O
paternal	O
origin	O
of	O
the	O
repeat	O
and	O
the	O
presence	O
of	O
the	O
repeat	O
contraction	O
in	O
a	O
sibling	O
increase	O
the	O
probability	O
of	O
the	O
CTG	O
repeat	O
contraction	O

Gonosomal	O
mosaicism	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
:	O
involvement	O
of	O
mitotic	O
events	O
in	O
(	O
CTG	O
)	O
n	O
repeat	O
variation	O
and	O
selection	O
against	O
extreme	O
expansion	O
in	O
sperm	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
caused	O
by	O
abnormal	O
expansion	O
of	O
a	O
polymorphic	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
DM	B-Disease
protein	O
kinase	O
gene	O
.	O

We	O
determined	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
lengths	O
in	O
a	O
broad	O
range	O
of	O
tissue	O
DNAs	O
from	O
patients	O
with	O
mild	O
,	O
classical	O
,	O
or	O
congenital	O
manifestation	O
of	O
DM	B-Disease
.	O

Differences	O
in	O
the	O
repeat	O
length	O
were	O
seen	O
in	O
somatic	O
tissues	O
from	O
single	O
DM	B-Disease
individuals	O
and	O
twins	O
.	O

Repeats	O
appeared	O
to	O
expand	O
to	O
a	O
similar	O
extent	O
in	O
tissues	O
originating	O
from	O
the	O
same	O
embryonal	O
origin	O
.	O

In	O
most	O
male	O
patients	O
carrying	O
intermediate	O
-	O
or	O
small	O
-	O
sized	O
expansions	O
in	O
blood	O
,	O
the	O
repeat	O
lengths	O
covered	O
a	O
markedly	O
wider	O
range	O
in	O
sperm	O
.	O

In	O
contrast	O
,	O
male	O
patients	O
with	O
large	O
allele	O
expansions	O
in	O
blood	O
(	O
>	O
700	O
CTGs	O
)	O
had	O
similar	O
or	O
smaller	O
repeats	O
in	O
sperm	O
,	O
when	O
detectable	O
.	O

Sperm	O
alleles	O
with	O
>	O
1	O
,	O
000	O
CTGs	O
were	O
not	O
seen	O
.	O

We	O
conclude	O
that	O
DM	B-Disease
patients	O
can	O
be	O
considered	O
gonosomal	O
mosaics	O
,	O
i	O
.	O

e	O
e	O
.	O
,	O
combined	O
somatic	O
and	O
germ	O
-	O
line	O
tissue	O
mosaics	O
.	O

Most	O
remarkably	O
,	O
we	O
observed	O
multiple	O
cases	O
where	O
the	O
length	O
distributions	O
of	O
intermediate	O
-	O
or	O
small	O
-	O
sized	O
alleles	O
in	O
fathers	O
sperm	O
were	O
significantly	O
different	O
from	O
that	O
in	O
their	O
offsprings	O
blood	O
.	O

Our	O
combined	O
findings	O
indicate	O
that	O
intergenerational	O
length	O
changes	O
in	O
the	O
unstable	O
CTG	O
repeat	O
are	O
most	O
likely	O
to	O
occur	O
during	O
early	O
embryonic	O
mitotic	O
divisions	O
in	O
both	O
somatic	O
and	O
germ	O
-	O
line	O
tissue	O
formation	O
.	O

Both	O
the	O
initial	O
CTG	O
length	O
,	O
the	O
overall	O
number	O
of	O
cell	O
divisions	O
involved	O
in	O
tissue	O
formation	O
,	O
and	O
perhaps	O
a	O
specific	O
selection	O
process	O
in	O
spermatogenesis	O
may	O
influence	O
the	O
dynamics	O
of	O
this	O
process	O
.	O

A	O
model	O
explaining	O
mitotic	O
instability	O
and	O
sex	O
-	O
dependent	O
segregation	O
phenomena	O
in	O
DM	B-Disease
manifestation	O
is	O
discussed	O

Regionally	O
clustered	O
APC	B-Disease
mutations	O
are	O
associated	O
with	O
a	O
severe	O
phenotype	O
and	O
occur	O
at	O
a	O
high	O
frequency	O
in	O
new	O
mutation	O
cases	O
of	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O

Germline	O
mutation	O
in	O
APC	O
at	O
5q21	O
-	O
22	O
results	O
in	O
the	O
dominantly	O
inherited	O
syndrome	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
.	O

Somatic	O
mutation	O
in	O
this	O
gene	O
is	O
an	O
early	O
event	O
in	O
colorectal	O
tumourigenesis	O
.	O

Both	O
types	O
of	O
mutation	O
are	O
concentrated	O
in	O
the	O
5	O
half	O
of	O
exon	O
15	O
.	O

We	O
have	O
used	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
heteroduplex	O
analysis	O
to	O
screen	O
for	O
variants	O
in	O
this	O
region	O
of	O
the	O
gene	O
in	O
a	O
total	O
of	O
45	O
affected	O
but	O
unrelated	O
individuals	O
.	O

Eighteen	O
patients	O
had	O
no	O
family	O
history	O
of	O
the	O
disease	O
;	O
of	O
these	O
11	O
were	O
classified	O
as	O
having	O
a	O
severe	O
phenotype	O
,	O
based	O
on	O
an	O
early	O
age	O
at	O
presentation	O
or	O
cancer	B-Disease
development	O
.	O

This	O
compared	O
with	O
6	O
of	O
27	O
familial	O
cases	O
.	O

A	O
5	O
bp	O
deletion	O
at	O
codon	O
1309	O
reported	O
to	O
occur	O
in	O
10	O
-	O
15	O
%	O
of	O
unselected	O
APC	B-Disease
patients	O
worldwide	O
,	O
was	O
found	O
in	O
5	O
of	O
the	O
18	O
new	O
mutation	O
cases	O
and	O
4	O
of	O
the	O
27	O
familial	O
cases	O
all	O
nine	O
were	O
classed	O
as	O
severe	O
.	O

A	O
further	O
3	O
new	O
mutations	O
and	O
1	O
familial	O
mutation	O
were	O
located	O
downstream	O
from	O
codon	O
1309	O
,	O
these	O
individuals	O
similarly	O
being	O
classed	O
as	O
phenotypically	O
severe	O
.	O

In	O
contrast	O
all	O
of	O
the	O
APC	B-Disease
mutations	O
detected	O
in	O
affected	O
individuals	O
with	O
an	O
average	O
phenotype	O
were	O
located	O
prior	O
to	O
codon	O
1309	O
.	O

The	O
frequent	O
association	O
of	O
a	O
severe	O
phenotype	O
with	O
fresh	O
mutation	O
may	O
explain	O
the	O
apparent	O
conflict	O
of	O
a	O
high	O
mutation	O
rate	O
(	O
20	O
-	O
30	O
%	O
)	O
in	O
a	O
condition	O
,	O
which	O
on	O
average	O
,	O
is	O
lethal	O
at	O
a	O
post	O
-	O
reproductive	O
age	O
.	O
.	O

Mutations	O
at	O
the	O
PAX6	O
locus	O
are	O
found	O
in	O
heterogeneous	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
Peters	B-Disease
'	I-Disease
anomaly	I-Disease
.	O

Mutation	O
or	O
deletion	O
of	O
the	O
PAX6	O
gene	O
underlies	O
many	O
cases	O
of	O
aniridia	B-Disease
.	O

Three	O
lines	O
of	O
evidence	O
now	O
converge	O
to	O
implicate	O
PAX6	O
more	O
widely	O
in	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
Peters	B-Disease
anomaly	I-Disease
.	O

First	O
,	O
a	O
child	O
with	O
Peters	B-Disease
anomaly	I-Disease
is	O
deleted	O
for	O
one	O
copy	O
of	O
PAX6	O
.	O

Second	O
,	O
affected	O
members	O
of	O
a	O
family	O
with	O
dominantly	O
inherited	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
,	O
including	O
Peters	B-Disease
anomaly	I-Disease
are	O
heterozygous	O
for	O
an	O
R26G	O
mutation	O
in	O
the	O
PAX6	O
paired	O
box	O
.	O

Third	O
,	O
a	O
proportion	O
of	O
Sey	O
/	O
+	O
Smalleye	O
mice	O
,	O
heterozygous	O
for	O
a	O
nonsense	O
mutation	O
in	O
murine	O
Pax	O
-	O
6	O
,	O
have	O
an	O
ocular	O
phenotype	O
resembling	O
Peters	B-Disease
anomaly	I-Disease
.	O

We	O
therefore	O
propose	O
that	O
a	O
variety	O
of	O
anterior	B-Disease
segment	I-Disease
anomalies	I-Disease
may	O
be	O
associated	O
with	O
PAX6	O
mutations	O
.	O
.	O

Huntington	B-Disease
disease	I-Disease
without	O
CAG	O
expansion	O
:	O
phenocopies	O
or	O
errors	O
in	O
assignment	O
?	O

Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
expanded	O
CAG	O
repeat	O
within	O
a	O
novel	O
gene	O
on	O
4p16	O
.	O

3	O
(	O
IT15	O
)	O
.	O

A	O
total	O
of	O
30	O
of	O
1	O
,	O
022	O
affected	O
persons	O
(	O
2	O
.	O
9	O
%	O
of	O
our	O
cohort	O
)	O
did	O
not	O
have	O
an	O
expanded	O
CAG	O
in	O
the	O
disease	O
range	O
.	O

The	O
reasons	O
for	O
not	O
observing	O
expansion	O
in	O
affected	O
individuals	O
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	O
length	O
both	O
for	O
diagnosis	O
of	O
affected	O
patients	O
and	O
for	O
predictive	O
testing	O
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
HD	B-Disease
.	O

Here	O
we	O
show	O
that	O
the	O
majority	O
(	O
18	O
)	O
of	O
the	O
individuals	O
with	O
normal	O
sized	O
alleles	O
represent	O
misdiagnosis	O
,	O
sample	O
mix	O
-	O
up	O
,	O
or	O
clerical	O
error	O
.	O

The	O
remaining	O
12	O
patients	O
represent	O
possible	O
phenocopies	O
for	O
HD	B-Disease
.	O

In	O
at	O
least	O
four	O
cases	O
,	O
family	O
studies	O
of	O
these	O
phenocopies	O
excluded	O
4p16	O
.	O

3	O
as	O
the	O
region	O
responsible	O
for	O
the	O
phenotype	O
.	O

Mutations	O
in	O
the	O
HD	B-Disease
gene	O
that	O
are	O
other	O
than	O
CAG	O
expansion	O
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases	O
;	O
however	O
,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons	O
,	O
retrospective	O
review	O
of	O
these	O
patients	O
clinical	O
features	O
identified	O
characteristics	O
not	O
typical	O
for	O
HD	B-Disease
.	O

This	O
study	O
shows	O
that	O
on	O
rare	O
occasions	O
mutations	O
in	O
other	O
,	O
as	O
-	O
yet	O
-	O
undefined	O
genes	O
can	O
present	O
with	O
a	O
clinical	O
phenotype	O
very	O
similar	O
to	O
that	O
of	O
HD	B-Disease

Frequent	O
detection	O
of	O
codon	O
877	O
mutation	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
advanced	B-Disease
prostate	I-Disease
cancers	I-Disease
.	O

Prostatic	O
tissue	O
specimens	O
derived	O
from	O
transurethral	O
resections	O
of	O
patients	O
with	O
metastatic	B-Disease
prostate	I-Disease
cancer	I-Disease
were	O
analyzed	O
for	O
genetic	O
alterations	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
.	O

Direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
-	O
derived	O
DNAs	O
of	O
6	O
of	O
24	O
specimens	O
revealed	O
a	O
codon	O
877	O
mutation	O
(	O
ACT	O
-	O
-	O
>	O
GCT	O
,	O
Thr	O
-	O
-	O
>	O
Ala	O
)	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
AR	O
gene	O
.	O

This	O
same	O
AR	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
a	O
metastatic	B-Disease
prostate	I-Disease
cancer	I-Disease
cell	O
line	O
,	O
LNCaP	O
,	O
where	O
this	O
mutation	O
confers	O
upon	O
the	O
AR	O
an	O
altered	O
ligand	O
-	O
binding	O
specificity	O
which	O
is	O
stimulated	O
by	O
estrogens	O
,	O
progestagens	O
,	O
and	O
antiandrogens	O
.	O

It	O
is	O
possible	O
that	O
analogous	O
to	O
an	O
activated	O
/	O
altered	O
growth	O
factor	O
receptor	O
oncogene	O
,	O
codon	O
877	O
mutant	O
AR	O
with	O
altered	O
ligand	O
binding	O
may	O
provide	O
a	O
selective	O
growth	O
advantage	O
in	O
the	O
genesis	O
of	O
a	O
subset	O
of	O
advanced	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O

Although	O
estrogens	O
are	O
used	O
infrequently	O
,	O
antiandrogens	O
are	O
used	O
increasingly	O
in	O
hormonal	O
therapy	O
for	O
patients	O
with	O
advanced	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O

The	O
stimulatory	O
effect	O
of	O
these	O
therapeutic	O
agents	O
on	O
the	O
codon	O
877	O
mutant	O
AR	O
further	O
suggests	O
that	O
this	O
frequently	O
observed	O
AR	O
mutation	O
may	O
contribute	O
to	O
the	O
treatment	O
refractory	O
disease	O
.	O
.	O

The	O
human	O
gene	O
for	O
alkaptonuria	B-Disease
(	O
AKU	B-Disease
)	O
maps	O
to	O
chromosome	O
3q	O
.	O

Alkaptonuria	B-Disease
(	O
AKU	B-Disease
;	O
McKusick	O
no	O
.	O
203500	O
)	O
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
the	O
lack	O
of	O
homogentisic	O
acid	O
oxidase	O
activity	O
.	O

Patients	O
excrete	O
large	O
amounts	O
of	O
homogentisic	O
acid	O
in	O
their	O
urine	O
and	O
a	O
black	O
ochronotic	O
pigment	O
is	O
deposited	O
in	O
their	O
cartilage	O
and	O
collagenous	O
tissues	O
.	O

Ochronosis	B-Disease
is	O
the	O
predominant	O
clinical	O
complication	O
of	O
the	O
disease	O
leading	O
to	O
ochronotic	B-Disease
arthropathy	I-Disease
,	O
dark	O
urine	O
,	O
pigment	O
changes	O
of	O
the	O
skin	O
,	O
and	O
other	O
clinical	O
features	O
.	O

A	O
mutation	O
causing	O
alkaptonuria	B-Disease
in	O
the	O
mouse	O
has	O
mapped	O
to	O
chromosome	O
16	O
.	O

Considering	O
conserved	O
synteny	O
,	O
we	O
were	O
able	O
to	O
map	O
the	O
human	O
gene	O
to	O
chromosome	O
3q	O
in	O
six	O
alkaptonuria	B-Disease
pedigrees	O
of	O
Slovak	O
origin	O
.	O
.	O

Structure	O
of	O
the	O
human	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
.	O

Intestinal	O
uptake	O
of	O
dietary	O
glucose	O
and	O
galactose	O
is	O
mediated	O
by	O
the	O
SGLT1	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
of	O
the	O
brush	O
border	O
.	O

An	O
SGLT1	O
missense	O
mutation	O
underlies	O
hereditary	B-Disease
glucose	I-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
,	O
characterized	O
by	O
potentially	O
fatal	O
diarrhea	B-Disease
;	O
conversely	O
,	O
oral	O
rehydration	O
therapy	O
exploits	O
normal	O
transport	O
to	O
alleviate	O
life	O
-	O
threatening	O
diarrhea	B-Disease
of	O
infectious	O
origin	O
.	O

We	O
have	O
mapped	O
the	O
entire	O
human	O
SGLT1	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
from	O
cosmid	O
and	O
lambda	O
phage	O
clones	O
representing	O
a	O
genomic	O
region	O
of	O
112	O
kilobases	O
.	O

Transcription	O
initiation	O
occurred	O
from	O
a	O
site	O
27	O
base	O
pairs	O
3	O
of	O
a	O
TATAA	O
sequence	O
.	O

All	O
exon	O
-	O
flanking	O
regions	O
were	O
sequenced	O
,	O
and	O
the	O
entire	O
112	O
-	O
kilobase	O
region	O
mapped	O
with	O
four	O
restriction	O
enzymes	O
.	O

SGLT1	O
is	O
comprised	O
of	O
15	O
exons	O
(	O
spanning	O
72	O
kilobases	O
)	O
;	O
a	O
possible	O
evolutionary	O
origin	O
from	O
a	O
six	O
-	O
membrane	O
-	O
span	O
ancestral	O
precursor	O
via	O
a	O
gene	O
duplication	O
event	O
is	O
suggested	O
from	O
comparison	O
of	O
exons	O
against	O
protein	O
secondary	O
structure	O
and	O
from	O
sequence	O
considerations	O
.	O

A	O
new	O
missense	O
mutation	O
in	O
exon	O
1	O
causing	O
glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
is	O
also	O
described	O
.	O

This	O
is	O
the	O
first	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
cotransporter	O
gene	O
structure	O
reported	O
.	O

These	O
data	O
facilitate	O
the	O
search	O
for	O
new	O
glucose	B-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
-	O
related	O
mutations	O
in	O
this	O
important	O
gene	O
and	O
provide	O
a	O
basis	O
for	O
future	O
evolutionary	O
comparisons	O
with	O
other	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
cotransporters	O
.	O
.	O

Four	O
novel	O
PEPD	O
alleles	O
causing	O
prolidase	B-Disease
deficiency	I-Disease
.	O

Mutations	O
at	O
the	O
PEPD	O
locus	O
cause	O
prolidase	B-Disease
deficiency	I-Disease
(	O
McKusick	O
170100	O
)	O
,	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
iminodipeptiduria	B-Disease
,	O
skin	B-Disease
ulcers	I-Disease
,	O
mental	B-Disease
retardation	I-Disease
,	O
and	O
recurrent	O
infections	O
.	O

Four	O
PEPD	O
mutations	O
from	O
five	O
severely	O
affected	O
individuals	O
were	O
characterized	O
by	O
analysis	O
of	O
reverse	O
-	O
transcribed	O
,	O
PCR	O
-	O
amplified	O
(	O
RT	O
-	O
PCR	O
)	O
cDNA	O
.	O

We	O
used	O
SSCP	O
analysis	O
on	O
four	O
overlapping	O
cDNA	O
fragments	O
covering	O
the	O
entire	O
coding	O
region	O
of	O
the	O
PEPD	O
gene	O
and	O
detected	O
abnormal	O
SSCP	O
bands	O
for	O
the	O
fragment	O
spanning	O
all	O
or	O
part	O
of	O
exons	O
13	O
-	O
15	O
in	O
three	O
of	O
the	O
probands	O
.	O

Direct	O
sequencing	O
of	O
the	O
mutant	O
cDNAs	O
showed	O
a	O
G	O
-	O
-	O
>	O
A	O
,	O
1342	O
substitution	O
(	O
G448R	O
)	O
in	O
two	O
patients	O
and	O
a	O
3	O
-	O
bp	O
deletion	O
(	O
delta	O
E452	O
or	O
delta	O
E453	O
)	O
in	O
another	O
.	O

In	O
the	O
other	O
two	O
probands	O
the	O
amplified	O
products	O
were	O
of	O
reduced	O
size	O
.	O

Direct	O
sequencing	O
of	O
these	O
mutant	O
cDNAs	O
revealed	O
a	O
deletion	O
of	O
exon	O
5	O
in	O
one	O
patient	O
and	O
of	O
exon	O
7	O
in	O
the	O
other	O
.	O

Intronic	O
sequences	O
flanking	O
exons	O
5	O
and	O
7	O
were	O
identified	O
using	O
inverse	O
PCR	O
followed	O
by	O
direct	O
sequencing	O
.	O

Conventional	O
PCR	O
and	O
direct	O
sequencing	O
then	O
established	O
the	O
intron	O
-	O
exon	O
borders	O
of	O
the	O
mutant	O
genomic	O
DNA	O
revealing	O
two	O
splice	O
acceptor	O
mutations	O
a	O
G	O
-	O
-	O
>	O
C	O
substitution	O
at	O
position	O
-	O
1	O
of	O
intron	O
4	O
and	O
an	O
A	O
-	O
-	O
>	O
G	O
substitution	O
at	O
position	O
-	O
2	O
of	O
intron	O
6	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
severe	O
form	O
of	O
prolidase	B-Disease
deficiency	I-Disease
is	O
caused	O
by	O
multiple	O
PEPD	O
alleles	O
.	O

In	O
this	O
report	O
we	O
attempt	O
to	O
begin	O
the	O
process	O
of	O
describing	O
these	O
alleles	O
and	O
cataloging	O
their	O
phenotypic	O
expression	O
.	O
.	O

Recombinations	O
in	O
individuals	O
homozygous	O
by	O
descent	O
localize	O
the	O
Friedreich	B-Disease
ataxia	I-Disease
locus	O
in	O
a	O
cloned	O
450	O
-	O
kb	O
interval	O
.	O

The	O
locus	O
for	O
Friedreich	B-Disease
ataxia	I-Disease
(	O
FRDA	B-Disease
)	O
,	O
a	O
severe	O
neurodegenerative	B-Disease
disease	I-Disease
,	O
is	O
tightly	O
linked	O
to	O
markers	O
D9S5	O
and	O
D9S15	O
,	O
and	O
analysis	O
of	O
rare	O
recombination	O
events	O
has	O
suggested	O
the	O
order	O
cen	O
-	O
FRDA	O
-	O
D9S5	O
-	O
D9S15	O
-	O
qter	O
.	O

We	O
report	O
here	O
the	O
construction	O
of	O
a	O
YAC	O
contig	O
extending	O
800	O
kb	O
centromeric	O
to	O
D9S5	O
and	O
the	O
isolation	O
of	O
five	O
new	O
microsatellite	O
markers	O
from	O
this	O
region	O
.	O

In	O
order	O
to	O
map	O
these	O
markers	O
with	O
respect	O
to	O
the	O
FRDA	B-Disease
locus	O
,	O
all	O
within	O
a	O
1	O
-	O
cM	O
confidence	O
interval	O
,	O
we	O
sought	O
to	O
increase	O
the	O
genetic	O
information	O
of	O
available	O
FRDA	B-Disease
families	O
by	O
considering	O
homozygosity	O
by	O
descent	O
and	O
association	O
with	O
founder	O
haplotypes	O
in	O
isolated	O
populations	O
.	O

This	O
approach	O
allowed	O
us	O
to	O
identify	O
one	O
phase	O
-	O
known	O
recombination	O
and	O
one	O
probable	O
historic	O
recombination	O
on	O
haplotypes	O
from	O
Reunion	O
Island	O
patients	O
,	O
both	O
of	O
which	O
place	O
three	O
of	O
the	O
five	O
markers	O
proximal	O
to	O
FRDA	B-Disease
.	O

This	O
represents	O
the	O
first	O
identification	O
of	O
close	O
FRDA	B-Disease
flanking	O
markers	O
on	O
the	O
centromeric	O
side	O
.	O

The	O
two	O
other	O
markers	O
allowed	O
us	O
to	O
narrow	O
the	O
breakpoint	O
of	O
a	O
previously	O
identified	O
distal	O
recombination	O
that	O
is	O
>	O
180	O
kb	O
from	O
D9S5	O
(	O
26P	O
)	O
.	O

Taken	O
together	O
,	O
the	O
results	O
place	O
the	O
FRDA	B-Disease
locus	O
in	O
a	O
450	O
-	O
kb	O
interval	O
,	O
which	O
is	O
small	O
enough	O
for	O
direct	O
search	O
of	O
candidate	O
genes	O
.	O

A	O
detailed	O
rare	O
cutter	O
restriction	O
map	O
and	O
a	O
cosmid	O
contig	O
covering	O
this	O
interval	O
were	O
constructed	O
and	O
should	O
facilitate	O
the	O
search	O
of	O
genes	O
in	O
this	O
region	O
.	O
.	O

Investigation	O
of	O
thermoregulatory	O
characteristics	O
in	O
patients	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

A	O
survey	O
instrument	O
is	O
used	O
to	O
assess	O
temperature	O
regulation	O
characteristics	O
in	O
children	O
with	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
compared	O
to	O
3	O
control	O
groups	O
sibs	O
of	O
PWS	B-Disease
patients	O
(	O
SIB	O
)	O
,	O
neurodevelopmentally	B-Disease
handicapped	I-Disease
children	O
(	O
ND	O
)	O
,	O
and	O
age	O
and	O
gender	O
matched	O
well	O
children	O
(	O
WC	O
)	O
.	O

Significant	O
differences	O
were	O
found	O
between	O
PWS	B-Disease
patients	O
,	O
SIB	O
controls	O
,	O
and	O
WC	O
controls	O
in	O
the	O
prevalence	O
of	O
febrile	O
convulsions	O
,	O
fever	O
-	O
associated	O
symptoms	O
,	O
and	O
temperature	O
less	O
than	O
94	O
degrees	O
F	O
.	O

No	O
differences	O
were	O
noted	O
in	O
any	O
variable	O
between	O
the	O
PWS	B-Disease
patients	O
and	O
the	O
ND	O
controls	O
,	O
suggesting	O
that	O
these	O
abnormalities	O
are	O
not	O
unique	O
to	O
PWS	B-Disease
,	O
but	O
can	O
occur	O
in	O
any	O
neurodevelopmentally	B-Disease
handicapped	I-Disease
individual	O
,	O
further	O
suggesting	O
these	O
do	O
not	O
necessarily	O
reflect	O
syndrome	O
-	O
specific	O
hypothalamic	B-Disease
abnormalities	I-Disease
.	O
.	O

Phenotypic	O
variation	O
including	O
retinitis	B-Disease
pigmentosa	I-Disease
,	O
pattern	B-Disease
dystrophy	I-Disease
,	O
and	O
fundus	B-Disease
flavimaculatus	I-Disease
in	O
a	O
single	O
family	O
with	O
a	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Mutations	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
have	O
been	O
reported	O
in	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
,	O
pattern	O
macular	B-Disease
dystrophy	I-Disease
,	O
and	O
retinitis	B-Disease
punctata	I-Disease
albescens	I-Disease
.	O

We	O
report	O
herein	O
the	O
occurrence	O
of	O
three	O
separate	O
phenotypes	O
within	O
a	O
single	O
family	O
with	O
a	O
novel	O
3	O
-	O
base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
.	O

DESIGN	O
Case	O
reports	O
with	O
clinical	O
features	O
,	O
fluorescein	O
angiography	O
,	O
kinetic	O
perimetry	O
,	O
electrophysiological	O
studies	O
,	O
and	O
molecular	O
genetics	O
.	O

SETTING	O
University	O
medical	O
centers	O
.	O

PATIENTS	O
A	O
75	O
-	O
year	O
-	O
old	O
woman	O
,	O
her	O
two	O
daughters	O
(	O
aged	O
44	O
and	O
50	O
years	O
)	O
,	O
and	O
her	O
49	O
-	O
year	O
-	O
old	O
son	O
were	O
screened	O
for	O
peripherin	O
/	O
RDS	O
mutations	O
because	O
of	O
the	O
presence	O
of	O
multiple	O
phenotypes	O
within	O
the	O
same	O
family	O
.	O

RESULTS	O
The	O
mother	O
presented	O
at	O
age	O
63	O
years	O
with	O
a	O
profoundly	O
abnormal	O
electroretinogram	O
(	O
ERG	O
)	O
and	O
adult	O
-	O
onset	O
retinitis	B-Disease
pigmentosa	I-Disease
that	O
progressed	O
dramatically	O
over	O
12	O
years	O
,	O
with	O
marked	O
loss	O
of	O
peripheral	O
visual	O
field	O
.	O

One	O
daughter	O
developed	O
pattern	B-Disease
macular	I-Disease
dystrophy	I-Disease
at	O
age	O
31	O
years	O
.	O

At	O
age	O
44	O
years	O
,	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
but	O
her	O
clinical	O
disease	O
was	O
limited	O
to	O
the	O
macula	O
.	O

Another	O
daughter	O
presented	O
at	O
age	O
42	O
years	O
with	O
macular	B-Disease
degeneration	I-Disease
and	O
over	O
10	O
years	O
developed	O
the	O
clinical	O
picture	O
of	O
fundus	B-Disease
flavimaculatus	I-Disease
.	O

Her	O
peripheral	O
visual	O
field	O
was	O
preserved	O
but	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
.	O

The	O
son	O
had	O
onset	O
of	O
macular	B-Disease
degeneration	I-Disease
at	O
age	O
44	O
years	O
.	O

Pericentral	B-Disease
scotomas	I-Disease
were	O
present	O
and	O
the	O
ERG	O
was	O
markedly	O
abnormal	O
.	O

Fluorescein	O
angiography	O
revealed	O
punctate	O
pigment	O
epithelial	O
transmission	O
defects	O
.	O

CONCLUSIONS	O
A	O
3	O
-	O
base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
can	O
produce	O
clinically	O
disparate	O
phenotypes	O
even	O
within	O
the	O
same	O
family	O
.	O
.	O

Assignment	O
of	O
the	O
human	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
to	O
chromosome	O
22q13	O
.	O
1	O
.	O

The	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
encodes	O
the	O
primary	O
carrier	O
protein	O
responsible	O
for	O
the	O
uptake	O
of	O
the	O
dietary	O
sugars	O
glucose	O
and	O
galactose	O
from	O
the	O
intestinal	O
lumen	O
.	O

SGLT1	O
transport	O
activity	O
is	O
currently	O
exploited	O
in	O
oral	O
rehydration	O
therapy	O
.	O

The	O
75	O
-	O
kDa	O
glycoprotein	O
is	O
localized	O
in	O
the	O
brush	O
border	O
of	O
the	O
intestinal	O
epithelium	O
and	O
is	O
predicted	O
to	O
comprise	O
12	O
membrane	O
spans	O
.	O

In	O
two	O
patients	O
with	O
the	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
glucose	I-Disease
/	I-Disease
galactose	I-Disease
malabsorption	I-Disease
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	O
mutation	O
in	O
SGLT1	O
,	O
and	O
the	O
Asp28	O
-	O
-	O
>	O
Asn	O
change	O
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
SGLT1	O
transport	O
activity	O
.	O

The	O
SGLT1	O
gene	O
was	O
previously	O
shown	O
to	O
reside	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
(	O
11	O
.	O
2	O
-	O
-	O
>	O
qter	O
)	O
.	O

We	O
have	O
used	O
a	O
cosmid	O
probe	O
for	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
which	O
refines	O
the	O
localization	O
to	O
22q13	O
.	O

1	O
,	O
and	O
provide	O
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
SGLT1	O
probe	O
as	O
a	O
diagnostic	O
for	O
genetic	B-Disease
diseases	I-Disease
associated	O
with	O
translocations	O
of	O
chromosome	O
22	O
.	O

Restriction	O
of	O
ocular	O
fundus	O
lesions	O
to	O
a	O
specific	O
subgroup	O
of	O
APC	B-Disease
mutations	O
in	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
patients	O
.	O

In	O
humans	O
,	O
alteration	O
of	O
the	O
tumor	B-Disease
suppressor	O
gene	O
,	O
APC	B-Disease
,	O
causes	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
,	O
a	O
condition	O
causing	O
predisposition	O
to	O
colorectal	B-Disease
cancer	I-Disease
.	O

The	O
syndrome	O
inconsistently	O
associates	O
characteristic	O
patches	O
of	O
congenital	B-Disease
hypertrophy	I-Disease
of	I-Disease
the	I-Disease
retinal	I-Disease
pigment	I-Disease
epithelium	I-Disease
(	O
CHRPE	B-Disease
)	O
.	O

Ocular	O
examination	O
revealed	O
that	O
patients	O
expressing	O
CHRPE	B-Disease
tend	O
to	O
cluster	O
within	O
specific	O
families	O
.	O

The	O
exact	O
APC	B-Disease
mutation	O
was	O
identified	O
in	O
42	O
unrelated	O
patients	O
.	O

In	O
all	O
cases	O
these	O
mutations	O
were	O
predicted	O
to	O
lead	O
to	O
the	O
synthesis	O
of	O
a	O
truncated	O
protein	O
.	O

The	O
extent	O
of	O
CHRPE	B-Disease
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
position	O
of	O
the	O
mutation	O
along	O
the	O
coding	O
sequence	O
.	O

CHRPE	B-Disease
lesions	O
are	O
almost	O
always	O
absent	O
if	O
the	O
mutation	O
occurs	O
before	O
exon	O
9	O
,	O
but	O
are	O
systematically	O
present	O
if	O
it	O
occurs	O
after	O
this	O
exon	O
.	O

Thus	O
,	O
the	O
range	O
of	O
phenotypic	O
expression	O
observed	O
among	O
affected	O
patients	O
may	O
result	O
in	O
part	O
from	O
different	O
allelic	O
manifestations	O
of	O
APC	B-Disease
mutations	O
.	O
.	O

The	O
effects	O
of	O
dystrophin	O
gene	O
mutations	O
on	O
the	O
ERG	O
in	O
mice	O
and	O
humans	O
.	O

PURPOSE	O
.	O

The	O
authors	O
earlier	O
findings	O
of	O
a	O
negative	O
electroretinogram	O
(	O
ERG	O
)	O
in	O
a	O
boy	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
led	O
them	O
to	O
investigate	O
dystrophin	O
gene	O
deletions	O
and	O
ERGs	O
in	O
five	O
boys	O
with	O
DMD	B-Disease
.	O

The	O
authors	O
wanted	O
to	O
determined	O
whether	O
there	O
were	O
similar	O
ERG	O
findings	O
in	O
an	O
animal	O
model	O
for	O
DMD	B-Disease
,	O
the	O
mdx	O
mouse	O
.	O

METHODS	O
.	O

Ganzfeld	O
ERGs	O
were	O
recorded	O
in	O
five	O
boys	O
with	O
DMD	B-Disease
after	O
a	O
complete	O
ophthalmic	O
examination	O
.	O

The	O
dystrophin	O
gene	O
was	O
analyzed	O
by	O
Southern	O
blot	O
hybridization	O
.	O

ERGs	O
were	O
recorded	O
in	O
anesthetized	O
mdx	O
and	O
control	O
mice	O
with	O
a	O
modified	O
Grass	O
photostimulator	O
(	O
Grass	O
Instrument	O
Company	O
,	O
Quincy	O
,	O
MA	O
)	O
.	O

RESULTS	O
.	O

Ophthalmic	O
examinations	O
in	O
all	O
five	O
boys	O
had	O
normal	O
findings	O
,	O
yet	O
an	O
abnormal	O
negative	O
ERG	O
was	O
recorded	O
for	O
each	O
subject	O
.	O

The	O
subjects	O
gene	O
deletions	O
were	O
variable	O
,	O
ranging	O
from	O
large	O
deletions	O
to	O
no	O
detectable	O
deletions	O
.	O

The	O
ERGs	O
of	O
the	O
mdx	O
mice	O
were	O
normal	O
and	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
the	O
control	O
mice	O
.	O

CONCLUSIONS	O
.	O

The	O
authors	O
believe	O
the	O
unique	O
ERG	O
recorded	O
for	O
the	O
human	O
subjects	O
is	O
a	O
manifestation	O
of	O
DMD	B-Disease
associated	O
with	O
defects	O
at	O
the	O
dystrophin	O
gene	O
locus	O
and	O
represents	O
a	O
new	O
clinical	O
entity	O
.	O

The	O
ERG	O
of	O
the	O
mdx	O
mouse	O
may	O
be	O
spared	O
for	O
several	O
reasons	O
,	O
including	O
milder	O
effects	O
of	O
the	O
mouse	O
gene	O
defect	O
,	O
differences	O
in	O
muscle	O
and	O
retinal	O
gene	O
product	O
,	O
or	O
species	O
differences	O
in	O
the	O
biochemical	O
role	O
of	O
dystrophin	O
.	O

The	O
ERG	O
shows	O
promise	O
of	O
becoming	O
a	O
noninvasive	O
diagnostic	O
tool	O
for	O
DMD	B-Disease
and	O
its	O
milder	O
allelic	O
forms	O
.	O
.	O

Association	O
of	O
the	O
APC	B-Disease
tumor	I-Disease
suppressor	O
protein	O
with	O
catenins	O
.	O

Mutations	O
of	O
APC	O
appear	O
to	O
initiate	O
sporadic	O
and	O
inherited	O
forms	O
of	O
human	O
colorectal	B-Disease
cancer	I-Disease
.	O

Although	O
these	O
mutations	O
have	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
APC	B-Disease
gene	O
product	O
.	O

Two	O
cellular	O
proteins	O
that	O
associate	O
with	O
APC	B-Disease
were	O
identified	O
by	O
nucleotide	O
sequence	O
analysis	O
and	O
peptide	O
mapping	O
as	O
the	O
E	O
-	O
cadherin	O
-	O
associated	O
proteins	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
.	O

A	O
27	O
-	O
residue	O
fragment	O
of	O
APC	O
containing	O
a	O
15	O
-	O
amino	O
acid	O
repeat	O
was	O
sufficient	O
for	O
the	O
interaction	O
with	O
the	O
catenins	O
.	O

These	O
results	O
suggest	O
an	O
important	O
link	O
between	O
tumor	B-Disease
initiation	O
and	O
cell	O
adhesion	O
.	O
.	O

Difference	O
in	O
methylation	O
patterns	O
within	O
the	O
D15S9	O
region	O
of	O
chromosome	O
15q11	O
-	O
13	O
in	O
first	O
cousins	O
with	O
Angelman	B-Disease
syndrome	I-Disease
and	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
.	O

Abnormalities	O
of	O
chromosome	O
region	O
15q11	O
-	O
13	O
are	O
associated	O
with	O
Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
and	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O

Differences	O
between	O
the	O
methylation	O
patterns	O
of	O
the	O
region	O
of	O
chromosome	O
15q11	O
-	O
13	O
which	O
hybridizes	O
to	O
the	O
highly	O
conserved	O
DNA	O
,	O
DN34	O
,	O
in	O
normal	O
individuals	O
and	O
in	O
patients	O
with	O
AS	B-Disease
and	O
PWS	B-Disease
have	O
been	O
described	O
.	O

We	O
report	O
on	O
a	O
family	O
in	O
which	O
first	O
cousins	O
are	O
affected	O
by	O
AS	B-Disease
and	O
PWS	B-Disease
as	O
a	O
result	O
of	O
a	O
familial	O
paracentric	O
inversion	O
of	O
15q11	O
-	O
q13	O
.	O

The	O
results	O
of	O
the	O
studies	O
on	O
this	O
family	O
demonstrate	O
the	O
differences	O
in	O
the	O
methylation	O
patterns	O
in	O
the	O
2	O
conditions	O
and	O
the	O
phenomenon	O
of	O
genomic	O
imprinting	O
,	O
whereby	O
genetic	O
information	O
is	O
expressed	O
differently	O
dependent	O
on	O
the	O
parent	O
of	O
origin	O
.	O
.	O

Haplotype	O
studies	O
in	O
Wilson	B-Disease
disease	I-Disease
.	O

In	O
51	O
families	O
with	O
Wilson	B-Disease
disease	I-Disease
,	O
we	O
have	O
studied	O
DNA	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(	O
CA	O
repeats	O
)	O
in	O
the	O
13q14	O
.	O

3	O
region	O
,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
Wilson	B-Disease
disease	I-Disease
gene	O
(	O
WND	B-Disease
)	O
.	O

In	O
addition	O
to	O
a	O
marker	O
(	O
D13S133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(	O
D13S314	O
,	O
D13S315	O
,	O
and	O
D13S316	O
)	O
close	O
to	O
the	O
WND	B-Disease
locus	O
.	O

We	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314	O
,	O
D13S133	O
,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
WND	B-Disease
mutation	O
.	O

We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
WND	B-Disease
and	O
normal	O
haplotypes	O
in	O
northern	O
European	O
families	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
Wilson	B-Disease
disease	I-Disease
.	O

Genetic	O
analysis	O
of	O
the	O
BRCA1	O
region	O
in	O
a	O
large	O
breast	O
/	O
ovarian	O
family	O
:	O
refinement	O
of	O
the	O
minimal	O
region	O
containing	O
BRCA1	O
.	O

We	O
have	O
analyzed	O
a	O
single	O
multi	O
-	O
affected	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
pedigree	O
(	O
BOV3	O
)	O
and	O
have	O
shown	O
consistent	O
inheritance	O
of	O
markers	O
on	O
chromosome	O
17q	O
with	O
the	O
disease	O
confirming	O
that	O
this	O
family	O
is	O
due	O
to	O
the	O
BRCA1	O
gene	O
.	O

Analysis	O
of	O
17q	O
haplotypes	O
shows	O
a	O
recombination	O
event	O
in	O
a	O
bilateral	O
breast	B-Disease
cancer	I-Disease
case	O
which	O
suggests	O
that	O
the	O
BRCA1	O
gene	O
lies	O
distal	O
to	O
D17S857	O
;	O
D17S857	O
is	O
thus	O
the	O
new	O
proximal	O
boundary	O
for	O
the	O
region	O
containing	O
BRCA1	O
.	O

Combining	O
this	O
information	O
with	O
previously	O
published	O
mapping	O
information	O
suggests	O
that	O
BRCA1	O
is	O
contained	O
in	O
a	O
region	O
estimated	O
at	O
1	O
-	O
1	O
.	O

5	O
Mb	O
in	O
length	O
.	O

All	O
seven	O
breast	B-Disease
tumour	I-Disease
/	O
blood	O
pairs	O
examined	O
from	O
this	O
family	O
show	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tumours	B-Disease
.	O

The	O
allel	O
retained	O
in	O
each	O
tumour	B-Disease
was	O
from	O
the	O
disease	O
-	O
bearing	O
chromosome	O
implicating	O
BRCA1	O
as	O
a	O
tumour	B-Disease
suppressor	O
gene	O
.	O

We	O
have	O
sequenced	O
the	O
17	O
beta	O
-	O
oestradiol	O
dehydrogenase	O
genes	O
(	O
EDH17B1	O
and	O
EDH17B2	O
)	O
which	O
have	O
been	O
suggested	O
as	O
candidate	O
genes	O
for	O
BRCA1	O
in	O
four	O
members	O
of	O
this	O
family	O
.	O

No	O
germline	O
mutations	O
were	O
detected	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
kinase	O
is	O
a	O
component	O
of	O
neuromuscular	O
junctions	O
.	O

The	O
clinical	O
manifestation	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
correlated	O
to	O
the	O
extent	O
of	O
expansion	O
of	O
an	O
unstable	O
[	O
CTG	O
]	O
n	O
DNA	O
motif	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
this	O
trinucleotide	O
motif	O
forms	O
part	O
of	O
the	O
last	O
,	O
3	O
untranslated	O
exon	O
of	O
a	O
gene	O
which	O
potentially	O
encodes	O
multiple	O
protein	O
isoforms	O
of	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
(	O
myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
,	O
DM	O
-	O
PK	O
)	O
.	O

We	O
report	O
here	O
on	O
the	O
development	O
of	O
antisera	O
against	O
synthetic	O
DM	O
-	O
PK	O
peptide	O
antigens	O
and	O
their	O
use	O
in	O
biochemical	O
and	O
histochemical	O
studies	O
.	O

Immunoreactive	O
DM	O
-	O
kinase	O
protein	O
of	O
53	O
kD	O
is	O
present	O
at	O
low	O
levels	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
extracts	O
of	O
DM	B-Disease
patients	O
and	O
normal	O
controls	O
.	O

Immunohistochemical	O
staining	O
revealed	O
that	O
DM	O
-	O
PK	O
is	O
localised	O
prominently	O
at	O
sites	O
of	O
neuromuscular	O
and	O
myotendinous	O
junctions	O
(	O
NMJs	O
and	O
MTJs	O
)	O
of	O
human	O
and	O
rodent	O
skeletal	O
muscles	O
.	O

Furthermore	O
,	O
very	O
low	O
levels	O
of	O
immunoreactive	O
DM	O
-	O
PK	O
protein	O
are	O
present	O
in	O
the	O
sarcoplasm	O
of	O
predominantly	O
type	O
I	O
fibres	O
in	O
various	O
muscles	O
.	O

Strikingly	O
,	O
presence	O
of	O
the	O
protein	O
can	O
also	O
be	O
demonstrated	O
for	O
NMJs	O
of	O
muscular	O
tissues	O
of	O
adult	O
and	O
congenital	O
cases	O
of	O
DM	B-Disease
,	O
with	O
no	O
gross	O
changes	O
in	O
structural	O
organisation	O
.	O

Our	O
findings	O
provide	O
a	O
basis	O
for	O
further	O
characterisation	O
of	O
the	O
role	O
of	O
the	O
kinase	O
in	O
protein	O
assembly	O
processes	O
or	O
signal	O
mediation	O
at	O
synaptic	O
sites	O
and	O
ultimately	O
for	O
the	O
understanding	O
of	O
the	O
complex	O
pathophysiology	O
of	O
DM	B-Disease
.	O
.	O

Markedly	O
accelerated	O
catabolism	O
of	O
apolipoprotein	O
A	O
-	O
II	O
(	O
ApoA	O
-	O
II	O
)	O
and	O
high	O
density	O
lipoproteins	O
containing	O
ApoA	O
-	O
II	O
in	O
classic	O
lecithin	O
:	O
cholesterol	B-Disease
acyltransferase	I-Disease
deficiency	I-Disease
and	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
.	O

Classic	B-Disease
(	I-Disease
complete	I-Disease
)	I-Disease
lecithin	I-Disease
cholesterol	I-Disease
acyltransferase	I-Disease
(	I-Disease
LCAT	I-Disease
)	I-Disease
deficiency	I-Disease
and	O
Fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
(	O
partial	B-Disease
LCAT	I-Disease
deficiency	I-Disease
)	O
are	O
genetic	O
syndromes	O
associated	O
with	O
markedly	O
decreased	O
plasma	O
levels	O
of	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
but	O
not	O
with	O
an	O
increased	O
risk	O
of	O
atherosclerotic	B-Disease
cardiovascular	I-Disease
disease	I-Disease
.	O

We	O
investigated	O
the	O
metabolism	O
of	O
the	O
HDL	O
apolipoproteins	O
(	O
apo	O
)	O
apoA	O
-	O
I	O
and	O
apoA	O
-	O
II	O
in	O
a	O
total	O
of	O
five	O
patients	O
with	O
LCAT	B-Disease
deficiency	I-Disease
,	O
one	O
with	O
classic	B-Disease
LCAT	I-Disease
deficiency	I-Disease
and	O
four	O
with	O
Fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
.	O

Plasma	O
levels	O
of	O
apoA	O
-	O
II	O
were	O
decreased	O
to	O
a	O
proportionately	O
greater	O
extent	O
(	O
23	O
%	O
of	O
normal	O
)	O
than	O
apoA	O
-	O
I	O
(	O
30	O
%	O
of	O
normal	O
)	O
.	O

In	O
addition	O
,	O
plasma	O
concentrations	O
of	O
HDL	O
particles	O
containing	O
both	O
apoA	O
-	O
I	O
and	O
apoA	O
-	O
II	O
(	O
LpA	O
-	O
I	O
A	O
-	O
II	O
)	O
were	O
much	O
lower	O
(	O
18	O
%	O
of	O
normal	O
)	O
than	O
those	O
of	O
particles	O
containing	O
only	O
apoA	O
-	O
I	O
(	O
LpA	O
-	O
I	O
)	O
(	O
51	O
%	O
of	O
normal	O
)	O
.	O

The	O
metabolic	O
basis	O
for	O
the	O
low	O
levels	O
of	O
apoA	O
-	O
II	O
and	O
LpA	O
-	O
I	O
A	O
-	O
II	O
was	O
investigated	O
in	O
all	O
five	O
patients	O
using	O
both	O
exogenous	O
radiotracer	O
and	O
endogenous	O
stable	O
isotope	O
labeling	O
techniques	O
.	O

The	O
mean	O
plasma	O
residence	O
time	O
of	O
apoA	O
-	O
I	O
was	O
decreased	O
at	O
2	O
.	O

08	O
+	O
/	O
-	O
0	O
.	O

27	O
d	O
(	O
controls	O
4	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
65	O
days	O
)	O
;	O
however	O
,	O
the	O
residence	O
time	O
of	O
apoA	O
-	O
II	O
was	O
even	O
shorter	O
at	O
1	O
.	O

66	O
+	O
/	O
-	O
0	O
.	O

24	O
d	O
(	O
controls	O
5	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
61	O
d	O
)	O
.	O

In	O
addition	O
,	O
the	O
catabolism	O
of	O
apoA	O
-	O
I	O
in	O
LpA	O
-	O
I	O
A	O
-	O
II	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
apoA	O
-	O
I	O
in	O
LpA	O
-	O
I	O
.	O

In	O
summary	O
,	O
genetic	O
syndromes	O
of	O
either	O
complete	B-Disease
or	I-Disease
partial	I-Disease
LCAT	I-Disease
deficiency	I-Disease
result	O
in	O
low	O
levels	O
of	O
HDL	O
through	O
preferential	O
hypercatabolism	O
of	O
apoA	O
-	O
II	O
and	O
HDL	O
particles	O
containing	O
apoA	O
-	O
II	O
.	O

Because	O
LpA	O
-	O
I	O
has	O
been	O
proposed	O
to	O
be	O
more	O
protective	O
than	O
LpA	O
-	O
I	O
A	O
-	O
II	O
against	O
atherosclerosis	B-Disease
,	O
this	O
selective	O
effect	O
on	O
the	O
metabolism	O
of	O
LpA	O
-	O
I	O
A	O
-	O
II	O
may	O
provide	O
a	O
potential	O
explanation	O
why	O
patients	O
with	O
classic	B-Disease
LCAT	I-Disease
deficiency	I-Disease
and	O
Fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
are	O
not	O
at	O
increased	O
risk	O
for	O
premature	O
atherosclerosis	B-Disease
despite	O
markedly	O
decreased	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
apoA	O
-	O
I	O

X	B-Disease
linked	I-Disease
recessive	I-Disease
thrombocytopenia	I-Disease
.	O

A	O
Saudi	O
Arab	O
boy	O
presented	O
in	O
early	O
childhood	O
with	O
thrombocytopenia	B-Disease
,	O
morphologically	O
large	O
and	O
normal	O
sized	O
platelets	O
,	O
increased	O
mean	O
platelet	O
volume	O
,	O
and	O
a	O
hypermegakaryocytic	O
bone	O
marrow	O
.	O

There	O
was	O
no	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
any	O
significant	O
immunological	B-Disease
abnormalities	I-Disease
.	O

Similar	O
findings	O
in	O
two	O
other	O
brothers	O
suggested	O
strongly	O
that	O
they	O
were	O
all	O
suffering	O
from	O
an	O
X	B-Disease
linked	I-Disease
recessive	I-Disease
thrombocytopenic	I-Disease
disorder	I-Disease
.	O

Results	O
of	O
DNA	O
analysis	O
with	O
the	O
probe	O
M27	O
beta	O
are	O
consistent	O
with	O
X	O
linkage	O
and	O
indicate	O
also	O
that	O
the	O
locus	O
of	O
the	O
relevant	O
gene	O
lies	O
close	O
to	O
or	O
is	O
identical	O
to	O
the	O
locus	O
of	O
the	O
gene	O
for	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
.	O

Because	O
of	O
various	O
features	O
which	O
include	O
the	O
presence	O
of	O
large	O
and	O
normal	O
sized	O
platelets	O
(	O
rather	O
than	O
small	O
platelets	O
)	O
and	O
freedom	O
from	O
significant	O
immune	B-Disease
deficiencies	I-Disease
,	O
it	O
is	O
likely	O
that	O
the	O
X	B-Disease
linked	I-Disease
recessive	I-Disease
thrombocytopenia	I-Disease
in	O
this	O
family	O
is	O
an	O
isolated	O
entity	O
quite	O
distinct	O
from	O
the	O
classical	O
WAS	B-Disease
phenotype	O
.	O

However	O
,	O
a	O
modified	O
expression	O
of	O
the	O
WAS	B-Disease
gene	O
producing	O
a	O
mild	O
phenotypic	O
variant	O
cannot	O
be	O
excluded	O
entirely	O
.	O
.	O

Macular	B-Disease
dystrophy	I-Disease
associated	O
with	O
mutations	O
at	O
codon	O
172	O
in	O
the	O
human	O
retinal	B-Disease
degeneration	I-Disease
slow	O
gene	O
.	O

BACKGROUND	O
Recently	O
,	O
mutations	O
in	O
the	O
retinal	B-Disease
degeneration	I-Disease
slow	O
(	O
rds	O
)	O
gene	O
which	O
codes	O
for	O
peripherin	O
-	O
rds	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
.	O

Because	O
this	O
gene	O
is	O
expressed	O
in	O
both	O
rods	O
and	O
cones	O
,	O
mutations	O
in	O
the	O
rds	O
gene	O
might	O
be	O
expected	O
to	O
cause	O
degeneration	O
affecting	O
either	O
the	O
scotopic	O
or	O
photopic	O
systems	O
.	O

Mutations	O
at	O
codon	O
172	O
of	O
the	O
rds	O
gene	O
have	O
been	O
identified	O
in	O
three	O
families	O
with	O
autosomal	O
dominantly	O
inherited	O
,	O
progressive	O
macular	B-Disease
dystrophy	I-Disease
.	O

METHODS	O
Affected	O
individuals	O
underwent	O
ophthalmic	O
examination	O
,	O
scotopic	O
perimetry	O
,	O
dark	O
adaptometry	O
,	O
measurement	O
of	O
color	O
-	O
contrast	O
sensitivity	O
,	O
and	O
electroretinography	O
to	O
characterize	O
the	O
photoreceptor	O
dysfunction	O
.	O

RESULTS	O
In	O
all	O
but	O
one	O
affected	O
member	O
,	O
symptoms	O
of	O
progressive	O
central	O
visual	B-Disease
loss	I-Disease
developed	O
in	O
the	O
third	O
or	O
fourth	O
decade	O
of	O
life	O
accompanied	O
by	O
central	B-Disease
scotoma	I-Disease
and	O
well	O
-	O
demarcated	O
atrophy	B-Disease
of	I-Disease
the	I-Disease
retinal	I-Disease
pigment	I-Disease
epithelium	I-Disease
and	O
choriocapillaris	B-Disease
of	I-Disease
the	I-Disease
macula	I-Disease
.	O

In	O
general	O
,	O
cone	O
and	O
rod	O
thresholds	O
were	O
elevated	O
,	O
and	O
color	O
-	O
contrast	O
sensitivity	O
was	O
absent	O
in	O
the	O
central	O
visual	O
field	O
.	O

Peripherally	O
,	O
the	O
scotopic	O
sensitivities	O
were	O
normal	O
,	O
as	O
was	O
the	O
recovery	O
from	O
bleach	O
.	O

Cone	O
electroretinograms	O
were	O
diminished	O
in	O
amplitude	O
,	O
and	O
delayed	O
in	O
all	O
affected	O
adults	O
except	O
one	O
.	O

Rod	O
electroretinograms	O
were	O
normal	O
or	O
near	O
normal	O
in	O
amplitude	O
,	O
and	O
had	O
normal	O
implicit	O
times	O
.	O

Affected	O
asymptomatic	O
children	O
had	O
macular	O
changes	O
,	O
abnormal	O
color	O
-	O
contrast	O
sensitivity	O
,	O
and	O
reduced	O
pattern	O
and	O
cone	O
electroretinograms	O
.	O

CONCLUSION	O
These	O
results	O
indicate	O
that	O
mutations	O
in	O
the	O
rds	O
gene	O
can	O
be	O
expressed	O
as	O
a	O
macular	B-Disease
dystrophy	I-Disease
,	O
with	O
evidence	O
of	O
primary	O
cone	B-Disease
dysfunction	I-Disease
and	O
preservation	O
of	O
peripheral	O
rod	O
function	O
.	O
.	O

Anonymous	O
marker	O
loci	O
within	O
400	O
kb	O
of	O
HLA	O
-	O
A	O
generate	O
haplotypes	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
hemochromatosis	B-Disease
gene	O
(	O
HFE	O
)	O

The	O
hemochromatosis	B-Disease
gene	O
(	O
HFE	O
)	O
maps	O
to	O
6p21	O
.	O

3	O
and	O
is	O
less	O
than	O
1	O
cM	O
from	O
the	O
HLA	O
class	O
I	O
genes	O
;	O
however	O
,	O
the	O
precise	O
physical	O
location	O
of	O
the	O
gene	O
has	O
remained	O
elusive	O
and	O
controversial	O
.	O

The	O
unambiguous	O
identification	O
of	O
a	O
crossover	O
event	O
within	O
hemochromatosis	B-Disease
families	O
is	O
very	O
difficult	O
;	O
it	O
is	O
particularly	O
hampered	O
by	O
the	O
variability	O
of	O
the	O
phenotypic	O
expression	O
as	O
well	O
as	O
by	O
the	O
sex	O
-	O
and	O
age	O
-	O
related	O
penetrance	O
of	O
the	O
disease	O
.	O

For	O
these	O
practical	O
considerations	O
,	O
traditional	O
linkage	O
analysis	O
could	O
prove	O
of	O
limited	O
value	O
in	O
further	O
refining	O
the	O
extrapolated	O
physical	O
position	O
of	O
HFE	O
.	O

We	O
therefore	O
embarked	O
upon	O
a	O
linkage	O
-	O
disequilibrium	O
analysis	O
of	O
HFE	O
and	O
normal	O
chromosomes	O
from	O
the	O
Brittany	O
population	O
.	O

In	O
the	O
present	O
report	O
,	O
66	O
hemochromatosis	B-Disease
families	O
yielding	O
151	O
hemochromatosis	B-Disease
chromosomes	O
and	O
182	O
normal	O
chromosomes	O
were	O
RFLP	O
-	O
typed	O
with	O
a	O
battery	O
of	O
probes	O
,	O
including	O
two	O
newly	O
derived	O
polymorphic	O
markers	O
from	O
the	O
6	O
.	O

7	O
and	O
HLA	O
-	O
F	O
loci	O
located	O
150	O
and	O
250	O
kb	O
telomeric	O
to	O
HLA	O
-	O
A	O
,	O
respectively	O
.	O

The	O
results	O
suggest	O
a	O
strong	O
peak	O
of	O
existing	O
linkage	O
disequilibrium	O
focused	O
within	O
the	O
i82	O
-	O
to	O
-	O
6	O
.	O

7	O
interval	O
(	O
approximately	O
250	O
kb	O
)	O
.	O

The	O
zone	O
of	O
linkage	O
disequilibrium	O
is	O
flanked	O
by	O
the	O
i97	O
locus	O
,	O
positioned	O
30	O
kb	O
proximal	O
to	O
i82	O
,	O
and	O
the	O
HLA	O
-	O
F	O
gene	O
,	O
found	O
250	O
kb	O
distal	O
to	O
HLA	O
-	O
A	O
,	O
markers	O
of	O
which	O
display	O
no	O
significant	O
association	O
with	O
HFE	O
.	O

These	O
data	O
support	O
the	O
possibility	O
that	O
HFE	O
resides	O
within	O
the	O
400	O
-	O
kb	O
expanse	O
of	O
DNA	O
between	O
i97	O
and	O
HLA	O
-	O
F	O
.	O

Alternatively	O
,	O
the	O
very	O
tight	O
association	O
of	O
HLA	O
-	O
A3	O
and	O
allele	O
1	O
of	O
the	O
6	O
.	O

7	O
locus	O
,	O
both	O
of	O
which	O
are	O
comprised	O
by	O
the	O
major	O
ancestral	O
or	O
founder	O
HFE	O
haplotype	O
in	O
Brittany	O
,	O
supports	O
the	O
possibility	O
that	O
the	O
disease	O
gene	O
may	O
reside	O
immediately	O
telomeric	O
to	O
the	O
6	O
.	O

7	O
locus	O
within	O
the	O
linkage	O
-	O
disequilibrium	O
zone	O
.	O

Additionally	O
,	O
hemochromatosis	B-Disease
haplotypes	O
possessing	O
HLA	O
-	O
A11	O
and	O
the	O
low	O
-	O
frequency	O
HLA	O
-	O
F	O
polymorphism	O
(	O
allele	O
2	O
)	O
are	O
supportive	O
of	O
a	O
separate	O
founder	O
chromosome	O
containing	O
a	O
second	O
,	O
independently	O
arising	O
mutant	O
allele	O
.	O

Overall	O
,	O
the	O
establishment	O
of	O
a	O
likely	O
"	O
hemochromatosis	B-Disease
critical	O
region	O
"	O
centromeric	O
boundary	O
and	O
the	O
identification	O
of	O
a	O
linkage	O
-	O
disequilibrium	O
zone	O
both	O
significantly	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
DNA	O
required	O
to	O
be	O
searched	O
for	O
novel	O
coding	O
sequences	O
constituting	O
the	O
HFE	B-Disease
defect	I-Disease

Genomic	O
structure	O
of	O
the	O
EWS	O
gene	O
and	O
its	O
relationship	O
to	O
EWSR1	O
,	O
a	O
site	O
of	O
tumor	B-Disease
-	O
associated	O
chromosome	O
translocation	O
.	O

The	O
EWS	O
gene	O
has	O
been	O
identified	O
based	O
on	O
its	O
location	O
at	O
the	O
chromosome	O
22	O
breakpoint	O
of	O
the	O
t	O
(	O
11	O
;	O
22	O
)	O
(	O
q24	O
;	O
q12	O
)	O
translocation	O
that	O
characterizes	O
Ewing	B-Disease
sarcoma	I-Disease
and	O
related	O
neuroectodermal	B-Disease
tumors	I-Disease
.	O

The	O
EWS	O
gene	O
spans	O
about	O
40	O
kb	O
of	O
DNA	O
and	O
is	O
encoded	O
by	O
17	O
exons	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
exons	O
is	O
identical	O
to	O
that	O
of	O
the	O
previously	O
described	O
cDNA	O
.	O

The	O
first	O
7	O
exons	O
encode	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
EWS	O
,	O
which	O
consists	O
of	O
a	O
repeated	O
degenerated	O
polypeptide	O
of	O
7	O
to	O
12	O
residues	O
rich	O
in	O
tyrosine	O
,	O
serine	O
,	O
threonine	O
,	O
glycine	O
,	O
and	O
glutamine	O
.	O

Exons	O
11	O
,	O
12	O
,	O
and	O
13	O
encode	O
the	O
putative	O
RNA	O
binding	O
domain	O
.	O

The	O
three	O
glycine	O
-	O
and	O
arginine	O
-	O
rich	O
motifs	O
of	O
the	O
gene	O
are	O
mainly	O
encoded	O
by	O
exons	O
8	O
-	O
9	O
,	O
14	O
,	O
and	O
16	O
.	O

The	O
DNA	O
sequence	O
in	O
the	O
5	O
region	O
of	O
the	O
gene	O
has	O
features	O
of	O
a	O
CpG	O
-	O
rich	O
island	O
and	O
lacks	O
canonical	O
promoter	O
elements	O
,	O
such	O
as	O
TATA	O
and	O
CCAAT	O
consensus	O
sequences	O
.	O

Positions	O
of	O
the	O
chromosome	O
22	O
breakpoints	O
were	O
determined	O
for	O
19	O
Ewing	B-Disease
tumors	I-Disease
.	O

They	O
were	O
localized	O
in	O
introns	O
7	O
or	O
8	O
in	O
18	O
cases	O
and	O
in	O
intron	O
10	O
in	O
1	O
case	O
.	O
.	O

Norrie	B-Disease
disease	I-Disease
gene	O
:	O
characterization	O
of	O
deletions	O
and	O
possible	O
function	O
.	O

Positional	O
cloning	O
experiments	O
have	O
resulted	O
recently	O
in	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Norrie	B-Disease
disease	I-Disease
(	O
pseudoglioma	B-Disease
;	O
NDP	B-Disease
)	O
,	O
a	O
severe	O
X	B-Disease
-	I-Disease
linked	I-Disease
neurodevelopmental	I-Disease
disorder	I-Disease
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
analysis	O
of	O
human	O
genomic	O
DNA	O
clones	O
encompassing	O
the	O
NDP	B-Disease
gene	O
.	O

The	O
gene	O
spans	O
28	O
kb	O
and	O
consists	O
of	O
3	O
exons	O
,	O
the	O
first	O
of	O
which	O
is	O
entirely	O
contained	O
within	O
the	O
5	O
untranslated	O
region	O
.	O

Detailed	O
analysis	O
of	O
genomic	O
deletions	O
in	O
Norrie	B-Disease
patients	O
shows	O
that	O
they	O
are	O
heterogeneous	O
,	O
both	O
in	O
size	O
and	O
in	O
position	O
.	O

By	O
PCR	O
analysis	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
NDP	B-Disease
gene	O
was	O
not	O
confined	O
to	O
the	O
eye	O
or	O
to	O
the	O
brain	O
.	O

An	O
extensive	O
DNA	O
and	O
protein	O
sequence	O
comparison	O
between	O
the	O
human	O
NDP	B-Disease
gene	O
and	O
related	O
genes	O
from	O
the	O
database	O
revealed	O
homology	O
with	O
cysteine	O
-	O
rich	O
protein	O
-	O
binding	O
domains	O
of	O
immediate	O
-	O
-	O
early	O
genes	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
.	O

We	O
propose	O
that	O
NDP	O
is	O
a	O
molecule	O
related	O
in	O
function	O
to	O
these	O
genes	O
and	O
may	O
be	O
involved	O
in	O
a	O
pathway	O
that	O
regulates	O
neural	O
cell	O
differentiation	O
and	O
proliferation	O
.	O
.	O

The	O
normal	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
allele	O
,	O
or	O
a	O
closely	O
linked	O
gene	O
,	O
influences	O
age	O
at	O
onset	O
of	O
HD	B-Disease
.	O

We	O
evaluated	O
the	O
hypothesis	O
that	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
influenced	O
by	O
the	O
normal	O
HD	B-Disease
allele	O
by	O
comparing	O
transmission	O
patterns	O
of	O
genetically	O
linked	O
markers	O
at	O
the	O
D4S10	O
locus	O
in	O
the	O
normal	O
parent	O
against	O
age	O
at	O
onset	O
in	O
the	O
affected	O
offspring	O
.	O

Analysis	O
of	O
information	O
from	O
21	O
sibships	O
in	O
14	O
kindreds	O
showed	O
a	O
significant	O
tendency	O
for	O
sibs	O
who	O
have	O
similar	O
onset	O
ages	O
to	O
share	O
the	O
same	O
D4S10	O
allele	O
from	O
the	O
normal	O
parent	O
.	O

Affected	O
sibs	O
who	O
inherited	O
different	O
D4S10	O
alleles	O
from	O
the	O
normal	O
parent	O
tended	O
to	O
have	O
more	O
variable	O
ages	O
at	O
onset	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
expression	O
of	O
HD	B-Disease
is	O
modulated	O
by	O
the	O
normal	O
HD	B-Disease
allele	O
or	O
by	O
a	O
closely	O
linked	O
locus	O
.	O
.	O

Further	O
investigation	O
of	O
the	O
HEXA	O
gene	O
intron	O
9	O
donor	O
splice	O
site	O
mutation	O
frequently	O
found	O
in	O
non	O
-	O
Jewish	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
patients	O
from	O
the	O
British	O
Isles	O
.	O

In	O
a	O
previous	O
study	O
we	O
found	O
that	O
a	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
causing	O
mutation	O
in	O
the	O
intron	O
9	O
donor	O
splice	O
site	O
of	O
the	O
HEXA	O
gene	O
occurs	O
at	O
high	O
frequency	O
in	O
non	O
-	O
Jewish	O
patients	O
and	O
carriers	O
from	O
the	O
British	O
Isles	O
.	O

It	O
was	O
found	O
more	O
frequently	O
in	O
subjects	O
of	O
Irish	O
,	O
Scottish	O
,	O
and	O
Welsh	O
origin	O
compared	O
with	O
English	O
origin	O
(	O
63	O
%	O
and	O
31	O
%	O
respectively	O
)	O
.	O

We	O
have	O
now	O
tested	O
,	O
in	O
a	O
blind	O
study	O
,	O
26	O
American	O
TSD	B-Disease
carriers	O
and	O
28	O
non	O
-	O
carriers	O
who	O
have	O
British	O
ancestry	O
for	O
the	O
intron	O
9	O
splice	O
site	O
mutation	O
.	O

Six	O
of	O
the	O
carriers	O
and	O
none	O
of	O
the	O
controls	O
were	O
positive	O
for	O
the	O
mutation	O
.	O

All	O
six	O
had	O
Irish	O
ancestry	O
,	O
compared	O
with	O
nine	O
of	O
the	O
20	O
other	O
(	O
intron	O
9	O
mutation	O
negative	O
)	O
TSD	B-Disease
carriers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
confirm	O
the	O
previously	O
found	O
high	O
frequency	O
of	O
the	O
intron	O
9	O
mutation	O
in	O
non	O
-	O
Jewish	O
TSD	B-Disease
families	O
of	O
British	O
Isles	O
,	O
particularly	O
Irish	O
,	O
origin	O
,	O
and	O
reinforce	O
the	O
need	O
to	O
screen	O
such	O
families	O
for	O
this	O
mutation	O
.	O

Molecular	O
mechanisms	O
of	O
oncogenic	O
mutations	O
in	O
tumors	B-Disease
from	O
patients	O
with	O
bilateral	B-Disease
and	I-Disease
unilateral	I-Disease
retinoblastoma	I-Disease
.	O

The	O
RB1	O
gene	O
from	O
12	O
human	O
retinoblastoma	B-Disease
tumors	I-Disease
has	O
been	O
analyzed	O
exon	O
-	O
by	O
-	O
exon	O
with	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O

Mutations	O
were	O
found	O
in	O
all	O
tumors	B-Disease
,	O
and	O
one	O
-	O
third	O
of	O
the	O
tumors	B-Disease
had	O
independent	O
mutations	O
in	O
both	O
alleles	O
neither	O
of	O
which	O
were	O
found	O
in	O
the	O
germ	O
line	O
,	O
confirming	O
their	O
true	O
sporadic	O
nature	O
.	O

In	O
the	O
remaining	O
two	O
-	O
thirds	O
of	O
the	O
tumors	B-Disease
only	O
one	O
mutation	O
was	O
found	O
,	O
consistent	O
with	O
the	O
loss	O
-	O
of	O
-	O
heterozygosity	O
theory	O
of	O
tumorigenesis	O
.	O

Point	O
mutations	O
,	O
the	O
majority	O
of	O
which	O
were	O
C	O
-	O
-	O
>	O
T	O
transitions	O
,	O
were	O
the	O
most	O
common	O
abnormality	O
and	O
usually	O
resulted	O
in	O
the	O
conversion	O
of	O
an	O
arginine	O
codon	O
to	O
a	O
stop	O
codon	O
.	O

Small	O
deletions	O
were	O
the	O
second	O
most	O
common	O
abnormality	O
and	O
most	O
often	O
created	O
a	O
downstream	O
stop	O
codon	O
as	O
the	O
result	O
of	O
a	O
reading	O
frameshift	O
.	O

Deletions	O
and	O
point	O
mutations	O
also	O
affected	O
splice	O
junctions	O
.	O

Direct	O
repeats	O
were	O
present	O
at	O
the	O
breakpoint	O
junctions	O
in	O
the	O
majority	O
of	O
deletions	O
,	O
supporting	O
a	O
slipped	O
-	O
mispairing	O
mechanism	O
.	O

Point	O
mutations	O
generally	O
produced	O
DNA	O
sequences	O
which	O
resulted	O
in	O
perfect	O
homology	O
with	O
endogenous	O
sequences	O
which	O
lay	O
within	O
14	O
bp	O
.	O
.	O

PAX6	O
mutations	O
in	O
aniridia	B-Disease
.	O

Aniridia	B-Disease
is	O
a	O
congenital	B-Disease
malformation	I-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
,	O
chiefly	O
characterised	O
by	O
iris	B-Disease
hypoplasia	I-Disease
,	O
which	O
can	O
cause	O
blindness	B-Disease
.	O

The	O
PAX6	O
gene	O
was	O
isolated	O
as	O
a	O
candidate	O
aniridia	B-Disease
gene	O
by	O
positional	O
cloning	O
from	O
the	O
smallest	O
region	O
of	O
overlap	O
of	O
aniridia	B-Disease
-	O
associated	O
deletions	O
.	O

Subsequently	O
PAX6	O
intragenic	O
mutations	O
were	O
demonstrated	O
in	O
Smalleye	O
,	O
a	O
mouse	O
mutant	O
which	O
is	O
an	O
animal	O
model	O
for	O
aniridia	B-Disease
,	O
and	O
six	O
human	O
aniridia	B-Disease
patients	O
.	O

In	O
this	O
paper	O
we	O
describe	O
four	O
additional	O
PAX6	O
point	O
mutations	O
in	O
aniridia	B-Disease
patients	O
,	O
both	O
sporadic	O
and	O
familial	O
.	O

These	O
mutations	O
highlight	O
regions	O
of	O
the	O
gene	O
which	O
are	O
essential	O
for	O
normal	O
PAX6	O
function	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
at	O
which	O
we	O
have	O
found	O
PAX6	O
mutations	O
suggests	O
that	O
lesions	O
in	O
PAX6	O
will	O
account	O
for	O
most	O
cases	O
of	O
aniridia	B-Disease
.	O
.	O

Detection	O
of	O
a	O
novel	O
arginine	O
vasopressin	O
defect	O
by	O
dideoxy	O
fingerprinting	O
.	O

Autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
a	O
familial	O
form	O
of	O
diabetes	B-Disease
insipidus	I-Disease
.	O

This	O
disorder	O
is	O
associated	O
with	O
variable	O
levels	O
of	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
and	O
diabetes	B-Disease
insipidus	I-Disease
of	O
varying	O
severity	O
,	O
which	O
responds	O
to	O
exogenous	O
AVP	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
the	O
AVP	O
genes	O
of	O
members	O
of	O
a	O
large	O
kindred	O
were	O
analyzed	O
.	O

A	O
new	O
method	O
,	O
called	O
dideoxy	O
fingerprinting	O
,	O
was	O
used	O
to	O
detect	O
an	O
AVP	O
mutation	O
that	O
was	O
characterized	O
by	O
DNA	O
sequencing	O
.	O

The	O
novel	O
defect	O
found	O
changes	O
the	O
last	O
codon	O
of	O
the	O
AVP	O
signal	O
peptide	O
from	O
alanine	O
to	O
threonine	O
,	O
which	O
should	O
perturb	O
cleavage	O
of	O
mature	O
AVP	O
from	O
its	O
precursor	O
protein	O
and	O
inhibit	O
its	O
secretion	O
or	O
action	O
.	O
.	O

Germinal	O
mosaicism	O
in	O
a	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
family	O
:	O
implications	O
for	O
genetic	O
counselling	O
.	O

In	O
this	O
study	O
we	O
describe	O
a	O
three	O
-	O
generation	O
family	O
in	O
which	O
two	O
siblings	O
were	O
affected	O
by	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
.	O

Immunohistochemical	O
analysis	O
of	O
muscle	O
dystrophin	O
and	O
haplotype	O
analysis	O
of	O
the	O
DMD	B-Disease
locus	O
revealed	O
that	O
the	O
X	O
chromosome	O
carrying	O
the	O
DMD	B-Disease
gene	O
was	O
transmitted	O
from	O
the	O
healthy	O
maternal	O
grandfather	O
to	O
his	O
three	O
daughters	O
,	O
including	O
the	O
probands	O
mother	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
grandfather	O
was	O
a	O
germinal	O
mosaic	O
for	O
the	O
DMD	B-Disease
gene	O
.	O

The	O
definition	O
of	O
the	O
carrier	O
status	O
in	O
two	O
possible	O
carriers	O
led	O
us	O
to	O
give	O
accurate	O
genetic	O
counselling	O
and	O
to	O
prevent	O
the	O
birth	O
of	O
an	O
affected	O
boy	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
the	O
usefulness	O
of	O
haplotype	O
analysis	O
and	O
immunohistochemical	O
muscle	O
dystrophin	O
studies	O
to	O
detect	O
hidden	O
germinal	O
mosaicism	O
and	O
to	O
improve	O
genetic	O
counselling	O
.	O
.	O

Genetic	O
mapping	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
to	O
a	O
small	O
interval	O
on	O
chromosome	O
17q12	O
-	O
21	O
:	O
exclusion	O
of	O
candidate	O
genes	O
EDH17B2	O
and	O
RARA	O
.	O

A	O
susceptibility	O
gene	O
for	O
hereditary	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
BRCA1	O
,	O
has	O
been	O
assigned	O
by	O
linkage	O
analysis	O
to	O
chromosome	O
17q21	O
.	O

Candidate	O
genes	O
in	O
this	O
region	O
include	O
EDH17B2	O
,	O
which	O
encodes	O
estradiol	O
17	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
II	O
(	O
17	O
beta	O
-	O
HSD	O
II	O
)	O
,	O
and	O
RARA	O
,	O
the	O
gene	O
for	O
retinoic	O
acid	O
receptor	O
alpha	O
.	O

We	O
have	O
typed	O
22	O
breast	B-Disease
and	I-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
with	O
eight	O
polymorphisms	O
from	O
the	O
chromosome	O
17q12	O
-	O
21	O
region	O
,	O
including	O
two	O
in	O
the	O
EDH17B2	O
gene	O
.	O

Genetic	O
recombination	O
with	O
the	O
breast	B-Disease
cancer	I-Disease
trait	O
excludes	O
RARA	O
from	O
further	O
consideration	O
as	O
a	O
candidate	O
gene	O
for	O
BRCA1	O
.	O

Both	O
BRCA1	O
and	O
EDH17B2	O
map	O
to	O
a	O
6	O
cM	O
interval	O
(	O
between	O
THRA1	O
and	O
D17S579	O
)	O
and	O
no	O
recombination	O
was	O
observed	O
between	O
the	O
two	O
genes	O
.	O

However	O
,	O
direct	O
sequencing	O
of	O
overlapping	O
PCR	O
products	O
containing	O
the	O
entire	O
EDH17B2	O
gene	O
in	O
four	O
unrelated	O
affected	O
women	O
did	O
not	O
uncover	O
any	O
sequence	O
variation	O
,	O
other	O
than	O
previously	O
described	O
polymorphisms	O
.	O

Mutations	O
in	O
the	O
EDH17B2	O
gene	O
,	O
therefore	O
do	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
hereditary	B-Disease
breast	I-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
.	O

Single	O
meiotic	O
crossovers	O
in	O
affected	O
women	O
suggest	O
that	O
BRCA1	O
is	O
flanked	O
by	O
the	O
loci	O
RARA	O
and	O
D17S78	O
.	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
with	O
possible	O
dominant	O
effects	O
on	O
plasma	O
high	O
density	O
lipoproteins	O
.	O

Plasma	O
HDL	O
are	O
a	O
negative	O
risk	O
factor	O
for	O
atherosclerosis	B-Disease
.	O

Cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
;	O
476	O
amino	O
acids	O
)	O
transfers	O
cholesteryl	O
ester	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
.	O

Subjects	O
with	O
homozygous	O
CETP	B-Disease
deficiency	I-Disease
caused	O
by	O
a	O
gene	O
splicing	O
defect	O
have	O
markedly	O
elevated	O
HDL	O
;	O
however	O
,	O
heterozygotes	O
have	O
only	O
mild	O
increases	O
in	O
HDL	O
.	O

We	O
describe	O
two	O
probands	O
with	O
a	O
CETP	O
missense	O
mutation	O
(	O
442	O
D	O
G	O
)	O
.	O

Although	O
heterozygous	O
,	O
they	O
have	O
threefold	O
increases	O
in	O
HDL	O
concentration	O
and	O
markedly	O
decreased	O
plasma	O
CETP	O
mass	O
and	O
activity	O
,	O
suggesting	O
that	O
the	O
mutation	O
has	O
dominant	O
effects	O
on	O
CETP	O
and	O
HDL	O
in	O
vivo	O
.	O

Cellular	O
expression	O
of	O
mutant	O
cDNA	O
results	O
in	O
secretion	O
of	O
only	O
30	O
%	O
of	O
wild	O
type	O
CETP	O
activity	O
.	O

Moreover	O
,	O
coexpression	O
of	O
wild	O
type	O
and	O
mutant	O
cDNAs	O
leads	O
to	O
inhibition	O
of	O
wild	O
type	O
secretion	O
and	O
activity	O
.	O

The	O
dominant	O
effects	O
of	O
the	O
CETP	O
missense	O
mutation	O
during	O
cellular	O
expression	O
probably	O
explains	O
why	O
the	O
probands	O
have	O
markedly	O
increased	O
HDL	O
in	O
the	O
heterozygous	O
state	O
,	O
and	O
suggests	O
that	O
the	O
active	O
molecular	O
species	O
of	O
CETP	O
may	O
be	O
multimeric	O
.	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
in	O
the	O
colchicine	O
era	O
:	O
the	O
fate	O
of	O
one	O
family	O
.	O

In	O
order	O
to	O
demonstrate	O
the	O
effect	O
of	O
prophylactic	O
colchicine	O
treatment	O
on	O
the	O
natural	O
history	O
of	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
,	O
a	O
family	O
is	O
presented	O
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	O
by	O
FMF	B-Disease
.	O

Each	O
patient	O
represents	O
a	O
different	O
stage	O
of	O
the	O
amyloidotic	B-Disease
kidney	I-Disease
disease	I-Disease
of	O
FMF	B-Disease
and	O
the	O
effect	O
of	O
continuous	O
colchicine	O
treatment	O
on	O
its	O
course	O
.	O

Considered	O
together	O
,	O
the	O
members	O
of	O
this	O
family	O
present	O
an	O
almost	O
complete	O
clinical	O
,	O
genetic	O
,	O
and	O
behavioral	O
picture	O
of	O
the	O
disease	O
.	O
.	O

Detection	O
of	O
a	O
new	O
submicroscopic	O
Norrie	B-Disease
disease	I-Disease
deletion	O
interval	O
with	O
a	O
novel	O
DNA	O
probe	O
isolated	O
by	O
differential	O
Alu	O
PCR	O
fingerprint	O
cloning	O
.	O

Differential	O
Alu	O
PCR	O
fingerprint	O
cloning	O
was	O
used	O
to	O
isolate	O
a	O
DNA	O
probe	O
from	O
the	O
Xp11	O
.	O

4	O
-	O
-	O
>	O
p11	O
.	O

21	O
region	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

This	O
novel	O
sequence	O
,	O
cpXr318	O
(	O
DXS742	O
)	O
,	O
detects	O
a	O
new	O
submicroscopic	O
deletion	O
interval	O
at	O
the	O
Norrie	B-Disease
disease	I-Disease
locus	O
(	O
NDP	O
)	O
.	O

Combining	O
our	O
data	O
with	O
the	O
consensus	O
genetic	O
map	O
of	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
we	O
propose	O
the	O
physical	O
order	O
Xcen	O
-	O
DXS14	O
-	O
DXS255	O
-	O
(	O
DXS426	O
,	O
TIMP	O
)	O
-	O
(	O
DXS742	O
-	O
(	O
[	O
MAOB	O
-	O
MAOA	O
-	O
DXS7	O
]	O
,	O
NDP	O
)	O
-	O
DXS77	O
-	O
DXS228	O
)	O
-	O
DXS209	O
-	O
DXS148	O
-	O
DXS196	O
-	O
+	O
+	O
+	O
Xpter	O
.	O

The	O
cpXr318	O
probe	O
and	O
a	O
subclone	O
from	O
a	O
cosmid	O
corresponding	O
to	O
the	O
DXS7	O
locus	O
were	O
converted	O
into	O
sequence	O
-	O
tagged	O
sites	O
.	O

Finally	O
,	O
DXS742	O
,	O
DSX7	O
,	O
DXS77	O
,	O
and	O
MAOA	O
were	O
integrated	O
into	O
a	O
physical	O
map	O
spanning	O
the	O
Norrie	B-Disease
disease	I-Disease
locus	O

Putative	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
gene	O
shares	O
unexpected	O
homology	O
with	O
ABC	O
transporters	O
.	O

Adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
disease	I-Disease
affecting	O
1	O
/	O
20	O
,	O
000	O
males	O
either	O
as	O
cerebral	B-Disease
ALD	I-Disease
in	O
childhood	O
or	O
as	O
adrenomyeloneuropathy	B-Disease
(	O
AMN	B-Disease
)	O
in	O
adults	O
.	O

Childhood	O
ALD	B-Disease
is	O
the	O
more	O
severe	O
form	O
,	O
with	O
onset	O
of	O
neurological	O
symptoms	O
between	O
5	O
-	O
12	O
years	O
of	O
age	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
demyelination	I-Disease
progresses	O
rapidly	O
and	O
death	O
occurs	O
within	O
a	O
few	O
years	O
.	O

AMN	B-Disease
is	O
a	O
milder	O
form	O
of	O
the	O
disease	O
with	O
onset	O
at	O
15	O
-	O
30	O
years	O
of	O
age	O
and	O
a	O
more	O
progressive	O
course	O
.	O

Adrenal	B-Disease
insufficiency	I-Disease
(	O
Addisons	B-Disease
disease	I-Disease
)	O
may	O
remain	O
the	O
only	O
clinical	O
manifestation	O
of	O
ALD	B-Disease
.	O

The	O
principal	O
biochemical	O
abnormality	O
of	O
ALD	B-Disease
is	O
the	O
accumulation	O
of	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
because	O
of	O
impaired	O
beta	O
-	O
oxidation	O
in	O
peroxisomes	O
.	O

The	O
normal	O
oxidation	O
of	O
VLCFA	O
-	O
CoA	O
in	O
patients	O
fibroblasts	O
suggested	O
that	O
the	O
gene	O
coding	O
for	O
the	O
VLCFA	O
-	O
CoA	O
synthetase	O
could	O
be	O
a	O
candidate	O
gene	O
for	O
ALD	B-Disease
.	O

Here	O
we	O
use	O
positional	O
cloning	O
to	O
identify	O
a	O
gene	O
partially	O
deleted	O
in	O
6	O
of	O
85	O
independent	O
patients	O
with	O
ALD	B-Disease
.	O

In	O
familial	O
cases	O
,	O
the	O
deletions	O
segregated	O
with	O
the	O
disease	O
.	O

An	O
identical	O
deletion	O
was	O
detected	O
in	O
two	O
brothers	O
presenting	O
with	O
different	O
clinical	O
ALD	B-Disease
phenotypes	O
.	O

Candidate	O
exons	O
were	O
identified	O
by	O
computer	O
analysis	O
of	O
genomic	O
sequences	O
and	O
used	O
to	O
isolate	O
complementary	O
DNAs	O
by	O
exon	O
connection	O
and	O
screening	O
of	O
cDNA	O
libraries	O
.	O

The	O
deduced	O
protein	O
sequence	O
shows	O
significant	O
sequence	O
identity	O
to	O
a	O
peroxisomal	O
membrane	O
protein	O
of	O
M	O
(	O
r	O
)	O
70K	O
that	O
is	O
involved	O
in	O
peroxisome	O
biogenesis	O
and	O
belongs	O
to	O
the	O
ATP	O
-	O
binding	O
cassette	O
superfamily	O
of	O
transporters	O
.	O
.	O

Targeted	O
modification	O
of	O
the	O
apolipoprotein	O
B	O
gene	O
results	O
in	O
hypobetalipoproteinemia	B-Disease
and	O
developmental	B-Disease
abnormalities	I-Disease
in	O
mice	O
.	O

Familial	B-Disease
hypobetalipoproteinemia	I-Disease
is	O
an	O
autosomal	B-Disease
codominant	I-Disease
disorder	I-Disease
resulting	O
in	O
a	O
dramatic	O
reduction	O
in	O
plasma	O
concentrations	O
of	O
apolipoprotein	O
(	O
apo	O
)	O
B	O
,	O
cholesterol	O
,	O
and	O
beta	O
-	O
migrating	O
lipoproteins	O
.	O

A	O
benefit	O
of	O
hypobetalipoproteinemia	B-Disease
is	O
that	O
mildly	O
affected	O
individuals	O
may	O
be	O
protected	O
from	O
coronary	B-Disease
vascular	I-Disease
disease	I-Disease
.	O

We	O
have	O
used	O
gene	O
targeting	O
to	O
generate	O
mice	O
with	O
a	O
modified	O
Apob	O
allele	O
.	O

Mice	O
containing	O
this	O
allele	O
display	O
all	O
of	O
the	O
hallmarks	O
of	O
human	O
hypobetalipoproteinemia	B-Disease
they	O
produce	O
a	O
truncated	O
apoB	O
protein	O
,	O
apoB70	O
,	O
and	O
have	O
markedly	O
decreased	O
plasma	O
concentrations	O
of	O
apoB	O
,	O
beta	O
-	O
lipoproteins	O
,	O
and	O
total	O
cholesterol	O
.	O

In	O
addition	O
,	O
the	O
mice	O
manifest	O
several	O
characteristics	O
that	O
are	O
occasionally	O
observed	O
in	O
human	O
hypobetalipoproteinemia	B-Disease
,	O
including	O
reduced	O
plasma	O
triglyceride	O
concentrations	O
,	O
fasting	O
chylomicronemia	B-Disease
,	O
and	O
reduced	O
high	O
density	O
lipoprotein	O
cholesterol	O
.	O

An	O
unexpected	O
finding	O
is	O
that	O
the	O
modified	O
Apob	O
allele	O
is	O
strongly	O
associated	O
with	O
exencephalus	B-Disease
and	O
hydrocephalus	B-Disease
.	O

These	O
mice	O
should	O
help	O
increase	O
our	O
understanding	O
of	O
hypobetalipoproteinemia	B-Disease
,	O
atherogenesis	B-Disease
,	O
and	O
the	O
etiology	O
of	O
exencephalus	B-Disease
and	O
hydrocephalus	B-Disease
.	O
.	O

A	O
novel	O
disease	O
with	O
deficiency	B-Disease
of	I-Disease
mitochondrial	I-Disease
very	I-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
CoA	I-Disease
dehydrogenase	I-Disease
.	O

Palmitoyl	O
-	O
CoA	O
dehydrogenase	O
activity	O
in	O
skin	O
fibroblasts	O
from	O
seven	O
patients	O
with	O
unidentified	O
defects	O
of	O
fatty	O
acid	O
oxidation	O
was	O
measured	O
in	O
the	O
presence	O
and	O
absence	O
of	O
antibodies	O
against	O
medium	O
-	O
chain	O
,	O
long	O
-	O
chain	O
,	O
and	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenases	O
(	O
VLCAD	O
)	O
.	O

Two	O
of	O
the	O
patients	O
,	O
4	O
-	O
5	O
month	O
old	O
boys	O
,	O
were	O
found	O
to	O
have	O
a	O
novel	O
disease	O
,	O
VLCAD	B-Disease
deficiency	I-Disease
,	O
as	O
judged	O
from	O
the	O
results	O
of	O
very	O
low	O
palmitoyl	O
-	O
CoA	O
dehydrogenase	O
activity	O
and	O
the	O
lack	O
of	O
immunoreactivity	O
toward	O
antibody	O
raised	O
to	O
purified	O
VLCAD	O
.	O
.	O

Molecular	O
characterization	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
patients	O
of	O
Chinese	O
descent	O
and	O
identification	O
of	O
new	O
base	O
substitutions	O
in	O
the	O
human	O
G6PD	O
gene	O
.	O

The	O
underlying	O
DNA	O
changes	O
associated	O
with	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
G6PD	I-Disease
)	I-Disease
-	I-Disease
deficient	I-Disease
Asians	O
have	O
not	O
been	O
extensively	O
investigated	O
.	O

To	O
fill	O
this	O
gap	O
,	O
we	O
sequenced	O
the	O
G6PD	O
gene	O
of	O
43	O
G6PD	B-Disease
-	I-Disease
deficient	I-Disease
Chinese	O
whose	O
G6PD	O
was	O
well	O
characterized	O
biochemically	O
.	O

DNA	O
samples	O
were	O
obtained	O
from	O
peripheral	O
blood	O
of	O
these	O
individuals	O
for	O
sequencing	O
using	O
a	O
direct	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
sequencing	O
procedure	O
.	O

From	O
these	O
43	O
samples	O
,	O
we	O
have	O
identified	O
five	O
different	O
types	O
of	O
nucleotide	O
substitutions	O
in	O
the	O
G6PD	O
gene	O
at	O
cDNA	O
1388	O
from	O
G	O
to	O
A	O
(	O
Arg	O
to	O
His	O
)	O
;	O
at	O
cDNA	O
1376	O
from	O
G	O
to	O
T	O
(	O
Arg	O
to	O
Leu	O
)	O
;	O
at	O
cDNA	O
1024	O
from	O
C	O
to	O
T	O
(	O
Leu	O
to	O
Phe	O
)	O
;	O
at	O
cDNA	O
392	O
from	O
G	O
to	O
T	O
(	O
Gly	O
to	O
Val	O
)	O
;	O
at	O
cDNA	O
95	O
from	O
A	O
to	O
G	O
(	O
His	O
to	O
Arg	O
)	O
.	O

These	O
five	O
nucleotide	O
substitutions	O
account	O
for	O
over	O
83	O
%	O
of	O
our	O
43	O
G6PD	B-Disease
-	I-Disease
deficient	I-Disease
samples	O
and	O
these	O
substitutions	O
have	O
not	O
been	O
reported	O
in	O
non	O
-	O
Asians	O
.	O

The	O
substitutions	O
found	O
at	O
cDNA	O
392	O
and	O
cDNA	O
1024	O
are	O
new	O
findings	O
.	O

The	O
substitutions	O
at	O
cDNA	O
1376	O
and	O
1388	O
account	O
for	O
over	O
50	O
%	O
of	O
the	O
43	O
samples	O
examined	O
indicating	O
a	O
high	O
prevalence	O
of	O
these	O
two	O
alleles	O
among	O
G6PD	B-Disease
-	I-Disease
deficient	I-Disease
Chinese	O
.	O

Our	O
findings	O
add	O
support	O
to	O
the	O
notion	O
that	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
much	O
of	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	B-Disease
deficiency	I-Disease
.	O
.	O

Identification	O
of	O
mutations	O
in	O
Danish	O
choroideremia	B-Disease
families	O
.	O

We	O
have	O
searched	O
for	O
mutations	O
in	O
the	O
choroideremia	B-Disease
gene	O
(	O
CHM	B-Disease
)	O
in	O
patients	O
from	O
12	O
Danish	O
families	O
in	O
which	O
CHM	B-Disease
is	O
segregating	O
.	O

Employing	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
,	O
and	O
direct	O
DNA	O
sequencing	O
,	O
different	O
mutations	O
have	O
been	O
identified	O
in	O
6	O
patients	O
.	O

All	O
the	O
mutations	O
will	O
interfere	O
with	O
the	O
correct	O
translation	O
of	O
the	O
mRNA	O
predicting	O
a	O
truncated	O
protein	O
or	O
no	O
gene	O
product	O
at	O
all	O
.	O
.	O

Structure	O
and	O
genomic	O
sequence	O
of	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
kinase	O
)	O
gene	O
.	O

The	O
mutation	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
CTG	O
trinucleotide	O
repeat	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
gene	O
encoding	O
for	O
a	O
protein	O
with	O
putative	O
serine	O
-	O
threonine	O
protein	O
kinase	O
activity	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
genomic	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
DM	B-Disease
kinase	O
gene	O
.	O

A	O
comparison	O
of	O
these	O
sequences	O
with	O
each	O
other	O
and	O
with	O
known	O
cDNA	O
sequences	O
from	O
both	O
species	O
,	O
led	O
us	O
to	O
predict	O
a	O
translation	O
initiation	O
codon	O
,	O
as	O
well	O
as	O
determine	O
the	O
organization	O
of	O
the	O
DM	B-Disease
kinase	O
gene	O
.	O

Several	O
polymorphisms	O
within	O
the	O
human	O
DM	B-Disease
kinase	O
gene	O
have	O
been	O
identified	O
,	O
and	O
PCR	O
assays	O
to	O
detect	O
two	O
of	O
these	O
are	O
described	O
.	O

The	O
complete	O
sequence	O
and	O
characterization	O
of	O
the	O
structure	O
of	O
the	O
DM	B-Disease
kinase	O
gene	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
novel	O
polymorphisms	O
within	O
the	O
gene	O
,	O
represent	O
an	O
important	O
step	O
in	O
a	O
further	O
understanding	O
of	O
the	O
genetics	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
and	O
the	O
molecular	O
biology	O
of	O
the	O
gene	O
.	O
.	O

Autosomal	O
recessive	O
transmission	O
of	O
hemophilia	B-Disease
A	I-Disease
due	O
to	O
a	O
von	B-Disease
Willebrand	I-Disease
factor	O
mutation	O
.	O

The	O
differential	O
diagnosis	O
of	O
the	O
genetic	B-Disease
bleeding	I-Disease
disorders	I-Disease
,	O
hemophilia	B-Disease
A	I-Disease
and	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
,	O
is	O
occasionally	O
confounded	O
by	O
the	O
close	O
molecular	O
relationship	O
of	O
coagulation	O
factor	O
VIII	O
and	O
von	B-Disease
Willebrand	I-Disease
factor	O
(	O
vWF	O
)	O
.	O

This	O
report	O
describes	O
the	O
autosomal	O
inheritance	O
of	O
a	O
hemophilia	B-Disease
A	I-Disease
phenotype	O
due	O
to	O
a	O
mutation	O
of	O
vWF	O
that	O
results	O
in	O
defective	O
factor	O
VIII	O
binding	O
.	O

The	O
proband	O
was	O
a	O
female	O
patient	O
with	O
low	O
levels	O
of	O
factor	O
VIII	O
activity	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
DNA	O
sequencing	O
were	O
employed	O
to	O
examine	O
exons	O
encoding	O
the	O
putative	O
factor	O
VIII	O
binding	O
domain	O
of	O
vWF	O
.	O

The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
point	O
mutation	O
causing	O
a	O
Thr	O
-	O
-	O
>	O
Met	O
substitution	O
at	O
amino	O
acid	O
position	O
28	O
in	O
the	O
mature	O
vWF	O
subunit	O
.	O

The	O
phenotypic	O
expression	O
of	O
the	O
mutation	O
was	O
determined	O
to	O
be	O
recessive	O
because	O
heterozygous	O
family	O
members	O
were	O
clinically	O
unaffected	O
.	O

Recombinant	O
vWF	O
containing	O
the	O
observed	O
amino	O
acid	O
substitution	O
was	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
.	O

The	O
mutant	O
vWF	O
was	O
processed	O
and	O
secreted	O
normally	O
,	O
and	O
was	O
functionally	O
equivalent	O
to	O
wild	O
-	O
type	O
vWF	O
in	O
its	O
ability	O
to	O
bind	O
to	O
platelets	O
.	O

However	O
,	O
the	O
mutant	O
failed	O
to	O
bind	O
factor	O
VIII	O
,	O
demonstrating	O
that	O
the	O
mutation	O
was	O
functionally	O
related	O
to	O
the	O
observed	O
hemophilia	B-Disease
phenotype	O
.	O

The	O
family	O
we	O
describe	O
demonstrates	O
the	O
recessive	O
inheritance	O
of	O
a	O
recently	O
recognized	O
class	O
of	O
genetic	O
bleeding	O
disorders	O
,	O
we	O
call	O
"	O
autosomal	O
hemophilia	B-Disease
.	O

"	O
We	O
conclude	O
that	O
vWF	O
mutation	O
may	O
be	O
an	O
under	O
recognized	O
cause	O
of	O
hemophilia	B-Disease
,	O
especially	O
in	O
cases	O
where	O
the	O
inheritance	O
pattern	O
is	O
not	O
consistent	O
with	O
X	O
-	O
linked	O
transmission	O
.	O

Somatic	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
mutation	O
in	O
clear	O
cell	O
papillary	B-Disease
cystadenoma	I-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
.	O

Papillary	B-Disease
cystadenoma	I-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
is	O
an	O
uncommon	O
benign	O
lesion	O
that	O
may	O
occur	O
sporadically	O
or	O
as	O
a	O
manifestation	O
of	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
disease	I-Disease
.	O

Neither	O
immunohistochemical	O
studies	O
nor	O
molecular	O
genetic	O
analyses	O
of	O
the	O
VHL	B-Disease
gene	O
have	O
been	O
reported	O
previously	O
for	O
this	O
lesion	O
.	O

The	O
authors	O
describe	O
two	O
cases	O
of	O
clear	O
cell	O
papillary	B-Disease
cystadenoma	I-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
,	O
both	O
of	O
which	O
were	O
initially	O
confused	O
with	O
metastatic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Both	O
lesions	O
showed	O
positive	O
immunohistochemical	O
staining	O
for	O
low	O
and	O
intermediate	O
molecular	O
weight	O
keratins	O
(	O
Cam	O
5	O
.	O
2	O
and	O
AE1	O
/	O
AE3	O
)	O
,	O
EMA	O
,	O
vimentin	O
,	O
alpha	O
1	O
-	O
antitrypsin	O
,	O
and	O
alpha	O
1	O
-	O
antichymotrypsin	O
.	O

Each	O
was	O
negative	O
for	O
CEA	O
.	O

Because	O
clear	O
cell	O
papillary	B-Disease
cystadenoma	I-Disease
is	O
similar	O
to	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
histologically	O
,	O
and	O
because	O
both	O
occur	O
as	O
components	O
of	O
the	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
disease	I-Disease
complex	O
,	O
the	O
authors	O
analyzed	O
both	O
cases	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
VHL	B-Disease
gene	O
.	O

A	O
somatic	O
VHL	B-Disease
gene	O
mutation	O
was	O
detected	O
in	O
one	O
of	O
the	O
two	O
tumors	B-Disease
by	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

Direct	O
sequencing	O
revealed	O
a	O
cytosine	O
to	O
thymine	O
transition	O
at	O
nucleotide	O
694	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
an	O
arginine	O
with	O
a	O
stop	O
codon	O
after	O
the	O
sixth	O
amino	O
acid	O
of	O
exon	O
3	O
.	O

As	O
the	O
VHL	B-Disease
gene	O
is	O
believed	O
to	O
function	O
as	O
a	O
tumor	B-Disease
suppressor	O
gene	O
,	O
VHL	B-Disease
gene	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
tumorigenesis	O
in	O
sporadic	O
cystadenomas	B-Disease
of	I-Disease
the	I-Disease
epididymis	I-Disease
.	O

Identification	O
of	O
WASP	O
mutations	O
in	O
patients	O
with	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
and	O
isolated	B-Disease
thrombocytopenia	I-Disease
reveals	O
allelic	O
heterogeneity	O
at	O
the	O
WAS	B-Disease
locus	O
.	O

Mutation	O
in	O
the	O
gene	O
encoding	O
the	O
recently	O
isolated	O
WASP	O
protein	O
has	O
now	O
been	O
identified	O
as	O
the	O
genetic	B-Disease
defect	I-Disease
responsible	O
for	O
the	O
X	B-Disease
-	I-Disease
linked	I-Disease
Wiskott	I-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
,	O
a	O
primary	O
immunodeficiency	B-Disease
disease	I-Disease
associated	O
with	O
extensive	O
phenotypic	O
variability	O
.	O

To	O
elucidate	O
the	O
range	O
of	O
WASP	O
mutations	O
responsible	O
for	O
WAS	B-Disease
,	O
we	O
used	O
PCR	O
-	O
SSCP	O
analysis	O
to	O
screen	O
for	O
WASP	O
gene	O
mutation	O
in	O
19	O
unrelated	O
boys	O
with	O
the	O
diagnosis	O
of	O
classical	O
or	O
attenuated	O
WAS	B-Disease
or	O
isolated	B-Disease
thrombocytopenia	I-Disease
.	O

All	O
19	O
patients	O
had	O
WASP	O
mutations	O
,	O
each	O
of	O
which	O
localized	O
to	O
the	O
initial	O
three	O
or	O
terminal	O
three	O
exons	O
of	O
the	O
gene	O
,	O
and	O
the	O
majority	O
of	O
which	O
were	O
unique	O
in	O
each	O
case	O
.	O

However	O
,	O
a	O
missense	O
mutation	O
which	O
results	O
in	O
substitution	O
of	O
the	O
arginine	O
at	O
WAS	B-Disease
codon	O
86	O
was	O
identified	O
in	O
three	O
boys	O
with	O
severe	O
WAS	B-Disease
as	O
well	O
as	O
in	O
one	O
boy	O
presenting	O
with	O
thrombocytopenia	B-Disease
alone	O
.	O

While	O
the	O
three	O
mutations	O
found	O
in	O
the	O
isolated	B-Disease
thrombocytopenia	I-Disease
patients	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
about	O
one	O
-	O
half	O
of	O
the	O
gene	O
alterations	O
detected	O
in	O
both	O
severe	O
and	O
attenuated	O
WAS	B-Disease
patients	O
result	O
in	O
frameshifted	O
transcript	O
and	O
premature	O
translation	O
termination	O
.	O

These	O
findings	O
therefore	O
confirm	O
the	O
association	O
of	O
WAS	B-Disease
with	O
WASP	O
mutation	O
and	O
identify	O
WASP	O
mutation	O
as	O
a	O
cause	O
for	O
isolated	O
congenital	B-Disease
thrombocytopenia	I-Disease
in	O
males	O
.	O

While	O
the	O
WASP	O
gene	O
defects	O
responsible	O
for	O
isolated	B-Disease
thrombocytopenia	I-Disease
and	O
other	O
mild	O
presentations	O
of	O
WAS	B-Disease
do	O
not	O
appear	O
distinct	O
from	O
those	O
resulting	O
in	O
severe	O
WAS	B-Disease
,	O
these	O
data	O
indicate	O
that	O
analysis	O
of	O
WASP	O
gene	O
mutation	O
provides	O
a	O
valuable	O
tool	O
for	O
distinguishing	O
the	O
spectrum	O
of	O
WAS	B-Disease
patients	O
and	O
the	O
subset	O
of	O
males	O
with	O
isolated	B-Disease
thrombocytopenia	I-Disease
who	O
represent	O
mild	O
cases	O
of	O
WAS	B-Disease
.	O
.	O

WASP	O
gene	O
mutations	O
in	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
and	O
X	B-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
.	O

The	O
WASP	O
gene	O
has	O
been	O
recently	O
cloned	O
from	O
Xp11	O
.	O

23	O
and	O
shown	O
to	O
be	O
mutated	O
in	O
three	O
patients	O
with	O
the	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
(	O
WAS	B-Disease
)	O
.	O

We	O
have	O
developed	O
a	O
screening	O
protocol	O
for	O
identifying	O
WASP	O
gene	O
alterations	O
in	O
genomic	O
DNA	O
and	O
have	O
identified	O
a	O
spectrum	O
of	O
novel	O
mutations	O
in	O
12	O
additional	O
unrelated	O
families	O
.	O

These	O
missense	O
,	O
nonsense	O
and	O
frameshift	O
mutations	O
involve	O
eight	O
of	O
the	O
12	O
exons	O
of	O
the	O
gene	O
.	O

Two	O
mutations	O
creating	O
premature	O
termination	O
codons	O
were	O
associated	O
with	O
lack	O
of	O
detectable	O
mRNA	O
on	O
Northern	O
blots	O
.	O

Four	O
amino	O
acid	O
substitutions	O
,	O
Leu27Phe	O
,	O
Thr48Ile	O
,	O
Val75Met	O
and	O
Arg477Lys	O
,	O
were	O
found	O
in	O
patients	O
with	O
congenital	B-Disease
thrombocytopenia	I-Disease
and	O
no	O
clinically	O
evident	O
immune	O
defect	O
indicating	O
that	O
the	O
WASP	O
gene	O
is	O
the	O
site	O
for	O
mutations	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
as	O
well	O
as	O
in	O
WAS	B-Disease
.	O

A	O
T	O
-	O
cell	O
line	O
from	O
a	O
WAS	B-Disease
patient	O
contained	O
two	O
independent	O
DNA	O
alterations	O
,	O
a	O
constitutional	O
frameshift	O
mutation	O
,	O
also	O
present	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
patient	O
,	O
and	O
compensatory	O
splice	O
site	O
mutation	O
unique	O
to	O
the	O
cell	O
line	O
.	O

The	O
distribution	O
of	O
eight	O
missense	O
mutations	O
provides	O
valuable	O
information	O
on	O
amino	O
acids	O
which	O
are	O
essential	O
for	O
normal	O
protein	O
function	O
,	O
and	O
suggests	O
that	O
sites	O
in	O
the	O
first	O
two	O
exons	O
are	O
hot	O
-	O
spots	O
for	O
mutation	O
.	O

Evidence	O
for	O
inter	O
-	O
generational	O
instability	O
in	O
the	O
CAG	O
repeat	O
in	O
the	O
MJD1	O
gene	O
and	O
for	O
conserved	O
haplotypes	O
at	O
flanking	O
markers	O
amongst	O
Japanese	O
and	O
Caucasian	O
subjects	O
with	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
.	O

The	O
size	O
of	O
the	O
(	O
CAG	O
)	O
n	O
repeat	O
array	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
MJD1	O
gene	O
and	O
the	O
haplotype	O
at	O
a	O
series	O
of	O
microsatellite	O
markers	O
surrounding	O
the	O
MJD1	O
gene	O
were	O
examined	O
in	O
a	O
large	O
cohort	O
of	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
.	O

Our	O
data	O
provide	O
five	O
novel	O
observations	O
.	O

First	O
,	O
MJD	B-Disease
is	O
associated	O
with	O
expansion	O
fo	O
the	O
array	O
from	O
the	O
normal	O
range	O
of	O
14	O
-	O
37	O
repeats	O
to	O
68	O
-	O
84	O
repeats	O
in	O
most	O
Japanese	O
and	O
Caucasian	O
subjects	O
,	O
but	O
no	O
subjects	O
were	O
observed	O
with	O
expansions	O
intermediate	O
in	O
size	O
between	O
those	O
of	O
the	O
normal	O
and	O
MJD	B-Disease
affected	O
groups	O
.	O

Second	O
,	O
the	O
expanded	O
allele	O
associated	O
with	O
MJD	B-Disease
displays	O
inter	O
-	O
generational	O
instability	O
,	O
particularly	O
in	O
male	O
meioses	O
,	O
and	O
this	O
instability	O
was	O
associated	O
with	O
the	O
clinical	O
phenomenon	O
of	O
anticipation	O
.	O

Third	O
,	O
the	O
size	O
of	O
the	O
expanded	O
allele	O
is	O
not	O
only	O
inversely	O
correlated	O
with	O
the	O
age	O
-	O
of	O
-	O
onset	O
of	O
MJD	B-Disease
(	O
r	O
=	O
-	O
0	O
.	O
738	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
is	O
also	O
correlated	O
with	O
the	O
frequency	O
of	O
other	O
clinical	O
features	O
[	O
e	O
.	O
g	O
.	O
pseudoexophthalmos	O
and	O
pyramidal	O
signs	O
were	O
more	O
frequent	O
in	O
subjects	O
with	O
large	O
repeats	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
05	O
respectively	O
)	O
]	O
.	O

Fourth	O
,	O
the	O
disease	O
phenotype	O
is	O
significantly	O
more	O
severe	O
and	O
had	O
an	O
early	O
age	O
of	O
onset	O
(	O
16	O
years	O
)	O
in	O
a	O
subject	O
homozygous	O
for	O
the	O
expanded	O
allele	O
,	O
which	O
contrasts	O
with	O
Huntington	B-Disease
disease	I-Disease
and	O
suggests	O
that	O
the	O
expanded	O
allele	O
in	O
the	O
MJD1	O
gene	O
could	O
exert	O
its	O
effect	O
either	O
by	O
a	O
dominant	O
negative	O
effect	O
(	O
putatively	O
excluded	O
in	O
HD	B-Disease
)	O
or	O
by	O
a	O
gain	O
of	O
function	O
effect	O
as	O
proposed	O
for	O
HD	B-Disease
.	O

Finally	O
,	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
MJD	B-Disease
share	O
haplotypes	O
at	O
several	O
markers	O
surrounding	O
the	O
MJD1	O
gene	O
,	O
which	O
are	O
uncommon	O
in	O
the	O
normal	O
Japanese	O
and	O
Caucasian	O
population	O
,	O
and	O
which	O
suggests	O
the	O
existence	O
either	O
of	O
common	O
founders	O
in	O
these	O
populations	O
or	O
of	O
chromosomes	O
susceptible	O
to	O
pathologic	O
expansion	O
of	O
the	O
CAG	O
repeat	O
in	O
the	O
MJD1	O
gene	O
.	O

A	O
4	O
-	O
megabase	O
YAC	O
contig	O
that	O
spans	O
the	O
Langer	B-Disease
-	I-Disease
Giedion	I-Disease
syndrome	I-Disease
region	O
on	O
human	O
chromosome	O
8q24	O
.	O
1	O
:	O
use	O
in	O
refining	O
the	O
location	O
of	O
the	O
trichorhinophalangeal	B-Disease
syndrome	I-Disease
and	O
multiple	O
exostoses	O
genes	O
(	O
TRPS1	O
and	O
EXT1	O
)	O
.	O

We	O
have	O
constructed	O
a	O
physical	O
map	O
covering	O
over	O
4	O
Mb	O
of	O
human	O
chromosome	O
8q24	O
.	O

1	O
and	O
used	O
this	O
map	O
to	O
refine	O
the	O
locations	O
of	O
the	O
genes	O
responsible	O
for	O
Langer	B-Disease
-	I-Disease
Giedion	I-Disease
syndrome	I-Disease
.	O

The	O
map	O
is	O
composed	O
of	O
overlapping	O
YAC	O
clones	O
that	O
were	O
identified	O
and	O
ordered	O
in	O
relation	O
to	O
sequence	O
tagged	O
sites	O
mapped	O
to	O
the	O
Langer	O
-	O
Giedion	O
chromosomal	O
region	O
on	O
somatic	O
cell	O
hybrids	O
.	O

The	O
minimal	O
region	O
of	O
overlap	O
of	O
Langer	B-Disease
-	I-Disease
Giedion	I-Disease
syndrome	I-Disease
deletions	O
,	O
previously	O
identified	O
by	O
analysis	O
of	O
15	O
patients	O
,	O
was	O
placed	O
on	O
the	O
map	O
by	O
analysis	O
of	O
2	O
patients	O
whose	O
deletions	O
define	O
the	O
endpoints	O
.	O

The	O
chromosome	O
8	O
breakpoint	O
of	O
a	O
balanced	O
t	O
(	O
8	O
;	O
9	O
)	O
(	O
q24	O
.	O
11	O
;	O
q33	O
.	O
3	O
)	O
translocation	O
from	O
a	O
patient	O
with	O
trichorhinophalangeal	B-Disease
syndrome	I-Disease
(	O
TRPS	B-Disease
I	O
)	O
was	O
found	O
to	O
be	O
located	O
just	O
within	O
the	O
proximal	O
end	O
of	O
the	O
minimal	O
deletion	O
region	O
.	O

A	O
deletion	O
of	O
8q24	O
.	O

11	O
-	O
q24	O
.	O

3	O
in	O
a	O
patient	O
with	O
multiple	O
exostoses	O
was	O
found	O
to	O
overlap	O
the	O
distal	O
end	O
of	O
the	O
LGS	B-Disease
deletion	O
region	O
,	O
indicating	O
that	O
the	O
EXT1	O
gene	O
is	O
distal	O
to	O
the	O
TRPS1	O
gene	O
and	O
supporting	O
the	O
hypothesis	O
that	O
Langer	B-Disease
-	I-Disease
Giedion	I-Disease
syndrome	I-Disease
is	O
due	O
to	O
loss	O
of	O
functional	O
copies	O
of	O
both	O
the	O
TRPS1	O
and	O
the	O
EXT1	O
genes	O

BRCA1	O
mutations	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
young	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

BACKGROUND	O
.	O

Inherited	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
are	O
associated	O
with	O
a	O
high	O
risk	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
some	O
families	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
BRCA1	O
mutations	O
to	O
breast	B-Disease
cancer	I-Disease
in	O
the	O
general	O
population	O
.	O

We	O
analyzed	O
DNA	O
samples	O
from	O
women	O
enrolled	O
in	O
a	O
population	O
-	O
based	O
study	O
of	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
to	O
assess	O
the	O
spectrum	O
and	O
frequency	O
of	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
in	O
young	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

METHODS	O
.	O

We	O
studied	O
80	O
women	O
in	O
whom	O
breast	B-Disease
cancer	I-Disease
was	O
diagnosed	O
before	O
the	O
age	O
of	O
35	O
,	O
and	O
who	O
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
family	O
history	O
.	O

Genomic	O
DNA	O
was	O
studied	O
for	O
BRCA1	O
mutations	O
by	O
analysis	O
involving	O
single	O
-	O
strand	O
conformation	O
polymorphisms	O
and	O
with	O
allele	O
-	O
specific	O
assays	O
.	O

Alterations	O
were	O
defined	O
by	O
DNA	O
sequencing	O
.	O

RESULTS	O
.	O

Germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
the	O
80	O
women	O
.	O

Four	O
additional	O
rare	O
sequence	O
variants	O
of	O
unknown	O
functional	O
importance	O
were	O
also	O
identified	O
.	O

Two	O
of	O
the	O
mutations	O
and	O
three	O
of	O
the	O
rare	O
sequence	O
variants	O
were	O
found	O
among	O
the	O
39	O
women	O
who	O
reported	O
no	O
family	O
history	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

None	O
of	O
the	O
mutations	O
and	O
only	O
one	O
of	O
the	O
rare	O
variants	O
was	O
identified	O
in	O
a	O
reference	O
population	O
of	O
73	O
unrelated	O
subjects	O
.	O

CONCLUSIONS	O
.	O

Alterations	O
in	O
BRCA1	O
were	O
identified	O
in	O
approximately	O
10	O
percent	O
of	O
this	O
cohort	O
of	O
young	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

The	O
risk	O
of	O
harboring	O
a	O
mutation	O
was	O
not	O
limited	O
to	O
women	O
with	O
family	O
histories	O
of	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

These	O
results	O
represent	O
a	O
minimal	O
estimate	O
of	O
the	O
frequency	O
of	O
BRCA1	O
mutations	O
in	O
this	O
population	O
.	O

Comprehensive	O
methods	O
of	O
identifying	O
BRCA1	O
mutations	O
and	O
understanding	O
their	O
importance	O
will	O
be	O
needed	O
before	O
testing	O
of	O
women	O
in	O
the	O
general	O
population	O
can	O
be	O
undertaken	O
.	O
.	O

Novel	O
inherited	O
mutations	O
and	O
variable	O
expressivity	O
of	O
BRCA1	O
alleles	O
,	O
including	O
the	O
founder	O
mutation	O
185delAG	O
in	O
Ashkenazi	O
Jewish	O
families	O
.	O

Thirty	O
-	O
seven	O
families	O
with	O
four	O
or	O
more	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
or	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
were	O
analyzed	O
for	O
mutations	O
in	O
BRCA1	O
.	O

Twelve	O
different	O
germ	O
-	O
line	O
mutations	O
,	O
four	O
novel	O
and	O
eight	O
previously	O
observed	O
,	O
were	O
detected	O
in	O
16	O
families	O
.	O

Five	O
families	O
of	O
Ashkenazi	O
Jewish	O
descent	O
carried	O
the	O
185delAG	O
mutation	O
and	O
shared	O
the	O
same	O
haplotype	O
at	O
eight	O
polymorphic	O
markers	O
spanning	O
approximately	O
850	O
kb	O
at	O
BRCA1	O
.	O

Expressivity	O
of	O
185delAG	O
in	O
these	O
families	O
varied	O
,	O
from	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
without	O
ovarian	B-Disease
cancer	I-Disease
.	O

Mutation	O
4184delTCAA	O
occurred	O
independently	O
in	O
two	O
families	O
.	O

In	O
one	O
family	O
,	O
penetrance	O
was	O
complete	O
,	O
with	O
females	O
developing	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
or	O
ovarian	B-Disease
cancer	I-Disease
and	O
the	O
male	O
carrier	O
developing	O
prostatic	B-Disease
cancer	I-Disease
,	O
whereas	O
,	O
in	O
the	O
other	O
family	O
,	O
penetrance	O
was	O
incomplete	O
and	O
only	O
breast	B-Disease
cancer	I-Disease
occurred	O
,	O
diagnosed	O
at	O
ages	O
38	O
-	O
81	O
years	O
.	O

Two	O
novel	O
nonsense	O
mutations	O
led	O
to	O
the	O
loss	O
of	O
mutant	O
BRCA1	O
transcript	O
in	O
families	O
with	O
10	O
and	O
6	O
cases	O
of	O
early	O
-	O
onset	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
.	O

A	O
665	O
-	O
nt	O
segment	O
of	O
the	O
BRCA1	O
3	O
-	O
UTR	O
and	O
1	O
.	O

3	O
kb	O
of	O
genomic	O
sequence	O
including	O
the	O
putative	O
promoter	O
region	O
were	O
invariant	O
by	O
single	O
-	O
strand	O
conformation	O
analysis	O
in	O
13	O
families	O
without	O
coding	O
-	O
sequence	O
mutations	O
.	O

Overall	O
in	O
our	O
series	O
,	O
BRCA1	O
mutations	O
have	O
been	O
detected	O
in	O
26	O
families	O
16	O
with	O
positive	O
BRCA1	O
lod	O
scores	O
,	O
7	O
with	O
negative	O
lod	O
scores	O
(	O
reflecting	O
multiple	O
sporadic	O
breast	B-Disease
cancers	I-Disease
)	O
,	O
and	O
3	O
not	O
tested	O
for	O
linkage	O
.	O

Three	O
other	O
families	O
have	O
positive	O
lod	O
scores	O
for	O
linkage	O
to	O
BRCA2	O
,	O
but	O
13	O
families	O
without	O
detected	O
BRCA1	O
mutations	O
have	O
negative	O
lod	O
scores	O
for	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
new	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
variant	O
,	O
G6PD	O
Orissa	O
(	O
44	O
Ala	O
-	O
-	O
>	O
Gly	O
)	O
,	O
is	O
the	O
major	O
polymorphic	O
variant	O
in	O
tribal	O
populations	O
in	O
India	O
.	O

Deficiency	B-Disease
of	I-Disease
glucose	I-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	O
G6PD	O
)	O
is	O
usually	O
found	O
at	O
high	O
frequencies	O
in	O
areas	O
of	O
the	O
world	O
where	O
malaria	B-Disease
has	O
been	O
endemic	O
.	O

The	O
frequency	O
and	O
genetic	O
basis	O
of	O
G6PD	B-Disease
deficiency	I-Disease
have	O
been	O
studied	O
in	O
Africa	O
,	O
around	O
the	O
Mediterranean	O
,	O
and	O
in	O
the	O
Far	O
East	O
,	O
but	O
little	O
such	O
information	O
is	O
available	O
about	O
the	O
situation	O
in	O
India	O
.	O

To	O
determine	O
the	O
extent	O
of	O
heterogeneity	O
of	O
G6PD	O
,	O
we	O
have	O
studied	O
several	O
different	O
Indian	O
populations	O
by	O
screening	O
for	O
G6PD	B-Disease
deficiency	I-Disease
,	O
followed	O
by	O
molecular	O
analysis	O
of	O
deficient	O
alleles	O
.	O

The	O
frequency	O
of	O
G6PD	B-Disease
deficiency	I-Disease
varies	O
between	O
3	O
%	O
and	O
15	O
%	O
in	O
different	O
tribal	O
and	O
urban	O
groups	O
.	O

Remarkably	O
,	O
a	O
previously	O
unreported	O
deficient	O
variant	O
,	O
G6PD	O
Orissa	O
(	O
44	O
Ala	O
-	O
-	O
>	O
Gly	O
)	O
,	O
is	O
responsible	O
for	O
most	O
of	O
the	O
G6PD	B-Disease
deficiency	I-Disease
in	O
tribal	O
Indian	O
populations	O
but	O
is	O
not	O
found	O
in	O
urban	O
populations	O
,	O
where	O
most	O
of	O
the	O
G6PD	B-Disease
deficiency	I-Disease
is	O
due	O
to	O
the	O
G6PD	O
Mediterranean	O
(	O
188	O
Ser	O
-	O
-	O
>	O
Phe	O
)	O
variant	O
.	O

The	O
KmNADP	O
of	O
G6PD	O
Orissa	O
is	O
fivefold	O
higher	O
than	O
that	O
of	O
the	O
normal	O
enzyme	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
alanine	O
residue	O
that	O
is	O
replaced	O
by	O
glycine	O
is	O
part	O
of	O
a	O
putative	O
coenzyme	O
-	O
binding	O
site	O
.	O
.	O

Evidence	O
for	O
linkage	O
of	O
bipolar	B-Disease
disorder	I-Disease
to	O
chromosome	O
18	O
with	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
.	O

A	O
susceptibility	O
gene	O
on	O
chromosome	O
18	O
and	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
have	O
been	O
suggested	O
for	O
bipolar	B-Disease
affective	I-Disease
disorder	I-Disease
(	O
BPAD	B-Disease
)	O
.	O

We	O
have	O
studied	O
28	O
nuclear	O
families	O
selected	O
for	O
apparent	O
unilineal	O
transmission	O
of	O
the	O
BPAD	B-Disease
phenotype	O
,	O
by	O
using	O
31	O
polymorphic	O
markers	O
spanning	O
chromosome	O
18	O
.	O

Evidence	O
for	O
linkage	O
was	O
tested	O
with	O
affected	O
-	O
sib	O
-	O
pair	O
and	O
LOD	O
score	O
methods	O
under	O
two	O
definitions	O
of	O
the	O
affected	O
phenotype	O
.	O

The	O
affected	O
-	O
sibpair	O
analyses	O
indicated	O
excess	O
allele	O
sharing	O
for	O
markers	O
on	O
18p	O
within	O
the	O
region	O
reported	O
previously	O
.	O

The	O
greatest	O
sharing	O
was	O
at	O
D18S37	O
64	O
%	O
in	O
bipolar	O
and	O
recurrent	O
unipolar	O
(	O
RUP	O
)	O
sib	O
pairs	O
(	O
P	O
=	O
.	O
0006	O
)	O
.	O

In	O
addition	O
,	O
excess	O
sharing	O
of	O
the	O
paternally	O
,	O
but	O
not	O
maternally	O
,	O
transmitted	O
alleles	O
was	O
observed	O
at	O
three	O
markers	O
on	O
18q	O
at	O
D18S41	O
,	O
51	O
bipolar	O
and	O
RUP	O
sib	O
pairs	O
were	O
concordant	O
for	O
paternally	O
transmitted	O
alleles	O
,	O
and	O
21	O
pairs	O
were	O
discordant	O
(	O
P	O
=	O
0004	O
)	O
.	O

The	O
evidence	O
for	O
linkage	O
to	O
loci	O
on	O
both	O
18p	O
and	O
18q	O
was	O
strongest	O
in	O
the	O
11	O
paternal	O
pedigrees	O
,	O
i	O
.	O

e	O
e	O
.	O
,	O
those	O
in	O
which	O
the	O
father	O
or	O
one	O
of	O
the	O
fathers	O
sibs	O
is	O
affected	O
.	O

In	O
these	O
pedigrees	O
,	O
the	O
greatest	O
allele	O
sharing	O
(	O
81	O
%	O
;	O
P	O
=	O
.	O
00002	O
)	O
and	O
the	O
highest	O
LOD	O
score	O
(	O
3	O
.	O
51	O
;	O
phi	O
=	O
0	O
.	O
0	O
)	O
were	O
observed	O
at	O
D18S41	O
.	O

Our	O
results	O
provide	O
further	O
support	O
for	O
linkage	O
of	O
BPAD	B-Disease
to	O
chromosome	O
18	O
and	O
the	O
first	O
molecular	O
evidence	O
for	O
a	O
parent	O
-	O
of	O
-	O
origin	O
effect	O
operating	O
in	O
this	O
disorder	O
.	O

The	O
number	O
of	O
loci	O
involved	O
,	O
and	O
their	O
precise	O
location	O
,	O
require	O
further	O
study	O

A	O
prevalent	O
mutation	O
for	O
galactosemia	B-Disease
among	O
black	O
Americans	O
.	O

OBJECTIVE	O
To	O
define	O
the	O
mutation	O
causing	O
galactosemia	B-Disease
in	O
patients	O
of	O
black	O
American	O
origin	O
who	O
have	O
no	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
activity	O
in	O
erythrocytes	O
but	O
good	O
clinical	O
outcome	O
.	O

METHODS	O
We	O
discovered	O
a	O
mutation	O
caused	O
by	O
a	O
C	O
-	O
-	O
>	O
T	O
transition	O
at	O
base	O
-	O
pair	O
1158	O
of	O
the	O
GALT	O
gene	O
that	O
results	O
in	O
a	O
serine	O
-	O
to	O
-	O
leucine	O
substitution	O
at	O
codon	O
135	O
(	O
S135L	O
)	O
.	O

We	O
developed	O
a	O
method	O
with	O
which	O
to	O
screen	O
populations	O
for	O
its	O
prevalence	O
.	O

We	O
compared	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
among	O
erythrocytes	O
,	O
leukocytes	O
,	O
and	O
transformed	O
lymphoblasts	O
,	O
as	O
well	O
as	O
total	O
body	O
oxidation	O
of	O
D	O
-	O
(	O
13C	O
)	O
-	O
galactose	O
to	O
13CO2	O
among	O
three	O
genotypes	O
for	O
GALT	O
(	O
S135L	O
/	O
S135L	O
,	O
Q188R	O
/	O
Q188R	O
,	O
and	O
Normal	O
/	O
Normal	O
)	O
.	O

RESULTS	O
We	O
found	O
a	O
48	O
%	O
prevalence	O
of	O
the	O
S135L	O
mutation	O
among	O
17	O
black	O
American	O
patients	O
with	O
classic	B-Disease
galactosemia	I-Disease
and	O
a	O
1	O
%	O
prevalence	O
in	O
a	O
population	O
of	O
50	O
black	O
Americans	O
without	O
galactosemia	B-Disease
.	O

The	O
S135L	O
mutation	O
was	O
not	O
found	O
in	O
84	O
white	O
patients	O
with	O
G	O
/	O
G	O
galactosemia	B-Disease
nor	O
in	O
87	O
white	O
control	O
subjects	O
without	O
galactosemia	B-Disease
.	O

We	O
found	O
normal	O
whole	O
body	O
oxidation	O
of	O
D	O
-	O
(	O
13C	O
)	O
-	O
galactose	O
by	O
the	O
patient	O
homozygous	O
for	O
S135L	O
and	O
various	O
degrees	O
of	O
enzyme	O
impairment	O
among	O
different	O
tissues	O
.	O

CONCLUSIONS	O
The	O
S135L	O
mutation	O
in	O
the	O
GALT	O
gene	O
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	B-Disease
among	O
black	O
patients	O
.	O

Because	O
GALT	O
activity	O
varies	O
in	O
different	O
tissues	O
of	O
patients	O
homozygous	O
for	O
S135L	O
,	O
they	O
may	O
have	O
a	O
better	O
clinical	O
outcome	O
than	O
patients	O
who	O
are	O
homozygous	O
for	O
Q188R	O
when	O
both	O
are	O
treated	O
from	O
infancy	O
.	O
.	O

A	O
high	O
incidence	O
of	O
BRCA1	O
mutations	O
in	O
20	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O

We	O
have	O
analyzed	O
20	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
,	O
the	O
majority	O
of	O
which	O
show	O
positive	O
evidence	O
of	O
linkage	O
to	O
chromosome	O
17q12	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

BRCA1	O
mutations	O
cosegregating	O
with	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
were	O
identified	O
in	O
16	O
families	O
,	O
including	O
1	O
family	O
with	O
a	O
case	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
.	O

Nine	O
of	O
these	O
mutations	O
have	O
not	O
been	O
reported	O
previously	O
.	O

The	O
majority	O
of	O
mutations	O
were	O
found	O
to	O
generate	O
a	O
premature	O
stop	O
codon	O
leading	O
to	O
the	O
formation	O
of	O
a	O
truncated	O
BRCA1	O
protein	O
of	O
2	O
%	O
-	O
88	O
%	O
of	O
the	O
expected	O
normal	O
length	O
.	O

Two	O
mutations	O
altered	O
the	O
RING	O
finger	O
domain	O
.	O

Sequencing	O
of	O
genomic	O
DNA	O
led	O
to	O
the	O
identification	O
of	O
a	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
BRCA1	O
in	O
12	O
families	O
,	O
and	O
cDNA	O
analysis	O
revealed	O
an	O
abnormal	O
or	O
missing	O
BRCA1	O
transcript	O
in	O
4	O
of	O
the	O
8	O
remaining	O
families	O
.	O

A	O
total	O
of	O
eight	O
mutations	O
were	O
associated	O
with	O
a	O
reduced	O
quantity	O
of	O
BRCA1	O
transcript	O
.	O

We	O
were	O
unable	O
to	O
detect	O
BRCA1	O
mutations	O
in	O
4	O
of	O
the	O
20	O
families	O
,	O
but	O
only	O
1	O
of	O
these	O
was	O
clearly	O
linked	O
to	O
BRCA1	O
.	O

It	O
is	O
expected	O
that	O
the	O
majority	O
of	O
clear	O
examples	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
syndrome	I-Disease
will	O
be	O
associated	O
with	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
BRCA1	O
.	O
.	O

Brca1	B-Disease
deficiency	I-Disease
results	O
in	O
early	O
embryonic	B-Disease
lethality	I-Disease
characterized	O
by	O
neuroepithelial	B-Disease
abnormalities	I-Disease
.	O

The	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc	O
-	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
at	O
least	O
80	O
%	O
of	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
as	O
well	O
as	O
some	O
non	O
-	O
familial	O
sporadic	O
ovarian	B-Disease
cancers	I-Disease
.	O

The	O
loss	O
of	O
wild	O
-	O
type	O
BRCA1	O
in	O
tumours	B-Disease
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
BRCA1	O
allele	O
suggests	O
that	O
BRCA1	O
encodes	O
a	O
tumour	B-Disease
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
BRCA1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation	O
,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	B-Disease
susceptibility	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function	O
,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
Brca1	O
allele	O
.	O

Analysis	O
of	O
mice	O
homozygous	O
for	O
the	O
mutant	O
allele	O
indicate	O
that	O
Brca1	O
is	O
critical	O
for	O
normal	O
development	O
,	O
as	O
these	O
mice	O
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(	O
E10	O
-	O
E13	O
)	O
.	O

Abnormalities	O
in	O
Brca1	B-Disease
-	I-Disease
deficient	I-Disease
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	B-Disease
bifida	I-Disease
and	O
anencephaly	B-Disease
.	O

In	O
addition	O
,	O
the	O
neuroepithelium	O
in	O
Brca1	B-Disease
-	I-Disease
deficient	I-Disease
embryos	O
appeared	O
disorganized	O
,	O
with	O
signs	O
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	O
death	O
.	O
.	O

Identification	O
of	O
mutations	O
in	O
the	O
ALD	O
-	O
gene	O
of	O
20	O
families	O
with	O
adrenoleukodystrophy	B-Disease
/	O
adrenomyeloneuropathy	B-Disease
.	O

Adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
,	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
inherited	I-Disease
metabolic	I-Disease
disorder	I-Disease
,	O
is	O
the	O
most	O
frequent	O
inborn	B-Disease
peroxisomal	I-Disease
disease	I-Disease
.	O

It	O
leads	O
to	O
demyelination	B-Disease
in	I-Disease
the	I-Disease
central	I-Disease
and	I-Disease
peripheral	I-Disease
nervous	I-Disease
system	I-Disease
.	O

Defective	O
beta	O
-	O
oxidation	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFAs	O
;	O
C22	O
0	O
-	O
C26	O
0	O
)	O
in	O
peroxisomes	O
has	O
been	O
shown	O
to	O
lead	O
to	O
an	O
accumulation	O
of	O
VLCFAs	O
in	O
leukoid	O
areas	O
of	O
the	O
central	O
nervous	O
system	O
,	O
peripheral	O
nerves	O
,	O
adrenal	O
gland	O
,	O
and	O
blood	O
.	O

The	O
ALD	B-Disease
gene	O
has	O
been	O
recently	O
identified	O
and	O
encodes	O
a	O
745	O
-	O
amino	O
-	O
acid	O
protein	O
.	O

We	O
screened	O
patients	O
with	O
adrenoleukodystrophy	B-Disease
/	O
adrenomyeloneuropathy	B-Disease
(	O
ALD	B-Disease
/	O
AMN	B-Disease
)	O
from	O
20	O
kindreds	O
for	O
mutations	O
in	O
the	O
ALD	B-Disease
gene	O
.	O

Eleven	O
missense	O
and	O
two	O
nonsense	O
mutations	O
,	O
five	O
deletions	O
,	O
and	O
one	O
insertion	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
eight	O
reverse	O
transcribed	O
fragments	O
of	O
the	O
ALD	B-Disease
-	O
gene	O
mRNA	O
.	O

Four	O
mutations	O
could	O
be	O
shown	O
to	O
be	O
de	O
novo	O
.	O

All	O
mutations	O
could	O
be	O
confirmed	O
in	O
carriers	O
by	O
sequencing	O
genomic	O
DNA	O
.	O

No	O
correlation	O
between	O
the	O
type	O
of	O
mutation	O
and	O
the	O
severity	O
of	O
the	O
phenotype	O
could	O
be	O
observed	O
.	O

The	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
ALD	B-Disease
gene	O
of	O
30	O
healthy	O
persons	O
.	O
.	O

The	O
murine	O
homolog	O
of	O
the	O
human	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
Brca1	O
maps	O
to	O
mouse	O
chromosome	O
11D	O
.	O

The	O
recently	O
cloned	O
human	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
17q21	O
.	O

We	O
have	O
isolated	O
murine	O
genomic	O
clones	O
containing	O
Brca1	O
as	O
a	O
first	O
step	O
in	O
generating	O
a	O
mouse	O
model	O
for	O
the	O
loss	O
of	O
BRCA1	O
function	O
.	O

A	O
mouse	O
genomic	O
library	O
was	O
screened	O
using	O
probes	O
corresponding	O
to	O
exon	O
11	O
of	O
the	O
human	O
BRCA1	O
gene	O
.	O

Two	O
overlapping	O
mouse	O
clones	O
were	O
identified	O
that	O
hybridized	O
to	O
human	O
BRCA1	O
exons	O
9	O
-	O
12	O
.	O

Sequence	O
analysis	O
of	O
1	O
.	O

4	O
kb	O
of	O
the	O
region	O
of	O
these	O
clones	O
corresponding	O
to	O
part	O
of	O
human	O
exon	O
11	O
revealed	O
72	O
%	O
nucleic	O
acid	O
identity	O
but	O
only	O
50	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
human	O
gene	O
.	O

The	O
longest	O
of	O
the	O
mouse	O
Brca1	O
genomic	O
clones	O
maps	O
to	O
chromosome	O
11D	O
,	O
as	O
determined	O
by	O
two	O
-	O
color	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
synteny	O
to	O
human	O
chromosome	O
17	O
was	O
confirmed	O
by	O
cohybridization	O
with	O
the	O
mouse	O
probe	O
for	O
the	O
NF1	O
-	O
gene	O
.	O

This	O
comparative	O
study	O
confirms	O
that	O
the	O
relative	O
location	O
of	O
the	O
BRCA1	O
gene	O
has	O
been	O
conserved	O
between	O
mice	O
and	O
humans	O
.	O

Atelosteogenesis	B-Disease
type	I-Disease
II	I-Disease
is	O
caused	O
by	O
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
-	O
transporter	O
gene	O
(	O
DTDST	O
)	O
:	O
evidence	O
for	O
a	O
phenotypic	O
series	O
involving	O
three	O
chondrodysplasias	B-Disease
.	O

Atelosteogenesis	B-Disease
type	I-Disease
II	I-Disease
(	O
AO	B-Disease
II	I-Disease
)	O
is	O
a	O
neonatally	O
lethal	O
chondrodysplasia	B-Disease
whose	O
clinical	O
and	O
histological	O
characteristics	O
resemble	O
those	O
of	O
another	O
chondrodysplasia	B-Disease
,	O
the	O
much	O
less	O
severe	O
diastrophic	B-Disease
dysplasia	I-Disease
(	O
DTD	B-Disease
)	O
.	O

The	O
similarity	O
suggests	O
a	O
shared	O
pathogenesis	O
involving	O
lesions	O
in	O
the	O
same	O
biochemical	O
pathway	O
and	O
perhaps	O
the	O
same	O
gene	O
.	O

DTD	B-Disease
is	O
caused	O
by	O
mutations	O
in	O
the	O
recently	O
identified	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
-	O
transporter	O
gene	O
(	O
DTDST	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
AOII	B-Disease
patients	O
also	O
have	O
DTDST	O
mutations	O
,	O
which	O
lead	O
to	O
defective	O
uptake	O
of	O
inorganic	O
sulfate	O
and	O
insufficient	O
sulfation	O
of	O
macromolecules	O
by	O
patient	O
mesenchymal	O
cells	O
in	O
vitro	O
.	O

Together	O
with	O
our	O
recent	O
observation	O
that	O
a	O
third	O
even	O
more	O
severe	O
chondrodysplasia	B-Disease
,	O
achondrogenesis	O
type	O
IB	O
,	O
is	O
also	O
caused	O
by	O
mutations	O
in	O
DTDST	O
,	O
these	O
results	O
demonstrate	O
a	O
phenotypic	O
series	O
of	O
three	O
chondrodysplasias	B-Disease
of	O
increasing	O
severity	O
caused	O
by	O
lesions	O
in	O
a	O
single	O
sulfate	O
-	O
transporter	O
gene	O
.	O

The	O
severity	O
of	O
the	O
phenotype	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
predicted	O
effect	O
of	O
the	O
mutations	O
on	O
the	O
residual	O
activity	O
of	O
the	O
DTDST	O
protein	O
.	O
.	O

Haplotype	O
and	O
phenotype	O
analysis	O
of	O
six	O
recurrent	O
BRCA1	O
mutations	O
in	O
61	O
families	O
:	O
results	O
of	O
an	O
international	O
study	O
.	O

Several	O
BRCA1	O
mutations	O
have	O
now	O
been	O
found	O
to	O
occur	O
in	O
geographically	O
diverse	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O

To	O
investigate	O
mutation	O
origin	O
and	O
mutation	O
-	O
specific	O
phenotypes	O
due	O
to	O
BRCA1	O
,	O
we	O
constructed	O
a	O
haplotype	O
of	O
nine	O
polymorphic	O
markers	O
within	O
or	O
immediately	O
flanking	O
the	O
BRCA1	O
locus	O
in	O
a	O
set	O
of	O
61	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
selected	O
for	O
having	O
one	O
of	O
six	O
recurrent	O
BRCA1	O
mutations	O
.	O

Tests	O
of	O
both	O
mutations	O
and	O
family	O
-	O
specific	O
differences	O
in	O
age	O
at	O
diagnosis	O
were	O
not	O
significant	O
.	O

A	O
comparison	O
of	O
the	O
six	O
mutations	O
in	O
the	O
relative	O
proportions	O
of	O
cases	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
was	O
suggestive	O
of	O
an	O
effect	O
(	O
P	O
=	O
.	O
069	O
)	O
,	O
with	O
57	O
%	O
of	O
women	O
presumed	O
affected	O
because	O
of	O
the	O
1294	O
del	O
40	O
BRCA1	O
mutation	O
having	O
ovarian	B-Disease
cancer	I-Disease
,	O
compared	O
with	O
14	O
%	O
of	O
affected	O
women	O
with	O
the	O
splice	O
-	O
site	O
mutation	O
in	O
intron	O
5	O
of	O
BRCA1	O
.	O

For	O
the	O
BRCA1	O
mutations	O
studied	O
here	O
,	O
the	O
individual	O
mutations	O
are	O
estimated	O
to	O
have	O
arisen	O
9	O
-	O
170	O
generations	O
ago	O
.	O

In	O
general	O
,	O
a	O
high	O
degree	O
of	O
haplotype	O
conservation	O
across	O
the	O
region	O
was	O
observed	O
,	O
with	O
haplotype	O
differences	O
most	O
often	O
due	O
to	O
mutations	O
in	O
the	O
short	O
-	O
tandem	O
-	O
repeat	O
markers	O
,	O
although	O
some	O
likely	O
instances	O
of	O
recombination	O
also	O
were	O
observed	O
.	O

For	O
several	O
of	O
the	O
instances	O
,	O
there	O
was	O
evidence	O
for	O
multiple	O
,	O
independent	O
,	O
BRCA1	O
mutational	O
events	O
.	O

Isolation	O
of	O
the	O
mouse	O
homologue	O
of	O
BRCA1	O
and	O
genetic	O
mapping	O
to	O
mouse	O
chromosome	O
11	O
.	O

The	O
BRCA1	O
gene	O
is	O
in	O
large	O
part	O
responsible	O
for	O
hereditary	B-Disease
human	I-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

Here	O
we	O
report	O
the	O
isolation	O
of	O
the	O
murine	O
Brca1	O
homologue	O
cDNA	O
clones	O
.	O

In	O
addition	O
,	O
we	O
identified	O
genomic	O
P1	O
clones	O
that	O
contain	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
mouse	O
Brca1	O
locus	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
the	O
mouse	O
and	O
human	O
coding	O
regions	O
are	O
75	O
%	O
identical	O
at	O
the	O
nucleotide	O
level	O
while	O
the	O
predicted	O
amino	O
acid	O
identity	O
is	O
only	O
58	O
%	O
.	O

A	O
DNA	O
sequence	O
variant	O
in	O
the	O
Brca1	O
locus	O
was	O
identified	O
and	O
used	O
to	O
map	O
this	O
gene	O
on	O
a	O
(	O
Mus	O
m	O
.	O
musculus	O
Czech	O
II	O
x	O
C57BL	O
/	O
KsJ	O
)	O
F1	O
x	O
C57BL	O
/	O
KsJ	O
intersubspecific	O
backcross	O
to	O
distal	O
mouse	O
chromosome	O
11	O
.	O

The	O
mapping	O
of	O
this	O
gene	O
to	O
a	O
region	O
highly	O
syntenic	O
with	O
human	O
chromosome	O
17	O
,	O
coupled	O
with	O
Southern	O
and	O
Northern	O
analyses	O
,	O
confirms	O
that	O
we	O
isolated	O
the	O
murine	O
Brca1	O
homologue	O
rather	O
than	O
a	O
related	O
RING	O
finger	O
gene	O
.	O

The	O
isolation	O
of	O
the	O
mouse	O
Brca1	O
homologue	O
will	O
facilitate	O
the	O
creation	O
of	O
mouse	O
models	O
for	O
germline	O
BRCA1	B-Disease
defects	I-Disease
.	O
.	O

Emerin	B-Disease
deficiency	I-Disease
at	O
the	O
nuclear	O
membrane	O
in	O
patients	O
with	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Mutations	O
in	O
the	O
STA	O
gene	O
at	O
the	O
Xq28	O
locus	O
have	O
been	O
found	O
in	O
patients	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
.	O

This	O
gene	O
encodes	O
a	O
hitherto	O
unknown	O
protein	O
named	O
emerin	O
.	O

To	O
elucidate	O
the	O
subcellular	O
localization	O
of	O
emerin	O
,	O
we	O
raised	O
two	O
antisera	O
against	O
synthetic	O
peptide	O
fragments	O
predicted	O
from	O
emerin	O
cDNA	O
.	O

Using	O
both	O
antisera	O
,	O
we	O
found	O
positive	O
nuclear	O
membrane	O
staining	O
in	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
in	O
the	O
normal	O
controls	O
and	O
in	O
patients	O
with	O
neuromuscular	B-Disease
diseases	I-Disease
other	O
than	O
EDMD	B-Disease
.	O

In	O
contrast	O
,	O
a	O
deficiency	O
in	O
immunofluorescent	O
staining	O
of	O
skeletal	O
and	O
cardiac	O
muscle	O
from	O
EDMD	B-Disease
patients	O
was	O
observed	O
.	O

A	O
34	O
kD	O
protein	O
is	O
immunoreactive	O
with	O
the	O
antisera	O
-	O
-	O
the	O
protein	O
is	O
equivalent	O
to	O
that	O
predicted	O
for	O
emerin	O
.	O

Together	O
,	O
our	O
findings	O
suggest	O
the	O
specific	O
deficiency	B-Disease
of	I-Disease
emerin	I-Disease
in	O
the	O
nuclear	O
membrane	O
of	O
muscle	O
cells	O
in	O
patients	O
with	O
EDMD	B-Disease
.	O
.	O

Growth	B-Disease
retardation	I-Disease
and	O
tumour	B-Disease
inhibition	O
by	O
BRCA1	O
.	O

Inherited	O
mutations	O
in	O
BRCA1	O
predispose	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
but	O
the	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
has	O
previously	O
been	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
retroviral	O
transfer	O
of	O
the	O
wild	O
-	O
type	O
BRCA1	O
gene	O
inhibits	O
growth	O
in	O
vitro	O
of	O
all	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
cell	O
lines	O
tested	O
,	O
but	O
not	O
colon	B-Disease
or	I-Disease
lung	I-Disease
cancer	I-Disease
cells	O
or	O
fibroblasts	O
.	O

Mutant	O
BRCA1	O
has	O
no	O
effect	O
on	O
growth	O
of	O
breast	B-Disease
cancer	I-Disease
cells	O
;	O
ovarian	B-Disease
cancer	I-Disease
cell	O
growth	O
is	O
not	O
affected	O
by	O
BRCA1	O
mutations	O
in	O
the	O
5	O
portion	O
of	O
the	O
gene	O
,	O
but	O
is	O
inhibited	O
by	O
3	O
BRCA1	O
mutations	O
.	O

Development	O
of	O
MCF	B-Disease
-	I-Disease
7	I-Disease
tumours	I-Disease
in	O
nude	O
mice	O
is	O
inhibited	O
when	O
MCF	O
-	O
7	O
cells	O
are	O
transfected	O
with	O
wild	O
-	O
type	O
,	O
but	O
not	O
mutant	O
,	O
BRCA1	O
.	O

Most	O
importantly	O
,	O
among	O
mice	O
with	O
established	O
MCF	B-Disease
-	I-Disease
7	I-Disease
tumours	I-Disease
,	O
peritoneal	O
treatment	O
with	O
a	O
retroviral	O
vector	O
expressing	O
wild	O
-	O
type	O
BRCA1	O
significantly	O
inhibits	O
tumour	B-Disease
growth	O
and	O
increased	O
survival	O
.	O
.	O

